CRP11	We used both family-based and cross-sectional tests of association with 8 beta(2)AR single  bbbbb1 nucleotide eeeee1  bbbbb2 beta(2)AR eeeee2  single nucleotide polymorphisms in 684 Puerto Rican and Mexican families
CRP11	This block does not appear to be compensated by oxysterol production in other cell compartments bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This block does not appear to be compensated by oxysterol production in other cell compartments bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This block does not appear to be compensated by oxysterol production in other cell compartments bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This block does not appear to be compensated by oxysterol production in other cell compartments bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This block does not appear to be compensated by oxysterol productio bbbbb1 n in othe eeeee1 r cell compartments bbbbb2  eeeee2 
CRP11	This block does not appear to be compensated by oxysterol production in other cell compartments bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in  bbbbb1 sterol eeeee1  bbbbb2 sterol-27-hydroxylase eeeee2  activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation
CRP11	Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in  bbbbb1 sterol eeeee1 -27-hydroxylase activity lead to specific blocks in oxysterol production and impaired  bbbbb2 LXR eeeee2 -dependent gene activation
CRP11	Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in  bbbbb1 oxysterol eeeee1  production and impaired  bbbbb2 LXR eeeee2 -dependent gene activation
CRP11	Defects resulting in slowed release of  bbbbb1 cholesterol eeeee1  from late endosomes and lysosomes or reduction in  bbbbb2 sterol-27-hydroxylase eeeee2  activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation
CRP11	Defects resulting in slowed release of  bbbbb1 cholesterol eeeee1  from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired  bbbbb2 LXR eeeee2 -dependent gene activation
CRP11	LXRs are thought to be activated predominantly by oxysterols generated enzymatically from  bbbbb1 cholesterol eeeee1  bbbbb2 LXRs eeeee2  are thought to be activated predominantly by oxysterols generated enzymatically from cholesterol in different cell organelles
CRP11	 bbbbb1 Oxysterol eeeee1  generation and  bbbbb2 liver X receptor eeeee2 -dependent reverse cholesterol transport: not all roads lead to Rome
CRP11	Oxysterol generation and liver X receptor-dependent reverse  bbbbb1 cholesterol eeeee1  bbbbb2 liver X receptor eeeee2 -dependent reverse cholesterol transport: not all roads lead to Rome
CRP11	Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse  bbbbb1 cholesterol eeeee1  bbbbb2 LXRs eeeee2 ) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway
CRP11	Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse  bbbbb1 cholesterol eeeee1  bbbbb2 nuclear liver X receptors eeeee2  (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway
CRP11	Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (LXRs) to increase expression of genes mediating removal of excess  bbbbb1 cholesterol eeeee1  bbbbb2 LXRs eeeee2 ) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway
CRP11	Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (LXRs) to increase expression of genes mediating removal of excess  bbbbb1 cholesterol eeeee1  bbbbb2 nuclear liver X receptors eeeee2  (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway
CRP11	Cell  bbbbb1 cholesterol eeeee1  metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors ( bbbbb2 LXRs eeeee2 ) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway
CRP11	Cell  bbbbb1 cholesterol eeeee1  metabolism is a tightly regulated process, dependent in part on activation of  bbbbb2 nuclear liver X receptors eeeee2  (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway
CRP11	Furthermore, we analyzed the beta-receptor-mediated  bbbbb1 adenylyl eeeee1  bbbbb2 adenylyl cyclase eeeee2  activity in isolated membranes from these cell lines
CRP11	Furthermore, we analyzed the beta-receptor-mediated  bbbbb1 adenylyl eeeee1  bbbbb2 beta-receptor eeeee2 -mediated adenylyl cyclase activity in isolated membranes from these cell lines
CRP11	Cembranoid and long-chain alkanol sites on the nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 nicotinic acetylcholine receptor eeeee2  and their allosteric interaction
CRP11	 bbbbb1 Long-chain alkanols eeeee1  are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor ( bbbbb2 AChR eeeee2 ) by binding to one or more specific sites on the AChR
CRP11	Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic  bbbbb1 acetylcholine eeeee1  receptor (AChR) by binding to one or more specific sites on the  bbbbb2 AChR eeeee2 
CRP11	Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic  bbbbb1 acetylcholine eeeee1  receptor ( bbbbb2 AChR eeeee2 ) by binding to one or more specific sites on the AChR
CRP11	Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 nicotinic acetylcholine receptor eeeee2  (AChR) by binding to one or more specific sites on the AChR
CRP11	In this study, [3H]tenocyclidine ( bbbbb1 [3H]TCP eeeee1 ), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica  bbbbb2 AChR eeeee2  and to investigate if these sites interact
CRP11	In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor  bbbbb1 phencyclidine eeeee1  (PCP), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica  bbbbb2 AChR eeeee2  and to investigate if these sites interact
CRP11	In this study,  bbbbb1 [3H]tenocyclidine eeeee1  ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica  bbbbb2 AChR eeeee2  and to investigate if these sites interact
CRP11	In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the  bbbbb1 cembranoid eeeee1  and long-chain alkanol sites on the desensitized Torpedo californica  bbbbb2 AChR eeeee2  and to investigate if these sites interact
CRP11	In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the cembranoid and  bbbbb1 long-chain alkanol eeeee1  sites on the desensitized Torpedo californica  bbbbb2 AChR eeeee2  and to investigate if these sites interact
CRP11	In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine ( bbbbb1 PCP eeeee1 ), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica  bbbbb2 AChR eeeee2  and to investigate if these sites interact
CRP11	Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the thiazide-sensitive  bbbbb1 NaCl eeeee1  co-transporter ( bbbbb2 NCCT eeeee2 )
CRP11	Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the thiazide-sensitive  bbbbb1 NaCl eeeee1  bbbbb2 thiazide-sensitive NaCl co-transporter eeeee2  (NCCT)
CRP11	Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the  bbbbb1 thiazide eeeee1 -sensitive NaCl co-transporter ( bbbbb2 NCCT eeeee2 )
CRP11	Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the  bbbbb1 thiazide eeeee1  bbbbb2 thiazide-sensitive NaCl co-transporter eeeee2  (NCCT)
CRP11	It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of  bbbbb1 aripiprazole eeeee1  bbbbb2 dopamine D(2) and 5-HT(1A) receptors eeeee2  and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser
CRP11	It has been claimed that partial agonism of the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D(2) and 5-HT(1A) receptors eeeee2  and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser
CRP11	It has been claimed that partial agonism of the  bbbbb1 dopamine eeeee1  D(2) and 5-HT(1A) receptors and antagonism of the  bbbbb2 5-HT(2) eeeee2  receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser
CRP11	It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and  bbbbb1 5-HT eeeee1  bbbbb2 dopamine D(2) and 5-HT(1A) receptors eeeee2  and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser
CRP11	It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(2) eeeee2  receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser
CRP11	It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D(2) and 5-HT(1A) receptors eeeee2  and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser
CRP11	It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called  bbbbb1 dopamine eeeee1  bbbbb2 5-HT(2) eeeee2  receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser
CRP11	Aripiprazole acts as a selective  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptor eeeee2  partial agonist
CRP11	However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	However, recent studies have questioned the role of the 5-HT-mediated systems in the mechanism of action of aripiprazole bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by  bbbbb1 cephalosporin eeeee1  bbbbb2 β-lactamase eeeee2 -producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates
CRP11	Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime- bbbbb1 avibactam eeeee1  bbbbb2 β-lactamase eeeee2 -producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates
CRP11	Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that  bbbbb1 ceftazidime eeeee1  bbbbb2 β-lactamase eeeee2 -producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates
CRP11	Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard  bbbbb1 carbapenem eeeee1  bbbbb2 β-lactamase eeeee2 -producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates
CRP11	Ceftazidime-avibactam: a novel  bbbbb1 cephalosporin eeeee1 / bbbbb2 β-lactamase eeeee2  inhibitor combination
CRP11	Avibactam (formerly  bbbbb1 NXL104 eeeee1 , AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of  bbbbb2 Ambler class A and C β-lactamases eeeee2  and some Ambler class D enzymes
CRP11	Avibactam (formerly NXL104, AVE1330A) is a synthetic non- bbbbb1 β-lactam eeeee1 ,  bbbbb2 β-lactamase eeeee2  inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes
CRP11	Avibactam (formerly NXL104, AVE1330A) is a synthetic non- bbbbb1 β-lactam eeeee1 , β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some  bbbbb2 Ambler class D eeeee2  enzymes
CRP11	Avibactam (formerly NXL104, AVE1330A) is a synthetic non- bbbbb1 β-lactam eeeee1 , β-lactamase inhibitor that inhibits the activities of  bbbbb2 Ambler class A and C β-lactamases eeeee2  and some Ambler class D enzymes
CRP11	Avibactam (formerly NXL104,  bbbbb1 AVE1330A eeeee1 ) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of  bbbbb2 Ambler class A and C β-lactamases eeeee2  and some Ambler class D enzymes
CRP11	 bbbbb1 Avibactam eeeee1  (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of  bbbbb2 Ambler class A and C β-lactamases eeeee2  and some Ambler class D enzymes
CRP11	 bbbbb1 Ceftazidime eeeee1 -avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus  bbbbb2 ß-lactamase eeeee2 -producing Gram-negative bacilli
CRP11	Ceftazidime- bbbbb1 avibactam eeeee1  appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus  bbbbb2 ß-lactamase eeeee2 -producing Gram-negative bacilli
CRP11	Although not a β-lactam, the chemical structure of  bbbbb1 avibactam eeeee1  closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to  bbbbb2 β-lactamases eeeee2 
CRP11	Although not a  bbbbb1 β-lactam eeeee1 , the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to  bbbbb2 β-lactamases eeeee2 
CRP11	Recent developments include the identification of non-peptidic small-molecules that selectively inhibit certain  bbbbb1 serine eeeee1  bbbbb2 serine proteases eeeee2  within the coagulation cascade
CRP11	Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor  bbbbb1 rivaroxaban eeeee1  bbbbb2 thrombin eeeee2  inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe
CRP11	Of these, the thrombin inhibitor  bbbbb1 dabigatran eeeee1  and  bbbbb2 factor Xa eeeee2  inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe
CRP11	Salicylates inhibit  bbbbb1 (125)I eeeee1 -ET-1 binding to recombinant  bbbbb2 rat ETA receptors eeeee2 
CRP11	They also prevent the intracellular  bbbbb1 Ca(2+) eeeee1  mobilizing action of ET-1 in cultured endothelial cells but not those of  bbbbb2 neuromedin B eeeee2  or UTP
CRP11	They also prevent the intracellular  bbbbb1 Ca(2+) eeeee1  mobilizing action of  bbbbb2 ET-1 eeeee2  in cultured endothelial cells but not those of neuromedin B or UTP
CRP11	It is concluded that salicylates are allosteric inhibitors of ETA receptors bbbbb1  eeeee1  bbbbb2  inh eeeee2 ibitors of ETA receptors
CRP11	It is concluded that salicylates are allosteric inhibitors of ETA receptors bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113- bbbbb1 Arg eeeee1 122) available on OPG for  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for RANKL binding,  bbbbb1 Leu eeeee1  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and  bbbbb1 Leu eeeee1 113-Arg122) available on OPG for  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Out of the three putative sites (i.e., Tyr70-Asp78,  bbbbb1 Tyr eeeee1 82-Glu96, and Leu113-Arg122) available on OPG for  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Out of the three putative sites (i.e., Tyr70- bbbbb1 Asp eeeee1 78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82- bbbbb1 Glu eeeee1 96, and Leu113-Arg122) available on OPG for  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Out of the three putative sites (i.e.,  bbbbb1 Tyr eeeee1 70-Asp78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for RANKL binding, Leu113- bbbbb1 Arg eeeee1  bbbbb2 RANKL eeeee2  binding, Leu113-Arg122 was used as a template for peptide synthesis
CRP11	Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the  bbbbb1 noradrenaline eeeee1  transporter ( bbbbb2 NAT eeeee2 , uptake 1)
CRP11	Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the  bbbbb1 noradrenaline eeeee1  bbbbb2 noradrenaline transporter eeeee2  (NAT, uptake 1)
CRP11	Two observations suggest that a depletion of storage vesicles by cyanine 863 accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with [3H]-NA was the metabolite  bbbbb1 [3H]-DHPG eeeee1 ; and second, inhibition of  bbbbb2 MAO eeeee2  significantly reduced the radioactive outflow in response to cyanine 863
CRP11	Two observations suggest that a depletion of storage vesicles by cyanine 863 accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with  bbbbb1 [3H]-NA eeeee1  was the metabolite [3H]-DHPG; and second, inhibition of  bbbbb2 MAO eeeee2  significantly reduced the radioactive outflow in response to cyanine 863
CRP11	However,  bbbbb1 desipramine eeeee1  at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the  bbbbb2 NAT eeeee2  and not an OCT as their primary site of action
CRP11	However,  bbbbb1 desipramine eeeee1  at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an  bbbbb2 OCT eeeee2  as their primary site of action
CRP11	Making use of the NAT as a powerful, neurone-specific transporter system, we loaded bbbbb1 [3H]-N-methyl-4-phenylpyridinium eeeee1  bbbbb2 NAT eeeee2  as a powerful, neurone-specific transporter system, we loaded[3H]-N-methyl-4-phenylpyridinium ([3H]-MPP+) into cultured rat SCG neurones
CRP11	Making use of the NAT as a powerful, neurone-specific transporter system, we loaded[3H]-N-methyl-4-phenylpyridinium ( bbbbb1 [3H]-MPP+ eeeee1  bbbbb2 NAT eeeee2  as a powerful, neurone-specific transporter system, we loaded[3H]-N-methyl-4-phenylpyridinium ([3H]-MPP+) into cultured rat SCG neurones
CRP11	The ensuing radioactive outflow from these cultures was enhanced by desipramine and  bbbbb1 reserpine eeeee1 , but reduced (in the presence of desipramine) by the  bbbbb2 OCT3 eeeee2  inhibitors cyanine 863, oestradiol and corticosterone
CRP11	The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of  bbbbb1 desipramine eeeee1 ) by the  bbbbb2 OCT3 eeeee2  inhibitors cyanine 863, oestradiol and corticosterone
CRP11	The ensuing radioactive outflow from these cultures was enhanced by  bbbbb1 desipramine eeeee1  and reserpine, but reduced (in the presence of desipramine) by the  bbbbb2 OCT3 eeeee2  inhibitors cyanine 863, oestradiol and corticosterone
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 ( bbbbb1 LTB4 eeeee1 ) and  bbbbb2 beta-glucuronidase eeeee2  concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 ( bbbbb1 LTB4 eeeee1 ) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and  bbbbb2 bradykinin eeeee2 -induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ), leukotriene B4 (LTB4) and  bbbbb2 beta-glucuronidase eeeee2  concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and  bbbbb2 bradykinin eeeee2 -induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum  bbbbb1 thromboxane B2 eeeee1  bbbbb2 beta-glucuronidase eeeee2  concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum  bbbbb1 thromboxane B2 eeeee1  (TxB2), and  bbbbb2 bradykinin eeeee2 -induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate  bbbbb1 prostaglandin E2 eeeee1  (PGE2), leukotriene B4 (LTB4) and  bbbbb2 beta-glucuronidase eeeee2  concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate  bbbbb1 prostaglandin E2 eeeee1  (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and  bbbbb2 bradykinin eeeee2 -induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2),  bbbbb1 leukotriene B4 eeeee1  (LTB4) and  bbbbb2 beta-glucuronidase eeeee2  concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2),  bbbbb1 leukotriene B4 eeeee1  (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and  bbbbb2 bradykinin eeeee2 -induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 ( bbbbb1 TxB2 eeeee1  bbbbb2 beta-glucuronidase eeeee2  concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling
CRP11	The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 ( bbbbb1 TxB2 eeeee1 ), and  bbbbb2 bradykinin eeeee2 -induced skin swelling
CRP11	In agreement with these data, the exogenous bbbbb1  tr eeeee1 e bbbbb2 atme eeeee2 nt of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src
CRP11	Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine ( bbbbb1 SAH eeeee1 ) hydrolase ( bbbbb2 SAHH eeeee2 ), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CRP11	Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine ( bbbbb1 SAH eeeee1  bbbbb2 adenosylhomocysteine (SAH) hydrolase eeeee2  (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CRP11	Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive  bbbbb1 adenosylhomocysteine eeeee1  (SAH) hydrolase ( bbbbb2 SAHH eeeee2 ), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CRP11	Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive  bbbbb1 adenosylhomocysteine eeeee1  bbbbb2 adenosylhomocysteine (SAH) hydrolase eeeee2  (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha ( bbbbb2 TNF-α eeeee2 ) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand  bbbbb2 RANKL eeeee2 , tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/ bbbbb2 osteoprotegerin eeeee2  (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL,  bbbbb2 tumor necrosis factor alpha eeeee2  (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin ( bbbbb2 OPG eeeee2 ) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of  bbbbb2 CCL3 eeeee2 (-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1  bbbbb2 CCR1 eeeee2 (-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of  bbbbb2 receptor activator of nuclear factor kappa-B eeeee2  (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and  bbbbb2 RANKL eeeee2 /osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1  bbbbb2 CCL3 eeeee2 (-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with  bbbbb1 Met eeeee1 -RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B ( bbbbb2 RANK eeeee2 ), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb1 Met eeeee1  bbbbb2 CCL3 eeeee2 (-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb1 Met eeeee1  bbbbb2 CCR5 eeeee2  and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb1 Met eeeee1  bbbbb2 CCR1 eeeee2 ). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb1 Met eeeee1  bbbbb2 CCR1 eeeee2 (-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with  bbbbb1 Met eeeee1  bbbbb2 CCL3 eeeee2 (-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES
CRP11	The marked antihypertensive efficacy of olmesartan medoxomil may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of  bbbbb1 A-II eeeee1  bbbbb2 AT1 eeeee2  receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II
CRP11	The marked antihypertensive efficacy of olmesartan medoxomil may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of  bbbbb1 A-II eeeee1  bbbbb2 A-II eeeee2 
CRP11	Effective inhibition of  bbbbb1 A-II eeeee1  is provided by the latest class of antihypertensive medications, the  bbbbb2 AT1 eeeee2  receptor blockers (ARBs)
CRP11	Effective inhibition of  bbbbb1 A-II eeeee1  bbbbb2 A-II eeeee2  is provided by the latest class of antihypertensive medications, the AT1 receptor blockers (ARBs)
CRP11	The angiotensin II ( bbbbb1 A-II eeeee1  bbbbb2 angiotensin II (A-II) type 1 (AT1) receptor eeeee2 -mediated effects of A-II play a key role in the pathophysiology of hypertension
CRP11	The angiotensin II ( bbbbb1 A-II eeeee1 ) type 1 (AT1) receptor-mediated effects of  bbbbb2 A-II eeeee2  play a key role in the pathophysiology of hypertension
CRP11	The  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II (A-II) type 1 (AT1) receptor eeeee2 -mediated effects of A-II play a key role in the pathophysiology of hypertension
CRP11	The  bbbbb1 angiotensin II eeeee1  (A-II) type 1 (AT1) receptor-mediated effects of  bbbbb2 A-II eeeee2  play a key role in the pathophysiology of hypertension
CRP11	The angiotensin II (A-II) type 1 (AT1) receptor-mediated effects of  bbbbb1 A-II eeeee1  bbbbb2 A-II eeeee2  play a key role in the pathophysiology of hypertension
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  kinases that have also been implicated in tumor pathobiology, including  bbbbb2 RET eeeee2 , KIT, AXL, and FLT3
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 MET eeeee2  and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and  bbbbb2 FLT3 eeeee2 
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  kinases that have also been implicated in tumor pathobiology, including RET, KIT,  bbbbb2 AXL eeeee2 , and FLT3
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 VEGF receptor 2 eeeee2  (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 receptor tyrosine kinases eeeee2  that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  kinases that have also been implicated in tumor pathobiology, including RET,  bbbbb2 KIT eeeee2 , AXL, and FLT3
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 kinase eeeee2  inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CRP11	Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor  bbbbb1 tyrosine eeeee1  bbbbb2 VEGFR2 eeeee2 ), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3
CRP11	Crystal structures of E2 in the  bbbbb1 estrogen eeeee1  receptor (ER) confirm the importance of the A ring in stabilizing E2 in the  bbbbb2 ER eeeee2 
CRP11	Crystal structures of E2 in the  bbbbb1 estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 ) confirm the importance of the A ring in stabilizing E2 in the ER
CRP11	Crystal structures of E2 in the  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  (ER) confirm the importance of the A ring in stabilizing E2 in the ER
CRP11	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor-α eeeee2  (ERα) and ERβ
CRP11	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to  bbbbb1 estrogen eeeee1  receptor-α ( bbbbb2 ERα eeeee2 ) and ERβ
CRP11	However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to  bbbbb1 estrogen eeeee1  receptor-α (ERα) and  bbbbb2 ERβ eeeee2 
CRP11	Crizotinib is an oral  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK
CRP11	Crizotinib is an oral  bbbbb1 tyrosine eeeee1  kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing  bbbbb2 ALK eeeee2 
CRP11	Crizotinib is an oral  bbbbb1 tyrosine eeeee1  kinase inhibitor (TKI), which silences the protein product of the  bbbbb2 ALK eeeee2  fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK
CRP11	This increased HDAC activity is then available for corticosteroid recruitment and predicts a cooperative interaction between corticosteroids and  bbbbb1 theophylline eeeee1  bbbbb2 HDAC eeeee2  activity is then available for corticosteroid recruitment and predicts a cooperative interaction between corticosteroids and theophylline
CRP11	This increased HDAC activity is then available for corticosteroid recruitment and predicts a cooperative interaction between  bbbbb1 corticosteroids eeeee1  bbbbb2 HDAC eeeee2  activity is then available for corticosteroid recruitment and predicts a cooperative interaction between corticosteroids and theophylline
CRP11	 bbbbb1 Fatty acid eeeee1  synthase ( bbbbb2 FAS eeeee2 ), the key metabolic multi-enzyme that is responsible for the terminal catalytic step in the de novo fatty acid biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas
CRP11	 bbbbb1 Fatty acid eeeee1  bbbbb2 Fatty acid synthase eeeee2  (FAS), the key metabolic multi-enzyme that is responsible for the terminal catalytic step in the de novo fatty acid biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas
CRP11	A topoisomerase IIalpha (TOP2A) inhibitors up-regulate  bbbbb1 fatty acid eeeee1  bbbbb2 TOP2A eeeee2 ) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes
CRP11	A topoisomerase IIalpha (TOP2A) inhibitors up-regulate  bbbbb1 fatty acid eeeee1  bbbbb2 fatty acid synthase eeeee2  gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes
CRP11	A topoisomerase IIalpha (TOP2A) inhibitors up-regulate  bbbbb1 fatty acid eeeee1  synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/ bbbbb2 neu eeeee2  and TOP2A genes
CRP11	A topoisomerase IIalpha (TOP2A) inhibitors up-regulate  bbbbb1 fatty acid eeeee1  synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS,  bbbbb2 Her-2 eeeee2 /neu and TOP2A genes
CRP11	A topoisomerase IIalpha (TOP2A) inhibitors up-regulate  bbbbb1 fatty acid eeeee1  synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving  bbbbb2 FAS eeeee2 , Her-2/neu and TOP2A genes
CRP11	A topoisomerase IIalpha (TOP2A) inhibitors up-regulate  bbbbb1 fatty acid eeeee1  synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and  bbbbb2 TOP2A eeeee2  genes
CRP11	Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia bbbbb1  eeeee1  bbbbb2 ctivi eeeee2 ty, while producing analgesia
CRP11	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of  bbbbb1 prostaglandin E2 eeeee1  (PGE2; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for  bbbbb2 COX-1 eeeee2  activity) with parallel assessments of pain
CRP11	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and  bbbbb1 thromboxane B2 eeeee1  bbbbb2 COX-1 eeeee2  and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain
CRP11	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and  bbbbb1 thromboxane B2 eeeee1  bbbbb2 COX-2 eeeee2 ) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain
CRP11	Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 ( bbbbb1 PGE2 eeeee1 ; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for  bbbbb2 COX-1 eeeee2  activity) with parallel assessments of pain
CRP11	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor ( bbbbb1 ketorolac eeeee1  bbbbb2 cytokines eeeee2  released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac)
CRP11	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor ( bbbbb1 ketorolac eeeee1  bbbbb2 cyclooxygenase (COX)-2 eeeee2  inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac)
CRP11	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor ( bbbbb1 celecoxib eeeee1  bbbbb2 cytokines eeeee2  released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac)
CRP11	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor ( bbbbb1 celecoxib eeeee1 ) in comparison to a dual COX-1/ bbbbb2 COX-2 eeeee2  inhibitor (ketorolac)
CRP11	A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor ( bbbbb1 celecoxib eeeee1 ) in comparison to a dual  bbbbb2 COX-1 eeeee2 /COX-2 inhibitor (ketorolac)
CRP11	Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in  bbbbb1 apixaban eeeee1  bbbbb2 BCRP eeeee2  (breast cancer resistance protein; abcg2) in apixaban disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats
CRP11	Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in  bbbbb1 apixaban eeeee1  bbbbb2 abcg2 eeeee2 ) in apixaban disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats
CRP11	Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in  bbbbb1 apixaban eeeee1  bbbbb2 P-gp eeeee2  (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in apixaban disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats
CRP11	Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in  bbbbb1 apixaban eeeee1  bbbbb2 abcb1 eeeee2 ) and BCRP (breast cancer resistance protein; abcg2) in apixaban disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats
CRP11	Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in  bbbbb1 apixaban eeeee1  bbbbb2 breast cancer resistance protein eeeee2 ; abcg2) in apixaban disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats
CRP11	Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in  bbbbb1 apixaban eeeee1  bbbbb2 P-glycoprotein eeeee2 ; abcb1) and BCRP (breast cancer resistance protein; abcg2) in apixaban disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats
CRP11	The effect of folic acid level on this end-point was modulated by the MTHFR genotype (P for interaction = 0.02), with TT cells grown at low  bbbbb1 folic acid eeeee1  bbbbb2 MTHFR eeeee2  genotype (P for interaction = 0.02), with TT cells grown at low folic acid concentration apparently resistant to the induction of radiation-induced bridges
CRP11	Effects of  bbbbb1 folic acid eeeee1  deficiency and  bbbbb2 MTHFR eeeee2  C677T polymorphism on spontaneous and radiation-induced micronuclei in human lymphocytes
CRP11	Effects of  bbbbb1 folic acid eeeee1  deficiency and MTHFR  bbbbb2 C677T eeeee2  polymorphism on spontaneous and radiation-induced micronuclei in human lymphocytes
CRP11	The C677T polymorphism of the  bbbbb1 methylene-tetrahydrofolate eeeee1  reductase ( bbbbb2 MTHFR eeeee2 ) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status
CRP11	The C677T polymorphism of the  bbbbb1 methylene-tetrahydrofolate eeeee1  bbbbb2 methylene-tetrahydrofolate reductase eeeee2  (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status
CRP11	The C677T polymorphism of the  bbbbb1 methylene-tetrahydrofolate eeeee1  bbbbb2 C677T eeeee2  polymorphism of the methylene-tetrahydrofolate reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status
CRP11	The results obtained indicate that  bbbbb1 folic acid eeeee1  deficiency induces to a comparable extent chromosome loss and breakage, irrespective of the  bbbbb2 MTHFR eeeee2  genotype
CRP11	Also nucleoplasmic bridges and buds were significantly increased under low  bbbbb1 folate eeeee1  supply; the increase in bridges was mainly observed in TT cells, highlighting a significant effect of the  bbbbb2 MTHFR eeeee2  genotype (P = 0.006) on this biomarker
CRP11	Folic acid concentration significantly affected radiation-induced micronuclei (P < 0.001): the increased incidence of radiation-induced micronuclei with low  bbbbb1 folic acid eeeee1  was mainly accounted for by carriers of the variant  bbbbb2 MTHFR eeeee2  allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance
CRP11	 bbbbb1 Folic acid eeeee1  concentration significantly affected radiation-induced micronuclei (P < 0.001): the increased incidence of radiation-induced micronuclei with low folic acid was mainly accounted for by carriers of the variant  bbbbb2 MTHFR eeeee2  allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance
CRP11	In this work the effect of  bbbbb1 folic acid eeeee1  deficiency on genome stability and radiosensitivity has been investigated in cultured lymphocytes of 12 subjects with different  bbbbb2 MTHFR eeeee2  genotype (four for each genotype)
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and  bbbbb1 rosuvastatin eeeee1  bbbbb2 BCRP eeeee2  and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and  bbbbb1 rosuvastatin eeeee1  [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and  bbbbb2 CYP3A4 eeeee2 
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and  bbbbb1 rosuvastatin eeeee1  [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal  bbbbb2 BCRP eeeee2  and CYP3A4
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and  bbbbb1 rosuvastatin eeeee1  bbbbb2 OATP1B1 eeeee2 , which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of  bbbbb1 simvastatin eeeee1  bbbbb2 BCRP eeeee2  and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of  bbbbb1 simvastatin eeeee1  [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and  bbbbb2 CYP3A4 eeeee2 
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of  bbbbb1 simvastatin eeeee1  [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal  bbbbb2 BCRP eeeee2  and CYP3A4
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of  bbbbb1 simvastatin eeeee1  bbbbb2 OATP1B1 eeeee2 , which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with  bbbbb1 GSK1292263 eeeee1  bbbbb2 BCRP eeeee2  and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CRP11	However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with  bbbbb1 GSK1292263 eeeee1  bbbbb2 OATP1B1 eeeee2 , which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4
CRP11	However,  bbbbb1 GSK1292263 eeeee1  inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and  bbbbb2 CYP3A4 eeeee2 
CRP11	However,  bbbbb1 GSK1292263 eeeee1  inhibited BCRP and OATP1B1, which are transporters involved in statin disposition. 4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal  bbbbb2 BCRP eeeee2  and CYP3A4
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  bbbbb2 HMG-coA reductase eeeee2  inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of  bbbbb1 simvastatin eeeee1  (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the  bbbbb2 HMG-coA reductase eeeee2  inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of  bbbbb1 GSK1292263 eeeee1  (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  bbbbb2 HMG-coA reductase eeeee2  inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and  bbbbb1 rosuvastatin eeeee1  (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1  bbbbb2 HMG-coA reductase eeeee2  inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by  bbbbb1 GSK1292263 eeeee1 , and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  bbbbb2 HMG-coA reductase eeeee2  inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of  bbbbb1 GSK1292263 eeeee1  (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and  bbbbb1 rosuvastatin eeeee1 . 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the  bbbbb2 HMG-coA reductase eeeee2  inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of  bbbbb1 GSK1292263 eeeee1 , a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4),  bbbbb2 Pgp eeeee2 , OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19,  bbbbb2 2D6 eeeee2 , 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or  bbbbb2 OCT2 eeeee2 
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6,  bbbbb2 3A4 eeeee2 ), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards  bbbbb2 CYPs eeeee2  (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs ( bbbbb2 CYP1A2 eeeee2 , 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2,  bbbbb2 2C9 eeeee2 , 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp,  bbbbb2 OATP1B3 eeeee2 , or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors  bbbbb1 simvastatin eeeee1  and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9,  bbbbb2 2C19 eeeee2 , 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  bbbbb2 GPR119 eeeee2  agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  bbbbb2 GPR119 eeeee2  agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  bbbbb2 CYP eeeee2  enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  bbbbb2 HMG-coA reductase eeeee2  inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. 1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. 2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro,  bbbbb1 GSK1292263 eeeee1  bbbbb2 transporters eeeee2  and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose). 3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2
CRP11	KCs were isolated after 4 weeks of ethanol treatment and intracellular Ca2+ ([ bbbbb1 Ca2+ eeeee1 ]i) was measured using fura-2, whereas  bbbbb2 TNF-alpha eeeee2  was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay
CRP11	KCs were isolated after 4 weeks of  bbbbb1 ethanol eeeee1  treatment and intracellular Ca2+ ([Ca2+]i) was measured using fura-2, whereas  bbbbb2 TNF-alpha eeeee2  was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay
CRP11	KCs were isolated after 4 weeks of ethanol treatment and intracellular  bbbbb1 Ca2+ eeeee1  ([Ca2+]i) was measured using fura-2, whereas  bbbbb2 TNF-alpha eeeee2  was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay
CRP11	Furthermore, thalidomide abolished the LPS-induced increase in CD14 expression and [ bbbbb1 Ca2+ eeeee1  bbbbb2 CD14 eeeee2  expression and [Ca2+]i elevation in KCs
CRP11	Thus,  bbbbb1 carvedilol eeeee1  blocks both  bbbbb2 beta 1 and beta 2 adrenoceptors eeeee2  at antihypertensive doses, with modest selectivity being observed for the beta 1 adrenoceptor subtype
CRP11	This same dose of  bbbbb1 carvedilol eeeee1  also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of  bbbbb2 angiotensin II eeeee2 
CRP11	This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to  bbbbb1 salbutamol eeeee1  in pithed rats whose blood pressure was elevated by a constant intravenous infusion of  bbbbb2 angiotensin II eeeee2 
CRP11	 bbbbb1 Carvedilol eeeee1  produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an  bbbbb2 alpha 1 adrenoceptor eeeee2  antagonist at antihypertensive doses
CRP11	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to  bbbbb1 B-HT 933 eeeee1 , suggesting that carvedilol is also an  bbbbb2 alpha 1 adrenoceptor eeeee2  antagonist at antihypertensive doses
CRP11	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to  bbbbb1 B-HT 933 eeeee1  bbbbb2 alpha 1 adrenoceptor eeeee2  mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CRP11	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that  bbbbb1 carvedilol eeeee1  bbbbb2 alpha 1 adrenoceptor eeeee2  mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CRP11	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that  bbbbb1 carvedilol eeeee1  bbbbb2 alpha 2 adrenoceptor eeeee2  mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CRP11	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to  bbbbb1 cirazoline eeeee1  in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an  bbbbb2 alpha 1 adrenoceptor eeeee2  antagonist at antihypertensive doses
CRP11	Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to  bbbbb1 cirazoline eeeee1  in the pithed rat, but had no effect on the  bbbbb2 alpha 2 adrenoceptor eeeee2  mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses
CRP11	In anesthetized spontaneous bbbbb1 ly hyperte eeeee1 nsive rats, the antihypertensive activity of carv bbbbb2 edilol was nearly abolished by combined p eeeee2 retreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors
CRP11	In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of bbbbb1  the ra eeeee1  bbbbb2  the rats with h eeeee2 igh doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors
CRP11	In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of bbbbb1  the ra eeeee1  bbbbb2 edilol was nearly abolished by combined p eeeee2 retreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that  bbbbb1 carvedilol eeeee1  bbbbb2 voltage dependent calcium channels eeeee2  and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that  bbbbb1 carvedilol eeeee1  bbbbb2 calcium channel eeeee2  activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular  bbbbb1 calcium eeeee1 , was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb2 calcium channel eeeee2  antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by  bbbbb1 carvedilol eeeee1  (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb2 calcium channel eeeee2  antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by  bbbbb1 carvedilol eeeee1  bbbbb2 calcium channel eeeee2  activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent  bbbbb1 calcium eeeee1  channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb2 calcium channel eeeee2  antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent  bbbbb1 calcium eeeee1  bbbbb2 voltage dependent calcium channels eeeee2  and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator,  bbbbb1 BAY-K-8644 eeeee1 , which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb2 calcium channel eeeee2  antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the  bbbbb1 calcium eeeee1  channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb2 calcium channel eeeee2  antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the  bbbbb1 calcium eeeee1  channel activator, BAY-K-8644, which is mediated through the opening of  bbbbb2 voltage dependent calcium channels eeeee2  and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb1 calcium eeeee1  bbbbb2 voltage dependent calcium channels eeeee2  and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a  bbbbb1 calcium eeeee1  bbbbb2 calcium channel eeeee2  activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies
CRP11	A) mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces  bbbbb1 nitric oxide eeeee1  bbbbb2 ET eeeee2  on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces nitric oxide synthesis and acts to clear ET from the circulation
CRP11	A) mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces  bbbbb1 nitric oxide eeeee1  bbbbb2 ET(B) eeeee2  is expressed primarily on vascular endothelial cells where it induces nitric oxide synthesis and acts to clear ET from the circulation
CRP11	A) mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces  bbbbb1 nitric oxide eeeee1  synthesis and acts to clear  bbbbb2 ET eeeee2  from the circulation
CRP11	Co-incubation with  bbbbb1 silica eeeee1  nanoparticles amplified the responsiveness of macrophages toward the  bbbbb2 TLR9 eeeee2  ligand ISS 1018
CRP11	Monoclonal antibody 25B1 generated against  bbbbb1 diisopropyl phosphorofluoridate eeeee1  inhibited fetal bovine serum acetylcholinesterase has been extensively characterized with respect to its  bbbbb2 anticholinesterase eeeee2  properties
CRP11	This approach allowed the determination of stability rank order of various phosphorylated acetylcholinesterases bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This approach allowed the determination of stability rank order of various phosphorylated acetylcholinesterases bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	This approach allowed the determination of stability rank order of various phosphorylated acetylch bbbbb1 olines eeeee1 terases bbbbb2  eeeee2 
CRP11	This approach  bbbbb1 allowed the dete eeeee1 rmination of stability rank order of various phosphorylated acetylcholinesterases bbbbb2  eeeee2 
CRP11	This approach allowed the determination of stability rank order of various phosphorylated acetylcholinesterases bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of acetylcholinesterase against denaturation by heat or  bbbbb1 guanidine eeeee1  following phosphorylation by organophosphorus  bbbbb2 anticholinesterase eeeee2  compounds
CRP11	In defects of AGAT, glyoxylate is transformed to oxalate, resulting in high levels of  bbbbb1 oxalate eeeee1  bbbbb2 AGAT eeeee2 , glyoxylate is transformed to oxalate, resulting in high levels of oxalate in the body
CRP11	In defects of AGAT, glyoxylate is transformed to  bbbbb1 oxalate eeeee1  bbbbb2 AGAT eeeee2 , glyoxylate is transformed to oxalate, resulting in high levels of oxalate in the body
CRP11	In defects of AGAT,  bbbbb1 glyoxylate eeeee1  bbbbb2 AGAT eeeee2 , glyoxylate is transformed to oxalate, resulting in high levels of oxalate in the body
CRP11	Once formed, the molecule can be converted to glycine by alanine- bbbbb1 glyoxylate eeeee1  aminotransferase ( bbbbb2 AGAT eeeee2 )
CRP11	Once formed, the molecule can be converted to glycine by alanine- bbbbb1 glyoxylate eeeee1  bbbbb2 alanine-glyoxylate aminotransferase eeeee2  (AGAT)
CRP11	Once formed, the molecule can be converted to glycine by  bbbbb1 alanine eeeee1 -glyoxylate aminotransferase ( bbbbb2 AGAT eeeee2 )
CRP11	Once formed, the molecule can be converted to glycine by  bbbbb1 alanine eeeee1  bbbbb2 alanine-glyoxylate aminotransferase eeeee2  (AGAT)
CRP11	To evaluate the effect of  bbbbb1 carvedilol eeeee1  on both myocardial  bbbbb2 HIF-1alpha eeeee2  expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy
CRP11	Levome bbbbb1 promazine eeeee1  bbbbb2 promazine was the mos eeeee2 t potent and fluphenazine the least potent of the four drugs in histamine H1 receptor binding. 7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in histamine H1 receptor binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system
CRP11	In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine,  bbbbb1 perphenazine eeeee1  and some of their metabolites for dopamine D2 receptors,  bbbbb2 alpha 1- and alpha 2 adrenoceptors eeeee2  in rat brain were previously reported from our laboratories
CRP11	In vitro binding affinities of  bbbbb1 chlorpromazine eeeee1 , fluphenazine, levomepromazine, perphenazine and some of their metabolites for dopamine D2 receptors,  bbbbb2 alpha 1- and alpha 2 adrenoceptors eeeee2  in rat brain were previously reported from our laboratories
CRP11	In vitro binding affinities of chlorpromazine,  bbbbb1 fluphenazine eeeee1 , levomepromazine, perphenazine and some of their metabolites for dopamine D2 receptors,  bbbbb2 alpha 1- and alpha 2 adrenoceptors eeeee2  in rat brain were previously reported from our laboratories
CRP11	In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, perphenazine and some of their metabolites for  bbbbb1 dopamine eeeee1  D2 receptors,  bbbbb2 alpha 1- and alpha 2 adrenoceptors eeeee2  in rat brain were previously reported from our laboratories
CRP11	In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, perphenazine and some of their metabolites for  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptors eeeee2 , alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories
CRP11	In vitro binding affinities of chlorpromazine, fluphenazine,  bbbbb1 levomepromazine eeeee1 , perphenazine and some of their metabolites for dopamine D2 receptors,  bbbbb2 alpha 1- and alpha 2 adrenoceptors eeeee2  in rat brain were previously reported from our laboratories
CRP11	Muscarinic cholinergic and  bbbbb1 histamine eeeee1  bbbbb2 histamine H1 receptor eeeee2  binding of phenothiazine drug metabolites
CRP11	The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for  bbbbb1 histamine eeeee1  bbbbb2 histamine H1 receptors eeeee2  in rat brain, using 3H-quinuclidinyl benzilate and 3H-mepyramine as radioligands
CRP11	The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for  bbbbb1 histamine eeeee1  bbbbb2 muscarinic cholinergic receptors eeeee2  and for histamine H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and 3H-mepyramine as radioligands
CRP11	The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of  bbbbb1 elzasonan eeeee1  bbbbb2 CYP eeeee2  form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of elzasonan
CRP11	The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of  bbbbb1 elzasonan eeeee1  bbbbb2 rCYP eeeee2  data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of elzasonan
CRP11	The metabolism of  bbbbb1 elzasonan eeeee1  has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes ( bbbbb2 rCYP eeeee2 )
CRP11	The metabolism of  bbbbb1 elzasonan eeeee1  has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed  bbbbb2 P450 enzymes eeeee2  (rCYP)
CRP11	Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by  bbbbb1 GW572016 eeeee1  bbbbb2 TGF-alpha eeeee2  also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016
CRP11	Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by  bbbbb1 GW572016 eeeee1  bbbbb2 Ras eeeee2 -CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016
CRP11	Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW bbbbb1 572016 a eeeee1 cts as a radiosensitizer bbbbb2  eeeee2 
CRP11	Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW bbbbb1 572016 a eeeee1 cts as a radiosensitizer bbbbb2  eeeee2 
CRP11	Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 Ras eeeee2 -dependent signaling pathways involved in radioresistance include those mediated by phosphatidylinositol 3'-kinase (PI3-K) and Raf
CRP11	Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by  bbbbb1 phosphatidylinositol eeeee1  3'-kinase ( bbbbb2 PI3-K eeeee2 ) and Raf
CRP11	Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by  bbbbb1 phosphatidylinositol eeeee1  3'-kinase (PI3-K) and  bbbbb2 Raf eeeee2 
CRP11	Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 3'-kinase eeeee2  (PI3-K) and Raf
CRP11	It has been suggested that this specific conversion of progesterone may be inv bbbbb1 olved in breast carci eeeee1  bbbbb2 ne may be eeeee2  involved in breast carcinogenesis
CRP11	It has been suggested that this specific conversion of progesterone may be inv bbbbb1 olved in breast carci eeeee1  bbbbb2 olved in breast carcinogenesis eeeee2 
CRP11	These include sulfatases, aromatase,  bbbbb1 hydroxysteroid eeeee1  bbbbb2 hydroxysteroid-dehydrogenases eeeee2 , sulfotransferases, hydroxylases and glucuronidases
CRP11	These include sulfatases, aromatase,  bbbbb1 hydroxysteroid eeeee1 -dehydrogenases, sulfotransferases, hydroxylases and  bbbbb2 glucuronidases eeeee2 
CRP11	These include sulfatases, aromatase,  bbbbb1 hydroxysteroid eeeee1 -dehydrogenases, sulfotransferases,  bbbbb2 hydroxylases eeeee2  and glucuronidases
CRP11	These include sulfatases, aromatase,  bbbbb1 hydroxysteroid eeeee1  bbbbb2 aromatase eeeee2 , hydroxysteroid-dehydrogenases, sulfotransferases, hydroxylases and glucuronidases
CRP11	These include sulfatases, aromatase,  bbbbb1 hydroxysteroid eeeee1 -dehydrogenases,  bbbbb2 sulfotransferases eeeee2 , hydroxylases and glucuronidases
CRP11	These include sulfatases, aromatase,  bbbbb1 hydroxysteroid eeeee1  bbbbb2 sulfatases eeeee2 , aromatase, hydroxysteroid-dehydrogenases, sulfotransferases, hydroxylases and glucuronidases
CRP11	A possible correlation has been postulated between breast cell proliferation and  bbbbb1 estrogen eeeee1  bbbbb2 estrogen sulfotransferase eeeee2  activity
CRP11	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb1 17beta-hydroxysteroid eeeee1  bbbbb2 sulfatase eeeee2  and 17beta-hydroxysteroid-dehydrogenase type 1 activities
CRP11	As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and  bbbbb1 17beta-hydroxysteroid eeeee1  bbbbb2 17beta-hydroxysteroid-dehydrogenase type 1 eeeee2  activities
CRP11	Moreover, we show that USP22 is acetylated on multiple  bbbbb1 lysine eeeee1  residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the  bbbbb2 DUBm eeeee2  with the core SAGA complex
CRP11	Moreover, we show that USP22 is acetylated on multiple  bbbbb1 lysine eeeee1  residues and that alteration of a single lysine (K129) within the  bbbbb2 ZnF-UBP domain eeeee2  is sufficient to alter interaction of the DUBm with the core SAGA complex
CRP11	Moreover, we show that USP22 is acetylated on multiple  bbbbb1 lysine eeeee1  residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core  bbbbb2 SAGA eeeee2  complex
CRP11	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single  bbbbb1 lysine eeeee1  (K129) within the ZnF-UBP domain is sufficient to alter interaction of the  bbbbb2 DUBm eeeee2  with the core SAGA complex
CRP11	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single  bbbbb1 lysine eeeee1  bbbbb2 USP22 eeeee2  is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex
CRP11	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single  bbbbb1 lysine eeeee1  (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core  bbbbb2 SAGA eeeee2  complex
CRP11	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the  bbbbb1 ZnF eeeee1 -UBP domain is sufficient to alter interaction of the  bbbbb2 DUBm eeeee2  with the core SAGA complex
CRP11	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the  bbbbb1 ZnF eeeee1  bbbbb2 USP22 eeeee2  is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex
CRP11	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the  bbbbb1 ZnF eeeee1  bbbbb2 ZnF-UBP domain eeeee2  is sufficient to alter interaction of the DUBm with the core SAGA complex
CRP11	Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the  bbbbb1 ZnF eeeee1 -UBP domain is sufficient to alter interaction of the DUBm with the core  bbbbb2 SAGA eeeee2  complex
CRP11	We found that this interaction is highly specific, requires the  bbbbb1 ZnF eeeee1 -UBP domain of USP22, and is disrupted by the inactivating H363Y mutation within  bbbbb2 SIRT1 eeeee2 
CRP11	We found that this interaction is highly specific, requires the  bbbbb1 ZnF eeeee1 -UBP domain of  bbbbb2 USP22 eeeee2 , and is disrupted by the inactivating H363Y mutation within SIRT1
CRP11	We found that this interaction is highly specific, requires the  bbbbb1 ZnF eeeee1 -UBP domain of USP22, and is disrupted by the inactivating  bbbbb2 H363Y eeeee2  mutation within SIRT1
CRP11	We found that this interaction is highly specific, requires the  bbbbb1 ZnF eeeee1  bbbbb2 ZnF-UBP domain eeeee2  of USP22, and is disrupted by the inactivating H363Y mutation within SIRT1
CRP11	The search terms were monoamine oxidase, neuroprotection, Parkinson disease,  bbbbb1 propargylamine eeeee1  bbbbb2 monoamine oxidase eeeee2 , neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline
CRP11	The search terms were monoamine oxidase, neuroprotection, Parkinson disease, propargylamine, rasagiline, and  bbbbb1 selegiline eeeee1  bbbbb2 monoamine oxidase eeeee2 , neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline
CRP11	The search terms were  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2 , neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline
CRP11	The search terms were monoamine oxidase, neuroprotection, Parkinson disease, propargylamine,  bbbbb1 rasagiline eeeee1  bbbbb2 monoamine oxidase eeeee2 , neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline
CRP11	Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived  bbbbb1 dopamine eeeee1  bbbbb2 MAO eeeee2 ) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived  bbbbb1 dopamine eeeee1  bbbbb2 MAO type B eeeee2  (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived  bbbbb1 dopamine eeeee1  bbbbb2 MAO-B eeeee2 ) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived  bbbbb1 dopamine eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	Inhibitors of  bbbbb1 monoamine eeeee1  oxidase ( bbbbb2 MAO eeeee2 ) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	Inhibitors of  bbbbb1 monoamine eeeee1  oxidase (MAO) with selectivity and specificity for  bbbbb2 MAO type B eeeee2  (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	Inhibitors of  bbbbb1 monoamine eeeee1  oxidase (MAO) with selectivity and specificity for MAO type B ( bbbbb2 MAO-B eeeee2 ) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	Inhibitors of  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine
CRP11	In fact, DOX also efficiently inhibited the choline transport system that influences PQ cellular uptake bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In fact, DOX also efficiently inhibited the choline transport system that influences PQ cellular uptake bbbbb1  eeeee1  bbbbb2  upt eeeee2 ake
CRP11	P-glycoprotein (P-gp) is an efflux pump belonging to the  bbbbb1 ATP eeeee1  bbbbb2 efflux pump eeeee2  belonging to the ATP-binding cassette transporter superfamily expressed in several organs
CRP11	P-glycoprotein (P-gp) is an efflux pump belonging to the  bbbbb1 ATP eeeee1  bbbbb2 ATP-binding cassette transporter eeeee2  superfamily expressed in several organs
CRP11	P-glycoprotein (P-gp) is an efflux pump belonging to the  bbbbb1 ATP eeeee1  bbbbb2 P-glycoprotein eeeee2  (P-gp) is an efflux pump belonging to the ATP-binding cassette transporter superfamily expressed in several organs
CRP11	P-glycoprotein (P-gp) is an efflux pump belonging to the  bbbbb1 ATP eeeee1  bbbbb2 P-gp eeeee2 ) is an efflux pump belonging to the ATP-binding cassette transporter superfamily expressed in several organs
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  and catalase in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  bbbbb1 glutathione eeeee1  peroxidase and  bbbbb2 catalase eeeee2  in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2 , glutathione peroxidase and catalase in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde ( bbbbb1 MDA eeeee1 ) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  bbbbb2 glutathione peroxidase eeeee2  and catalase in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde ( bbbbb1 MDA eeeee1 ) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and  bbbbb2 catalase eeeee2  in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde ( bbbbb1 MDA eeeee1 ) levels and significantly decreased enzymatic antioxidants  bbbbb2 superoxide dismutase eeeee2 , glutathione peroxidase and catalase in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants  bbbbb1 superoxide eeeee1  dismutase,  bbbbb2 glutathione peroxidase eeeee2  and catalase in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants  bbbbb1 superoxide eeeee1  dismutase, glutathione peroxidase and  bbbbb2 catalase eeeee2  in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2 , glutathione peroxidase and catalase in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue  bbbbb1 malondialdehyde eeeee1  (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase,  bbbbb2 glutathione peroxidase eeeee2  and catalase in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue  bbbbb1 malondialdehyde eeeee1  (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and  bbbbb2 catalase eeeee2  in the frontal cortex tissue
CRP11	Rats intoxicated with Cd for 30 days, significantly increased tissue  bbbbb1 malondialdehyde eeeee1  (MDA) levels and significantly decreased enzymatic antioxidants  bbbbb2 superoxide dismutase eeeee2 , glutathione peroxidase and catalase in the frontal cortex tissue
CRP11	The  bbbbb1 aromatic-L-amino acid eeeee1  bbbbb2 aromatic-L-amino acid decarboxylase eeeee2  inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells
CRP11	To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors  bbbbb1 carbidopa eeeee1  bbbbb2 AAAD eeeee2  levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CRP11	To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa ( bbbbb1 alpha-methyl-dopahydrazine eeeee1  bbbbb2 AAAD eeeee2  levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CRP11	To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine ( bbbbb1 NSD-1015 eeeee1  bbbbb2 AAAD eeeee2  levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CRP11	To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa ( bbbbb1 MFMD eeeee1  bbbbb2 AAAD eeeee2  levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CRP11	To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and  bbbbb1 3-hydroxybenzylhydrazine eeeee1  bbbbb2 AAAD eeeee2  levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CRP11	To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine),  bbbbb1 alpha-monofluoromethyldopa eeeee1  bbbbb2 AAAD eeeee2  levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells
CRP11	Incretin-receptor activation leads to  bbbbb1 glucose eeeee1  bbbbb2 Incretin-receptor eeeee2  activation leads to glucose-dependent insulin secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis
CRP11	This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides  bbbbb1 glucose eeeee1 -dependent insulinotropic polypeptide ( bbbbb2 GIP eeeee2 ) and glucagon-like peptide-1 (GLP-1)
CRP11	This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides  bbbbb1 glucose eeeee1  bbbbb2 incretin eeeee2  peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
CRP11	This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides  bbbbb1 glucose eeeee1 -dependent insulinotropic polypeptide (GIP) and  bbbbb2 glucagon-like peptide-1 eeeee2  (GLP-1)
CRP11	This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides  bbbbb1 glucose eeeee1  bbbbb2 glucose-dependent insulinotropic polypeptide eeeee2  (GIP) and glucagon-like peptide-1 (GLP-1)
CRP11	This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides  bbbbb1 glucose eeeee1 -dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 ( bbbbb2 GLP-1 eeeee2 )
CRP11	Intrahypothalamic administration of orexin-A (1 or 5 pmol/mouse) significantly and dose-dependently suppressed the development of postischemic  bbbbb1 glucose eeeee1  bbbbb2 orexin-A eeeee2  (1 or 5 pmol/mouse) significantly and dose-dependently suppressed the development of postischemic glucose intolerance on day 1 and development of neuronal damage on day 3
CRP11	The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of  bbbbb1 SB334867 eeeee1  as well as by hypothalamic  bbbbb2 BDNF eeeee2  knockdown
CRP11	The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of  bbbbb1 SB334867 eeeee1  bbbbb2 orexin-A eeeee2 , and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown
CRP11	Small interfering RNA directed BDNF, orexin-A, and SB334867 [ bbbbb1 N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea eeeee1  bbbbb2 orexin-A eeeee2 , and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus
CRP11	Small interfering RNA directed BDNF, orexin-A, and SB334867 [ bbbbb1 N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea eeeee1  bbbbb2 BDNF eeeee2 , orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus
CRP11	Small interfering RNA directed BDNF, orexin-A, and  bbbbb1 SB334867 eeeee1  bbbbb2 orexin-A eeeee2 , and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus
CRP11	Small interfering RNA directed BDNF, orexin-A, and  bbbbb1 SB334867 eeeee1  bbbbb2 BDNF eeeee2 , orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus
CRP11	Orexin-A suppresses postischemic  bbbbb1 glucose eeeee1  bbbbb2 Orexin-A eeeee2  suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor
CRP11	Orexin-A suppresses postischemic  bbbbb1 glucose eeeee1  intolerance and neuronal damage through hypothalamic  bbbbb2 brain-derived neurotrophic factor eeeee2 
CRP11	Orexin-A (a  bbbbb1 glucose eeeee1 -sensing neuropeptide in the hypothalamus) and  bbbbb2 brain-derived neurotrophic factor eeeee2  (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism
CRP11	Orexin-A (a  bbbbb1 glucose eeeee1 -sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor ( bbbbb2 BDNF eeeee2 ; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism
CRP11	Orexin-A (a  bbbbb1 glucose eeeee1 -sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the  bbbbb2 neurotrophin eeeee2  family) play roles in many physiologic functions, including regulation of glucose metabolism
CRP11	Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of  bbbbb1 glucose eeeee1  bbbbb2 brain-derived neurotrophic factor eeeee2  (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism
CRP11	Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of  bbbbb1 glucose eeeee1  bbbbb2 BDNF eeeee2 ; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism
CRP11	Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of  bbbbb1 glucose eeeee1  bbbbb2 Orexin-A eeeee2  (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism
CRP11	Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of  bbbbb1 glucose eeeee1  bbbbb2 neurotrophin eeeee2  family) play roles in many physiologic functions, including regulation of glucose metabolism
CRP11	In addition, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression (mRNA encoding  bbbbb1 cholesterol eeeee1  bbbbb2 cholesterol side-chain cleavage p450 enzyme eeeee2 ) in CD4+ T cells were increased in these mice
CRP11	In addition, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression (mRNA encoding  bbbbb1 cholesterol eeeee1  bbbbb2 CYP11A1 eeeee2  mRNA expression (mRNA encoding cholesterol side-chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice
CRP11	In addition,  bbbbb1 corticosterone eeeee1  levels in splenic tissue or serum and CYP11A1 mRNA expression (mRNA encoding  bbbbb2 cholesterol side-chain cleavage p450 enzyme eeeee2 ) in CD4+ T cells were increased in these mice
CRP11	In addition,  bbbbb1 corticosterone eeeee1  levels in splenic tissue or serum and  bbbbb2 CYP11A1 eeeee2  mRNA expression (mRNA encoding cholesterol side-chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice
CRP11	When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice,  bbbbb1 corticosterone eeeee1  bbbbb2 CYP11A1 eeeee2  inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation
CRP11	When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice,  bbbbb1 corticosterone eeeee1  levels in splenic tissue or serum and  bbbbb2 CYP11A1 eeeee2  mRNA expression were decreased at 14 days after tumor inoculation
CRP11	IGN AND METHODS: We tested the effect of  bbbbb1 sorafenib eeeee1  on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the  bbbbb2 KIT eeeee2 (D816V) mutant
CRP11	IGN AND METHODS: We tested the effect of  bbbbb1 sorafenib eeeee1  on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or  bbbbb2 D835Y eeeee2  point mutation, and the KIT(D816V) mutant
CRP11	IGN AND METHODS: We tested the effect of  bbbbb1 sorafenib eeeee1  on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta,  bbbbb2 FLT3 eeeee2  with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant
CRP11	IGN AND METHODS: We tested the effect of  bbbbb1 sorafenib eeeee1  on the proliferation of hematopoietic cells transformed by ETV6- bbbbb2 PDGFRbeta eeeee2 , FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant
CRP11	IGN AND METHODS: We tested the effect of  bbbbb1 sorafenib eeeee1  on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT( bbbbb2 D816V eeeee2 ) mutant
CRP11	IGN AND METHODS: We tested the effect of  bbbbb1 sorafenib eeeee1  on the proliferation of hematopoietic cells transformed by  bbbbb2 ETV6 eeeee2 -PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant
CRP11	Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor  bbbbb1 tyrosine eeeee1  bbbbb2 receptor tyrosine kinases eeeee2  from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CRP11	Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor  bbbbb1 tyrosine eeeee1  kinases from the platelet-derived growth factor receptor (PDGFR) and  bbbbb2 vascular endothelial growth factor receptor eeeee2  (VEGFR) families
CRP11	Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor  bbbbb1 tyrosine eeeee1  kinases from the  bbbbb2 platelet-derived growth factor receptor eeeee2  (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CRP11	Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor  bbbbb1 tyrosine eeeee1  kinases from the platelet-derived growth factor receptor ( bbbbb2 PDGFR eeeee2 ) and vascular endothelial growth factor receptor (VEGFR) families
CRP11	Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor  bbbbb1 tyrosine eeeee1  kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor ( bbbbb2 VEGFR eeeee2 ) families
CRP11	Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor  bbbbb1 tyrosine eeeee1  bbbbb2 B-RAF eeeee2  inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families
CRP11	Activated  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2  are implicated in the pathogenesis of chronic and acute leukemia, and represent attractive targets for therapy
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal  bbbbb1 zinc eeeee1  bbbbb2 transient receptor potential mucolipin 1 eeeee2 ), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal  bbbbb1 zinc eeeee1  bbbbb2 ion channel eeeee2  TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal  bbbbb1 zinc eeeee1  levels in cells deficient in TRPML1, suggested a role for  bbbbb2 TRPML1 eeeee2  in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal  bbbbb1 zinc eeeee1  bbbbb2 TRPML1 eeeee2  (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal  bbbbb1 zinc eeeee1  levels in cells deficient in  bbbbb2 TRPML1 eeeee2 , suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in  bbbbb1 zinc eeeee1  bbbbb2 transient receptor potential mucolipin 1 eeeee2 ), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in  bbbbb1 zinc eeeee1  bbbbb2 ion channel eeeee2  TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in  bbbbb1 zinc eeeee1  bbbbb2 TRPML1 eeeee2  (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in  bbbbb1 zinc eeeee1  bbbbb2 TRPML1 eeeee2 , suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of  bbbbb1 zinc eeeee1  permeability of the lysosomal  bbbbb2 ion channel eeeee2  TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport
CRP11	The recent identification of  bbbbb1 zinc eeeee1  permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for  bbbbb2 TRPML1 eeeee2  in zinc transport
CRP11	The recent identification of  bbbbb1 zinc eeeee1  permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in  bbbbb2 TRPML1 eeeee2 , suggested a role for TRPML1 in zinc transport
CRP11	 bbbbb1 Zinc eeeee1 -dependent lysosomal enlargement in TRPML1-deficient cells involves  bbbbb2 MTF-1 eeeee2  transcription factor and ZnT4 (Slc30a4) transporter
CRP11	 bbbbb1 Zinc eeeee1 -dependent lysosomal enlargement in TRPML1-deficient cells involves MTF-1 transcription factor and  bbbbb2 ZnT4 eeeee2  (Slc30a4) transporter
CRP11	 bbbbb1 Zinc eeeee1 -dependent lysosomal enlargement in  bbbbb2 TRPML1 eeeee2 -deficient cells involves MTF-1 transcription factor and ZnT4 (Slc30a4) transporter
CRP11	 bbbbb1 Zinc eeeee1 -dependent lysosomal enlargement in TRPML1-deficient cells involves MTF-1 transcription factor and ZnT4 ( bbbbb2 Slc30a4 eeeee2 ) transporter
CRP11	Cellular zinc is controlled by zinc-chelating proteins and by  bbbbb1 zinc eeeee1  bbbbb2 zinc-chelating proteins eeeee2  and by zinc transporters
CRP11	Cellular zinc is controlled by zinc-chelating proteins and by  bbbbb1 zinc eeeee1  bbbbb2 zinc transporters eeeee2 
CRP11	Cellular zinc is controlled by  bbbbb1 zinc eeeee1  bbbbb2 zinc-chelating proteins eeeee2  and by zinc transporters
CRP11	Cellular zinc is controlled by  bbbbb1 zinc eeeee1 -chelating proteins and by  bbbbb2 zinc transporters eeeee2 
CRP11	In agreement with the previously published data, an acute siRNA (small interfering RNA)-driven TRPML1 KD (knockdown) leads to the build-up of large cytoplasmic vesicles positive for LysoTracker™ and zinc staining, when cells are exposed to high concentrations of  bbbbb1 zinc eeeee1  bbbbb2 TRPML1 eeeee2  KD (knockdown) leads to the build-up of large cytoplasmic vesicles positive for LysoTracker™ and zinc staining, when cells are exposed to high concentrations of zinc
CRP11	In agreement with the previously published data, an acute siRNA (small interfering RNA)-driven TRPML1 KD (knockdown) leads to the build-up of large cytoplasmic vesicles positive for LysoTracker™ and  bbbbb1 zinc eeeee1  bbbbb2 TRPML1 eeeee2  KD (knockdown) leads to the build-up of large cytoplasmic vesicles positive for LysoTracker™ and zinc staining, when cells are exposed to high concentrations of zinc
CRP11	 bbbbb1 Cysteinyl leukotriene eeeee1  bbbbb2 Cysteinyl leukotriene receptor 1 eeeee2  is involved in N-methyl-D-aspartate-mediated neuronal injury in mice
CRP11	Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast bbbbb1  (0. eeeee1 1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor bbbbb2  eeeee2 
CRP11	Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast bbbbb1  (0. eeeee1 1 mg/kg) and ketamine inhibited the  bbbbb2 upregulated exp eeeee2 ression of the CysLT1 receptor
CRP11	Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor bbbbb1  eeeee1  bbbbb2 upregulated exp eeeee2 ression of the CysLT1 receptor
CRP11	Pranlukast, ketamine and edaravone decreased NMDA-induce bbbbb1 d in eeeee1 jury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor bbbbb2  eeeee2 
CRP11	Pranlukast, ketamine and edaravone decreased NMDA-induce bbbbb1 d in eeeee1 jury; pranlukast (0.1 mg/kg) and ketamine inhibited the  bbbbb2 upregulated exp eeeee2 ression of the CysLT1 receptor
CRP11	In the current study dietary relevant mixtures of isoflavones and their metabolites,  bbbbb1 lignans eeeee1  and their metabolites, coumestrol, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their  bbbbb2 PPARγ eeeee2  activating abilities
CRP11	In the current study dietary relevant mixtures of  bbbbb1 isoflavones eeeee1  and their metabolites, lignans and their metabolites, coumestrol, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their  bbbbb2 PPARγ eeeee2  activating abilities
CRP11	In the current study dietary relevant mixtures of isoflavones and their metabolites, lignans and their metabolites,  bbbbb1 coumestrol eeeee1 , and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their  bbbbb2 PPARγ eeeee2  activating abilities
CRP11	The pleiotropic effects of  bbbbb1 vitamin A eeeee1  are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs,  bbbbb2 RXRs eeeee2  and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of  bbbbb1 vitamin A eeeee1  are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of  bbbbb2 nuclear receptors eeeee2  (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of  bbbbb1 vitamin A eeeee1  are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors ( bbbbb2 RARs eeeee2 , RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of  bbbbb1 vitamin A eeeee1  are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and  bbbbb2 PPARβ/δ eeeee2 ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of  bbbbb1 vitamin A eeeee1  are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ),  bbbbb2 polymorphic retinoic acid (RA) response elements eeeee2  and multiple coregulators
CRP11	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite,  bbbbb1 all-trans retinoic acid eeeee1  (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and  bbbbb2 PPARβ/δ eeeee2 ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid ( bbbbb1 atRA eeeee1 ), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and  bbbbb2 PPARβ/δ eeeee2 ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), polymorphic  bbbbb1 retinoic acid eeeee1  bbbbb2 RXRs eeeee2  and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), polymorphic  bbbbb1 retinoic acid eeeee1  bbbbb2 nuclear receptors eeeee2  (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), polymorphic  bbbbb1 retinoic acid eeeee1  bbbbb2 RARs eeeee2 , RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), polymorphic  bbbbb1 retinoic acid eeeee1  bbbbb2 PPARβ/δ eeeee2 ), polymorphic retinoic acid (RA) response elements and multiple coregulators
CRP11	The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), polymorphic  bbbbb1 retinoic acid eeeee1  bbbbb2 polymorphic retinoic acid (RA) response elements eeeee2  and multiple coregulators
CRP11	Likewise, GYKI 52466 (30-100 microM)) shifted the concentration-response curve for the effects of cyclothiazide on  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.c. decay time constants to the right. 8
CRP11	Cyclothiazide (330 microM) shifted the concentration-response curve for the effects of GYKI 52466 on  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.c. peak amplitude to the right (GYKI 52466 IC50 26.9 +/- 9.4 microM)
CRP11	Cyclothiazide (330 microM) shifted the concentration-response curve for the effects of GYKI 52466 on AMPA receptor-mediated e.p.s.c. peak amplitude to the right ( bbbbb1 GYKI 52466 eeeee1  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.c. peak amplitude to the right (GYKI 52466 IC50 26.9 +/- 9.4 microM)
CRP11	In conclusion, cyclothiazide and the 2,3-benzodiazep bbbbb1 ines eeeee1  bbbbb2 ines seem to  eeeee2 bind to different sites on AMPA receptors but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site
CRP11	Cyclothiazide prolonged the decay time constant of  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2 -mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c. onset kinetics and increasing e.p.s.c. amplitude. 7
CRP11	I 52466 decreased the peak amplitude of hippocampal area CA1  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2 -mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics
CRP11	Interactions of 2,3-benzodiazepines and cyclothiazide at  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptors eeeee2 : patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. 1
CRP11	Analysis of coenzyme binding by human placental  bbbbb1 3 beta-hydroxy-5-ene-steroid eeeee1  bbbbb2 human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase eeeee2  and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental  bbbbb1 3 beta-hydroxy-5-ene-steroid eeeee1  dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.  bbbbb2 3 beta-Hydroxy-5-ene-steroid dehydrogenase eeeee2  and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental  bbbbb1 3 beta-hydroxy-5-ene-steroid eeeee1  dehydrogenase and  bbbbb2 steroid 5----4-ene-isomerase eeeee2  using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental  bbbbb1 3 beta-hydroxy-5-ene-steroid eeeee1  dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and  bbbbb2 steroid 5----4-ene-isomerase eeeee2  copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.  bbbbb1 3 beta-Hydroxy-5-ene-steroid eeeee1  bbbbb2 human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase eeeee2  and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.  bbbbb1 3 beta-Hydroxy-5-ene-steroid eeeee1  bbbbb2 3 beta-Hydroxy-5-ene-steroid dehydrogenase eeeee2  and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.  bbbbb1 3 beta-Hydroxy-5-ene-steroid eeeee1  bbbbb2 steroid 5----4-ene-isomerase eeeee2  using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.  bbbbb1 3 beta-Hydroxy-5-ene-steroid eeeee1  dehydrogenase and  bbbbb2 steroid 5----4-ene-isomerase eeeee2  copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using  bbbbb1 5'-[p-(fluorosulfonyl)benzoyl]adenosine eeeee1 , an affinity labeling cofactor analog.  bbbbb2 3 beta-Hydroxy-5-ene-steroid dehydrogenase eeeee2  and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes
CRP11	Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and steroid 5----4-ene-isomerase using  bbbbb1 5'-[p-(fluorosulfonyl)benzoyl]adenosine eeeee1 , an affinity labeling cofactor analog. 3 beta-Hydroxy-5-ene-steroid dehydrogenase and  bbbbb2 steroid 5----4-ene-isomerase eeeee2  copurify as a single, homogeneous protein from human placental microsomes
CRP11	Unlike bacterial  bbbbb1 3-keto-5-ene-steroid eeeee1  bbbbb2 3-keto-5-ene-steroid isomerase eeeee2 , the human isomerase reaction is stimulated by diphosphopyridine nucleotides (NADH, NAD+)
CRP11	Affinity alkylation with 2  bbbbb1 alpha-bromoacetoxyprogesterone eeeee1  suggests that the  bbbbb2 dehydrogenase eeeee2  and isomerase substrate steroids bind at different sites on the same protein
CRP11	 bbbbb1 NS-398 eeeee1  induces apoptosis in COX-2 expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S/KS cells that does not express  bbbbb2 COX-2 eeeee2 
CRP11	 bbbbb1 NS-398 eeeee1  induces apoptosis in  bbbbb2 COX-2 eeeee2  expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S/KS cells that does not express COX-2
CRP11	Selective COX-2 inhibitors reduce  bbbbb1 prostaglandin eeeee1  bbbbb2 COX-2 eeeee2  inhibitors reduce prostaglandin synthesis, restore apoptosis, and inhibit cancer cell proliferation
CRP11	Results of this inhibition caused changes in the sterol content of the cellular membrane bbbbb1  eeeee1  bbbbb2 ar m eeeee2 embrane
CRP11	In subjects with dysmenorrhea the increase in pain following the administration of  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin eeeee2  was significantly lower during atosiban than during placebo infusion
CRP11	NS: Atosiban reduces  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin eeeee2 -induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea
CRP11	 bbbbb1 Vasopressin eeeee1  bbbbb2 Vasopressin eeeee2  injections elevated area under the curve in both healthy volunteers and dysmenorrhea subjects
CRP11	At each menstruation a bolus injection of 10 pmol/kg of vasopressin was administered before and during infusion of either 300 microg/min of  bbbbb1 atosiban eeeee1  bbbbb2 vasopressin eeeee2  was administered before and during infusion of either 300 microg/min of atosiban or placebo
CRP11	At each menstruation a bolus injection of 10 pmol/kg of  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin eeeee2  was administered before and during infusion of either 300 microg/min of atosiban or placebo
CRP11	While  bbbbb1 fluoropyrimidine eeeee1  antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent  bbbbb2 TS eeeee2  inhibitors
CRP11	 bbbbb1 Thymidylate eeeee1  bbbbb2 Thymidylate synthase eeeee2 : a critical target in cancer therapy? For the last four decades, synthesis and testing of potentially active drugs (e.g., antimetabolites) have focused on structural modification of existing metabolites as precursors of DNA and RNA synthesis
CRP11	 bbbbb1 Thymidylate eeeee1  bbbbb2 Thymidylate synthase eeeee2  (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CRP11	 bbbbb1 Thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 ) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis
CRP11	The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that  bbbbb1 thymidine eeeee1  bbbbb2 thymidine phosphorylase eeeee2 , the activating enzyme for 5-FU, is expressed at a higher level in tumor tissue compared with normal tissue counterparts
CRP11	The availability of the  bbbbb1 5-FU eeeee1  prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that  bbbbb2 thymidine phosphorylase eeeee2 , the activating enzyme for 5-FU, is expressed at a higher level in tumor tissue compared with normal tissue counterparts
CRP11	Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with  bbbbb1 amino acid eeeee1  residues Arg218, Arg222 and Lys444, identifies the ligand- bbbbb2 HSA eeeee2  interaction for the transportation affinity of the ligand at the specific site of the target
CRP11	Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218,  bbbbb1 Arg eeeee1 222 and Lys444, identifies the ligand- bbbbb2 HSA eeeee2  interaction for the transportation affinity of the ligand at the specific site of the target
CRP11	Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and  bbbbb1 Lys eeeee1 444, identifies the ligand- bbbbb2 HSA eeeee2  interaction for the transportation affinity of the ligand at the specific site of the target
CRP11	Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with amino acid residues  bbbbb1 Arg eeeee1 218, Arg222 and Lys444, identifies the ligand- bbbbb2 HSA eeeee2  interaction for the transportation affinity of the ligand at the specific site of the target
CRP11	To improve on this alpha2-adrenoceptor subtype selectivity, a series of  bbbbb1 yohimbine eeeee1  dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on  bbbbb2 human alpha2-adrenoceptor eeeee2  subtypes expressed in Chinese hamster ovary cells
CRP11	To improve on this alpha2-adrenoceptor subtype selectivity, a series of  bbbbb1 yohimbine eeeee1  bbbbb2 alpha2-adrenoceptor eeeee2  subtype selectivity, a series of yohimbine dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on human alpha2-adrenoceptor subtypes expressed in Chinese hamster ovary cells
CRP11	Initial studies showed that  bbbbb1 yohimbine eeeee1  was about 4- and 15-fold more selective for the human alpha2C-adrenoceptor in comparison with the  bbbbb2 alpha2A- and alpha2B-adrenoceptors eeeee2 , respectively
CRP11	Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the alpha2B-adrenoceptor; and  bbbbb1 yohimbine eeeee1  bbbbb2 alpha2A- and alpha2C-adrenoceptor eeeee2  versus the alpha2B-adrenoceptor; and yohimbine dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the alpha2C-adrenoceptor
CRP11	Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the alpha2B-adrenoceptor; and  bbbbb1 yohimbine eeeee1  bbbbb2 alpha2B-adrenoceptor eeeee2 ; and yohimbine dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the alpha2C-adrenoceptor
CRP11	The yohimbine dimers n = 3 and n = 24 showed the highest potency and selectivity (32- and 82-fold. respectively) for the alpha2C-adrenoceptor in receptor binding and in functional studies (42- and 29-fold, respectively) measuring  bbbbb1 cAMP eeeee1  bbbbb2 alpha2C-adrenoceptor eeeee2  in receptor binding and in functional studies (42- and 29-fold, respectively) measuring cAMP changes using a cell-based luciferase reporter gene assay
CRP11	This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v)  bbbbb1 ethanol eeeee1  bbbbb2 5-HT4 eeeee2  and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CRP11	This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v)  bbbbb1 ethanol eeeee1  bbbbb2 5-HT2 eeeee2  antagonist, on mucosal injury produced by 50% (v/v) ethanol
CRP11	This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v)  bbbbb1 ethanol eeeee1  bbbbb2 5-HT1 eeeee2  receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol
CRP11	On the contrary, pretreatment with 5-HT worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, glycoprotein content or  bbbbb1 PGE2 eeeee1  bbbbb2 glycoprotein eeeee2  content or PGE2 levels, although the non-protein SH fraction was significantly decreased
CRP11	On the contrary, pretreatment with 5-HT worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, glycoprotein content or PGE2 levels, although the non-protein  bbbbb1 SH eeeee1  bbbbb2 glycoprotein eeeee2  content or PGE2 levels, although the non-protein SH fraction was significantly decreased
CRP11	Treatment with geldanamycin, however, does not affect the activation of lysophosphatide acy bbbbb1 ltransferase eeeee1 , which is a plasma membrane enzyme coupled to t bbbbb2 he T- eeeee2 cell receptor after T-cell stimulation
CRP11	Treatment with geldanamycin, however, does not affect the activation of lysophosphatide acy bbbbb1 ltransferase eeeee1 , which is a plasma membrane enzyme coupled to the T-c bbbbb2 ell re eeeee2 ceptor after T-cell stimulation
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor,  bbbbb1 formyl-methionyl-leucyl-phenylalanine eeeee1 , (FMLP) and neutrophil-activating factor (NAF)/ bbbbb2 IL-8 eeeee2 , but not toward complement fragment C5a (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor,  bbbbb1 formyl-methionyl-leucyl-phenylalanine eeeee1 , (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a ( bbbbb2 C5a eeeee2 )
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor,  bbbbb1 formyl-methionyl-leucyl-phenylalanine eeeee1  bbbbb2 cytokines eeeee2  have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor,  bbbbb1 formyl-methionyl-leucyl-phenylalanine eeeee1 , (FMLP) and neutrophil-activating factor ( bbbbb2 NAF eeeee2 )/IL-8, but not toward complement fragment C5a (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor,  bbbbb1 formyl-methionyl-leucyl-phenylalanine eeeee1 , (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward  bbbbb2 complement fragment C5a eeeee2  (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor,  bbbbb1 formyl-methionyl-leucyl-phenylalanine eeeee1 , (FMLP) and  bbbbb2 neutrophil-activating factor eeeee2  (NAF)/IL-8, but not toward complement fragment C5a (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, ( bbbbb1 FMLP eeeee1 ) and neutrophil-activating factor (NAF)/ bbbbb2 IL-8 eeeee2 , but not toward complement fragment C5a (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, ( bbbbb1 FMLP eeeee1 ) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a ( bbbbb2 C5a eeeee2 )
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, ( bbbbb1 FMLP eeeee1  bbbbb2 cytokines eeeee2  have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, ( bbbbb1 FMLP eeeee1 ) and neutrophil-activating factor ( bbbbb2 NAF eeeee2 )/IL-8, but not toward complement fragment C5a (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, ( bbbbb1 FMLP eeeee1 ) and neutrophil-activating factor (NAF)/IL-8, but not toward  bbbbb2 complement fragment C5a eeeee2  (C5a)
CRP11	These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, ( bbbbb1 FMLP eeeee1 ) and  bbbbb2 neutrophil-activating factor eeeee2  (NAF)/IL-8, but not toward complement fragment C5a (C5a)
CRP11	The activity of thioredoxin reductase and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2  was determined in liver and heart tissues in an attempt to correlate enzymatic activity with heart recovery after ischaemia-reperfusion
CRP11	The activity of thioredoxin reductase and  bbbbb1 glutathione eeeee1  bbbbb2 thioredoxin reductase eeeee2  and glutathione peroxidase was determined in liver and heart tissues in an attempt to correlate enzymatic activity with heart recovery after ischaemia-reperfusion
CRP11	Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione peroxidase eeeee2 
CRP11	Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and  bbbbb1 glutathione eeeee1  bbbbb2 selenocysteine enzymes eeeee2 , such as thioredoxin reductase and glutathione peroxidase
CRP11	Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and  bbbbb1 glutathione eeeee1  bbbbb2 thioredoxin reductase eeeee2  and glutathione peroxidase
CRP11	Auranofin, an antirheumatic gold compound, is an inhibitor of  bbbbb1 selenocysteine eeeee1  enzymes, such as thioredoxin reductase and  bbbbb2 glutathione peroxidase eeeee2 
CRP11	Auranofin, an antirheumatic gold compound, is an inhibitor of  bbbbb1 selenocysteine eeeee1  bbbbb2 selenocysteine enzymes eeeee2 , such as thioredoxin reductase and glutathione peroxidase
CRP11	Auranofin, an antirheumatic gold compound, is an inhibitor of  bbbbb1 selenocysteine eeeee1  enzymes, such as  bbbbb2 thioredoxin reductase eeeee2  and glutathione peroxidase
CRP11	There was significantly less thioredoxin reductase activity in rat liver extracts, whereas the level of  bbbbb1 glutathione eeeee1  bbbbb2 thioredoxin reductase eeeee2  activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of auranofin used was able to selectively inhibit one of these enzyme systems
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and  bbbbb1 formalin eeeee1 , were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC,  bbbbb2 PKA eeeee2 , TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and  bbbbb1 formalin eeeee1 , were performed to evaluate the antinociceptive action of CAT and to determine the involvement of  bbbbb2 PKC eeeee2 , PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and  bbbbb1 formalin eeeee1 , were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and  bbbbb2 ASIC eeeee2  in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and  bbbbb1 formalin eeeee1 , were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA,  bbbbb2 TRPV1 eeeee2 , TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and  bbbbb1 formalin eeeee1 , were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1,  bbbbb2 TRPM8 eeeee2  and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and  bbbbb1 formalin eeeee1 , were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1,  bbbbb2 TRPA1 eeeee2 , TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The  bbbbb1 acetic acid eeeee1 -induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC,  bbbbb2 PKA eeeee2 , TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The  bbbbb1 acetic acid eeeee1 -induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of  bbbbb2 PKC eeeee2 , PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The  bbbbb1 acetic acid eeeee1 -induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and  bbbbb2 ASIC eeeee2  in its antinociceptive mechanism
CRP11	Methods The  bbbbb1 acetic acid eeeee1 -induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA,  bbbbb2 TRPV1 eeeee2 , TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The  bbbbb1 acetic acid eeeee1 -induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1,  bbbbb2 TRPM8 eeeee2  and ASIC in its antinociceptive mechanism
CRP11	Methods The  bbbbb1 acetic acid eeeee1 -induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1,  bbbbb2 TRPA1 eeeee2 , TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of  bbbbb1 CAT eeeee1  and to determine the involvement of PKC,  bbbbb2 PKA eeeee2 , TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of  bbbbb1 CAT eeeee1  and to determine the involvement of  bbbbb2 PKC eeeee2 , PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of  bbbbb1 CAT eeeee1  and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and  bbbbb2 ASIC eeeee2  in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of  bbbbb1 CAT eeeee1  and to determine the involvement of PKC, PKA,  bbbbb2 TRPV1 eeeee2 , TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of  bbbbb1 CAT eeeee1  and to determine the involvement of PKC, PKA, TRPV1, TRPA1,  bbbbb2 TRPM8 eeeee2  and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of  bbbbb1 CAT eeeee1  and to determine the involvement of PKC, PKA, TRPV1,  bbbbb2 TRPA1 eeeee2 , TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by  bbbbb1 glutamate eeeee1  and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC,  bbbbb2 PKA eeeee2 , TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by  bbbbb1 glutamate eeeee1  and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of  bbbbb2 PKC eeeee2 , PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by  bbbbb1 glutamate eeeee1  and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and  bbbbb2 ASIC eeeee2  in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by  bbbbb1 glutamate eeeee1  and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA,  bbbbb2 TRPV1 eeeee2 , TRPA1, TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by  bbbbb1 glutamate eeeee1  and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1,  bbbbb2 TRPM8 eeeee2  and ASIC in its antinociceptive mechanism
CRP11	Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by  bbbbb1 glutamate eeeee1  and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1,  bbbbb2 TRPA1 eeeee2 , TRPM8 and ASIC in its antinociceptive mechanism
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of CAT bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the an bbbbb1 tin eeeee1 ociceptive mechanism of CAT bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the an bbbbb1 tin eeeee1 ociceptive mechanism of CAT bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the an bbbbb1 tin eeeee1 ociceptive mechanism of CAT bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the an bbbbb1 tin eeeee1 ociceptive mechanism of CAT bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the an bbbbb1 tin eeeee1 ociceptive mechanism of CAT bbbbb2  eeeee2 
CRP11	Finally, the involvement of PKC and PKA was also studied, and we showed that both play a role in the an bbbbb1 tin eeeee1 ociceptive mechanism of CAT bbbbb2  eeeee2 
CRP11	Our data also indicate that  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO
CRP11	Other groups received either an infusion of the selective  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)
CRP11	In patients with chronic obstructive pulmonary disease, however, increased  bbbbb1 polySia eeeee1  levels and processing of the  bbbbb2 NCAM eeeee2  carrier were observed
CRP11	Here, we describe a novel function of polysialylated NCAM ( bbbbb1 polySia eeeee1  bbbbb2 polysialylated NCAM eeeee2  (polySia-NCAM) in innate immunity of the lung
CRP11	Here, we describe a novel function of polysialylated NCAM ( bbbbb1 polySia eeeee1  bbbbb2 polySia-NCAM eeeee2 ) in innate immunity of the lung
CRP11	As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble  bbbbb1 polySia eeeee1  bbbbb2 IL-1β eeeee2  or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM
CRP11	As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble  bbbbb1 polySia eeeee1  bbbbb2 metalloprotease eeeee2 -mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM
CRP11	As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble  bbbbb1 polySia eeeee1  bbbbb2 NCAM-140 eeeee2  was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM
CRP11	As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble  bbbbb1 polySia eeeee1  bbbbb2 polySia-NCAM eeeee2 
CRP11	As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble  bbbbb1 polySia eeeee1  bbbbb2 ectodomain eeeee2  shedding, resulting in the secretion of soluble polySia-NCAM
CRP11	As shown in a cell culture model,  bbbbb1 polySia eeeee1 -NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by  bbbbb2 IL-1β eeeee2  or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM
CRP11	As shown in a cell culture model,  bbbbb1 polySia eeeee1 -NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced  bbbbb2 metalloprotease eeeee2 -mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM
CRP11	As shown in a cell culture model,  bbbbb1 polySia eeeee1 -NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble  bbbbb2 polySia-NCAM eeeee2 
CRP11	As shown in a cell culture model,  bbbbb1 polySia eeeee1 -NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated  bbbbb2 ectodomain eeeee2  shedding, resulting in the secretion of soluble polySia-NCAM
CRP11	Interestingly, pol bbbbb1 ySia ch eeeee1  bbbbb2 ySia chains  eeeee2 of secreted NCAM neutralized the cytotoxic activity of extracellular histones as well as DNA/histone-network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms
CRP11	Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK)
CRP11	Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of  bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 )
CRP11	Here, we explore whether 1) glucose,  bbbbb1 metformin eeeee1 , or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in  bbbbb2 AMPK eeeee2  activity modulate insulin secretion from human islets
CRP11	Here, we explore whether 1) glucose,  bbbbb1 metformin eeeee1 , or leptin regulates  bbbbb2 AMPK eeeee2  activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets
CRP11	Here, we explore whether 1) glucose,  bbbbb1 metformin eeeee1 , or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate  bbbbb2 insulin eeeee2  secretion from human islets
CRP11	Here, we explore whether 1)  bbbbb1 glucose eeeee1 , metformin, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in  bbbbb2 AMPK eeeee2  activity modulate insulin secretion from human islets
CRP11	Here, we explore whether 1)  bbbbb1 glucose eeeee1 , metformin, or leptin regulates  bbbbb2 AMPK eeeee2  activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets
CRP11	Here, we explore whether 1)  bbbbb1 glucose eeeee1 , metformin, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate  bbbbb2 insulin eeeee2  secretion from human islets
CRP11	 bbbbb1 Metformin eeeee1 , but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated  bbbbb2 insulin eeeee2  secretion
CRP11	Metformin, but not leptin, regulates  bbbbb1 AMP eeeee1 -activated protein kinase in pancreatic islets: impact on glucose-stimulated  bbbbb2 insulin eeeee2  secretion
CRP11	Metformin, but not leptin, regulates  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  in pancreatic islets: impact on glucose-stimulated insulin secretion
CRP11	Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on  bbbbb1 glucose eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  in pancreatic islets: impact on glucose-stimulated insulin secretion
CRP11	Discovery of liver-targeted inhibitors of  bbbbb1 stearoyl-CoA eeeee1  desaturase ( bbbbb2 SCD1 eeeee2 )
CRP11	Discovery of liver-targeted inhibitors of  bbbbb1 stearoyl-CoA eeeee1  bbbbb2 stearoyl-CoA desaturase eeeee2  (SCD1)
CRP11	Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for  bbbbb1 stearoyl-coenzyme A eeeee1  (CoA) desaturase 1 ( bbbbb2 SCD1 eeeee2 ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model
CRP11	Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for  bbbbb1 stearoyl-coenzyme A eeeee1  bbbbb2 stearoyl-coenzyme A (CoA) desaturase 1 eeeee2  (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model
CRP11	Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A ( bbbbb1 CoA eeeee1 ) desaturase 1 ( bbbbb2 SCD1 eeeee2 ) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model
CRP11	Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A ( bbbbb1 CoA eeeee1  bbbbb2 stearoyl-coenzyme A (CoA) desaturase 1 eeeee2  (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model
CRP11	The above drugs also blocked or decreased high  bbbbb1 K(+) eeeee1 -induced secretion, but had much less effect on  bbbbb2 TRH eeeee2 -induced secretion
CRP11	The mechanism by which 30% medium hyposmolarity induces PRL secretion by GH4C1 cells was compared with that induced by 100 nmol/l TRH or 30 mmol/l  bbbbb1 K+ eeeee1  bbbbb2 TRH eeeee2  or 30 mmol/l K+
CRP11	The mechanism by which 30% medium hyposmolarity induces PRL secretion by GH4C1 cells was compared with that induced by 100 nmol/l TRH or 30 mmol/l  bbbbb1 K+ eeeee1  bbbbb2 PRL eeeee2  secretion by GH4C1 cells was compared with that induced by 100 nmol/l TRH or 30 mmol/l K+
CRP11	The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the  bbbbb1 Ca2(+) eeeee1 -calmodulin interaction, depressed hyposmolarity-induced  bbbbb2 PRL eeeee2  secretion in a dose-dependent manner (r = -0.991, p less than 0.01)
CRP11	Role of extracellular  bbbbb1 calcium eeeee1  and calmodulin in prolactin secretion induced by hyposmolarity,  bbbbb2 thyrotropin-releasing hormone eeeee2 , and high K+ in GH4C1 cells
CRP11	Role of extracellular  bbbbb1 calcium eeeee1  and  bbbbb2 calmodulin eeeee2  in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells
CRP11	Role of extracellular calcium and calmodulin in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high  bbbbb1 K+ eeeee1  bbbbb2 thyrotropin-releasing hormone eeeee2 , and high K+ in GH4C1 cells
CRP11	Role of extracellular calcium and calmodulin in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high  bbbbb1 K+ eeeee1  bbbbb2 prolactin eeeee2  secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells
CRP11	Role of extracellular calcium and calmodulin in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high  bbbbb1 K+ eeeee1  bbbbb2 calmodulin eeeee2  in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells
CRP11	Secretion induced by TRH, hyposmolarity, bbbbb1  o eeeee1 r high K+ was optimal at pH 7.3-7.65 and was significantly depressed at pH 6.0 or 8.0, indicating that rel bbbbb2 eas eeeee2 e of hormone induced by all 3 stimuli is due to an active cell process requiring a physiologic extracellular pH and is not produced by nonspecific cell toxicity
CRP11	Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l  bbbbb1 verapamil eeeee1 , or inhibiting  bbbbb2 calmodulin eeeee2  activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Removing medium Ca2+, blocking  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channels eeeee2  with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Removing medium Ca2+, blocking  bbbbb1 Ca2+ eeeee1  channels with 50 mumol/l verapamil, or inhibiting  bbbbb2 calmodulin eeeee2  activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l  bbbbb1 pimozide eeeee1  bbbbb2 Ca2+ channels eeeee2  with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Removing medium  bbbbb1 Ca2+ eeeee1 , blocking  bbbbb2 Ca2+ channels eeeee2  with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Removing medium  bbbbb1 Ca2+ eeeee1 , blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting  bbbbb2 calmodulin eeeee2  activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l  bbbbb1 chlorpromazine eeeee1  bbbbb2 Ca2+ channels eeeee2  with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l  bbbbb1 trifluoperazine eeeee1  bbbbb2 Ca2+ channels eeeee2  with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion
CRP11	Ibrutinib ( bbbbb1 Imbruvica(R) eeeee1 ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of  bbbbb2 BTK eeeee2 
CRP11	Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's  bbbbb1 tyrosine eeeee1  kinase ( bbbbb2 BTK eeeee2 ) that inhibits B-cell antigen receptor signalling downstream of BTK
CRP11	Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's  bbbbb1 tyrosine eeeee1  kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of  bbbbb2 BTK eeeee2 
CRP11	Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's  bbbbb1 tyrosine eeeee1  kinase (BTK) that inhibits  bbbbb2 B-cell antigen receptor eeeee2  signalling downstream of BTK
CRP11	Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's  bbbbb1 tyrosine eeeee1  bbbbb2 Bruton's tyrosine kinase eeeee2  (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK
CRP11	Nine mammalian  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase ( bbbbb2 BCAT(m) eeeee2 )
CRP11	Nine mammalian  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and  bbbbb2 mitochondrial branched-chain amino acid aminotransferase eeeee2  (BCAT(m))
CRP11	Nine mammalian  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase ( bbbbb2 mitAspAT eeeee2 ), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including  bbbbb2 mitochondrial aspartate aminotransferase eeeee2  (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP)-containing enzymes catalyze cysteine S-conjugate  bbbbb2 beta-lyase eeeee2  reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial  bbbbb1 aspartate eeeee1  aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase ( bbbbb2 BCAT(m) eeeee2 )
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial  bbbbb1 aspartate eeeee1  aminotransferase (mitAspAT), and  bbbbb2 mitochondrial branched-chain amino acid aminotransferase eeeee2  (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial  bbbbb1 aspartate eeeee1  aminotransferase ( bbbbb2 mitAspAT eeeee2 ), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial  bbbbb1 aspartate eeeee1  bbbbb2 mitochondrial aspartate aminotransferase eeeee2  (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial  bbbbb1 aspartate eeeee1  bbbbb2 beta-lyase eeeee2  reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 )-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase ( bbbbb2 BCAT(m) eeeee2 )
CRP11	Nine mammalian pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 )-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and  bbbbb2 mitochondrial branched-chain amino acid aminotransferase eeeee2  (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 )-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase ( bbbbb2 mitAspAT eeeee2 ), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 )-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including  bbbbb2 mitochondrial aspartate aminotransferase eeeee2  (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 )-containing enzymes catalyze cysteine S-conjugate  bbbbb2 beta-lyase eeeee2  reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial  bbbbb1 branched-chain amino acid eeeee1  aminotransferase ( bbbbb2 BCAT(m) eeeee2 )
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial  bbbbb1 branched-chain amino acid eeeee1  bbbbb2 mitochondrial branched-chain amino acid aminotransferase eeeee2  (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial  bbbbb1 branched-chain amino acid eeeee1  bbbbb2 mitAspAT eeeee2 ), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial  bbbbb1 branched-chain amino acid eeeee1  bbbbb2 mitochondrial aspartate aminotransferase eeeee2  (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial  bbbbb1 branched-chain amino acid eeeee1  bbbbb2 beta-lyase eeeee2  reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze  bbbbb1 cysteine S-conjugate eeeee1  beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase ( bbbbb2 BCAT(m) eeeee2 )
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze  bbbbb1 cysteine S-conjugate eeeee1  beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and  bbbbb2 mitochondrial branched-chain amino acid aminotransferase eeeee2  (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze  bbbbb1 cysteine S-conjugate eeeee1  beta-lyase reactions, including mitochondrial aspartate aminotransferase ( bbbbb2 mitAspAT eeeee2 ), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze  bbbbb1 cysteine S-conjugate eeeee1  beta-lyase reactions, including  bbbbb2 mitochondrial aspartate aminotransferase eeeee2  (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze  bbbbb1 cysteine S-conjugate eeeee1   bbbbb2 beta-lyase eeeee2  reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m))
CRP11	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate  bbbbb1 halide eeeee1  bbbbb2 beta-lyases eeeee2  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CRP11	Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a  bbbbb1 thioacyl halide eeeee1  bbbbb2 beta-lyases eeeee2  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CRP11	Most halogenated cysteine S-conjugates are metabolized by  bbbbb1 cysteine S-conjugate eeeee1   bbbbb2 beta-lyases eeeee2  to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins
CRP11	Since oxidised calmodulin looses its ability to activate  bbbbb1 calcium eeeee1  bbbbb2 calmodulin eeeee2  looses its ability to activate calcium ATPase, enzyme activities were followed in full skin biopsies from lesional skin of patients with acute vitiligo (n=6) and healthy controls (n=6)
CRP11	Since oxidised calmodulin looses its ability to activate  bbbbb1 calcium eeeee1  bbbbb2 calcium ATPase eeeee2 , enzyme activities were followed in full skin biopsies from lesional skin of patients with acute vitiligo (n=6) and healthy controls (n=6)
CRP11	Computer simulation of native and oxidised calmodulin confirmed the loss of all four calcium ions from their specific EF-hand domains bbbbb1  eeeee1  bbbbb2 ss of all  eeeee2 four calcium ions from their specific EF-hand domains
CRP11	Computer simulation of native and oxidised calmodulin confirmed the loss of all four calcium ions from bbbbb1  their  eeeee1  bbbbb2 ss of all  eeeee2 four calcium ions from their specific EF-hand domains
CRP11	Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined calcium binding to calmodulin in the presence and absence of H(2)O(2) utilising (45) bbbbb1 calcium eeeee1  bbbbb2 calmodulin eeeee2  in the presence and absence of H(2)O(2) utilising (45)calcium
CRP11	Since 10(-3)M H(2)O(2) oxidises  bbbbb1 methionine eeeee1  and tryptophan residues in proteins, we examined calcium binding to  bbbbb2 calmodulin eeeee2  in the presence and absence of H(2)O(2) utilising (45)calcium
CRP11	Since 10(-3)M  bbbbb1 H(2)O(2) eeeee1  oxidises methionine and tryptophan residues in proteins, we examined calcium binding to  bbbbb2 calmodulin eeeee2  in the presence and absence of H(2)O(2) utilising (45)calcium
CRP11	Since 10(-3)M H(2)O(2) oxidises methionine and  bbbbb1 tryptophan eeeee1  residues in proteins, we examined calcium binding to  bbbbb2 calmodulin eeeee2  in the presence and absence of H(2)O(2) utilising (45)calcium
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azi bbbbb1 do-[alpha- eeeee1 32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb2  eeeee2 
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azi bbbbb1 do-[alpha- eeeee1 32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb2  eeeee2 
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  the eeeee2  presence of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2 senc eeeee2 e of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  the eeeee2  presence of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2 senc eeeee2 e of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  the eeeee2  presence of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2 senc eeeee2 e of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or M bbbbb1 gATP in a con eeeee1  bbbbb2  the eeeee2  presence of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or M bbbbb1 gATP in a con eeeee1  bbbbb2 senc eeeee2 e of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  the eeeee2  presence of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2 senc eeeee2 e of MgADP or MgATP in a concentration-dependent manner
CRP11	The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from SUR1 in the presence of MgADP or MgATP in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Cooperative binding of ATP and MgADP in the  bbbbb1 sulfonylurea eeeee1  bbbbb2 sulfonylurea receptor eeeee2  is modulated by glibenclamide
CRP11	The ATP-sensitive  bbbbb1 potassium eeeee1  bbbbb2 ATP-sensitive potassium (KATP) channels eeeee2  in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion
CRP11	The ATP-sensitive  bbbbb1 potassium eeeee1  (KATP) channels in pancreatic beta cells are critical in the regulation of glucose-induced  bbbbb2 insulin eeeee2  secretion
CRP11	The  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium (KATP) channels eeeee2  in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion
CRP11	The  bbbbb1 ATP eeeee1 -sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of glucose-induced  bbbbb2 insulin eeeee2  secretion
CRP11	The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of  bbbbb1 glucose eeeee1  bbbbb2 ATP-sensitive potassium (KATP) channels eeeee2  in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the  bbbbb1 ATP eeeee1 -binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming  bbbbb2 Kir6.2 eeeee2  subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the  bbbbb1 ATP eeeee1  bbbbb2 SUR1 eeeee2  subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the  bbbbb1 ATP eeeee1  bbbbb2 KATP channel eeeee2  is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two  bbbbb1 nucleotide eeeee1 -binding folds (NBF1 and NBF2) and the pore-forming  bbbbb2 Kir6.2 eeeee2  subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two  bbbbb1 nucleotide eeeee1  bbbbb2 SUR1 eeeee2  subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two  bbbbb1 nucleotide eeeee1  bbbbb2 KATP channel eeeee2  is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two  bbbbb1 nucleotide eeeee1 -binding folds (NBF1 and  bbbbb2 NBF2 eeeee2 ) and the pore-forming Kir6.2 subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two  bbbbb1 nucleotide eeeee1  bbbbb2 nucleotide-binding folds eeeee2  (NBF1 and NBF2) and the pore-forming Kir6.2 subunits
CRP11	The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two  bbbbb1 nucleotide eeeee1 -binding folds ( bbbbb2 NBF1 eeeee2  and NBF2) and the pore-forming Kir6.2 subunits
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound  bbbbb1 MgATP eeeee1  bbbbb2 SUR1 eeeee2  binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound  bbbbb1 MgATP eeeee1  bbbbb2 NBF2 eeeee2  or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound  bbbbb1 MgATP eeeee1  bbbbb2 NBF1 eeeee2  and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds  bbbbb1 8-azido-ATP eeeee1  strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at  bbbbb2 NBF1 eeeee2 
CRP11	These results suggest that SUR1 binds  bbbbb1 8-azido-ATP eeeee1  strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at  bbbbb2 NBF2 eeeee2 , stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds  bbbbb1 8-azido-ATP eeeee1  strongly at NBF1 and that MgADP, either by direct binding to  bbbbb2 NBF2 eeeee2  or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound  bbbbb1 8-azido-ATP eeeee1  bbbbb2 NBF2 eeeee2 , stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound  bbbbb1 8-azido-ATP eeeee1  bbbbb2 SUR1 eeeee2  binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound  bbbbb1 8-azido-ATP eeeee1  bbbbb2 NBF2 eeeee2  or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound  bbbbb1 8-azido-ATP eeeee1  bbbbb2 NBF1 eeeee2  and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that  bbbbb1 MgADP eeeee1 , either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at  bbbbb2 NBF1 eeeee2 
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that  bbbbb1 MgADP eeeee1 , either by direct binding to NBF2 or by hydrolysis of bound MgATP at  bbbbb2 NBF2 eeeee2 , stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that  bbbbb1 MgADP eeeee1  bbbbb2 SUR1 eeeee2  binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that  bbbbb1 MgADP eeeee1  bbbbb2 NBF1 eeeee2  and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1
CRP11	Although electrophysiological studies provide clues to the complex control of KATP channels by  bbbbb1 ATP eeeee1 , MgADP, and pharmacological agents, the molecular mechanism of  bbbbb2 KATP-channel eeeee2  regulation remains unclear
CRP11	Although electrophysiological studies provide clues to the complex control of KATP channels by ATP,  bbbbb1 MgADP eeeee1 , and pharmacological agents, the molecular mechanism of  bbbbb2 KATP-channel eeeee2  regulation remains unclear
CRP11	We demonstrate that only treatment of HaCaT with  bbbbb1 GLA eeeee1  and EPA or a  bbbbb2 PPARgamma eeeee2  ligand (roziglitazone), induced COX-2 expression (protein and mRNA)
CRP11	We demonstrate that only treatment of HaCaT with GLA and  bbbbb1 EPA eeeee1  or a  bbbbb2 PPARgamma eeeee2  ligand (roziglitazone), induced COX-2 expression (protein and mRNA)
CRP11	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of  bbbbb1 AA eeeee1  bbbbb2 PLA2 eeeee2  inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CRP11	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of  bbbbb1 AA eeeee1  bbbbb2 COX-2 eeeee2  induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CRP11	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and  bbbbb1 arachidonic acid eeeee1  mobilization suggesting involvement of AA metabolites in  bbbbb2 PPAR eeeee2  activation
CRP11	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and  bbbbb1 arachidonic acid eeeee1  bbbbb2 PLA2 eeeee2  inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CRP11	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and  bbbbb1 arachidonic acid eeeee1  bbbbb2 COX-2 eeeee2  induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CRP11	Finally, PLA2 inhibitor methyl  bbbbb1 arachidonyl fluorophosphonate eeeee1  blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in  bbbbb2 PPAR eeeee2  activation
CRP11	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the  bbbbb1 PUFA eeeee1  effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in  bbbbb2 PPAR eeeee2  activation
CRP11	Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the  bbbbb1 PUFA eeeee1  bbbbb2 PLA2 eeeee2  inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation
CRP11	These findings demonstrate that n-3 and n- bbbbb1 6 P eeeee1 UFA increased PPARgamma activit bbbbb2 y is  eeeee2 necessary for the COX-2 induction in HaCaT human keratinocyte cells
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and  bbbbb1 arachidic acid eeeee1  a saturated fatty acid, modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and  bbbbb1 arachidic acid eeeee1  a saturated fatty acid, modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid ( bbbbb1 GLA eeeee1 ) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid ( bbbbb1 GLA eeeee1 ) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a  bbbbb1 n-6 PUFA eeeee1 , and arachidic acid a saturated fatty acid, modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a  bbbbb1 n-6 PUFA eeeee1 , and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA,  bbbbb1 gamma-linoleic acid eeeee1  (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA,  bbbbb1 gamma-linoleic acid eeeee1  (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a  bbbbb1 n-3 PUFA eeeee1 , gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a  bbbbb1 n-3 PUFA eeeee1 , gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether  bbbbb1 eicosapentaenoic acid eeeee1  (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether  bbbbb1 eicosapentaenoic acid eeeee1  (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a  bbbbb1 saturated fatty acid eeeee1 , modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a  bbbbb1 saturated fatty acid eeeee1 , modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid ( bbbbb1 EPA eeeee1 ) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), an enzyme pivotal to skin inflammation and reparation
CRP11	We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid ( bbbbb1 EPA eeeee1 ) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 ( bbbbb2 COX-2 eeeee2 ), an enzyme pivotal to skin inflammation and reparation
CRP11	The inhibitory effects of  bbbbb1 GW9662 eeeee1  and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in  bbbbb2 COX-2 eeeee2  induction
CRP11	The inhibitory effects of  bbbbb1 GW9662 eeeee1  and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that  bbbbb2 PPARgamma eeeee2  is implicated in COX-2 induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and  bbbbb1 GLA eeeee1  suggest that PPARgamma is implicated in  bbbbb2 COX-2 eeeee2  induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and  bbbbb1 GLA eeeee1  suggest that  bbbbb2 PPARgamma eeeee2  is implicated in COX-2 induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and  bbbbb1 GLA eeeee1  bbbbb2 COX-2 eeeee2  expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and  bbbbb1 GLA eeeee1  bbbbb2 PPARgamma eeeee2  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CRP11	The inhibitory effects of GW9662 and  bbbbb1 T0070907 eeeee1  (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in  bbbbb2 COX-2 eeeee2  induction
CRP11	The inhibitory effects of GW9662 and  bbbbb1 T0070907 eeeee1  (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that  bbbbb2 PPARgamma eeeee2  is implicated in COX-2 induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by  bbbbb1 EPA eeeee1  and GLA suggest that PPARgamma is implicated in  bbbbb2 COX-2 eeeee2  induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by  bbbbb1 EPA eeeee1  and GLA suggest that  bbbbb2 PPARgamma eeeee2  is implicated in COX-2 induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by  bbbbb1 EPA eeeee1  bbbbb2 COX-2 eeeee2  expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CRP11	The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by  bbbbb1 EPA eeeee1  bbbbb2 PPARgamma eeeee2  antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction
CRP11	To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the  bbbbb1 GABA eeeee1  receptor, was isolated from Caenorhabditis elegans (gab-1, corresponding to the GenBank locus ZC482.1) and coexpressed in Xenopus oocytes with the  bbbbb2 HG1 eeeee2  alleles
CRP11	To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the  bbbbb1 GABA eeeee1  receptor, was isolated from Caenorhabditis elegans (gab-1, corresponding to the  bbbbb2 GenBank locus ZC482.1 eeeee2 ) and coexpressed in Xenopus oocytes with the HG1 alleles
CRP11	To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the  bbbbb1 GABA eeeee1  bbbbb2 GABA receptor eeeee2 , was isolated from Caenorhabditis elegans (gab-1, corresponding to the GenBank locus ZC482.1) and coexpressed in Xenopus oocytes with the HG1 alleles
CRP11	To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the  bbbbb1 GABA eeeee1  receptor, was isolated from Caenorhabditis elegans ( bbbbb2 gab-1 eeeee2 , corresponding to the GenBank locus ZC482.1) and coexpressed in Xenopus oocytes with the HG1 alleles
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes,  bbbbb1 gamma-aminobutyric acid eeeee1  bbbbb2 HG1A eeeee2  allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (GABA)-responsive channels with different sensitivity to the agonist were formed
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes,  bbbbb1 gamma-aminobutyric acid eeeee1  bbbbb2 HG1E eeeee2  allele in Xenopus oocytes, gamma-aminobutyric acid (GABA)-responsive channels with different sensitivity to the agonist were formed
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes,  bbbbb1 gamma-aminobutyric acid eeeee1  bbbbb2 gab-1 eeeee2  was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (GABA)-responsive channels with different sensitivity to the agonist were formed
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes,  bbbbb1 gamma-aminobutyric acid eeeee1  bbbbb2 gamma-aminobutyric acid (GABA)-responsive channels eeeee2  with different sensitivity to the agonist were formed
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid ( bbbbb1 GABA eeeee1  bbbbb2 HG1A eeeee2  allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (GABA)-responsive channels with different sensitivity to the agonist were formed
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid ( bbbbb1 GABA eeeee1  bbbbb2 HG1E eeeee2  allele in Xenopus oocytes, gamma-aminobutyric acid (GABA)-responsive channels with different sensitivity to the agonist were formed
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid ( bbbbb1 GABA eeeee1  bbbbb2 gab-1 eeeee2  was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (GABA)-responsive channels with different sensitivity to the agonist were formed
CRP11	When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid ( bbbbb1 GABA eeeee1  bbbbb2 gamma-aminobutyric acid (GABA)-responsive channels eeeee2  with different sensitivity to the agonist were formed
CRP11	Two alleles of the HG1 gene, which encodes a putative  bbbbb1 GABA eeeee1  bbbbb2 GABA receptor alpha/gamma eeeee2  subunit, were isolated from Haemonchus contortus
CRP11	Two alleles of the HG1 gene, which encodes a putative  bbbbb1 GABA eeeee1  bbbbb2 HG1 eeeee2  gene, which encodes a putative GABA receptor alpha/gamma subunit, were isolated from Haemonchus contortus
CRP11	However, when coapplied with 10 micro m GABA, ivermectin potentia bbbbb1 ted  eeeee1 the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated bbbbb2  the GABA resp eeeee2 onse of the GAB-1/HG1E receptor
CRP11	However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1 bbbbb1 E receptor eeeee1  bbbbb2  iver eeeee2 mectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CRP11	However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1 bbbbb1 E receptor eeeee1  bbbbb2  m  eeeee2 GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CRP11	However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated bbbbb1  the eeeee1  bbbbb2  iver eeeee2 mectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CRP11	However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated bbbbb1  the eeeee1  bbbbb2  m  eeeee2 GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor
CRP11	However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated bbbbb1  the eeeee1  bbbbb2  the GABA resp eeeee2 onse of the GAB-1/HG1E receptor
CRP11	Study of the nematode putative  bbbbb1 GABA eeeee1  bbbbb2 GABA type-A receptor eeeee2  subunits: evidence for modulation by ivermectin
CRP11	In addition, phenoxybenzamine sho bbbbb1 wed little or no eeeee1  calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c bbbbb2  eeeee2 
CRP11	It was saturable, with between 1 and 2 mol of  bbbbb1 phenoxybenzamine eeeee1  bound to 1 mol of  bbbbb2 calmodulin eeeee2 
CRP11	The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and  bbbbb1 clonidine eeeee1  bbbbb2 calmodulin eeeee2  was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions
CRP11	The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as  bbbbb1 prazosin eeeee1  bbbbb2 calmodulin eeeee2  was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions
CRP11	The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin,  bbbbb1 yohimbine eeeee1  bbbbb2 calmodulin eeeee2  was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions
CRP11	The binding of  bbbbb1 phenoxybenzamine eeeee1  to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to  bbbbb2 calmodulin eeeee2  when examined under the same experimental conditions
CRP11	The binding of  bbbbb1 phenoxybenzamine eeeee1  to calmodulin was fairly selective in that other  bbbbb2 alpha-adrenergic eeeee2  agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions
CRP11	To determine the factors that influence the interaction between phenoxybenzamine and calmodulin, the binding of  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 calmodulin eeeee2 , the binding of phenoxybenzamine to calmodulin was determined by equilibrium dialysis under a variety of experimental conditions
CRP11	To determine the factors that influence the interaction between  bbbbb1 phenoxybenzamine eeeee1  and calmodulin, the binding of phenoxybenzamine to  bbbbb2 calmodulin eeeee2  was determined by equilibrium dialysis under a variety of experimental conditions
CRP11	The site at which  bbbbb1 phenoxybenzamine eeeee1  bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to  bbbbb2 calmodulin eeeee2 
CRP11	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 calmodulin eeeee2  appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin
CRP11	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and  bbbbb1 spiroperidol eeeee1  bbbbb2 calmodulin eeeee2  appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin
CRP11	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including  bbbbb1 penfluridol eeeee1  bbbbb2 calmodulin eeeee2  appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin
CRP11	The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol,  bbbbb1 pimozide eeeee1  bbbbb2 calmodulin eeeee2  appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin
CRP11	However, in contrast to the reversible binding of most phenothiazines to calmodulin,  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 calmodulin eeeee2 , phenoxybenzamine bound to calmodulin irreversibly
CRP11	However, in contrast to the reversible binding of most  bbbbb1 phenothiazines eeeee1  to calmodulin, phenoxybenzamine bound to  bbbbb2 calmodulin eeeee2  irreversibly
CRP11	The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor a bbbbb1 gonist 2-th eeeee1 iazolylethylamine and was reduced or blocked by the H1-re bbbbb2 ceptor anta eeeee2 gonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine
CRP11	Histamine enhances the depolarizing afterpotential of immunohistochemically identified  bbbbb1 vasopressin eeeee1  neurons in the rat supraoptic nucleus via  bbbbb2 H1-receptor eeeee2  activation
CRP11	We have identified 3-hydroxypyridin-2-thione ( bbbbb1 3-HPT eeeee1 ) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits HDAC 6 and  bbbbb2 HDAC 8 eeeee2  with an IC50 of 681 and 3675 nM, respectively
CRP11	We have identified 3-hydroxypyridin-2-thione ( bbbbb1 3-HPT eeeee1 ) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits  bbbbb2 HDAC 6 eeeee2  and HDAC 8 with an IC50 of 681 and 3675 nM, respectively
CRP11	We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition.  bbbbb1 3-HPT eeeee1  bbbbb2 HDAC eeeee2  inhibition. 3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively
CRP11	We have identified  bbbbb1 3-hydroxypyridin-2-thione eeeee1  (3-HPT) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits HDAC 6 and  bbbbb2 HDAC 8 eeeee2  with an IC50 of 681 and 3675 nM, respectively
CRP11	We have identified  bbbbb1 3-hydroxypyridin-2-thione eeeee1  (3-HPT) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits  bbbbb2 HDAC 6 eeeee2  and HDAC 8 with an IC50 of 681 and 3675 nM, respectively
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions ( bbbbb1 Cl(-) eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-), Br(-), I(-), NO3(-),  bbbbb1 H2PO4(-) eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-), Br(-),  bbbbb1 I(-) eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate ( bbbbb1 TsO(-) eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-),  bbbbb1 HSO4(-) eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-), Br(-), I(-),  bbbbb1 NO3(-) eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and  bbbbb1 tosylate eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Complexes of mono-, bi- (RB), and tridentate (RT) receptors with a range of anions (Cl(-),  bbbbb1 Br(-) eeeee1  bbbbb2 mono-, bi- (RB), and tridentate (RT) receptors eeeee2  with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods
CRP11	Structure and energetics of gas phase  bbbbb1 halogen eeeee1 -bonding in  bbbbb2 mono-, bi-, and tri-dentate anion receptors eeeee2  as studied by BIRD
CRP11	We demonstrate here that minoxidil is a potent activator of purified PGHS-1 (AC50 = 80 microM), as assayed by  bbbbb1 oxygen eeeee1  bbbbb2 PGHS-1 eeeee2  (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production
CRP11	Activation of cytoprotective  bbbbb1 prostaglandin eeeee1  bbbbb2 prostaglandin synthase-1 eeeee2  by minoxidil as a possible explanation for its hair growth-stimulating effect
CRP11	These NSAIDs are well-known inhibitors of both the cytoprotective isoform of  bbbbb1 prostaglandin eeeee1  endoperoxide synthase-1 ( bbbbb2 PGHS-1 eeeee2 ) and of the inducible form (PGHS-2)
CRP11	These NSAIDs are well-known inhibitors of both the cytoprotective isoform of  bbbbb1 prostaglandin eeeee1  bbbbb2 prostaglandin endoperoxide synthase-1 eeeee2  (PGHS-1) and of the inducible form (PGHS-2)
CRP11	These NSAIDs are well-known inhibitors of both the cytoprotective isoform of  bbbbb1 prostaglandin eeeee1  endoperoxide synthase-1 (PGHS-1) and of the inducible form ( bbbbb2 PGHS-2 eeeee2 )
CRP11	Oxidation with hydrogen peroxide was similarly assessed, and adhesion of lysozyme and fibrinogen from  bbbbb1 phosphate eeeee1  bbbbb2 lysozyme eeeee2  and fibrinogen from phosphate buffered saline was then assayed by QCM and imaged by AFM
CRP11	Oxidation with hydrogen peroxide was similarly assessed, and adhesion of lysozyme and fibrinogen from  bbbbb1 phosphate eeeee1  bbbbb2 fibrinogen eeeee2  from phosphate buffered saline was then assayed by QCM and imaged by AFM
CRP11	 bbbbb1 Tertiary amine eeeee1 -functionalized sensors adsorbed multilayers of aggregated  bbbbb2 lysozyme eeeee2 , whereas tertiary amine N-oxides and triethylene glycol-terminated monolayers are consistent with small protein aggregates
CRP11	BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an  bbbbb1 ATP eeeee1  bbbbb2 ATP binding site eeeee2 
CRP11	BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an  bbbbb1 ATP eeeee1  bbbbb2 BiP eeeee2  is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an ATP binding site
CRP11	BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an  bbbbb1 ATP eeeee1  bbbbb2 heptapeptide sequence eeeee2  and an ATP binding site
CRP11	BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an  bbbbb1 ATP eeeee1  bbbbb2 chaperone protein eeeee2  containing a polypeptide binding site recognizing specific heptapeptide sequence and an ATP binding site
CRP11	 bbbbb1 Aspirin eeeee1  and salicylate bind to immunoglobulin heavy chain binding protein ( bbbbb2 BiP eeeee2 ) and inhibit its ATPase activity in human fibroblasts
CRP11	Aspirin and  bbbbb1 salicylate eeeee1  bind to immunoglobulin heavy chain binding protein ( bbbbb2 BiP eeeee2 ) and inhibit its ATPase activity in human fibroblasts
CRP11	NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  bbbbb1 phosphatidylinositol eeeee1  3-kinase (PI3K)/ bbbbb2 Akt eeeee2 
CRP11	NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3K)/Akt
CRP11	NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  bbbbb1 phosphatidylinositol eeeee1  3-kinase ( bbbbb2 PI3K eeeee2 )/Akt
CRP11	NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 EGF eeeee2 -induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt
CRP11	NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 EGF receptor eeeee2  (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt
CRP11	NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 EGFR eeeee2 ) and phosphatidylinositol 3-kinase (PI3K)/Akt
CRP11	We use EGF as a metastatic inducer of MDA-MB-231 cells to investigate the effect of  bbbbb1 NFD eeeee1  bbbbb2 EGF eeeee2  as a metastatic inducer of MDA-MB-231 cells to investigate the effect of NFD on cell migration and invasion
CRP11	However, TGF-beta1 and high  bbbbb1 D-glucose eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose were ineffective in cells expressing a truncated, negative dominant TbetaRII
CRP11	However, TGF-beta1 and high  bbbbb1 D-glucose eeeee1  were ineffective in cells expressing a truncated, negative dominant  bbbbb2 TbetaRII eeeee2 
CRP11	D-glucose stimulation of L-arginine transport and  bbbbb1 nitric oxide eeeee1  synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional  bbbbb2 type II TGF-beta receptors eeeee2  in human umbilical vein endothelium
CRP11	D-glucose stimulation of L-arginine transport and  bbbbb1 nitric oxide eeeee1  synthesis results from activation of  bbbbb2 mitogen-activated protein kinases p42/44 eeeee2  and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium
CRP11	D-glucose stimulation of L-arginine transport and  bbbbb1 nitric oxide eeeee1  synthesis results from activation of mitogen-activated protein kinases p42/44 and  bbbbb2 Smad2 eeeee2  requiring functional type II TGF-beta receptors in human umbilical vein endothelium
CRP11	 bbbbb1 D-glucose eeeee1  stimulation of L-arginine transport and nitric oxide synthesis results from activation of  bbbbb2 mitogen-activated protein kinases p42/44 eeeee2  and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium
CRP11	D-glucose stimulation of  bbbbb1 L-arginine eeeee1  transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional  bbbbb2 type II TGF-beta receptors eeeee2  in human umbilical vein endothelium
CRP11	D-glucose stimulation of  bbbbb1 L-arginine eeeee1  transport and nitric oxide synthesis results from activation of  bbbbb2 mitogen-activated protein kinases p42/44 eeeee2  and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium
CRP11	D-glucose stimulation of  bbbbb1 L-arginine eeeee1  transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and  bbbbb2 Smad2 eeeee2  requiring functional type II TGF-beta receptors in human umbilical vein endothelium
CRP11	TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by  bbbbb1 PD-98059 eeeee1  ( bbbbb2 MEK1/2 eeeee2  inhibitor)
CRP11	TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by  bbbbb1 PD-98059 eeeee1  bbbbb2 mapk eeeee2 ) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)
CRP11	TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by  bbbbb1 PD-98059 eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)
CRP11	TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by  bbbbb1 PD-98059 eeeee1  bbbbb2 p42/44 eeeee2 (mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 ( bbbbb2 MEK1/2 eeeee2  inhibitor)
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased p42/44( bbbbb2 mapk eeeee2 ) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased  bbbbb2 p42/44 eeeee2 (mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor)
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial  bbbbb1 NO eeeee1  synthase (eNOS) protein abundance, but did not alter  bbbbb2 eNOS eeeee2  phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial  bbbbb1 NO eeeee1  synthase ( bbbbb2 eNOS eeeee2 ) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial  bbbbb1 NO eeeee1  bbbbb2 endothelial NO synthase eeeee2  (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial  bbbbb1 NO eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial  bbbbb1 NO eeeee1  bbbbb2 hCAT-1 eeeee2  mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from  bbbbb1 L-[(3)H]arginine eeeee1  (index of NO synthesis) and endothelial NO synthase ( bbbbb2 eNOS eeeee2 ) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from  bbbbb1 L-[(3)H]arginine eeeee1  (index of NO synthesis) and  bbbbb2 endothelial NO synthase eeeee2  (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from  bbbbb1 L-[(3)H]arginine eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from  bbbbb1 L-[(3)H]arginine eeeee1  bbbbb2 hCAT-1 eeeee2  mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)),  bbbbb1 L-[(3)H]citrulline eeeee1  formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase ( bbbbb2 eNOS eeeee2 ) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)),  bbbbb1 L-[(3)H]citrulline eeeee1  formation from L-[(3)H]arginine (index of NO synthesis) and  bbbbb2 endothelial NO synthase eeeee2  (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)),  bbbbb1 L-[(3)H]citrulline eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)),  bbbbb1 L-[(3)H]citrulline eeeee1  bbbbb2 hCAT-1 eeeee2  mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of  bbbbb1 NO eeeee1  synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter  bbbbb2 eNOS eeeee2  phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of  bbbbb1 NO eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of  bbbbb1 NO eeeee1  bbbbb2 hCAT-1 eeeee2  mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter  bbbbb2 eNOS eeeee2  phosphorylation
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase ( bbbbb2 eNOS eeeee2 ) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and  bbbbb2 endothelial NO synthase eeeee2  (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	TGF-beta1 and high  bbbbb1 D-glucose eeeee1  bbbbb2 TGF-beta1 eeeee2  and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation
CRP11	We studied whether D-glucose-stimulation of L-arginine transport and  bbbbb1 nitric oxide eeeee1  synthesis involves  bbbbb2 TGF-beta1 eeeee2  in primary cultures of HUVEC
CRP11	We studied whether D-glucose-stimulation of  bbbbb1 L-arginine eeeee1  transport and nitric oxide synthesis involves  bbbbb2 TGF-beta1 eeeee2  in primary cultures of HUVEC
CRP11	TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal  bbbbb1 D-glucose eeeee1  bbbbb2 TGF-beta1 eeeee2  increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport
CRP11	TGF-beta1 increases  bbbbb1 L-arginine eeeee1  bbbbb2 TGF-beta1 eeeee2  increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport
CRP11	TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased  bbbbb1 L-arginine eeeee1  bbbbb2 TGF-beta1 eeeee2  increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport
CRP11	TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high  bbbbb1 D-glucose eeeee1  bbbbb2 TGF-beta1 eeeee2  increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport
CRP11	We investigated whether  bbbbb1 ethanol eeeee1  extract of Inula helenium L. (EIH) activates p38 MAPK/ bbbbb2 Nrf2 eeeee2 /HO-1 pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice
CRP11	We investigated whether  bbbbb1 ethanol eeeee1  extract of Inula helenium L. (EIH) activates p38  bbbbb2 MAPK eeeee2 /Nrf2/HO-1 pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice
CRP11	We investigated whether  bbbbb1 ethanol eeeee1  extract of Inula helenium L. (EIH) activates p38 MAPK/Nrf2/ bbbbb2 HO-1 eeeee2  pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice
CRP11	We investigated whether  bbbbb1 ethanol eeeee1  extract of Inula helenium L. (EIH) activates  bbbbb2 p38 eeeee2  MAPK/Nrf2/HO-1 pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice
CRP11	We recently proposed that  bbbbb1 heme eeeee1  oxygenase-1 (HO-1) negatively regulates  bbbbb2 HMGB1 eeeee2  in inflammatory conditions
CRP11	We recently proposed that  bbbbb1 heme eeeee1  bbbbb2 heme oxygenase-1 eeeee2  (HO-1) negatively regulates HMGB1 in inflammatory conditions
CRP11	We recently proposed that  bbbbb1 heme eeeee1  oxygenase-1 ( bbbbb2 HO-1 eeeee2 ) negatively regulates HMGB1 in inflammatory conditions
CRP11	Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by  bbbbb1 ethanol eeeee1  bbbbb2 Nrf2 eeeee2  signaling pathway by ethanol extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice
CRP11	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at  bbbbb1 Ser eeeee1 10, phosphorylation of Cdk1 at Tyr15, expression of  bbbbb2 cyclin B1 eeeee2 , and decreased expression of Cdc25c
CRP11	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at  bbbbb1 Ser eeeee1 10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of  bbbbb2 Cdc25c eeeee2 
CRP11	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at  bbbbb1 Ser eeeee1 10, phosphorylation of  bbbbb2 Cdk1 eeeee2  at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c
CRP11	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at  bbbbb1 Tyr eeeee1 15, expression of  bbbbb2 cyclin B1 eeeee2 , and decreased expression of Cdc25c
CRP11	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at  bbbbb1 Tyr eeeee1 15, expression of cyclin B1, and decreased expression of  bbbbb2 Cdc25c eeeee2 
CRP11	Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at  bbbbb1 Tyr eeeee1  bbbbb2 Histone 3 eeeee2  at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c
CRP11	AD this protective mech bbbbb1 anism seem eeeee1 s to be inefficient, probably due to the presence of high concentrations of 27OHC, mic bbbbb2 rova eeeee2 scular dysfunction and the decreased efficiency of ApoE4 as lipid transporter and Aβ scavenger. 24OHC itself was cytotoxic
CRP11	AD this protective mechanism seems to be inefficient, probably due to the presence of high c bbbbb1 oncentratio eeeee1 ns of 27OHC, mic bbbbb2 rova eeeee2 scular dysfunction and the decreased efficiency of ApoE4 as lipid transporter and Aβ scavenger. 24OHC itself was cytotoxic
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE.  bbbbb1 24OHC eeeee1  bbbbb2 liver X receptor eeeee2  (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE.  bbbbb1 24OHC eeeee1  bbbbb2 LXR eeeee2 ), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE.  bbbbb1 24OHC eeeee1  bbbbb2 ApoE eeeee2 . 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into  bbbbb1 24S-hydroxycholesterol eeeee1  (24OHC) which, via the  bbbbb2 liver X receptor eeeee2  (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into  bbbbb1 24S-hydroxycholesterol eeeee1  (24OHC) which, via the liver X receptor ( bbbbb2 LXR eeeee2 ), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into  bbbbb1 24S-hydroxycholesterol eeeee1  (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte  bbbbb2 ApoE eeeee2 . 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol ( bbbbb1 24OHC eeeee1 ) which, via the  bbbbb2 liver X receptor eeeee2  (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol ( bbbbb1 24OHC eeeee1 ) which, via the liver X receptor ( bbbbb2 LXR eeeee2 ), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol ( bbbbb1 24OHC eeeee1 ) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte  bbbbb2 ApoE eeeee2 . 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain  bbbbb1 cholesterol eeeee1  bbbbb2 liver X receptor eeeee2  (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain  bbbbb1 cholesterol eeeee1  bbbbb2 LXR eeeee2 ), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain  bbbbb1 cholesterol eeeee1  bbbbb2 ApoE eeeee2 . 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific  bbbbb1 cholesterol eeeee1  24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the  bbbbb2 liver X receptor eeeee2  (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific  bbbbb1 cholesterol eeeee1  24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor ( bbbbb2 LXR eeeee2 ), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific  bbbbb1 cholesterol eeeee1  24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte  bbbbb2 ApoE eeeee2 . 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain  bbbbb1 cholesterol eeeee1  into 24S-hydroxycholesterol (24OHC) which, via the  bbbbb2 liver X receptor eeeee2  (LXR), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain  bbbbb1 cholesterol eeeee1  into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor ( bbbbb2 LXR eeeee2 ), can increase the expression and synthesis of astrocyte ApoE. 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	The neurospecific cholesterol 24-hydroxylase converts excess brain  bbbbb1 cholesterol eeeee1  into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte  bbbbb2 ApoE eeeee2 . 24OHC effluxes directly from brain into plasma where it is considered an indicator of brain cholesterol turnover
CRP11	E,  bbbbb1 24OHC eeeee1 ,  bbbbb2 tau eeeee2  and soluble APP were correlated in Alzheimer disease (AD) samples
CRP11	E,  bbbbb1 24OHC eeeee1 , tau and  bbbbb2 soluble APP eeeee2  were correlated in Alzheimer disease (AD) samples
CRP11	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its  bbbbb1 proline eeeee1  hydroxylation and subsequent binding to the  bbbbb2 von Hippel-Lindau protein eeeee2 -Elongin B-Elogin C (VBC) complex
CRP11	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its  bbbbb1 proline eeeee1  hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C ( bbbbb2 VBC eeeee2 ) complex
CRP11	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its  bbbbb1 proline eeeee1  bbbbb2 HIF-1α eeeee2  in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its proline hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex
CRP11	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its  bbbbb1 proline eeeee1  hydroxylation and subsequent binding to the von Hippel-Lindau protein- bbbbb2 Elongin B eeeee2 -Elogin C (VBC) complex
CRP11	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its  bbbbb1 proline eeeee1  hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B- bbbbb2 Elogin C eeeee2  (VBC) complex
CRP11	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its  bbbbb1 proline eeeee1  bbbbb2 vascular endothelial growth factor eeeee2  (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its proline hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex
CRP11	While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its  bbbbb1 proline eeeee1  bbbbb2 VEGF eeeee2 ) mRNA, HIF-1α is degraded under normoxia, which involves its proline hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex
CRP11	Although torafugu PPARs showed a high similarity in the primary structure to other vertebrate counterparts, torafugu PPARalpha2 and gamma contained additional sequences of 21 and 28  bbbbb1 amino acids eeeee1  bbbbb2 Although torafugu PPARs eeeee2  showed a high similarity in the primary structure to other vertebrate counterparts, torafugu PPARalpha2 and gamma contained additional sequences of 21 and 28 amino acids, respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts
CRP11	Although torafugu PPARs showed a high similarity in the primary structure to other vertebrate counterparts, torafugu PPARalpha2 and gamma contained additional sequences of 21 and 28  bbbbb1 amino acids eeeee1  bbbbb2 torafugu PPARalpha2 and gamma eeeee2  contained additional sequences of 21 and 28 amino acids, respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts
CRP11	The activities of torafugu PPARalpha1 and alpha2 were also enhanced 5.6- and 6.3-fold by ETYA at 1 microM, respectively, but not by  bbbbb1 Wy-14643 eeeee1  bbbbb2 PPARalpha1 and alpha2 eeeee2  were also enhanced 5.6- and 6.3-fold by ETYA at 1 microM, respectively, but not by Wy-14643 at this concentration
CRP11	The activities of torafugu PPARalpha1 and alpha2 were also enhanced 5.6- and 6.3-fold by  bbbbb1 ETYA eeeee1  bbbbb2 PPARalpha1 and alpha2 eeeee2  were also enhanced 5.6- and 6.3-fold by ETYA at 1 microM, respectively, but not by Wy-14643 at this concentration
CRP11	On the other hand, the activities of torafugu PPARbeta and gamma were not changed by Wy-14643, ETYA,  bbbbb1 rosiglitazone eeeee1  bbbbb2 torafugu PPARbeta and gamma eeeee2  were not changed by Wy-14643, ETYA, rosiglitazone, nor PUFAs
CRP11	On the other hand, the activities of torafugu PPARbeta and gamma were not changed by Wy-14643,  bbbbb1 ETYA eeeee1  bbbbb2 torafugu PPARbeta and gamma eeeee2  were not changed by Wy-14643, ETYA, rosiglitazone, nor PUFAs
CRP11	On the other hand, the activities of torafugu PPARbeta and gamma were not changed by  bbbbb1 Wy-14643 eeeee1  bbbbb2 torafugu PPARbeta and gamma eeeee2  were not changed by Wy-14643, ETYA, rosiglitazone, nor PUFAs
CRP11	Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the  bbbbb1 acyl-CoA eeeee1  bbbbb2 PPARbeta eeeee2 , and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the acyl-CoA oxidase PPAR response element
CRP11	Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the  bbbbb1 acyl-CoA eeeee1  bbbbb2 peroxisome proliferator-activated receptors eeeee2  (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the acyl-CoA oxidase PPAR response element
CRP11	Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the  bbbbb1 acyl-CoA eeeee1  bbbbb2 PPARalpha2 eeeee2 , PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the acyl-CoA oxidase PPAR response element
CRP11	Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the  bbbbb1 acyl-CoA eeeee1  bbbbb2 PPARalpha1 eeeee2 , PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the acyl-CoA oxidase PPAR response element
CRP11	Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the  bbbbb1 acyl-CoA eeeee1  bbbbb2 PPARs eeeee2 ), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the acyl-CoA oxidase PPAR response element
CRP11	Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the  bbbbb1 acyl-CoA eeeee1  bbbbb2 acyl-CoA oxidase PPAR response element eeeee2 
CRP11	Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the  bbbbb1 acyl-CoA eeeee1  bbbbb2 PPARgamma eeeee2 , from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the acyl-CoA oxidase PPAR response element
CRP11	N mediated antiproliferative activities of  bbbbb1 lenalidomide eeeee1  and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced  bbbbb2 cytokine eeeee2  production in T cells
CRP11	N mediated antiproliferative activities of lenalidomide and  bbbbb1 pomalidomide eeeee1  in myeloma cells, as well as lenalidomide- and pomalidomide-induced  bbbbb2 cytokine eeeee2  production in T cells
CRP11	Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  bbbbb1 pomalidomide eeeee1  bbbbb2 CRBN eeeee2 (YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression
CRP11	Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified  bbbbb1 pomalidomide eeeee1  bbbbb2 CRBN eeeee2  wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression
CRP11	Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not  bbbbb1 thalidomide eeeee1  bbbbb2 CRBN eeeee2  in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA)
CRP11	Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not  bbbbb1 thalidomide eeeee1  bbbbb2 CRBN eeeee2 , but not thalidomide-binding defective CRBN(YW/AA)
CRP11	Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing  bbbbb1 thalidomide eeeee1  bbbbb2 CRBN eeeee2  in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA)
CRP11	Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing  bbbbb1 thalidomide eeeee1 -binding competent wild-type CRBN, but not thalidomide-binding defective  bbbbb2 CRBN eeeee2 (YW/AA)
CRP11	Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and  bbbbb1 F(2)-isoprostane eeeee1  bbbbb2 caspase eeeee2  activity and F(2)-isoprostane production
CRP11	Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and  bbbbb1 F(2)-isoprostane eeeee1  bbbbb2 MAPK eeeee2 ) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CRP11	Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and  bbbbb1 F(2)-isoprostane eeeee1  bbbbb2 p38 eeeee2 (MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CRP11	Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the  bbbbb1 Mn eeeee1  bbbbb2 MAPK eeeee2 ) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CRP11	Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the  bbbbb1 Mn eeeee1  bbbbb2 p38 eeeee2 (MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production
CRP11	Notably, the antioxidant Trolox™ reversed the  bbbbb1 Mn eeeee1  (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced  bbbbb2 caspase eeeee2  activity and F(2)-isoprostane production
CRP11	Mn (10 and 20 mg/kg) increased caspase activity and  bbbbb1 F(2)-isoprostane eeeee1  bbbbb2 caspase eeeee2  activity and F(2)-isoprostane production (a biological marker of lipid peroxidation)
CRP11	Attenuation of increased endocannabinoid signaling with a CB1R neutral antagonist might offer a new therapeutic direction for treatment of  bbbbb1 alcohol eeeee1  bbbbb2 CB1R eeeee2  neutral antagonist might offer a new therapeutic direction for treatment of alcohol abuse
CRP11	Similar to the CB1R antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease oral alcohol self-administration, without affecting total fluid intake and block the development of alcohol-conditioned place preference bbbbb1  eeeee1  bbbbb2 -con eeeee2 ditioned place preference
CRP11	Similar to the CB1R antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease oral alcohol self-administration, without affecting total fluid intake and block the development of alcohol-conditioned place preference bbbbb1  eeeee1  bbbbb2 pmen eeeee2 t of alcohol-conditioned place preference
CRP11	Design, Synthesis and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of  bbbbb1 Alcohol eeeee1  bbbbb2 Cannabinoid Receptor eeeee2  Ligands with Potential for Treatment of Alcohol Abuse
CRP11	We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development of novel  bbbbb1 alcohol eeeee1  bbbbb2 CB1Rs eeeee2  and thus may serve as a promising lead for the development of novel alcohol abuse therapies
CRP11	Catalase, glutathione- bbbbb1 S eeeee1 -transferase and  bbbbb2 xanthine oxidase eeeee2  activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione- bbbbb1 S eeeee1  bbbbb2 Catalase eeeee2 , glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione- bbbbb1 S eeeee1  bbbbb2 glutathione-S-transferase eeeee2  and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and  bbbbb1 xanthine eeeee1  bbbbb2 xanthine oxidase eeeee2  activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and  bbbbb1 xanthine eeeee1  bbbbb2 Catalase eeeee2 , glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and  bbbbb1 xanthine eeeee1  bbbbb2 glutathione-S-transferase eeeee2  and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase,  bbbbb1 glutathione eeeee1 -S-transferase and  bbbbb2 xanthine oxidase eeeee2  activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase,  bbbbb1 glutathione eeeee1  bbbbb2 Catalase eeeee2 , glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase,  bbbbb1 glutathione eeeee1  bbbbb2 glutathione-S-transferase eeeee2  and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein  bbbbb1 carbonyl eeeee1  bbbbb2 xanthine oxidase eeeee2  activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein  bbbbb1 carbonyl eeeee1  bbbbb2 Catalase eeeee2 , glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein  bbbbb1 carbonyl eeeee1  bbbbb2 glutathione-S-transferase eeeee2  and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and  bbbbb1 4-hydroxy-2-nonenal eeeee1  bbbbb2 xanthine oxidase eeeee2  activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and  bbbbb1 4-hydroxy-2-nonenal eeeee1  bbbbb2 Catalase eeeee2 , glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Catalase, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and  bbbbb1 4-hydroxy-2-nonenal eeeee1  bbbbb2 glutathione-S-transferase eeeee2  and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity
CRP11	Statins are inhibitors of the enzyme  bbbbb1 3-hydroxy-3-methylglutaryl coenzyme A eeeee1  bbbbb2 3-hydroxy-3-methylglutaryl coenzyme A reductase eeeee2 , the rate-limiting step in cholesterol biosynthesis
CRP11	We found that  bbbbb1 atorvastatin eeeee1  withdrawal decreased levels of nitric oxide and  bbbbb2 mitochondrial superoxide dismutase eeeee2  activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that  bbbbb1 atorvastatin eeeee1  withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased  bbbbb2 NADPH oxidase eeeee2  activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased  bbbbb1 NADPH eeeee1  bbbbb2 mitochondrial superoxide dismutase eeeee2  activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial  bbbbb1 superoxide eeeee1  bbbbb2 mitochondrial superoxide dismutase eeeee2  activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial  bbbbb1 superoxide eeeee1  dismutase activity, whereas increased  bbbbb2 NADPH oxidase eeeee2  activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker  bbbbb1 3-nitrotyrosine eeeee1  bbbbb2 mitochondrial superoxide dismutase eeeee2  activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that atorvastatin withdrawal decreased levels of  bbbbb1 nitric oxide eeeee1  and  bbbbb2 mitochondrial superoxide dismutase eeeee2  activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	We found that atorvastatin withdrawal decreased levels of  bbbbb1 nitric oxide eeeee1  and mitochondrial superoxide dismutase activity, whereas increased  bbbbb2 NADPH oxidase eeeee2  activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex
CRP11	Immunoprecipitation of mitochondrial SOD followed by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesti bbbbb1 ng th eeeee1 e mechanism underlying bbbbb2  the atorvastatin withdrawal-induc eeeee2 ed decrease in enzyme activity
CRP11	Immunoprecipitation of mitochondrial SOD followed by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesti bbbbb1 ng th eeeee1  bbbbb2 ng the mechan eeeee2 ism underlying the atorvastatin withdrawal-induced decrease in enzyme activity
CRP11	Immunoprecipitation of mitochondrial SOD followed by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesting the mechanism underlying the atorvasta bbbbb1 tin withdr eeeee1  bbbbb2  the atorvastatin withdrawal-induc eeeee2 ed decrease in enzyme activity
CRP11	Immunoprecipitation of mitochondrial SOD followed by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesting the mechanism underlying the atorvasta bbbbb1 tin withdr eeeee1  bbbbb2 ng the mechan eeeee2 ism underlying the atorvastatin withdrawal-induced decrease in enzyme activity
CRP11	Immunoprecipitation of mitochondrial  bbbbb1 SOD followed eeeee1  by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesting the mechanism underlying bbbbb2  the atorvastatin withdrawal-induc eeeee2 ed decrease in enzyme activity
CRP11	Immunoprecipitation of mitochondrial  bbbbb1 SOD followed eeeee1  by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesti bbbbb2 ng the mechan eeeee2 ism underlying the atorvastatin withdrawal-induced decrease in enzyme activity
CRP11	DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS), but the types of damage and signaling responses remain incompletely understood
CRP11	DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of  bbbbb1 thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 ), but the types of damage and signaling responses remain incompletely understood
CRP11	When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to  bbbbb1 raltitrexed eeeee1  (RTX), which specifically inhibits  bbbbb2 TS eeeee2 
CRP11	To our knowledge, this is the first demonstration in mammalian cells that depletion of RAD51 causes sensitivity to  bbbbb1 thymidylate eeeee1  bbbbb2 RAD51 eeeee2  causes sensitivity to thymidylate deprivation
CRP11	Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site  bbbbb1 Tyr eeeee1  bbbbb2 linker domain eeeee2 ), which position the active site Tyr of the C-terminal domain within the catalytic pocket
CRP11	Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the  bbbbb1 C eeeee1  bbbbb2 alpha-helices eeeee2  (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket
CRP11	The structures of  bbbbb1 thymidine eeeee1  bbbbb2 thymidine kinase eeeee2  from herpes simplex virus type 1 in complex with substrates and a substrate analogue
CRP11	 bbbbb1 Ca eeeee1  bbbbb2 Ca eeeee2 vity and water molecules reduce the substrate specificity to such an extent that TK can phosphorylate various substrate analogues useful in pharmaceutical applications
CRP11	 bbbbb1 Ca eeeee1 vity and water molecules reduce the substrate  bbbbb2 specificity to such an extent th eeeee2 at TK can phosphorylate various substrate analogues useful in pharmaceutical applications
CRP11	Cavity and water molecules reduce the substrate  bbbbb1 specificity to such an e eeeee1  bbbbb2 Ca eeeee2 vity and water molecules reduce the substrate specificity to such an extent that TK can phosphorylate various substrate analogues useful in pharmaceutical applications
CRP11	Cavity and water molecules reduce the substrate  bbbbb1 specificity to such an e eeeee1  bbbbb2 specificity to such an extent th eeeee2 at TK can phosphorylate various substrate analogues useful in pharmaceutical applications
CRP11	TK catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an  bbbbb1 anhydride eeeee1  bbbbb2 TK eeeee2  catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride
CRP11	TK catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of  bbbbb1 dTMP eeeee1  bbbbb2 TK eeeee2  catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride
CRP11	TK catalyzes the phosphorylation of  bbbbb1 dT eeeee1  bbbbb2 TK eeeee2  catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride
CRP11	TK catalyzes the phosphorylation of dT resulting in an  bbbbb1 ester eeeee1  bbbbb2 TK eeeee2  catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride
CRP11	 bbbbb1 TK eeeee1  bbbbb2 TK eeeee2  catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride
CRP11	The presented  bbbbb1 TK eeeee1  bbbbb2 TK eeeee2  structures indicate that there are only small differences between these two modes of action
CRP11	The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or  bbbbb1 idoxuridine-5'-phosphate eeeee1  bbbbb2 TK eeeee2  complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CRP11	The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate ( bbbbb1 5-iodo-dUMP eeeee1  bbbbb2 TK eeeee2  complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CRP11	The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine ( bbbbb1 dT eeeee1  bbbbb2 TK eeeee2  complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CRP11	The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate ( bbbbb1 dTMP eeeee1  bbbbb2 TK eeeee2  complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CRP11	The structures of TK complexed with ADP at the ATP-site and  bbbbb1 deoxythymidine-5'-monophosphate eeeee1  bbbbb2 TK eeeee2  complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CRP11	The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP),  bbbbb1 deoxythymidine eeeee1  bbbbb2 TK eeeee2  complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CRP11	The structures of TK complexed with ADP at the  bbbbb1 ATP eeeee1  bbbbb2 TK eeeee2  complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively
CRP11	 bbbbb1 Thymidine eeeee1  kinase from Herpes simplex virus type 1 ( bbbbb2 TK eeeee2 ) was crystallized in an N-terminally truncated but fully active form
CRP11	 bbbbb1 Thymidine eeeee1  bbbbb2 Thymidine kinase eeeee2  from Herpes simplex virus type 1 (TK) was crystallized in an N-terminally truncated but fully active form
CRP11	Three  bbbbb1 retinol eeeee1  dehydrogenases (RDHs) were tested for steroid converting abilities:  bbbbb2 human and murine RDH 12 eeeee2  and human RDH13
CRP11	Three  bbbbb1 retinol eeeee1  bbbbb2 retinol dehydrogenases eeeee2  (RDHs) were tested for steroid converting abilities: human and murine RDH 12 and human RDH13
CRP11	Three  bbbbb1 retinol eeeee1  dehydrogenases (RDHs) were tested for steroid converting abilities: human and murine RDH 12 and  bbbbb2 human RDH13 eeeee2 
CRP11	Three  bbbbb1 retinol eeeee1  dehydrogenases ( bbbbb2 RDHs eeeee2 ) were tested for steroid converting abilities: human and murine RDH 12 and human RDH13
CRP11	H12, a  bbbbb1 retinol eeeee1  bbbbb2 retinol dehydrogenase eeeee2  causing Leber's congenital amaurosis, is also involved in steroid metabolism
CRP11	Isolation and function of the  bbbbb1 amino acid eeeee1  transporter PAT1 (slc36a1) from rabbit and discrimination between transport via PAT1 and  bbbbb2 system IMINO eeeee2  in renal brush-border membrane vesicles
CRP11	Isolation and function of the  bbbbb1 amino acid eeeee1  transporter PAT1 ( bbbbb2 slc36a1 eeeee2 ) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles
CRP11	Isolation and function of the  bbbbb1 amino acid eeeee1  transporter PAT1 (slc36a1) from rabbit and discrimination between transport via  bbbbb2 PAT1 eeeee2  and system IMINO in renal brush-border membrane vesicles
CRP11	Isolation and function of the  bbbbb1 amino acid eeeee1  bbbbb2 amino acid transporter PAT1 eeeee2  (slc36a1) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles
CRP11	The purpose of this investigation was to determine whether this pH-dependent uptake represents H(+)/ bbbbb1 amino acid eeeee1  cotransport via a  bbbbb2 PAT1 eeeee2 -like transport system
CRP11	The purpose of this investigation was to determine whether this pH-dependent uptake represents  bbbbb1 H(+) eeeee1 /amino acid cotransport via a  bbbbb2 PAT1 eeeee2 -like transport system
CRP11	In the presence of Na+ and under conditions in which PAT1 transport function was suppressed, a second proline uptake system was detected th bbbbb1 at exhi eeeee1  bbbbb2 onditions i eeeee2 n which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the IMINO system
CRP11	In the presence of Na+ and under conditions in which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited function bbbbb1 al characteris eeeee1  bbbbb2 onditions i eeeee2 n which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the IMINO system
CRP11	In the presence of Na+ and under conditions in which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibi bbbbb1 ted fun eeeee1  bbbbb2 onditions i eeeee2 n which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the IMINO system
CRP11	The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475  bbbbb1 amino acids eeeee1  bbbbb2 poly(A) tail) eeeee2  and the open reading frame codes for a protein of 475 amino acids (92% identity to human PAT1)
CRP11	The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475  bbbbb1 amino acids eeeee1  bbbbb2 open reading frame eeeee2  codes for a protein of 475 amino acids (92% identity to human PAT1)
CRP11	The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475  bbbbb1 amino acids eeeee1  bbbbb2 rabbit PAT1 eeeee2  cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475 amino acids (92% identity to human PAT1)
CRP11	Based on our previously published work on CXCR4 antagonists, we have synthesized a series of  bbbbb1 aryl sulfonamides eeeee1  bbbbb2 CXCR4 eeeee2  antagonists, we have synthesized a series of aryl sulfonamides that inhibit the CXCR4/CXCL12 interaction
CRP11	The CSN/IRF5 interaction occurred on the carboxyl and  bbbbb1 amino eeeee1  termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce  bbbbb2 IRF5 eeeee2  protein stability
CRP11	The CSN/IRF5 interaction occurred on the carboxyl and  bbbbb1 amino eeeee1  bbbbb2 CSN eeeee2 /IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CRP11	The CSN/IRF5 interaction occurred on the carboxyl and  bbbbb1 amino eeeee1  bbbbb2 IRF5 eeeee2  interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CRP11	The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from  bbbbb1 amino acids eeeee1  bbbbb2 IRF5 eeeee2 ; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CRP11	The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from  bbbbb1 amino acids eeeee1  bbbbb2 CSN eeeee2 /IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CRP11	The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from  bbbbb1 amino acids eeeee1  bbbbb2 IRF5 eeeee2  interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CRP11	The CSN/IRF5 interaction occurred on the  bbbbb1 carboxyl eeeee1  and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce  bbbbb2 IRF5 eeeee2  protein stability
CRP11	The CSN/IRF5 interaction occurred on the  bbbbb1 carboxyl eeeee1  bbbbb2 CSN eeeee2 /IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CRP11	The CSN/IRF5 interaction occurred on the  bbbbb1 carboxyl eeeee1  bbbbb2 IRF5 eeeee2  interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability
CRP11	BG did not show a clastogenic effect, but was anti-clastogenic in both cell lines used, bbbbb1  and at all concentrations teste eeeee1 d (2.5, 5 and 10 microg/mL) in combination with damage inducing agents (methylmethane sulfonate in ce bbbbb2 ll line CHO-k1, and eeeee2  methylmethane sulfonate or 2-aminoanthracene in cell line HTC)
CRP11	BG did not show a clastogenic effect, but was anti-clastogenic in both cell lines used, and at all concentrations tested  bbbbb1 (2.5, eeeee1  5 and 10 microg/mL) in combination with damage inducing agents (methylmethane sulfonate in ce bbbbb2 ll line CHO-k1, and eeeee2  methylmethane sulfonate or 2-aminoanthracene in cell line HTC)
CRP11	Several in vitro studies were conducted to evaluate the effect of  bbbbb1 triclosan eeeee1  on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2,  bbbbb2 5-lipoxygenase eeeee2  and 15-lipoxygenase
CRP11	Several in vitro studies were conducted to evaluate the effect of  bbbbb1 triclosan eeeee1  on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-lipoxygenase and  bbbbb2 15-lipoxygenase eeeee2 
CRP11	Several in vitro studies were conducted to evaluate the effect of  bbbbb1 triclosan eeeee1  on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1,  bbbbb2 cyclo-oxygenase 2 eeeee2 , 5-lipoxygenase and 15-lipoxygenase
CRP11	Several in vitro studies were conducted to evaluate the effect of  bbbbb1 triclosan eeeee1  on 4 primary enzymes of the pathways of arachidonic acid metabolism,  bbbbb2 cyclo-oxygenase 1 eeeee2 , cyclo-oxygenase 2, 5-lipoxygenase and 15-lipoxygenase
CRP11	Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of  bbbbb1 arachidonic acid eeeee1  metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2,  bbbbb2 5-lipoxygenase eeeee2  and 15-lipoxygenase
CRP11	Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of  bbbbb1 arachidonic acid eeeee1  metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-lipoxygenase and  bbbbb2 15-lipoxygenase eeeee2 
CRP11	Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of  bbbbb1 arachidonic acid eeeee1  metabolism, cyclo-oxygenase 1,  bbbbb2 cyclo-oxygenase 2 eeeee2 , 5-lipoxygenase and 15-lipoxygenase
CRP11	Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of  bbbbb1 arachidonic acid eeeee1  metabolism,  bbbbb2 cyclo-oxygenase 1 eeeee2 , cyclo-oxygenase 2, 5-lipoxygenase and 15-lipoxygenase
CRP11	In addition to the effect on ROS,  bbbbb1 puerarin eeeee1  ameliorated MPTP-reduced  bbbbb2 lysosome-associated membrane protein type 2A eeeee2  (Lamp 2A) expression
CRP11	Puerarin administration enhanced glutathione ( bbbbb1 GSH eeeee1 ) activity, glial cell line-derived neurotrophic factor (GDNF) expression and  bbbbb2 PI3K eeeee2 /Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione ( bbbbb1 GSH eeeee1 ) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/ bbbbb2 Akt eeeee2  pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione ( bbbbb1 GSH eeeee1 ) activity, glial cell line-derived neurotrophic factor ( bbbbb2 GDNF eeeee2 ) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione ( bbbbb1 GSH eeeee1 ) activity,  bbbbb2 glial cell line-derived neurotrophic factor eeeee2  (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate  bbbbb1 MPTP eeeee1  bbbbb2 PI3K eeeee2 /Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate  bbbbb1 MPTP eeeee1  bbbbb2 Akt eeeee2  pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate  bbbbb1 MPTP eeeee1  bbbbb2 GDNF eeeee2 ) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate  bbbbb1 MPTP eeeee1  bbbbb2 glial cell line-derived neurotrophic factor eeeee2  (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced  bbbbb1 glutathione eeeee1  (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and  bbbbb2 PI3K eeeee2 /Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced  bbbbb1 glutathione eeeee1  (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/ bbbbb2 Akt eeeee2  pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced  bbbbb1 glutathione eeeee1  (GSH) activity, glial cell line-derived neurotrophic factor ( bbbbb2 GDNF eeeee2 ) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced  bbbbb1 glutathione eeeee1  (GSH) activity,  bbbbb2 glial cell line-derived neurotrophic factor eeeee2  (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive  bbbbb1 oxygen eeeee1  bbbbb2 PI3K eeeee2 /Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive  bbbbb1 oxygen eeeee1  bbbbb2 Akt eeeee2  pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive  bbbbb1 oxygen eeeee1  bbbbb2 GDNF eeeee2 ) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive  bbbbb1 oxygen eeeee1  bbbbb2 glial cell line-derived neurotrophic factor eeeee2  (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice
CRP11	GW572016 radiosensitized EGFR-overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to  bbbbb1 GW572016 eeeee1  bbbbb2 EGFR eeeee2 -overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization
CRP11	 bbbbb1 GW572016 eeeee1  radiosensitized EGFR-overexpressing cell lines, but  bbbbb2 HER2 eeeee2 -overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization
CRP11	In addition it has significant antiinflammatory action bbbbb1  eeeee1  bbbbb2 on eeeee2 
CRP11	In addition it has significant antiinflammatory action bbbbb1  eeeee1  bbbbb2 ammatory eeeee2  action
CRP11	In addition it has significant antiinflammatory action bbbbb1  eeeee1  bbbbb2 ddition it has significant antiinf eeeee2 lammatory action
CRP11	Conversely, Sult1a1, 2a1/2, and 3a1 mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of  bbbbb1 acetaminophen eeeee1  bbbbb2 Sult1a1, 2a1/2, and 3a1 eeeee2  mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of acetaminophen in liver S9 fractions
CRP11	 bbbbb1 Androgen eeeee1  receptor ( bbbbb2 AR eeeee2 ) signaling is essential for prostate cancer (PCa) development in humans
CRP11	 bbbbb1 Androgen eeeee1  bbbbb2 Androgen receptor eeeee2  (AR) signaling is essential for prostate cancer (PCa) development in humans
CRP11	Overexpression of p14ARF in PCa cells significantly attenuates the activities of  bbbbb1 androgen eeeee1  response region (ARR2)- bbbbb2 probasin and prostate-specific antigen (PSA) promoters eeeee2 
CRP11	Overexpression of p14ARF in PCa cells significantly attenuates the activities of  bbbbb1 androgen eeeee1  response region ( bbbbb2 ARR2 eeeee2 )-probasin and prostate-specific antigen (PSA) promoters
CRP11	Overexpression of p14ARF in PCa cells significantly attenuates the activities of  bbbbb1 androgen eeeee1  bbbbb2 androgen response region eeeee2  (ARR2)-probasin and prostate-specific antigen (PSA) promoters
CRP11	Overexpression of p14ARF in PCa cells significantly attenuates the activities of  bbbbb1 androgen eeeee1  bbbbb2 p14ARF eeeee2  in PCa cells significantly attenuates the activities of androgen response region (ARR2)-probasin and prostate-specific antigen (PSA) promoters
CRP11	F represses  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  transactivation in prostate cancer
CRP11	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1 -terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of  bbbbb2 p14ARF eeeee2  and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1 -terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of  bbbbb2 AR eeeee2 
CRP11	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1 -terminal domain and the ligand-binding domain of AR, and the  bbbbb2 human double minute 2 (HDM2)-binding motif eeeee2  of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1 -terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and  bbbbb2 AR eeeee2  proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1 -terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of  bbbbb2 p14ARF eeeee2  is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1  bbbbb2 p14ARF eeeee2  binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the  bbbbb1 N eeeee1 -terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins.  bbbbb2 p14ARF eeeee2  perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  bbbbb2 p14ARF eeeee2  and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  bbbbb2 human double minute 2 (HDM2)-binding motif eeeee2  of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  bbbbb2 AR eeeee2 , and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  bbbbb2 AR eeeee2  proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  bbbbb2 p14ARF eeeee2  is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  bbbbb2 p14ARF eeeee2  binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the  bbbbb1 N eeeee1  bbbbb2 p14ARF eeeee2  perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  bbbbb2 p14ARF eeeee2  and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  bbbbb2 human double minute 2 (HDM2)-binding motif eeeee2  of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  bbbbb2 AR eeeee2 , and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  bbbbb2 AR eeeee2  proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  bbbbb2 p14ARF eeeee2  is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  bbbbb2 p14ARF eeeee2  binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and  bbbbb1 C eeeee1  bbbbb2 p14ARF eeeee2  perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1  bbbbb2 p14ARF eeeee2  and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1  bbbbb2 human double minute 2 (HDM2)-binding motif eeeee2  of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2 , and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2  proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1  bbbbb2 p14ARF eeeee2  is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1  bbbbb2 p14ARF eeeee2  binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the  bbbbb1 androgen eeeee1  bbbbb2 p14ARF eeeee2  perturbs the androgen-induced interaction between the N terminus and C terminus of AR
CRP11	Here, we provide evidence that p14ARF physically interacts with AR and functions as an AR corespressor in both an  bbbbb1 androgen eeeee1  bbbbb2 p14ARF eeeee2  physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner
CRP11	Here, we provide evidence that p14ARF physically interacts with AR and functions as an AR corespressor in both an  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2  and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner
CRP11	Here, we provide evidence that p14ARF physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and  bbbbb1 androgen eeeee1  bbbbb2 p14ARF eeeee2  physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner
CRP11	Here, we provide evidence that p14ARF physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2  and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner
CRP11	With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of human dihydroorotate dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM) bbbbb1  eeeee1  bbbbb2 human dihydroorotate dehydrogenase eeeee2  (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM)
CRP11	With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of human dihydroorotate dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM) bbbbb1  eeeee1  bbbbb2 human dihydroorotate dehydrogenase eeeee2  (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM)
CRP11	With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of human  bbbbb1 dihydroorotate eeeee1  bbbbb2 human dihydroorotate dehydrogenase eeeee2  (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM)
CRP11	Kinetics of inhibition of human and rat  bbbbb1 dihydroorotate eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid
CRP11	Mitochondrially-bound  bbbbb1 dihydroorotate eeeee1  dehydrogenase ( bbbbb2 EC 1.3.99.11 eeeee2 ) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate
CRP11	Mitochondrially-bound  bbbbb1 dihydroorotate eeeee1  bbbbb2 dihydroorotate dehydrogenase eeeee2  (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate
CRP11	Here, we describe a study of the inhibition of the purified recombinant human and rat dihydroorotate dehydrogenase by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and  bbbbb1 polyporic acid eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity
CRP11	Here, we describe a study of the inhibition of the purified recombinant human and rat dihydroorotate dehydrogenase by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid ( bbbbb1 quinone eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity
CRP11	Here, we describe a study of the inhibition of the purified recombinant human and rat dihydroorotate dehydrogenase by ten compounds. 1,4-Naphthoquinone,  bbbbb1 5,8-hydroxy-naphthoquinone eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity
CRP11	Here, we describe a study of the inhibition of the purified recombinant human and rat  bbbbb1 dihydroorotate eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity
CRP11	Here, we describe a study of the inhibition of the purified recombinant human and rat dihydroorotate dehydrogenase by ten compounds.  bbbbb1 1,4-Naphthoquinone eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity
CRP11	Here, we describe a study of the inhibition of the purified recombinant human and rat dihydroorotate dehydrogenase by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds  bbbbb1 juglon eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity
CRP11	Here, we describe a study of the inhibition of the purified recombinant human and rat dihydroorotate dehydrogenase by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon,  bbbbb1 plumbagin eeeee1  bbbbb2 human and rat dihydroorotate dehydrogenase eeeee2  by ten compounds. 1,4-Naphthoquinone, 5,8-hydroxy-naphthoquinone and the natural compounds juglon, plumbagin and polyporic acid (quinone derivative) were found to function as alternative electron acceptors with 10-30% of control enzyme activity
CRP11	Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human  bbbbb1 dihydroorotate eeeee1  bbbbb2 human dihydroorotate dehydrogenase eeeee2  [W
CRP11	Despite this broad spectrum of biological and clinical relevance, there have been no comparative studies on drug- bbbbb1 dihydroorotate eeeee1  bbbbb2 dihydroorotate dehydrogenase eeeee2  interactions
CRP11	Dichloroally]-lawsone was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for mammalian  bbbbb1 dihydroorotate eeeee1  bbbbb2 mammalian dihydroorotate dehydrogenases eeeee2 
CRP11	Loffler, Species-related inhibition of human and rat  bbbbb1 dihyroorotate eeeee1  bbbbb2 human and rat dihyroorotate dehydrogenase eeeee2  by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem
CRP11	With respect to the quinone co-substrate of the  bbbbb1 dihydroorotate eeeee1  bbbbb2 dihydroorotate dehydrogenase eeeee2 , atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase
CRP11	With respect to the quinone co-substrate of the  bbbbb1 dihydroorotate eeeee1  dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of  bbbbb2 human dihydroorotate dehydrogenase eeeee2 
CRP11	With respect to the  bbbbb1 quinone eeeee1  co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of  bbbbb2 human dihydroorotate dehydrogenase eeeee2 
CRP11	With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human  bbbbb1 dihydroorotate eeeee1  bbbbb2 dihydroorotate dehydrogenase eeeee2 , atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase
CRP11	With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human  bbbbb1 dihydroorotate eeeee1  bbbbb2 human dihydroorotate dehydrogenase eeeee2 
CRP11	With respect to the quinone co-substrate of the dihydroorotate dehydrogenase,  bbbbb1 atovaquone eeeee1  bbbbb2 dihydroorotate dehydrogenase eeeee2 , atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase
CRP11	With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and  bbbbb1 dichloroally-lawsone eeeee1  bbbbb2 dihydroorotate dehydrogenase eeeee2 , atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase
CRP11	The PAO inhibitor,  bbbbb1 MDL-72,527 eeeee1 , only partially blocked oxidation of spermine while a previously reported  bbbbb2 PAO eeeee2  substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction
CRP11	The PAO inhibitor, MDL-72,527, only partially blocked oxidation of  bbbbb1 spermine eeeee1  while a previously reported  bbbbb2 PAO eeeee2  substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction
CRP11	The PAO inhibitor, MDL-72,527, only partially blocked oxidation of  bbbbb1 spermine eeeee1  bbbbb2 PAO eeeee2  inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction
CRP11	The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate,  bbbbb1 N (1)-( n -octanesulphonyl)spermine eeeee1  bbbbb2 PAO eeeee2  inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction
CRP11	Identification and characterization of a novel flavin-containing  bbbbb1 spermine eeeee1  bbbbb2 spermine oxidase eeeee2  of mammalian cell origin
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/ bbbbb1 spermine eeeee1  N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb2 PAO eeeee2 ) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/ bbbbb1 spermine eeeee1  N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb2 polyamine oxidase eeeee2  (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/ bbbbb1 spermine eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/ bbbbb1 spermine eeeee1  N(1)-acetyltransferase ( bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and  bbbbb1 spermidine eeeee1  are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb2 PAO eeeee2 ) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and  bbbbb1 spermidine eeeee1  are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb2 polyamine oxidase eeeee2  (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and  bbbbb1 putrescine eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and  bbbbb1 putrescine eeeee1  bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb1 polyamine eeeee1  oxidase ( bbbbb2 PAO eeeee2 ) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb1 polyamine eeeee1  bbbbb2 polyamine oxidase eeeee2  (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb1 polyamine eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb1 polyamine eeeee1  bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by  bbbbb1 spermidine eeeee1 /spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb2 PAO eeeee2 ) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by  bbbbb1 spermidine eeeee1 /spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb2 polyamine oxidase eeeee2  (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by  bbbbb1 spermidine eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by  bbbbb1 spermidine eeeee1 /spermine N(1)-acetyltransferase ( bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine  bbbbb1 N eeeee1 (1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb2 PAO eeeee2 ) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine  bbbbb1 N eeeee1 (1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb2 polyamine oxidase eeeee2  (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine  bbbbb1 N eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine  bbbbb1 N eeeee1 (1)-acetyltransferase ( bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism,  bbbbb1 spermine eeeee1  and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb2 PAO eeeee2 ) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism,  bbbbb1 spermine eeeee1  and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb2 polyamine oxidase eeeee2  (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce  bbbbb1 spermidine eeeee1  bbbbb2 spermidine/spermine N(1)-acetyltransferase eeeee2  (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce  bbbbb1 spermidine eeeee1  bbbbb2 SSAT eeeee2 ) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively
CRP11	During  bbbbb1 polyamine eeeee1  catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase ( bbbbb2 PAO eeeee2 ) to produce spermidine and putrescine, respectively
CRP11	During  bbbbb1 polyamine eeeee1  catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by  bbbbb2 polyamine oxidase eeeee2  (PAO) to produce spermidine and putrescine, respectively
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine,  bbbbb1 spermidine eeeee1  or the preferred  bbbbb2 PAO eeeee2  substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine,  bbbbb1 spermidine eeeee1  bbbbb2 oxidase eeeee2 -transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured  bbbbb1 spermine eeeee1  over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred  bbbbb2 PAO eeeee2  substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured  bbbbb1 spermine eeeee1  bbbbb2 oxidase eeeee2 -transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over  bbbbb1 N (1)-acetylspermine eeeee1  and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred  bbbbb2 PAO eeeee2  substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over  bbbbb1 N (1)-acetylspermine eeeee1  bbbbb2 oxidase eeeee2 -transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate,  bbbbb1 N (1), N (12)-diacetylspermine eeeee1  bbbbb2 oxidase eeeee2  strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate,  bbbbb1 N (1), N (12)-diacetylspermine eeeee1  bbbbb2 oxidase eeeee2 -transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on  bbbbb1 N (1)-acetylspermidine eeeee1 , spermidine or the preferred  bbbbb2 PAO eeeee2  substrate, N (1), N (12)-diacetylspermine
CRP11	Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on  bbbbb1 N (1)-acetylspermidine eeeee1  bbbbb2 oxidase eeeee2 -transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release ( bbbbb1 sulfonylureas eeeee1 , glinides), or target the peroxisome proliferator-activated receptor ( bbbbb2 PPARgamma eeeee2 ) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release ( bbbbb1 sulfonylureas eeeee1 , glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving  bbbbb2 insulin eeeee2  resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release ( bbbbb1 sulfonylureas eeeee1 , glinides), or target the  bbbbb2 peroxisome proliferator-activated receptor eeeee2  (PPARgamma) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance ( bbbbb1 thiazolidinediones eeeee1  bbbbb2 insulin eeeee2  release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance ( bbbbb1 thiazolidinediones eeeee1  bbbbb2 insulin eeeee2  resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance ( bbbbb1 thiazolidinediones eeeee1  bbbbb2 sulfonylurea receptor eeeee2  stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the  bbbbb1 sulfonylurea eeeee1  receptor stimulating  bbbbb2 insulin eeeee2  release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the  bbbbb1 sulfonylurea eeeee1  receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor ( bbbbb2 PPARgamma eeeee2 ) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the  bbbbb1 sulfonylurea eeeee1  receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving  bbbbb2 insulin eeeee2  resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the  bbbbb1 sulfonylurea eeeee1  receptor stimulating insulin release (sulfonylureas, glinides), or target the  bbbbb2 peroxisome proliferator-activated receptor eeeee2  (PPARgamma) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the  bbbbb1 sulfonylurea eeeee1  bbbbb2 sulfonylurea receptor eeeee2  stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas,  bbbbb1 glinides eeeee1 ), or target the peroxisome proliferator-activated receptor ( bbbbb2 PPARgamma eeeee2 ) improving insulin resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas,  bbbbb1 glinides eeeee1 ), or target the peroxisome proliferator-activated receptor (PPARgamma) improving  bbbbb2 insulin eeeee2  resistance (thiazolidinediones)
CRP11	Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas,  bbbbb1 glinides eeeee1 ), or target the  bbbbb2 peroxisome proliferator-activated receptor eeeee2  (PPARgamma) improving insulin resistance (thiazolidinediones)
CRP11	This dual mode of action of sulfonylureas and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the  bbbbb1 sulfonylurea eeeee1  bbbbb2 sulfonylurea receptor eeeee2  and PPARgamma
CRP11	This dual mode of action of sulfonylureas and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the  bbbbb1 sulfonylurea eeeee1  receptor and  bbbbb2 PPARgamma eeeee2 
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and  bbbbb1 ATP eeeee1 -dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by  bbbbb2 purinergic receptor eeeee2  blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and  bbbbb1 ATP eeeee1 -dependent 2-NBDG uptake were inhibited by  bbbbb2 adenosine-phosphate phosphatase eeeee2  and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and  bbbbb1 ATP eeeee1  bbbbb2 insulin eeeee2  each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent  bbbbb1 2-NBD-Glucose eeeee1  (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by  bbbbb2 purinergic receptor eeeee2  blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent  bbbbb1 2-NBD-Glucose eeeee1  (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  bbbbb2 adenosine-phosphate phosphatase eeeee2  and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent  bbbbb1 2-NBD-Glucose eeeee1  bbbbb2 insulin eeeee2  each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose ( bbbbb1 2-NBDG eeeee1 ) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by  bbbbb2 purinergic receptor eeeee2  blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose ( bbbbb1 2-NBDG eeeee1 ) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  bbbbb2 adenosine-phosphate phosphatase eeeee2  and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose ( bbbbb1 2-NBDG eeeee1  bbbbb2 insulin eeeee2  each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  bbbbb1 adenosine-phosphate eeeee1  phosphatase and by  bbbbb2 purinergic receptor eeeee2  blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  bbbbb1 adenosine-phosphate eeeee1  bbbbb2 adenosine-phosphate phosphatase eeeee2  and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  bbbbb1 adenosine-phosphate eeeee1  bbbbb2 insulin eeeee2  each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation,  bbbbb1 ATP eeeee1 , and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by  bbbbb2 purinergic receptor eeeee2  blockade (suramin)
CRP11	Electrical stimulation,  bbbbb1 ATP eeeee1 , and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by  bbbbb2 adenosine-phosphate phosphatase eeeee2  and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation,  bbbbb1 ATP eeeee1 , and  bbbbb2 insulin eeeee2  each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade ( bbbbb1 suramin eeeee1  bbbbb2 insulin eeeee2  each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent  bbbbb1 2-NBDG eeeee1  uptake were inhibited by adenosine-phosphate phosphatase and by  bbbbb2 purinergic receptor eeeee2  blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent  bbbbb1 2-NBDG eeeee1  uptake were inhibited by  bbbbb2 adenosine-phosphate phosphatase eeeee2  and by purinergic receptor blockade (suramin)
CRP11	Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent  bbbbb1 2-NBDG eeeee1  bbbbb2 insulin eeeee2  each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin)
CRP11	ATP is released from skeletal muscle by contractile activity and can autocrinely signal through purinergic receptors, and we hypothesized it may influence  bbbbb1 glucose eeeee1  bbbbb2 purinergic receptors eeeee2 , and we hypothesized it may influence glucose uptake
CRP11	Skeletal muscle  bbbbb1 glucose eeeee1  uptake in response to exercise is preserved in  bbbbb2 insulin eeeee2 -resistant conditions, but the signals involved are debated
CRP11	ATP stimula bbbbb1 ted eeeee1  2-NBDG uptake in normal and insulin-resi bbbbb2 stant a eeeee2 dult muscle fibers, resembling the reported effect of exercise
CRP11	 bbbbb1 ATP eeeee1  caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or  bbbbb2 PI3Kγ eeeee2  kinase-dead mutants, and potentiated by myristoylated PI3Kγ
CRP11	 bbbbb1 ATP eeeee1  caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving  bbbbb2 AS160 eeeee2 /Rab8A reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ
CRP11	 bbbbb1 ATP eeeee1  caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/ bbbbb2 Rab8A eeeee2  reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ
CRP11	 bbbbb1 ATP eeeee1  caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative  bbbbb2 Akt eeeee2  or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ
CRP11	 bbbbb1 ATP eeeee1  caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3Kγ  bbbbb2 kinase eeeee2 -dead mutants, and potentiated by myristoylated PI3Kγ
CRP11	 bbbbb1 ATP eeeee1  caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by  bbbbb2 myristoylated PI3Kγ eeeee2 
CRP11	ATP-dependent  bbbbb1 2-NBDG eeeee1  uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the  bbbbb2 phosphatidylinositol 3-kinase-γ eeeee2  (PI3Kγ) inhibitor AS605240
CRP11	ATP-dependent  bbbbb1 2-NBDG eeeee1  uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ ( bbbbb2 PI3Kγ eeeee2 ) inhibitor AS605240
CRP11	ATP-dependent  bbbbb1 2-NBDG eeeee1  uptake was also inhibited by the  bbbbb2 G protein βγ eeeee2  subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor AS605240
CRP11	ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor  bbbbb1 AS605240 eeeee1  bbbbb2 G protein βγ eeeee2  subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor AS605240
CRP11	 bbbbb1 ATP eeeee1 -dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the  bbbbb2 phosphatidylinositol 3-kinase-γ eeeee2  (PI3Kγ) inhibitor AS605240
CRP11	 bbbbb1 ATP eeeee1 -dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ ( bbbbb2 PI3Kγ eeeee2 ) inhibitor AS605240
CRP11	 bbbbb1 ATP eeeee1 -dependent 2-NBDG uptake was also inhibited by the  bbbbb2 G protein βγ eeeee2  subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor AS605240
CRP11	Electrical Stimuli Release ATP to Increase GLUT4 Translocation and  bbbbb1 Glucose eeeee1  Uptake via  bbbbb2 PI3Kγ eeeee2 -Akt-AS160 in Skeletal Muscle Cells
CRP11	Electrical Stimuli Release ATP to Increase GLUT4 Translocation and  bbbbb1 Glucose eeeee1  Uptake via PI3Kγ-Akt- bbbbb2 AS160 eeeee2  in Skeletal Muscle Cells
CRP11	Electrical Stimuli Release ATP to Increase GLUT4 Translocation and  bbbbb1 Glucose eeeee1  Uptake via PI3Kγ- bbbbb2 Akt eeeee2 -AS160 in Skeletal Muscle Cells
CRP11	Electrical stimulation transiently elevated extracellular ATP and caused Akt phosphorylation that was additive to insulin and inhibited by  bbbbb1 suramin eeeee1  bbbbb2 insulin eeeee2  and inhibited by suramin
CRP11	Electrical stimulation transiently elevated extracellular  bbbbb1 ATP eeeee1  and caused Akt phosphorylation that was additive to  bbbbb2 insulin eeeee2  and inhibited by suramin
CRP11	Electrical stimulation transiently elevated extracellular  bbbbb1 ATP eeeee1  and caused  bbbbb2 Akt eeeee2  phosphorylation that was additive to insulin and inhibited by suramin
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced  bbbbb1 ATP eeeee1  bbbbb2 Akt eeeee2  as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced  bbbbb1 ATP eeeee1  bbbbb2 PI3K eeeee2 ) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced  bbbbb1 ATP eeeee1 -dependent 2-NBDG uptake and  bbbbb2 Akt eeeee2  phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced  bbbbb1 ATP eeeee1  bbbbb2 Akt eeeee2  and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced  bbbbb1 ATP eeeee1  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced  bbbbb1 ATP eeeee1  bbbbb2 Akt eeeee2  mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent  bbbbb1 2-NBDG eeeee1  bbbbb2 Akt eeeee2  as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent  bbbbb1 2-NBDG eeeee1  bbbbb2 PI3K eeeee2 ) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent  bbbbb1 2-NBDG eeeee1  uptake and  bbbbb2 Akt eeeee2  phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent  bbbbb1 2-NBDG eeeee1  bbbbb2 Akt eeeee2  and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent  bbbbb1 2-NBDG eeeee1  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent  bbbbb1 2-NBDG eeeee1  bbbbb2 Akt eeeee2  mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous  bbbbb1 ATP eeeee1  transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or  bbbbb2 Akt eeeee2  as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous  bbbbb1 ATP eeeee1  transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase ( bbbbb2 PI3K eeeee2 ) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous  bbbbb1 ATP eeeee1  transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and  bbbbb2 Akt eeeee2  phosphorylation
CRP11	Exogenous  bbbbb1 ATP eeeee1  transiently activated Akt and, inhibiting  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	Exogenous  bbbbb1 ATP eeeee1  transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative  bbbbb2 Akt eeeee2  mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the  bbbbb1 DA eeeee1  transporter (DAT) and the vesicular monoamine transporter ( bbbbb2 VMAT2 eeeee2 ) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the  bbbbb1 DA eeeee1  bbbbb2 DA transporter eeeee2  (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the  bbbbb1 DA eeeee1  transporter (DAT) and the  bbbbb2 vesicular monoamine transporter eeeee2  (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the  bbbbb1 DA eeeee1  transporter ( bbbbb2 DAT eeeee2 ) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic  bbbbb1 cocaine eeeee1  bbbbb2 VMAT2 eeeee2 ) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic  bbbbb1 cocaine eeeee1  bbbbb2 DA transporter eeeee2  (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic  bbbbb1 cocaine eeeee1  bbbbb2 vesicular monoamine transporter eeeee2  (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic  bbbbb1 cocaine eeeee1  bbbbb2 DAT eeeee2 ) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of  bbbbb1 DA eeeee1 , as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter ( bbbbb2 VMAT2 eeeee2 ) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of  bbbbb1 DA eeeee1 , as well as two DA nerve terminal indices, namely, the  bbbbb2 DA transporter eeeee2  (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of  bbbbb1 DA eeeee1 , as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the  bbbbb2 vesicular monoamine transporter eeeee2  (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of  bbbbb1 DA eeeee1 , as well as two DA nerve terminal indices, namely, the DA transporter ( bbbbb2 DAT eeeee2 ) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two  bbbbb1 DA eeeee1  nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter ( bbbbb2 VMAT2 eeeee2 ) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two  bbbbb1 DA eeeee1  nerve terminal indices, namely, the  bbbbb2 DA transporter eeeee2  (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two  bbbbb1 DA eeeee1  nerve terminal indices, namely, the DA transporter (DAT) and the  bbbbb2 vesicular monoamine transporter eeeee2  (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two  bbbbb1 DA eeeee1  nerve terminal indices, namely, the DA transporter ( bbbbb2 DAT eeeee2 ) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular  bbbbb1 monoamine eeeee1  transporter ( bbbbb2 VMAT2 eeeee2 ) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular  bbbbb1 monoamine eeeee1  bbbbb2 DA transporter eeeee2  (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular  bbbbb1 monoamine eeeee1  bbbbb2 vesicular monoamine transporter eeeee2  (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular  bbbbb1 monoamine eeeee1  bbbbb2 DAT eeeee2 ) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users
CRP11	Striatal  bbbbb1 dopamine eeeee1 ,  bbbbb2 dopamine transporter eeeee2 , and vesicular monoamine transporter in chronic cocaine users
CRP11	Striatal  bbbbb1 dopamine eeeee1 , dopamine transporter, and  bbbbb2 vesicular monoamine transporter eeeee2  in chronic cocaine users
CRP11	Striatal dopamine, dopamine transporter, and vesicular  bbbbb1 monoamine eeeee1  bbbbb2 dopamine transporter eeeee2 , and vesicular monoamine transporter in chronic cocaine users
CRP11	Striatal dopamine, dopamine transporter, and vesicular  bbbbb1 monoamine eeeee1  bbbbb2 vesicular monoamine transporter eeeee2  in chronic cocaine users
CRP11	Striatal dopamine,  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2 , and vesicular monoamine transporter in chronic cocaine users
CRP11	Striatal dopamine,  bbbbb1 dopamine eeeee1  transporter, and  bbbbb2 vesicular monoamine transporter eeeee2  in chronic cocaine users
CRP11	Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic  bbbbb1 cocaine eeeee1  bbbbb2 dopamine transporter eeeee2 , and vesicular monoamine transporter in chronic cocaine users
CRP11	Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic  bbbbb1 cocaine eeeee1  bbbbb2 vesicular monoamine transporter eeeee2  in chronic cocaine users
CRP11	Striatal DAT protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas DAT determined by [3H]WIN 35,42 bbbbb1 8  eeeee1 binding w bbbbb2 as normal eeeee2 
CRP11	Striatal DAT protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas DAT determined by [3H]WIN 35,428 binding w bbbbb1 as eeeee1  bbbbb2 as normal eeeee2 
CRP11	IVE: Mitiglinide, a rapid- and short-acting insulinotropic  bbbbb1 sulfonylurea eeeee1  bbbbb2 sulfonylurea receptor eeeee2  ligand, exhibits hypoglycemic action unlike other sulfonylureas
CRP11	Mitiglinide reduced fasting plasma  bbbbb1 glucose eeeee1  and  bbbbb2 GA eeeee2  levels after 4 weeks and Hb(A1c) levels after 8 weeks
CRP11	Mitiglinide reduced fasting plasma  bbbbb1 glucose eeeee1  and GA levels after 4 weeks and  bbbbb2 Hb(A1c) eeeee2  levels after 8 weeks
CRP11	The efficacy of the treatment was determined by monitoring plasma  bbbbb1 glucose eeeee1 , hemoglobin A1c (Hb(A1c)), and glycated albumin ( bbbbb2 GA eeeee2 ) levels and using homeostasis model assessment of insulin resistance (HOMA-IR)
CRP11	The efficacy of the treatment was determined by monitoring plasma  bbbbb1 glucose eeeee1 ,  bbbbb2 hemoglobin A1c eeeee2  (Hb(A1c)), and glycated albumin (GA) levels and using homeostasis model assessment of insulin resistance (HOMA-IR)
CRP11	The efficacy of the treatment was determined by monitoring plasma  bbbbb1 glucose eeeee1 , hemoglobin A1c ( bbbbb2 Hb(A1c) eeeee2 ), and glycated albumin (GA) levels and using homeostasis model assessment of insulin resistance (HOMA-IR)
CRP11	The efficacy of the treatment was determined by monitoring plasma  bbbbb1 glucose eeeee1 , hemoglobin A1c (Hb(A1c)), and glycated albumin (GA) levels and using homeostasis model assessment of  bbbbb2 insulin eeeee2  resistance (HOMA-IR)
CRP11	The efficacy of the treatment was determined by monitoring plasma  bbbbb1 glucose eeeee1 , hemoglobin A1c (Hb(A1c)), and  bbbbb2 glycated albumin eeeee2  (GA) levels and using homeostasis model assessment of insulin resistance (HOMA-IR)
CRP11	Activity-dependent cleavage of brain  bbbbb1 glutamic acid eeeee1  bbbbb2 glutamic acid decarboxylase 65 eeeee2  by calpain
CRP11	Activity-dependent cleavage of brain  bbbbb1 glutamic acid eeeee1  decarboxylase 65 by  bbbbb2 calpain eeeee2 
CRP11	 bbbbb1 Calcium eeeee1 -chelating reagents such as EDTA and 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester prevented the cleavage of  bbbbb2 GAD65 eeeee2 
CRP11	Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the  bbbbb1 N eeeee1  bbbbb2 l-glutamic acid decarboxylase isoform 65 eeeee2  (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69)
CRP11	Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the  bbbbb1 N eeeee1  bbbbb2 GAD65 eeeee2 ) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69)
CRP11	Previously, we reported that  bbbbb1 l-glutamic acid eeeee1  bbbbb2 l-glutamic acid decarboxylase isoform 65 eeeee2  (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69)
CRP11	Previously, we reported that  bbbbb1 l-glutamic acid eeeee1  decarboxylase isoform 65 ( bbbbb2 GAD65 eeeee2 ) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69)
CRP11	Previously, we reported that  bbbbb1 l-glutamic acid eeeee1  decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus,  bbbbb2 GAD65(Delta1-69) eeeee2 
CRP11	Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks  bbbbb1 amino acid eeeee1  bbbbb2 l-glutamic acid decarboxylase isoform 65 eeeee2  (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69)
CRP11	Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks  bbbbb1 amino acid eeeee1  bbbbb2 GAD65 eeeee2 ) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69)
CRP11	Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks  bbbbb1 amino acid eeeee1  1-69 from the N-terminus,  bbbbb2 GAD65(Delta1-69) eeeee2 
CRP11	In addition, our data suggested that calpain, a  bbbbb1 calcium eeeee1 -dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated  bbbbb2 GAD65 eeeee2  in the brain
CRP11	In addition, our data suggested that calpain, a  bbbbb1 calcium eeeee1 -dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length  bbbbb2 GAD65 eeeee2  to truncated GAD65 in the brain
CRP11	In addition, our data suggested that calpain, a  bbbbb1 calcium eeeee1  bbbbb2 calcium-dependent cysteine protease eeeee2 , is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain
CRP11	In addition, our data suggested that calpain, a  bbbbb1 calcium eeeee1  bbbbb2 calpain eeeee2 , a calcium-dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain
CRP11	In addition, our data suggested that calpain, a calcium-dependent  bbbbb1 cysteine eeeee1  protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated  bbbbb2 GAD65 eeeee2  in the brain
CRP11	In addition, our data suggested that calpain, a calcium-dependent  bbbbb1 cysteine eeeee1  protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length  bbbbb2 GAD65 eeeee2  to truncated GAD65 in the brain
CRP11	In addition, our data suggested that calpain, a calcium-dependent  bbbbb1 cysteine eeeee1  bbbbb2 calcium-dependent cysteine protease eeeee2 , is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain
CRP11	In addition, our data suggested that calpain, a calcium-dependent  bbbbb1 cysteine eeeee1  bbbbb2 calpain eeeee2 , a calcium-dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on  bbbbb2 XRs eeeee2 
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 Aryl hydrocarbon receptor eeeee2  (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  receptor ( bbbbb2 AhR eeeee2 )]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 pregnane X receptor eeeee2  (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 PXR eeeee2 ), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 XRs eeeee2 ; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 constitutive androstane receptor eeeee2  (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 xenobiotic receptors eeeee2  [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and  bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 CAR eeeee2 ), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on  bbbbb2 XRs eeeee2 
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  receptor (CAR), and  bbbbb2 Aryl hydrocarbon receptor eeeee2  (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  receptor (CAR), and Aryl hydrocarbon receptor ( bbbbb2 AhR eeeee2 )]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  bbbbb2 pregnane X receptor eeeee2  (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  bbbbb2 PXR eeeee2 ), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  bbbbb2 XRs eeeee2 ; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  bbbbb2 constitutive androstane receptor eeeee2  (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  bbbbb2 xenobiotic receptors eeeee2  [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive  bbbbb1 androstane eeeee1  receptor ( bbbbb2 CAR eeeee2 ), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites ( bbbbb1 noroxycodone eeeee1  bbbbb2 AhR eeeee2  by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites ( bbbbb1 noroxycodone eeeee1  bbbbb2 CAR eeeee2 , or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites ( bbbbb1 noroxycodone eeeee1  bbbbb2 PXR eeeee2 , CAR, or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites (noroxycodone and  bbbbb1 oxymorphone eeeee1  bbbbb2 AhR eeeee2  by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites (noroxycodone and  bbbbb1 oxymorphone eeeee1  bbbbb2 CAR eeeee2 , or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites (noroxycodone and  bbbbb1 oxymorphone eeeee1  bbbbb2 PXR eeeee2 , CAR, or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by  bbbbb1 oxycodone eeeee1  bbbbb2 AhR eeeee2  by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by  bbbbb1 oxycodone eeeee1  bbbbb2 CAR eeeee2 , or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by  bbbbb1 oxycodone eeeee1  bbbbb2 PXR eeeee2 , CAR, or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone)
CRP11	Neither oxycodone nor its metabolites activated PXR, CAR, or AhR bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Neither oxycodone nor its metabolites activated PXR, CAR, or AhR bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Neither oxycodone nor its metabolites activated PXR, CAR, or AhR bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Neither oxycodone nor its metabolites activated PXR, CAR, or AhR bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Neither oxycodone nor its metabolites activated PXR, CAR, or AhR bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Neither oxycodone nor its metabolites activated PXR, CAR, or AhR bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The objective of this study was to determine the influence of  bbbbb1 oxycodone eeeee1  administration (15 mg/kg intraperitoneally twice daily for 8 days) on liver expression of  bbbbb2 XRs eeeee2 , transporters, and DMEs in rats
CRP11	Desipramine treatment decreases 3H-nisoxetine binding and  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2  mRNA in SK-N-SHSY5Y cells
CRP11	In this study, we treated SK-N-SHSY5Y cells with 100 nM desipramine for 24 or 72 h, and measured  bbbbb1 3H-nisoxetine eeeee1  binding (as an estimate of NETs) and  bbbbb2 NET eeeee2  mRNA by quantitative reverse transcription polymerase chain reaction
CRP11	In this study, we treated SK-N-SHSY5Y cells with 100 nM desipramine for 24 or 72 h, and measured  bbbbb1 3H-nisoxetine eeeee1  binding (as an estimate of  bbbbb2 NETs eeeee2 ) and NET mRNA by quantitative reverse transcription polymerase chain reaction
CRP11	In this study, we treated SK-N-SHSY5Y cells with 100 nM  bbbbb1 desipramine eeeee1  for 24 or 72 h, and measured 3H-nisoxetine binding (as an estimate of NETs) and  bbbbb2 NET eeeee2  mRNA by quantitative reverse transcription polymerase chain reaction
CRP11	In this study, we treated SK-N-SHSY5Y cells with 100 nM  bbbbb1 desipramine eeeee1  for 24 or 72 h, and measured 3H-nisoxetine binding (as an estimate of  bbbbb2 NETs eeeee2 ) and NET mRNA by quantitative reverse transcription polymerase chain reaction
CRP11	The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine re-uptake transporter eeeee2  (NET) in vivo and in vitro, on both an acute and a chronic basis
CRP11	The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the  bbbbb1 norepinephrine eeeee1  re-uptake transporter ( bbbbb2 NET eeeee2 ) in vivo and in vitro, on both an acute and a chronic basis
CRP11	However, a significant decrease (64 +/- 8% of paired control) of NET mRNA was observed only at th bbbbb1 e 72-h time eeeee1  bbbbb2 eas eeeee2 e (64 +/- 8% of paired control) of NET mRNA was observed only at the 72-h time point
CRP11	Blockade of the renin-angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin eeeee2  system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua
CRP11	Blockade of the renin-angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  throughout the cardiovascular and renal continua
CRP11	Blockade of the renin-angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by  bbbbb1 angiotensin II eeeee1  bbbbb2 renin eeeee2 -angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua
CRP11	Blockade of the renin- bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin eeeee2  system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua
CRP11	Blockade of the renin- bbbbb1 angiotensin eeeee1  system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by  bbbbb2 angiotensin II eeeee2  throughout the cardiovascular and renal continua
CRP11	Blockade of the renin- bbbbb1 angiotensin eeeee1  bbbbb2 renin eeeee2 -angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua
CRP11	Telmisartan is an  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II receptor eeeee2  blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure
CRP11	The present study examined the effect of silymarin  bbbbb1 flavonolignans eeeee1  on OATP1B1-, OATP1B3-, and  bbbbb2 OATP2B1 eeeee2 -mediated transport in cell lines stably expressing these transporters and in human hepatocytes
CRP11	The present study examined the effect of silymarin  bbbbb1 flavonolignans eeeee1  on  bbbbb2 OATP1B1 eeeee2 -, OATP1B3-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes
CRP11	The present study examined the effect of silymarin  bbbbb1 flavonolignans eeeee1  on OATP1B1-,  bbbbb2 OATP1B3 eeeee2 -, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes
CRP11	The extent of silymarin-drug interactions depends on OATP isoform specificity and concentrations of flavonolignans bbbbb1  at the site  eeeee1 of drug transport bbbbb2  eeeee2 
CRP11	Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous  bbbbb1 NO eeeee1  formation, there is little information about how  bbbbb2 eNOS eeeee2  polymorphisms and haplotypes affect the responses to sildenafil
CRP11	Although genetic polymorphisms in the endothelial  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 eNOS eeeee2 ) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil
CRP11	Although genetic polymorphisms in the endothelial  bbbbb1 nitric oxide eeeee1  synthase (eNOS) gene may impair endogenous NO formation, there is little information about how  bbbbb2 eNOS eeeee2  polymorphisms and haplotypes affect the responses to sildenafil
CRP11	Although genetic polymorphisms in the endothelial  bbbbb1 nitric oxide eeeee1  bbbbb2 endothelial nitric oxide synthase eeeee2  (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil
CRP11	Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to  bbbbb1 sildenafil eeeee1  bbbbb2 eNOS eeeee2 ) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil
CRP11	Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to  bbbbb1 sildenafil eeeee1  bbbbb2 endothelial nitric oxide synthase eeeee2  (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil
CRP11	Endothelial  bbbbb1 nitric oxide eeeee1  bbbbb2 Endothelial nitric oxide synthase eeeee2  genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction
CRP11	 bbbbb1 Acetyl-coenzyme A eeeee1  bbbbb2 Acetyl-coenzyme A carboxylase eeeee2  (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation
CRP11	 bbbbb1 Acetyl-coenzyme A eeeee1  carboxylase (ACC) enzymes exist as two isoforms, ACC1 and  bbbbb2 ACC2 eeeee2 , which play critical roles in fatty acid biosynthesis and oxidation
CRP11	 bbbbb1 Acetyl-coenzyme A eeeee1  carboxylase (ACC) enzymes exist as two isoforms,  bbbbb2 ACC1 eeeee2  and ACC2, which play critical roles in fatty acid biosynthesis and oxidation
CRP11	 bbbbb1 Acetyl-coenzyme A eeeee1  carboxylase ( bbbbb2 ACC eeeee2 ) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation
CRP11	Discovery of  bbbbb1 acetyl-coenzyme A eeeee1  bbbbb2 acetyl-coenzyme A carboxylase 2 eeeee2  inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP Assay for high-throughput screening
CRP11	Discovery of acetyl-coenzyme A carboxylase 2 inhibitors: comparison of a fluorescence intensity-based  bbbbb1 phosphate eeeee1  bbbbb2 acetyl-coenzyme A carboxylase 2 eeeee2  inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP Assay for high-throughput screening
CRP11	Discovery of acetyl-coenzyme A carboxylase 2 inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based  bbbbb1 ADP eeeee1  bbbbb2 acetyl-coenzyme A carboxylase 2 eeeee2  inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP Assay for high-throughput screening
CRP11	Two assay formats for these ATP-utilizing enzymes amenable to high-throughput screening are compared: a fluorescence intensity-based assay to detect inorganic phosphate and a fluoresce bbbbb1 nce polarization-b eeeee1  bbbbb2 Two assay formats for these A eeeee2 TP-utilizing enzymes amenable to high-throughput screening are compared: a fluorescence intensity-based assay to detect inorganic phosphate and a fluorescence polarization-based assay to detect ADP
CRP11	 bbbbb1 Two assay formats eeeee1  bbbbb2 Two assay formats for these A eeeee2 TP-utilizing enzymes amenable to high-throughput screening are compared: a fluorescence intensity-based assay to detect inorganic phosphate and a fluorescence polarization-based assay to detect ADP
CRP11	Among these agents, peptidic derivatives of  bbbbb1 AVP eeeee1  bbbbb2 AVP eeeee2  turned out to have intrinsic antidiuretic properties in vivo when given over days or weeks
CRP11	 bbbbb1 Vasopressin eeeee1  bbbbb2 Vasopressin eeeee2  antagonists as aquaretic agents for the treatment of hyponatremia
CRP11	It is a state of relative water excess due to stimulated arginine vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 arginine vasopressin eeeee2  (AVP) and fluid intake greater than obligatory losses
CRP11	It is a state of relative water excess due to stimulated arginine vasopressin ( bbbbb1 AVP eeeee1  bbbbb2 AVP eeeee2 ) and fluid intake greater than obligatory losses
CRP11	It is a state of relative water excess due to stimulated  bbbbb1 arginine vasopressin eeeee1  bbbbb2 arginine vasopressin eeeee2  (AVP) and fluid intake greater than obligatory losses
CRP11	It is a state of relative water excess due to stimulated  bbbbb1 arginine vasopressin eeeee1  ( bbbbb2 AVP eeeee2 ) and fluid intake greater than obligatory losses
CRP11	In this respect, pharmacologic research has yielded a number of compounds exhibiting antagonistic qualities at the  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V2 receptor eeeee2 
CRP11	A inhibitor blocked the protective effect of  bbbbb1 genistein eeeee1  on endothelial permeability and also ablated  bbbbb2 thrombin eeeee2 -induced MLC-phosphorylation in ECs
CRP11	A inhibitor blocked the protective effect of  bbbbb1 genistein eeeee1  on endothelial permeability and also ablated thrombin-induced  bbbbb2 MLC eeeee2 -phosphorylation in ECs
CRP11	Genistein had no effect on resting intracellular [ bbbbb1 Ca(2+) eeeee1 ] or  bbbbb2 thrombin eeeee2 -induced increase in Ca(2+) mobilization
CRP11	Genistein had no effect on resting intracellular [Ca(2+)] or thrombin-induced increase in  bbbbb1 Ca(2+) eeeee1  bbbbb2 thrombin eeeee2 -induced increase in Ca(2+) mobilization
CRP11	Inhibition of PKA significantly attenuated the effect of  bbbbb1 genistein eeeee1  bbbbb2 PKA eeeee2  significantly attenuated the effect of genistein on thrombin-induced EC permeability, MLC phosphorylation, and RhoA membrane translocation in ECs
CRP11	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/ bbbbb1 Thr eeeee1  bbbbb2 thrombin eeeee2  and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)
CRP11	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/ bbbbb1 Thr eeeee1  bbbbb2 thrombin eeeee2 -induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)
CRP11	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on  bbbbb1 Ser eeeee1  bbbbb2 thrombin eeeee2  and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)
CRP11	Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on  bbbbb1 Ser eeeee1  bbbbb2 thrombin eeeee2 -induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs)
CRP11	Rasagiline: a novel anti-Parkinsonian  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase-B eeeee2  inhibitor with neuroprotective activity
CRP11	However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of  bbbbb1 rasagiline eeeee1  does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating  bbbbb2 Bcl-2 eeeee2  family proteins
CRP11	However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the  bbbbb1 N-propargyl eeeee1  bbbbb2 MAO-B eeeee2 , but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins
CRP11	Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase (MAO)-B eeeee2  inhibitor, anti-Parkinsonian drug
CRP11	A and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis ( bbbbb1 BAPTA eeeee1 ), two Ca2+ chelators, but not nifedipine, an  bbbbb2 L-type Ca2+ channel eeeee2  blocker, prevented GRIP1 degradation
CRP11	A and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type  bbbbb1 Ca2+ eeeee1  channel blocker, prevented  bbbbb2 GRIP1 eeeee2  degradation
CRP11	A and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type  bbbbb1 Ca2+ eeeee1  bbbbb2 L-type Ca2+ channel eeeee2  blocker, prevented GRIP1 degradation
CRP11	A and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two  bbbbb1 Ca2+ eeeee1  chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented  bbbbb2 GRIP1 eeeee2  degradation
CRP11	A and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two  bbbbb1 Ca2+ eeeee1  chelators, but not nifedipine, an  bbbbb2 L-type Ca2+ channel eeeee2  blocker, prevented GRIP1 degradation
CRP11	A and  bbbbb1 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis eeeee1  (BAPTA), two Ca2+ chelators, but not nifedipine, an  bbbbb2 L-type Ca2+ channel eeeee2  blocker, prevented GRIP1 degradation
CRP11	Glutamate stimulates  bbbbb1 glutamate eeeee1  receptor interacting protein 1 degradation by  bbbbb2 ubiquitin eeeee2 -proteasome system to regulate surface expression of GluR2
CRP11	Glutamate stimulates  bbbbb1 glutamate eeeee1  bbbbb2 glutamate receptor interacting protein 1 eeeee2  degradation by ubiquitin-proteasome system to regulate surface expression of GluR2
CRP11	Glutamate stimulates  bbbbb1 glutamate eeeee1  receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of  bbbbb2 GluR2 eeeee2 
CRP11	Glutamate stimulates  bbbbb1 glutamate eeeee1  receptor interacting protein 1 degradation by ubiquitin- bbbbb2 proteasome eeeee2  system to regulate surface expression of GluR2
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdow bbbbb1 n of eeeee1  bbbbb2 , and knockdo eeeee2 wn of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdow bbbbb1 n of eeeee1  GRIP1 by RNAi aga bbbbb2 inst  eeeee2 GRIP1 reduced surface GluR2 in neurons
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdow bbbbb1 n of eeeee1  bbbbb2 ulate eeeee2 d reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdow bbbbb1 n of eeeee1  GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons bbbbb2  eeeee2 
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdow bbbbb1 n of eeeee1  bbbbb2 urface amo eeeee2 unt of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2 bbbbb1 , an eeeee1  bbbbb2 , and knockdo eeeee2 wn of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2 bbbbb1 , an eeeee1 d knockdown of GRIP1 by RNAi aga bbbbb2 inst  eeeee2 GRIP1 reduced surface GluR2 in neurons
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2 bbbbb1 , an eeeee1  bbbbb2 ulate eeeee2 d reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2 bbbbb1 , an eeeee1 d knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons bbbbb2  eeeee2 
CRP11	Furthermore, MG132 prevented glutamate-stimulated reduction in surface amount of GluR2 bbbbb1 , an eeeee1  bbbbb2 urface amo eeeee2 unt of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons
CRP11	Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ( bbbbb1 MG132 eeeee1 ), a proteasome inhibitor and by expression of  bbbbb2 K48R eeeee2 -ubiquitin, a dominant negative form of ubiquitin
CRP11	Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ( bbbbb1 MG132 eeeee1 ), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of  bbbbb2 ubiquitin eeeee2 
CRP11	Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal ( bbbbb1 MG132 eeeee1 ), a proteasome inhibitor and by expression of K48R- bbbbb2 ubiquitin eeeee2 , a dominant negative form of ubiquitin
CRP11	Down-regulation of GRIP1 by glutamate was blocked by  bbbbb1 carbobenzoxyl-leucinyl-leucinyl-leucinal eeeee1  (MG132), a proteasome inhibitor and by expression of  bbbbb2 K48R eeeee2 -ubiquitin, a dominant negative form of ubiquitin
CRP11	Down-regulation of GRIP1 by glutamate was blocked by  bbbbb1 carbobenzoxyl-leucinyl-leucinyl-leucinal eeeee1  (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of  bbbbb2 ubiquitin eeeee2 
CRP11	Down-regulation of GRIP1 by glutamate was blocked by  bbbbb1 carbobenzoxyl-leucinyl-leucinyl-leucinal eeeee1  (MG132), a proteasome inhibitor and by expression of K48R- bbbbb2 ubiquitin eeeee2 , a dominant negative form of ubiquitin
CRP11	Down-regulation of GRIP1 by  bbbbb1 glutamate eeeee1  was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of  bbbbb2 K48R eeeee2 -ubiquitin, a dominant negative form of ubiquitin
CRP11	Down-regulation of GRIP1 by  bbbbb1 glutamate eeeee1  was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a  bbbbb2 proteasome eeeee2  inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin
CRP11	Down-regulation of GRIP1 by  bbbbb1 glutamate eeeee1  was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of  bbbbb2 ubiquitin eeeee2 
CRP11	Down-regulation of GRIP1 by  bbbbb1 glutamate eeeee1  was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R- bbbbb2 ubiquitin eeeee2 , a dominant negative form of ubiquitin
CRP11	Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of  bbbbb1 glutamate eeeee1  receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 ( bbbbb2 PICK1 eeeee2 ) in rat primary cortical neuron cultures
CRP11	Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of  bbbbb1 glutamate eeeee1  receptor (GluR) 1, GluR2 and  bbbbb2 protein interacting with C kinase 1 eeeee2  (PICK1) in rat primary cortical neuron cultures
CRP11	Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of  bbbbb1 glutamate eeeee1  receptor (GluR) 1,  bbbbb2 GluR2 eeeee2  and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures
CRP11	Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of  bbbbb1 glutamate eeeee1  receptor  bbbbb2 (GluR) 1 eeeee2 , GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures
CRP11	Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of  bbbbb1 glutamate eeeee1  bbbbb2 GRIP1 eeeee2 , but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures
CRP11	The glutamate receptor interacting protein 1 (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptors eeeee2  to other signaling proteins
CRP11	The glutamate receptor interacting protein 1 (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering  bbbbb1 AMPA eeeee1  bbbbb2 glutamate receptor interacting protein 1 eeeee2  (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins
CRP11	The glutamate receptor interacting protein 1 (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering  bbbbb1 AMPA eeeee1  bbbbb2 GRIP1 eeeee2 ) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins
CRP11	The  bbbbb1 glutamate eeeee1  receptor interacting protein 1 (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering  bbbbb2 AMPA receptors eeeee2  to other signaling proteins
CRP11	The  bbbbb1 glutamate eeeee1  bbbbb2 glutamate receptor interacting protein 1 eeeee2  (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins
CRP11	The  bbbbb1 glutamate eeeee1  receptor interacting protein 1 ( bbbbb2 GRIP1 eeeee2 ) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins
CRP11	Both microtubule and actin are required for insulin-induced  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2 -induced glucose uptake
CRP11	Both microtubule and actin are required for insulin-induced  bbbbb1 glucose eeeee1  bbbbb2 actin eeeee2  are required for insulin-induced glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter isoform 4 eeeee2  (GLUT4) and glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2 -induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  bbbbb1 glucose eeeee1  transporter isoform 4 ( bbbbb2 GLUT4 eeeee2 ) and glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface  bbbbb1 glucose eeeee1  bbbbb2 actin eeeee2  remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and  bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2 -induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake
CRP11	Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and  bbbbb1 glucose eeeee1  bbbbb2 actin eeeee2  remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  bbbbb2 Ca(v)1.3 eeeee2  knockouts [Ca(v)1.3(-/-)]. (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  bbbbb2 Ca(v)1.2 eeeee2  channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)]. (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the  bbbbb2 LTCC eeeee2  transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to  bbbbb2 Ca(v)1.2 eeeee2 DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  bbbbb2 Ca(v)1.2 eeeee2 DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)]. (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and  bbbbb2 Ca(v)1.4 alpha(1) eeeee2  subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that  bbbbb2 Ca(v)1.1 eeeee2  and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  bbbbb2 Ca(v)1.3 eeeee2 (-/-)]. (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)].  bbbbb1 (+)-[(3)H]isradipine eeeee1  bbbbb2 Ca(v) eeeee2 -DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)]. (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding
CRP11	It is also unknown to what extent Ca(v)1.1 and Ca(v)1.4 contribute to L-type-specific  bbbbb1 DHP eeeee1  bbbbb2 Ca(v)1.4 eeeee2  contribute to L-type-specific DHP binding activity in brain
CRP11	It is also unknown to what extent Ca(v)1.1 and Ca(v)1.4 contribute to L-type-specific  bbbbb1 DHP eeeee1  bbbbb2 Ca(v)1.1 eeeee2  and Ca(v)1.4 contribute to L-type-specific DHP binding activity in brain
CRP11	The L-type  bbbbb1 calcium eeeee1  channel (LTCC) isoforms  bbbbb2 Ca(v)1.2 eeeee2  and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain
CRP11	The L-type  bbbbb1 calcium eeeee1  channel (LTCC) isoforms Ca(v)1.2 and  bbbbb2 Ca(v)1.3 eeeee2  display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain
CRP11	The L-type  bbbbb1 calcium eeeee1  bbbbb2 L-type calcium channel eeeee2  (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain
CRP11	The L-type  bbbbb1 calcium eeeee1  channel ( bbbbb2 LTCC eeeee2 ) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain
CRP11	Expression and 1,4-dihydropyridine-binding properties of brain L-type  bbbbb1 calcium eeeee1  bbbbb2 L-type calcium channel eeeee2  isoforms
CRP11	In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the- bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-glucose-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups
CRP11	In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the- bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2 -curve to the total area-under-the-glucose-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups
CRP11	In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the- bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-glucose-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups
CRP11	In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the- bbbbb1 glucose eeeee1  bbbbb2 insulin eeeee2  secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-glucose-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups
CRP11	The effectiveness of IL-1 inhibition was first evaluated in a mouse model of  bbbbb1 monosodium urate eeeee1  bbbbb2 IL-1 eeeee2  inhibition was first evaluated in a mouse model of monosodium urate crystal-induced inflammation
CRP11	Phosphorylation of this subunit by  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-dependent protein kinase eeeee2  has previously been found to activate the complex
CRP11	Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive  bbbbb1 NADH eeeee1  bbbbb2 NADH-->UQ oxidoreductase eeeee2  activity of complex I, which was insensitive to cAMP stimulation
CRP11	Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive  bbbbb1 NADH eeeee1 -->UQ oxidoreductase activity of  bbbbb2 complex I eeeee2 , which was insensitive to cAMP stimulation
CRP11	Association of DRD2 polymorphisms and  bbbbb1 chlorpromazine eeeee1  bbbbb2 DRD2 eeeee2  polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients
CRP11	We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with  bbbbb1 chlorpromazine eeeee1  bbbbb2 Ser311Cys eeeee2 , rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks
CRP11	We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with  bbbbb1 chlorpromazine eeeee1  bbbbb2 DRD2 eeeee2  gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas  bbbbb1 tazarotene eeeee1  bbbbb2 RARs eeeee2 ) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas  bbbbb1 tazarotene eeeee1  bbbbb2 retinoic acid receptors eeeee2  (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas  bbbbb1 tazarotene eeeee1  bbbbb2 RAR-alpha, -beta and -gamma eeeee2 , without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas  bbbbb1 tazarotene eeeee1  preferentially binds to and activates  bbbbb2 RAR-beta and -gamma eeeee2  in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear  bbbbb1 retinoic acid eeeee1  receptors ( bbbbb2 RARs eeeee2 ) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid receptors eeeee2  (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear  bbbbb1 retinoic acid eeeee1  receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes,  bbbbb2 RAR-alpha, -beta and -gamma eeeee2 , without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear  bbbbb1 retinoic acid eeeee1  receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to  bbbbb2 RAR-alpha eeeee2 
CRP11	One is that the binding of retinoids to nuclear  bbbbb1 retinoic acid eeeee1  receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates  bbbbb2 RAR-beta and -gamma eeeee2  in preference to RAR-alpha
CRP11	One is that the binding of  bbbbb1 retinoids eeeee1  to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes,  bbbbb2 RAR-alpha, -beta and -gamma eeeee2 , without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of  bbbbb1 retinoids eeeee1  to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to  bbbbb2 RAR-alpha eeeee2 
CRP11	One is that the binding of  bbbbb1 retinoids eeeee1  to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates  bbbbb2 RAR-beta and -gamma eeeee2  in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy:  bbbbb1 acitretin eeeee1  bbbbb2 RARs eeeee2 ) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy:  bbbbb1 acitretin eeeee1  bbbbb2 retinoic acid receptors eeeee2  (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy:  bbbbb1 acitretin eeeee1  activates the three receptor subtypes,  bbbbb2 RAR-alpha, -beta and -gamma eeeee2 , without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy:  bbbbb1 acitretin eeeee1  activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to  bbbbb2 RAR-alpha eeeee2 
CRP11	One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy:  bbbbb1 acitretin eeeee1  activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates  bbbbb2 RAR-beta and -gamma eeeee2  in preference to RAR-alpha
CRP11	Furthermore, CK induced activation of nuclear  bbbbb1 ery eeeee1 throid 2-related factor 2 (Nrf2)-mediated antioxid bbbbb2 ant  eeeee2 enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells
CRP11	CK significantly inhibited DMN-induced increases in serum  bbbbb1 alanine eeeee1  aminotransferase ( bbbbb2 ALT eeeee2 ) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum  bbbbb1 alanine eeeee1  aminotransferase (ALT) and  bbbbb2 aspartate aminotransferase eeeee2  (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum  bbbbb1 alanine eeeee1  aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and  bbbbb2 collagen eeeee2  content
CRP11	CK significantly inhibited DMN-induced increases in serum  bbbbb1 alanine eeeee1  aminotransferase (ALT) and aspartate aminotransferase ( bbbbb2 AST eeeee2 ) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum  bbbbb1 alanine eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic  bbbbb1 malondialdehyde eeeee1  bbbbb2 ALT eeeee2 ) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic  bbbbb1 malondialdehyde eeeee1  bbbbb2 aspartate aminotransferase eeeee2  (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic  bbbbb1 malondialdehyde eeeee1  and  bbbbb2 collagen eeeee2  content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic  bbbbb1 malondialdehyde eeeee1  bbbbb2 AST eeeee2 ) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic  bbbbb1 malondialdehyde eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and  bbbbb1 aspartate eeeee1  bbbbb2 ALT eeeee2 ) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and  bbbbb1 aspartate eeeee1  bbbbb2 aspartate aminotransferase eeeee2  (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and  bbbbb1 aspartate eeeee1  aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and  bbbbb2 collagen eeeee2  content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and  bbbbb1 aspartate eeeee1  aminotransferase ( bbbbb2 AST eeeee2 ) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and  bbbbb1 aspartate eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content
CRP11	Platycodi Radix attenuates  bbbbb1 dimethylnitrosamine eeeee1 -induced liver fibrosis in rats by inducing  bbbbb2 Nrf2 eeeee2 -mediated antioxidant enzymes
CRP11	 bbbbb1 Simvastatin eeeee1  and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent  bbbbb2 CYP3A eeeee2  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CRP11	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI,  bbbbb1 telaprevir eeeee1  bbbbb2 CYP3A eeeee2  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CRP11	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or  bbbbb1 boceprevir eeeee1  bbbbb2 CYP3A eeeee2  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CRP11	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or  bbbbb1 cobicistat eeeee1  bbbbb2 CYP3A eeeee2  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CRP11	Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as  bbbbb1 ritonavir eeeee1  bbbbb2 CYP3A eeeee2  have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CRP11	Simvastatin and  bbbbb1 lovastatin eeeee1  metabolized through CYP3A have the highest potency for drug-drug interaction with potent  bbbbb2 CYP3A eeeee2  inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated
CRP11	The  bbbbb1 HMG-CoA eeeee1  bbbbb2 HMG-CoA reductase eeeee2  inhibitors are a class of drugs also known as statins
CRP11	 bbbbb1 Atorvastatin eeeee1  is also a CYP3A substrate, but less potent drug-drug interactions have been reported with  bbbbb2 CYP3A eeeee2  inhibitors
CRP11	Drug-drug interactions are dependent on statins' pharmacokinetic profile:  bbbbb1 simvastatin eeeee1 , lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this  bbbbb2 CYP eeeee2 
CRP11	Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and  bbbbb1 atorvastatin eeeee1  are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this  bbbbb2 CYP eeeee2 
CRP11	Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin,  bbbbb1 lovastatin eeeee1  and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this  bbbbb2 CYP eeeee2 
CRP11	All HIV PIs except  bbbbb1 nelfinavir eeeee1  are coadministered with a low dose of ritonavir, a potent  bbbbb2 CYP3A eeeee2  inhibitor to improve their pharmacokinetic properties
CRP11	Drug-drug interactions between  bbbbb1 HMG-CoA eeeee1  bbbbb2 HMG-CoA reductase eeeee2  inhibitors (statins) and antiviral protease inhibitors
CRP11	Drug-drug interactions between  bbbbb1 HMG-CoA eeeee1  reductase inhibitors (statins) and antiviral  bbbbb2 protease eeeee2  inhibitors
CRP11	Determinants of voltage-dependent inactivation affect Mibefradil block of  bbbbb1 calcium eeeee1  bbbbb2 calcium channels eeeee2 
CRP11	Modulation of the voltage-dependent inactivation properties by the natur bbbbb1 e of th eeeee1  bbbbb2 e of the coexpr eeeee2 essed beta subunit or the alpha1 splice variant altered block at the Mibefradil receptor site
CRP11	To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of  bbbbb1 Mibefradil eeeee1  bbbbb2 Ca2+ channel eeeee2 -Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of  bbbbb1 Mibefradil eeeee1  on various recombinant  bbbbb2 Ca2+ channels eeeee2  expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channel eeeee2 -Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channels eeeee2  expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the Ca2+ channel- bbbbb1 Mibefradil eeeee1  interaction, we examined the effect of Mibefradil on various recombinant  bbbbb2 Ca2+ channels eeeee2  expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channel eeeee2 -Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the  bbbbb1 Ca2+ eeeee1  channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant  bbbbb2 Ca2+ channels eeeee2  expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channel eeeee2 -Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channels eeeee2  expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration
CRP11	Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type  bbbbb1 Ca2+ eeeee1  bbbbb2 T-type Ca2+ channels eeeee2 
CRP11	Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other  bbbbb1 Ca2+ eeeee1  antagonists by its ability to potently block  bbbbb2 T-type Ca2+ channels eeeee2 
CRP11	However, this molecule has also been shown to inhibit other  bbbbb1 Ca2+ eeeee1  bbbbb2 Ca2+ channel eeeee2  subtypes
CRP11	The voltage gated  bbbbb1 calcium eeeee1  bbbbb2 voltage gated calcium channel eeeee2  family is a major target for a range of therapeutic drugs
CRP11	RAR-alpha, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after  bbbbb1 retinoic acid eeeee1  bbbbb2 RAR-beta eeeee2  and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after retinoic acid supplementation
CRP11	RAR-alpha, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after  bbbbb1 retinoic acid eeeee1  bbbbb2 RAR-alpha eeeee2 , RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after retinoic acid supplementation
CRP11	RAR-alpha, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after  bbbbb1 retinoic acid eeeee1  bbbbb2 RAR-beta eeeee2  protein was undetectable in chronically activated HSC and remained absent after retinoic acid supplementation
CRP11	RAR-alpha, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after  bbbbb1 retinoic acid eeeee1  bbbbb2 RAR-gamma eeeee2  mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after retinoic acid supplementation
CRP11	Many stimuli cause HSC to activate, lose their  bbbbb1 Vitamin A eeeee1  and produce  bbbbb2 collagen eeeee2 
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or  bbbbb1 retinoic acid eeeee1  without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and  bbbbb2 RAR-gamma eeeee2 , the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or  bbbbb1 retinoic acid eeeee1  without increases in HSC retinoid concentration. mRNA levels for RAR-alpha,  bbbbb2 RAR-beta eeeee2  and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or  bbbbb1 retinoic acid eeeee1  without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the  bbbbb2 nuclear receptors eeeee2  for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or  bbbbb1 retinoic acid eeeee1  without increases in HSC retinoid concentration. mRNA levels for  bbbbb2 RAR-alpha eeeee2 , RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC  bbbbb1 retinoid eeeee1  concentration. mRNA levels for RAR-alpha, RAR-beta and  bbbbb2 RAR-gamma eeeee2 , the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC  bbbbb1 retinoid eeeee1  concentration. mRNA levels for RAR-alpha,  bbbbb2 RAR-beta eeeee2  and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC  bbbbb1 retinoid eeeee1  concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the  bbbbb2 nuclear receptors eeeee2  for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC  bbbbb1 retinoid eeeee1  concentration. mRNA levels for  bbbbb2 RAR-alpha eeeee2 , RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either  bbbbb1 retinol eeeee1  or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and  bbbbb2 RAR-gamma eeeee2 , the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either  bbbbb1 retinol eeeee1  or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha,  bbbbb2 RAR-beta eeeee2  and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either  bbbbb1 retinol eeeee1  or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the  bbbbb2 nuclear receptors eeeee2  for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	Markers of activation in freshly isolated HSC were decreased by either  bbbbb1 retinol eeeee1  or retinoic acid without increases in HSC retinoid concentration. mRNA levels for  bbbbb2 RAR-alpha eeeee2 , RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation
CRP11	We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular  bbbbb1 retinoid eeeee1  levels; (3) maintain expression of HSC  bbbbb2 nuclear receptors for retinoic acid eeeee2  (RAR) in HSC that are becoming activated or are chronically activated
CRP11	We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular  bbbbb1 retinoid eeeee1  levels; (3) maintain expression of HSC nuclear receptors for retinoic acid ( bbbbb2 RAR eeeee2 ) in HSC that are becoming activated or are chronically activated
CRP11	We also determine if  bbbbb1 retinoids eeeee1 : (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC  bbbbb2 nuclear receptors for retinoic acid eeeee2  (RAR) in HSC that are becoming activated or are chronically activated
CRP11	We also determine if  bbbbb1 retinoids eeeee1 : (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for retinoic acid ( bbbbb2 RAR eeeee2 ) in HSC that are becoming activated or are chronically activated
CRP11	We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for  bbbbb1 retinoic acid eeeee1  bbbbb2 nuclear receptors for retinoic acid eeeee2  (RAR) in HSC that are becoming activated or are chronically activated
CRP11	We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for  bbbbb1 retinoic acid eeeee1  ( bbbbb2 RAR eeeee2 ) in HSC that are becoming activated or are chronically activated
CRP11	An  bbbbb1 11 beta hydroxysteroid eeeee1  bbbbb2 11 beta hydroxysteroid dehydrogenase eeeee2  (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction
CRP11	An  bbbbb1 11 beta hydroxysteroid eeeee1  dehydrogenase ( bbbbb2 11 beta HSD eeeee2 ) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction
CRP11	An 11 beta hydroxysteroid dehydrogenase (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links  bbbbb1 steroid eeeee1  bbbbb2 11 beta hydroxysteroid dehydrogenase eeeee2  (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction
CRP11	An 11 beta hydroxysteroid dehydrogenase (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links  bbbbb1 steroid eeeee1  bbbbb2 11 beta HSD eeeee2 ) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction
CRP11	We have named this activity 11 beta HSD2 to distinguish it from the  bbbbb1 NADP eeeee1  bbbbb2 11 beta HSD2 eeeee2  to distinguish it from the NADP-dependent 11 beta HSD
CRP11	We interpret these results as evidence of 20 reducta bbbbb1 se activity which uses eeeee1  bbbbb2 se activity which uses the reduced c eeeee2 ofactor at the expense of the color reaction
CRP11	Localization of an  bbbbb1 11 beta hydroxysteroid eeeee1  bbbbb2 11 beta hydroxysteroid dehydrogenase eeeee2  activity to the distal nephron
CRP11	These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate ( bbbbb1 NADP eeeee1  bbbbb2 dehydrogenase eeeee2  activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent 11 beta hydroxysteroid dehydrogenase recently purified and cloned from rat liver
CRP11	These results demonstrate the presence of a dehydrogenase activity separate from the  bbbbb1 nicotinamide-adenine dinucleotide phosphate eeeee1  bbbbb2 dehydrogenase eeeee2  activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent 11 beta hydroxysteroid dehydrogenase recently purified and cloned from rat liver
CRP11	These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent  bbbbb1 11 beta hydroxysteroid eeeee1  bbbbb2 11 beta hydroxysteroid dehydrogenase eeeee2  recently purified and cloned from rat liver
CRP11	These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent  bbbbb1 11 beta hydroxysteroid eeeee1  bbbbb2 dehydrogenase eeeee2  activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent 11 beta hydroxysteroid dehydrogenase recently purified and cloned from rat liver
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 ascorbate peroxidase eeeee2  (APX) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 CAT eeeee2 ) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 APX eeeee2 ) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione reductase eeeee2  (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  (CAT) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and  bbbbb1 glutathione eeeee1  reductase ( bbbbb2 GR eeeee2 ) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in  bbbbb1 ascorbate eeeee1  bbbbb2 ascorbate peroxidase eeeee2  (APX) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in  bbbbb1 ascorbate eeeee1  peroxidase (APX) activity during the exponential growth and a more important role of catalase ( bbbbb2 CAT eeeee2 ) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in  bbbbb1 ascorbate eeeee1  peroxidase ( bbbbb2 APX eeeee2 ) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in  bbbbb1 ascorbate eeeee1  peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and  bbbbb2 glutathione reductase eeeee2  (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in  bbbbb1 ascorbate eeeee1  peroxidase (APX) activity during the exponential growth and a more important role of  bbbbb2 catalase eeeee2  (CAT) and glutathione reductase (GR) activities during the slow growth phase
CRP11	Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in  bbbbb1 ascorbate eeeee1  peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase ( bbbbb2 GR eeeee2 ) activities during the slow growth phase
CRP11	Other ligands (e.g. denopamine for beta(1);  bbbbb1 clenbuterol eeeee1  bbbbb2 beta(1) eeeee2 ; clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy
CRP11	Other ligands (e.g. denopamine for beta(1); clenbuterol, AZ 40140d,  bbbbb1 salbutamol eeeee1  bbbbb2 beta(1) eeeee2 ; clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy
CRP11	Other ligands (e.g.  bbbbb1 denopamine eeeee1  for beta(1); clenbuterol, AZ 40140d, salbutamol for  bbbbb2 beta(2) eeeee2 ) were found to have subtype-selective intrinsic efficacy
CRP11	Other ligands (e.g. denopamine for beta(1); clenbuterol,  bbbbb1 AZ 40140d eeeee1  bbbbb2 beta(1) eeeee2 ; clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy
CRP11	TAL APPROACH: Stable clonal CHO-K1 cell lines, transfected with either the human beta(1), beta(2) or beta(3)-adrenoceptor, were used, and whole-cell  bbbbb1 [(3)H]-CGP 12177 eeeee1  bbbbb2 human beta(1), beta(2) or beta(3)-adrenoceptor eeeee2 , were used, and whole-cell [(3)H]-CGP 12177 radioligand binding and [(3)H]-cAMP accumulation were measured
CRP11	TAL APPROACH: Stable clonal CHO-K1 cell lines, transfected with either the human beta(1), beta(2) or beta(3)-adrenoceptor, were used, and whole-cell [(3)H]-CGP 12177 radioligand binding and  bbbbb1 [(3)H]-cAMP eeeee1  bbbbb2 human beta(1), beta(2) or beta(3)-adrenoceptor eeeee2 , were used, and whole-cell [(3)H]-CGP 12177 radioligand binding and [(3)H]-cAMP accumulation were measured
CRP11	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and  bbbbb1 formoterol eeeee1 , for the beta(2)-adrenoceptor over the  bbbbb2 beta(1) eeeee2  or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity
CRP11	KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g.  bbbbb1 salmeterol eeeee1  and formoterol, for the beta(2)-adrenoceptor over the beta(1) or  bbbbb2 beta(3) eeeee2 ), while others (e.g. isoprenaline) had little affinity-selectivity
CRP11	In the present report, we show that Fer associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e.  bbbbb1 Tyr eeeee1  bbbbb2 Fer eeeee2  associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and Tyr1021
CRP11	In the present report, we show that Fer associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and  bbbbb1 Tyr eeeee1  bbbbb2 Fer eeeee2  associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and Tyr1021
CRP11	In the present report, we show that Fer associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579,  bbbbb1 Tyr eeeee1  bbbbb2 Fer eeeee2  associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and Tyr1021
CRP11	In the present report, we show that Fer associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581,  bbbbb1 Tyr eeeee1  bbbbb2 Fer eeeee2  associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and Tyr1021
CRP11	Fer is a cytoplasmic  bbbbb1 tyrosine eeeee1  kinase that is activated in response to  bbbbb2 platelet-derived growth factor eeeee2  (PDGF) stimulation
CRP11	Fer is a cytoplasmic  bbbbb1 tyrosine eeeee1  kinase that is activated in response to platelet-derived growth factor ( bbbbb2 PDGF eeeee2 ) stimulation
CRP11	Fer is a cytoplasmic  bbbbb1 tyrosine eeeee1  bbbbb2 Fer eeeee2  is a cytoplasmic tyrosine kinase that is activated in response to platelet-derived growth factor (PDGF) stimulation
CRP11	Fer is a cytoplasmic  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  that is activated in response to platelet-derived growth factor (PDGF) stimulation
CRP11	The Fer  bbbbb1 tyrosine eeeee1  kinase is important for platelet-derived growth factor-BB-induced  bbbbb2 Stat3 eeeee2  phosphorylation, colony formation in soft agar and tumor growth in vivo
CRP11	The Fer  bbbbb1 tyrosine eeeee1  kinase is important for  bbbbb2 platelet-derived growth factor-BB eeeee2 -induced Stat3 phosphorylation, colony formation in soft agar and tumor growth in vivo
CRP11	The Fer  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  is important for platelet-derived growth factor-BB-induced Stat3 phosphorylation, colony formation in soft agar and tumor growth in vivo
CRP11	The Fer  bbbbb1 tyrosine eeeee1  bbbbb2 Fer eeeee2  tyrosine kinase is important for platelet-derived growth factor-BB-induced Stat3 phosphorylation, colony formation in soft agar and tumor growth in vivo
CRP11	NS: These findi bbbbb1 ng eeeee1 s suggest that the degree of NET blockade can bbbbb2  be eeeee2  assessed with the plasma or urine DHPG/NE ratio and the pressor effect of tyramine
CRP11	NS: These findi bbbbb1 ng eeeee1 s suggest that the degree of NET blockade can be assessed with the plasma or urine DHPG/NE ratio and the presso bbbbb2 r e eeeee2 ffect of tyramine
CRP11	NS: These  bbbbb1 find eeeee1 ings suggest that the degree of NET blockade can bbbbb2  be eeeee2  assessed with the plasma or urine DHPG/NE ratio and the pressor effect of tyramine
CRP11	NS: These  bbbbb1 find eeeee1 ings suggest that the degree of NET blockade can be assessed with the plasma or urine DHPG/NE ratio and the presso bbbbb2 r e eeeee2 ffect of tyramine
CRP11	A total of 68 chemicals including derivatives of naphthalene, phenanthrene, fluoranthene,  bbbbb1 pyrene eeeee1 , biphenyl, and flavone were examined for their abilities to interact with  bbbbb2 human P450s 2A13 and 2A6 eeeee2 
CRP11	A total of 68 chemicals including derivatives of naphthalene, phenanthrene, fluoranthene, pyrene,  bbbbb1 biphenyl eeeee1 , and flavone were examined for their abilities to interact with  bbbbb2 human P450s 2A13 and 2A6 eeeee2 
CRP11	A total of 68 chemicals including derivatives of naphthalene,  bbbbb1 phenanthrene eeeee1 , fluoranthene, pyrene, biphenyl, and flavone were examined for their abilities to interact with  bbbbb2 human P450s 2A13 and 2A6 eeeee2 
CRP11	A total of 68 chemicals including derivatives of naphthalene, phenanthrene,  bbbbb1 fluoranthene eeeee1 , pyrene, biphenyl, and flavone were examined for their abilities to interact with  bbbbb2 human P450s 2A13 and 2A6 eeeee2 
CRP11	A total of 68 chemicals including derivatives of  bbbbb1 naphthalene eeeee1 , phenanthrene, fluoranthene, pyrene, biphenyl, and flavone were examined for their abilities to interact with  bbbbb2 human P450s 2A13 and 2A6 eeeee2 
CRP11	A total of 68 chemicals including derivatives of naphthalene, phenanthrene, fluoranthene, pyrene, biphenyl, and  bbbbb1 flavone eeeee1  were examined for their abilities to interact with  bbbbb2 human P450s 2A13 and 2A6 eeeee2 
CRP11	Fifty-one of these 68 chemicals induced stronger Type I binding spectra ( bbbbb1 iron eeeee1  low- to high-spin state shift) with P450 2A13 than those seen with  bbbbb2 P450 2A6 eeeee2 , i.e., the spectral binding intensities (ΔAmax/Ks ratio) determined with these chemicals were always higher for P450 2A13
CRP11	Fifty-one of these 68 chemicals induced stronger Type I binding spectra ( bbbbb1 iron eeeee1  low- to high-spin state shift) with  bbbbb2 P450 2A13 eeeee2  than those seen with P450 2A6, i.e., the spectral binding intensities (ΔAmax/Ks ratio) determined with these chemicals were always higher for P450 2A13
CRP11	Fifty-one of these 68 chemicals induced stronger Type I binding spectra ( bbbbb1 iron eeeee1  low- to high-spin state shift) with P450 2A13 than those seen with P450 2A6, i.e., the spectral binding intensities (ΔAmax/Ks ratio) determined with these chemicals were always higher for  bbbbb2 P450 2A13 eeeee2 
CRP11	NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 cytokines eeeee2 , cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS)
CRP11	NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS)
CRP11	NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), and inducible nitric oxide synthase (iNOS)
CRP11	NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 COX-2 eeeee2 ), and inducible nitric oxide synthase (iNOS)
CRP11	NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 NF-κB eeeee2  activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS)
CRP11	NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 )
CRP11	Mercury induces the expression of cyclooxygenase-2 and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2 
CRP11	Mercury induces the expression of cyclooxygenase-2 and inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 cyclooxygenase-2 eeeee2  and inducible nitric oxide synthase
CRP11	We found that  bbbbb1 ATP eeeee1  appears to be released through pannexin1 hemichannels ( bbbbb2 Panx1 eeeee2  HCs)
CRP11	We found that  bbbbb1 ATP eeeee1  appears to be released through  bbbbb2 pannexin1 eeeee2  hemichannels (Panx1 HCs)
CRP11	 bbbbb1 ATP eeeee1  release, Etd(+) uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of  bbbbb2 pannexin1 eeeee2  knockout mice
CRP11	ATP release,  bbbbb1 Etd(+) eeeee1  uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of  bbbbb2 pannexin1 eeeee2  knockout mice
CRP11	Immunocytochemical analyses and function were consistent with pannexin1 localization to T-tubules intercalated with dihydropyridine and  bbbbb1 ryanodine eeeee1  bbbbb2 ryanodine receptors eeeee2  in slow (soleus) and fast (extensor digitorum longus, EDL) muscles
CRP11	Immunocytochemical analyses and function were consistent with pannexin1 localization to T-tubules intercalated with dihydropyridine and  bbbbb1 ryanodine eeeee1  bbbbb2 pannexin1 eeeee2  localization to T-tubules intercalated with dihydropyridine and ryanodine receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles
CRP11	Immunocytochemical analyses and function were consistent with pannexin1 localization to T-tubules intercalated with  bbbbb1 dihydropyridine eeeee1  and  bbbbb2 ryanodine receptors eeeee2  in slow (soleus) and fast (extensor digitorum longus, EDL) muscles
CRP11	Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or  bbbbb1 glucose eeeee1  transporter ( bbbbb2 GLUT4 eeeee2 ), and blocked by dual blockade
CRP11	Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter eeeee2  (GLUT4), and blocked by dual blockade
CRP11	Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent  bbbbb1 glucose eeeee1  derivative, was decreased by inhibition of HCs or glucose transporter ( bbbbb2 GLUT4 eeeee2 ), and blocked by dual blockade
CRP11	Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent  bbbbb1 glucose eeeee1  derivative, was decreased by inhibition of HCs or  bbbbb2 glucose transporter eeeee2  (GLUT4), and blocked by dual blockade
CRP11	MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles  bbbbb1 ATP eeeee1  bbbbb2 P2Y1R eeeee2  blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles ATP activates P2Y1 but not P2X receptors
CRP11	During repetitive stimulation of skeletal muscle, extracellular ATP levels raise, activating purinergic receptors, increasing  bbbbb1 Ca(2+) eeeee1  bbbbb2 purinergic receptors eeeee2 , increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation
CRP11	In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited b bbbbb1 y antian eeeee1  bbbbb2 y antiandrogens eeeee2 
CRP11	In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited b bbbbb1 y antian eeeee1  bbbbb2 eff eeeee2 ect was inhibited by antiandrogens
CRP11	In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited b bbbbb1 y antian eeeee1  bbbbb2 ree bone cell systems tested, and this eeeee2  effect was inhibited by antiandrogens
CRP11	The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2 
CRP11	We examined the ability of ICI 182,780 ( bbbbb1 ICI eeeee1 ) to block uterine cell proliferation via  bbbbb2 protein kinase b eeeee2 /AKT pathway in the uterus of the rat during the estrous cycle
CRP11	We examined the ability of ICI 182,780 ( bbbbb1 ICI eeeee1 ) to block uterine cell proliferation via protein kinase b/ bbbbb2 AKT eeeee2  pathway in the uterus of the rat during the estrous cycle
CRP11	We examined the ability of  bbbbb1 ICI 182,780 eeeee1  (ICI) to block uterine cell proliferation via  bbbbb2 protein kinase b eeeee2 /AKT pathway in the uterus of the rat during the estrous cycle
CRP11	We examined the ability of  bbbbb1 ICI 182,780 eeeee1  (ICI) to block uterine cell proliferation via protein kinase b/ bbbbb2 AKT eeeee2  pathway in the uterus of the rat during the estrous cycle
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine  bbbbb1 estrogen eeeee1  receptor alpha ( bbbbb2 ERα eeeee2 ) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine  bbbbb1 estrogen eeeee1  receptor alpha (ERα) content, had no effect on uterine  bbbbb2 progesterone receptor eeeee2  (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine  bbbbb1 estrogen eeeee1  receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of  bbbbb2 cyclin D1 eeeee2 , in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor alpha eeeee2  (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine  bbbbb1 estrogen eeeee1  receptor alpha (ERα) content, had no effect on uterine progesterone receptor ( bbbbb2 PR eeeee2 ) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine  bbbbb1 progesterone eeeee1  bbbbb2 ERα eeeee2 ) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptor eeeee2  (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine  bbbbb1 progesterone eeeee1  receptor (PR) protein expression and caused marked nuclear localization of  bbbbb2 cyclin D1 eeeee2 , in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine  bbbbb1 progesterone eeeee1  bbbbb2 estrogen receptor alpha eeeee2  (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine  bbbbb1 progesterone eeeee1  receptor ( bbbbb2 PR eeeee2 ) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals
CRP11	Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the  bbbbb1 cyclopropyl-substituted phenylalanine eeeee1  bbbbb2 DPP-4 eeeee2 ) inhibitors, among them, the cyclopropyl-substituted phenylalanine derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 μM
CRP11	Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the  bbbbb1 cyclopropyl-substituted phenylalanine eeeee1  bbbbb2 dipeptidyl peptidase 4 eeeee2  (DPP-4) inhibitors, among them, the cyclopropyl-substituted phenylalanine derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 μM
CRP11	Pertussis toxin normalised  bbbbb1 isoproterenol eeeee1  responses in  bbbbb2 NCX eeeee2  cells, indicating that beta2AR effects were mediated by Gi
CRP11	Pertussis toxin normalised  bbbbb1 isoproterenol eeeee1  responses in NCX cells, indicating that beta2AR effects were mediated by  bbbbb2 Gi eeeee2 
CRP11	Pertussis toxin normalised  bbbbb1 isoproterenol eeeee1  bbbbb2 Pertussis toxin eeeee2  normalised isoproterenol responses in NCX cells, indicating that beta2AR effects were mediated by Gi
CRP11	Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/ bbbbb1 Ca(2+) eeeee1  bbbbb2 beta-adrenoceptor eeeee2  response in myocytes overexpressing the Na+/Ca(2+)-exchanger
CRP11	Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/ bbbbb1 Ca(2+) eeeee1  bbbbb2 Na+/Ca(2+)-exchanger eeeee2 
CRP11	Loss of beta-adrenoceptor response in myocytes overexpressing the  bbbbb1 Na+ eeeee1  bbbbb2 beta-adrenoceptor eeeee2  response in myocytes overexpressing the Na+/Ca(2+)-exchanger
CRP11	Loss of beta-adrenoceptor response in myocytes overexpressing the  bbbbb1 Na+ eeeee1  bbbbb2 Na+/Ca(2+)-exchanger eeeee2 
CRP11	Increased Na+/ bbbbb1 Ca(2+) eeeee1 -exchanger (NCX) and altered  bbbbb2 beta-adrenoceptor eeeee2  (betaAR) responses are observed in failing human heart
CRP11	Increased Na+/ bbbbb1 Ca(2+) eeeee1 -exchanger (NCX) and altered beta-adrenoceptor ( bbbbb2 betaAR eeeee2 ) responses are observed in failing human heart
CRP11	Increased Na+/ bbbbb1 Ca(2+) eeeee1  bbbbb2 Na+/Ca(2+)-exchanger eeeee2  (NCX) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart
CRP11	Increased Na+/ bbbbb1 Ca(2+) eeeee1 -exchanger ( bbbbb2 NCX eeeee2 ) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart
CRP11	Increased  bbbbb1 Na+ eeeee1 /Ca(2+)-exchanger (NCX) and altered  bbbbb2 beta-adrenoceptor eeeee2  (betaAR) responses are observed in failing human heart
CRP11	Increased  bbbbb1 Na+ eeeee1 /Ca(2+)-exchanger (NCX) and altered beta-adrenoceptor ( bbbbb2 betaAR eeeee2 ) responses are observed in failing human heart
CRP11	Increased  bbbbb1 Na+ eeeee1  bbbbb2 Na+/Ca(2+)-exchanger eeeee2  (NCX) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart
CRP11	Increased  bbbbb1 Na+ eeeee1 /Ca(2+)-exchanger ( bbbbb2 NCX eeeee2 ) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart
CRP11	The present study determined the influence of a  bbbbb1 retinoid eeeee1  bbbbb2 retinoid X receptor eeeee2  agonist bexarotene on angiogenesis and metastasis in solid tumours
CRP11	A selective  bbbbb1 retinoid eeeee1  bbbbb2 retinoid X receptor eeeee2  agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
CRP11	Subsequent α-tocopherol administration partially or completely reversed all t bbbbb1 hese values  eeeee1  bbbbb2 hese values to contro eeeee2 l levels
CRP11	Subsequent α-tocopherol administration partially bbbbb1  or compl eeeee1 etely reversed all t bbbbb2 hese values to contro eeeee2 l levels
CRP11	Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to  bbbbb1 phosphotyrosine eeeee1  bbbbb2 phosphotyrosine phosphatase eeeee2  overactivation and cell death in the rat hippocampus
CRP11	Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to  bbbbb1 phosphotyrosine eeeee1  bbbbb2 somatostatinergic receptor eeeee2 -effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus
CRP11	 bbbbb1 Vitamin E eeeee1  deficiency impairs the somatostatinergic receptor-effector system and leads to  bbbbb2 phosphotyrosine phosphatase eeeee2  overactivation and cell death in the rat hippocampus
CRP11	 bbbbb1 Vitamin E eeeee1  deficiency impairs the  bbbbb2 somatostatinergic receptor eeeee2 -effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus
CRP11	No changes in  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  expression were detected in vitamin-E-deficient rats
CRP11	No changes in somatostatin expression were detected in  bbbbb1 vitamin-E eeeee1  bbbbb2 somatostatin eeeee2  expression were detected in vitamin-E-deficient rats
CRP11	These rats, however, showed a significant increase in the somatostatin receptor density and dissociation constant, which correlated with a significant increase in the protein levels of  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptor eeeee2  density and dissociation constant, which correlated with a significant increase in the protein levels of somatostatin receptors
CRP11	These rats, however, showed a significant increase in the somatostatin receptor density and dissociation constant, which correlated with a significant increase in the protein levels of  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptors eeeee2 
CRP11	These rats, however, showed a significant increase in the  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptor eeeee2  density and dissociation constant, which correlated with a significant increase in the protein levels of somatostatin receptors
CRP11	These rats, however, showed a significant increase in the  bbbbb1 somatostatin eeeee1  receptor density and dissociation constant, which correlated with a significant increase in the protein levels of  bbbbb2 somatostatin receptors eeeee2 
CRP11	We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by α-tocopherol in the rat dentate gyrus, increasing  bbbbb1 cyclic adenosine monophosphate eeeee1  bbbbb2 cyclic adenosine monophosphate response element binding protein eeeee2  phosphorylation
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors  bbbbb1 adenylyl eeeee1  cyclase and  bbbbb2 phosphotyrosine phosphatase eeeee2  by diminishing Gi protein functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors  bbbbb1 adenylyl eeeee1  cyclase and phosphotyrosine phosphatase by diminishing  bbbbb2 Gi protein eeeee2  functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors  bbbbb1 adenylyl eeeee1  bbbbb2 somatostatin receptors eeeee2  to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality
CRP11	Nevertheless,  bbbbb1 vitamin E eeeee1  deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and  bbbbb2 phosphotyrosine phosphatase eeeee2  by diminishing Gi protein functionality
CRP11	Nevertheless,  bbbbb1 vitamin E eeeee1  deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing  bbbbb2 Gi protein eeeee2  functionality
CRP11	Nevertheless,  bbbbb1 vitamin E eeeee1  deficiency impaired the ability of the  bbbbb2 somatostatin receptors eeeee2  to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the  bbbbb1 somatostatin eeeee1  receptors to couple to the effectors adenylyl cyclase and  bbbbb2 phosphotyrosine phosphatase eeeee2  by diminishing Gi protein functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the  bbbbb1 somatostatin eeeee1  receptors to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing  bbbbb2 Gi protein eeeee2  functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin receptors eeeee2  to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and  bbbbb1 phosphotyrosine eeeee1  bbbbb2 phosphotyrosine phosphatase eeeee2  by diminishing Gi protein functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and  bbbbb1 phosphotyrosine eeeee1  phosphatase by diminishing  bbbbb2 Gi protein eeeee2  functionality
CRP11	Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and  bbbbb1 phosphotyrosine eeeee1  bbbbb2 somatostatin receptors eeeee2  to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of  bbbbb1 tocopherol eeeee1  bbbbb2 somatostatin eeeee2  and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of  bbbbb1 tocopherol eeeee1  on the  bbbbb2 somatostatin eeeee2  signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E,  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E,  bbbbb1 somatostatin eeeee1  and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the  bbbbb2 somatostatin eeeee2  signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of  bbbbb1 tocopherols eeeee1  and examine the link among vitamin E,  bbbbb2 somatostatin eeeee2  and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of  bbbbb1 tocopherols eeeee1  and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the  bbbbb2 somatostatin eeeee2  signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among  bbbbb1 vitamin E eeeee1 ,  bbbbb2 somatostatin eeeee2  and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus
CRP11	To gain a better understanding of the molecular actions of tocopherols and examine the link among  bbbbb1 vitamin E eeeee1 , somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the  bbbbb2 somatostatin eeeee2  signaling pathway and neuronal survival in the rat hippocampus
CRP11	Furthermore, vitamin E deficiency significantly increased  bbbbb1 phosphotyrosine eeeee1  phosphatase activity and PTPη expression, as well as  bbbbb2 PKCδ eeeee2  activation, and decreased extracellular-signal-regulated kinase phosphorylation
CRP11	Furthermore, vitamin E deficiency significantly increased  bbbbb1 phosphotyrosine eeeee1  phosphatase activity and PTPη expression, as well as PKCδ activation, and decreased  bbbbb2 extracellular-signal-regulated kinase eeeee2  phosphorylation
CRP11	Furthermore, vitamin E deficiency significantly increased  bbbbb1 phosphotyrosine eeeee1  bbbbb2 phosphotyrosine phosphatase eeeee2  activity and PTPη expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation
CRP11	Furthermore, vitamin E deficiency significantly increased  bbbbb1 phosphotyrosine eeeee1  phosphatase activity and  bbbbb2 PTPη eeeee2  expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation
CRP11	Furthermore,  bbbbb1 vitamin E eeeee1  deficiency significantly increased phosphotyrosine phosphatase activity and PTPη expression, as well as  bbbbb2 PKCδ eeeee2  activation, and decreased extracellular-signal-regulated kinase phosphorylation
CRP11	Furthermore,  bbbbb1 vitamin E eeeee1  deficiency significantly increased phosphotyrosine phosphatase activity and PTPη expression, as well as PKCδ activation, and decreased  bbbbb2 extracellular-signal-regulated kinase eeeee2  phosphorylation
CRP11	Furthermore,  bbbbb1 vitamin E eeeee1  deficiency significantly increased  bbbbb2 phosphotyrosine phosphatase eeeee2  activity and PTPη expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation
CRP11	Furthermore,  bbbbb1 vitamin E eeeee1  deficiency significantly increased phosphotyrosine phosphatase activity and  bbbbb2 PTPη eeeee2  expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation
CRP11	Multiple rat brain calpastatin forms are produced by distinct starting points and alternative splicing of the  bbbbb1 N eeeee1 -terminal exons. 5'-RACE was performed on  bbbbb2 rat brain calpastatin eeeee2  mRNA and two new translation initiation ATG's were found
CRP11	Plant homeodomain (PHD)-type  bbbbb1 zinc eeeee1  bbbbb2 Plant homeodomain (PHD)-type zinc fingers eeeee2  play an important role in recognizing chromatin modifications and recruiting regulatory proteins to specific genes
CRP11	We demonstrate that the PHD1-PHD2 region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to  bbbbb1 lysine eeeee1  bbbbb2 PHD1-PHD2 eeeee2  region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to lysine 4-methylated histone H3 tails
CRP11	We demonstrate that the PHD1-PHD2 region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to  bbbbb1 lysine eeeee1  bbbbb2 PHD finger eeeee2  contributes to the preferred binding of PHD1-PHD2 to lysine 4-methylated histone H3 tails
CRP11	In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of AF10,  bbbbb1 zinc eeeee1  bbbbb2 PHD1-PHD2 eeeee2  region of the Caenorhabditis elegans ortholog of AF10, zinc finger protein 1 (ZFP-1)
CRP11	In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of AF10,  bbbbb1 zinc eeeee1  bbbbb2 AF10 eeeee2 , zinc finger protein 1 (ZFP-1)
CRP11	In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of AF10,  bbbbb1 zinc eeeee1  finger protein 1 ( bbbbb2 ZFP-1 eeeee2 )
CRP11	In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of AF10,  bbbbb1 zinc eeeee1  bbbbb2 zinc finger protein 1 eeeee2  (ZFP-1)
CRP11	AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the  bbbbb1 N eeeee1  bbbbb2 N-terminal PHD fingers eeeee2  of AF10
CRP11	AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the  bbbbb1 N eeeee1  bbbbb2 MLL eeeee2 -AF10 fusion protein, which lacks the N-terminal PHD fingers of AF10
CRP11	AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the  bbbbb1 N eeeee1  bbbbb2 AF10 eeeee2  fusion protein, which lacks the N-terminal PHD fingers of AF10
CRP11	AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the  bbbbb1 N eeeee1  bbbbb2 AF10 eeeee2  has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the N-terminal PHD fingers of AF10
CRP11	AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Irbesartan is a long-acting  bbbbb1 angiotensin II eeeee1  antagonist acting specifically at the level of the Type 1-receptor subtype ( bbbbb2 AT1 eeeee2 -receptor)
CRP11	AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Irbesartan is a long-acting  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)
CRP11	AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Irbesartan is a long-acting  bbbbb1 angiotensin II eeeee1  bbbbb2 AT1 eeeee2 -receptor antagonism in hypertension: what has been learned with irbesartan? Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)
CRP11	AT1-receptor antagonism in hypertension: what has been learned with  bbbbb1 irbesartan eeeee1 ? Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype ( bbbbb2 AT1 eeeee2 -receptor)
CRP11	AT1-receptor antagonism in hypertension: what has been learned with  bbbbb1 irbesartan eeeee1 ? Irbesartan is a long-acting  bbbbb2 angiotensin II eeeee2  antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)
CRP11	AT1-receptor antagonism in hypertension: what has been learned with  bbbbb1 irbesartan eeeee1  bbbbb2 AT1 eeeee2 -receptor antagonism in hypertension: what has been learned with irbesartan? Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)
CRP11	AT1-receptor antagonism in hypertension: what has been learned with irbesartan?  bbbbb1 Irbesartan eeeee1  bbbbb2 AT1 eeeee2 -receptor antagonism in hypertension: what has been learned with irbesartan? Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)
CRP11	An investigation of the absolute configuration of the potent  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 receptor eeeee2  antagonist GT-2331 using vibrational circular dichroism
CRP11	GT-2331 [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of histamine by the  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 receptor eeeee2 , and as such, is an important biomarker for pharmaceutical companies conducting research in this field
CRP11	GT-2331 [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of  bbbbb1 histamine eeeee1  by the  bbbbb2 histamine H3 receptor eeeee2 , and as such, is an important biomarker for pharmaceutical companies conducting research in this field
CRP11	Management of AUB is based on the underlying etiology and the severity of the bleeding and primary goals are prevention of complications, such as anemia and reestablis bbbbb1 hmen eeeee1  bbbbb2 hmen eeeee2 t of regular cyclical bleeding, while the management of DUB can in part be directed by the amount of flow, the degree of associated anemia, as well as patient and family comfort with different treatment modalities
CRP11	Management of AUB is based on the underlying etiology and the severity of the bleeding and primary goals are prevention of complic bbbbb1 ations, such as eeeee1  anemia and reestablis bbbbb2 hmen eeeee2 t of regular cyclical bleeding, while the management of DUB can in part be directed by the amount of flow, the degree of associated anemia, as well as patient and family comfort with different treatment modalities
CRP11	Management of AUB is based on the underlying etiology and the severi bbbbb1 ty of the bl eeeee1 eeding and primary goals are prevention of complications, such as anemia and reestablis bbbbb2 hmen eeeee2 t of regular cyclical bleeding, while the management of DUB can in part be directed by the amount of flow, the degree of associated anemia, as well as patient and family comfort with different treatment modalities
CRP11	Cerebral  bbbbb1 histamine eeeee1  H1 receptor ( bbbbb2 H(1)R eeeee2 ) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [(11)C]-doxepin
CRP11	Cerebral  bbbbb1 histamine eeeee1  bbbbb2 histamine H1 receptor eeeee2  (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [(11)C]-doxepin
CRP11	Decreased  bbbbb1 histamine eeeee1  bbbbb2 histamine H1 receptor eeeee2  binding in the brain of depressed patients
CRP11	Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although  bbbbb1 propranolol eeeee1  bbbbb2 Beta 2-Adrenoceptor eeeee2  density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists  bbbbb1 propranolol eeeee1  [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma  bbbbb2 renin eeeee2  activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists  bbbbb1 propranolol eeeee1  [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte  bbbbb2 beta 2-adrenoceptor eeeee2  density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by  bbbbb1 (+/-)-[125I]-iodocyanopindolol eeeee1  bbbbb2 beta-adrenoceptor eeeee2  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by  bbbbb1 (+/-)-[125I]-iodocyanopindolol eeeee1  (ICYP) binding--and plasma  bbbbb2 renin eeeee2  activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by  bbbbb1 (+/-)-[125I]-iodocyanopindolol eeeee1  bbbbb2 beta 2-adrenoceptor eeeee2  density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and  bbbbb1 mepindolol eeeee1  (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma  bbbbb2 renin eeeee2  activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and  bbbbb1 mepindolol eeeee1  (strong ISA) on lymphocyte  bbbbb2 beta 2-adrenoceptor eeeee2  density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol ( bbbbb1 ICYP eeeee1  bbbbb2 beta-adrenoceptor eeeee2  antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol ( bbbbb1 ICYP eeeee1 ) binding--and plasma  bbbbb2 renin eeeee2  activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol ( bbbbb1 ICYP eeeee1  bbbbb2 beta 2-adrenoceptor eeeee2  density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)],  bbbbb1 alprenolol eeeee1  (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma  bbbbb2 renin eeeee2  activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)],  bbbbb1 alprenolol eeeee1  (weak ISA) and mepindolol (strong ISA) on lymphocyte  bbbbb2 beta 2-adrenoceptor eeeee2  density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years
CRP11	The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for  bbbbb1 4-chloropropofol eeeee1  bbbbb2 Na(V)1.4 eeeee2 , respectively, and 29.2 microM for 4-chloropropofol in Na(V)1.2
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle  bbbbb1 sodium eeeee1  channels ( bbbbb2 Na(V)1.4 eeeee2 ) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle  bbbbb1 sodium eeeee1  channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on  bbbbb2 neuronal sodium channels eeeee2  (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle  bbbbb1 sodium eeeee1  bbbbb2 voltage-operated human skeletal muscle sodium channels eeeee2  (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle  bbbbb1 sodium eeeee1  channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels ( bbbbb2 Na(V)1.2 eeeee2 ) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound ( bbbbb1 4-chloropropofol eeeee1  bbbbb2 Na(V)1.4 eeeee2 ) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound ( bbbbb1 4-chloropropofol eeeee1 ) on  bbbbb2 neuronal sodium channels eeeee2  (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound ( bbbbb1 4-chloropropofol eeeee1  bbbbb2 voltage-operated human skeletal muscle sodium channels eeeee2  (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound ( bbbbb1 4-chloropropofol eeeee1 ) on neuronal sodium channels ( bbbbb2 Na(V)1.2 eeeee2 ) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of  bbbbb1 propofol eeeee1  on voltage-operated human skeletal muscle sodium channels ( bbbbb2 Na(V)1.4 eeeee2 ) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of  bbbbb1 propofol eeeee1  on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on  bbbbb2 neuronal sodium channels eeeee2  (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of  bbbbb1 propofol eeeee1  on  bbbbb2 voltage-operated human skeletal muscle sodium channels eeeee2  (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of  bbbbb1 propofol eeeee1  on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels ( bbbbb2 Na(V)1.2 eeeee2 ) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal  bbbbb1 sodium eeeee1  bbbbb2 Na(V)1.4 eeeee2 ) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal  bbbbb1 sodium eeeee1  bbbbb2 neuronal sodium channels eeeee2  (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal  bbbbb1 sodium eeeee1  bbbbb2 voltage-operated human skeletal muscle sodium channels eeeee2  (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293
CRP11	TAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal  bbbbb1 sodium eeeee1  channels ( bbbbb2 Na(V)1.2 eeeee2 ) heterologously expressed in human embryonic kidney cell line 293
CRP11	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol,  bbbbb1 4-bromopropofol eeeee1  and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in  bbbbb2 Na(V)1.2 eeeee2 
CRP11	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and  bbbbb1 4-chloropropofol eeeee1  in Na(V)1.4, and 450 nM for 4-chloropropofol in  bbbbb2 Na(V)1.2 eeeee2 
CRP11	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for  bbbbb1 4-chloropropofol eeeee1  bbbbb2 Na(V)1.4 eeeee2 , and 450 nM for 4-chloropropofol in Na(V)1.2
CRP11	Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for  bbbbb1 4-iodopropofol eeeee1 , 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in  bbbbb2 Na(V)1.2 eeeee2 
CRP11	Voltage-operated  bbbbb1 sodium eeeee1  bbbbb2 Voltage-operated sodium channels eeeee2  constitute major target sites for local anaesthetic-like action
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of  bbbbb1 hydroxocobalamin eeeee1  bbbbb2 Methylenetetrahydrofolate reductase eeeee2  deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of  bbbbb1 hydroxocobalamin eeeee1  (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of  bbbbb2 methionine synthase eeeee2  (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs  bbbbb1 methyltetrahydrofolate eeeee1  synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of  bbbbb2 methionine synthase eeeee2  (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and  bbbbb1 adenosyl cobalamin eeeee1  bbbbb2 Methylenetetrahydrofolate reductase eeeee2  deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and  bbbbb1 adenosyl cobalamin eeeee1  and deficiencies of  bbbbb2 methionine synthase eeeee2  (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	 bbbbb1 Methylenetetrahydrofolate eeeee1  bbbbb2 Methylenetetrahydrofolate reductase eeeee2  deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	 bbbbb1 Methylenetetrahydrofolate eeeee1  reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of  bbbbb2 methionine synthase eeeee2  (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of  bbbbb1 methionine eeeee1  bbbbb2 Methylenetetrahydrofolate reductase eeeee2  deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase eeeee2  (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both  bbbbb1 methyl eeeee1  bbbbb2 Methylenetetrahydrofolate reductase eeeee2  deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both  bbbbb1 methyl eeeee1 - and adenosyl cobalamin and deficiencies of  bbbbb2 methionine synthase eeeee2  (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective  bbbbb1 methyl cobalamin eeeee1  bbbbb2 Methylenetetrahydrofolate reductase eeeee2  deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis
CRP11	Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small  bbbbb1 proline eeeee1  bbbbb2 anterior gradient-2 eeeee2 , trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CRP11	Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small  bbbbb1 proline eeeee1  bbbbb2 CRP-ductin eeeee2 , ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CRP11	Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small  bbbbb1 proline eeeee1  bbbbb2 small proline-rich protein-2A eeeee2 , were dramatically over-expressed
CRP11	Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small  bbbbb1 proline eeeee1  bbbbb2 trefoil factor-1 eeeee2 , CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CRP11	Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small  bbbbb1 proline eeeee1  bbbbb2 ghrelin eeeee2 , and small proline-rich protein-2A, were dramatically over-expressed
CRP11	Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small  bbbbb1 proline eeeee1  bbbbb2 X-inactive-specific transcript eeeee2 , anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed
CRP11	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of  bbbbb1 17beta-hydroxysteroid eeeee1  dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of  bbbbb2 HSD17beta5 eeeee2  (involved in testosterone production)
CRP11	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of  bbbbb1 17beta-hydroxysteroid eeeee1  bbbbb2 17beta-hydroxysteroid dehydrogenase-7 eeeee2  (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)
CRP11	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of  bbbbb1 17beta-hydroxysteroid eeeee1  dehydrogenase-7 ( bbbbb2 HSD17beta7 eeeee2 ; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)
CRP11	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in  bbbbb1 testosterone eeeee1  bbbbb2 17beta-hydroxysteroid dehydrogenase-7 eeeee2  (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)
CRP11	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in  bbbbb1 testosterone eeeee1  bbbbb2 HSD17beta7 eeeee2 ; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)
CRP11	Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in  bbbbb1 estradiol eeeee1  production) and decreased expression of  bbbbb2 HSD17beta5 eeeee2  (involved in testosterone production)
CRP11	Several genes involved with  bbbbb1 steroid eeeee1  metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 ( bbbbb2 HSD17beta7 eeeee2 ; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and thioether  bbbbb1 S eeeee1  bbbbb2 betaine-homocysteine methyltransferase eeeee2  and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and thioether  bbbbb1 S eeeee1  bbbbb2 thioether S-methyltransferase eeeee2 , were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and thioether  bbbbb1 S eeeee1  bbbbb2 methionine adenosyltransferase-1a eeeee2 , betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine- bbbbb1 homocysteine eeeee1  bbbbb2 betaine-homocysteine methyltransferase eeeee2  and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine- bbbbb1 homocysteine eeeee1  methyltransferase and  bbbbb2 thioether S-methyltransferase eeeee2 , were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine- bbbbb1 homocysteine eeeee1  bbbbb2 methionine adenosyltransferase-1a eeeee2 , betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and  bbbbb1 thioether eeeee1  bbbbb2 betaine-homocysteine methyltransferase eeeee2  and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and  bbbbb1 thioether eeeee1  bbbbb2 thioether S-methyltransferase eeeee2 , were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and  bbbbb1 thioether eeeee1  bbbbb2 methionine adenosyltransferase-1a eeeee2 , betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a,  bbbbb1 betaine eeeee1  bbbbb2 betaine-homocysteine methyltransferase eeeee2  and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a,  bbbbb1 betaine eeeee1 -homocysteine methyltransferase and  bbbbb2 thioether S-methyltransferase eeeee2 , were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a,  bbbbb1 betaine eeeee1  bbbbb2 methionine adenosyltransferase-1a eeeee2 , betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as  bbbbb1 methionine eeeee1  adenosyltransferase-1a,  bbbbb2 betaine-homocysteine methyltransferase eeeee2  and thioether S-methyltransferase, were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as  bbbbb1 methionine eeeee1  adenosyltransferase-1a, betaine-homocysteine methyltransferase and  bbbbb2 thioether S-methyltransferase eeeee2 , were suppressed
CRP11	The expression of key genes important in methionine metabolism, such as  bbbbb1 methionine eeeee1  bbbbb2 methionine adenosyltransferase-1a eeeee2 , betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed
CRP11	We rescued cells lethally depleted of endogenous Cdk1 with an exogenous Cdk1 conferring sensitivity to one  bbbbb1 ATP eeeee1  bbbbb2 Cdk1 eeeee2  conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (RO3306)
CRP11	We rescued cells lethally depleted of endogenous Cdk1 with an exogenous Cdk1 conferring sensitivity to one  bbbbb1 ATP eeeee1  bbbbb2 Cdk1 eeeee2  with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (RO3306)
CRP11	We rescued cells lethally depleted of endogenous Cdk1 with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor ( bbbbb1 1NMPP1 eeeee1  bbbbb2 Cdk1 eeeee2  with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (RO3306)
CRP11	We rescued cells lethally depleted of endogenous Cdk1 with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another ( bbbbb1 RO3306 eeeee1  bbbbb2 Cdk1 eeeee2  with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (RO3306)
CRP11	The complexity of Cdk1 regulation has made it difficult to determine whether these different roles require different thresholds of kinase activity and whether the surge of activity as inhibitory  bbbbb1 phosphates eeeee1  bbbbb2 kinase eeeee2  activity and whether the surge of activity as inhibitory phosphates are removed at mitotic onset is essential for cell proliferation
CRP11	The complexity of Cdk1 regulation has made it difficult to determine whether these different roles require different thresholds of kinase activity and whether the surge of activity as inhibitory  bbbbb1 phosphates eeeee1  bbbbb2 Cdk1 eeeee2  regulation has made it difficult to determine whether these different roles require different thresholds of kinase activity and whether the surge of activity as inhibitory phosphates are removed at mitotic onset is essential for cell proliferation
CRP11	At no  bbbbb1 1NMPP1 eeeee1  concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for Cdk1 are not simply controlled by different  bbbbb2 Cdk1 eeeee2  activity thresholds
CRP11	We also rescued  bbbbb1 RO3306 eeeee1 -resistant clones using exogenous Cdk1 without inhibitory phosphorylation sites, indicating that the mitotic surge of  bbbbb2 Cdk1 eeeee2  activity is dispensable for cell proliferation
CRP11	Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific  bbbbb1 [(3)H]histamine eeeee1  bbbbb2 H(2)R eeeee2  antagonists, including several important therapeutics, displaced less than 30% of specific [(3)H]histamine binding to the hH(4)R at concentrations up to 10 microM
CRP11	Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific  bbbbb1 [(3)H]histamine eeeee1  bbbbb2 H(1)R eeeee2  and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific [(3)H]histamine binding to the hH(4)R at concentrations up to 10 microM
CRP11	Evaluation of  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-, H2-, and H3-receptor eeeee2  ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist
CRP11	Evaluation of  bbbbb1 histamine eeeee1  H1-, H2-, and H3-receptor ligands at the  bbbbb2 human histamine H4 receptor eeeee2 : identification of 4-methylhistamine as the first potent and selective H4 receptor agonist
CRP11	Evaluation of  bbbbb1 histamine eeeee1  H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective  bbbbb2 H4 receptor eeeee2  agonist
CRP11	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-, H2-, and H3-receptor eeeee2  ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist
CRP11	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human  bbbbb1 histamine eeeee1  bbbbb2 human histamine H4 receptor eeeee2 : identification of 4-methylhistamine as the first potent and selective H4 receptor agonist
CRP11	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human  bbbbb1 histamine eeeee1  H4 receptor: identification of 4-methylhistamine as the first potent and selective  bbbbb2 H4 receptor eeeee2  agonist
CRP11	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of  bbbbb1 4-methylhistamine eeeee1  bbbbb2 histamine H1-, H2-, and H3-receptor eeeee2  ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist
CRP11	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of  bbbbb1 4-methylhistamine eeeee1  bbbbb2 human histamine H4 receptor eeeee2 : identification of 4-methylhistamine as the first potent and selective H4 receptor agonist
CRP11	The  bbbbb1 histamine eeeee1  bbbbb2 histamine H(4) receptor eeeee2  (H(4)R) is involved in the chemotaxis of leukocytes and mast cells to sites of inflammation and is suggested to be a potential drug target for asthma and allergy
CRP11	The  bbbbb1 histamine eeeee1  H(4) receptor ( bbbbb2 H(4)R eeeee2 ) is involved in the chemotaxis of leukocytes and mast cells to sites of inflammation and is suggested to be a potential drug target for asthma and allergy
CRP11	Interestingly, we identified 4-methylhistamine as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other  bbbbb1 histamine eeeee1  bbbbb2 hH(4)R eeeee2  over the other histamine receptor subtypes
CRP11	Interestingly, we identified 4-methylhistamine as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other  bbbbb1 histamine eeeee1  bbbbb2 histamine receptor eeeee2  subtypes
CRP11	Interestingly, we identified 4-methylhistamine as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other  bbbbb1 histamine eeeee1  bbbbb2 H(4)R eeeee2  ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes
CRP11	Most of the tested H(2)R agonists and  bbbbb1 imidazole eeeee1  bbbbb2 H(2)R eeeee2  agonists and imidazole-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists
CRP11	Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor,  bbbbb1 wortmannin eeeee1  bbbbb2 insulin eeeee2 -stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin
CRP11	Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor,  bbbbb1 wortmannin eeeee1  bbbbb2 ucOC eeeee2  (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin
CRP11	Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the  bbbbb1 phosphatidylinositol eeeee1  3-kinase ( bbbbb2 PI3-kinase eeeee2 ) inhibitor, wortmannin
CRP11	Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 insulin eeeee2 -stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin
CRP11	Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 phosphatidylinositol 3-kinase eeeee2  (PI3-kinase) inhibitor, wortmannin
CRP11	Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 ucOC eeeee2  (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved  bbbbb1 poly (ADP-ribose) eeeee1  bbbbb2 caspase 3 eeeee2 , cleaved poly (ADP-ribose) polymerase and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved  bbbbb1 poly (ADP-ribose) eeeee1  bbbbb2 deoxyribonucleotide transferase eeeee2 -mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved  bbbbb1 poly (ADP-ribose) eeeee1  polymerase and  bbbbb2 Bcl-xL eeeee2 
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved  bbbbb1 poly (ADP-ribose) eeeee1  bbbbb2 poly (ADP-ribose) polymerase eeeee2  and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated  bbbbb1 deoxyuridine triphosphate eeeee1  nick-end labeling analysis kit and Western blotting for cleaved  bbbbb2 caspase 3 eeeee2 , cleaved poly (ADP-ribose) polymerase and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated  bbbbb1 deoxyuridine triphosphate eeeee1  bbbbb2 deoxyribonucleotide transferase eeeee2 -mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated  bbbbb1 deoxyuridine triphosphate eeeee1  nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and  bbbbb2 Bcl-xL eeeee2 
CRP11	Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated  bbbbb1 deoxyuridine triphosphate eeeee1  nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved  bbbbb2 poly (ADP-ribose) polymerase eeeee2  and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal  bbbbb1 deoxyribonucleotide eeeee1  transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved  bbbbb2 caspase 3 eeeee2 , cleaved poly (ADP-ribose) polymerase and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal  bbbbb1 deoxyribonucleotide eeeee1  bbbbb2 deoxyribonucleotide transferase eeeee2 -mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and Bcl-xL
CRP11	Apoptosis was evaluated using various methods including a terminal  bbbbb1 deoxyribonucleotide eeeee1  transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and  bbbbb2 Bcl-xL eeeee2 
CRP11	Apoptosis was evaluated using various methods including a terminal  bbbbb1 deoxyribonucleotide eeeee1  transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved  bbbbb2 poly (ADP-ribose) polymerase eeeee2  and Bcl-xL
CRP11	Sedation and  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. 1
CRP11	SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or  bbbbb1 LY294002 eeeee1  bbbbb2 p21 eeeee2  siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and LY294002
CRP11	SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or  bbbbb1 LY294002 eeeee1  whereas it was lessened after co-administration of  bbbbb2 p21 eeeee2  siRNA and LY294002
CRP11	SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and  bbbbb1 LY294002 eeeee1  bbbbb2 p21 eeeee2  siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and LY294002
CRP11	SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and  bbbbb1 LY294002 eeeee1  bbbbb2 p21 eeeee2  siRNA and LY294002
CRP11	 bbbbb1 SU5416 eeeee1 -treated situation, cell viability was not different before and after administration of either  bbbbb2 p21 eeeee2  siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and LY294002
CRP11	 bbbbb1 SU5416 eeeee1 -treated situation, cell viability was not different before and after administration of either p21 siRNA or LY294002 whereas it was lessened after co-administration of  bbbbb2 p21 eeeee2  siRNA and LY294002
CRP11	In the present study, we evaluated the effects of  bbbbb1 SU5416 eeeee1  on cell survival,  bbbbb2 p21 eeeee2 , and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells
CRP11	In the present study, we evaluated the effects of  bbbbb1 SU5416 eeeee1  on cell survival, p21, and  bbbbb2 PI3K eeeee2 /Akt signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells
CRP11	In the present study, we evaluated the effects of  bbbbb1 SU5416 eeeee1  on cell survival, p21, and PI3K/ bbbbb2 Akt eeeee2  signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells
CRP11	While CHOP plasmid transfection diminished p21 and  bbbbb1 phospho eeeee1  bbbbb2 phospho-Akt eeeee2  protein levels, CHOP siRNA transfection did not alter the protein levels
CRP11	While CHOP plasmid transfection diminished p21 and  bbbbb1 phospho eeeee1 -Akt protein levels,  bbbbb2 CHOP eeeee2  siRNA transfection did not alter the protein levels
CRP11	While CHOP plasmid transfection diminished p21 and  bbbbb1 phospho eeeee1  bbbbb2 CHOP eeeee2  plasmid transfection diminished p21 and phospho-Akt protein levels, CHOP siRNA transfection did not alter the protein levels
CRP11	While CHOP plasmid transfection diminished p21 and  bbbbb1 phospho eeeee1  bbbbb2 p21 eeeee2  and phospho-Akt protein levels, CHOP siRNA transfection did not alter the protein levels
CRP11	After  bbbbb1 SU5416 eeeee1  treatment, cell viability, PARP-1, and caspase-3 protein levels were not changed. p53 and p27 protein levels decreased while  bbbbb2 p21 eeeee2  protein levels increased
CRP11	After  bbbbb1 SU5416 eeeee1  treatment, cell viability, PARP-1, and caspase-3 protein levels were not changed. p53 and  bbbbb2 p27 eeeee2  protein levels decreased while p21 protein levels increased
CRP11	After  bbbbb1 SU5416 eeeee1  treatment, cell viability, PARP-1, and caspase-3 protein levels were not changed.  bbbbb2 p53 eeeee2  and p27 protein levels decreased while p21 protein levels increased
CRP11	Role of oestrogen receptors on the modulation of  bbbbb1 NADPH eeeee1  bbbbb2 NADPH-diaphorase eeeee2 -positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats
CRP11	Role of oestrogen receptors on the modulation of  bbbbb1 NADPH eeeee1  bbbbb2 oestrogen receptors eeeee2  on the modulation of NADPH-diaphorase-positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats
CRP11	Role of  bbbbb1 oestrogen eeeee1  receptors on the modulation of  bbbbb2 NADPH-diaphorase eeeee2 -positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats
CRP11	Role of  bbbbb1 oestrogen eeeee1  bbbbb2 oestrogen receptors eeeee2  on the modulation of NADPH-diaphorase-positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats
CRP11	Modulation of the nitric oxide producing system (demonstrated via the  bbbbb1 NADPH eeeee1  bbbbb2 NADPH-diaphorase eeeee2  histochemical reaction) by oestradiol has been established in several structures of the rat brain
CRP11	Modulation of the nitric oxide producing system (demonstrated via the NADPH-diaphorase histochemical reaction) by  bbbbb1 oestradiol eeeee1  bbbbb2 NADPH-diaphorase eeeee2  histochemical reaction) by oestradiol has been established in several structures of the rat brain
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by  bbbbb1 oestradiol eeeee1  in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of  bbbbb2 oestrogen receptors eeeee2  (ERα and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by  bbbbb1 oestradiol eeeee1  in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors ( bbbbb2 ERα eeeee2  and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by  bbbbb1 oestradiol eeeee1  bbbbb2 NADPH-diaphorase eeeee2  activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by  bbbbb1 oestradiol eeeee1  in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and  bbbbb2 ERβ eeeee2 ) in this regulation
CRP11	The present study aimed to explore the possible regulation of  bbbbb1 NADPH eeeee1 -diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of  bbbbb2 oestrogen receptors eeeee2  (ERα and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of  bbbbb1 NADPH eeeee1 -diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors ( bbbbb2 ERα eeeee2  and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of  bbbbb1 NADPH eeeee1  bbbbb2 NADPH-diaphorase eeeee2  activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of  bbbbb1 NADPH eeeee1 -diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and  bbbbb2 ERβ eeeee2 ) in this regulation
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of  bbbbb1 oestrogen eeeee1  bbbbb2 oestrogen receptors eeeee2  (ERα and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of  bbbbb1 oestrogen eeeee1  receptors ( bbbbb2 ERα eeeee2  and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of  bbbbb1 oestrogen eeeee1  bbbbb2 NADPH-diaphorase eeeee2  activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and ERβ) in this regulation
CRP11	The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of  bbbbb1 oestrogen eeeee1  receptors (ERα and  bbbbb2 ERβ eeeee2 ) in this regulation
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [ bbbbb1 2,3-bis(4-hydroxyphenyl)-propionitrile eeeee1 ], a selective  bbbbb2 ERα eeeee2  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [ bbbbb1 2,3-bis(4-hydroxyphenyl)-propionitrile eeeee1 ], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [ bbbbb1 2,3-bis(4-hydroxyphenyl)-propionitrile eeeee1  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist- bbbbb1 DPN eeeee1  [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  bbbbb2 ERα eeeee2  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist- bbbbb1 DPN eeeee1  [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist- bbbbb1 DPN eeeee1  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP ( bbbbb1 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol eeeee1  bbbbb2 ERα eeeee2  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP ( bbbbb1 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol eeeee1  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP ( bbbbb1 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol eeeee1  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist- bbbbb1 PPT eeeee1  [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  bbbbb2 ERα eeeee2  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist- bbbbb1 PPT eeeee1  [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist- bbbbb1 PPT eeeee1  [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist- bbbbb1 PHTPP eeeee1  bbbbb2 ERα eeeee2  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist- bbbbb1 PHTPP eeeee1  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist- bbbbb1 PHTPP eeeee1  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [ bbbbb1 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol eeeee1  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [ bbbbb1 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol eeeee1 ]-1H-pyrazole dihydrochloride] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [ bbbbb1 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol eeeee1  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of  bbbbb1 oestradiol eeeee1 , a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  bbbbb2 ERα eeeee2  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of  bbbbb1 oestradiol eeeee1 , a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of  bbbbb1 oestradiol eeeee1 , a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of  bbbbb1 oestradiol eeeee1 , a selective  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [ bbbbb1 4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol eeeee1 ], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective  bbbbb2 ERα eeeee2  antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [ bbbbb1 4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol eeeee1 ], a selective  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [ bbbbb1 4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol eeeee1 ], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]- bbbbb1 1H-pyrazole dihydrochloride eeeee1  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]- bbbbb1 1H-pyrazole dihydrochloride eeeee1 ] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]- bbbbb1 1H-pyrazole dihydrochloride eeeee1  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist- bbbbb1 MPP eeeee1  bbbbb2 ERβ eeeee2  agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist- bbbbb1 MPP eeeee1  [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective  bbbbb2 ERβ eeeee2  antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist- bbbbb1 MPP eeeee1  bbbbb2 ERα eeeee2  agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)
CRP11	 bbbbb1 Jaceosidin eeeee1 , isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM- bbbbb2 Chk1/2 eeeee2  activation
CRP11	Knockdown of p21 using specific siRNAs partially abrogated  bbbbb1 jaceosidin eeeee1  bbbbb2 p21 eeeee2  using specific siRNAs partially abrogated jaceosidin-induced cell growth inhibition
CRP11	Moreover, jaceosidin tre bbbbb1 atment res eeeee1 ulted in phosphorylation of ERK, and pretreatment with t bbbbb2 he ERK eeeee2  inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin
CRP11	Ku55933, an ATM inhibitor, reversed  bbbbb1 jaceosidin eeeee1  bbbbb2 ATM eeeee2  inhibitor, reversed jaceosidin-induced cell growth inhibition, in part
CRP11	Additional mechanistic studies revealed that  bbbbb1 jaceosidin eeeee1  treatment resulted in an increase in phosphorylation of Cdc25C and ATM- bbbbb2 Chk1/2 eeeee2 
CRP11	An arti bbbbb1 ficial salt eeeee1  bridge was added in the 6-helical bundle by substitut bbbbb2 ion o eeeee2 f lysine for Ile646
CRP11	An artificial salt bridge was added in the 6-helical bundle by substitution of lysine for Ile646 bbbbb1  eeeee1  bbbbb2 ion o eeeee2 f lysine for Ile646
CRP11	An artificial salt bridge was added bbbbb1   eeeee1 in the 6-helical bundle by substitut bbbbb2 ion o eeeee2 f lysine for Ile646
CRP11	The gp41 subunit contains several functional domains: the  bbbbb1 N eeeee1  bbbbb2 N-terminal heptad repeat (NHR) domains eeeee2  fold a triple stranded coiled-coil forming a meta-stable prefusion intermediate
CRP11	Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances,  bbbbb1 arsenic eeeee1  bbbbb2 Pirh2 eeeee2  inhibits, whereas ectopic expression of Pirh2 enhances, arsenic-induced degradation of ΔNp63 protein
CRP11	Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances,  bbbbb1 arsenic eeeee1  bbbbb2 Pirh2 eeeee2  enhances, arsenic-induced degradation of ΔNp63 protein
CRP11	Importantly, we found that knockdown of ΔNp63 sensitizes, whereas ectopic expression of ΔNp63 inhibits, growth suppression induced by arsenic bbbbb1  eeeee1  bbbbb2 enic eeeee2 
CRP11	Importantly, we found that knockdown of ΔNp63 sensitizes, whereas ectopic expression of ΔNp63 inhibits, growth suppression induced by arsenic bbbbb1  eeeee1  bbbbb2 tizes eeeee2 , whereas ectopic expression of ΔNp63 inhibits, growth suppression induced by arsenic
CRP11	Importantly, we found that knockdown of ΔNp63 sensitizes, whereas ectopic expression of ΔNp63 inhibits, growth suppression induced by arsenic bbbbb1  eeeee1  bbbbb2 f ΔNp eeeee2 63 inhibits, growth suppression induced by arsenic
CRP11	The present study examined the potential membrane retention of desipramine (DMI) following exposures of 293-hNET cells to DMI, and its effect on  bbbbb1 [3H]NE eeeee1  bbbbb2 hNET eeeee2  cells to DMI, and its effect on [3H]NE uptake
CRP11	The present study examined the potential membrane retention of desipramine ( bbbbb1 DMI eeeee1 ) following exposures of 293- bbbbb2 hNET eeeee2  cells to DMI, and its effect on [3H]NE uptake
CRP11	The present study examined the potential membrane retention of desipramine (DMI) following exposures of 293-hNET cells to  bbbbb1 DMI eeeee1  bbbbb2 hNET eeeee2  cells to DMI, and its effect on [3H]NE uptake
CRP11	The present study examined the potential membrane retention of  bbbbb1 desipramine eeeee1  (DMI) following exposures of 293- bbbbb2 hNET eeeee2  cells to DMI, and its effect on [3H]NE uptake
CRP11	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using  bbbbb1 [3H]DMI eeeee1 . [3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the  bbbbb2 NET eeeee2 
CRP11	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using  bbbbb1 [3H]DMI eeeee1 . [3H]DMI trapped in membranes was displaceable by the structurally unrelated  bbbbb2 NET eeeee2  inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET
CRP11	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor,  bbbbb1 nisoxetine eeeee1 , in a concentration-dependent manner, implying interaction of retained [3H]DMI with the  bbbbb2 NET eeeee2 
CRP11	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained  bbbbb1 [3H]DMI eeeee1  bbbbb2 NET eeeee2  inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET
CRP11	Uptake inhibition was paralleled by persistent retention of  bbbbb1 DMI eeeee1  associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the  bbbbb2 NET eeeee2 
CRP11	Uptake inhibition was paralleled by persistent retention of  bbbbb1 DMI eeeee1  associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated  bbbbb2 NET eeeee2  inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET
CRP11	Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI.  bbbbb1 [3H]DMI eeeee1  trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the  bbbbb2 NET eeeee2 
CRP11	The persistent membrane retention of desipramine causes lasting inhibition of  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2  function
CRP11	Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor  bbbbb1 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine eeeee1  bbbbb2 ALK eeeee2 ) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials
CRP11	Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor  bbbbb1 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine eeeee1  bbbbb2 anaplastic lymphoma kinase eeeee2  (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials
CRP11	Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine ( bbbbb1 LDK378 eeeee1  bbbbb2 ALK eeeee2 ) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials
CRP11	Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine ( bbbbb1 LDK378 eeeee1  bbbbb2 anaplastic lymphoma kinase eeeee2  (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 ( bbbbb1 raclopride eeeee1  bbbbb2 N/OFQ eeeee2  and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 ( bbbbb1 raclopride eeeee1  bbbbb2 DA receptor eeeee2  subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 ( bbbbb1 raclopride eeeee1  bbbbb2 NOP receptor eeeee2  antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 ( bbbbb1 raclopride eeeee1 , amisulpride) and D3 (S33084) receptor antagonists, and by using  bbbbb2 D2 receptor eeeee2  knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 ( bbbbb1 raclopride eeeee1  bbbbb2 D1 eeeee2 /D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 ( bbbbb1 raclopride eeeee1  bbbbb2 D5 eeeee2  (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 ( bbbbb1 raclopride eeeee1 , amisulpride) and  bbbbb2 D3 eeeee2  (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 ( bbbbb1 SCH23390 eeeee1 ), D2/ bbbbb2 D3 eeeee2  (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 ( bbbbb1 SCH23390 eeeee1  bbbbb2 N/OFQ eeeee2  and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 ( bbbbb1 SCH23390 eeeee1  bbbbb2 DA receptor eeeee2  subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 ( bbbbb1 SCH23390 eeeee1 ),  bbbbb2 D2 eeeee2 /D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 ( bbbbb1 SCH23390 eeeee1  bbbbb2 NOP receptor eeeee2  antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 ( bbbbb1 SCH23390 eeeee1 ), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using  bbbbb2 D2 receptor eeeee2  knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 ( bbbbb1 SCH23390 eeeee1 ), D2/D3 (raclopride, amisulpride) and  bbbbb2 D3 eeeee2  (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride,  bbbbb1 amisulpride eeeee1  bbbbb2 N/OFQ eeeee2  and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride,  bbbbb1 amisulpride eeeee1  bbbbb2 DA receptor eeeee2  subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride,  bbbbb1 amisulpride eeeee1  bbbbb2 NOP receptor eeeee2  antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride,  bbbbb1 amisulpride eeeee1 ) and D3 (S33084) receptor antagonists, and by using  bbbbb2 D2 receptor eeeee2  knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride,  bbbbb1 amisulpride eeeee1  bbbbb2 D1 eeeee2 /D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride,  bbbbb1 amisulpride eeeee1  bbbbb2 D5 eeeee2  (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride,  bbbbb1 amisulpride eeeee1 ) and  bbbbb2 D3 eeeee2  (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1  bbbbb2 D3 eeeee2  (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1  bbbbb2 N/OFQ eeeee2  and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1  bbbbb2 DA receptor eeeee2  subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1  bbbbb2 D2 eeeee2 /D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1  bbbbb2 NOP receptor eeeee2  antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1 ) receptor antagonists, and by using  bbbbb2 D2 receptor eeeee2  knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1  bbbbb2 D1 eeeee2 /D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 ( bbbbb1 S33084 eeeee1  bbbbb2 D5 eeeee2  (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice
CRP11	We demonstrate that motor actions of NOP receptor ligands rely on the modulation of endogenous  bbbbb1 dopamine eeeee1  bbbbb2 NOP receptor eeeee2  ligands rely on the modulation of endogenous dopamine
CRP11	A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous  bbbbb1 dopamine eeeee1  to the motor actions of nociceptin/orphanin FQ (N/OFQ) receptor ( bbbbb2 NOP receptor eeeee2 ) ligands
CRP11	A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous  bbbbb1 dopamine eeeee1  to the motor actions of  bbbbb2 nociceptin/orphanin FQ (N/OFQ) receptor eeeee2  (NOP receptor) ligands
CRP11	Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and  bbbbb1 dopamine eeeee1  bbbbb2 D2/D3 receptor eeeee2  agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it
CRP11	 bbbbb1 Amisulpride eeeee1  also attenuated the hypolocomotion induced by the  bbbbb2 D2/D3 receptor eeeee2  agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it
CRP11	Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist  bbbbb1 pramipexole eeeee1  bbbbb2 D2/D3 receptor eeeee2  agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it
CRP11	Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas  bbbbb1 raclopride eeeee1  bbbbb2 D2/D3 receptor eeeee2  agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it
CRP11	Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and  bbbbb1 S33084 eeeee1  bbbbb2 D2/D3 receptor eeeee2  agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it
CRP11	Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and dopamine precursor  bbbbb1 L-3,4-dihydroxyphenylalanine eeeee1  bbbbb2 D2/D3 receptor eeeee2  agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it
CRP11	 bbbbb1 KN-62 eeeee1  did not affect  bbbbb2 D1 and D4 receptor eeeee2  responses
CRP11	The selective CaMKIIα inhibitor KN-62 reversed the blockade produced by ionomycin and  bbbbb1 K(+) eeeee1  bbbbb2 CaMKIIα eeeee2  inhibitor KN-62 reversed the blockade produced by ionomycin and K(+)-depolarization
CRP11	SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), ionomycin and  bbbbb1 K(+) eeeee1 -depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating  bbbbb2 D3 and D1 dopamine receptors eeeee2 
CRP11	SNr synaptosomes two procedures that increase cytoplasmic  bbbbb1 Ca(2+) eeeee1 , ionomycin and K(+)-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating  bbbbb2 D3 and D1 dopamine receptors eeeee2 
CRP11	SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), ionomycin and K(+)-depolarization, blocked the additional stimulation of  bbbbb1 cAMP eeeee1  accumulation produced by coactivating  bbbbb2 D3 and D1 dopamine receptors eeeee2 
CRP11	SNr synaptosomes two procedures that increase cytoplasmic Ca(2+),  bbbbb1 ionomycin eeeee1  and K(+)-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating  bbbbb2 D3 and D1 dopamine receptors eeeee2 
CRP11	SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), ionomycin and K(+)-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating D3 and D1  bbbbb1 dopamine eeeee1  bbbbb2 D3 and D1 dopamine receptors eeeee2 
CRP11	 bbbbb1 K(+) eeeee1 -depolarized tissues,  bbbbb2 D3 receptors eeeee2  potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62
CRP11	 bbbbb1 K(+) eeeee1 -depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when  bbbbb2 CaMKIIα eeeee2  was blocked with KN-62
CRP11	 bbbbb1 K(+) eeeee1 -depolarized tissues, D3 receptors potentiated  bbbbb2 D1 receptor eeeee2 -induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62
CRP11	K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with  bbbbb1 KN-62 eeeee1  bbbbb2 D3 receptors eeeee2  potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62
CRP11	K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with  bbbbb1 KN-62 eeeee1  bbbbb2 D1 receptor eeeee2 -induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62
CRP11	K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of  bbbbb1 [(3)H]GABA eeeee1  bbbbb2 D3 receptors eeeee2  potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62
CRP11	K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of  bbbbb1 [(3)H]GABA eeeee1  release only when  bbbbb2 CaMKIIα eeeee2  was blocked with KN-62
CRP11	K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of  bbbbb1 [(3)H]GABA eeeee1  bbbbb2 D1 receptor eeeee2 -induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62
CRP11	In the presence of this inhibitor, the selective D3 agonist  bbbbb1 PD 128,907 eeeee1  reduced the ED50 for the  bbbbb2 D1 eeeee2  agonist SKF 38393 from 56 to 4 nM
CRP11	In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist  bbbbb1 SKF 38393 eeeee1  bbbbb2 D3 eeeee2  agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM
CRP11	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively.  bbbbb1 5-Methylurapidil eeeee1  bbbbb2 alpha 1A- and alpha 1B- adrenoceptors eeeee2  was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas spiperone was alpha 1B-selective. 6
CRP11	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and  bbbbb1 phentolamine eeeee1  bbbbb2 alpha 1A- and alpha 1B- adrenoceptors eeeee2  was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas spiperone was alpha 1B-selective. 6
CRP11	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas  bbbbb1 spiperone eeeee1  bbbbb2 alpha 1A-adrenoceptors eeeee2 , whereas spiperone was alpha 1B-selective. 6
CRP11	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas  bbbbb1 spiperone eeeee1  bbbbb2 alpha 1A- and alpha 1B- adrenoceptors eeeee2  was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas spiperone was alpha 1B-selective. 6
CRP11	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with  bbbbb1 CEC eeeee1 , and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the  bbbbb2 alpha 1A-adrenoceptors eeeee2 , whereas spiperone was alpha 1B-selective. 6
CRP11	The affinity of the same antagonists for the alpha 1A- and alpha 1B- adrenoceptors was evaluated by utilizing membranes from rat hippocampus pretreated with  bbbbb1 CEC eeeee1  bbbbb2 alpha 1A- and alpha 1B- adrenoceptors eeeee2  was evaluated by utilizing membranes from rat hippocampus pretreated with CEC, and rat liver, respectively. 5-Methylurapidil and phentolamine were confirmed as selective for the alpha 1A-adrenoceptors, whereas spiperone was alpha 1B-selective. 6
CRP11	Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of hSULT2A1: glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and  bbbbb1 1,1'-azobis(N,N-dimethylformamide eeeee1  bbbbb2 hSULT2A1 eeeee2 : glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide)
CRP11	Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of hSULT2A1: glutathione disulfide,  bbbbb1 5,5'-dithiobis(2-nitrobenzoic acid) eeeee1  bbbbb2 hSULT2A1 eeeee2 : glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide)
CRP11	Three  bbbbb1 thiol eeeee1  oxidants were used as model compounds to investigate their effects on homogeneous preparations of  bbbbb2 hSULT2A1 eeeee2 : glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide)
CRP11	Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of hSULT2A1: glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) ( bbbbb1 diamide eeeee1  bbbbb2 hSULT2A1 eeeee2 : glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide)
CRP11	Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of hSULT2A1:  bbbbb1 glutathione disulfide eeeee1  bbbbb2 hSULT2A1 eeeee2 : glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide)
CRP11	Studies on the kinetics of the hSULT2A1-catalyzed sulfation of dehydroepiandrosterone (DHEA) showed the effects of  bbbbb1 disulfide eeeee1  bbbbb2 hSULT2A1 eeeee2 -catalyzed sulfation of dehydroepiandrosterone (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme
CRP11	We have examined the hypothesis that the formation of  bbbbb1 disulfide eeeee1  bonds in  bbbbb2 hSULT2A1 eeeee2  can reversibly regulate the catalytic function of the enzyme
CRP11	Modification of the Catalytic Function of Human  bbbbb1 Hydroxysteroid eeeee1  bbbbb2 Human Hydroxysteroid Sulfotransferase hSULT2A1 eeeee2  by Formation of Disulfide Bonds
CRP11	Increased Cat3-mediated cationic  bbbbb1 amino acid eeeee1  transport functionally compensates in  bbbbb2 Cat1 eeeee2  knockout cell lines
CRP11	High affinity  bbbbb1 L-arginine eeeee1  transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional  bbbbb2 Cat1 eeeee2 
CRP11	High affinity  bbbbb1 L-arginine eeeee1  transport was investigated in embryonic fibroblast cells derived from  bbbbb2 Cat1 eeeee2  knockout mice that lack functional Cat1
CRP11	Even though Cat3 expression is normally limited to adult brain, there was a large increase in the amount of Cat3 protein present at the plasma membrane of Cat1( bbbbb1 -/-) emb eeeee1  bbbbb2 as a eeeee2  large increase in the amount of Cat3 protein present at the plasma membrane of Cat1(-/-) embryonic fibroblast cells
CRP11	Even though Cat3 expression is normally limited to adult brain, there was a large increase in the amount of Cat3 protein present at the plasma membrane of Cat1( bbbbb1 -/-) emb eeeee1  bbbbb2 amou eeeee2 nt of Cat3 protein present at the plasma membrane of Cat1(-/-) embryonic fibroblast cells
CRP11	However, the apparent affinity for  bbbbb1 lysine eeeee1  transport was 2.4 times lower in  bbbbb2 Cat1 eeeee2 (-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport
CRP11	The results show that transient arsenite pre-treatm bbbbb1 ent  eeeee1  bbbbb2  tr eeeee2 ansient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2
CRP11	Pre-treatment with arsenite increased protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after  bbbbb1 H2O2 eeeee1  bbbbb2 ERK1/2 eeeee2 ) phosphorylation after H2O2
CRP11	Pre-treatment with arsenite increased protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after  bbbbb1 H2O2 eeeee1  bbbbb2 extracellular signal regulated kinase 1/2 eeeee2  (ERK1/2) phosphorylation after H2O2
CRP11	Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of  bbbbb1 hydrogen peroxide eeeee1  bbbbb2 HSPs eeeee2 ) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death
CRP11	Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of  bbbbb1 hydrogen peroxide eeeee1  bbbbb2 heat shock proteins eeeee2  (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death
CRP11	However, while Akt phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by  bbbbb1 CHX eeeee1  bbbbb2 Erk1/2 eeeee2  phosphorylation was further enhanced by CHX
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  kinase 2, annexin II, and  bbbbb2 actin eeeee2 
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  bbbbb2 Src eeeee2 , proline-rich tyrosine kinase 2, annexin II, and actin
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  kinase 2,  bbbbb2 annexin II eeeee2 , and actin
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  bbbbb2 nectin-3 eeeee2 , afadin, Src, proline-rich tyrosine kinase 2, annexin II, and actin
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  bbbbb2 β1-integrin eeeee2 , nectin-3, afadin, Src, proline-rich tyrosine kinase 2, annexin II, and actin
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  bbbbb2 proline-rich tyrosine kinase 2 eeeee2 , annexin II, and actin
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  bbbbb2 afadin eeeee2 , Src, proline-rich tyrosine kinase 2, annexin II, and actin
CRP11	Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich  bbbbb1 tyrosine eeeee1  bbbbb2 ICAM2 eeeee2  was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich tyrosine kinase 2, annexin II, and actin
CRP11	Following  bbbbb1 CdCl₂ eeeee1  treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for  bbbbb2 ICAM2 eeeee2  by 6-16 h
CRP11	Reduction of cerebral infarct size by the AT1-receptor blocker  bbbbb1 candesartan eeeee1 , the  bbbbb2 HMG-CoA reductase eeeee2  inhibitor rosuvastatin and their combination
CRP11	Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor  bbbbb1 rosuvastatin eeeee1  bbbbb2 AT1 eeeee2 -receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination
CRP11	Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the  bbbbb1 HMG-CoA eeeee1  bbbbb2 AT1 eeeee2 -receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination
CRP11	Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the  bbbbb1 HMG-CoA eeeee1  bbbbb2 HMG-CoA reductase eeeee2  inhibitor rosuvastatin and their combination
CRP11	AME was used to test whether any potential effect was due to activation of endothelial  bbbbb1 nitric oxide eeeee1  bbbbb2 endothelial nitric oxide synthase eeeee2  (eNOS)
CRP11	AME was used to test whether any potential effect was due to activation of endothelial  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 eNOS eeeee2 )
CRP11	Disruption of the cell-cycle boxes also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate ( bbbbb1 MMS eeeee1  bbbbb2 cell-cycle boxes eeeee2  also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate (MMS)
CRP11	Disruption of the cell-cycle boxes also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate ( bbbbb1 MMS eeeee1  bbbbb2 DNA polymerase eeeee2 -defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate (MMS)
CRP11	Disruption of the cell-cycle boxes also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent  bbbbb1 methyl methane sulfonate eeeee1  bbbbb2 cell-cycle boxes eeeee2  also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate (MMS)
CRP11	Disruption of the cell-cycle boxes also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent  bbbbb1 methyl methane sulfonate eeeee1  bbbbb2 DNA polymerase eeeee2 -defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate (MMS)
CRP11	B-cell receptor (BCR) associated kinases including spleen  bbbbb1 tyrosine eeeee1  bbbbb2 B-cell receptor eeeee2  (BCR) associated kinases including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell malignancies
CRP11	B-cell receptor (BCR) associated kinases including spleen  bbbbb1 tyrosine eeeee1  kinase ( bbbbb2 SYK eeeee2 ) contribute to the pathogenesis of B-cell malignancies
CRP11	B-cell receptor (BCR) associated kinases including spleen  bbbbb1 tyrosine eeeee1  bbbbb2 kinases eeeee2  including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell malignancies
CRP11	B-cell receptor (BCR) associated kinases including spleen  bbbbb1 tyrosine eeeee1  bbbbb2 BCR eeeee2 ) associated kinases including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell malignancies
CRP11	B-cell receptor (BCR) associated kinases including spleen  bbbbb1 tyrosine eeeee1  bbbbb2 spleen tyrosine kinase eeeee2  (SYK) contribute to the pathogenesis of B-cell malignancies
CRP11	 bbbbb1 P505-15 eeeee1  (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other  bbbbb2 kinases eeeee2 
CRP11	P505-15 (also known as  bbbbb1 PRT062607 eeeee1 ) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other  bbbbb2 kinases eeeee2 
CRP11	The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of  bbbbb1 fludarabine eeeee1  bbbbb2 SYK eeeee2  inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
CRP11	This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected]  bbbbb1 IMQ eeeee1  bbbbb2 perforin eeeee2 (+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] IMQ
CRP11	This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected]  bbbbb1 IMQ eeeee1  bbbbb2 perforin eeeee2  expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] IMQ
CRP11	This functional synergism prompted our current experiments addressing the question whether  bbbbb1 IMQ eeeee1  may influence  bbbbb2 perforin eeeee2 -release and/or induce perforin in CTLs in vitro
CRP11	This functional synergism prompted our current experiments addressing the question whether  bbbbb1 IMQ eeeee1  may influence perforin-release and/or induce  bbbbb2 perforin eeeee2  in CTLs in vitro
CRP11	Human  bbbbb1 ether eeeee1  bbbbb2 Human ether-a-go-go-related gene eeeee2  channel blockers and its structural analysis for drug design
CRP11	The human  bbbbb1 ether eeeee1 -a-go-go-related gene (hERG) is a  bbbbb2 K+ channel eeeee2  protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death
CRP11	The human  bbbbb1 ether eeeee1  bbbbb2 human ether-a-go-go-related gene eeeee2  (hERG) is a K+ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death
CRP11	The human  bbbbb1 ether eeeee1 -a-go-go-related gene ( bbbbb2 hERG eeeee2 ) is a K+ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death
CRP11	The human ether-a-go-go-related gene (hERG) is a  bbbbb1 K+ eeeee1  bbbbb2 K+ channel eeeee2  protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death
CRP11	The human ether-a-go-go-related gene (hERG) is a  bbbbb1 K+ eeeee1  bbbbb2 human ether-a-go-go-related gene eeeee2  (hERG) is a K+ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death
CRP11	The human ether-a-go-go-related gene (hERG) is a  bbbbb1 K+ eeeee1  bbbbb2 hERG eeeee2 ) is a K+ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death
CRP11	Published literature on the nitric oxide- bbbbb1 cyclic guanosine monophosphate eeeee1  (cGMP) pathway for penile erection and on  bbbbb2 PDE5 eeeee2  inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed
CRP11	Published literature on the nitric oxide- bbbbb1 cyclic guanosine monophosphate eeeee1  (cGMP) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic  bbbbb2 PDE5 eeeee2  inhibition are assessed
CRP11	Published literature on the  bbbbb1 nitric oxide eeeee1 -cyclic guanosine monophosphate (cGMP) pathway for penile erection and on  bbbbb2 PDE5 eeeee2  inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed
CRP11	Published literature on the  bbbbb1 nitric oxide eeeee1 -cyclic guanosine monophosphate (cGMP) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic  bbbbb2 PDE5 eeeee2  inhibition are assessed
CRP11	Published literature on the nitric oxide-cyclic guanosine monophosphate ( bbbbb1 cGMP eeeee1 ) pathway for penile erection and on  bbbbb2 PDE5 eeeee2  inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed
CRP11	Published literature on the nitric oxide-cyclic guanosine monophosphate ( bbbbb1 cGMP eeeee1 ) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic  bbbbb2 PDE5 eeeee2  inhibition are assessed
CRP11	Therefore, in men with ED, elevation of  bbbbb1 cGMP eeeee1  in corpus cavernosal tissue via selective inhibition of cGMP-specific  bbbbb2 PDE5 eeeee2  is a means of improving erectile function at minimal risk of adverse events
CRP11	Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 receptors eeeee2  (D2Rs)
CRP11	Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express  bbbbb1 dopamine eeeee1  D2 receptors ( bbbbb2 D2Rs eeeee2 )
CRP11	Administration of haloperidol increased  bbbbb1 Ser eeeee1 240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express  bbbbb2 dopamine D2 receptors eeeee2  (D2Rs)
CRP11	Administration of haloperidol increased  bbbbb1 Ser eeeee1 240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors ( bbbbb2 D2Rs eeeee2 )
CRP11	Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of  bbbbb1 GABA eeeee1 -ergic medium spiny neurons (MSNs), which express  bbbbb2 dopamine D2 receptors eeeee2  (D2Rs)
CRP11	Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of  bbbbb1 GABA eeeee1 -ergic medium spiny neurons (MSNs), which express dopamine D2 receptors ( bbbbb2 D2Rs eeeee2 )
CRP11	These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphoryla bbbbb1 tio eeeee1 n of rpS6 at Ser2 bbbbb2 40/ eeeee2 244, in a subpopulation of striatal MSNs expressing D2Rs
CRP11	These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphoryla bbbbb1 tio eeeee1 n of rpS6 at Ser240/244, in a subpopulation o bbbbb2 f striat eeeee2 al MSNs expressing D2Rs
CRP11	These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphoryla bbbbb1 tio eeeee1 n of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing  bbbbb2 D2Rs eeeee2 
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and  bbbbb1 cAMP eeeee1  bbbbb2 dopamine- and cAMP-regulated phosphoprotein of 32 kDa eeeee2  (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and  bbbbb1 cAMP eeeee1 -regulated phosphoprotein of 32 kDa ( bbbbb2 DARPP-32 eeeee2 ), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and  bbbbb1 cAMP eeeee1 -regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 ( bbbbb2 PP-1 eeeee2 )
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and  bbbbb1 cAMP eeeee1 -regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of  bbbbb2 protein phosphatase-1 eeeee2  (PP-1)
CRP11	We also found that the effect of haloperidol on  bbbbb1 Ser eeeee1 240/244 phosphorylation was prevented by functional inactivation of  bbbbb2 dopamine- and cAMP-regulated phosphoprotein of 32 kDa eeeee2  (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of haloperidol on  bbbbb1 Ser eeeee1 240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa ( bbbbb2 DARPP-32 eeeee2 ), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of haloperidol on  bbbbb1 Ser eeeee1 240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 ( bbbbb2 PP-1 eeeee2 )
CRP11	We also found that the effect of haloperidol on  bbbbb1 Ser eeeee1 240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of  bbbbb2 protein phosphatase-1 eeeee2  (PP-1)
CRP11	We also found that the effect of  bbbbb1 haloperidol eeeee1  on Ser240/244 phosphorylation was prevented by functional inactivation of  bbbbb2 dopamine- and cAMP-regulated phosphoprotein of 32 kDa eeeee2  (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of  bbbbb1 haloperidol eeeee1  on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa ( bbbbb2 DARPP-32 eeeee2 ), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of  bbbbb1 haloperidol eeeee1  on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 ( bbbbb2 PP-1 eeeee2 )
CRP11	We also found that the effect of  bbbbb1 haloperidol eeeee1  on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of  bbbbb2 protein phosphatase-1 eeeee2  (PP-1)
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of  bbbbb1 dopamine eeeee1  bbbbb2 dopamine- and cAMP-regulated phosphoprotein of 32 kDa eeeee2  (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of  bbbbb1 dopamine eeeee1 - and cAMP-regulated phosphoprotein of 32 kDa ( bbbbb2 DARPP-32 eeeee2 ), an endogenous inhibitor of protein phosphatase-1 (PP-1)
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of  bbbbb1 dopamine eeeee1 - and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 ( bbbbb2 PP-1 eeeee2 )
CRP11	We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of  bbbbb1 dopamine eeeee1 - and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of  bbbbb2 protein phosphatase-1 eeeee2  (PP-1)
CRP11	Here, we examined the effects produced by haloperidol, a typical antipsychotic drug, on the phosphorylation of rpS6 at  bbbbb1 Ser eeeee1  bbbbb2 rpS6 eeeee2  at Ser240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders
CRP11	Here, we examined the effects produced by  bbbbb1 haloperidol eeeee1 , a typical antipsychotic drug, on the phosphorylation of  bbbbb2 rpS6 eeeee2  at Ser240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders
CRP11	In line with this observation, incubation of striatal slices with okadaic acid and calyculin A, two inhibitors of PP-1, increased  bbbbb1 Ser eeeee1  bbbbb2 PP-1 eeeee2 , increased Ser240/244 phosphorylation
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and  bbbbb1 cAMP eeeee1  bbbbb2 mTORC1 eeeee2 -dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and  bbbbb1 cAMP eeeee1 -regulated phosphoprotein of 32 kDa and inhibition of  bbbbb2 protein phosphatase-1 eeeee2 
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and  bbbbb1 cAMP eeeee1  bbbbb2 dopamine- and cAMP-regulated phosphoprotein of 32 kDa eeeee2  and inhibition of protein phosphatase-1
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and  bbbbb1 cAMP eeeee1  bbbbb2 ribosomal protein S6 eeeee2  via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via  bbbbb1 dopamine eeeee1  bbbbb2 mTORC1 eeeee2 -dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via  bbbbb1 dopamine eeeee1 - and cAMP-regulated phosphoprotein of 32 kDa and inhibition of  bbbbb2 protein phosphatase-1 eeeee2 
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via  bbbbb1 dopamine eeeee1  bbbbb2 dopamine- and cAMP-regulated phosphoprotein of 32 kDa eeeee2  and inhibition of protein phosphatase-1
CRP11	Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via  bbbbb1 dopamine eeeee1  bbbbb2 ribosomal protein S6 eeeee2  via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1
CRP11	This effect was prevented by rapamycin, an inhibitor of the mammalian target of  bbbbb1 rapamycin eeeee1  complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 ( bbbbb2 S6K1 eeeee2 )
CRP11	This effect was prevented by rapamycin, an inhibitor of the mammalian target of  bbbbb1 rapamycin eeeee1  complex 1 (mTORC1), or by PF470867, a selective inhibitor of the  bbbbb2 p70 ribosomal S6 kinase 1 eeeee2  (S6K1)
CRP11	This effect was prevented by rapamycin, an inhibitor of the mammalian target of  bbbbb1 rapamycin eeeee1  complex 1 ( bbbbb2 mTORC1 eeeee2 ), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)
CRP11	This effect was prevented by rapamycin, an inhibitor of the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin complex 1 eeeee2  (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)
CRP11	This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by  bbbbb1 PF470867 eeeee1  bbbbb2 mTORC1 eeeee2 ), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)
CRP11	This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by  bbbbb1 PF470867 eeeee1  bbbbb2 mammalian target of rapamycin complex 1 eeeee2  (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)
CRP11	This effect was prevented by  bbbbb1 rapamycin eeeee1 , an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 ( bbbbb2 S6K1 eeeee2 )
CRP11	This effect was prevented by  bbbbb1 rapamycin eeeee1 , an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the  bbbbb2 p70 ribosomal S6 kinase 1 eeeee2  (S6K1)
CRP11	Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of  bbbbb1 ibuprofen eeeee1  bbbbb2 PPARgamma eeeee2  with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors
CRP11	Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like  bbbbb1 ibuprofen eeeee1  bbbbb2 PPARgamma eeeee2  with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors
CRP11	Activation of PPARgamma with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like  bbbbb1 ibuprofen eeeee1  bbbbb2 RhoA eeeee2 -inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors
CRP11	These findings support that PPARgamma plays an essenti bbbbb1 al role i eeeee1 n mediating the RhoA-inhibiting effect of ibuprofen bbbbb2  eeeee2 
CRP11	High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered prostacyclin ( bbbbb1 PGI2 eeeee1  bbbbb2 prostacyclin (PGI2) synthase eeeee2  (PGIS) in solution
CRP11	High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered prostacyclin ( bbbbb1 PGI2 eeeee1 ) synthase ( bbbbb2 PGIS eeeee2 ) in solution
CRP11	High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered  bbbbb1 prostacyclin eeeee1  bbbbb2 prostacyclin (PGI2) synthase eeeee2  (PGIS) in solution
CRP11	High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered  bbbbb1 prostacyclin eeeee1  (PGI2) synthase ( bbbbb2 PGIS eeeee2 ) in solution
CRP11	The binding of  bbbbb1 U46619 eeeee1  to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered  bbbbb2 PGIS eeeee2  in a concentration-dependent manner
CRP11	The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at  bbbbb1 C-11 eeeee1 , H2C, and H20 of U46619 were observed upon U46619 binding to the engineered  bbbbb2 PGIS eeeee2  in a concentration-dependent manner
CRP11	The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon  bbbbb1 U46619 eeeee1  bbbbb2 PGIS eeeee2  protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner
CRP11	The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and  bbbbb1 H20 eeeee1  of U46619 were observed upon U46619 binding to the engineered  bbbbb2 PGIS eeeee2  in a concentration-dependent manner
CRP11	The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of  bbbbb1 U46619 eeeee1  were observed upon U46619 binding to the engineered  bbbbb2 PGIS eeeee2  in a concentration-dependent manner
CRP11	The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11,  bbbbb1 H2C eeeee1 , and H20 of U46619 were observed upon U46619 binding to the engineered  bbbbb2 PGIS eeeee2  in a concentration-dependent manner
CRP11	These studies have provided the structural information for the interaction of the PGIS with its substrate mimic bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These studies have provided the structural information for the interaction of the PGIS with its substrate mimic bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	These studies have provided the structural information for the interactio bbbbb1 n o eeeee1 f the PGIS with its substrate mimic bbbbb2  eeeee2 
CRP11	These studies have provided the structural  bbbbb1 inf eeeee1 ormation for the interaction of the PGIS with its substrate mimic bbbbb2  eeeee2 
CRP11	The bound conformation of U46619 fits the crystal structure of the PGIS substrate binding pocket considerably better than that of the unbound  bbbbb1 U46619 eeeee1  bbbbb2 PGIS eeeee2  substrate binding pocket considerably better than that of the unbound U46619
CRP11	Characterization of the substrate mimic bound to engineered prostacyclin synthase in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of  bbbbb1 prostacyclin eeeee1  bbbbb2 prostacyclin synthase eeeee2  in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin
CRP11	Characterization of the substrate mimic bound to engineered  bbbbb1 prostacyclin eeeee1  bbbbb2 prostacyclin synthase eeeee2  in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin
CRP11	The detailed conformational change and 3D structure of the PGIS-bound U46619 were further demonstrated by 2D  bbbbb1 1H eeeee1  bbbbb2 PGIS eeeee2 -bound U46619 were further demonstrated by 2D 1H NMR experiments using the transferred NOE technique
CRP11	The transport  bbbbb1 amiloride eeeee1 -sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange ( bbbbb2 NHE1 eeeee2  isoform)
CRP11	In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous S100P (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of gemcitabine (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96:  bbbbb1 gemcitabine eeeee1  bbbbb2 S100P eeeee2  (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of gemcitabine (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001)
CRP11	The constitutive  bbbbb1 androstane eeeee1  bbbbb2 constitutive androstane receptor eeeee2  (CAR) not only displays a high basal transcriptional activity but also acts as a ligand-dependent transcriptional factor
CRP11	The constitutive  bbbbb1 androstane eeeee1  receptor ( bbbbb2 CAR eeeee2 ) not only displays a high basal transcriptional activity but also acts as a ligand-dependent transcriptional factor
CRP11	The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and  bbbbb1 steroid eeeee1  receptor coactivator 1 ( bbbbb2 SRC1 eeeee2 )
CRP11	The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and  bbbbb1 steroid eeeee1  bbbbb2 mCAR eeeee2 ) interact with chemicals and steroid receptor coactivator 1 (SRC1)
CRP11	The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and  bbbbb1 steroid eeeee1  bbbbb2 steroid receptor coactivator 1 eeeee2  (SRC1)
CRP11	The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and  bbbbb1 steroid eeeee1  bbbbb2 CAR eeeee2  ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and steroid receptor coactivator 1 (SRC1)
CRP11	The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and  bbbbb1 steroid eeeee1  bbbbb2 CAR eeeee2  proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and steroid receptor coactivator 1 (SRC1)
CRP11	The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and  bbbbb1 steroid eeeee1  bbbbb2 bsCAR eeeee2 ) and the mouse (mCAR) interact with chemicals and steroid receptor coactivator 1 (SRC1)
CRP11	Quantitative analysis of the interaction of constitutive  bbbbb1 androstane eeeee1  bbbbb2 constitutive androstane receptor eeeee2  with chemicals and steroid receptor coactivator 1 using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse
CRP11	Quantitative analysis of the interaction of constitutive  bbbbb1 androstane eeeee1  receptor with chemicals and  bbbbb2 steroid receptor coactivator 1 eeeee2  using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse
CRP11	Quantitative analysis of the interaction of constitutive androstane receptor with chemicals and  bbbbb1 steroid eeeee1  bbbbb2 constitutive androstane receptor eeeee2  with chemicals and steroid receptor coactivator 1 using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse
CRP11	Quantitative analysis of the interaction of constitutive androstane receptor with chemicals and  bbbbb1 steroid eeeee1  bbbbb2 steroid receptor coactivator 1 eeeee2  using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse
CRP11	Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2 
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of  bbbbb1 estramustine phosphate eeeee1  and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of  bbbbb1 estramustine phosphate eeeee1  and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of  bbbbb1 estramustine phosphate eeeee1  and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of  bbbbb1 estramustine phosphate eeeee1  and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites,  bbbbb1 estramustine eeeee1 , estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites,  bbbbb1 estramustine eeeee1 , estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites,  bbbbb1 estramustine eeeee1 , estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites,  bbbbb1 estramustine eeeee1 , estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and  bbbbb1 hydroxyflutamide eeeee1 , to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and  bbbbb1 hydroxyflutamide eeeee1 , to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and  bbbbb1 hydroxyflutamide eeeee1 , to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and  bbbbb1 hydroxyflutamide eeeee1 , to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol,  bbbbb1 bicalutamide eeeee1 , and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol,  bbbbb1 bicalutamide eeeee1 , and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol,  bbbbb1 bicalutamide eeeee1 , and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol,  bbbbb1 bicalutamide eeeee1 , and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including  bbbbb1 alpha-estradiol eeeee1 , bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including  bbbbb1 alpha-estradiol eeeee1 , bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including  bbbbb1 alpha-estradiol eeeee1 , bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including  bbbbb1 alpha-estradiol eeeee1 , bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and  bbbbb1 beta-estradiol eeeee1 , as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and  bbbbb1 beta-estradiol eeeee1 , as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and  bbbbb1 beta-estradiol eeeee1 , as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and  bbbbb1 beta-estradiol eeeee1 , as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb1 androgen eeeee1  receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb1 androgen eeeee1  receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb1 androgen eeeee1  receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of  bbbbb1 [3H]methyltrienolone eeeee1  in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of  bbbbb1 [3H]methyltrienolone eeeee1  in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of  bbbbb1 [3H]methyltrienolone eeeee1  in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of  bbbbb1 [3H]methyltrienolone eeeee1  in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine,  bbbbb1 estrone eeeee1 , and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine,  bbbbb1 estrone eeeee1 , and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine,  bbbbb1 estrone eeeee1 , and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine,  bbbbb1 estrone eeeee1 , and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb1 androgen eeeee1  receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine,  bbbbb1 estromustine eeeee1 , estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine,  bbbbb1 estromustine eeeee1 , estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine,  bbbbb1 estromustine eeeee1 , estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine,  bbbbb1 estromustine eeeee1 , estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of  bbbbb1 triamcinolone acetonide eeeee1 , the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type  bbbbb2 AR eeeee2  cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of  bbbbb1 triamcinolone acetonide eeeee1 , the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m- bbbbb2 AR eeeee2 ) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of  bbbbb1 triamcinolone acetonide eeeee1 , the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated  bbbbb2 androgen receptor eeeee2  (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of  bbbbb1 triamcinolone acetonide eeeee1 , the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type  bbbbb2 androgen receptor eeeee2  in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells
CRP11	Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted  bbbbb1 as an agonist of the m eeeee1  bbbbb2 ul eeeee2 ation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR
CRP11	Analogous to the antiandrogens, bicalutamide and hydroxyflutamide, binding of estramustine phosphate metabolites to the  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  was observed
CRP11	Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated  bbbbb1 androgen eeeee1  bbbbb2 AR eeeee2 -target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor
CRP11	Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2 
CRP11	Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated  bbbbb1 androgen eeeee1  bbbbb2 PSA eeeee2 ) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor
CRP11	Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated  bbbbb1 androgen eeeee1  bbbbb2 prostate-specific antigen eeeee2  (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor
CRP11	The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine and serine/threonine kinases eeeee2 
CRP11	The combined strategy resulted in a global survey of  bbbbb1 bosutinib eeeee1  targets comprised of over 45 novel  bbbbb2 tyrosine and serine/threonine kinases eeeee2 
CRP11	The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/ bbbbb1 threonine eeeee1  bbbbb2 tyrosine and serine/threonine kinases eeeee2 
CRP11	The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and  bbbbb1 serine eeeee1  bbbbb2 tyrosine and serine/threonine kinases eeeee2 
CRP11	Here, we characterized the target profile of the dual SRC/ABL inhibitor  bbbbb1 bosutinib eeeee1  employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant  bbbbb2 kinase eeeee2  panel
CRP11	Here, we characterized the target profile of the dual SRC/ABL inhibitor  bbbbb1 bosutinib eeeee1  employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro  bbbbb2 kinase eeeee2  assays against a large recombinant kinase panel
CRP11	By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal anti-inflammatory drugs induces conformational changes in the human  bbbbb1 prostaglandin endoperoxide H(2) eeeee1  synthase enzyme ( bbbbb2 PGHS-2 eeeee2 )
CRP11	By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal anti-inflammatory drugs induces conformational changes in the human  bbbbb1 prostaglandin endoperoxide H(2) eeeee1  bbbbb2 human prostaglandin endoperoxide H(2) synthase enzyme eeeee2  (PGHS-2)
CRP11	Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human  bbbbb1 prostaglandin endoperoxide H2 eeeee1  synthase-2 ( bbbbb2 cyclooxygenase-2 eeeee2 )
CRP11	Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human  bbbbb1 prostaglandin endoperoxide H2 eeeee1  bbbbb2 human prostaglandin endoperoxide H2 synthase-2 eeeee2  (cyclooxygenase-2)
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core  bbbbb1 PLGA eeeee1  bbbbb2 PDGF eeeee2 ) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core  bbbbb1 PLGA eeeee1  bbbbb2 platelet-derived GF eeeee2  (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core  bbbbb1 PLGA eeeee1  bbbbb2 vascular endothelial GF eeeee2  (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core  bbbbb1 PLGA eeeee1  bbbbb2 VEGF eeeee2 ), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  bbbbb1 PLGA eeeee1  bbbbb2 PDGF eeeee2 ) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  bbbbb1 PLGA eeeee1  bbbbb2 platelet-derived GF eeeee2  (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  bbbbb1 PLGA eeeee1  bbbbb2 vascular endothelial GF eeeee2  (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core  bbbbb1 PLGA eeeee1  bbbbb2 VEGF eeeee2 ), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA
CRP11	The goal of the present study was to examine the 5-HT1A properties of ziprasidone in vivo using as a marker of central 5-HT1A activity the inhibition of firing of  bbbbb1 serotonin eeeee1  bbbbb2 5-HT1A eeeee2  properties of ziprasidone in vivo using as a marker of central 5-HT1A activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus
CRP11	The goal of the present study was to examine the 5-HT1A properties of ziprasidone in vivo using as a marker of central 5-HT1A activity the inhibition of firing of  bbbbb1 serotonin eeeee1  bbbbb2 5-HT1A eeeee2  activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus
CRP11	The goal of the present study was to examine the 5-HT1A properties of  bbbbb1 ziprasidone eeeee1  in vivo using as a marker of central  bbbbb2 5-HT1A eeeee2  activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus
CRP11	Because all three agents also bind to alpha 1 receptors, antagonists of which inhibit  bbbbb1 serotonin eeeee1  bbbbb2 alpha 1 receptors eeeee2 , antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity
CRP11	Because all three agents also bind to alpha 1 receptors, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a  bbbbb1 NE eeeee1  bbbbb2 alpha 1 receptors eeeee2 , antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity
CRP11	Because all three agents also bind to alpha 1 receptors, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with  bbbbb1 desipramine eeeee1  bbbbb2 alpha 1 receptors eeeee2 , antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity
CRP11	Because all three agents also bind to alpha 1 receptors, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine ( bbbbb1 DMI eeeee1  bbbbb2 alpha 1 receptors eeeee2 , antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity
CRP11	While it is an antagonist at these latter receptors,  bbbbb1 ziprasidone eeeee1  behaves as a 5-HT1A agonist in vitro in  bbbbb2 adenylate cyclase eeeee2  measurements
CRP11	While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in  bbbbb1 adenylate eeeee1  bbbbb2 5-HT1A eeeee2  agonist in vitro in adenylate cyclase measurements
CRP11	While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in  bbbbb1 adenylate eeeee1  bbbbb2 adenylate cyclase eeeee2  measurements
CRP11	Fs were pre-treated with  bbbbb1 berberine eeeee1  prior to induction by  bbbbb2 transforming growth factor (TGF)-β1 eeeee2 
CRP11	ION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and  bbbbb1 progesterone eeeee1  bbbbb2 ER eeeee2 )-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	ION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptor eeeee2  (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	ION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and  bbbbb1 progesterone eeeee1  receptor ( bbbbb2 PR eeeee2 )-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	ION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and  bbbbb1 progesterone eeeee1  bbbbb2 estrogen receptor eeeee2  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	ION: Medroxyprogesterone acetate (MPA) induces  bbbbb1 estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 )-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	ION: Medroxyprogesterone acetate (MPA) induces  bbbbb1 estrogen eeeee1  receptor (ER)-positive and  bbbbb2 progesterone receptor eeeee2  (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	ION: Medroxyprogesterone acetate (MPA) induces  bbbbb1 estrogen eeeee1  receptor (ER)-positive and progesterone receptor ( bbbbb2 PR eeeee2 )-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	ION: Medroxyprogesterone acetate (MPA) induces  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by  bbbbb1 MPA eeeee1  and progesterone, and the levels of  bbbbb2 ER eeeee2  and PR expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by  bbbbb1 MPA eeeee1  and progesterone, and the levels of ER and  bbbbb2 PR eeeee2  expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and  bbbbb1 progesterone eeeee1 , and the levels of  bbbbb2 ER eeeee2  and PR expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and  bbbbb1 progesterone eeeee1 , and the levels of ER and  bbbbb2 PR eeeee2  expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of  bbbbb1 MPA eeeee1 , the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of  bbbbb2 ER eeeee2  and PR expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of  bbbbb1 MPA eeeee1 , the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and  bbbbb2 PR eeeee2  expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and PR expression in MPA-treated and  bbbbb1 progesterone eeeee1  bbbbb2 ER eeeee2  and PR expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and PR expression in MPA-treated and  bbbbb1 progesterone eeeee1  bbbbb2 PR eeeee2  expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and PR expression in  bbbbb1 MPA eeeee1  bbbbb2 ER eeeee2  and PR expression in MPA-treated and progesterone-treated mammary glands
CRP11	Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and PR expression in  bbbbb1 MPA eeeee1  bbbbb2 PR eeeee2  expression in MPA-treated and progesterone-treated mammary glands
CRP11	Inhibited BChE undergoes aging to release saligenin and  bbbbb1 o-cresol eeeee1  bbbbb2 BChE eeeee2  undergoes aging to release saligenin and o-cresol
CRP11	Inhibited BChE undergoes aging to release  bbbbb1 saligenin eeeee1  bbbbb2 BChE eeeee2  undergoes aging to release saligenin and o-cresol
CRP11	Cresyl saligenin phosphate makes multiple adducts on free  bbbbb1 histidine eeeee1 , but does not form an adduct on histidine 438 of  bbbbb2 human butyrylcholinesterase eeeee2 
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun  bbbbb1 NH2 eeeee1  bbbbb2 Fas-associated death domain-containing protein eeeee2  (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun  bbbbb1 NH2 eeeee1  bbbbb2 FADD eeeee2 ) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun  bbbbb1 NH2 eeeee1 -terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of  bbbbb2 JNK eeeee2 /FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun  bbbbb1 NH2 eeeee1 -terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that  bbbbb2 Bcl-2 eeeee2  phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun  bbbbb1 NH2 eeeee1 -terminal kinase ( bbbbb2 JNK eeeee2 ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun  bbbbb1 NH2 eeeee1 -terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/ bbbbb2 FADD eeeee2  plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun  bbbbb1 NH2 eeeee1  bbbbb2 c-jun NH2-terminal kinase eeeee2  (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194  bbbbb1 serine eeeee1  through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of  bbbbb2 JNK eeeee2 /FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194  bbbbb1 serine eeeee1  through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that  bbbbb2 Bcl-2 eeeee2  phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194  bbbbb1 serine eeeee1  through c-jun NH2-terminal kinase ( bbbbb2 JNK eeeee2 ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194  bbbbb1 serine eeeee1  through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/ bbbbb2 FADD eeeee2  plays an important role in cell growth suppression by paclitaxel
CRP11	We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194  bbbbb1 serine eeeee1  through  bbbbb2 c-jun NH2-terminal kinase eeeee2  (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1 , c-erbB-2 receptors, p53 expressions and  bbbbb2 phosphorylated FADD eeeee2 /JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1  bbbbb2 phosphorylated Bcl-2 eeeee2  (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1 , c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/ bbbbb2 JNK eeeee2 ) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1 , c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK ( bbbbb2 P-FADD eeeee2 /JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1  bbbbb2 P-Bcl-2 eeeee2 ) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1 , c-erbB-2 receptors,  bbbbb2 p53 eeeee2  expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1 , c-erbB-2 receptors, p53 expressions and phosphorylated FADD/ bbbbb2 JNK eeeee2  (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen,  bbbbb1 progesterone eeeee1  bbbbb2 estrogen, progesterone, c-erbB-2 receptors eeeee2 , p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1 , progesterone, c-erbB-2 receptors, p53 expressions and  bbbbb2 phosphorylated FADD eeeee2 /JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1  bbbbb2 phosphorylated Bcl-2 eeeee2  (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1 , progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/ bbbbb2 JNK eeeee2 ) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1 , progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK ( bbbbb2 P-FADD eeeee2 /JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1  bbbbb2 P-Bcl-2 eeeee2 ) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1 , progesterone, c-erbB-2 receptors,  bbbbb2 p53 eeeee2  expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1 , progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/ bbbbb2 JNK eeeee2  (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with  bbbbb1 estrogen eeeee1  bbbbb2 estrogen, progesterone, c-erbB-2 receptors eeeee2 , p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens
CRP11	Since both are substrates, co-administration of  bbbbb1 rivaroxaban eeeee1  and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and  bbbbb2 P-gp eeeee2  inducers
CRP11	Since both are substrates, co-administration of  bbbbb1 rivaroxaban eeeee1  and apixaban with strong  bbbbb2 cytochrome P450 (CYP) 3A4 eeeee2  and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers
CRP11	Since both are substrates, co-administration of  bbbbb1 rivaroxaban eeeee1  and apixaban with strong cytochrome P450 (CYP) 3A4 and  bbbbb2 permeability glycoprotein eeeee2  (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers
CRP11	Since both are substrates, co-administration of  bbbbb1 rivaroxaban eeeee1  and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein ( bbbbb2 P-gp eeeee2 ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers
CRP11	Since both are substrates, co-administration of  bbbbb1 rivaroxaban eeeee1  and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong  bbbbb2 CYP3A4 eeeee2  and P-gp inducers
CRP11	Since both are substrates, co-administration of rivaroxaban and  bbbbb1 apixaban eeeee1  with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and  bbbbb2 P-gp eeeee2  inducers
CRP11	Since both are substrates, co-administration of rivaroxaban and  bbbbb1 apixaban eeeee1  with strong  bbbbb2 cytochrome P450 (CYP) 3A4 eeeee2  and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers
CRP11	Since both are substrates, co-administration of rivaroxaban and  bbbbb1 apixaban eeeee1  with strong cytochrome P450 (CYP) 3A4 and  bbbbb2 permeability glycoprotein eeeee2  (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers
CRP11	Since both are substrates, co-administration of rivaroxaban and  bbbbb1 apixaban eeeee1  with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein ( bbbbb2 P-gp eeeee2 ) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers
CRP11	Since both are substrates, co-administration of rivaroxaban and  bbbbb1 apixaban eeeee1  with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong  bbbbb2 CYP3A4 eeeee2  and P-gp inducers
CRP11	Although parenteral oral direct thrombin inhibitors (DTIs), such as  bbbbb1 argatroban eeeee1  and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic  bbbbb2 thrombin eeeee2  antagonists
CRP11	Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as  bbbbb1 dabigatran eeeee1  bbbbb2 thrombin eeeee2  inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists
CRP11	Baseline copper ( bbbbb1 Cu eeeee1 ) level, Cu uptake, and Cu cytotoxicity were also reduced in  bbbbb2 CLDN3 eeeee2 KD and CLDN4KD cells
CRP11	Baseline copper ( bbbbb1 Cu eeeee1 ) level, Cu uptake, and Cu cytotoxicity were also reduced in CLDN3KD and  bbbbb2 CLDN4 eeeee2 KD cells
CRP11	Baseline copper (Cu) level, Cu uptake, and  bbbbb1 Cu eeeee1  cytotoxicity were also reduced in  bbbbb2 CLDN3 eeeee2 KD and CLDN4KD cells
CRP11	Baseline copper (Cu) level, Cu uptake, and  bbbbb1 Cu eeeee1  cytotoxicity were also reduced in CLDN3KD and  bbbbb2 CLDN4 eeeee2 KD cells
CRP11	Baseline copper (Cu) level,  bbbbb1 Cu eeeee1  uptake, and Cu cytotoxicity were also reduced in  bbbbb2 CLDN3 eeeee2 KD and CLDN4KD cells
CRP11	Baseline copper (Cu) level,  bbbbb1 Cu eeeee1  uptake, and Cu cytotoxicity were also reduced in CLDN3KD and  bbbbb2 CLDN4 eeeee2 KD cells
CRP11	Baseline  bbbbb1 copper eeeee1  (Cu) level, Cu uptake, and Cu cytotoxicity were also reduced in  bbbbb2 CLDN3 eeeee2 KD and CLDN4KD cells
CRP11	Baseline  bbbbb1 copper eeeee1  (Cu) level, Cu uptake, and Cu cytotoxicity were also reduced in CLDN3KD and  bbbbb2 CLDN4 eeeee2 KD cells
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the  bbbbb1 copper eeeee1  bbbbb2 copper and cisplatin influx transporter eeeee2  CTR1
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the  bbbbb1 copper eeeee1  bbbbb2 Claudin-3 eeeee2  and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the  bbbbb1 copper eeeee1  bbbbb2 claudin-4 eeeee2  regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the  bbbbb1 copper eeeee1  and cisplatin influx transporter  bbbbb2 CTR1 eeeee2 
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and  bbbbb1 cisplatin eeeee1  bbbbb2 copper and cisplatin influx transporter eeeee2  CTR1
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and  bbbbb1 cisplatin eeeee1  bbbbb2 Claudin-3 eeeee2  and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and  bbbbb1 cisplatin eeeee1  bbbbb2 claudin-4 eeeee2  regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1
CRP11	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and  bbbbb1 cisplatin eeeee1  influx transporter  bbbbb2 CTR1 eeeee2 
CRP11	Cu-dependent tyrosinase activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA bbbbb1  eeeee1  bbbbb2 lso m eeeee2 arkedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA
CRP11	Cu-dependent tyrosinase activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Cu-dependent tyrosinase activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Cu-dependent tyrosinase activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA bbbbb1  eeeee1  bbbbb2 vity  eeeee2 was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA
CRP11	The net accumulation of platinum ( bbbbb1 Pt eeeee1 ) and the Pt-DNA adduct levels were reduced in CLDN3KD and  bbbbb2 CLDN4 eeeee2 KD cells
CRP11	The net accumulation of platinum ( bbbbb1 Pt eeeee1 ) and the Pt-DNA adduct levels were reduced in  bbbbb2 CLDN3 eeeee2 KD and CLDN4KD cells
CRP11	The net accumulation of platinum (Pt) and the  bbbbb1 Pt eeeee1 -DNA adduct levels were reduced in CLDN3KD and  bbbbb2 CLDN4 eeeee2 KD cells
CRP11	The net accumulation of platinum (Pt) and the  bbbbb1 Pt eeeee1 -DNA adduct levels were reduced in  bbbbb2 CLDN3 eeeee2 KD and CLDN4KD cells
CRP11	The net accumulation of  bbbbb1 platinum eeeee1  (Pt) and the Pt-DNA adduct levels were reduced in CLDN3KD and  bbbbb2 CLDN4 eeeee2 KD cells
CRP11	The net accumulation of  bbbbb1 platinum eeeee1  (Pt) and the Pt-DNA adduct levels were reduced in  bbbbb2 CLDN3 eeeee2 KD and CLDN4KD cells
CRP11	We found that knockdown of the expression of either CLDN3 or CLDN4 produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to  bbbbb1 cisplatin eeeee1  bbbbb2 CLDN4 eeeee2  produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to cisplatin (cDDP)
CRP11	We found that knockdown of the expression of either CLDN3 or CLDN4 produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to  bbbbb1 cisplatin eeeee1  bbbbb2 CLDN3 eeeee2  or CLDN4 produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to cisplatin (cDDP)
CRP11	The endogenous mRNA levels of  bbbbb1 copper eeeee1  bbbbb2 copper influx transporter eeeee2  CTR1 were found to be significantly reduced in the knockdown cells, and exogenous expression of CTR1 restored their sensitivity to cDDP
CRP11	The endogenous mRNA levels of  bbbbb1 copper eeeee1  influx transporter CTR1 were found to be significantly reduced in the knockdown cells, and exogenous expression of  bbbbb2 CTR1 eeeee2  restored their sensitivity to cDDP
CRP11	The endogenous mRNA levels of  bbbbb1 copper eeeee1  influx transporter  bbbbb2 CTR1 eeeee2  were found to be significantly reduced in the knockdown cells, and exogenous expression of CTR1 restored their sensitivity to cDDP
CRP11	 bbbbb1 Dimethylarginine eeeee1  bbbbb2 Dimethylarginine dimethylaminohydrolase eeeee2  (DDAH) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney
CRP11	 bbbbb1 Dimethylarginine eeeee1  dimethylaminohydrolase ( bbbbb2 DDAH eeeee2 ) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney
CRP11	We found that the removal of urea with urease is necessary since  bbbbb1 urea eeeee1  bbbbb2 urease eeeee2  is necessary since urea also produces a positive reaction
CRP11	Arginase or  bbbbb1 nitric oxide eeeee1  bbbbb2 nitric oxide synthase eeeee2  isoenzymes were not found to influence L-citrulline production
CRP11	Arginase or  bbbbb1 nitric oxide eeeee1  bbbbb2 Arginase eeeee2  or nitric oxide synthase isoenzymes were not found to influence L-citrulline production
CRP11	Deproteinization with  bbbbb1 sulfosalicylic acid eeeee1  was found to be optimal and that  bbbbb2 protease eeeee2  inhibitors were not necessary
CRP11	Determination of  bbbbb1 dimethylarginine eeeee1  bbbbb2 dimethylarginine dimethylaminohydrolase eeeee2  activity in the kidney
CRP11	Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptors eeeee2 
CRP11	Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptors eeeee2  for many of their pharmacological actions may be due to blockade of adenosine receptors
CRP11	Xanthines are classical antagonists for  bbbbb1 adenosine eeeee1  receptors for many of their pharmacological actions may be due to blockade of  bbbbb2 adenosine receptors eeeee2 
CRP11	Xanthines are classical antagonists for  bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptors eeeee2  for many of their pharmacological actions may be due to blockade of adenosine receptors
CRP11	The involvement of  bbbbb1 adenylate eeeee1  bbbbb2 adenylate cyclase eeeee2  in these responses remains unresolved
CRP11	The subregion of the adenosine receptor that interacts with the  bbbbb1 N6 eeeee1 -substituent is different for  bbbbb2 A1 and A2 receptors eeeee2 , particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity
CRP11	The subregion of the  bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptor eeeee2  that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity
CRP11	The subregion of the  bbbbb1 adenosine eeeee1  receptor that interacts with the N6-substituent is different for  bbbbb2 A1 and A2 receptors eeeee2 , particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity
CRP11	The subregion of the adenosine receptor that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to  bbbbb1 phenyl eeeee1  bbbbb2 A1 and A2 receptors eeeee2 , particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity
CRP11	 bbbbb1 Adenosine eeeee1  bbbbb2 Adenosine receptors eeeee2 : development of selective agonists and antagonists
CRP11	Certain analogs of caffeine in which the methyl group at the 1- or 7-position is replaced with a propargyl o bbbbb1 r propyl  eeeee1  bbbbb2 r propyl group disp eeeee2 lay selectivity for A2 receptors
CRP11	 bbbbb1 Caffeine eeeee1  and theophylline are virtually non-selective for  bbbbb2 A2 and A2 receptors eeeee2 
CRP11	Caffeine and  bbbbb1 theophylline eeeee1  are virtually non-selective for  bbbbb2 A2 and A2 receptors eeeee2 
CRP11	Adenosine modulates a variety of physiological functions through interaction with A1 and A2  bbbbb1 adenosine eeeee1  bbbbb2 A1 and A2 adenosine receptors eeeee2 , where agonists mediate inhibition and stimulation, respectively, of adenylate cyclase
CRP11	Adenosine modulates a variety of physiological functions through interaction with A1 and A2  bbbbb1 adenosine eeeee1  receptors, where agonists mediate inhibition and stimulation, respectively, of  bbbbb2 adenylate cyclase eeeee2 
CRP11	 bbbbb1 Adenosine eeeee1  modulates a variety of physiological functions through interaction with  bbbbb2 A1 and A2 adenosine receptors eeeee2 , where agonists mediate inhibition and stimulation, respectively, of adenylate cyclase
CRP11	 bbbbb1 Adenosine eeeee1  modulates a variety of physiological functions through interaction with A1 and A2 adenosine receptors, where agonists mediate inhibition and stimulation, respectively, of  bbbbb2 adenylate cyclase eeeee2 
CRP11	Adenosine modulates a variety of physiological functions through interaction with A1 and A2 adenosine receptors, where agonists mediate inhibition and stimulation, respectively, of  bbbbb1 adenylate eeeee1  bbbbb2 A1 and A2 adenosine receptors eeeee2 , where agonists mediate inhibition and stimulation, respectively, of adenylate cyclase
CRP11	Adenosine modulates a variety of physiological functions through interaction with A1 and A2 adenosine receptors, where agonists mediate inhibition and stimulation, respectively, of  bbbbb1 adenylate eeeee1  bbbbb2 adenylate cyclase eeeee2 
CRP11	The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long  bbbbb1 C eeeee1  bbbbb2 5-HT receptors eeeee2 , as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other  bbbbb1 5-HT eeeee1  bbbbb2 serotonin (5-HT) receptors eeeee2  of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other  bbbbb1 5-HT eeeee1  bbbbb2 5-HT receptors eeeee2 , as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other  bbbbb1 5-HT eeeee1  bbbbb2 5-HT6 eeeee2 ) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 serotonin (5-HT) receptors eeeee2  of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The serotonin ( bbbbb1 5-HT eeeee1 ) receptors of type 6 (5-HT6) are quite different from all other  bbbbb2 5-HT receptors eeeee2 , as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The serotonin ( bbbbb1 5-HT eeeee1 ) receptors of type 6 ( bbbbb2 5-HT6 eeeee2 ) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The  bbbbb1 serotonin eeeee1  bbbbb2 serotonin (5-HT) receptors eeeee2  of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The  bbbbb1 serotonin eeeee1  (5-HT) receptors of type 6 (5-HT6) are quite different from all other  bbbbb2 5-HT receptors eeeee2 , as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	The  bbbbb1 serotonin eeeee1  (5-HT) receptors of type 6 ( bbbbb2 5-HT6 eeeee2 ) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop
CRP11	A lot of controversies still exist regarding their binding affinity, effects of 5-HT6 ligands on brain  bbbbb1 catecholamines eeeee1  bbbbb2 5-HT6 eeeee2  ligands on brain catecholamines, behavioral syndromes regulated by them, and brain distribution
CRP11	 bbbbb1 Serotonin eeeee1  bbbbb2 Serotonin receptors eeeee2  of type 6 (5-HT6): from neuroscience to clinical pharmacology
CRP11	 bbbbb1 Serotonin eeeee1  receptors of type 6 ( bbbbb2 5-HT6 eeeee2 ): from neuroscience to clinical pharmacology
CRP11	Structural basis of inhibition of the human  bbbbb1 NAD+ eeeee1  bbbbb2 human NAD+-dependent deacetylase SIRT5 eeeee2  by suramin
CRP11	We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5  bbbbb1 NAD(+) eeeee1  bbbbb2 human SIRT5 eeeee2  and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM
CRP11	We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5  bbbbb1 NAD(+) eeeee1  bbbbb2 SIRT5 NAD(+)-dependent deacetylase eeeee2  activity with an IC(50) value of 22 microM
CRP11	A streamlined and high-yielding synthesis of aprepitant (1), a potent  bbbbb1 substance P eeeee1  bbbbb2 substance P (SP) receptor eeeee2  antagonist, is described
CRP11	A streamlined and high-yielding synthesis of aprepitant (1), a potent substance P ( bbbbb1 SP eeeee1  bbbbb2 substance P (SP) receptor eeeee2  antagonist, is described
CRP11	The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the  bbbbb1 BDZ eeeee1  bbbbb2 BDZ receptor eeeee2 , including Ro 15-1788 and the beta CCs
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb1 BDZ eeeee1  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb1 BDZ eeeee1  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant  bbbbb1 BDZ eeeee1  which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam,  bbbbb1 nitrazepam eeeee1  and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam,  bbbbb1 nitrazepam eeeee1  and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam,  bbbbb1 clonazepam eeeee1 , nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam,  bbbbb1 clonazepam eeeee1 , nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb1 BDZ eeeee1  receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb1 BDZ eeeee1  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs ( bbbbb1 diazepam eeeee1 , clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs ( bbbbb1 diazepam eeeee1 , clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist ( bbbbb1 Ro 15-1788 eeeee1  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and  bbbbb1 lorazepam eeeee1 ) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and  bbbbb1 lorazepam eeeee1 ) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant  bbbbb1 BDZs eeeee1  (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant  bbbbb1 BDZs eeeee1  (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity  bbbbb2 BDZ receptors eeeee2  (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors ( bbbbb1 Ro 5-4864 eeeee1 ) at high nanomolar concentrations and by a  bbbbb2 BDZ receptor eeeee2  weak partial agonist (Ro 15-1788) at micromolar concentrations
CRP11	BuChE activity in CSF was significantly lower after rivastigmine than after placebo for up to 3.6 hours after dosing, but bbbbb1  this differ eeeee1  bbbbb2 fter eeeee2  placebo for up to 3.6 hours after dosing, but this difference was not sustained
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that  bbbbb1 rivastigmine eeeee1  bbbbb2 AChE eeeee2 ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that  bbbbb1 rivastigmine eeeee1  bbbbb2 acetylcholinesterase eeeee2  (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that  bbbbb1 rivastigmine eeeee1  (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits  bbbbb2 AChE eeeee2  in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713;  bbbbb1 Exelon eeeee1  bbbbb2 AChE eeeee2 ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713;  bbbbb1 Exelon eeeee1  bbbbb2 acetylcholinesterase eeeee2  (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713;  bbbbb1 Exelon eeeee1 , Novartis Pharma AG, Basel, Switzerland) selectively inhibits  bbbbb2 AChE eeeee2  in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine ( bbbbb1 ENA-713 eeeee1  bbbbb2 AChE eeeee2 ) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine ( bbbbb1 ENA-713 eeeee1  bbbbb2 acetylcholinesterase eeeee2  (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine ( bbbbb1 ENA-713 eeeee1 ; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits  bbbbb2 AChE eeeee2  in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for  bbbbb1 rivastigmine eeeee1  and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase ( bbbbb2 BuChE eeeee2 ) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for  bbbbb1 rivastigmine eeeee1  and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte  bbbbb2 AChE eeeee2  activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for  bbbbb1 rivastigmine eeeee1  and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF  bbbbb2 AChE eeeee2  activity, and plasma and CSF butyrylcholinesterase (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for  bbbbb1 rivastigmine eeeee1  and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF  bbbbb2 butyrylcholinesterase eeeee2  (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite  bbbbb1 NAP 226-90 eeeee1  ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase ( bbbbb2 BuChE eeeee2 ) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite  bbbbb1 NAP 226-90 eeeee1  ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte  bbbbb2 AChE eeeee2  activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite  bbbbb1 NAP 226-90 eeeee1  ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF  bbbbb2 AChE eeeee2  activity, and plasma and CSF butyrylcholinesterase (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite  bbbbb1 NAP 226-90 eeeee1  ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF  bbbbb2 butyrylcholinesterase eeeee2  (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 ( bbbbb1 [-] [3-([1-dimethylaminolethyl)-phenol] eeeee1 ), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase ( bbbbb2 BuChE eeeee2 ) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 ( bbbbb1 [-] [3-([1-dimethylaminolethyl)-phenol] eeeee1 ), erythrocyte  bbbbb2 AChE eeeee2  activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 ( bbbbb1 [-] [3-([1-dimethylaminolethyl)-phenol] eeeee1 ), erythrocyte AChE activity, CSF  bbbbb2 AChE eeeee2  activity, and plasma and CSF butyrylcholinesterase (BuChE) activity
CRP11	CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 ( bbbbb1 [-] [3-([1-dimethylaminolethyl)-phenol] eeeee1 ), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF  bbbbb2 butyrylcholinesterase eeeee2  (BuChE) activity
CRP11	Exchange protein directly activated by  bbbbb1 cAMP eeeee1  (EPAC) and cAMP-dependent protein kinase ( bbbbb2 PKA eeeee2 ) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by  bbbbb1 cAMP eeeee1  (EPAC) and  bbbbb2 cAMP-dependent protein kinase eeeee2  (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by  bbbbb1 cAMP eeeee1  ( bbbbb2 EPAC eeeee2 ) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by  bbbbb1 cAMP eeeee1  bbbbb2 Exchange protein directly activated by cAMP eeeee2  (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and  bbbbb1 cAMP eeeee1 -dependent protein kinase ( bbbbb2 PKA eeeee2 ) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-dependent protein kinase eeeee2  (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and  bbbbb1 cAMP eeeee1  bbbbb2 EPAC eeeee2 ) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and  bbbbb1 cAMP eeeee1  bbbbb2 Exchange protein directly activated by cAMP eeeee2  (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger  bbbbb1 cAMP eeeee1  bbbbb2 PKA eeeee2 ) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-dependent protein kinase eeeee2  (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger  bbbbb1 cAMP eeeee1  bbbbb2 EPAC eeeee2 ) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger  bbbbb1 cAMP eeeee1  bbbbb2 Exchange protein directly activated by cAMP eeeee2  (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP
CRP11	Cytokines, lipopolysaccharides and other inflammatory mediators such as  bbbbb1 prostaglandin eeeee1  bbbbb2 Cytokines eeeee2 , lipopolysaccharides and other inflammatory mediators such as prostaglandin and leukotriene are related to the secretion and production of mucin
CRP11	Cytokines, lipopolysaccharides and other inflammatory mediators such as prostaglandin and  bbbbb1 leukotriene eeeee1  bbbbb2 Cytokines eeeee2 , lipopolysaccharides and other inflammatory mediators such as prostaglandin and leukotriene are related to the secretion and production of mucin
CRP11	Pranlukast hydrate (ONO-1078, 1 bbbbb1 00 microM)  eeeee1 downregulated the leukotriene D(4)-induced MUC2/5AC g bbbbb2 ene expr eeeee2 ession and mucin secretion
CRP11	Pranlukast hydrate (ONO-1078, 1 bbbbb1 00 microM)  eeeee1  bbbbb2 00 microM) downregul eeeee2 ated the leukotriene D(4)-induced MUC2/5AC gene expression and mucin secretion
CRP11	Pranlukast hydrate (ONO-1078, 1 bbbbb1 00 microM)  eeeee1 downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and mucin secr bbbbb2 etion eeeee2 
CRP11	The effect of leukotriene D(4) and the leukotriene receptor antagonist,  bbbbb1 pranlukast hydrate eeeee1  (ONO-1078) on the regulation of  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of leukotriene D(4) and the leukotriene receptor antagonist,  bbbbb1 pranlukast hydrate eeeee1  (ONO-1078) on the regulation of MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate ( bbbbb1 ONO-1078 eeeee1 ) on the regulation of  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate ( bbbbb1 ONO-1078 eeeee1 ) on the regulation of MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of  bbbbb1 leukotriene D(4) eeeee1  and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of  bbbbb1 leukotriene D(4) eeeee1  and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of  bbbbb1 leukotriene D(4) eeeee1  and the  bbbbb2 leukotriene receptor eeeee2  antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of leukotriene D(4) and the  bbbbb1 leukotriene eeeee1  receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of  bbbbb2 MUC2/5AC eeeee2  gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of leukotriene D(4) and the  bbbbb1 leukotriene eeeee1  receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and  bbbbb2 mucin eeeee2  secretion were observed in human airway NCI-H292 epithelial cells
CRP11	The effect of leukotriene D(4) and the  bbbbb1 leukotriene eeeee1  bbbbb2 leukotriene receptor eeeee2  antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells
CRP11	ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the  bbbbb1 estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 )
CRP11	ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  (ER)
CRP11	The present study investigates enzyme activities of the urea cycle, transamidinase and  bbbbb1 ornithine eeeee1  bbbbb2 transamidinase eeeee2  and ornithine-proline inter-conversion in the hypertrophied kidney after unilateral nephrectomy in mice
CRP11	The present study investigates enzyme activities of the urea cycle, transamidinase and ornithine- bbbbb1 proline eeeee1  bbbbb2 transamidinase eeeee2  and ornithine-proline inter-conversion in the hypertrophied kidney after unilateral nephrectomy in mice
CRP11	The specific activity of only  bbbbb1 ornithine eeeee1  aminotransferase ( bbbbb2 OAT eeeee2 ), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy
CRP11	The specific activity of only  bbbbb1 ornithine eeeee1  bbbbb2 ornithine aminotransferase eeeee2  (OAT), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy
CRP11	Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and  bbbbb1 vitamin K eeeee1  bbbbb2 factor IIa eeeee2  inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development
CRP11	Furthermore, knockdown of Brms1L significantly attenuated GnRH-induced FSHβ expression bbbbb1  eeeee1  bbbbb2 d FSHβ ex eeeee2 pression
CRP11	Furthermore, knockdown of Brms1L significantly attenuated GnRH-induced FSHβ expression bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Furthermore, knockdown of Brms1L significantly attenuated GnRH-induced FSHβ expression bbbbb1  eeeee1  bbbbb2 nuated eeeee2  GnRH-induced FSHβ expression
CRP11	H caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun  bbbbb1 N eeeee1 -terminal kinase ( bbbbb2 JNK eeeee2 ) inhibition
CRP11	H caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun  bbbbb1 N eeeee1  bbbbb2 c-Jun N-terminal kinase eeeee2  (JNK) inhibition
CRP11	H caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun  bbbbb1 N eeeee1  bbbbb2 β-catenin eeeee2  levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition
CRP11	LβT2 cells transfected with FSHβ promoter luciferase fusion constructs,  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  responsiveness was conferred by the proximal promoter (-944/-1) and was markedly decreased by β-catenin knockdown
CRP11	LβT2 cells transfected with FSHβ promoter luciferase fusion constructs,  bbbbb1 GnRH eeeee1  responsiveness was conferred by the proximal promoter (-944/-1) and was markedly decreased by  bbbbb2 β-catenin eeeee2  knockdown
CRP11	LβT2 cells transfected with FSHβ promoter luciferase fusion constructs,  bbbbb1 GnRH eeeee1  bbbbb2 FSHβ promoter eeeee2  luciferase fusion constructs, GnRH responsiveness was conferred by the proximal promoter (-944/-1) and was markedly decreased by β-catenin knockdown
CRP11	For example, involvement of β-catenin in LHβ induction by  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  has been discovered
CRP11	β-catenin regulates  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 -induced FSHβ gene expression
CRP11	β-catenin regulates  bbbbb1 GnRH eeeee1  bbbbb2 β-catenin eeeee2  regulates GnRH-induced FSHβ gene expression
CRP11	However, none of the T-cell factor/lymphoid enhancer factor binding sites in that region were required for promoter activation by  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 
CRP11	However, none of the T-cell factor/lymphoid enhancer factor binding sites in that region were required for promoter activation by  bbbbb1 GnRH eeeee1  bbbbb2 T-cell factor/lymphoid enhancer factor binding sites eeeee2  in that region were required for promoter activation by GnRH
CRP11	The regulation of gonadotropin synthesis by  bbbbb1 GnRH eeeee1  bbbbb2 gonadotropin eeeee2  synthesis by GnRH plays an essential role in the neuroendocrine control of reproduction
CRP11	The regulation of gonadotropin synthesis by  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  plays an essential role in the neuroendocrine control of reproduction
CRP11	 bbbbb1 Nobiletin eeeee1  attenuates metastasis via both ERK and PI3K/Akt pathways in  bbbbb2 HGF eeeee2 -treated liver cancer HepG2 cells
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including  bbbbb1 apigenin eeeee1 , tricetin, tangeretin, and nobiletin on  bbbbb2 HGF eeeee2 /c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including  bbbbb1 apigenin eeeee1  bbbbb2 HGF eeeee2  as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including  bbbbb1 apigenin eeeee1 , tricetin, tangeretin, and nobiletin on HGF/ bbbbb2 c-Met eeeee2 -mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and  bbbbb1 nobiletin eeeee1  on  bbbbb2 HGF eeeee2 /c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and  bbbbb1 nobiletin eeeee1  bbbbb2 HGF eeeee2  as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and  bbbbb1 nobiletin eeeee1  on HGF/ bbbbb2 c-Met eeeee2 -mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin,  bbbbb1 tricetin eeeee1 , tangeretin, and nobiletin on  bbbbb2 HGF eeeee2 /c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin,  bbbbb1 tricetin eeeee1  bbbbb2 HGF eeeee2  as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin,  bbbbb1 tricetin eeeee1 , tangeretin, and nobiletin on HGF/ bbbbb2 c-Met eeeee2 -mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin,  bbbbb1 tangeretin eeeee1 , and nobiletin on  bbbbb2 HGF eeeee2 /c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin,  bbbbb1 tangeretin eeeee1  bbbbb2 HGF eeeee2  as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis
CRP11	We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin,  bbbbb1 tangeretin eeeee1 , and nobiletin on HGF/ bbbbb2 c-Met eeeee2 -mediated tumor invasion and metastasis
CRP11	Furthermore,  bbbbb1 nobiletin eeeee1  could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not  bbbbb2 phosphorylated JNK1/2 eeeee2  and p38
CRP11	Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the  bbbbb1 retinoid eeeee1  receptors RARbeta and  bbbbb2 RARgamma eeeee2 
CRP11	Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the  bbbbb1 retinoid eeeee1  bbbbb2 retinoid receptors eeeee2  RARbeta and RARgamma
CRP11	Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the  bbbbb1 retinoid eeeee1  receptors  bbbbb2 RARbeta eeeee2  and RARgamma
CRP11	Angiotensin II ( bbbbb1 Ang II eeeee1  bbbbb2 Ang II eeeee2 ) level in plasma and mesenteric arteries was measured by radioimmunoassay
CRP11	Angiotensin II ( bbbbb1 Ang II eeeee1  bbbbb2 Angiotensin II eeeee2  (Ang II) level in plasma and mesenteric arteries was measured by radioimmunoassay
CRP11	 bbbbb1 Angiotensin II eeeee1  ( bbbbb2 Ang II eeeee2 ) level in plasma and mesenteric arteries was measured by radioimmunoassay
CRP11	 bbbbb1 Angiotensin II eeeee1  bbbbb2 Angiotensin II eeeee2  (Ang II) level in plasma and mesenteric arteries was measured by radioimmunoassay
CRP11	 bbbbb1 Ang II eeeee1  bbbbb2 Ang II eeeee2  level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05)
CRP11	 bbbbb1 Ang II eeeee1  bbbbb2 Ang II eeeee2  level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group
CRP11	Iontophoresis of +/- propranolol, whose serotonergic actions include antagonism and partial agonism at 5-HT1 receptors, also increased  bbbbb1 serotonin eeeee1  bbbbb2 5-HT1 eeeee2  receptors, also increased serotonin and decreased firing (n=4)
CRP11	Prior neuroan bbbbb1 atomical  eeeee1 knowledge favors a midbrain origin for these afferents, while some of the drug findings suggest that their terminals posses bbbbb2 s inhi eeeee2 bitory serotonergic autoreceptors, possibly of 5-HT1b subtype
CRP11	Prior neuroan bbbbb1 atomical  eeeee1 knowledge favors a midbrain origin for these afferents, while some of the drug findings suggest that their terminals possess inhibitory serotonergic autore bbbbb2 cepto eeeee2 rs, possibly of 5-HT1b subtype
CRP11	Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised  bbbbb1 serotonin eeeee1  bbbbb2 5-HT1 eeeee2  and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)
CRP11	Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised  bbbbb1 serotonin eeeee1  bbbbb2 5-HT2 eeeee2  antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)
CRP11	Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by  bbbbb1 clomipramine eeeee1  bbbbb2 5-HT1 eeeee2  and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)
CRP11	Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by  bbbbb1 clomipramine eeeee1  bbbbb2 5-HT2 eeeee2  antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)
CRP11	Activity of the mutant  bbbbb1 delta-aminolevulinate eeeee1  bbbbb2 delta-aminolevulinate synthase eeeee2  protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate, consistent with the clinical response of the patient to pyridoxine treatment
CRP11	A novel mutation of the erythroid-specific  bbbbb1 gamma-Aminolevulinate eeeee1  bbbbb2 erythroid-specific gamma-Aminolevulinate synthase eeeee2  gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia
CRP11	A novel missense mutation, G663A, in exon 5 of the erythroid-specific  bbbbb1 delta-aminolevulinate eeeee1  bbbbb2 erythroid-specific delta-aminolevulinate synthase eeeee2  gene (ALAS2) was identified in a Japanese male with pyridoxine-responsive sideroblastic anemia
CRP11	A novel missense mutation, G663A, in exon 5 of the erythroid-specific  bbbbb1 delta-aminolevulinate eeeee1  bbbbb2 G663A eeeee2 , in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) was identified in a Japanese male with pyridoxine-responsive sideroblastic anemia
CRP11	A novel missense mutation, G663A, in exon 5 of the erythroid-specific  bbbbb1 delta-aminolevulinate eeeee1  synthase gene ( bbbbb2 ALAS2 eeeee2 ) was identified in a Japanese male with pyridoxine-responsive sideroblastic anemia
CRP11	We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent CCK-A receptor antagonist  bbbbb1 lintitript eeeee1  bbbbb2 CCK eeeee2  in the emptying of a solid/liquid meal administering the new, highly specific and potent CCK-A receptor antagonist lintitript
CRP11	Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of  bbbbb1 Cu(I) eeeee1  -Loaded hCCS Domain 1 and Analysis of Disulfide-Free  bbbbb2 hSOD1 eeeee2  Mutants
CRP11	Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of Cu(I) -Loaded hCCS Domain 1 and Analysis of  bbbbb1 Disulfide eeeee1  bbbbb2 hSOD1 eeeee2  Maturation from the Solution Structure of Cu(I) -Loaded hCCS Domain 1 and Analysis of Disulfide-Free hSOD1 Mutants
CRP11	Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of Cu(I) -Loaded hCCS Domain 1 and Analysis of  bbbbb1 Disulfide eeeee1 -Free  bbbbb2 hSOD1 eeeee2  Mutants
CRP11	Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of Cu(I) -Loaded hCCS Domain 1 and Analysis of  bbbbb1 Disulfide eeeee1  bbbbb2 hCCS Domain 1 eeeee2  and Analysis of Disulfide-Free hSOD1 Mutants
CRP11	NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in bbbbb1  order eeeee1  bbbbb2 he hS eeeee2 OD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition
CRP11	NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in bbbbb1  order eeeee1  bbbbb2 are u eeeee2 nable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition
CRP11	NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in bbbbb1  order eeeee1  bbbbb2 exam eeeee2 ine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition
CRP11	The NMR solution structure of the  bbbbb1 copper(I) eeeee1 -loaded form of hCCSD1 reported here contributes further to characterization of the copper-transfer mechanism to  bbbbb2 hSOD1 eeeee2 
CRP11	 bbbbb1 Superoxide eeeee1  dismutase 1 (SOD1) maturation within the cell is mainly accomplished with the SOD1-specific chaperone,  bbbbb2 CCS eeeee2 , a dimeric protein with three distinct domains in each monomer
CRP11	 bbbbb1 Superoxide eeeee1  dismutase 1 (SOD1) maturation within the cell is mainly accomplished with the  bbbbb2 SOD1-specific chaperone eeeee2 , CCS, a dimeric protein with three distinct domains in each monomer
CRP11	 bbbbb1 Superoxide eeeee1  bbbbb2 Superoxide dismutase 1 eeeee2  (SOD1) maturation within the cell is mainly accomplished with the SOD1-specific chaperone, CCS, a dimeric protein with three distinct domains in each monomer
CRP11	 bbbbb1 Superoxide eeeee1  dismutase 1 ( bbbbb2 SOD1 eeeee2 ) maturation within the cell is mainly accomplished with the SOD1-specific chaperone, CCS, a dimeric protein with three distinct domains in each monomer
CRP11	Inhibition of cyclic AMP production by  bbbbb1 ergovaline eeeee1  was blocked by the  bbbbb2 dopamine receptor eeeee2  antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM)
CRP11	Inhibition of cyclic AMP production by ergovaline was blocked by the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine receptor eeeee2  antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM)
CRP11	Inhibition of  bbbbb1 cyclic AMP eeeee1  production by ergovaline was blocked by the  bbbbb2 dopamine receptor eeeee2  antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM)
CRP11	Ergovaline inhibition of radioligand binding to the D2  bbbbb1 dopamine eeeee1  receptor and ergot alkaloid inhibition of vasoactive intestinal peptide ( bbbbb2 VIP eeeee2 )-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2  bbbbb1 dopamine eeeee1  bbbbb2 D2 dopamine receptor eeeee2  and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2  bbbbb1 dopamine eeeee1  receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a  bbbbb2 rat D2 dopamine receptor eeeee2 , were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2  bbbbb1 dopamine eeeee1  receptor and ergot alkaloid inhibition of  bbbbb2 vasoactive intestinal peptide eeeee2  (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated  bbbbb1 cyclic AMP eeeee1  bbbbb2 D2 dopamine receptor eeeee2  and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated  bbbbb1 cyclic AMP eeeee1  production in GH4ZR7 cells, stably transfected with a  bbbbb2 rat D2 dopamine receptor eeeee2 , were evaluated
CRP11	 bbbbb1 Ergovaline eeeee1  inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide ( bbbbb2 VIP eeeee2 )-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	 bbbbb1 Ergovaline eeeee1  inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a  bbbbb2 rat D2 dopamine receptor eeeee2 , were evaluated
CRP11	 bbbbb1 Ergovaline eeeee1  inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of  bbbbb2 vasoactive intestinal peptide eeeee2  (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2  bbbbb1 dopamine eeeee1  bbbbb2 VIP eeeee2 )-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2  bbbbb1 dopamine eeeee1  bbbbb2 D2 dopamine receptor eeeee2  and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2  bbbbb1 dopamine eeeee1  bbbbb2 rat D2 dopamine receptor eeeee2 , were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2  bbbbb1 dopamine eeeee1  bbbbb2 vasoactive intestinal peptide eeeee2  (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and  bbbbb1 ergot alkaloid eeeee1  bbbbb2 D2 dopamine receptor eeeee2  and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated
CRP11	Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and  bbbbb1 ergot alkaloid eeeee1  inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a  bbbbb2 rat D2 dopamine receptor eeeee2 , were evaluated
CRP11	Ergovaline binding and activation of D2  bbbbb1 dopamine eeeee1  bbbbb2 D2 dopamine receptors eeeee2  in GH4ZR7 cells
CRP11	Our results indicate that ergot compounds, especially ergovaline, bind to D2 dopamine receptors and elicit second messenger responses similar to that of dopamine bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, sorafenib demonstrated significant activity against several receptor  bbbbb1 tyrosine eeeee1  bbbbb2 receptor tyrosine kinases eeeee2  involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT
CRP11	In addition, sorafenib demonstrated significant activity against several receptor  bbbbb1 tyrosine eeeee1  kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and  bbbbb2 c-KIT eeeee2 
CRP11	In addition, sorafenib demonstrated significant activity against several receptor  bbbbb1 tyrosine eeeee1  kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta  bbbbb2 Flt-3 eeeee2 , and c-KIT
CRP11	In addition, sorafenib demonstrated significant activity against several receptor  bbbbb1 tyrosine eeeee1  kinases involved in neovascularization and tumor progression, including  bbbbb2 vascular-endothelial growth factor (VEGFR)-2 eeeee2 , VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT
CRP11	In addition, sorafenib demonstrated significant activity against several receptor  bbbbb1 tyrosine eeeee1  kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2,  bbbbb2 VEGFR-3 eeeee2 , platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT
CRP11	In addition, sorafenib demonstrated significant activity against several receptor  bbbbb1 tyrosine eeeee1  kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3,  bbbbb2 platelet-derived growth factor (PDGFR)-beta eeeee2  Flt-3, and c-KIT
CRP11	Aergic synapses in the PVN impinge directly on oxytocinergic neurons or on excitatory glutamatergic synapses, which also impinge on oxytocinergic neurons, these results suggest that the blockade of CB1 receptors decreases  bbbbb1 GABA eeeee1  bbbbb2 CB1 receptors eeeee2  decreases GABA release in the PVN, increasing in turn glutamatergic neurotransmission to activate oxytocinergic neurons mediating penile erection
CRP11	Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective  bbbbb1 cannabinoid eeeee1  bbbbb2 Cannabinoid CB1 receptors eeeee2  in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CRP11	Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective  bbbbb1 cannabinoid eeeee1  bbbbb2 cannabinoid CB1 receptor eeeee2  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CRP11	 bbbbb1 Cannabinoid eeeee1  bbbbb2 Cannabinoid CB1 receptors eeeee2  in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CRP11	 bbbbb1 Cannabinoid eeeee1  CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective  bbbbb2 cannabinoid CB1 receptor eeeee2  antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CRP11	Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [ bbbbb1 N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide eeeee1  bbbbb2 Cannabinoid CB1 receptors eeeee2  in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CRP11	Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] ( bbbbb1 SR 141716A eeeee1  bbbbb2 Cannabinoid CB1 receptors eeeee2  in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. [N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection
CRP11	It is physiologically generated by  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine-γ-lyase eeeee2 , cystathionine-β-synthase, and 3-mercaptopyruvate sulfurtransferase
CRP11	It is physiologically generated by  bbbbb1 cystathionine eeeee1 -γ-lyase,  bbbbb2 cystathionine-β-synthase eeeee2 , and 3-mercaptopyruvate sulfurtransferase
CRP11	It is physiologically generated by  bbbbb1 cystathionine eeeee1 -γ-lyase, cystathionine-β-synthase, and  bbbbb2 3-mercaptopyruvate sulfurtransferase eeeee2 
CRP11	It is physiologically generated by cystathionine-γ-lyase,  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine-γ-lyase eeeee2 , cystathionine-β-synthase, and 3-mercaptopyruvate sulfurtransferase
CRP11	It is physiologically generated by cystathionine-γ-lyase,  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine-β-synthase eeeee2 , and 3-mercaptopyruvate sulfurtransferase
CRP11	It is physiologically generated by cystathionine-γ-lyase,  bbbbb1 cystathionine eeeee1 -β-synthase, and  bbbbb2 3-mercaptopyruvate sulfurtransferase eeeee2 
CRP11	It is physiologically generated by cystathionine-γ-lyase, cystathionine-β-synthase, and  bbbbb1 3-mercaptopyruvate eeeee1  bbbbb2 cystathionine-γ-lyase eeeee2 , cystathionine-β-synthase, and 3-mercaptopyruvate sulfurtransferase
CRP11	It is physiologically generated by cystathionine-γ-lyase, cystathionine-β-synthase, and  bbbbb1 3-mercaptopyruvate eeeee1  bbbbb2 cystathionine-β-synthase eeeee2 , and 3-mercaptopyruvate sulfurtransferase
CRP11	It is physiologically generated by cystathionine-γ-lyase, cystathionine-β-synthase, and  bbbbb1 3-mercaptopyruvate eeeee1  bbbbb2 3-mercaptopyruvate sulfurtransferase eeeee2 
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177. bbbbb1 (-)-[(3)H]-CGP12177 eeeee1  bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the beta(1)-adrenoceptors with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of  bbbbb1 (-)-isoprenaline eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the beta(1)-adrenoceptors with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site.  bbbbb1 (-)-Isoprenaline eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the beta(1)-adrenoceptors with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and  bbbbb1 (-)-CGP12177 eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the  bbbbb1 cyclic AMP eeeee1 -enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the beta(1)-adrenoceptors with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in  bbbbb1 cyclic AMP eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and  bbbbb1 (-)-CGP12177 eeeee1 .(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of (-)-isoprenaline and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the beta(1)-adrenoceptors with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6.  bbbbb1 (-)-CGP12177 eeeee1  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We compared the binding affinity and antagonist potency of 12 clinically used beta-blockers against the cyclic AMP-enhancing effects of  bbbbb1 (-)-isoprenaline eeeee1  and (-)-CGP12177.(-)-[(3)H]-CGP12177 bound to a high affinity site (H; K(H)=0.47 nM) and low affinity site (L); K(L)=235 nM). (-)-[(3)H]-CGP12177 dissociated from the  bbbbb2 beta(1)-adrenoceptors eeeee2  with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site. (-)-Isoprenaline and (-)-CGP12177 caused 96-fold and 12-fold maximal increases in cyclic AMP levels with -logEC(50)M of 8.2 and 7.6. (-)-CGP12177 antagonised the effects of (-)-isoprenaline with a pK(B) of 9.9
CRP11	We conclude that (-)-[(3)H]-CGP12177 binds at two sites in the recombinant beta(1)-adrenoceptor.  bbbbb1 (-)-CGP12177 eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2 . (-)-CGP12177 is an antagonist of catecholamine effects through the H-site and a non-conventional partial agonist through the L-site
CRP11	We conclude that (-)-[(3)H]-CGP12177 binds at two sites in the recombinant beta(1)-adrenoceptor. (-)-CGP12177 is an antagonist of  bbbbb1 catecholamine eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2 . (-)-CGP12177 is an antagonist of catecholamine effects through the H-site and a non-conventional partial agonist through the L-site
CRP11	Oral lorcaserin (BELVIQ(®)), a selective  bbbbb1 serotonin eeeee1   bbbbb2 5-HT2C eeeee2  receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes)
CRP11	Isoform-specific inhibition of L-type  bbbbb1 calcium eeeee1  bbbbb2 L-type calcium channels eeeee2  by dihydropyridines is independent of isoform-specific gating properties
CRP11	We thus conclude that the more bbbbb1  po eeeee1  bbbbb2  potent niso eeeee2 ldipine inhibition of smooth muscle versus cardiac L-type Ca2+ channels is not attributable to differences in channel inactivation or activation
CRP11	Dihydropyridines (DHPs) block L-type  bbbbb1 Ca2+ eeeee1  bbbbb2 L-type Ca2+ channels eeeee2  more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state
CRP11	Using computer analysis, we recently identified nuclear  bbbbb1 aryl hydrocarbon eeeee1  receptor (AhR) binding sites termed "dioxin response elements" ( bbbbb2 DREs eeeee2 ) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear  bbbbb1 aryl hydrocarbon eeeee1  receptor ( bbbbb2 AhR eeeee2 ) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear  bbbbb1 aryl hydrocarbon eeeee1  receptor (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter  bbbbb2 ABCG2 eeeee2  (Accession No
CRP11	Using computer analysis, we recently identified nuclear  bbbbb1 aryl hydrocarbon eeeee1  receptor (AhR) binding sites termed " bbbbb2 dioxin response elements eeeee2 " (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear  bbbbb1 aryl hydrocarbon eeeee1  receptor (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of  bbbbb2 efflux transporter eeeee2  ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed " bbbbb1 dioxin eeeee1  response elements" ( bbbbb2 DREs eeeee2 ) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed " bbbbb1 dioxin eeeee1  bbbbb2 AhR eeeee2 ) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed " bbbbb1 dioxin eeeee1  response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter  bbbbb2 ABCG2 eeeee2  (Accession No
CRP11	Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed " bbbbb1 dioxin eeeee1  bbbbb2 dioxin response elements eeeee2 " (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed " bbbbb1 dioxin eeeee1  response elements" (DREs) in the 5'-untranslated region (5'-UTR) of  bbbbb2 efflux transporter eeeee2  ABCG2 (Accession No
CRP11	Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed " bbbbb1 dioxin eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No
CRP11	Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the  bbbbb1 arylhydrocarbon eeeee1  bbbbb2 ABCG2 eeeee2  transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway
CRP11	Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the  bbbbb1 arylhydrocarbon eeeee1  bbbbb2 arylhydrocarbon receptor eeeee2  signaling pathway
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and  bbbbb1 docetaxel eeeee1  bbbbb2 pxr eeeee2  knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and  bbbbb1 docetaxel eeeee1  bbbbb2 PXR eeeee2  ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and  bbbbb1 docetaxel eeeee1  bbbbb2 mdr1a eeeee2 .fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and  bbbbb1 docetaxel eeeee1  bbbbb2 pxr eeeee2 (-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant  bbbbb1 taxanes eeeee1  bbbbb2 pxr eeeee2  knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant  bbbbb1 taxanes eeeee1  bbbbb2 PXR eeeee2  ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant  bbbbb1 taxanes eeeee1  bbbbb2 mdr1a eeeee2 .fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant  bbbbb1 taxanes eeeee1  bbbbb2 pxr eeeee2 (-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes,  bbbbb1 paclitaxel eeeee1  bbbbb2 pxr eeeee2  knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes,  bbbbb1 paclitaxel eeeee1  bbbbb2 PXR eeeee2  ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes,  bbbbb1 paclitaxel eeeee1  bbbbb2 mdr1a eeeee2 .fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes,  bbbbb1 paclitaxel eeeee1  bbbbb2 pxr eeeee2 (-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile ( bbbbb1 PCN eeeee1  bbbbb2 pxr eeeee2  knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile ( bbbbb1 PCN eeeee1  bbbbb2 mdr1a eeeee2 .fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile ( bbbbb1 PCN eeeee1  bbbbb2 pxr eeeee2 (-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with  bbbbb1 pregnenolone-16α-carbonitrile eeeee1  bbbbb2 pxr eeeee2  knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with  bbbbb1 pregnenolone-16α-carbonitrile eeeee1  bbbbb2 mdr1a eeeee2 .fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with  bbbbb1 pregnenolone-16α-carbonitrile eeeee1  bbbbb2 pxr eeeee2 (-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel
CRP11	We investigated the ability of the initial fragment hit,  bbbbb1 3-hydroxy-pyridine-2(1H)-one eeeee1 , to fill this subpocket with the aid of complex structure information. 3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one exhibited the predicted binding mode and demonstrated high inhibitory activity for  bbbbb2 human DAAO eeeee2  in enzyme- and cell-based assays
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including  bbbbb1 d-serine eeeee1  bbbbb2 d-Amino Acid Oxidase eeeee2  Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel  bbbbb1 d-Amino Acid eeeee1  bbbbb2 d-Amino Acid Oxidase eeeee2  Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel  bbbbb1 d-Amino Acid eeeee1  Oxidase Inhibitors. d-Amino acid oxidase ( bbbbb2 DAAO eeeee2 ) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel  bbbbb1 d-Amino Acid eeeee1  Oxidase Inhibitors.  bbbbb2 d-Amino acid oxidase eeeee2  (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel  bbbbb1 d-Amino Acid eeeee1  Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the  bbbbb2 N-methyl-d-aspartate receptor eeeee2 
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the  bbbbb1 N-methyl-d-aspartate eeeee1  bbbbb2 d-Amino Acid Oxidase eeeee2  Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the  bbbbb1 N-methyl-d-aspartate eeeee1  bbbbb2 DAAO eeeee2 ) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the  bbbbb1 N-methyl-d-aspartate eeeee1  bbbbb2 d-Amino acid oxidase eeeee2  (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the  bbbbb1 N-methyl-d-aspartate eeeee1  bbbbb2 N-methyl-d-aspartate receptor eeeee2 
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  bbbbb1 d-Amino acid eeeee1  bbbbb2 d-Amino Acid Oxidase eeeee2  Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  bbbbb1 d-Amino acid eeeee1  oxidase ( bbbbb2 DAAO eeeee2 ) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  bbbbb1 d-Amino acid eeeee1  bbbbb2 d-Amino acid oxidase eeeee2  (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors.  bbbbb1 d-Amino acid eeeee1  oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the  bbbbb2 N-methyl-d-aspartate receptor eeeee2 
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of  bbbbb1 d-amino acids eeeee1  bbbbb2 d-Amino Acid Oxidase eeeee2  Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor
CRP11	Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors. d-Amino acid oxidase (DAAO) catalyzes the oxidation of  bbbbb1 d-amino acids eeeee1  including d-serine, a coagonist of the  bbbbb2 N-methyl-d-aspartate receptor eeeee2 
CRP11	There is evidence in a mouse model of HAT that Substance P ( bbbbb1 SP eeeee1  bbbbb2 Substance P (SP) receptor eeeee2  antagonism reduces the neuroinflammatory reaction to CNS trypanosome infection
CRP11	There is evidence in a mouse model of HAT that  bbbbb1 Substance P eeeee1  bbbbb2 Substance P (SP) receptor eeeee2  antagonism reduces the neuroinflammatory reaction to CNS trypanosome infection
CRP11	In this study we investigated the effects of combination chemotherapy with melarsoprol and a humanised  bbbbb1 SP eeeee1  bbbbb2 humanised SP receptor eeeee2  antagonist aprepitant (EMEND) in this mouse model
CRP11	In this study we investigated the effects of combination chemotherapy with  bbbbb1 melarsoprol eeeee1  and a  bbbbb2 humanised SP receptor eeeee2  antagonist aprepitant (EMEND) in this mouse model
CRP11	Combination chemotherapy with a  bbbbb1 substance P eeeee1  bbbbb2 substance P receptor eeeee2  antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis
CRP11	 bbbbb1 Celastrol eeeee1 , a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha ( bbbbb2 TNF-α eeeee2 )-induced NF-κB reporter gene activity
CRP11	The effects of repeated administration of the tricyclic antidepressant drug, desipramine ( bbbbb1 DMI eeeee1 ), on behaviour (locomotor activity and rearing) and the number and affinity of brain  bbbbb2 beta-adrenoceptor eeeee2  and 5-HT2A receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats. 2
CRP11	The effects of repeated administration of the tricyclic antidepressant drug, desipramine ( bbbbb1 DMI eeeee1 ), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and  bbbbb2 5-HT2A eeeee2  receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats. 2
CRP11	The effects of repeated administration of the  bbbbb1 tricyclic eeeee1  antidepressant drug, desipramine (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain  bbbbb2 beta-adrenoceptor eeeee2  and 5-HT2A receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats. 2
CRP11	The effects of repeated administration of the  bbbbb1 tricyclic eeeee1  antidepressant drug, desipramine (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and  bbbbb2 5-HT2A eeeee2  receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats. 2
CRP11	The effects of repeated administration of the tricyclic antidepressant drug,  bbbbb1 desipramine eeeee1  (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain  bbbbb2 beta-adrenoceptor eeeee2  and 5-HT2A receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats. 2
CRP11	The effects of repeated administration of the tricyclic antidepressant drug,  bbbbb1 desipramine eeeee1  (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and  bbbbb2 5-HT2A eeeee2  receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats. 2
CRP11	The neuroinflammatory response to  bbbbb1 MPTP eeeee1  was markedly attenuated, and indices of oxidative stress and  bbbbb2 JNK eeeee2  activation were significantly prevented with EHT
CRP11	Reductions in striatal  bbbbb1 dopamine eeeee1  and  bbbbb2 tyrosine hydroxylase eeeee2  content were also less pronounced with EHT treatment
CRP11	Reductions in striatal dopamine and  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine hydroxylase eeeee2  content were also less pronounced with EHT treatment
CRP11	In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, iNOS induction, and  bbbbb1 nitric oxide eeeee1  bbbbb2 NFκB eeeee2  activation, iNOS induction, and nitric oxide production
CRP11	In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, iNOS induction, and  bbbbb1 nitric oxide eeeee1  bbbbb2 iNOS eeeee2  induction, and nitric oxide production
CRP11	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist  bbbbb1 AM4054 eeeee1  bbbbb2 CB(1) receptor eeeee2 -mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist  bbbbb1 AM4054 eeeee1  bbbbb2 CB(1) eeeee2  neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist  bbbbb1 AM4054 eeeee1  bbbbb2 CB(1) eeeee2  inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist  bbbbb1 AM4113 eeeee1  were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  bbbbb2 CB(1) eeeee2  full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist  bbbbb1 AM4113 eeeee1  bbbbb2 CB(1) eeeee2  inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist SR141716A ( bbbbb1 rimonabant eeeee1 ) and the  bbbbb2 CB(1) eeeee2  neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist SR141716A ( bbbbb1 rimonabant eeeee1 ) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  bbbbb2 CB(1) eeeee2  full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist  bbbbb1 SR141716A eeeee1  (rimonabant) and the  bbbbb2 CB(1) eeeee2  neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054
CRP11	In the present studies, the CB(1) inverse agonist  bbbbb1 SR141716A eeeee1  (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel  bbbbb2 CB(1) eeeee2  full agonist AM4054
CRP11	 bbbbb1 Cannabinoid eeeee1  receptor 1 ( bbbbb2 CB(1) eeeee2 ) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications
CRP11	 bbbbb1 Cannabinoid eeeee1  bbbbb2 Cannabinoid receptor 1 eeeee2  (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications
CRP11	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist  bbbbb1 AM4113 eeeee1  bbbbb2 CB(1) eeeee2  discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CRP11	Results indicate that  bbbbb1 AM4054 eeeee1  serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the  bbbbb2 CB(1) eeeee2  agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CRP11	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the  bbbbb1 AM4054 eeeee1  bbbbb2 CB(1) eeeee2  discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CRP11	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist  bbbbb1 rimonabant eeeee1  bbbbb2 CB(1) eeeee2  discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CRP11	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of  bbbbb1 AM4054 eeeee1  bbbbb2 CB(1) eeeee2  discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CRP11	Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist  bbbbb1 Δ(9)-tetrahydrocannabinol eeeee1  bbbbb2 CB(1) eeeee2  discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054
CRP11	 bbbbb1 Cannabinoid eeeee1  discrimination and antagonism by  bbbbb2 CB(1) eeeee2  neutral and inverse agonist antagonists
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 Erk eeeee2  and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 glial fibrillary acidic protein eeeee2  - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 mitogen-activated protein kinase eeeee2  (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-dependent protein kinase eeeee2  (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 MAPK eeeee2 ) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1 -dependent protein kinase ( bbbbb2 PKA eeeee2 ) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 low-, medium- and high molecular weight neurofilament subunits eeeee2 : NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 NF-L eeeee2 , NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 vimentin eeeee2 ) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 NF-M eeeee2  and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 p38MAPK eeeee2 ) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 GFAP eeeee2  - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and  bbbbb1 cAMP eeeee1  bbbbb2 NF-H eeeee2 ); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and cAMP-dependent protein kinase (PKA) activities
CRP11	Six days after  bbbbb1 (PhTe)(2) eeeee1  injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in  bbbbb2 NeuN eeeee2  positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death
CRP11	Six days after  bbbbb1 (PhTe)(2) eeeee1  injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for  bbbbb2 NeuN eeeee2 , suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death
CRP11	Six days after (PhTe)(2) injection we found persistent astrogliosis, increased  bbbbb1 propidium iodide eeeee1  (PI) positive cells in  bbbbb2 NeuN eeeee2  positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death
CRP11	Six days after (PhTe)(2) injection we found persistent astrogliosis, increased  bbbbb1 propidium iodide eeeee1  (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for  bbbbb2 NeuN eeeee2 , suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death
CRP11	Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to  bbbbb1 (PhTe)(2) eeeee1  bbbbb2 NeuN eeeee2  positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death
CRP11	Neurodegeneration was related with decreased  bbbbb1 [(3)H]glutamate eeeee1  uptake and decreased  bbbbb2 Akt eeeee2  immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in (PhTe)(2) injected rat
CRP11	Neurodegeneration was related with decreased  bbbbb1 [(3)H]glutamate eeeee1  uptake and decreased Akt immunoreactivity, however  bbbbb2 phospho-GSK-3-β eeeee2  (Ser9) was not altered in (PhTe)(2) injected rat
CRP11	Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however phospho-GSK-3-β ( bbbbb1 Ser eeeee1  bbbbb2 Akt eeeee2  immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in (PhTe)(2) injected rat
CRP11	Intravenous (I.V.) cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine receptor eeeee2  antagonist, SCH 23390
CRP11	Intravenous (I.V.)  bbbbb1 cocaine eeeee1  (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the  bbbbb2 dopamine receptor eeeee2  antagonist, SCH 23390
CRP11	At nonconvulsant doses, the  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2  blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP
CRP11	 bbbbb1 Monoamine eeeee1  transporter and  bbbbb2 sodium channel eeeee2  mechanisms in the rapid pressor response to cocaine
CRP11	 bbbbb1 Monoamine eeeee1  bbbbb2 Monoamine transporter eeeee2  and sodium channel mechanisms in the rapid pressor response to cocaine
CRP11	Monoamine transporter and  bbbbb1 sodium eeeee1  bbbbb2 sodium channel eeeee2  mechanisms in the rapid pressor response to cocaine
CRP11	Monoamine transporter and  bbbbb1 sodium eeeee1  bbbbb2 Monoamine transporter eeeee2  and sodium channel mechanisms in the rapid pressor response to cocaine
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT,  bbbbb1 betaCIT eeeee1 , CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine ( bbbbb1 cocaethylene eeeee1 , CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine,  bbbbb1 norcocaine eeeee1 , and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to  bbbbb1 cocaine eeeee1  (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and  bbbbb1 benztropine eeeee1 ) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT,  bbbbb1 CPT eeeee1 , (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb1 monoamine eeeee1  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene,  bbbbb1 CFT eeeee1 , betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	 bbbbb1 Monoamine eeeee1  uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT,  bbbbb1 (+)-cocaine eeeee1 , norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse  bbbbb2 monoamine transporter eeeee2  selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response
CRP11	The present data suggest that the inhibition of dopamine,  bbbbb1 norepinephrine eeeee1  bbbbb2 dopamine, norepinephrine, or serotonin transporter eeeee2  functions, either alone or in combination, does not mediate the rapid pressor response to cocaine
CRP11	The present data suggest that the inhibition of  bbbbb1 dopamine eeeee1  bbbbb2 dopamine, norepinephrine, or serotonin transporter eeeee2  functions, either alone or in combination, does not mediate the rapid pressor response to cocaine
CRP11	The present data suggest that the inhibition of dopamine, norepinephrine, or  bbbbb1 serotonin eeeee1  bbbbb2 dopamine, norepinephrine, or serotonin transporter eeeee2  functions, either alone or in combination, does not mediate the rapid pressor response to cocaine
CRP11	The present data suggest that the inhibition of dopamine, norepinephrine, or serotonin transporter functions, either alone or in combination, does not mediate the rapid pressor response to  bbbbb1 cocaine eeeee1  bbbbb2 dopamine, norepinephrine, or serotonin transporter eeeee2  functions, either alone or in combination, does not mediate the rapid pressor response to cocaine
CRP11	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the  bbbbb1 COOH eeeee1  bbbbb2 PC3 eeeee2  is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CRP11	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the  bbbbb1 COOH eeeee1  bbbbb2 type I proinsulin-processing enzyme eeeee2  that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CRP11	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the  bbbbb1 COOH eeeee1  bbbbb2 insulin eeeee2  by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CRP11	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and  bbbbb1 C eeeee1  bbbbb2 PC3 eeeee2  is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CRP11	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and  bbbbb1 C eeeee1  bbbbb2 type I proinsulin-processing enzyme eeeee2  that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CRP11	PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and  bbbbb1 C eeeee1  bbbbb2 insulin eeeee2  by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide
CRP11	Here, using differentiated SH-SY5Y neuron-like cells as a model, we examined whether  bbbbb1 24-OHC eeeee1  is actively eliminated via  bbbbb2 transporters eeeee2  induced by its accumulation
CRP11	The expression of ABCA1 and ABCG1 was induced by  bbbbb1 24-OHC eeeee1 , as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors  bbbbb2 LXR eeeee2 /RXR
CRP11	The expression of ABCA1 and ABCG1 was induced by  bbbbb1 24-OHC eeeee1 , as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/ bbbbb2 RXR eeeee2 
CRP11	The expression of ABCA1 and ABCG1 was induced by  bbbbb1 24-OHC eeeee1 , as well as TO901317 and retinoic acid, which are ligands of the  bbbbb2 nuclear receptors eeeee2  LXR/RXR
CRP11	When the expression of ABCA1 and ABCG1 was induced,  bbbbb1 24-OHC eeeee1  bbbbb2 ABCA1 eeeee2  and ABCG1 was induced, 24-OHC efflux was stimulated in the presence of high density lipoprotein (HDL), whereas apolipoprotein A-I was not an efficient acceptor
CRP11	When the expression of ABCA1 and ABCG1 was induced,  bbbbb1 24-OHC eeeee1  bbbbb2 ABCG1 eeeee2  was induced, 24-OHC efflux was stimulated in the presence of high density lipoprotein (HDL), whereas apolipoprotein A-I was not an efficient acceptor
CRP11	High cholesterol turnover catalyzed by  bbbbb1 cholesterol eeeee1  bbbbb2 cholesterol 24-hydroxylase eeeee2  is essential for neural functions, especially learning
CRP11	Furthermore, the treatment of primary cerebral neurons with LXR/RXR ligands suppressed the toxicity of  bbbbb1 24-OHC eeeee1  bbbbb2 RXR eeeee2  ligands suppressed the toxicity of 24-OHC
CRP11	Furthermore, the treatment of primary cerebral neurons with LXR/RXR ligands suppressed the toxicity of  bbbbb1 24-OHC eeeee1  bbbbb2 LXR eeeee2 /RXR ligands suppressed the toxicity of 24-OHC
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 t an eeeee2 alysis indicated that liver, kidney, and pancreas expressed PHBP mRNA
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 ed that liver, kidney, and pancreas e eeeee2 xpressed PHBP mRNA
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 ssed PHBP mRNA eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 t an eeeee2 alysis indicated that liver, kidney, and pancreas expressed PHBP mRNA
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 ed that liver, kidney, and pancreas e eeeee2 xpressed PHBP mRNA
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 ssed PHBP mRNA eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 t an eeeee2 alysis indicated that liver, kidney, and pancreas expressed PHBP mRNA
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 ed that liver, kidney, and pancreas e eeeee2 xpressed PHBP mRNA
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2 ssed PHBP mRNA eeeee2 
CRP11	The results of Northern blot analysis indicated that liver, kidney, and pancreas expressed PHBP mRNA bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Both subunits had novel  bbbbb1 N-terminal amino acid eeeee1  sequences, indicating that  bbbbb2 PHBP eeeee2  was a novel hyaluronan-binding protein in human plasma
CRP11	The amino acid sequence deduced from the  bbbbb1 nucleotide eeeee1  sequence of the cloned PHBP cDNA exhibited significant homology to that of hepatocyte growth factor activator ( bbbbb2 HGFA eeeee2 )
CRP11	The amino acid sequence deduced from the  bbbbb1 nucleotide eeeee1  sequence of the cloned PHBP cDNA exhibited significant homology to that of  bbbbb2 hepatocyte growth factor activator eeeee2  (HGFA)
CRP11	The  bbbbb1 amino acid eeeee1  sequence deduced from the nucleotide sequence of the cloned PHBP cDNA exhibited significant homology to that of hepatocyte growth factor activator ( bbbbb2 HGFA eeeee2 )
CRP11	The  bbbbb1 amino acid eeeee1  sequence deduced from the nucleotide sequence of the cloned PHBP cDNA exhibited significant homology to that of  bbbbb2 hepatocyte growth factor activator eeeee2  (HGFA)
CRP11	Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a  bbbbb1 serine eeeee1  bbbbb2 serine protease domain eeeee2 , similar to hepatocyte growth factor activator
CRP11	Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a  bbbbb1 serine eeeee1  bbbbb2 PHBP eeeee2 ) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator
CRP11	Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a  bbbbb1 serine eeeee1  bbbbb2 hyaluronan-binding protein eeeee2  (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator
CRP11	Measurement of Transport Activities of 3β-Hydroxy-Δ(5)-bile Acids in  bbbbb1 Bile Salt eeeee1  bbbbb2 Bile Salt Export Pump eeeee2  and Multidrug Resistance-Associated Proteins Using LC-MS/MS
CRP11	Measurement of Transport Activities of 3β-Hydroxy-Δ(5)-bile Acids in  bbbbb1 Bile Salt eeeee1  Export Pump and  bbbbb2 Multidrug Resistance-Associated Proteins eeeee2  Using LC-MS/MS
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme  bbbbb1 spermidine eeeee1 /spermine-N(1)-acetyltransferase (SSAT1) and by  bbbbb2 thialysine acetyltransferase eeeee2  (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme  bbbbb1 spermidine eeeee1  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme  bbbbb1 spermidine eeeee1 /spermine-N(1)-acetyltransferase ( bbbbb2 SSAT1 eeeee2 ) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme  bbbbb1 spermidine eeeee1 /spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ( bbbbb2 SSAT2 eeeee2 ) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/ bbbbb1 spermine eeeee1 -N(1)-acetyltransferase (SSAT1) and by  bbbbb2 thialysine acetyltransferase eeeee2  (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/ bbbbb1 spermine eeeee1  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/ bbbbb1 spermine eeeee1 -N(1)-acetyltransferase ( bbbbb2 SSAT1 eeeee2 ) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/ bbbbb1 spermine eeeee1 -N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ( bbbbb2 SSAT2 eeeee2 ) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by  bbbbb1 polyamine eeeee1  catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  bbbbb2 thialysine acetyltransferase eeeee2  (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by  bbbbb1 polyamine eeeee1  catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ( bbbbb2 SSAT2 eeeee2 ) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  bbbbb1 thialysine eeeee1  bbbbb2 thialysine acetyltransferase eeeee2  (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  bbbbb1 thialysine eeeee1  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  bbbbb1 thialysine eeeee1  bbbbb2 SSAT1 eeeee2 ) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)
CRP11	We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by  bbbbb1 thialysine eeeee1  acetyltransferase ( bbbbb2 SSAT2 eeeee2 ) to its monoacetylated derivative (MAT)
CRP11	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/ bbbbb1 spermine eeeee1  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  and thialysine acetyltransferase
CRP11	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/ bbbbb1 spermine eeeee1 -N(1)-acetyltransferase and  bbbbb2 thialysine acetyltransferase eeeee2 
CRP11	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the  bbbbb1 spermidine eeeee1  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  and thialysine acetyltransferase
CRP11	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the  bbbbb1 spermidine eeeee1 /spermine-N(1)-acetyltransferase and  bbbbb2 thialysine acetyltransferase eeeee2 
CRP11	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and  bbbbb1 thialysine eeeee1  bbbbb2 spermidine/spermine-N(1)-acetyltransferase eeeee2  and thialysine acetyltransferase
CRP11	Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and  bbbbb1 thialysine eeeee1  bbbbb2 thialysine acetyltransferase eeeee2 
CRP11	However, SSAT1-deficient mice metabolize  bbbbb1 TETA eeeee1  bbbbb2 SSAT1 eeeee2 -deficient mice metabolize TETA at the same rate as the wild-type mice, indicating the existence of another N-acetylase respons 2ible for its metabolism in mice
CRP11	Here, we show that siRNA-mediated knockdown of SSAT2 in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of  bbbbb1 TETA eeeee1  bbbbb2 SSAT1 eeeee2 -deficient or wild-type mice reduced the metabolism of TETA to MAT
CRP11	By contrast, 1,12-diamino-3,6,9-triazado bbbbb1 deca eeeee1 ne(SpmTrien), a bbbbb2  char eeeee2 ge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CRP11	By contrast, 1,12-diamino-3,6,9-triazado bbbbb1 deca eeeee1 ne(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recomb bbbbb2 inant eeeee2  SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CRP11	By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient spermine analog, was an extr bbbbb1 emely po eeeee1  bbbbb2  char eeeee2 ge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CRP11	By contrast, 1,12-diamino-3,6,9-triazadodecane(Sp bbbbb1 mTrien), eeeee1  a bbbbb2  char eeeee2 ge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CRP11	By contrast, 1,12-diamino-3,6,9-triazadodecane(Sp bbbbb1 mTrien), eeeee1  a charge-deficient spermine analog, was an extremely poor substrate of human recomb bbbbb2 inant eeeee2  SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CRP11	By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient spermine analo bbbbb1 g, w eeeee1 as an extremely poor substrate of human recomb bbbbb2 inant eeeee2  SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes
CRP11	In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or  bbbbb1 clonidine eeeee1 ; this enhancement was inhibited by the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist WB 4101 (100 nM)
CRP11	In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of  bbbbb1 Ca2+ eeeee1  contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist WB 4101 (100 nM)
CRP11	In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by  bbbbb1 methoxamine eeeee1  or clonidine; this enhancement was inhibited by the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist WB 4101 (100 nM)
CRP11	In beta-escin-skinned strips of  bbbbb1 chloroethylclonidine eeeee1 -pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist WB 4101 (100 nM)
CRP11	In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by  bbbbb1 norepinephrine eeeee1  was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective  bbbbb2 alpha 1A-adrenoceptor eeeee2  antagonist WB 4101 (100 nM)
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than  bbbbb1 that eeeee1  bbbbb2  of myosin light chain produced by norepinephrine wa eeeee2 s greater than that produced by clonidine
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than  bbbbb1 that eeeee1  produced by clonidine bbbbb2  eeeee2 
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than  bbbbb1 that eeeee1  produced by clonidine bbbbb2  eeeee2 
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than  bbbbb1 that eeeee1  produced by clonidine bbbbb2  eeeee2 
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine bbbbb1  eeeee1  bbbbb2  of myosin light chain produced by norepinephrine wa eeeee2 s greater than that produced by clonidine
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Alpha 1-adrenoceptor subtypes mediating the regulation and modulation of  bbbbb1 Ca2+ eeeee1  bbbbb2 Alpha 1-adrenoceptor eeeee2  subtypes mediating the regulation and modulation of Ca2+ sensitization in rabbit thoracic aorta
CRP11	Herein, we report ischemic-reperfused myocardial infarction (MI) repair with siRNA against Src homology region 2 domain-containing  bbbbb1 tyrosine eeeee1  bbbbb2 Src homology region 2 domain-containing tyrosine phosphatase-1 eeeee2  (SHP-1), which is known as a key factor involved in regulating the progress of apoptosis in many cell types
CRP11	Herein, we report ischemic-reperfused myocardial infarction (MI) repair with siRNA against Src homology region 2 domain-containing  bbbbb1 tyrosine eeeee1  phosphatase-1 ( bbbbb2 SHP-1 eeeee2 ), which is known as a key factor involved in regulating the progress of apoptosis in many cell types
CRP11	Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: Use of  bbbbb1 deoxycholic acid eeeee1  bbbbb2 SHP-1 eeeee2  gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier
CRP11	Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight  bbbbb1 polyethyleneimine eeeee1  bbbbb2 SHP-1 eeeee2  gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier
CRP11	 bbbbb1 Sorafenib eeeee1 : recent update on activity as a single agent and in combination with  bbbbb2 interferon-alpha2 eeeee2  in patients with advanced-stage renal cell carcinoma
CRP11	Sorafenib (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinases eeeee2  that are known to be involved in tumor cell proliferation and tumor angiogenesis
CRP11	Cellular  bbbbb1 retinaldehyde eeeee1 -binding protein ( bbbbb2 CRALBP eeeee2 ), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular  bbbbb1 retinaldehyde eeeee1 -binding protein (CRALBP), transcribed from the RLBP1 gene, is a  bbbbb2 36-kDa water-soluble protein eeeee2  with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular  bbbbb1 retinaldehyde eeeee1 -binding protein (CRALBP), transcribed from the  bbbbb2 RLBP1 eeeee2  gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular  bbbbb1 retinaldehyde eeeee1  bbbbb2 Cellular retinaldehyde-binding protein eeeee2  (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in  bbbbb1 retinal eeeee1  bbbbb2 CRALBP eeeee2 ), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in  bbbbb1 retinal eeeee1  bbbbb2 36-kDa water-soluble protein eeeee2  with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in  bbbbb1 retinal eeeee1  bbbbb2 RLBP1 eeeee2  gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in  bbbbb1 retinal eeeee1  bbbbb2 Cellular retinaldehyde-binding protein eeeee2  (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the  bbbbb1 retinal eeeee1  bbbbb2 CRALBP eeeee2 ), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the  bbbbb1 retinal eeeee1  bbbbb2 36-kDa water-soluble protein eeeee2  with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the  bbbbb1 retinal eeeee1  bbbbb2 RLBP1 eeeee2  gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the  bbbbb1 retinal eeeee1  bbbbb2 Cellular retinaldehyde-binding protein eeeee2  (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316  bbbbb1 amino acids eeeee1  bbbbb2 CRALBP eeeee2 ), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316  bbbbb1 amino acids eeeee1  bbbbb2 RLBP1 eeeee2  gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316  bbbbb1 amino acids eeeee1  bbbbb2 Cellular retinaldehyde-binding protein eeeee2  (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells
CRP11	The follow-up period (37+/-33 months) revealed no differences in the incidence of arrhythmia between the 34 patients in whom the phenotypic manifestation of the syndrome was transient and the 24 patients in whom it  bbbbb1 was pe eeeee1  bbbbb2 was persistent eeeee2  (log-rank, 0.639)
CRP11	A mutation in the cardiac  bbbbb1 sodium eeeee1  channel gene ( bbbbb2 SCN5A eeeee2 ) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome)
CRP11	A mutation in the cardiac  bbbbb1 sodium eeeee1  bbbbb2 cardiac sodium channel eeeee2  gene (SCN5A) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome)
CRP11	W-7 did not induce a loss of cell surface beta 2-microglobulin, a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of  bbbbb1 W-7 eeeee1  bbbbb2 beta 2-microglobulin eeeee2 , a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of W-7 was specific for membrane receptors and not a result of bulk depletion of plasma membrane
CRP11	The extent of EGF receptor loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when  bbbbb1 W-7 eeeee1  bbbbb2 EGF receptors eeeee2  do not reappear at the surface when W-7 is removed
CRP11	The extent of EGF receptor loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when  bbbbb1 W-7 eeeee1  bbbbb2 alpha 2-macroglobulin eeeee2 , and the EGF receptors do not reappear at the surface when W-7 is removed
CRP11	Since both TFP and  bbbbb1 W-7 eeeee1  are potent inhibitors of calmodulin, we investigated the possibility that inhibition of  bbbbb2 calmodulin eeeee2  was responsible for the loss of receptors
CRP11	Since both  bbbbb1 TFP eeeee1  and W-7 are potent inhibitors of calmodulin, we investigated the possibility that inhibition of  bbbbb2 calmodulin eeeee2  was responsible for the loss of receptors
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb1 androgen eeeee1  bbbbb2 PRAB eeeee2  and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb1 androgen eeeee1  bbbbb2 ERbeta eeeee2 ), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb1 androgen eeeee1  bbbbb2 progesterone receptors A and B eeeee2  (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb1 androgen eeeee1  bbbbb2 estrogen receptor subtypes alpha and beta eeeee2  (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb1 androgen eeeee1  bbbbb2 PRB eeeee2 ), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb1 androgen eeeee1  bbbbb2 ERalpha eeeee2  and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb1 progesterone eeeee1  receptors A and B ( bbbbb2 PRAB eeeee2  and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb1 progesterone eeeee1  bbbbb2 ERbeta eeeee2 ), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb1 progesterone eeeee1  receptors A and B (PRAB and PRB), and  bbbbb2 androgen receptor eeeee2  messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptors A and B eeeee2  (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb1 progesterone eeeee1  bbbbb2 estrogen receptor subtypes alpha and beta eeeee2  (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb1 progesterone eeeee1  receptors A and B (PRAB and  bbbbb2 PRB eeeee2 ), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb1 progesterone eeeee1  bbbbb2 ERalpha eeeee2  and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of  bbbbb1 estrogen eeeee1  receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B ( bbbbb2 PRAB eeeee2  and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of  bbbbb1 estrogen eeeee1  receptor subtypes alpha and beta (ERalpha and  bbbbb2 ERbeta eeeee2 ), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of  bbbbb1 estrogen eeeee1  receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and  bbbbb2 androgen receptor eeeee2  messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of  bbbbb1 estrogen eeeee1  receptor subtypes alpha and beta (ERalpha and ERbeta),  bbbbb2 progesterone receptors A and B eeeee2  (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor subtypes alpha and beta eeeee2  (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of  bbbbb1 estrogen eeeee1  receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and  bbbbb2 PRB eeeee2 ), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	OME MEASURE(S): The expression of  bbbbb1 estrogen eeeee1  receptor subtypes alpha and beta ( bbbbb2 ERalpha eeeee2  and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively
CRP11	Comparative study on transcriptional activity of 17 parabens mediated by  bbbbb1 estrogen eeeee1  receptor α and β and  bbbbb2 androgen receptor eeeee2 
CRP11	Comparative study on transcriptional activity of 17 parabens mediated by  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor α and β eeeee2  and androgen receptor
CRP11	Comparative study on transcriptional activity of 17 parabens mediated by estrogen receptor α and β and  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2 
CRP11	Comparative study on transcriptional activity of 17 parabens mediated by estrogen receptor α and β and  bbbbb1 androgen eeeee1  bbbbb2 estrogen receptor α and β eeeee2  and androgen receptor
CRP11	Comparative study on transcriptional activity of 17  bbbbb1 parabens eeeee1  mediated by  bbbbb2 estrogen receptor α and β eeeee2  and androgen receptor
CRP11	Fourteen of 17  bbbbb1 parabens eeeee1  exhibited hERα and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed  bbbbb2 AR eeeee2  agonistic or antagonistic activity
CRP11	Fourteen of 17 parabens exhibited hERα and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17  bbbbb1 parabens eeeee1  bbbbb2 hERα eeeee2  and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity
CRP11	Fourteen of 17 parabens exhibited hERα and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17  bbbbb1 parabens eeeee1  bbbbb2 hERβ eeeee2  agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human  bbbbb1 estrogen eeeee1  receptor α ( bbbbb2 hERα eeeee2 ), hERβ and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human  bbbbb1 estrogen eeeee1  receptor α (hERα), hERβ and androgen receptor ( bbbbb2 hAR eeeee2 ) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human  bbbbb1 estrogen eeeee1  receptor α (hERα), hERβ and  bbbbb2 androgen receptor eeeee2  (hAR) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human  bbbbb1 estrogen eeeee1  bbbbb2 human estrogen receptor α eeeee2  (hERα), hERβ and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human  bbbbb1 estrogen eeeee1  receptor α (hERα),  bbbbb2 hERβ eeeee2  and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and  bbbbb1 androgen eeeee1  bbbbb2 hERα eeeee2 ), hERβ and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and  bbbbb1 androgen eeeee1  receptor ( bbbbb2 hAR eeeee2 ) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and  bbbbb1 androgen eeeee1  bbbbb2 androgen receptor eeeee2  (hAR) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and  bbbbb1 androgen eeeee1  bbbbb2 human estrogen receptor α eeeee2  (hERα), hERβ and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and  bbbbb1 androgen eeeee1  bbbbb2 hERβ eeeee2  and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of  bbbbb1 parabens eeeee1  which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α ( bbbbb2 hERα eeeee2 ), hERβ and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of  bbbbb1 parabens eeeee1  which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and androgen receptor ( bbbbb2 hAR eeeee2 ) were investigated
CRP11	The structure-activity relationships of  bbbbb1 parabens eeeee1  which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and  bbbbb2 androgen receptor eeeee2  (hAR) were investigated
CRP11	The structure-activity relationships of  bbbbb1 parabens eeeee1  which are widely used as preservatives for transcriptional activities mediated by  bbbbb2 human estrogen receptor α eeeee2  (hERα), hERβ and androgen receptor (hAR) were investigated
CRP11	The structure-activity relationships of  bbbbb1 parabens eeeee1  which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα),  bbbbb2 hERβ eeeee2  and androgen receptor (hAR) were investigated
CRP11	The estrogenic activity of butylparaben was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a carbo bbbbb1 xyles eeeee1  bbbbb2 ion eeeee2  with rat liver microsomes, and the decrease of activity was blocked by a carboxylesterase inhibitor
CRP11	The estrogenic activity of butylparaben was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a carbo bbbbb1 xyles eeeee1  bbbbb2 , and eeeee2  the decrease of activity was blocked by a carboxylesterase inhibitor
CRP11	The estrogenic activity of butylparaben was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a carbo bbbbb1 xyles eeeee1  bbbbb2 y i eeeee2 ncubation with rat liver microsomes, and the decrease of activity was blocked by a carboxylesterase inhibitor
CRP11	The estrogenic activity of butylparaben was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a carbo bbbbb1 xyles eeeee1 terase inhibitor bbbbb2  eeeee2 
CRP11	The estrogenic activity of b bbbbb1 utylpara eeeee1 ben was markedly decreased by incubation with rat liver microsomes bbbbb2 , and eeeee2  the decrease of activity was blocked by a carboxylesterase inhibitor
CRP11	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the  bbbbb1 chlorpromazine eeeee1  bbbbb2 cyclic nucleotide phosphodiesterase eeeee2  and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the  bbbbb1 chlorpromazine eeeee1  bbbbb2 myosin light chain kinase eeeee2 , and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 cyclic nucleotide phosphodiesterase eeeee2  and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 myosin light chain kinase eeeee2 , and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate  bbbbb1 cyclic nucleotide eeeee1  phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine- bbbbb2 calmodulin eeeee2  adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate  bbbbb1 cyclic nucleotide eeeee1  bbbbb2 cyclic nucleotide phosphodiesterase eeeee2  and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate  bbbbb1 cyclic nucleotide eeeee1  phosphodiesterase and  bbbbb2 myosin light chain kinase eeeee2 , and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 calmodulin eeeee2  adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 cyclic nucleotide phosphodiesterase eeeee2  and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 myosin light chain kinase eeeee2 , and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct
CRP11	Phenoxybenzamine, an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels calmodulin in the presence of  bbbbb1 calcium eeeee1  bbbbb2 calmodulin eeeee2  in the presence of calcium
CRP11	By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of  bbbbb1 cortisol eeeee1  to cortisone) to prevent activation of the  bbbbb2 mineralocorticoid receptor eeeee2  (MR) by cortisol
CRP11	By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of  bbbbb1 cortisol eeeee1  to cortisone) to prevent activation of the mineralocorticoid receptor ( bbbbb2 MR eeeee2 ) by cortisol
CRP11	By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by  bbbbb1 cortisol eeeee1  bbbbb2 11beta-HSD2 eeeee2  plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol
CRP11	By contrast, 11beta-HSD2 plays a pivotal role in  bbbbb1 aldosterone eeeee1  target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the  bbbbb2 mineralocorticoid receptor eeeee2  (MR) by cortisol
CRP11	By contrast, 11beta-HSD2 plays a pivotal role in  bbbbb1 aldosterone eeeee1  target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor ( bbbbb2 MR eeeee2 ) by cortisol
CRP11	By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to  bbbbb1 cortisone eeeee1 ) to prevent activation of the  bbbbb2 mineralocorticoid receptor eeeee2  (MR) by cortisol
CRP11	By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to  bbbbb1 cortisone eeeee1 ) to prevent activation of the mineralocorticoid receptor ( bbbbb2 MR eeeee2 ) by cortisol
CRP11	Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which  bbbbb1 cortisol eeeee1  bbbbb2 11beta-HSD2 eeeee2  gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia
CRP11	At a pre-receptor level, glucocorticoid action is modulated by  bbbbb1 11beta-hydroxysteroid eeeee1  dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to cortisol to facilitate  bbbbb2 glucocorticoid receptor eeeee2  (GR)-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by  bbbbb1 11beta-hydroxysteroid eeeee1  dehydrogenases (11beta-HSDs).  bbbbb2 11Beta-HSD1 eeeee2  activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by  bbbbb1 11beta-hydroxysteroid eeeee1  bbbbb2 11beta-hydroxysteroid dehydrogenases eeeee2  (11beta-HSDs). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by  bbbbb1 11beta-hydroxysteroid eeeee1  dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor ( bbbbb2 GR eeeee2 )-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by  bbbbb1 11beta-hydroxysteroid eeeee1  dehydrogenases ( bbbbb2 11beta-HSDs eeeee2 ). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to  bbbbb1 cortisol eeeee1  bbbbb2 11beta-hydroxysteroid dehydrogenases eeeee2  (11beta-HSDs). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates cortisone to  bbbbb1 cortisol eeeee1  bbbbb2 11beta-HSDs eeeee2 ). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates  bbbbb1 cortisone eeeee1  bbbbb2 11beta-hydroxysteroid dehydrogenases eeeee2  (11beta-HSDs). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CRP11	At a pre-receptor level, glucocorticoid action is modulated by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs). 11Beta-HSD1 activates  bbbbb1 cortisone eeeee1  bbbbb2 11beta-HSDs eeeee2 ). 11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action
CRP11	Novel inhibitors complexed with  bbbbb1 glutamate eeeee1  bbbbb2 glutamate dehydrogenase eeeee2 : allosteric regulation by control of protein dynamics
CRP11	Mammalian  bbbbb1 glutamate eeeee1  dehydrogenase ( bbbbb2 GDH eeeee2 ) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme
CRP11	Mammalian  bbbbb1 glutamate eeeee1  bbbbb2 Mammalian glutamate dehydrogenase eeeee2  (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme
CRP11	Selenocysteine ( bbbbb1 Sec eeeee1 ) is cotranslationally inserted into protein in response to  bbbbb2 UGA eeeee2  codons and is the 21st amino acid in the genetic code
CRP11	Selenocysteine (Sec) is cotranslationally inserted into protein in response to UGA codons and is the 21st  bbbbb1 amino acid eeeee1  bbbbb2 UGA eeeee2  codons and is the 21st amino acid in the genetic code
CRP11	 bbbbb1 Selenocysteine eeeee1  (Sec) is cotranslationally inserted into protein in response to  bbbbb2 UGA eeeee2  codons and is the 21st amino acid in the genetic code
CRP11	By identifying the pathway of  bbbbb1 Sec eeeee1  biosynthesis in mammals, this study not only functionally characterized  bbbbb2 SecS eeeee2  but also assigned the function of the O-phosphoseryl-tRNA([Ser]Sec) kinase
CRP11	By identifying the pathway of  bbbbb1 Sec eeeee1  biosynthesis in mammals, this study not only functionally characterized SecS but also assigned the function of the  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 
CRP11	By identifying the pathway of Sec biosynthesis in mammals, this study not only functionally characterized SecS but also assigned the function of the  bbbbb1 O-phosphoseryl eeeee1  bbbbb2 SecS eeeee2  but also assigned the function of the O-phosphoseryl-tRNA([Ser]Sec) kinase
CRP11	By identifying the pathway of Sec biosynthesis in mammals, this study not only functionally characterized SecS but also assigned the function of the  bbbbb1 O-phosphoseryl eeeee1  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 
CRP11	Moreover, it was found that  bbbbb1 Sec eeeee1  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb2 selenophosphate synthetase eeeee2 , and SecS
CRP11	Moreover, it was found that  bbbbb1 Sec eeeee1  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec),  bbbbb2 seryl-tRNA synthetase eeeee2 , O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that  bbbbb1 Sec eeeee1  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 , selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that  bbbbb1 Sec eeeee1  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and  bbbbb2 SecS eeeee2 
CRP11	Moreover, it was found that  bbbbb1 Sec eeeee1  bbbbb2 Sec eeeee2  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb1 O-phosphoseryl eeeee1 -tRNA([Ser]Sec) kinase,  bbbbb2 selenophosphate synthetase eeeee2 , and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb1 O-phosphoseryl eeeee1  bbbbb2 seryl-tRNA synthetase eeeee2 , O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb1 O-phosphoseryl eeeee1  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 , selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb1 O-phosphoseryl eeeee1 -tRNA([Ser]Sec) kinase, selenophosphate synthetase, and  bbbbb2 SecS eeeee2 
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb1 O-phosphoseryl eeeee1  bbbbb2 Sec eeeee2  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec),  bbbbb1 seryl eeeee1 -tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb2 selenophosphate synthetase eeeee2 , and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec),  bbbbb1 seryl eeeee1  bbbbb2 seryl-tRNA synthetase eeeee2 , O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec),  bbbbb1 seryl eeeee1 -tRNA synthetase,  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 , selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec),  bbbbb1 seryl eeeee1 -tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and  bbbbb2 SecS eeeee2 
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec),  bbbbb1 seryl eeeee1  bbbbb2 Sec eeeee2  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide,  bbbbb1 ATP eeeee1 , and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb2 selenophosphate synthetase eeeee2 , and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide,  bbbbb1 ATP eeeee1 , and serine using tRNA([Ser]Sec),  bbbbb2 seryl-tRNA synthetase eeeee2 , O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide,  bbbbb1 ATP eeeee1 , and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 , selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide,  bbbbb1 ATP eeeee1 , and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and  bbbbb2 SecS eeeee2 
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide,  bbbbb1 ATP eeeee1  bbbbb2 Sec eeeee2  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb1 selenophosphate eeeee1  bbbbb2 selenophosphate synthetase eeeee2 , and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb1 selenophosphate eeeee1  bbbbb2 seryl-tRNA synthetase eeeee2 , O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb1 selenophosphate eeeee1  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 , selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb1 selenophosphate eeeee1  synthetase, and  bbbbb2 SecS eeeee2 
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb1 selenophosphate eeeee1  bbbbb2 Sec eeeee2  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and  bbbbb1 serine eeeee1  using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb2 selenophosphate synthetase eeeee2 , and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and  bbbbb1 serine eeeee1  using tRNA([Ser]Sec),  bbbbb2 seryl-tRNA synthetase eeeee2 , O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and  bbbbb1 serine eeeee1  using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 , selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and  bbbbb1 serine eeeee1  using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and  bbbbb2 SecS eeeee2 
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and  bbbbb1 serine eeeee1  bbbbb2 Sec eeeee2  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from  bbbbb1 selenide eeeee1 , ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase,  bbbbb2 selenophosphate synthetase eeeee2 , and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from  bbbbb1 selenide eeeee1 , ATP, and serine using tRNA([Ser]Sec),  bbbbb2 seryl-tRNA synthetase eeeee2 , O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from  bbbbb1 selenide eeeee1 , ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase,  bbbbb2 O-phosphoseryl-tRNA([Ser]Sec) kinase eeeee2 , selenophosphate synthetase, and SecS
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from  bbbbb1 selenide eeeee1 , ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and  bbbbb2 SecS eeeee2 
CRP11	Moreover, it was found that Sec was synthesized on the tRNA scaffold from  bbbbb1 selenide eeeee1  bbbbb2 Sec eeeee2  was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator  bbbbb1 sulforaphane eeeee1  bbbbb2 NAD(P)H oxidase eeeee2  inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator  bbbbb1 sulforaphane eeeee1  bbbbb2 TGF-β eeeee2  in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant  bbbbb1 N-acetyl-cysteine eeeee1  (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2- bbbbb2 ARE eeeee2 ) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant  bbbbb1 N-acetyl-cysteine eeeee1  (NAC), the NF-E2-related factor 2-antioxidant response element ( bbbbb2 Nrf2 eeeee2 -ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant  bbbbb1 N-acetyl-cysteine eeeee1  (NAC), the NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant  bbbbb1 N-acetyl-cysteine eeeee1  (NAC), the  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant  bbbbb1 N-acetyl-cysteine eeeee1  bbbbb2 NAD(P)H oxidase eeeee2  inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant  bbbbb1 N-acetyl-cysteine eeeee1  bbbbb2 TGF-β eeeee2  in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H eeeee1  oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2- bbbbb2 ARE eeeee2 ) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H eeeee1  oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element ( bbbbb2 Nrf2 eeeee2 -ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H eeeee1  oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H eeeee1  oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H eeeee1  bbbbb2 NAD(P)H oxidase eeeee2  inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the  bbbbb1 NAD(P)H eeeee1  bbbbb2 TGF-β eeeee2  in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium ( bbbbb1 DPI eeeee1 ), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2- bbbbb2 ARE eeeee2 ) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium ( bbbbb1 DPI eeeee1 ), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element ( bbbbb2 Nrf2 eeeee2 -ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium ( bbbbb1 DPI eeeee1 ), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium ( bbbbb1 DPI eeeee1 ), the antioxidant N-acetyl-cysteine (NAC), the  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium ( bbbbb1 DPI eeeee1  bbbbb2 TGF-β eeeee2  in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine ( bbbbb1 NAC eeeee1 ), the NF-E2-related factor 2-antioxidant response element (Nrf2- bbbbb2 ARE eeeee2 ) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine ( bbbbb1 NAC eeeee1 ), the NF-E2-related factor 2-antioxidant response element ( bbbbb2 Nrf2 eeeee2 -ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine ( bbbbb1 NAC eeeee1 ), the NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine ( bbbbb1 NAC eeeee1 ), the  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine ( bbbbb1 NAC eeeee1  bbbbb2 NAD(P)H oxidase eeeee2  inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine ( bbbbb1 NAC eeeee1  bbbbb2 TGF-β eeeee2  in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor  bbbbb1 diphenyleneiodonium eeeee1  (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2- bbbbb2 ARE eeeee2 ) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor  bbbbb1 diphenyleneiodonium eeeee1  (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element ( bbbbb2 Nrf2 eeeee2 -ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor  bbbbb1 diphenyleneiodonium eeeee1  (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor  bbbbb1 diphenyleneiodonium eeeee1  (DPI), the antioxidant N-acetyl-cysteine (NAC), the  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor  bbbbb1 diphenyleneiodonium eeeee1  bbbbb2 TGF-β eeeee2  in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of  bbbbb1 TSA eeeee1 , the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2- bbbbb2 ARE eeeee2 ) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of  bbbbb1 TSA eeeee1 , the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element ( bbbbb2 Nrf2 eeeee2 -ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of  bbbbb1 TSA eeeee1 , the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of  bbbbb1 TSA eeeee1 , the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of  bbbbb1 TSA eeeee1 , the  bbbbb2 NAD(P)H oxidase eeeee2  inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Human immortalized corneal fibroblasts were treated with TGF-β in the presence of  bbbbb1 TSA eeeee1  bbbbb2 TGF-β eeeee2  in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA
CRP11	Furthermore, TSA also decreased cellular ROS and  bbbbb1 H(2)O(2) eeeee1  accumulation induced by  bbbbb2 TGF-β eeeee2 , whereas it elevated intracellular GSH level and cellular total antioxidant capacity
CRP11	Furthermore, TSA also decreased cellular ROS and H(2)O(2) accumulation induced by TGF-β, whereas it elevated intracellular  bbbbb1 GSH eeeee1  bbbbb2 TGF-β eeeee2 , whereas it elevated intracellular GSH level and cellular total antioxidant capacity
CRP11	Trichostatin A inhibits transforming growth factor-β-induced reactive  bbbbb1 oxygen eeeee1  species accumulation and myofibroblast differentiation via enhanced  bbbbb2 NF-E2-related factor 2 eeeee2 -antioxidant response element signaling
CRP11	Trichostatin A inhibits transforming growth factor-β-induced reactive  bbbbb1 oxygen eeeee1  bbbbb2 transforming growth factor-β eeeee2 -induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling
CRP11	Trichostatin A inhibits transforming growth factor-β-induced reactive  bbbbb1 oxygen eeeee1  species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2- bbbbb2 antioxidant response element eeeee2  signaling
CRP11	The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by  bbbbb1 TSA eeeee1  on transforming growth factor-β ( bbbbb2 TGF-β) eeeee2 -induced myofibroblast differentiation of corneal fibroblasts in vitro
CRP11	The present study aimed at investigating the role of reactive  bbbbb1 oxygen eeeee1  species (ROS) scavenging by TSA on  bbbbb2 transforming growth factor-β eeeee2  (TGF-β)-induced myofibroblast differentiation of corneal fibroblasts in vitro
CRP11	The present study aimed at investigating the role of reactive  bbbbb1 oxygen eeeee1  species (ROS) scavenging by TSA on transforming growth factor-β ( bbbbb2 TGF-β) eeeee2 -induced myofibroblast differentiation of corneal fibroblasts in vitro
CRP11	Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with  bbbbb1 DPI eeeee1  bbbbb2 Nrf2 eeeee2 -ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC
CRP11	Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with  bbbbb1 DPI eeeee1  bbbbb2 ARE eeeee2  activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC
CRP11	Treatment with  bbbbb1 TSA eeeee1  and the  bbbbb2 Nrf2 eeeee2 -ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC
CRP11	Treatment with  bbbbb1 TSA eeeee1  and the Nrf2- bbbbb2 ARE eeeee2  activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC
CRP11	Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or  bbbbb1 NAC eeeee1  bbbbb2 Nrf2 eeeee2 -ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC
CRP11	Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or  bbbbb1 NAC eeeee1  bbbbb2 ARE eeeee2  activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC
CRP11	ROS, H(2)O(2), intracellular glutathione ( bbbbb1 GSH eeeee1 ) level, cellular total antioxidant capacity, and the activation of  bbbbb2 Nrf2 eeeee2 -ARE signaling were determined with various assays
CRP11	ROS, H(2)O(2), intracellular glutathione ( bbbbb1 GSH eeeee1 ) level, cellular total antioxidant capacity, and the activation of Nrf2- bbbbb2 ARE eeeee2  signaling were determined with various assays
CRP11	ROS,  bbbbb1 H(2)O(2) eeeee1 , intracellular glutathione (GSH) level, cellular total antioxidant capacity, and the activation of  bbbbb2 Nrf2 eeeee2 -ARE signaling were determined with various assays
CRP11	ROS,  bbbbb1 H(2)O(2) eeeee1 , intracellular glutathione (GSH) level, cellular total antioxidant capacity, and the activation of Nrf2- bbbbb2 ARE eeeee2  signaling were determined with various assays
CRP11	ROS, H(2)O(2), intracellular  bbbbb1 glutathione eeeee1  (GSH) level, cellular total antioxidant capacity, and the activation of  bbbbb2 Nrf2 eeeee2 -ARE signaling were determined with various assays
CRP11	ROS, H(2)O(2), intracellular  bbbbb1 glutathione eeeee1  (GSH) level, cellular total antioxidant capacity, and the activation of Nrf2- bbbbb2 ARE eeeee2  signaling were determined with various assays
CRP11	 bbbbb1 Glutathione eeeee1  bbbbb2 Glutathione-S-transferase eeeee2 , a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine
CRP11	Glutathione- bbbbb1 S eeeee1  bbbbb2 Glutathione-S-transferase eeeee2 , a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine
CRP11	The hypothalamic defence area (HDA) is a potential source of descending fibres containing  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II eeeee2  that innervate the NTS
CRP11	 bbbbb1 Angiotensin eeeee1  bbbbb2 Angiotensin AT1 receptor eeeee2  antagonist losartan and the defence reaction in the anaesthetised rat
CRP11	Angiotensin II acting on  bbbbb1 angiotensin eeeee1  bbbbb2 Angiotensin II eeeee2  acting on angiotensin AT1 receptors at the central nervous system appears to have an important role in these modulatory processes
CRP11	Angiotensin II acting on  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin AT1 receptors eeeee2  at the central nervous system appears to have an important role in these modulatory processes
CRP11	 bbbbb1 Angiotensin II eeeee1  bbbbb2 Angiotensin II eeeee2  acting on angiotensin AT1 receptors at the central nervous system appears to have an important role in these modulatory processes
CRP11	Monitoring of plasma  bbbbb1 UdR eeeee1  concentrations have the potential to help clinicians to guide scheduling of capecitabine or other  bbbbb2 TS eeeee2  inhibitors in clinical trials
CRP11	Monitoring of plasma UdR concentrations have the potential to help clinicians to guide scheduling of  bbbbb1 capecitabine eeeee1  or other  bbbbb2 TS eeeee2  inhibitors in clinical trials
CRP11	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS)
CRP11	Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of  bbbbb1 thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 )
CRP11	Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by AOX on reduction of the  bbbbb1 nitroimino eeeee1  group and by  bbbbb2 CYPs eeeee2  via oxidation reactions
CRP11	The procedure was to reduce liver AOX activity by providing tungsten or  bbbbb1 hydralazine eeeee1  in the drinking water or to use the  bbbbb2 AOX eeeee2 -deficient DBA/2 mouse strain
CRP11	The procedure was to reduce liver AOX activity by providing  bbbbb1 tungsten eeeee1  or hydralazine in the drinking water or to use the  bbbbb2 AOX eeeee2 -deficient DBA/2 mouse strain
CRP11	Aldehyde oxidase importance in vivo in xenobiotic metabolism:  bbbbb1 imidacloprid eeeee1  bbbbb2 Aldehyde oxidase eeeee2  importance in vivo in xenobiotic metabolism: imidacloprid nitroreduction in mice
CRP11	 bbbbb1 Aldehyde eeeee1  bbbbb2 Aldehyde oxidase eeeee2  importance in vivo in xenobiotic metabolism: imidacloprid nitroreduction in mice
CRP11	 bbbbb1 Aldehyde eeeee1  oxidase ( bbbbb2 AOX eeeee2 ) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s (CYPs) and other detoxification systems
CRP11	 bbbbb1 Aldehyde eeeee1  oxidase (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s ( bbbbb2 CYPs eeeee2 ) and other detoxification systems
CRP11	 bbbbb1 Aldehyde eeeee1  bbbbb2 Aldehyde oxidase eeeee2  (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s (CYPs) and other detoxification systems
CRP11	 bbbbb1 Aldehyde eeeee1  oxidase (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to  bbbbb2 cytochrome P450s eeeee2  (CYPs) and other detoxification systems
CRP11	When mice were treated ip with the major neonicotinoid  bbbbb1 imidacloprid eeeee1  (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the  bbbbb2 AOX eeeee2 -deficient mice
CRP11	When mice were treated ip with the major neonicotinoid  bbbbb1 imidacloprid eeeee1  (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  bbbbb2 AOX eeeee2 -generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated  bbbbb1 nitrosoguanidine eeeee1  metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the  bbbbb2 AOX eeeee2 -deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated  bbbbb1 nitrosoguanidine eeeee1  bbbbb2 CYP eeeee2  oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with  bbbbb1 hydralazine eeeee1  and 86% in the  bbbbb2 AOX eeeee2 -deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with  bbbbb1 hydralazine eeeee1  bbbbb2 CYP eeeee2  oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid ( bbbbb1 IMI eeeee1 ), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the  bbbbb2 AOX eeeee2 -deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid ( bbbbb1 IMI eeeee1 ), metabolism by CYP oxidation reactions was not appreciably affected, whereas the  bbbbb2 AOX eeeee2 -generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with  bbbbb1 tungsten eeeee1  and 56% with hydralazine and 86% in the  bbbbb2 AOX eeeee2 -deficient mice
CRP11	When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with  bbbbb1 tungsten eeeee1  bbbbb2 CYP eeeee2  oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice
CRP11	The other  bbbbb1 IMI eeeee1  nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with tungsten, hydralazine, and in the  bbbbb2 AOX eeeee2 -deficient mice, respectively
CRP11	The other IMI nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with tungsten,  bbbbb1 hydralazine eeeee1 , and in the  bbbbb2 AOX eeeee2 -deficient mice, respectively
CRP11	The other IMI nitroreduction metabolite, desnitro- bbbbb1 IMI eeeee1 , was decreased by 55%, 65%, and 81% with tungsten, hydralazine, and in the  bbbbb2 AOX eeeee2 -deficient mice, respectively
CRP11	The other IMI nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with  bbbbb1 tungsten eeeee1 , hydralazine, and in the  bbbbb2 AOX eeeee2 -deficient mice, respectively
CRP11	Liver AOX activity was reduced by 45% with  bbbbb1 tungsten eeeee1  and 61% with hydralazine and 81% in  bbbbb2 AOX eeeee2 -deficient mice relative to controls
CRP11	Liver AOX activity was reduced by 45% with tungsten and 61% with  bbbbb1 hydralazine eeeee1  and 81% in  bbbbb2 AOX eeeee2 -deficient mice relative to controls
CRP11	Two types of agent which have been shown to inhibit angiogenesis are the teratogen,  bbbbb1 thalidomide eeeee1 , and the selective inhibitors of  bbbbb2 cyclo-oxygenase 2 eeeee2  (COX-2)
CRP11	Two types of agent which have been shown to inhibit angiogenesis are the teratogen,  bbbbb1 thalidomide eeeee1 , and the selective inhibitors of cyclo-oxygenase 2 ( bbbbb2 COX-2 eeeee2 )
CRP11	Advances in antihypertensive combination therapy: benefits of low-dose  bbbbb1 thiazide eeeee1  diuretics in conjunction with omapatrilat, a  bbbbb2 vasopeptidase eeeee2  inhibitor
CRP11	The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers,  bbbbb1 calcium eeeee1  antagonists, and  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors
CRP11	The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers,  bbbbb1 calcium eeeee1  antagonists, and angiotensin-converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors
CRP11	The preferred initial agents for the treatment of high blood pressure are low-dose  bbbbb1 thiazide eeeee1  diuretics, beta blockers, calcium antagonists, and  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors
CRP11	The preferred initial agents for the treatment of high blood pressure are low-dose  bbbbb1 thiazide eeeee1  diuretics, beta blockers, calcium antagonists, and angiotensin-converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors
CRP11	The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers, calcium antagonists, and  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors
CRP11	The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers, calcium antagonists, and  bbbbb1 angiotensin eeeee1 -converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors
CRP11	Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and  bbbbb1 bradykinin eeeee1  bbbbb2 ACE eeeee2  inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin
CRP11	Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and  bbbbb1 bradykinin eeeee1  bbbbb2 bradykinin eeeee2 
CRP11	Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and  bbbbb1 bradykinin eeeee1  bbbbb2 atrial and brain natriuretic peptides eeeee2  and bradykinin
CRP11	The action of these alpha-2 c bbbbb1 ompounds t eeeee1 o alter [3H]-5-H bbbbb2 T rele eeeee2 ase suggests the presence of heteroreceptors localized on 5-HT terminals in the spinal cord
CRP11	The action of these alpha-2 c bbbbb1 ompounds t eeeee1 o alter [3H]-5-HT release suggests the presence of heteroreceptors localized on 5-HT terminals i bbbbb2 n the  eeeee2 spinal cord
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of  bbbbb1 [125I]ICYP eeeee1  vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the  bbbbb2 5-HT receptor eeeee2  site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of  bbbbb1 [125I]ICYP eeeee1  vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory  bbbbb2 5-HT autoreceptor eeeee2  and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of  bbbbb1 [125I]ICYP eeeee1  bbbbb2 5-HT1B eeeee2  compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory  bbbbb1 5-HT eeeee1  autoreceptor and the  bbbbb2 5-HT receptor eeeee2  site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory  bbbbb1 5-HT eeeee1  bbbbb2 5-HT autoreceptor eeeee2  and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory  bbbbb1 5-HT eeeee1  bbbbb2 5-HT1B eeeee2  compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by  bbbbb1 [125I]ICYP eeeee1  bbbbb2 5-HT receptor eeeee2  site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by  bbbbb1 [125I]ICYP eeeee1  bbbbb2 5-HT autoreceptor eeeee2  and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by  bbbbb1 [125I]ICYP eeeee1  bbbbb2 5-HT1B eeeee2  compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT receptor eeeee2  site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT autoreceptor eeeee2  and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT1B eeeee2  compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of  bbbbb1 [3H]-5-HT eeeee1  release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the  bbbbb2 5-HT receptor eeeee2  site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of  bbbbb1 [3H]-5-HT eeeee1  release demonstrated the pharmacological similarity of the presynaptic inhibitory  bbbbb2 5-HT autoreceptor eeeee2  and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of  bbbbb1 [3H]-5-HT eeeee1  bbbbb2 5-HT1B eeeee2  compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193)
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl,  bbbbb1 5-methoxytryptamine eeeee1 , 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl,  bbbbb1 5-methoxytryptamine eeeee1 , 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl,  bbbbb1 5-methoxytryptamine eeeee1 , 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl,  bbbbb1 5-methoxytryptamine eeeee1 , 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole),  bbbbb1 5-carboxyamidotryptamine HCl eeeee1 , 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole),  bbbbb1 5-carboxyamidotryptamine HCl eeeee1 , 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole),  bbbbb1 5-carboxyamidotryptamine HCl eeeee1 , 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole),  bbbbb1 5-carboxyamidotryptamine HCl eeeee1 , 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate).  bbbbb1 [125I]ICYP eeeee1  binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate).  bbbbb1 [125I]ICYP eeeee1  binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate).  bbbbb1 [125I]ICYP eeeee1  binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate).  bbbbb1 [125I]ICYP eeeee1  binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 ( bbbbb1 5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole eeeee1 ), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 ( bbbbb1 5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole eeeee1 ), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 ( bbbbb1 5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole eeeee1 ), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 ( bbbbb1 5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole eeeee1 ), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were  bbbbb1 RU 24969 eeeee1  (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were  bbbbb1 RU 24969 eeeee1  (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were  bbbbb1 RU 24969 eeeee1  (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were  bbbbb1 RU 24969 eeeee1  (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine,  bbbbb1 5-HT eeeee1  and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine,  bbbbb1 5-HT eeeee1  and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine,  bbbbb1 5-HT eeeee1  and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine,  bbbbb1 5-HT eeeee1  and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing  bbbbb1 [125I]ICYP eeeee1  binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing  bbbbb1 [125I]ICYP eeeee1  binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing  bbbbb1 [125I]ICYP eeeee1  binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing  bbbbb1 [125I]ICYP eeeee1  binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and  bbbbb1 CGS 12066B eeeee1  (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and  bbbbb1 CGS 12066B eeeee1  (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and  bbbbb1 CGS 12066B eeeee1  (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and  bbbbb1 CGS 12066B eeeee1  (7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B ( bbbbb1 7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate eeeee1 ). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2,  bbbbb2 5-HT3 eeeee2  or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B ( bbbbb1 7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate eeeee1 ). [125I]ICYP binding was not altered by compounds with activity at  bbbbb2 5-HT1A eeeee2 , 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B ( bbbbb1 7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate eeeee1 ). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A, 5-HT1C,  bbbbb2 5-HT2 eeeee2 , 5-HT3 or alpha-2 receptor sites
CRP11	The most potent compounds at displacing [125I]ICYP binding were RU 24969 (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole), 5-carboxyamidotryptamine HCl, 5-methoxytryptamine, 5-HT and CGS 12066B ( bbbbb1 7-trifluoromethyl-4(4 methyl-1-pyrolo[1,2-a]-quinoxaline malate eeeee1 ). [125I]ICYP binding was not altered by compounds with activity at 5-HT1A,  bbbbb2 5-HT1C eeeee2 , 5-HT2, 5-HT3 or alpha-2 receptor sites
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were  bbbbb1 RU24969 eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than  bbbbb1 5-HT eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of  bbbbb1 [3H]-5-HT eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than  bbbbb1 5-methoxytryptamine eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl =  bbbbb1 CGS 12066B eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 =  bbbbb1 5-carboxyamidotryptamine eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM  bbbbb1 K(+) eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by  bbbbb1 [125I]ICYP eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Similar to the pharmacological characteristics of the 5HT1B site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine  bbbbb1 HCl eeeee1  bbbbb2 5HT1B eeeee2  site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT
CRP11	Characterization of 5-hydroxytryptamine1B receptors in rat spinal cord via [125I]iodocyanopindolol binding and inhibition of  bbbbb1 [3H]-5-hydroxytryptamine eeeee1  bbbbb2 5-hydroxytryptamine1B eeeee2  receptors in rat spinal cord via [125I]iodocyanopindolol binding and inhibition of [3H]-5-hydroxytryptamine release
CRP11	The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the  bbbbb1 His eeeee1  bbbbb2 TcCA eeeee2 ) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle
CRP11	The anticonvulsant action of  bbbbb1 dextromethorphan eeeee1  or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to  bbbbb2 sigma1 receptor eeeee2 -activated modulation of AP-1 transcription factors
CRP11	The anticonvulsant action of  bbbbb1 dextromethorphan eeeee1  or dimemorfan was significantly counteracted by a selective  bbbbb2 sigma1 receptor eeeee2  antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors
CRP11	The anticonvulsant action of  bbbbb1 dextromethorphan eeeee1  or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of  bbbbb2 AP-1 eeeee2  transcription factors
CRP11	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of  bbbbb1 dextromethorphan eeeee1  bbbbb2 sigma1 receptor eeeee2  antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors
CRP11	The anticonvulsant action of dextromethorphan or  bbbbb1 dimemorfan eeeee1  was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to  bbbbb2 sigma1 receptor eeeee2 -activated modulation of AP-1 transcription factors
CRP11	The anticonvulsant action of dextromethorphan or  bbbbb1 dimemorfan eeeee1  was significantly counteracted by a selective  bbbbb2 sigma1 receptor eeeee2  antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors
CRP11	The anticonvulsant action of dextromethorphan or  bbbbb1 dimemorfan eeeee1  was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of  bbbbb2 AP-1 eeeee2  transcription factors
CRP11	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or  bbbbb1 dimemorfan eeeee1  bbbbb2 sigma1 receptor eeeee2  antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors
CRP11	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist  bbbbb1 BD 1047 eeeee1 , suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to  bbbbb2 sigma1 receptor eeeee2 -activated modulation of AP-1 transcription factors
CRP11	The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist  bbbbb1 BD 1047 eeeee1 , suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of  bbbbb2 AP-1 eeeee2  transcription factors
CRP11	A series of 4,5-diaryloxazole analogs were designed and the interaction between oxaprozin and cyclooxygenase-2 studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of  bbbbb1 oxaprozin eeeee1  bbbbb2 cyclooxygenase-2 eeeee2  studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin
CRP11	A series of  bbbbb1 4,5-diaryloxazole eeeee1  analogs were designed and the interaction between oxaprozin and  bbbbb2 cyclooxygenase-2 eeeee2  studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin
CRP11	In the study reported here, the effects of acute PLZ treatment on the levels of various amino acids, some of which are also metabolized by  bbbbb1 pyridoxal phosphate eeeee1  bbbbb2 pyridoxal phosphate-dependent transaminases eeeee2  were compared in rat whole brain
CRP11	In the study reported here, the effects of acute  bbbbb1 PLZ eeeee1  treatment on the levels of various amino acids, some of which are also metabolized by  bbbbb2 pyridoxal phosphate-dependent transaminases eeeee2  were compared in rat whole brain
CRP11	Effects of the antidepressant/antipanic drug phenelzine on  bbbbb1 alanine eeeee1  and  bbbbb2 alanine transaminase eeeee2  in rat brain. 1
CRP11	Effects of the antidepressant/antipanic drug phenelzine on alanine and  bbbbb1 alanine eeeee1  bbbbb2 alanine transaminase eeeee2  in rat brain. 1
CRP11	Effects of the antidepressant/antipanic drug  bbbbb1 phenelzine eeeee1  on alanine and  bbbbb2 alanine transaminase eeeee2  in rat brain. 1
CRP11	Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme,  bbbbb1 GABA eeeee1  transaminase ( bbbbb2 GABA-T eeeee2 ). 2
CRP11	Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme,  bbbbb1 GABA eeeee1  bbbbb2 GABA transaminase eeeee2  (GABA-T). 2
CRP11	Acute and chronic PLZ administration increase brain  bbbbb1 GABA eeeee1  levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase ( bbbbb2 GABA-T eeeee2 ). 2
CRP11	Acute and chronic PLZ administration increase brain  bbbbb1 GABA eeeee1  levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme,  bbbbb2 GABA transaminase eeeee2  (GABA-T). 2
CRP11	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on  bbbbb1 alanine eeeee1  bbbbb2 alanine transaminase eeeee2  (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CRP11	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on  bbbbb1 alanine eeeee1  transaminase ( bbbbb2 ALA-T eeeee2 ), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CRP11	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase ( bbbbb1 ALA eeeee1  bbbbb2 alanine transaminase eeeee2  (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CRP11	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase ( bbbbb1 ALA eeeee1  bbbbb2 ALA-T eeeee2 ), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CRP11	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with  bbbbb1 GABA eeeee1  bbbbb2 alanine transaminase eeeee2  (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CRP11	The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with  bbbbb1 GABA eeeee1  bbbbb2 ALA-T eeeee2 ), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced
CRP11	As with GABA, the metabolism of alanine involves a  bbbbb1 pyridoxal phosphate eeeee1  bbbbb2 pyridoxal phosphate-dependent transaminase eeeee2 . 3
CRP11	As with  bbbbb1 GABA eeeee1 , the metabolism of alanine involves a  bbbbb2 pyridoxal phosphate-dependent transaminase eeeee2 . 3
CRP11	Similarly, with the src-pY527 substrate,  bbbbb1 alendronate eeeee1  bbbbb2 src eeeee2 -pY527 substrate, alendronate inhibition was also PTP dependent
CRP11	Two substrates were employed in this study: fluorescein  bbbbb1 diphosphate eeeee1  and the phosphotyrosyl peptide  bbbbb2 src eeeee2 -pY527
CRP11	Here we report that alendronate is a potent inhibitor of the protein- bbbbb1 tyrosine eeeee1  bbbbb2 protein-tyrosine-phosphatase-meg1 eeeee2  (PTPmeg1)
CRP11	Here we report that alendronate is a potent inhibitor of the protein- bbbbb1 tyrosine eeeee1 -phosphatase-meg1 ( bbbbb2 PTPmeg1 eeeee2 )
CRP11	PTP inhibition by hisphosphonates or vanadate was diminished by the metal bbbbb1  chelating  eeeee1 agent EDTA, or by the reducing agent dithiot bbbbb2 hre eeeee2 itol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition
CRP11	PTP inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion an bbbbb1 d the oxida eeeee1  bbbbb2 ish eeeee2 ed by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition
CRP11	The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to  bbbbb1 alendronate eeeee1 , with IC50 values of less than 1 microM;  bbbbb2 PTPsigma eeeee2 , however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CRP11	The hydrolysis of fluorescein  bbbbb1 diphosphate eeeee1  by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM;  bbbbb2 PTPsigma eeeee2 , however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CRP11	The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM  bbbbb1 alendronate eeeee1  bbbbb2 PTP epsilon eeeee2  and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CRP11	The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM  bbbbb1 alendronate eeeee1  bbbbb2 PTPmeg1 eeeee2  was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate
CRP11	Alendronate inhibition of protein- bbbbb1 tyrosine eeeee1  bbbbb2 protein-tyrosine-phosphatase-meg1 eeeee2 
CRP11	The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron tran bbbbb1 s eeeee1  bbbbb2 s el eeeee2 ectron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs
CRP11	The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins  bbbbb1 cytochrom eeeee1  bbbbb2 s el eeeee2 ectron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs
CRP11	Activation of the anti-cancer agent  bbbbb1 upamostat eeeee1  by the  bbbbb2 mARC eeeee2  enzyme system
CRP11	Upamostat (Mesupron®) is a new small molecule  bbbbb1 serine eeeee1  bbbbb2 serine protease eeeee2  inhibitor
CRP11	A novel membrane sensor for  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonist "fexofenadine"
CRP11	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist  bbbbb1 fenoterol eeeee1  bbbbb2 betaAR eeeee2  agonist isoproterenol and by the selective beta2AR agonist fenoterol
CRP11	Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist  bbbbb1 isoproterenol eeeee1  and by the selective  bbbbb2 beta2AR eeeee2  agonist fenoterol
CRP11	The activity of superoxide dismutase was down-regulated while the level of  bbbbb1 malondialdehyde eeeee1  bbbbb2 superoxide dismutase eeeee2  was down-regulated while the level of malondialdehyde was up-regulated in rat brain
CRP11	The activity of  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  was down-regulated while the level of malondialdehyde was up-regulated in rat brain
CRP11	Amyloid-induced platelet aggregation was independent of  bbbbb1 thromboxane A2 eeeee1  bbbbb2 Amyloid eeeee2 -induced platelet aggregation was independent of thromboxane A2 formation and ADP secretion but enhanced by feedback stimulation through these pathways
CRP11	Amyloid-induced platelet aggregation was independent of thromboxane A2 formation and  bbbbb1 ADP eeeee1  bbbbb2 Amyloid eeeee2 -induced platelet aggregation was independent of thromboxane A2 formation and ADP secretion but enhanced by feedback stimulation through these pathways
CRP11	Treatments that raised cAMP ( bbbbb1 iloprost eeeee1 ), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE,  bbbbb2 tissue-type plasminogen activator eeeee2  [tPA]) induced almost complete inhibition
CRP11	Treatments that raised cAMP ( bbbbb1 iloprost eeeee1 ), sequestered Ca2+ (BAPTA-AM) or prevented  bbbbb2 amyloid eeeee2 -platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition
CRP11	Treatments that raised cAMP ( bbbbb1 iloprost eeeee1 ), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [ bbbbb2 tPA eeeee2 ]) induced almost complete inhibition
CRP11	Treatments that raised  bbbbb1 cAMP eeeee1  (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE,  bbbbb2 tissue-type plasminogen activator eeeee2  [tPA]) induced almost complete inhibition
CRP11	Treatments that raised  bbbbb1 cAMP eeeee1  (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented  bbbbb2 amyloid eeeee2 -platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition
CRP11	Treatments that raised  bbbbb1 cAMP eeeee1  (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [ bbbbb2 tPA eeeee2 ]) induced almost complete inhibition
CRP11	Treatments that raised cAMP (iloprost), sequestered Ca2+ ( bbbbb1 BAPTA-AM eeeee1 ) or prevented amyloid-platelet interaction (sRAGE,  bbbbb2 tissue-type plasminogen activator eeeee2  [tPA]) induced almost complete inhibition
CRP11	Treatments that raised cAMP (iloprost), sequestered Ca2+ ( bbbbb1 BAPTA-AM eeeee1 ) or prevented  bbbbb2 amyloid eeeee2 -platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition
CRP11	Treatments that raised cAMP (iloprost), sequestered Ca2+ ( bbbbb1 BAPTA-AM eeeee1 ) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [ bbbbb2 tPA eeeee2 ]) induced almost complete inhibition
CRP11	Treatments that raised cAMP (iloprost), sequestered  bbbbb1 Ca2+ eeeee1  (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE,  bbbbb2 tissue-type plasminogen activator eeeee2  [tPA]) induced almost complete inhibition
CRP11	Treatments that raised cAMP (iloprost), sequestered  bbbbb1 Ca2+ eeeee1  (BAPTA-AM) or prevented  bbbbb2 amyloid eeeee2 -platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition
CRP11	Treatments that raised cAMP (iloprost), sequestered  bbbbb1 Ca2+ eeeee1  (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [ bbbbb2 tPA eeeee2 ]) induced almost complete inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) ( bbbbb1 SB203580 eeeee1 ), COX-1 (indomethacin), and glycoprotein Ib alpha ( bbbbb2 Nk-protease eeeee2 , 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) ( bbbbb1 SB203580 eeeee1  bbbbb2 CD36 eeeee2  (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) ( bbbbb1 SB203580 eeeee1 ),  bbbbb2 COX-1 eeeee2  (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) ( bbbbb1 SB203580 eeeee1 ), COX-1 (indomethacin), and  bbbbb2 glycoprotein Ib alpha eeeee2  (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 ( bbbbb1 indomethacin eeeee1 ), and glycoprotein Ib alpha ( bbbbb2 Nk-protease eeeee2 , 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 ( bbbbb1 indomethacin eeeee1  bbbbb2 p38 eeeee2 (MAPK) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 ( bbbbb1 indomethacin eeeee1  bbbbb2 MAPK eeeee2 ) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 ( bbbbb1 indomethacin eeeee1  bbbbb2 CD36 eeeee2  (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CRP11	Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 ( bbbbb1 indomethacin eeeee1 ), and  bbbbb2 glycoprotein Ib alpha eeeee2  (Nk-protease, 6D1 antibody) induced approximately 50% inhibition
CRP11	The cellular mechanism for these observations is high affinity blockade of IKr (encoded by HERG). 2 In a chronic transfection model using CHO-K1 cells,  bbbbb1 cisapride eeeee1  bbbbb2 IKr eeeee2  (encoded by HERG). 2 In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C). 3 Channel inhibition exhibited time-, voltage- and frequency-dependence
CRP11	The cellular mechanism for these observations is high affinity blockade of IKr (encoded by HERG). 2 In a chronic transfection model using CHO-K1 cells,  bbbbb1 cisapride eeeee1  bbbbb2 HERG eeeee2 ). 2 In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16. 4 nM at 20-22 degrees C and 23.6 nM at 37 degrees C). 3 Channel inhibition exhibited time-, voltage- and frequency-dependence
CRP11	Inhibition of the human ether-a-go-go-related gene (HERG)  bbbbb1 potassium eeeee1  bbbbb2 human ether-a-go-go-related gene (HERG) potassium channel eeeee2  by cisapride: affinity for open and inactivated states. 1 Cisapride is a prokinetic agent which has been associated with QT prolongation, torsades de pointes and cardiac arrest
CRP11	Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. 1  bbbbb1 Cisapride eeeee1  bbbbb2 human ether-a-go-go-related gene (HERG) potassium channel eeeee2  by cisapride: affinity for open and inactivated states. 1 Cisapride is a prokinetic agent which has been associated with QT prolongation, torsades de pointes and cardiac arrest
CRP11	Inhibition of the human  bbbbb1 ether eeeee1  bbbbb2 human ether-a-go-go-related gene (HERG) potassium channel eeeee2  by cisapride: affinity for open and inactivated states. 1 Cisapride is a prokinetic agent which has been associated with QT prolongation, torsades de pointes and cardiac arrest
CRP11	In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [ bbbbb1 AMP eeeee1 ] began to increase at 26 min and  bbbbb2 AMPK eeeee2  activity was elevated at 36 min
CRP11	The increase in AMPK activity was always preceded by and correlated with increased cytosolic [ bbbbb1 AMP eeeee1  bbbbb2 AMPK eeeee2  activity was always preceded by and correlated with increased cytosolic [AMP]
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in  bbbbb1 AMP eeeee1  bbbbb2 AMPK eeeee2 ) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio ( bbbbb1 AMP eeeee1  bbbbb2 AMPK eeeee2 ) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio ( bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to- bbbbb1 ATP eeeee1  bbbbb2 AMPK eeeee2 ) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to- bbbbb1 ATP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ bbbbb1 ATP eeeee1  bbbbb2 AMPK eeeee2 ) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ bbbbb1 ATP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	 bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	 bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([ bbbbb1 AMP eeeee1  bbbbb2 AMPK eeeee2 ) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([ bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the  bbbbb1 AMP eeeee1  bbbbb2 AMPK eeeee2 ) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	AMP-activated protein kinase (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP)
CRP11	In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated  bbbbb1 acetyl-CoA eeeee1  bbbbb2 AMPK eeeee2 , and phosphorylated acetyl-CoA carboxylase were elevated at 61 min
CRP11	In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated  bbbbb1 acetyl-CoA eeeee1  bbbbb2 AMPK eeeee2  activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min
CRP11	In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated  bbbbb1 acetyl-CoA eeeee1  bbbbb2 phosphorylated acetyl-CoA carboxylase eeeee2  were elevated at 61 min
CRP11	In hearts treated with metformin, [ bbbbb1 AMP eeeee1 ] was increased at 50 min and AMPK activity, phosphorylated  bbbbb2 AMPK eeeee2 , and phosphorylated acetyl-CoA carboxylase were elevated at 61 min
CRP11	In hearts treated with metformin, [ bbbbb1 AMP eeeee1 ] was increased at 50 min and  bbbbb2 AMPK eeeee2  activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min
CRP11	In hearts treated with metformin, [ bbbbb1 AMP eeeee1 ] was increased at 50 min and AMPK activity, phosphorylated AMPK, and  bbbbb2 phosphorylated acetyl-CoA carboxylase eeeee2  were elevated at 61 min
CRP11	This study tests the hypothesis that these  bbbbb1 biguanides eeeee1  increase  bbbbb2 AMPK eeeee2  activity in the heart by increasing cytosolic [AMP]
CRP11	This study tests the hypothesis that these biguanides increase AMPK activity in the heart by increasing cytosolic [ bbbbb1 AMP eeeee1  bbbbb2 AMPK eeeee2  activity in the heart by increasing cytosolic [AMP]
CRP11	At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on  bbbbb1 acetyl-CoA eeeee1  bbbbb2 acetyl-CoA carboxylase eeeee2 , an AMPK target
CRP11	At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on  bbbbb1 acetyl-CoA eeeee1  bbbbb2 AMPK-alpha eeeee2 , and phosphorylation of Ser(79) on acetyl-CoA carboxylase, an AMPK target
CRP11	At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on  bbbbb1 acetyl-CoA eeeee1  bbbbb2 AMPK eeeee2  activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on acetyl-CoA carboxylase, an AMPK target
CRP11	At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on  bbbbb1 acetyl-CoA eeeee1  carboxylase, an  bbbbb2 AMPK eeeee2  target
CRP11	Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing  bbbbb1 AMP eeeee1  bbbbb2 AMPK eeeee2  activity without increasing AMP/ATP
CRP11	Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing AMP/ bbbbb1 ATP eeeee1  bbbbb2 AMPK eeeee2  activity without increasing AMP/ATP
CRP11	Total AMP content and total AMP/ATP did not change bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Total AMP c bbbbb1 ont eeeee1 ent and total AMP/ATP did not change bbbbb2  eeeee2 
CRP11	Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  in the heart by increasing cytosolic AMP concentration
CRP11	Metformin and phenformin activate  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  in the heart by increasing cytosolic AMP concentration
CRP11	Both  bbbbb1 ONO-5046 eeeee1  and  bbbbb2 G-CSF eeeee2  attenuated the parameters increased by acid-induced lung injury in rats
CRP11	Thirty minutes before  bbbbb1 HCl eeeee1  instillation,  bbbbb2 G-CSF eeeee2  (150 microg kg(-1)) was injected subcutaneously or ONO-5046 (10 mg kg(-1) h(-1)) was infused continuously into the right jugular vein
CRP11	Thirty minutes before HCl instillation, G-CSF (150 microg kg(-1)) was injected subcutaneously or  bbbbb1 ONO-5046 eeeee1  bbbbb2 G-CSF eeeee2  (150 microg kg(-1)) was injected subcutaneously or ONO-5046 (10 mg kg(-1) h(-1)) was infused continuously into the right jugular vein
CRP11	We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor ( bbbbb1 ONO-5046 eeeee1  bbbbb2 granulocyte-colony stimulating factor eeeee2  (G-CSF), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor (ONO-5046) on acid lung injury in rats
CRP11	We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor ( bbbbb1 ONO-5046 eeeee1  bbbbb2 G-CSF eeeee2 ), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor (ONO-5046) on acid lung injury in rats
CRP11	Fluorescence lifetime analysis and effect of  bbbbb1 magnesium eeeee1  ions on binding of NADH to  bbbbb2 human aldehyde dehydrogenase 1 eeeee2 
CRP11	Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human  bbbbb1 aldehyde eeeee1  bbbbb2 human aldehyde dehydrogenase 1 eeeee2 
CRP11	 bbbbb1 Aldehyde eeeee1  bbbbb2 Aldehyde dehydrogenase 1 eeeee2  (ALDH1A1) catalyzes the oxidation of toxic aldehydes to carboxylic acids
CRP11	 bbbbb1 Aldehyde eeeee1  dehydrogenase 1 ( bbbbb2 ALDH1A1 eeeee2 ) catalyzes the oxidation of toxic aldehydes to carboxylic acids
CRP11	This shift in conformational population at higher Mg(2+) ion co bbbbb1 ncentrati eeeee1 ons and to lower en bbbbb2 zyme  eeeee2 activity may be due to longer residence time of the NADH in the ALDH1 pocket
CRP11	We used this technique to investigate the effects of  bbbbb1 Mg(2+) eeeee1  ions on the  bbbbb2 ALDH1A1 eeeee2 -NADH binding characteristics and enzyme catalysis
CRP11	We used this technique to investigate the effects of Mg(2+) ions on the ALDH1A1- bbbbb1 NADH eeeee1  bbbbb2 ALDH1A1 eeeee2 -NADH binding characteristics and enzyme catalysis
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of  bbbbb1 magnesium eeeee1  ion to one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of  bbbbb1 magnesium eeeee1  bbbbb2 ALDH1 eeeee2 -NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM  bbbbb1 Mg(2+) eeeee1 ) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM  bbbbb1 Mg(2+) eeeee1 ) and a distinct shift in steady-state conformational population from one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1- bbbbb1 NADH eeeee1  complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM  bbbbb1 Mg(2+) eeeee1  bbbbb2 ALDH1 eeeee2 -NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM  bbbbb1 Mg(2+) eeeee1  bbbbb2 ALDH1 eeeee2 -NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM  bbbbb1 Mg(2+) eeeee1 ) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM  bbbbb1 Mg(2+) eeeee1 ) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the  bbbbb1 Mg(2+) eeeee1  ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the  bbbbb2 ALDH1 eeeee2 -NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1- bbbbb1 NADH eeeee1  bbbbb2 ALDH1 eeeee2 -NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+)
CRP11	From the resolved free and bound  bbbbb1 NADH eeeee1  fluorescence signatures, the KD values for both NADH conformations in  bbbbb2 ALDH1A1 eeeee2  ranged from about 24 μM to 1 μM for Mg(2+) ion concentrations of 0-6000 μM, respectively
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on  bbbbb1 Fe2+ eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of  bbbbb1 gamma-butyrobetaine eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of  bbbbb1 gamma-butyrobetaine eeeee1  hydroxylase from rat liver.  bbbbb2 gamma-Butyrobetaine hydroxylase eeeee2  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+,  bbbbb1 alpha-ketoglutarate eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of  bbbbb1 L-carnitine eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from  bbbbb1 gamma-butyrobetaine eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate,  bbbbb1 ascorbate eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver.  bbbbb1 gamma-Butyrobetaine eeeee1  bbbbb2 gamma-Butyrobetaine hydroxylase eeeee2  catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and  bbbbb1 oxygen eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Purification of gamma-butyrobetaine hydroxylase from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in  bbbbb1 carnitine eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  from rat liver. gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen
CRP11	Initial attempts to purify the protein from rat liver showed that  bbbbb1 gamma-butyrobetaine eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  is unstable
CRP11	We, therefore, determined the influence of various compounds on the stability of  bbbbb1 gamma-butyrobetaine eeeee1  bbbbb2 gamma-butyrobetaine hydroxylase eeeee2  at different storage temperatures
CRP11	Multilevel regulation of 2- bbbbb1 cys eeeee1  bbbbb2 2-cys peroxiredoxin eeeee2  reaction cycle by s-nitrosylation
CRP11	In particular, nitrosylation promoted  bbbbb1 disulfide eeeee1  formation involving the pair of catalytic cysteines (Cys-52 and Cys-173) and disrupted the oligomeric structure of  bbbbb2 Prx1 eeeee2 , leading to loss of peroxidase activity
CRP11	In particular, nitrosylation promoted  bbbbb1 disulfide eeeee1  formation involving the pair of catalytic cysteines (Cys-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of  bbbbb2 peroxidase eeeee2  activity
CRP11	In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2- bbbbb1 Cys eeeee1  bbbbb2 2-Cys Prxs eeeee2 , a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2- bbbbb1 Cys eeeee1  bbbbb2 Prx1 eeeee2 ), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2- bbbbb1 Cys eeeee1  Prxs, a group of thioredoxin ( bbbbb2 Trx eeeee2 )-dependent peroxidases
CRP11	In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2- bbbbb1 Cys eeeee1  bbbbb2 mammalian peroxiredoxin-1 eeeee2  (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2- bbbbb1 Cys eeeee1  Prxs, a group of thioredoxin (Trx)-dependent  bbbbb2 peroxidases eeeee2 
CRP11	In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2- bbbbb1 Cys eeeee1  Prxs, a group of  bbbbb2 thioredoxin eeeee2  (Trx)-dependent peroxidases
CRP11	In this study we investigated how NO/ bbbbb1 SNO eeeee1  may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the  bbbbb2 2-Cys Prxs eeeee2 , a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how NO/ bbbbb1 SNO eeeee1  may affect the redox cycle of mammalian peroxiredoxin-1 ( bbbbb2 Prx1 eeeee2 ), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how NO/ bbbbb1 SNO eeeee1  may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin ( bbbbb2 Trx eeeee2 )-dependent peroxidases
CRP11	In this study we investigated how NO/ bbbbb1 SNO eeeee1  may affect the redox cycle of  bbbbb2 mammalian peroxiredoxin-1 eeeee2  (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how NO/ bbbbb1 SNO eeeee1  may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent  bbbbb2 peroxidases eeeee2 
CRP11	In this study we investigated how NO/ bbbbb1 SNO eeeee1  may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of  bbbbb2 thioredoxin eeeee2  (Trx)-dependent peroxidases
CRP11	In this study we investigated how  bbbbb1 NO eeeee1 /SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the  bbbbb2 2-Cys Prxs eeeee2 , a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how  bbbbb1 NO eeeee1 /SNO may affect the redox cycle of mammalian peroxiredoxin-1 ( bbbbb2 Prx1 eeeee2 ), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how  bbbbb1 NO eeeee1 /SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin ( bbbbb2 Trx eeeee2 )-dependent peroxidases
CRP11	In this study we investigated how  bbbbb1 NO eeeee1 /SNO may affect the redox cycle of  bbbbb2 mammalian peroxiredoxin-1 eeeee2  (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases
CRP11	In this study we investigated how  bbbbb1 NO eeeee1 /SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent  bbbbb2 peroxidases eeeee2 
CRP11	In this study we investigated how  bbbbb1 NO eeeee1 /SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of  bbbbb2 thioredoxin eeeee2  (Trx)-dependent peroxidases
CRP11	Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective cyclooxygenase-2 inhibitor,  bbbbb1 celecoxib eeeee1  bbbbb2 apelin eeeee2 -knockout mice with a selective cyclooxygenase-2 inhibitor, celecoxib, improved vascular function, and also attenuated obesity
CRP11	Simvastatin, an  bbbbb1 HMG-CoA eeeee1  reductase inhibitor with mild inhibition of  bbbbb2 LFA-1 eeeee2 , induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CRP11	Simvastatin, an  bbbbb1 HMG-CoA eeeee1  reductase inhibitor with mild inhibition of LFA-1, induced the production of  bbbbb2 interleukin (IL)-18 eeeee2 , tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CRP11	Simvastatin, an  bbbbb1 HMG-CoA eeeee1  reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and  bbbbb2 interferon (IFN)-gamma eeeee2  in human peripheral blood mononuclear cells (PBMC)
CRP11	Simvastatin, an  bbbbb1 HMG-CoA eeeee1  bbbbb2 HMG-CoA reductase eeeee2  inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CRP11	Simvastatin, an  bbbbb1 HMG-CoA eeeee1  reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18,  bbbbb2 tumor necrosis factor (TNF)-alpha eeeee2  and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)
CRP11	In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamm bbbbb1 a in PB eeeee1  bbbbb2 40 as well as the eeeee2  production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CRP11	In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamm bbbbb1 a in PB eeeee1  bbbbb2 a in PBMC, contri eeeee2 buting to the anti-inflammatory effect of simvastatin
CRP11	In the presence bbbbb1  of IL-18,  eeeee1 simvastatin suppressed the expression of ICAM-1 and CD bbbbb2 40 as well as the eeeee2  production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CRP11	In the presence bbbbb1  of IL-18,  eeeee1 simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamm bbbbb2 a in PBMC, contri eeeee2 buting to the anti-inflammatory effect of simvastatin
CRP11	In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti bbbbb1 -inflammato eeeee1  bbbbb2 40 as well as the eeeee2  production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CRP11	In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the p bbbbb1 roduction  eeeee1 of IL-12, TNF-alpha and IFN-gamm bbbbb2 a in PBMC, contri eeeee2 buting to the anti-inflammatory effect of simvastatin
CRP11	In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD bbbbb1 40 as w eeeee1  bbbbb2 40 as well as the eeeee2  production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin
CRP11	In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD bbbbb1 40 as w eeeee1 ell as the production of IL-12, TNF-alpha and IFN-gamm bbbbb2 a in PBMC, contri eeeee2 buting to the anti-inflammatory effect of simvastatin
CRP11	The effects of statins on immune response depend on the inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A ( bbbbb1 HMG-CoA eeeee1  bbbbb2 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase eeeee2  and leukocyte function-associated antigen (LFA)-1, which is a ligand of intercellular adhesion molecule (ICAM)-1
CRP11	The effects of statins on immune response depend on the inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A ( bbbbb1 HMG-CoA eeeee1 ) reductase and leukocyte function-associated antigen (LFA)-1, which is a ligand of  bbbbb2 intercellular adhesion molecule (ICAM)-1 eeeee2 
CRP11	The effects of statins on immune response depend on the inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A ( bbbbb1 HMG-CoA eeeee1 ) reductase and  bbbbb2 leukocyte function-associated antigen (LFA)-1 eeeee2 , which is a ligand of intercellular adhesion molecule (ICAM)-1
CRP11	The effects of statins on immune response depend on the inhibition of  bbbbb1 3-hydroxy-3-methylglutaryl coenzyme-A eeeee1  bbbbb2 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase eeeee2  and leukocyte function-associated antigen (LFA)-1, which is a ligand of intercellular adhesion molecule (ICAM)-1
CRP11	The effects of statins on immune response depend on the inhibition of  bbbbb1 3-hydroxy-3-methylglutaryl coenzyme-A eeeee1  (HMG-CoA) reductase and leukocyte function-associated antigen (LFA)-1, which is a ligand of  bbbbb2 intercellular adhesion molecule (ICAM)-1 eeeee2 
CRP11	The effects of statins on immune response depend on the inhibition of  bbbbb1 3-hydroxy-3-methylglutaryl coenzyme-A eeeee1  (HMG-CoA) reductase and  bbbbb2 leukocyte function-associated antigen (LFA)-1 eeeee2 , which is a ligand of intercellular adhesion molecule (ICAM)-1
CRP11	The N-glycosyltransferase is predicted to transfer either glucose or a pseudosugar ( bbbbb1 cyclitol eeeee1  bbbbb2 N-glycosyltransferase eeeee2  is predicted to transfer either glucose or a pseudosugar (cyclitol) to the aglycone
CRP11	The  bbbbb1 N eeeee1  bbbbb2 N-glycosyltransferase eeeee2  is predicted to transfer either glucose or a pseudosugar (cyclitol) to the aglycone
CRP11	The N-glycosyltransferase is predicted to transfer either  bbbbb1 glucose eeeee1  bbbbb2 N-glycosyltransferase eeeee2  is predicted to transfer either glucose or a pseudosugar (cyclitol) to the aglycone
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 etic enzymes was iden eeeee2 tified upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 fied eeeee2  upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 etic enzymes was iden eeeee2 tified upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 fied eeeee2  upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 etic enzymes was iden eeeee2 tified upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 fied eeeee2  upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	A gene cassette encoding C7-cyclitol biosynth bbbbb1 e eeeee1 tic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb2  eeeee2 
CRP11	A gene cassette encoding C7-cyclitol biosynth bbbbb1 e eeeee1  bbbbb2 etic enzymes was iden eeeee2 tified upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynth bbbbb1 e eeeee1 tic enzymes was identi bbbbb2 fied eeeee2  upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynth bbbbb1 e eeeee1 tic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb2  eeeee2 
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 etic enzymes was iden eeeee2 tified upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs bbbbb1  eeeee1  bbbbb2 fied eeeee2  upstream of the benzopyranopyrrole-specific ORFs
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of bbbbb1  the benzop eeeee1 yranopyrrole-specific ORFs bbbbb2  eeeee2 
CRP11	A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of bbbbb1  the benzop eeeee1 yranopyrrole-specific ORFs bbbbb2  eeeee2 
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb1 N eeeee1  bbbbb2 halogenases eeeee2 , an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb1 N eeeee1  bbbbb2 nonribosomal peptide synthetases eeeee2  (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb1 N eeeee1  bbbbb2 N-glycosyltransferase eeeee2 ) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb1 N eeeee1  bbbbb2 NRPS eeeee2 ) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb1 N eeeee1  bbbbb2 PKS eeeee2 ) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb1 N eeeee1  bbbbb2 O-methyltransferase eeeee2 , and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an  bbbbb1 N eeeee1  bbbbb2 polyketide synthases eeeee2  (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb1 O eeeee1  bbbbb2 halogenases eeeee2 , an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb1 O eeeee1  bbbbb2 nonribosomal peptide synthetases eeeee2  (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb1 O eeeee1 -methyltransferase, and an  bbbbb2 N-glycosyltransferase eeeee2 ) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb1 O eeeee1  bbbbb2 NRPS eeeee2 ) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb1 O eeeee1  bbbbb2 PKS eeeee2 ) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb1 O eeeee1  bbbbb2 O-methyltransferase eeeee2 , and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an  bbbbb1 O eeeee1  bbbbb2 polyketide synthases eeeee2  (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure
CRP11	Dominant expression of mRNA for  bbbbb1 prostaglandin D eeeee1  bbbbb2 prostaglandin D synthase eeeee2  in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain
CRP11	Glutathione-independent  bbbbb1 prostaglandin D eeeee1  synthase [ bbbbb2 prostaglandin-H2 D-isomerase eeeee2 ; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent  bbbbb1 prostaglandin D eeeee1  synthase [prostaglandin-H2 D-isomerase;  bbbbb2 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase eeeee2 , EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent  bbbbb1 prostaglandin D eeeee1  bbbbb2 prostaglandin D synthase eeeee2  [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent  bbbbb1 prostaglandin D eeeee1  synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase,  bbbbb2 EC 5.3.99.2 eeeee2 ] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase;  bbbbb1 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate eeeee1  bbbbb2 prostaglandin-H2 D-isomerase eeeee2 ; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase;  bbbbb1 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate eeeee1  bbbbb2 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase eeeee2 , EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase;  bbbbb1 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate eeeee1  bbbbb2 prostaglandin D synthase eeeee2  [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase;  bbbbb1 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate eeeee1  D-isomerase,  bbbbb2 EC 5.3.99.2 eeeee2 ] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [ bbbbb1 prostaglandin-H2 eeeee1  bbbbb2 prostaglandin-H2 D-isomerase eeeee2 ; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [ bbbbb1 prostaglandin-H2 eeeee1  D-isomerase;  bbbbb2 (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase eeeee2 , EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [ bbbbb1 prostaglandin-H2 eeeee1  bbbbb2 prostaglandin D synthase eeeee2  [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Glutathione-independent prostaglandin D synthase [ bbbbb1 prostaglandin-H2 eeeee1  D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase,  bbbbb2 EC 5.3.99.2 eeeee2 ] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system
CRP11	Short-time treatment with compounds favoring mitochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Short-time treatment with compounds favoring mitochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells bbbbb1  eeeee1  bbbbb2 e cel eeeee2 lular ROS levels especially in transformed cells
CRP11	Short-time treatment with compounds favoring mitochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Short-time treatment with compounds fav bbbbb1 oring m eeeee1 itochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells bbbbb2  eeeee2 
CRP11	Short-time treatment with compounds fav bbbbb1 oring m eeeee1 itochondrial fusion strongly decreased the cellular ROS levels especially in transformed cells bbbbb2  eeeee2 
CRP11	Herein, the derangement of the  bbbbb1 cAMP eeeee1 / bbbbb2 PKA eeeee2  pathway and its impact on transformation-linked changes of mitochondrial functions is investigated
CRP11	Oncogenic K-ras expression is associated with derangement of the  bbbbb1 cAMP eeeee1  bbbbb2 K-ras eeeee2  expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration
CRP11	Oncogenic K-ras expression is associated with derangement of the  bbbbb1 cAMP eeeee1 / bbbbb2 PKA eeeee2  pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate ( bbbbb1 ATP eeeee1  bbbbb2 complex I eeeee2  activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate ( bbbbb1 ATP eeeee1  bbbbb2 K-ras eeeee2 -transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate ( bbbbb1 ATP eeeee1  bbbbb2 PKA eeeee2  activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by  bbbbb1 glucose eeeee1  deprivation, enhanced  bbbbb2 complex I eeeee2  activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by  bbbbb1 glucose eeeee1  bbbbb2 PKA eeeee2  activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive  bbbbb1 oxygen eeeee1  bbbbb2 complex I eeeee2  activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive  bbbbb1 oxygen eeeee1  bbbbb2 K-ras eeeee2 -transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive  bbbbb1 oxygen eeeee1  bbbbb2 PKA eeeee2  activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular  bbbbb1 adenosine triphosphate eeeee1  bbbbb2 complex I eeeee2  activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular  bbbbb1 adenosine triphosphate eeeee1  bbbbb2 K-ras eeeee2 -transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular  bbbbb1 adenosine triphosphate eeeee1  bbbbb2 PKA eeeee2  activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels
CRP11	In previous papers, it has been shown that K-ras transformed mouse cells are much more sensitive as compared with normal cells to  bbbbb1 glucose eeeee1  bbbbb2 K-ras eeeee2  transformed mouse cells are much more sensitive as compared with normal cells to glucose withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I
CRP11	In previous papers, it has been shown that K-ras transformed mouse cells are much more sensitive as compared with normal cells to  bbbbb1 glucose eeeee1  withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of  bbbbb2 mitochondrial complex I eeeee2 
CRP11	Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/ bbbbb1 cAMP eeeee1 -dependent protein kinase (cAMP/ bbbbb2 PKA eeeee2 ) pathway, which is known to regulate several mitochondrial functions
CRP11	Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/ bbbbb1 cAMP eeeee1  bbbbb2 cAMP-dependent protein kinase eeeee2  (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions
CRP11	Recent observations suggest that transformed cells have a derangement in the  bbbbb1 cyclic adenosine monophosphate eeeee1 /cAMP-dependent protein kinase (cAMP/ bbbbb2 PKA eeeee2 ) pathway, which is known to regulate several mitochondrial functions
CRP11	Recent observations suggest that transformed cells have a derangement in the  bbbbb1 cyclic adenosine monophosphate eeeee1 / bbbbb2 cAMP-dependent protein kinase eeeee2  (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions
CRP11	Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/cAMP-dependent protein kinase ( bbbbb1 cAMP eeeee1 / bbbbb2 PKA eeeee2 ) pathway, which is known to regulate several mitochondrial functions
CRP11	Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/cAMP-dependent protein kinase ( bbbbb1 cAMP eeeee1  bbbbb2 cAMP-dependent protein kinase eeeee2  (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions
CRP11	Delivery of selegiline transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic MAO-A activity (ie, reduced risk of tyramine-provoked events) while still providing sufficient levels of  bbbbb1 selegiline eeeee1  bbbbb2 MAO-A eeeee2  activity (ie, reduced risk of tyramine-provoked events) while still providing sufficient levels of selegiline in the brain to produce an antidepressant effect
CRP11	Delivery of selegiline transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic MAO-A activity (ie, reduced risk of  bbbbb1 tyramine eeeee1  bbbbb2 MAO-A eeeee2  activity (ie, reduced risk of tyramine-provoked events) while still providing sufficient levels of selegiline in the brain to produce an antidepressant effect
CRP11	Currently, the use of orally administered MAO inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary  bbbbb1 tyramine eeeee1  bbbbb2 MAO eeeee2  inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine
CRP11	Non-selective inhibition of  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects
CRP11	Non-selective inhibition of  bbbbb1 monoamine eeeee1  oxidase ( bbbbb2 MAO eeeee2 ) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  bbbbb1 PD-0325901 eeeee1  bbbbb2 NRAS eeeee2 , PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  bbbbb1 PD-0325901 eeeee1  bbbbb2 BRAF eeeee2 , farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  bbbbb1 PD-0325901 eeeee1  bbbbb2 farnesyltransferase eeeee2  inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  bbbbb1 PD-0325901 eeeee1  for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either  bbbbb2 vascular endothelial growth factor eeeee2  or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS,  bbbbb1 PD-0325901 eeeee1  for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for  bbbbb2 mammalian target of rapamycin eeeee2 , and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  bbbbb1 rapamycin eeeee1  bbbbb2 NRAS eeeee2 , PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  bbbbb1 rapamycin eeeee1  bbbbb2 BRAF eeeee2 , farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  bbbbb1 rapamycin eeeee1  bbbbb2 farnesyltransferase eeeee2  inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  bbbbb1 rapamycin eeeee1  analogues for mammalian target of rapamycin, and agents that inhibit either  bbbbb2 vascular endothelial growth factor eeeee2  or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  bbbbb1 rapamycin eeeee1  bbbbb2 mitogen-activated protein kinase eeeee2 /extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase,  bbbbb1 rapamycin eeeee1  bbbbb2 extracellular signal-regulated kinase kinase eeeee2 , rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including  bbbbb1 sorafenib eeeee1  for BRAF, farnesyltransferase inhibitors for  bbbbb2 NRAS eeeee2 , PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including  bbbbb1 sorafenib eeeee1  for BRAF,  bbbbb2 farnesyltransferase eeeee2  inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including  bbbbb1 sorafenib eeeee1  for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either  bbbbb2 vascular endothelial growth factor eeeee2  or its receptors
CRP11	For some, pharmacologic inhibitors are available, including  bbbbb1 sorafenib eeeee1  for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for  bbbbb2 mitogen-activated protein kinase eeeee2 /extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including  bbbbb1 sorafenib eeeee1  for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for  bbbbb2 mammalian target of rapamycin eeeee2 , and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including  bbbbb1 sorafenib eeeee1  for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/ bbbbb2 extracellular signal-regulated kinase kinase eeeee2 , rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 NRAS eeeee2 , PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 BRAF eeeee2 , farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 farnesyltransferase eeeee2  inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of  bbbbb1 rapamycin eeeee1 , and agents that inhibit either  bbbbb2 vascular endothelial growth factor eeeee2  or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mitogen-activated protein kinase eeeee2 /extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin eeeee2 , and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 extracellular signal-regulated kinase kinase eeeee2 , rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors
CRP11	Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with  bbbbb1 triiodothyronine eeeee1  (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a  bbbbb2 peroxisome proliferator-activated receptor alpha eeeee2  agonist bezafibrate (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition
CRP11	Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a peroxisome proliferator-activated receptor alpha agonist bezafibrate (Bzf; 30 μg/100 g BW, oral) and were found to improve in the  bbbbb1 Bzf eeeee1  bbbbb2 peroxisome proliferator-activated receptor alpha eeeee2  agonist bezafibrate (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition
CRP11	Cardiac hypertrophy, structural remodeling, and expression of the genes associated with  bbbbb1 fatty acid eeeee1  metabolism were examined in rats treated with triiodothyronine (T3) alone (8 μg/100 g body weight (BW), i.p.) for 15 days or along with a  bbbbb2 peroxisome proliferator-activated receptor alpha eeeee2  agonist bezafibrate (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition
CRP11	Hyperthyroidism-induced oxidative stress, reduction in cytochrome c oxidase activity, and myocardial  bbbbb1 ATP eeeee1  bbbbb2 cytochrome c oxidase eeeee2  activity, and myocardial ATP concentration were also significantly checked by Bzf
CRP11	 bbbbb1 Benzodiazepine eeeee1  bbbbb2 Benzodiazepine receptor eeeee2  binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam
CRP11	Similarly, at 1, 2, and 3 bbbbb1  h after a sin eeeee1  bbbbb2  h after a single dose o eeeee2 f 0.05 mg/kg, corresponding to cortex concentrations of 3.7-5.8 ng/g, receptor binding was also increased
CRP11	A great deal of attention has been focused on  bbbbb1 the high  eeeee1 mutation rate in the BRAF oncogene, which approaches 60%, because BRAF it bbbbb2 self eeeee2  is an appealing drug substrate and because of the central contribution of BRAF function to melanoma development that the mutation rate signifies
CRP11	Hypertension treatment guidelines recommend combination therapy with diuretics and other antihypertensive agents, including  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II type 1 (AT1) receptor eeeee2  antagonists
CRP11	 bbbbb1 Amine eeeee1  bbbbb2 Amine oxidase eeeee2  activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the  bbbbb1 semicarbazide eeeee1  bbbbb2 monoamine oxidase A eeeee2  (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the  bbbbb1 semicarbazide eeeee1  bbbbb2 MAO eeeee2 ) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the  bbbbb1 semicarbazide eeeee1 -sensitive clorgyline-resistant amine oxidase ( bbbbb2 SSAO eeeee2 ) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the  bbbbb1 semicarbazide eeeee1  bbbbb2 semicarbazide-sensitive clorgyline-resistant amine oxidase eeeee2  (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase A eeeee2  (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both  bbbbb1 monoamine eeeee1  oxidase A ( bbbbb2 MAO eeeee2 ) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both  bbbbb1 monoamine eeeee1  oxidase A (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase ( bbbbb2 SSAO eeeee2 ) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both  bbbbb1 monoamine eeeee1  oxidase A (MAO) and of the  bbbbb2 semicarbazide-sensitive clorgyline-resistant amine oxidase eeeee2  (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive  bbbbb1 clorgyline eeeee1  bbbbb2 monoamine oxidase A eeeee2  (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive  bbbbb1 clorgyline eeeee1  bbbbb2 MAO eeeee2 ) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive  bbbbb1 clorgyline eeeee1 -resistant amine oxidase ( bbbbb2 SSAO eeeee2 ) were higher in isolated fat cells than in the original whole tissue
CRP11	It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive  bbbbb1 clorgyline eeeee1  bbbbb2 semicarbazide-sensitive clorgyline-resistant amine oxidase eeeee2  (SSAO) were higher in isolated fat cells than in the original whole tissue
CRP11	 bbbbb1 Amine eeeee1  bbbbb2 Amine oxidase eeeee2  activity, previously described in homogenates of brown adipose tissue of the rat, has now been investigated in preparations of isolated fat cells
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated  bbbbb1 BSP eeeee1  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and  bbbbb2 OATP8 eeeee2 -, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated  bbbbb1 BSP eeeee1  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-,  bbbbb2 OATP-B eeeee2 - and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated  bbbbb1 BSP eeeee1  uptake by 50%, whereas inhibition of OATP-C-,  bbbbb2 OATP-B eeeee2 -, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated  bbbbb1 BSP eeeee1  uptake by 50%, whereas inhibition of  bbbbb2 OATP-C eeeee2 -, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated  bbbbb1 BSP eeeee1  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and  bbbbb2 OATP-A eeeee2 -mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated  bbbbb1 BSP eeeee1  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and  bbbbb2 OATP-A eeeee2 -mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated  bbbbb1 BSP eeeee1  uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited  bbbbb2 OATP-C eeeee2 - and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  bbbbb2 OATP-B eeeee2 -, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  bbbbb2 OATP8 eeeee2 -mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  bbbbb2 OATP-C eeeee2 -, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L  bbbbb1 rifampicin eeeee1  bbbbb2 OATP-A eeeee2 -mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated  bbbbb1 BSP eeeee1  transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and  bbbbb2 OATP8 eeeee2 -, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated  bbbbb1 BSP eeeee1  transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-,  bbbbb2 OATP-B eeeee2 - and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated  bbbbb1 BSP eeeee1  bbbbb2 OATP8 eeeee2 -mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated  bbbbb1 BSP eeeee1  transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and  bbbbb2 OATP-A eeeee2 -mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated  bbbbb1 BSP eeeee1  transport was below 15%. 100 micromol/L rifampicin inhibited  bbbbb2 OATP-C eeeee2 - and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and  bbbbb2 OATP8 eeeee2 -, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-,  bbbbb2 OATP-B eeeee2 - and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and  bbbbb2 OATP-A eeeee2 -mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	 bbbbb1 Rifampicin eeeee1  (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited  bbbbb2 OATP-C eeeee2 - and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated  bbbbb1 BSP eeeee1  bbbbb2 OATP-B eeeee2 -, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated  bbbbb1 BSP eeeee1  bbbbb2 OATP8 eeeee2 -mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated  bbbbb1 BSP eeeee1  bbbbb2 OATP-C eeeee2 -, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated  bbbbb1 BSP eeeee1  bbbbb2 OATP-A eeeee2 -mediated BSP transport was below 15%. 100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively
CRP11	Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether  bbbbb1 rifampicin eeeee1  bbbbb2 OATPs eeeee2  of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers
CRP11	Therefore, we investigated the effects of  bbbbb1 rifamycin SV eeeee1  and rifampicin on the  bbbbb2 OATPs eeeee2  of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers
CRP11	Therefore, we investigated the effects of rifamycin SV and  bbbbb1 rifampicin eeeee1  on the  bbbbb2 OATPs eeeee2  of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers
CRP11	H3 receptor antagonism, inhibition of metabolisation of neuronal  bbbbb1 histamine eeeee1  bbbbb2 H3 receptor eeeee2  antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease
CRP11	H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of  bbbbb1 acetylcholine eeeee1  bbbbb2 H3 receptor eeeee2  antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease
CRP11	Some compounds with (sub)nanomolar activities on the  bbbbb1 histamine eeeee1 -related targets are also active in the nanomolar concentration range on both  bbbbb2 cholinesterase eeeee2  targets being 5- to 40-times more potent than tacrine
CRP11	Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than  bbbbb1 tacrine eeeee1  bbbbb2 cholinesterase eeeee2  targets being 5- to 40-times more potent than tacrine
CRP11	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor  bbbbb1 tacrine eeeee1  bbbbb2 N-methyltransferase eeeee2 , chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CRP11	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor  bbbbb1 tacrine eeeee1  bbbbb2 histamine H3 receptor eeeee2  ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CRP11	Novel highly affine  bbbbb1 histamine eeeee1  H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain,  bbbbb2 N-methyltransferase eeeee2 , chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CRP11	Novel highly affine  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 receptor eeeee2  ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CRP11	Novel highly affine  bbbbb1 histamine eeeee1  H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the  bbbbb2 acetylcholinesterase eeeee2  inhibitor tacrine
CRP11	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain,  bbbbb1 N eeeee1  bbbbb2 N-methyltransferase eeeee2 , chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CRP11	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain,  bbbbb1 N eeeee1  bbbbb2 histamine H3 receptor eeeee2  ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CRP11	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain,  bbbbb1 N eeeee1 -methyltransferase, chemically show structural elements of the  bbbbb2 acetylcholinesterase eeeee2  inhibitor tacrine
CRP11	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 receptor eeeee2  ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine
CRP11	Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main  bbbbb1 histamine eeeee1  metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the  bbbbb2 acetylcholinesterase eeeee2  inhibitor tacrine
CRP11	Multiple enzyme inhibitions by  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 receptor eeeee2  antagonists as potential procognitive agents
CRP11	Loss of any of the enzymes needed to make either  bbbbb1 putrescine eeeee1  or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking spermine synthase ( bbbbb2 SpmS eeeee2 ) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Loss of any of the enzymes needed to make either  bbbbb1 putrescine eeeee1  or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking  bbbbb2 spermine synthase eeeee2  (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Loss of any of the enzymes needed to make either putrescine or  bbbbb1 spermidine eeeee1  (which also -prevent the production of spermine) is lethal, but male mice lacking spermine synthase ( bbbbb2 SpmS eeeee2 ) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Loss of any of the enzymes needed to make either putrescine or  bbbbb1 spermidine eeeee1  (which also -prevent the production of spermine) is lethal, but male mice lacking  bbbbb2 spermine synthase eeeee2  (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking  bbbbb1 spermine eeeee1  synthase ( bbbbb2 SpmS eeeee2 ) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking  bbbbb1 spermine eeeee1  bbbbb2 spermine synthase eeeee2  (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of  bbbbb1 spermine eeeee1 ) is lethal, but male mice lacking spermine synthase ( bbbbb2 SpmS eeeee2 ) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of  bbbbb1 spermine eeeee1 ) is lethal, but male mice lacking  bbbbb2 spermine synthase eeeee2  (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background
CRP11	Use of (Gyro) Gy and  bbbbb1 spermine eeeee1  bbbbb2 spermine synthase eeeee2  transgenic mice to study functions of spermine
CRP11	Use of (Gyro) Gy and spermine synthase transgenic mice to study functions of  bbbbb1 spermine eeeee1  bbbbb2 spermine synthase eeeee2  transgenic mice to study functions of spermine
CRP11	They include  bbbbb1 serotonin eeeee1  antagonists, dopaminergic agonists, valproic acid, reserpine,  bbbbb2 somatostatin eeeee2  analogs and thiazolidinediones
CRP11	They include serotonin antagonists, dopaminergic agonists, valproic acid,  bbbbb1 reserpine eeeee1 ,  bbbbb2 somatostatin eeeee2  analogs and thiazolidinediones
CRP11	They include serotonin antagonists, dopaminergic agonists,  bbbbb1 valproic acid eeeee1 , reserpine,  bbbbb2 somatostatin eeeee2  analogs and thiazolidinediones
CRP11	They include serotonin antagonists, dopaminergic agonists, valproic acid, reserpine, somatostatin analogs and  bbbbb1 thiazolidinediones eeeee1  bbbbb2 somatostatin eeeee2  analogs and thiazolidinediones
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for  bbbbb1 estrogen eeeee1 /progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 ( bbbbb2 HER2 eeeee2 ), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for  bbbbb1 estrogen eeeee1 /progesterone receptors (ER/ bbbbb2 PR eeeee2 ) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for  bbbbb1 estrogen eeeee1 /progesterone receptors (ER/PR) and  bbbbb2 human epidermal growth factor receptor 2 eeeee2  (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for  bbbbb1 estrogen eeeee1  bbbbb2 estrogen eeeee2 /progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for  bbbbb1 estrogen eeeee1 / bbbbb2 progesterone receptors eeeee2  (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for  bbbbb1 estrogen eeeee1 /progesterone receptors ( bbbbb2 ER eeeee2 /PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/ bbbbb1 progesterone eeeee1  receptors (ER/PR) and human epidermal growth factor receptor 2 ( bbbbb2 HER2 eeeee2 ), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/ bbbbb1 progesterone eeeee1  receptors (ER/ bbbbb2 PR eeeee2 ) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/ bbbbb1 progesterone eeeee1  receptors (ER/PR) and  bbbbb2 human epidermal growth factor receptor 2 eeeee2  (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/ bbbbb1 progesterone eeeee1  bbbbb2 estrogen eeeee2 /progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/ bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptors eeeee2  (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/ bbbbb1 progesterone eeeee1  receptors ( bbbbb2 ER eeeee2 /PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis
CRP11	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS:  bbbbb1 Thymidylate eeeee1  bbbbb2 Thymidylate synthase eeeee2  (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS:  bbbbb1 Thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 ) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS:  bbbbb1 Thymidylate eeeee1  bbbbb2 Thymidylate synthase eeeee2  expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil ( bbbbb1 5-FU eeeee1  bbbbb2 Thymidylate synthase eeeee2  expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase (TS) is an important enzyme for DNA synthesis and the target for  bbbbb1 5-fluorouracil eeeee1  bbbbb2 Thymidylate synthase eeeee2  expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	 bbbbb1 Thymidylate eeeee1  synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS:  bbbbb2 Thymidylate synthase eeeee2  (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	 bbbbb1 Thymidylate eeeee1  synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase ( bbbbb2 TS eeeee2 ) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	 bbbbb1 Thymidylate eeeee1  bbbbb2 Thymidylate synthase eeeee2  expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? BACKGROUND AND AIMS: Thymidylate synthase (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU)
CRP11	Different VDRAs are known to have differential effects on serum  bbbbb1 calcium eeeee1  (Ca), which may also affect serum PTH levels since serum Ca regulates  bbbbb2 PTH eeeee2  secretion mediated by the Ca-sensing receptor (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum  bbbbb1 calcium eeeee1  (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the  bbbbb2 Ca-sensing receptor eeeee2  (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum  bbbbb1 calcium eeeee1  (Ca), which may also affect serum  bbbbb2 PTH eeeee2  levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum  bbbbb1 calcium eeeee1  (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor ( bbbbb2 CaSR eeeee2 )
CRP11	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the  bbbbb1 Ca eeeee1  bbbbb2 PTH eeeee2  secretion mediated by the Ca-sensing receptor (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the  bbbbb1 Ca eeeee1  bbbbb2 Ca-sensing receptor eeeee2  (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the  bbbbb1 Ca eeeee1  bbbbb2 PTH eeeee2  levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the  bbbbb1 Ca eeeee1 -sensing receptor ( bbbbb2 CaSR eeeee2 )
CRP11	Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum  bbbbb1 Ca eeeee1  bbbbb2 PTH eeeee2  levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum calcium ( bbbbb1 Ca eeeee1 ), which may also affect serum PTH levels since serum Ca regulates  bbbbb2 PTH eeeee2  secretion mediated by the Ca-sensing receptor (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum calcium ( bbbbb1 Ca eeeee1 ), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the  bbbbb2 Ca-sensing receptor eeeee2  (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum calcium ( bbbbb1 Ca eeeee1 ), which may also affect serum  bbbbb2 PTH eeeee2  levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR)
CRP11	Different VDRAs are known to have differential effects on serum calcium ( bbbbb1 Ca eeeee1 ), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor ( bbbbb2 CaSR eeeee2 )
CRP11	Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum  bbbbb1 Ca eeeee1  bbbbb2 PTH eeeee2  mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol
CRP11	Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum  bbbbb1 Ca eeeee1  bbbbb2 PTH eeeee2  effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol
CRP11	In pig parathyroid cells, paricalcitol and the act bbbbb1 iv eeeee1 e form of doxercalciferol induced VDR translocation from bbbbb2  the eeeee2  cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CRP11	In pig parathyroid cells, paricalcitol and the act bbbbb1 iv eeeee1 e form of doxercalciferol induced VDR translocation from the cyto bbbbb2 pla eeeee2 sm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CRP11	In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expr bbbbb1 ession an eeeee1  bbbbb2  the eeeee2  cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CRP11	In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expr bbbbb1 ession an eeeee1  bbbbb2 pla eeeee2 sm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively
CRP11	 bbbbb1 Vitamin D eeeee1  receptor agonists (VDRAs) directly suppress  bbbbb2 parathyroid hormone eeeee2  (PTH) mRNA expression
CRP11	 bbbbb1 Vitamin D eeeee1  receptor agonists (VDRAs) directly suppress parathyroid hormone ( bbbbb2 PTH eeeee2 ) mRNA expression
CRP11	 bbbbb1 Vitamin D eeeee1  bbbbb2 Vitamin D receptor eeeee2  agonists (VDRAs) directly suppress parathyroid hormone (PTH) mRNA expression
CRP11	In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum  bbbbb1 Ca eeeee1  and PTH, and also the expression of PTH, VDR, and  bbbbb2 CaSR eeeee2  mRNA
CRP11	In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum  bbbbb1 Ca eeeee1  and PTH, and also the expression of  bbbbb2 PTH eeeee2 , VDR, and CaSR mRNA
CRP11	In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum  bbbbb1 Ca eeeee1  and PTH, and also the expression of PTH,  bbbbb2 VDR eeeee2 , and CaSR mRNA
CRP11	In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum  bbbbb1 Ca eeeee1  and  bbbbb2 PTH eeeee2 , and also the expression of PTH, VDR, and CaSR mRNA
CRP11	In this study, we compared the effects of  bbbbb1 paricalcitol eeeee1  and doxercalciferol on regulating serum Ca and PTH, and also the expression of PTH, VDR, and  bbbbb2 CaSR eeeee2  mRNA
CRP11	In this study, we compared the effects of  bbbbb1 paricalcitol eeeee1  and doxercalciferol on regulating serum Ca and PTH, and also the expression of  bbbbb2 PTH eeeee2 , VDR, and CaSR mRNA
CRP11	In this study, we compared the effects of  bbbbb1 paricalcitol eeeee1  and doxercalciferol on regulating serum Ca and PTH, and also the expression of PTH,  bbbbb2 VDR eeeee2 , and CaSR mRNA
CRP11	In this study, we compared the effects of  bbbbb1 paricalcitol eeeee1  and doxercalciferol on regulating serum Ca and  bbbbb2 PTH eeeee2 , and also the expression of PTH, VDR, and CaSR mRNA
CRP11	In this study, we compared the effects of paricalcitol and  bbbbb1 doxercalciferol eeeee1  on regulating serum Ca and PTH, and also the expression of PTH, VDR, and  bbbbb2 CaSR eeeee2  mRNA
CRP11	In this study, we compared the effects of paricalcitol and  bbbbb1 doxercalciferol eeeee1  on regulating serum Ca and PTH, and also the expression of  bbbbb2 PTH eeeee2 , VDR, and CaSR mRNA
CRP11	In this study, we compared the effects of paricalcitol and  bbbbb1 doxercalciferol eeeee1  on regulating serum Ca and PTH, and also the expression of PTH,  bbbbb2 VDR eeeee2 , and CaSR mRNA
CRP11	In this study, we compared the effects of paricalcitol and  bbbbb1 doxercalciferol eeeee1  on regulating serum Ca and  bbbbb2 PTH eeeee2 , and also the expression of PTH, VDR, and CaSR mRNA
CRP11	The kinetics of onset of  bbbbb1 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid eeeee1  (AMPA) receptor desensitization by glutamate, and the extent of attenuation of  bbbbb2 AMPA receptor eeeee2  desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	The kinetics of onset of  bbbbb1 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid eeeee1   bbbbb2 (AMPA) receptor eeeee2  desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by  bbbbb1 cyclothiazide eeeee1  bbbbb2 (AMPA) receptor eeeee2  desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( bbbbb1 AMPA eeeee1 ) receptor desensitization by glutamate, and the extent of attenuation of  bbbbb2 AMPA receptor eeeee2  desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( bbbbb1 AMPA eeeee1  bbbbb2 (AMPA) receptor eeeee2  desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by  bbbbb1 glutamate eeeee1 , and the extent of attenuation of  bbbbb2 AMPA receptor eeeee2  desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by glutamate, and the extent of attenuation of  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2  desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by glutamate, and the extent of attenuation of  bbbbb1 AMPA eeeee1  bbbbb2 (AMPA) receptor eeeee2  desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons
CRP11	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to  bbbbb1 cyclothiazide eeeee1  bbbbb2 GluR-B eeeee2 , revealed that heteromeric AMPA receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CRP11	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric  bbbbb1 AMPA eeeee1  receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the  bbbbb2 GluR-B eeeee2  subunit
CRP11	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric  bbbbb1 AMPA eeeee1  receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations  bbbbb2 GluR-AoBi eeeee2  or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CRP11	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric  bbbbb1 AMPA eeeee1  receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or  bbbbb2 GluR-AiBo eeeee2 , could be generated independently of the presence of the GluR-B subunit
CRP11	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric  bbbbb1 AMPA eeeee1  bbbbb2 GluR-A eeeee2 , in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CRP11	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric  bbbbb1 AMPA eeeee1  bbbbb2 GluR-B eeeee2 , revealed that heteromeric AMPA receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CRP11	Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptors eeeee2  with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit
CRP11	However, recovery from modulati bbbbb1 on b eeeee1  bbbbb2 on by cyclothi eeeee2 azide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide. 5
CRP11	The complex patterns of sensitivity to cyclothiazide seen in hippocampal neurons could be reconstituted by assembly of recombinant  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2  subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and GluR-B subunits
CRP11	The complex patterns of sensitivity to cyclothiazide seen in hippocampal neurons could be reconstituted by assembly of recombinant  bbbbb1 AMPA eeeee1  receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and  bbbbb2 GluR-B eeeee2  subunits
CRP11	The complex patterns of sensitivity to cyclothiazide seen in hippocampal neurons could be reconstituted by assembly of recombinant  bbbbb1 AMPA eeeee1  receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the  bbbbb2 GluR-A eeeee2  and GluR-B subunits
CRP11	The amplitudes of these components varied widely between cells, suggesting the existence of at least three populations of  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2  subtypes, the relative density of which varied from cell to cell. 3
CRP11	We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by  bbbbb1 adenosine triphosphate eeeee1  bbbbb2 adenosine triphosphate-binding cassette A1 eeeee2 - (ABCA1), dependent cholesterol efflux from macrophages
CRP11	We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by  bbbbb1 adenosine triphosphate eeeee1 -binding cassette A1- ( bbbbb2 ABCA1 eeeee2 ), dependent cholesterol efflux from macrophages
CRP11	We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse  bbbbb1 cholesterol eeeee1  transport as evaluated by  bbbbb2 adenosine triphosphate-binding cassette A1 eeeee2 - (ABCA1), dependent cholesterol efflux from macrophages
CRP11	We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse  bbbbb1 cholesterol eeeee1  transport as evaluated by adenosine triphosphate-binding cassette A1- ( bbbbb2 ABCA1 eeeee2 ), dependent cholesterol efflux from macrophages
CRP11	A1-facilitated cholesterol efflux and lipid parameters did not differ between equol-pro bbbbb1 ducing and  eeeee1 non-equol-producing women bbbbb2  eeeee2 
CRP11	When  bbbbb1 menadione eeeee1  was omitted from the diet, however, 4HPR-dosed animals had elevated  bbbbb2 prothrombin eeeee2  times
CRP11	Hence, the degree of retinoid-induced hemorrhage, but not the incidence of bone fractures, was inversely related to  bbbbb1 vitamin K eeeee1  levels in the diet. 13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma  bbbbb2 osteocalcin eeeee2 , an effect that correlated with retinoid-induced bone effects
CRP11	Hence, the degree of  bbbbb1 retinoid eeeee1 -induced hemorrhage, but not the incidence of bone fractures, was inversely related to vitamin K levels in the diet. 13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma  bbbbb2 osteocalcin eeeee2 , an effect that correlated with retinoid-induced bone effects
CRP11	 bbbbb1 Oxygen eeeee1  radical scavengers, superoxide dismutase and  bbbbb2 catalase eeeee2 , significantly attenuated the contraction
CRP11	 bbbbb1 Oxygen eeeee1  radical scavengers,  bbbbb2 superoxide dismutase eeeee2  and catalase, significantly attenuated the contraction
CRP11	A nicotinic receptor antagonist ( bbbbb1 hexamethonium eeeee1 ) attenuated the contraction in part and an  bbbbb2 alpha-adrenoceptor eeeee2  antagonist (prazosin) nearly abolished the contraction
CRP11	A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an alpha-adrenoceptor antagonist ( bbbbb1 prazosin eeeee1  bbbbb2 nicotinic receptor eeeee2  antagonist (hexamethonium) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction
CRP11	 bbbbb1 Nicotine eeeee1 -induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and  bbbbb2 COX-1 eeeee2  metabolites
CRP11	Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive  bbbbb1 oxygen eeeee1  species and  bbbbb2 COX-1 eeeee2  metabolites
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog  bbbbb1 rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol eeeee1  (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS,  bbbbb1 mazindol eeeee1  bbbbb2 hNET eeeee2  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol ( bbbbb1 WY-46824 eeeee1 ), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the  bbbbb1 DVS eeeee1  analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester ( bbbbb1 RTI-55 eeeee1 ) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by  bbbbb1 [(3)H]NIS eeeee1  was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog  bbbbb1 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester eeeee1  (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol,  bbbbb1 tricyclic eeeee1  bbbbb2 hNET eeeee2  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and  bbbbb1 cocaine eeeee1  bbbbb2 hNET eeeee2  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for  bbbbb1 DVS eeeee1  at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as  bbbbb1 NIS eeeee1  bbbbb2 hNET eeeee2  in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish  bbbbb1 DVS eeeee1 , the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the  bbbbb1 cocaine eeeee1  analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824),  bbbbb1 methylphenidate eeeee1 , and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other  bbbbb2 hNET eeeee2  antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine
CRP11	Initial evaluation of the pharmacological properties of  bbbbb1 DVS eeeee1  (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the  bbbbb2 hNET eeeee2  expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (NIS) binding
CRP11	Desvenlafaxine succinate ( bbbbb1 DVS eeeee1 ) is a recently introduced antagonist of the  bbbbb2 human norepinephrine and serotonin transporters eeeee2  (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human  bbbbb1 norepinephrine eeeee1  bbbbb2 human norepinephrine and serotonin transporters eeeee2  (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human  bbbbb1 norepinephrine eeeee1  and serotonin transporters (hNET and  bbbbb2 hSERT eeeee2 , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human  bbbbb1 norepinephrine eeeee1  and serotonin transporters ( bbbbb2 hNET eeeee2  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	 bbbbb1 Desvenlafaxine succinate eeeee1  (DVS) is a recently introduced antagonist of the  bbbbb2 human norepinephrine and serotonin transporters eeeee2  (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and  bbbbb1 serotonin eeeee1  bbbbb2 human norepinephrine and serotonin transporters eeeee2  (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and  bbbbb1 serotonin eeeee1  transporters (hNET and  bbbbb2 hSERT eeeee2 , respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and  bbbbb1 serotonin eeeee1  transporters ( bbbbb2 hNET eeeee2  and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause
CRP11	Desvenlafaxine succinate identifies novel antagonist binding determinants in the human  bbbbb1 norepinephrine eeeee1  bbbbb2 human norepinephrine transporter eeeee2 
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE ( bbbbb1 cymserine eeeee1  analogues, MF-8622) and the dual inhibitor of both  bbbbb2 AChE eeeee2  and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE ( bbbbb1 cymserine eeeee1  analogues, MF-8622) and the dual inhibitor of both AChE and  bbbbb2 BuChE eeeee2 , rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE ( bbbbb1 cymserine eeeee1  analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and  bbbbb2 BuChE eeeee2  in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE ( bbbbb1 cymserine eeeee1  analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both  bbbbb2 AChE eeeee2  and BuChE in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE,  bbbbb1 rivastigmine eeeee1  bbbbb2 BuChE eeeee2  (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues,  bbbbb1 MF-8622 eeeee1 ) and the dual inhibitor of both  bbbbb2 AChE eeeee2  and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues,  bbbbb1 MF-8622 eeeee1 ) and the dual inhibitor of both AChE and  bbbbb2 BuChE eeeee2 , rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues,  bbbbb1 MF-8622 eeeee1 ) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and  bbbbb2 BuChE eeeee2  in AD and related dementias
CRP11	Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues,  bbbbb1 MF-8622 eeeee1 ) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both  bbbbb2 AChE eeeee2  and BuChE in AD and related dementias
CRP11	Using ram seminal vesicle microsomes as a source of PHS and  bbbbb1 prostacyclin eeeee1  bbbbb2 prostacyclin synthase eeeee2 , we have examined the interaction of PB and exogenous hydroperoxides
CRP11	Using ram seminal vesicle microsomes as a source of PHS and  bbbbb1 prostacyclin eeeee1  bbbbb2 PHS eeeee2  and prostacyclin synthase, we have examined the interaction of PB and exogenous hydroperoxides
CRP11	Using ram seminal vesicle microsomes as a source of PHS and prostacyclin synthase, we have examined the interaction of  bbbbb1 PB eeeee1  bbbbb2 prostacyclin synthase eeeee2 , we have examined the interaction of PB and exogenous hydroperoxides
CRP11	Using ram seminal vesicle microsomes as a source of PHS and prostacyclin synthase, we have examined the interaction of  bbbbb1 PB eeeee1  bbbbb2 PHS eeeee2  and prostacyclin synthase, we have examined the interaction of PB and exogenous hydroperoxides
CRP11	Using ram seminal vesicle microsomes as a source of PHS and prostacyclin synthase, we have examined the interaction of PB and exogenous  bbbbb1 hydroperoxides eeeee1  bbbbb2 prostacyclin synthase eeeee2 , we have examined the interaction of PB and exogenous hydroperoxides
CRP11	Using ram seminal vesicle microsomes as a source of PHS and prostacyclin synthase, we have examined the interaction of PB and exogenous  bbbbb1 hydroperoxides eeeee1  bbbbb2 PHS eeeee2  and prostacyclin synthase, we have examined the interaction of PB and exogenous hydroperoxides
CRP11	Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at  bbbbb1 PB eeeee1  bbbbb2 Prostacyclin synthase eeeee2  is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM
CRP11	Prostacyclin synthase is even more sensitive to inactivation by the combined PB and  bbbbb1 H2O2 eeeee1  bbbbb2 Prostacyclin synthase eeeee2  is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM
CRP11	 bbbbb1 Prostacyclin eeeee1  bbbbb2 Prostacyclin synthase eeeee2  is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM
CRP11	Prostacyclin synthase is even more sensitive to inactivation by the combined  bbbbb1 PB eeeee1  bbbbb2 Prostacyclin synthase eeeee2  is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM
CRP11	Inactivation of  bbbbb1 prostaglandin H eeeee1  synthase and  bbbbb2 prostacyclin synthase eeeee2  by phenylbutazone
CRP11	Inactivation of  bbbbb1 prostaglandin H eeeee1  bbbbb2 prostaglandin H synthase eeeee2  and prostacyclin synthase by phenylbutazone
CRP11	Inactivation of prostaglandin H synthase and  bbbbb1 prostacyclin eeeee1  bbbbb2 prostacyclin synthase eeeee2  by phenylbutazone
CRP11	Inactivation of prostaglandin H synthase and  bbbbb1 prostacyclin eeeee1  bbbbb2 prostaglandin H synthase eeeee2  and prostacyclin synthase by phenylbutazone
CRP11	Most reducing cofactors for the peroxidase protect PHS and  bbbbb1 prostacyclin eeeee1  bbbbb2 PHS eeeee2  and prostacyclin synthase from inactivation by hydroperoxides
CRP11	Most reducing cofactors for the peroxidase protect PHS and  bbbbb1 prostacyclin eeeee1  bbbbb2 prostacyclin synthase eeeee2  from inactivation by hydroperoxides
CRP11	Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of  bbbbb1 prostaglandin H eeeee1  synthase ( bbbbb2 PHS eeeee2 )
CRP11	Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of  bbbbb1 prostaglandin H eeeee1  bbbbb2 prostaglandin H synthase eeeee2  (PHS)
CRP11	The increase in SAA expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen,  bbbbb1 valproic acid eeeee1  bbbbb2 SAA eeeee2  expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin
CRP11	The increase in SAA expression is specific to  bbbbb1 ritodrine eeeee1 -induced liver damage, because  bbbbb2 SAA eeeee2  expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin
CRP11	The increase in SAA expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as  bbbbb1 acetaminophen eeeee1  bbbbb2 SAA eeeee2  expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin
CRP11	The increase in SAA expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or  bbbbb1 metformin eeeee1  bbbbb2 SAA eeeee2  expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin
CRP11	This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and  bbbbb1 alanine eeeee1  bbbbb2 alanine aminotransferase eeeee2 
CRP11	This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and  bbbbb1 alanine eeeee1  bbbbb2 SAA eeeee2  levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and alanine aminotransferase
CRP11	This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and  bbbbb1 alanine eeeee1  bbbbb2 aspartate aminotransferase eeeee2  and alanine aminotransferase
CRP11	This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as  bbbbb1 aspartate eeeee1  aminotransferase and  bbbbb2 alanine aminotransferase eeeee2 
CRP11	This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as  bbbbb1 aspartate eeeee1  bbbbb2 SAA eeeee2  levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and alanine aminotransferase
CRP11	This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as  bbbbb1 aspartate eeeee1  bbbbb2 aspartate aminotransferase eeeee2  and alanine aminotransferase
CRP11	The histamine H2 rece bbbbb1 ptor anta eeeee1 gonist cimetidi bbbbb2 ne blocked t eeeee2 he FHA-HIS binding on 14-37% of the platelets
CRP11	The histamine H2 rece bbbbb1 ptor anta eeeee1  bbbbb2 ptor antagon eeeee2 ist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets
CRP11	The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  bbbbb1 histamine eeeee1  bbbbb2 FHA eeeee2 -HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine
CRP11	The binding of FHA-HIS was inhibited on 35-79% of the platelets by the  bbbbb1 histamine eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonists diphenhydramine and clemastine
CRP11	Fluoresceinated human albumin conjugated with histamine (FHA-HIS) has been used for the demonstration of  bbbbb1 histamine eeeee1  bbbbb2 histamine receptors eeeee2  on human platelets
CRP11	Fluoresceinated human albumin conjugated with histamine (FHA-HIS) has been used for the demonstration of  bbbbb1 histamine eeeee1  bbbbb2 FHA eeeee2 -HIS) has been used for the demonstration of histamine receptors on human platelets
CRP11	Fluoresceinated human albumin conjugated with histamine (FHA-HIS) has been used for the demonstration of  bbbbb1 histamine eeeee1  bbbbb2 Fluoresceinated human albumin eeeee2  conjugated with histamine (FHA-HIS) has been used for the demonstration of histamine receptors on human platelets
CRP11	Fluoresceinated human albumin conjugated with  bbbbb1 histamine eeeee1  (FHA-HIS) has been used for the demonstration of  bbbbb2 histamine receptors eeeee2  on human platelets
CRP11	Fluoresceinated human albumin conjugated with  bbbbb1 histamine eeeee1  ( bbbbb2 FHA eeeee2 -HIS) has been used for the demonstration of histamine receptors on human platelets
CRP11	Fluoresceinated human albumin conjugated with  bbbbb1 histamine eeeee1  bbbbb2 Fluoresceinated human albumin eeeee2  conjugated with histamine (FHA-HIS) has been used for the demonstration of histamine receptors on human platelets
CRP11	Demonstration of  bbbbb1 histamine eeeee1  bbbbb2 histamine receptors eeeee2  on human platelets by flow cytometry
CRP11	In this study, we present the synthesis and pharmacological properties of new analogues of arginine vasopressin modified in the N-terminal part of the molecule with proline derivatives:  bbbbb1 indoline-2-carboxylic acid eeeee1  bbbbb2 arginine vasopressin eeeee2  modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid
CRP11	In this study, we present the synthesis and pharmacological properties of new analogues of arginine vasopressin modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid ( bbbbb1 Ica eeeee1  bbbbb2 arginine vasopressin eeeee2  modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid
CRP11	In this study, we present the synthesis and pharmacological properties of new analogues of  bbbbb1 arginine vasopressin eeeee1  bbbbb2 arginine vasopressin eeeee2  modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid
CRP11	In this study, we present the synthesis and pharmacological properties of new analogues of arginine vasopressin modified in the N-terminal part of the molecule with  bbbbb1 proline eeeee1  bbbbb2 arginine vasopressin eeeee2  modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid
CRP11	In this study, we present the synthesis and pharmacological properties of new analogues of arginine vasopressin modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and  bbbbb1 (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid eeeee1  bbbbb2 arginine vasopressin eeeee2  modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid
CRP11	On the other hand, peptides modified with (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxyl bbbbb1 ic acid, apart from  eeeee1  bbbbb2 ic acid, apart from  eeeee2 their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to arginine vasopressin
CRP11	Design, synthesis and structure-activity relationship of new arginine vasopressin analogues containing  bbbbb1 proline eeeee1  bbbbb2 arginine vasopressin eeeee2  analogues containing proline derivatives in position 2
CRP11	Design, synthesis and structure-activity relationship of new  bbbbb1 arginine vasopressin eeeee1  bbbbb2 arginine vasopressin eeeee2  analogues containing proline derivatives in position 2
CRP11	We also determined their binding affinity to the human  bbbbb1 oxytocin eeeee1  bbbbb2 human oxytocin receptor eeeee2 
CRP11	The ROS production was confirmed by  bbbbb1 DCF-DA eeeee1  probing assay in  bbbbb2 Sod eeeee2 -deficient strains
CRP11	In the absence of superoxide dismutase (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive  bbbbb1 oxygen eeeee1  bbbbb2 sod1 eeeee2 Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	In the absence of superoxide dismutase (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive  bbbbb1 oxygen eeeee1  bbbbb2 superoxide dismutase eeeee2  (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	In the absence of superoxide dismutase (in sod1Δ mutant strain) sensitivity to the essential oil and  bbbbb1 nerolidol eeeee1  bbbbb2 sod1 eeeee2 Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	In the absence of superoxide dismutase (in sod1Δ mutant strain) sensitivity to the essential oil and  bbbbb1 nerolidol eeeee1  bbbbb2 superoxide dismutase eeeee2  (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	In the absence of superoxide dismutase (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and  bbbbb1 nerolidol eeeee1  bbbbb2 sod1 eeeee2 Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	In the absence of superoxide dismutase (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and  bbbbb1 nerolidol eeeee1  bbbbb2 superoxide dismutase eeeee2  (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	In the absence of  bbbbb1 superoxide eeeee1  dismutase (in  bbbbb2 sod1 eeeee2 Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	In the absence of  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS)
CRP11	Effects of High Iron and  bbbbb1 Glucose eeeee1  Concentrations over the Relative Expression of  bbbbb2 Bcl2 eeeee2 , Bax, and Mfn2 in MIN6 Cells
CRP11	Effects of High Iron and  bbbbb1 Glucose eeeee1  Concentrations over the Relative Expression of Bcl2,  bbbbb2 Bax eeeee2 , and Mfn2 in MIN6 Cells
CRP11	Effects of High Iron and  bbbbb1 Glucose eeeee1  Concentrations over the Relative Expression of Bcl2, Bax, and  bbbbb2 Mfn2 eeeee2  in MIN6 Cells
CRP11	Effects of High  bbbbb1 Iron eeeee1  and Glucose Concentrations over the Relative Expression of  bbbbb2 Bcl2 eeeee2 , Bax, and Mfn2 in MIN6 Cells
CRP11	Effects of High  bbbbb1 Iron eeeee1  and Glucose Concentrations over the Relative Expression of Bcl2,  bbbbb2 Bax eeeee2 , and Mfn2 in MIN6 Cells
CRP11	Effects of High  bbbbb1 Iron eeeee1  and Glucose Concentrations over the Relative Expression of Bcl2, Bax, and  bbbbb2 Mfn2 eeeee2  in MIN6 Cells
CRP11	Heme oxygenase (HO) activity, iron uptake,  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity, iron uptake,  bbbbb1 superoxide eeeee1  bbbbb2 Heme oxygenase eeeee2  (HO) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity, iron uptake,  bbbbb1 superoxide eeeee1  bbbbb2 HO eeeee2 ) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity,  bbbbb1 iron eeeee1  uptake,  bbbbb2 superoxide dismutase eeeee2  activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity,  bbbbb1 iron eeeee1  bbbbb2 Heme oxygenase eeeee2  (HO) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity,  bbbbb1 iron eeeee1  bbbbb2 HO eeeee2 ) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity, iron uptake, superoxide dismutase activity, and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2  activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity, iron uptake, superoxide dismutase activity, and  bbbbb1 glutathione eeeee1  bbbbb2 Heme oxygenase eeeee2  (HO) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined
CRP11	Heme oxygenase (HO) activity, iron uptake, superoxide dismutase activity, and  bbbbb1 glutathione eeeee1  bbbbb2 HO eeeee2 ) activity, iron uptake, superoxide dismutase activity, and glutathione content were also determined
CRP11	MIN6 cells were pre-incubated with different  bbbbb1 iron eeeee1  and/or glucose concentrations, and the relative mRNA abundance of the Bcl2/ bbbbb2 Bax eeeee2  ratio and of Mfn2 genes was measured by qRT-PCR
CRP11	MIN6 cells were pre-incubated with different  bbbbb1 iron eeeee1  and/or glucose concentrations, and the relative mRNA abundance of the Bcl2/Bax ratio and of  bbbbb2 Mfn2 eeeee2  genes was measured by qRT-PCR
CRP11	MIN6 cells were pre-incubated with different  bbbbb1 iron eeeee1  and/or glucose concentrations, and the relative mRNA abundance of the  bbbbb2 Bcl2 eeeee2 /Bax ratio and of Mfn2 genes was measured by qRT-PCR
CRP11	MIN6 cells were pre-incubated with different iron and/or  bbbbb1 glucose eeeee1  concentrations, and the relative mRNA abundance of the Bcl2/ bbbbb2 Bax eeeee2  ratio and of Mfn2 genes was measured by qRT-PCR
CRP11	MIN6 cells were pre-incubated with different iron and/or  bbbbb1 glucose eeeee1  concentrations, and the relative mRNA abundance of the Bcl2/Bax ratio and of  bbbbb2 Mfn2 eeeee2  genes was measured by qRT-PCR
CRP11	MIN6 cells were pre-incubated with different iron and/or  bbbbb1 glucose eeeee1  concentrations, and the relative mRNA abundance of the  bbbbb2 Bcl2 eeeee2 /Bax ratio and of Mfn2 genes was measured by qRT-PCR
CRP11	The purpose of this study was to describe the effect of different  bbbbb1 iron eeeee1  and/or glucose concentrations over Mfn2,  bbbbb2 Bax eeeee2 , and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells)
CRP11	The purpose of this study was to describe the effect of different  bbbbb1 iron eeeee1  and/or glucose concentrations over  bbbbb2 Mfn2 eeeee2 , Bax, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells)
CRP11	The purpose of this study was to describe the effect of different  bbbbb1 iron eeeee1  and/or glucose concentrations over Mfn2, Bax, and  bbbbb2 Bcl2 eeeee2  expressions in a β-pancreatic cell line (MIN6 cells)
CRP11	The purpose of this study was to describe the effect of different iron and/or  bbbbb1 glucose eeeee1  concentrations over Mfn2,  bbbbb2 Bax eeeee2 , and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells)
CRP11	The purpose of this study was to describe the effect of different iron and/or  bbbbb1 glucose eeeee1  concentrations over  bbbbb2 Mfn2 eeeee2 , Bax, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells)
CRP11	The purpose of this study was to describe the effect of different iron and/or  bbbbb1 glucose eeeee1  concentrations over Mfn2, Bax, and  bbbbb2 Bcl2 eeeee2  expressions in a β-pancreatic cell line (MIN6 cells)
CRP11	The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between  bbbbb1 abacavir eeeee1  bbbbb2 HLA-B*57:01 eeeee2 + drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response
CRP11	Cells from HLA-B*57:01+ Human Subjects Are Activated with  bbbbb1 Abacavir eeeee1  bbbbb2 HLA-B*57:01 eeeee2 + Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms
CRP11	We have identified adenosine deaminase, an enzyme involved in  bbbbb1 purine eeeee1  metabolism whose deficiency is associated with severe combined immunodeficiency, as a  bbbbb2 Grb3-3 eeeee2  binding protein that is not able to bind to Grb2
CRP11	We have identified adenosine deaminase, an enzyme involved in  bbbbb1 purine eeeee1  metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to  bbbbb2 Grb2 eeeee2 
CRP11	We have identified  bbbbb1 adenosine eeeee1  bbbbb2 adenosine deaminase eeeee2 , an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2
CRP11	We have identified  bbbbb1 adenosine eeeee1  deaminase, an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a  bbbbb2 Grb3-3 eeeee2  binding protein that is not able to bind to Grb2
CRP11	We have identified  bbbbb1 adenosine eeeee1  deaminase, an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to  bbbbb2 Grb2 eeeee2 
CRP11	 bbbbb1 Adenosine eeeee1  deaminase is a specific partner for the Grb2 isoform  bbbbb2 Grb3-3 eeeee2 
CRP11	 bbbbb1 Adenosine eeeee1  deaminase is a specific partner for the  bbbbb2 Grb2 eeeee2  isoform Grb3-3
CRP11	 bbbbb1 Adenosine eeeee1  bbbbb2 Adenosine deaminase eeeee2  is a specific partner for the Grb2 isoform Grb3-3
CRP11	Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as  bbbbb1 adenylate eeeee1  bbbbb2 mucin eeeee2  secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin
CRP11	Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as  bbbbb1 adenylate eeeee1  bbbbb2 adenylate cyclase eeeee2  activator, forskolin
CRP11	Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger,  bbbbb1 cAMP eeeee1  bbbbb2 mucin eeeee2  secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin
CRP11	Using  bbbbb1 [(3)H]glucosamine eeeee1 -labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by  bbbbb2 EGFR eeeee2  kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K
CRP11	Using  bbbbb1 [(3)H]glucosamine eeeee1 -labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on  bbbbb2 mucin eeeee2  secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K
CRP11	Using  bbbbb1 [(3)H]glucosamine eeeee1 -labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR  bbbbb2 kinase eeeee2  inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K
CRP11	Using  bbbbb1 [(3)H]glucosamine eeeee1 -labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of  bbbbb2 PI3K eeeee2 
CRP11	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor,  bbbbb1 PD153035 eeeee1 , as well as wortmannin, a specific inhibitor of  bbbbb2 PI3K eeeee2 
CRP11	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as  bbbbb1 wortmannin eeeee1  bbbbb2 EGFR eeeee2  kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K
CRP11	Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as  bbbbb1 wortmannin eeeee1  bbbbb2 kinase eeeee2  inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K
CRP11	In many systems, the integration of converging regulatory signals that relay on G protein-coupled receptor (GPCR) activation into functional cellular pathways requires the involvement of receptor  bbbbb1 tyrosine eeeee1  bbbbb2 G protein-coupled receptor eeeee2  (GPCR) activation into functional cellular pathways requires the involvement of receptor tyrosine kinase
CRP11	In many systems, the integration of converging regulatory signals that relay on G protein-coupled receptor (GPCR) activation into functional cellular pathways requires the involvement of receptor  bbbbb1 tyrosine eeeee1  bbbbb2 receptor tyrosine kinase eeeee2 
CRP11	In many systems, the integration of converging regulatory signals that relay on G protein-coupled receptor (GPCR) activation into functional cellular pathways requires the involvement of receptor  bbbbb1 tyrosine eeeee1  bbbbb2 GPCR eeeee2 ) activation into functional cellular pathways requires the involvement of receptor tyrosine kinase
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by  bbbbb1 PP2 eeeee1 , a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by  bbbbb2 ERK eeeee2  inhibitor, PD98059
CRP11	The gastric mucin secretory responses to  bbbbb1 isoproterenol eeeee1 , furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent  bbbbb2 EGFR eeeee2  autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to  bbbbb1 isoproterenol eeeee1 , furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase  bbbbb2 Src eeeee2  responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to  bbbbb1 isoproterenol eeeee1 , furthermore, were inhibited by PP2, a selective inhibitor of  bbbbb2 tyrosine kinase eeeee2  Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to  bbbbb1 isoproterenol eeeee1 , furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by  bbbbb2 ERK eeeee2  inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of  bbbbb1 tyrosine eeeee1  kinase Src responsible for ligand-independent  bbbbb2 EGFR eeeee2  autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of  bbbbb1 tyrosine eeeee1  kinase  bbbbb2 Src eeeee2  responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of  bbbbb1 tyrosine eeeee1  bbbbb2 gastric mucin eeeee2  secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of  bbbbb1 tyrosine eeeee1  kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by  bbbbb2 ERK eeeee2  inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor,  bbbbb1 PD98059 eeeee1  bbbbb2 EGFR eeeee2  autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor,  bbbbb1 PD98059 eeeee1  bbbbb2 Src eeeee2  responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor,  bbbbb1 PD98059 eeeee1  bbbbb2 tyrosine kinase eeeee2  Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059
CRP11	The DFT-predicted geometric parameters for {ES-NO}7 are in good agreement with the crystallographically determined substrate-bound active site configuration of CDO and are con bbbbb1 sist eeeee1  bbbbb2 bst eeeee2 rate-bound active site configuration of CDO and are consistent with known iron-nitrosyl model complexes
CRP11	The DFT-predicted geometric parameters for {ES-NO}7 are in good agreement with the crystallographically determined substrate-bound active site configuration of CDO and are consistent with know bbbbb1 n iron-nitros eeeee1  bbbbb2 bst eeeee2 rate-bound active site configuration of CDO and are consistent with known iron-nitrosyl model complexes
CRP11	However, upon addition of NO to CDO in the presence of substrate l-cysteine, a low-spin { bbbbb1 FeNO eeeee1  bbbbb2 CDO eeeee2  in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops
CRP11	However, upon addition of NO to CDO in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the  bbbbb1 iron eeeee1  bbbbb2 CDO eeeee2  in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops
CRP11	The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived  bbbbb1 histidines eeeee1 , thus representing a new variant on the  bbbbb2 2-histidine-1-carboxylate (2H1C) facial triad motif eeeee2 
CRP11	The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the  bbbbb1 2-histidine-1-carboxylate eeeee1  bbbbb2 CDO eeeee2  comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif
CRP11	The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the  bbbbb1 2-histidine-1-carboxylate eeeee1  bbbbb2 2-histidine-1-carboxylate (2H1C) facial triad motif eeeee2 
CRP11	The active site coordination of CDO comprises a mononuclear  bbbbb1 iron eeeee1  ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the  bbbbb2 2-histidine-1-carboxylate (2H1C) facial triad motif eeeee2 
CRP11	The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate ( bbbbb1 2H1C eeeee1  bbbbb2 CDO eeeee2  comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif
CRP11	The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate ( bbbbb1 2H1C eeeee1  bbbbb2 2-histidine-1-carboxylate (2H1C) facial triad motif eeeee2 
CRP11	In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme  bbbbb1 iron eeeee1  bbbbb2 2H1C class of non-heme iron enzymes eeeee2 
CRP11	In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme  bbbbb1 iron eeeee1  bbbbb2 CDO eeeee2  exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes
CRP11	In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the  bbbbb1 2H1C eeeee1  bbbbb2 2H1C class of non-heme iron enzymes eeeee2 
CRP11	In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the  bbbbb1 2H1C eeeee1  bbbbb2 CDO eeeee2  exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes
CRP11	Characterization of the nitrosyl adduct of substrate-bound mouse  bbbbb1 cysteine eeeee1  bbbbb2 mouse cysteine dioxygenase eeeee2  by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications
CRP11	Mammalian  bbbbb1 cysteine eeeee1  bbbbb2 Mammalian cysteine dioxygenase eeeee2  (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism
CRP11	Mammalian  bbbbb1 cysteine eeeee1  dioxygenase ( bbbbb2 CDO eeeee2 ) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the  bbbbb1 bidentate thiol/amine eeeee1  coordination of l-cysteine in the NO-bound  bbbbb2 CDO eeeee2  active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the  bbbbb1 bidentate thiol/amine eeeee1  bbbbb2 CDO eeeee2  (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound  bbbbb1 iron-nitrosyl eeeee1  CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound  bbbbb2 CDO eeeee2  active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound  bbbbb1 iron-nitrosyl eeeee1   bbbbb2 CDO eeeee2  (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site
CRP11	The unusual { bbbbb1 FeNO eeeee1 }7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound  bbbbb2 CDO eeeee2  active site
CRP11	The unusual { bbbbb1 FeNO eeeee1 }7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl  bbbbb2 CDO eeeee2  (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of  bbbbb1 l-cysteine eeeee1  in the NO-bound  bbbbb2 CDO eeeee2  active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of  bbbbb1 l-cysteine eeeee1  bbbbb2 CDO eeeee2  (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES- bbbbb1 NO eeeee1 }7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound  bbbbb2 CDO eeeee2  active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES- bbbbb1 NO eeeee1  bbbbb2 CDO eeeee2  (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site
CRP11	The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the  bbbbb1 NO eeeee1  bbbbb2 CDO eeeee2  (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site
CRP11	Inhibition of cardiac voltage-gated  bbbbb1 sodium eeeee1  channels ( bbbbb2 VGSCs eeeee2 ) is antiarrhythmic and cardioprotective
CRP11	Inhibition of cardiac voltage-gated  bbbbb1 sodium eeeee1  bbbbb2 voltage-gated sodium channels eeeee2  (VGSCs) is antiarrhythmic and cardioprotective
CRP11	With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for bbbbb1  the estr eeeee1  bbbbb2 tr eeeee2 adiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor
CRP11	With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor bbbbb1  eeeee1  bbbbb2 tr eeeee2 adiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor
CRP11	With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen  bbbbb1 receptor eeeee1  bbbbb2 tr eeeee2 adiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor
CRP11	 bbbbb1 Estrogen eeeee1  bbbbb2 Estrogen receptor-alpha eeeee2  (ER) antagonists have been widely used for breast cancer therapy
CRP11	 bbbbb1 Estrogen eeeee1  receptor-alpha ( bbbbb2 ER eeeee2 ) antagonists have been widely used for breast cancer therapy
CRP11	Jostling for position: optimizing linker location in the design of  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2 -targeting PROTACs
CRP11	The ER-targeting PROTACs are composed of an  bbbbb1 estradiol eeeee1  on one end and a hypoxia-inducing factor 1alpha ( bbbbb2 HIF-1alpha eeeee2 )-derived synthetic pentapeptide on the other
CRP11	The ER-targeting PROTACs are composed of an  bbbbb1 estradiol eeeee1  on one end and a  bbbbb2 hypoxia-inducing factor 1alpha eeeee2  (HIF-1alpha)-derived synthetic pentapeptide on the other
CRP11	 bbbbb1 Histamine eeeee1  bbbbb2 Histamine H(1) eeeee2  blockade is one of the more prominent actions of the multi-receptor acting antipsychotic clozapine
CRP11	The current studies with Sprague-Dawley rats were conducted to determine the participation of histaminergic H(1) receptor subtype in sensorimotor plasticity and memory function affected by  bbbbb1 clozapine eeeee1  bbbbb2 histaminergic H(1) receptor eeeee2  subtype in sensorimotor plasticity and memory function affected by clozapine using tests of prepulse inhibition (PPI) and radial-arm maze choice accuracy
CRP11	 bbbbb1 Histamine eeeee1  bbbbb2 Histamine H1 receptor eeeee2  involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine
CRP11	Crystallographic analysis of the human  bbbbb1 phenylalanine eeeee1  bbbbb2 human phenylalanine hydroxylase catalytic domain eeeee2  with bound catechol inhibitors at 2.0 A resolution
CRP11	Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human  bbbbb1 phenylalanine eeeee1  bbbbb2 human phenylalanine hydroxylase eeeee2  (hPheOH), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A
CRP11	Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human  bbbbb1 phenylalanine eeeee1  hydroxylase ( bbbbb2 hPheOH eeeee2 ), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A
CRP11	The  bbbbb1 aromatic amino acid eeeee1  bbbbb2 aromatic amino acid hydroxylases eeeee2  represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by catechol derivatives
CRP11	Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-  bbbbb1 cystine eeeee1  bbbbb2 x(c)- cystine transporter eeeee2 : a new action for an old drug
CRP11	Accordingly, we previously suggested that the x(c)- plasma membrane  bbbbb1 cystine eeeee1  bbbbb2 x(c)- plasma membrane cystine transporter eeeee2  provided a target for lymphoid cancer therapy
CRP11	In five ra bbbbb1 ts, 90- eeeee1  bbbbb2 ive rats, 90-100% tumor g eeeee2 rowth suppression, relative to controls, was obtained
CRP11	We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50)  bbbbb1 lactate eeeee1  dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing  bbbbb2 albumin eeeee2  release
CRP11	We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50)  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2 : 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release
CRP11	Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to  bbbbb1 phosphatidic acid eeeee1  bbbbb2 PKC eeeee2 ) and is converted to phosphatidic acid by DAG kinase (DGK)
CRP11	Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to  bbbbb1 phosphatidic acid eeeee1  bbbbb2 protein kinase C eeeee2  (PKC) and is converted to phosphatidic acid by DAG kinase (DGK)
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and  bbbbb1 Ser eeeee1  bbbbb2 DGKgamma eeeee2  because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and  bbbbb1 Ser eeeee1 -779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable  bbbbb2 DGKgamma eeeee2  mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and  bbbbb1 Ser eeeee1 -779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type  bbbbb2 DGKgamma eeeee2  and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and  bbbbb1 Ser eeeee1  bbbbb2 gammaPKC eeeee2  resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with  bbbbb1 glutamic acid eeeee1  bbbbb2 DGKgamma eeeee2  because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with  bbbbb1 glutamic acid eeeee1  to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable  bbbbb2 DGKgamma eeeee2  mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with  bbbbb1 glutamic acid eeeee1  to mimic phosphorylation exhibited significantly higher activity compared with wild type  bbbbb2 DGKgamma eeeee2  and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with  bbbbb1 glutamic acid eeeee1  bbbbb2 gammaPKC eeeee2  resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which  bbbbb1 Ser eeeee1  bbbbb2 DGKgamma eeeee2  because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which  bbbbb1 Ser eeeee1 -776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable  bbbbb2 DGKgamma eeeee2  mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which  bbbbb1 Ser eeeee1 -776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type  bbbbb2 DGKgamma eeeee2  and an unphosphorylatable DGKgamma mutant
CRP11	The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which  bbbbb1 Ser eeeee1  bbbbb2 gammaPKC eeeee2  resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant
CRP11	Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated Ser-776 and  bbbbb1 Ser eeeee1  bbbbb2 gammaPKC eeeee2  phosphorylated Ser-776 and Ser-779 in the AD of DGKgamma
CRP11	Mass spectrometric analysis and mutation studies revealed that gammaPKC  bbbbb1 phosphorylated Ser eeeee1 -776 and Ser-779 in the AD of  bbbbb2 DGKgamma eeeee2 
CRP11	Phosphorylation and up-regulation of  bbbbb1 diacylglycerol eeeee1  kinase gamma via its interaction with  bbbbb2 protein kinase C gamma eeeee2 
CRP11	Phosphorylation and up-regulation of  bbbbb1 diacylglycerol eeeee1  bbbbb2 diacylglycerol kinase gamma eeeee2  via its interaction with protein kinase C gamma
CRP11	Here we show molecular mechanisms of functional coupling of the two kinases. gammaPKC directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/ bbbbb1 diolein eeeee1  bbbbb2 kinases eeeee2 . gammaPKC directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/diolein in vitro
CRP11	Here we show molecular mechanisms of functional coupling of the two kinases. gammaPKC directly associated with DGKgamma through its accessory domain (AD), depending on  bbbbb1 Ca2+ eeeee1  bbbbb2 kinases eeeee2 . gammaPKC directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/diolein in vitro
CRP11	Here we show molecular mechanisms of functional coupling of the two kinases. gammaPKC directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as  bbbbb1 phosphatidylserine eeeee1  bbbbb2 kinases eeeee2 . gammaPKC directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/diolein in vitro
CRP11	To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of  bbbbb1 d-galactosamine eeeee1  (GalN), we focused on the role of polyprimidine tract-binding protein ( bbbbb2 PTB eeeee2 ) in islet insulin synthesis
CRP11	To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of  bbbbb1 d-galactosamine eeeee1  (GalN), we focused on the role of polyprimidine tract-binding protein (PTB) in islet  bbbbb2 insulin eeeee2  synthesis
CRP11	To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of  bbbbb1 d-galactosamine eeeee1  (GalN), we focused on the role of  bbbbb2 polyprimidine tract-binding protein eeeee2  (PTB) in islet insulin synthesis
CRP11	To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine ( bbbbb1 GalN eeeee1 ), we focused on the role of polyprimidine tract-binding protein ( bbbbb2 PTB eeeee2 ) in islet insulin synthesis
CRP11	To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine ( bbbbb1 GalN eeeee1 ), we focused on the role of polyprimidine tract-binding protein (PTB) in islet  bbbbb2 insulin eeeee2  synthesis
CRP11	To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine ( bbbbb1 GalN eeeee1 ), we focused on the role of  bbbbb2 polyprimidine tract-binding protein eeeee2  (PTB) in islet insulin synthesis
CRP11	Levels of mRNA encoding insulin 1, ICA512, and PC1/3 were increased in the pancreatic islets of  bbbbb1 GalN eeeee1  bbbbb2 PC1/3 eeeee2  were increased in the pancreatic islets of GalN-treated rats
CRP11	This cDNA clone, designated EAA3a, shares a 90%  bbbbb1 nucleotide eeeee1  identity with the previously reported rat GluR5-2b cDNA splice variant and differed from  bbbbb2 human GluR5-1d eeeee2  in the amino and carboxy terminal regions
CRP11	This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and  bbbbb1 carboxy eeeee1  bbbbb2 EAA3a eeeee2 , shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions
CRP11	This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and  bbbbb1 carboxy eeeee1  bbbbb2 rat GluR5-2b eeeee2  cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions
CRP11	This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the  bbbbb1 amino eeeee1  bbbbb2 EAA3a eeeee2 , shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions
CRP11	This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the  bbbbb1 amino eeeee1  bbbbb2 rat GluR5-2b eeeee2  cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the  bbbbb1 non-N-methyl-D-aspartate eeeee1  bbbbb2 N-methyl-D-aspartate (NMDA) receptor eeeee2  antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the  bbbbb1 non-N-methyl-D-aspartate eeeee1  bbbbb2 conA eeeee2 ) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the  bbbbb1 non-N-methyl-D-aspartate eeeee1  bbbbb2 concanavalin A eeeee2  (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX ( bbbbb1 6-cyano-7-nitro-quinoxalinedione eeeee1  bbbbb2 conA eeeee2 ) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX ( bbbbb1 6-cyano-7-nitro-quinoxalinedione eeeee1  bbbbb2 concanavalin A eeeee2  (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate ( bbbbb1 NMDA eeeee1  bbbbb2 N-methyl-D-aspartate (NMDA) receptor eeeee2  antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate ( bbbbb1 NMDA eeeee1  bbbbb2 conA eeeee2 ) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate ( bbbbb1 NMDA eeeee1  bbbbb2 concanavalin A eeeee2  (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	 bbbbb1 Kainate eeeee1 -evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non- bbbbb2 N-methyl-D-aspartate (NMDA) receptor eeeee2  antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	 bbbbb1 Kainate eeeee1 -evoked currents showed partial desensitization that was reduced on incubation with concanavalin A ( bbbbb2 conA eeeee2 ) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	 bbbbb1 Kainate eeeee1 -evoked currents showed partial desensitization that was reduced on incubation with  bbbbb2 concanavalin A eeeee2  (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist  bbbbb1 CNQX eeeee1  bbbbb2 conA eeeee2 ) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist  bbbbb1 CNQX eeeee1  bbbbb2 concanavalin A eeeee2  (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not  bbbbb1 cyclothiazide eeeee1  and were attenuated by the non- bbbbb2 N-methyl-D-aspartate (NMDA) receptor eeeee2  antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not  bbbbb1 cyclothiazide eeeee1  bbbbb2 conA eeeee2 ) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not  bbbbb1 cyclothiazide eeeee1  bbbbb2 concanavalin A eeeee2  (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)
CRP11	Cell lines stably expressing EAA3a protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate ( bbbbb1 AMPA eeeee1  bbbbb2 ligand-gated ion channels eeeee2  responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA)
CRP11	Cell lines stably expressing EAA3a protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate,  bbbbb1 L-glutamate eeeee1  bbbbb2 ligand-gated ion channels eeeee2  responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA)
CRP11	Cell lines stably expressing EAA3a protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate,  bbbbb1 kainate eeeee1  bbbbb2 ligand-gated ion channels eeeee2  responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA)
CRP11	Cell lines stably expressing EAA3a protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and  bbbbb1 (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate eeeee1  bbbbb2 ligand-gated ion channels eeeee2  responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA)
CRP11	NA cloning and functional properties of human  bbbbb1 glutamate eeeee1  receptor EAA3 ( bbbbb2 GluR5 eeeee2 ) in homomeric and heteromeric configuration
CRP11	NA cloning and functional properties of human  bbbbb1 glutamate eeeee1  receptor  bbbbb2 EAA3 eeeee2  (GluR5) in homomeric and heteromeric configuration
CRP11	NA cloning and functional properties of human  bbbbb1 glutamate eeeee1  bbbbb2 human glutamate receptor eeeee2  EAA3 (GluR5) in homomeric and heteromeric configuration
CRP11	We have isolated a new member of the human  bbbbb1 glutamate eeeee1  bbbbb2 human glutamate receptor eeeee2  family from a fetal brain cDNA library
CRP11	While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the  bbbbb1 bile acid eeeee1  synthesis,  bbbbb2 Cyp7a1 eeeee2 , was significantly increased by EGCG
CRP11	While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the  bbbbb1 bile acid eeeee1  bbbbb2 hepatic bile acid transporters eeeee2  were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by EGCG
CRP11	While protein levels of the main hepatic  bbbbb1 bile acid eeeee1  transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis,  bbbbb2 Cyp7a1 eeeee2 , was significantly increased by EGCG
CRP11	While protein levels of the main hepatic  bbbbb1 bile acid eeeee1  bbbbb2 hepatic bile acid transporters eeeee2  were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by EGCG
CRP11	While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by  bbbbb1 EGCG eeeee1  bbbbb2 Cyp7a1 eeeee2 , was significantly increased by EGCG
CRP11	While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by  bbbbb1 EGCG eeeee1  bbbbb2 hepatic bile acid transporters eeeee2  were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by EGCG
CRP11	In contrast, EGCG markedly downregulated major  bbbbb1 bile acid eeeee1  transporters (Asbt and Ostα) and regulatory molecules (Shp and  bbbbb2 Fgf15 eeeee2 ) in the ileum
CRP11	In contrast, EGCG markedly downregulated major  bbbbb1 bile acid eeeee1  bbbbb2 bile acid transporters eeeee2  (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum
CRP11	In contrast, EGCG markedly downregulated major  bbbbb1 bile acid eeeee1  transporters ( bbbbb2 Asbt eeeee2  and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum
CRP11	In contrast, EGCG markedly downregulated major  bbbbb1 bile acid eeeee1  transporters (Asbt and  bbbbb2 Ostα eeeee2 ) and regulatory molecules (Shp and Fgf15) in the ileum
CRP11	In contrast, EGCG markedly downregulated major  bbbbb1 bile acid eeeee1  transporters (Asbt and Ostα) and regulatory molecules ( bbbbb2 Shp eeeee2  and Fgf15) in the ileum
CRP11	Cholestatic effect of  bbbbb1 epigallocatechin gallate eeeee1  in rats is mediated via decreased expression of  bbbbb2 Mrp2 eeeee2 
CRP11	The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells has been demonstrated by competition binding studies with tritiated diprenorphine and [D-Ala2, D-Leu5]enkephalin ( bbbbb1 DADLE eeeee1  bbbbb2 enkephalin eeeee2  (DADLE)
CRP11	The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells has been demonstrated by competition binding studies with tritiated diprenorphine and  bbbbb1 [D-Ala2, D-Leu5]enkephalin eeeee1  bbbbb2 enkephalin eeeee2  (DADLE)
CRP11	The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells has been demonstrated by competition binding studies with  bbbbb1 tritiated diprenorphine eeeee1  and [D-Ala2, D-Leu5] bbbbb2 enkephalin eeeee2  (DADLE)
CRP11	However, in the presence of 100 mM Na+, which is required for opiate inhibition of  bbbbb1 adenylate eeeee1  bbbbb2 adenylate cyclase eeeee2  activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM
CRP11	This finding, together w bbbbb1 ith  eeeee1  bbbbb2  finding, tog eeeee2 ether with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that 3H-NMPB, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of mAch receptor occupancy by cholinergic drugs in the brain
CRP11	This finding, toget bbbbb1 her eeeee1  bbbbb2  finding, tog eeeee2 ether with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that 3H-NMPB, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of mAch receptor occupancy by cholinergic drugs in the brain
CRP11	Apparent muscarinic  bbbbb1 acetylcholine eeeee1  bbbbb2 muscarinic acetylcholine (mAch) receptor eeeee2  occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Apparent muscarinic  bbbbb1 acetylcholine eeeee1  (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective  bbbbb2 M1 eeeee2  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by  bbbbb1 scopolamine eeeee1 , an antagonist, and biperiden, a relatively selective  bbbbb2 M1 eeeee2  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and  bbbbb1 3H-quinuclidinyl benzilate eeeee1  bbbbb2 M1 eeeee2  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate ( bbbbb1 3H-NMPB eeeee1  bbbbb2 M1 eeeee2  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands:  bbbbb1 3H-N-methyl piperidyl benzilate eeeee1  bbbbb2 M1 eeeee2  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and  bbbbb1 biperiden eeeee1  bbbbb2 muscarinic acetylcholine (mAch) receptor eeeee2  occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate ( bbbbb1 3H-QNB eeeee1  bbbbb2 M1 eeeee2  antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)
CRP11	Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was  bbbbb1 3H-QNB eeeee1  bbbbb2 mAch receptors eeeee2  in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CRP11	Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was  bbbbb1 3H-QNB eeeee1  bbbbb2 mAch receptors eeeee2 . 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CRP11	Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by  bbbbb1 scopolamine eeeee1  bbbbb2 mAch receptors eeeee2  in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CRP11	Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by  bbbbb1 scopolamine eeeee1  bbbbb2 mAch receptors eeeee2 . 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CRP11	Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors.  bbbbb1 3H-NMPB eeeee1  bbbbb2 mAch receptors eeeee2  in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors. 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CRP11	Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors.  bbbbb1 3H-NMPB eeeee1  bbbbb2 mAch receptors eeeee2 . 3H-NMPB binding in vivo was much more sensitive to direct competitive inhibition by scopolamine than was 3H-QNB
CRP11	Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme  bbbbb1 ribonucleotide eeeee1  bbbbb2 ribonucleotide reductase eeeee2 , resulting in reduced dNTP pools and inhibition of DNA synthesis
CRP11	Apart from the consequences of  bbbbb1 iron eeeee1  deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme  bbbbb2 ribonucleotide reductase eeeee2 , resulting in reduced dNTP pools and inhibition of DNA synthesis
CRP11	Furthermore, gallium also seems to affect intracellular availability of  bbbbb1 iron eeeee1  already taken up via this pathway, probably due to its inhibitory activity on  bbbbb2 vacuolar-type H(+)-ATPases eeeee2 
CRP11	Furthermore, gallium also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on vacuolar-type  bbbbb1 H(+) eeeee1  bbbbb2 vacuolar-type H(+)-ATPases eeeee2 
CRP11	Both the abundance of transferrin receptors and upregulation of  bbbbb1 ribonucleotide eeeee1  bbbbb2 transferrin receptors eeeee2  and upregulation of ribonucleotide reductase render tumors susceptible to gallium-induced cytotoxicity
CRP11	Both the abundance of transferrin receptors and upregulation of  bbbbb1 ribonucleotide eeeee1  bbbbb2 ribonucleotide reductase eeeee2  render tumors susceptible to gallium-induced cytotoxicity
CRP11	The most potent compound 5 (HJC0123) has demonstr bbbbb1 ated to  eeeee1 inhibit STA bbbbb2 T3 eeeee2  promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values
CRP11	The most potent compound 5 (HJC0123) has demonstr bbbbb1 ated to  eeeee1  bbbbb2 ated to inhibit S eeeee2 TAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values
CRP11	Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of  bbbbb1 5-methoxytryptamine eeeee1  bbbbb2 rat CYP eeeee2  isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6
CRP11	Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to  bbbbb1 serotonin eeeee1  bbbbb2 rat CYP eeeee2  isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6
CRP11	Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the  bbbbb1 O eeeee1  bbbbb2 rat CYP eeeee2  isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of  bbbbb1 serotonin eeeee1  bbbbb2 CYP eeeee2 ) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of  bbbbb1 serotonin eeeee1  bbbbb2 rat cytochrome P450 eeeee2  (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to  bbbbb1 serotonin eeeee1  bbbbb2 CYP eeeee2 ) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to  bbbbb1 serotonin eeeee1  bbbbb2 rat cytochrome P450 eeeee2  (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the  bbbbb1 O eeeee1  bbbbb2 CYP eeeee2 ) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the  bbbbb1 O eeeee1  bbbbb2 rat cytochrome P450 eeeee2  (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the O-demethylation of  bbbbb1 5-methoxytryptamine eeeee1  bbbbb2 CYP eeeee2 ) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	The aim of present study was to identify rat cytochrome P450 (CYP) isoforms which can catalyze the O-demethylation of  bbbbb1 5-methoxytryptamine eeeee1  bbbbb2 rat cytochrome P450 eeeee2  (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain
CRP11	Effect of 5-azacytidine and  bbbbb1 procainamide eeeee1  on  bbbbb2 CD3-zeta chain eeeee2  expression in Jurkat T cells
CRP11	Effect of  bbbbb1 5-azacytidine eeeee1  and procainamide on  bbbbb2 CD3-zeta chain eeeee2  expression in Jurkat T cells
CRP11	Apart from jolkinol D, all derivatives (2-14) showed potential as MDR reversal agents bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from  bbbbb1 Grundmann's ketone eeeee1  bbbbb2 OSC eeeee2 )-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone
CRP11	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from  bbbbb1 Grundmann's ketone eeeee1  bbbbb2 oxidosqualene cyclase(1) eeeee2  (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone
CRP11	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the  bbbbb1 oxidosqualene eeeee1  cyclase(1) ( bbbbb2 OSC eeeee2 )-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone
CRP11	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the  bbbbb1 oxidosqualene eeeee1  bbbbb2 oxidosqualene cyclase(1) eeeee2  (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone
CRP11	The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous fin bbbbb1 dings th eeeee1  bbbbb2 and eeeee2  l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice
CRP11	The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent wit bbbbb1 h previou eeeee1  bbbbb2 and eeeee2  l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice
CRP11	The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake i bbbbb1 n mice eeeee1  bbbbb2 and eeeee2  l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice
CRP11	The irreversible MAO-B inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/k bbbbb1 g) also eeeee1  bbbbb2 and eeeee2  l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice
CRP11	Reduction of oral  bbbbb1 ethanol eeeee1  self-administration in rats by  bbbbb2 monoamine oxidase eeeee2  inhibitors
CRP11	Reduction of oral ethanol self-administration in rats by  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  inhibitors
CRP11	The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor,  bbbbb1 clorgyline eeeee1  bbbbb2 MAO-A eeeee2  inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration
CRP11	The reversible MAO-A inhibitor,  bbbbb1 befloxatone eeeee1  (0.3-3 mg/kg), and the irreversible  bbbbb2 MAO-A eeeee2  inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration
CRP11	The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced  bbbbb1 ethanol eeeee1  bbbbb2 MAO-A eeeee2  inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration
CRP11	The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced  bbbbb1 ethanol eeeee1  bbbbb2 MAO-A eeeee2  inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration
CRP11	The aim of the present study was, therefore, to evaluate several MAO inhibitors for their capacity to affect ethanol self-administration in rats trained to self-administer  bbbbb1 ethanol eeeee1  bbbbb2 MAO eeeee2  inhibitors for their capacity to affect ethanol self-administration in rats trained to self-administer ethanol (10% v/v) orally in a free-choice two-lever operant task
CRP11	The aim of the present study was, therefore, to evaluate several MAO inhibitors for their capacity to affect  bbbbb1 ethanol eeeee1  bbbbb2 MAO eeeee2  inhibitors for their capacity to affect ethanol self-administration in rats trained to self-administer ethanol (10% v/v) orally in a free-choice two-lever operant task
CRP11	The nonselective and irreversible MAO inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by  bbbbb1 ethanol eeeee1  bbbbb2 MAO eeeee2  inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (MAO) inhibitors, which increase the synaptic availability of serotonin and  bbbbb1 dopamine eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (MAO) inhibitors, which increase the synaptic availability of serotonin and  bbbbb1 dopamine eeeee1  bbbbb2 MAO eeeee2 ) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of  bbbbb1 dopamine eeeee1  and serotonin in the control of ethanol intake in animals suggests that  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of  bbbbb1 dopamine eeeee1  and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase ( bbbbb2 MAO eeeee2 ) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (MAO) inhibitors, which increase the synaptic availability of  bbbbb1 serotonin eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (MAO) inhibitors, which increase the synaptic availability of  bbbbb1 serotonin eeeee1  bbbbb2 MAO eeeee2 ) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of  bbbbb1 ethanol eeeee1  intake in animals suggests that  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of  bbbbb1 ethanol eeeee1  intake in animals suggests that monoamine oxidase ( bbbbb2 MAO eeeee2 ) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that  bbbbb1 monoamine eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that  bbbbb1 monoamine eeeee1  oxidase ( bbbbb2 MAO eeeee2 ) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and  bbbbb1 serotonin eeeee1  in the control of ethanol intake in animals suggests that  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and  bbbbb1 serotonin eeeee1  in the control of ethanol intake in animals suggests that monoamine oxidase ( bbbbb2 MAO eeeee2 ) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of  bbbbb1 alcohol eeeee1  bbbbb2 monoamine oxidase eeeee2  (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of  bbbbb1 alcohol eeeee1  bbbbb2 MAO eeeee2 ) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence
CRP11	Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of  bbbbb1 histamine eeeee1  bbbbb2 IgE eeeee2 -mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue
CRP11	Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of  bbbbb1 histamine eeeee1  bbbbb2 histamine receptor 1 eeeee2  at the inflamed tissue
CRP11	The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun  bbbbb1 N eeeee1 -terminal kinases, and p38 mitogen-activated protein kinase,  bbbbb2 nuclear factor-κB eeeee2 , and caspase-1
CRP11	The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun  bbbbb1 N eeeee1 -terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and  bbbbb2 caspase-1 eeeee2 
CRP11	The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun  bbbbb1 N eeeee1  bbbbb2 c-Jun eeeee2  N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CRP11	The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun  bbbbb1 N eeeee1  bbbbb2 N-terminal kinases eeeee2 , and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CRP11	The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun  bbbbb1 N eeeee1  bbbbb2 cytokines eeeee2  was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CRP11	The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun  bbbbb1 N eeeee1 -terminal kinases, and  bbbbb2 p38 eeeee2  mitogen-activated protein kinase, nuclear factor-κB, and caspase-1
CRP11	The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun  bbbbb1 N eeeee1 -terminal kinases, and p38  bbbbb2 mitogen-activated protein kinase eeeee2 , nuclear factor-κB, and caspase-1
CRP11	Evaluation of the positive effects on insulin-resistance and β-cell measurements of  bbbbb1 vildagliptin eeeee1  bbbbb2 insulin eeeee2 -resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients
CRP11	Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to  bbbbb1 metformin eeeee1  bbbbb2 insulin eeeee2 -resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[ bbbbb1 Gly2 eeeee1 ]- bbbbb2 GLP-2 eeeee2  significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[ bbbbb1 Gly2 eeeee1 ]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of  bbbbb2 topoisomerase I eeeee2  inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[ bbbbb1 Gly2 eeeee1 ]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]- bbbbb2 GLP-2 eeeee2  significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor  bbbbb1 irinotecan hydrochloride eeeee1  bbbbb2 GLP-2 eeeee2  significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor  bbbbb1 irinotecan hydrochloride eeeee1  bbbbb2 GLP-2 eeeee2  analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor  bbbbb1 irinotecan hydrochloride eeeee1  or the antimetabolite 5-fluorouracil. h[Gly2]- bbbbb2 GLP-2 eeeee2  significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite  bbbbb1 5-fluorouracil eeeee1  bbbbb2 GLP-2 eeeee2  significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite  bbbbb1 5-fluorouracil eeeee1  bbbbb2 GLP-2 eeeee2  analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite  bbbbb1 5-fluorouracil eeeee1  bbbbb2 topoisomerase I eeeee2  inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite  bbbbb1 5-fluorouracil eeeee1 . h[Gly2]- bbbbb2 GLP-2 eeeee2  significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[ bbbbb1 Gly2 eeeee1  bbbbb2 GLP-2 eeeee2  significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[ bbbbb1 Gly2 eeeee1  bbbbb2 GLP-2 eeeee2  analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[ bbbbb1 Gly2 eeeee1  bbbbb2 topoisomerase I eeeee2  inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[Gly2]-GLP-2 significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil. h[ bbbbb1 Gly2 eeeee1 ]- bbbbb2 GLP-2 eeeee2  significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan
CRP11	Native GLP-1 stimulates insulin secretion in a  bbbbb1 glucose eeeee1 -dependent manner, as well as suppressing  bbbbb2 glucagon eeeee2  production and slowing gastric emptying
CRP11	Native GLP-1 stimulates insulin secretion in a  bbbbb1 glucose eeeee1  bbbbb2 GLP-1 eeeee2  stimulates insulin secretion in a glucose-dependent manner, as well as suppressing glucagon production and slowing gastric emptying
CRP11	Molecular mechanism regulating 24-hour rhythm of  bbbbb1 dopamine eeeee1  bbbbb2 dopamine d3 receptor eeeee2  expression in mouse ventral striatum
CRP11	The  bbbbb1 dopamine eeeee1  D3 receptor ( bbbbb2 DRD3 eeeee2 ) in the ventral striatum is thought to influence motivation and motor functions
CRP11	The  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D3 receptor eeeee2  (DRD3) in the ventral striatum is thought to influence motivation and motor functions
CRP11	The serum or  bbbbb1 dexamethasone eeeee1 -induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of REV-ERBα, suggesting that  bbbbb2 REV-ERBα eeeee2  functions as a regulator of DRD3 oscillations in the cellular autonomous clock
CRP11	The serum or  bbbbb1 dexamethasone eeeee1 -induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of REV-ERBα, suggesting that REV-ERBα functions as a regulator of  bbbbb2 DRD3 eeeee2  oscillations in the cellular autonomous clock
CRP11	The transcription of DRD3 was enhanced by the  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid-related orphan receptor α eeeee2  (RORα), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of RORα
CRP11	The transcription of DRD3 was enhanced by the  bbbbb1 retinoic acid eeeee1 -related orphan receptor α (RORα), and its activation was inhibited by the orphan receptor  bbbbb2 REV-ERBα eeeee2 , an endogenous antagonist of RORα
CRP11	The transcription of DRD3 was enhanced by the  bbbbb1 retinoic acid eeeee1 -related orphan receptor α (RORα), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of  bbbbb2 RORα eeeee2 
CRP11	The transcription of DRD3 was enhanced by the  bbbbb1 retinoic acid eeeee1 -related orphan receptor α (RORα), and its activation was inhibited by the  bbbbb2 orphan receptor eeeee2  REV-ERBα, an endogenous antagonist of RORα
CRP11	The transcription of DRD3 was enhanced by the  bbbbb1 retinoic acid eeeee1  bbbbb2 DRD3 eeeee2  was enhanced by the retinoic acid-related orphan receptor α (RORα), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of RORα
CRP11	The transcription of DRD3 was enhanced by the  bbbbb1 retinoic acid eeeee1 -related orphan receptor α ( bbbbb2 RORα eeeee2 ), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of RORα
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb1 adenosine eeeee1  bbbbb2 Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase) eeeee2 , 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb1 adenosine eeeee1  bbbbb2 nucleoside triphosphate diphosphohydrolase eeeee2 ), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb1 adenosine eeeee1  bbbbb2 NTPDase eeeee2  (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb1 adenosine eeeee1  bbbbb2 5'-nucleotidase eeeee2  and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb1 adenosine eeeee1  deaminase ( bbbbb2 ADA eeeee2 ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb1 adenosine eeeee1  bbbbb2 adenosine deaminase eeeee2  (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP ( bbbbb1 nucleotide eeeee1  bbbbb2 Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase) eeeee2 , 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP ( bbbbb1 nucleotide eeeee1  bbbbb2 nucleoside triphosphate diphosphohydrolase eeeee2 ), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP ( bbbbb1 nucleotide eeeee1  bbbbb2 NTPDase eeeee2  (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP ( bbbbb1 nucleotide eeeee1  pyrophosphatase/phosphodiesterase),  bbbbb2 5'-nucleotidase eeeee2  and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP ( bbbbb1 nucleotide eeeee1  pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase ( bbbbb2 ADA eeeee2 ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP ( bbbbb1 nucleotide eeeee1  pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb2 adenosine deaminase eeeee2  (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase ( bbbbb1 nucleoside triphosphate eeeee1  diphosphohydrolase),  bbbbb2 Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase) eeeee2 , 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase ( bbbbb1 nucleoside triphosphate eeeee1  bbbbb2 nucleoside triphosphate diphosphohydrolase eeeee2 ), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase ( bbbbb1 nucleoside triphosphate eeeee1  bbbbb2 NTPDase eeeee2  (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase ( bbbbb1 nucleoside triphosphate eeeee1  diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase),  bbbbb2 5'-nucleotidase eeeee2  and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase ( bbbbb1 nucleoside triphosphate eeeee1  diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase ( bbbbb2 ADA eeeee2 ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase ( bbbbb1 nucleoside triphosphate eeeee1  diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb2 adenosine deaminase eeeee2  (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of  bbbbb1 caffeic acid eeeee1  on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase),  bbbbb2 Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase) eeeee2 , 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of  bbbbb1 caffeic acid eeeee1  on ectonucleotidase activities such as NTPDase ( bbbbb2 nucleoside triphosphate diphosphohydrolase eeeee2 ), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of  bbbbb1 caffeic acid eeeee1  on ectonucleotidase activities such as  bbbbb2 NTPDase eeeee2  (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of  bbbbb1 caffeic acid eeeee1  on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase),  bbbbb2 5'-nucleotidase eeeee2  and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of  bbbbb1 caffeic acid eeeee1  on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase ( bbbbb2 ADA eeeee2 ) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	This study evaluated the effects of  bbbbb1 caffeic acid eeeee1  on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and  bbbbb2 adenosine deaminase eeeee2  (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation
CRP11	 bbbbb1 Tyrosine eeeee1  bbbbb2 Tyrosine kinase eeeee2  blockers: new hope for successful cancer therapy
CRP11	The following TK blockers for treatment of various human tumors are in clinical development: La bbbbb1 patinib  eeeee1  bbbbb2 patinib (Lapati eeeee2 nib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)
CRP11	During the last few years, thorough analysis of the mechanism underlying  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2 's activity led to novel cancer therapy using TKs blockers
CRP11	During the last few years, thorough analysis of the mechanism underlying  bbbbb1 tyrosine eeeee1  kinase's activity led to novel cancer therapy using  bbbbb2 TKs eeeee2  blockers
CRP11	Others kinase inhibitors used recently in cancer therapy include  bbbbb1 Dasatinib eeeee1  (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include  bbbbb1 Dasatinib eeeee1  (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include  bbbbb1 Dasatinib eeeee1  (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase,  bbbbb1 AMN107 eeeee1  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase,  bbbbb1 AMN107 eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase,  bbbbb1 AMN107 eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase,  bbbbb1 AMN107 eeeee1  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ( bbbbb1 Iressa eeeee1 ), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ( bbbbb1 Iressa eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib ( bbbbb1 Iressa eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ( bbbbb1 SU 11248 eeeee1 , Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ( bbbbb1 SU 11248 eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib ( bbbbb1 SU 11248 eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248,  bbbbb1 Sutent eeeee1 ) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248,  bbbbb1 Sutent eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248,  bbbbb1 Sutent eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and  bbbbb1 INNO-406 eeeee1  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and  bbbbb1 INNO-406 eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and  bbbbb1 INNO-406 eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and  bbbbb1 INNO-406 eeeee1  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase,  bbbbb1 Gefitinib eeeee1  (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase,  bbbbb1 Gefitinib eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase,  bbbbb1 Gefitinib eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and  bbbbb1 Sunitinib eeeee1  (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and  bbbbb1 Sunitinib eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and  bbbbb1 Sunitinib eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774,  bbbbb1 Tarceva eeeee1 ) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774,  bbbbb1 Tarceva eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774,  bbbbb1 Tarceva eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa),  bbbbb1 Erlotinib eeeee1  (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa),  bbbbb1 Erlotinib eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa),  bbbbb1 Erlotinib eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) specific for ABL  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib ( bbbbb1 BMS-354825 eeeee1 ) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ( bbbbb1 OSI-774 eeeee1 , Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for  bbbbb2 c-KIT eeeee2  kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ( bbbbb1 OSI-774 eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib ( bbbbb1 OSI-774 eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 ( bbbbb1 NS-187 eeeee1  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 ( bbbbb1 NS-187 eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 ( bbbbb1 NS-187 eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 ( bbbbb1 NS-187 eeeee1  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 ( bbbbb1 Nilotinib eeeee1  bbbbb2 kinase eeeee2 , AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 ( bbbbb1 Nilotinib eeeee1  bbbbb2 ABL eeeee2  non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 ( bbbbb1 Nilotinib eeeee1  bbbbb2 non-receptor cytoplasmic kinase eeeee2 , Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 ( bbbbb1 Nilotinib eeeee1  bbbbb2 VEGF receptor eeeee2  kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase
CRP11	 bbbbb1 Tyrosine eeeee1  bbbbb2 Tyrosine kinases eeeee2  (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth
CRP11	 bbbbb1 Tyrosine eeeee1  kinases ( bbbbb2 TKs eeeee2 ) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth
CRP11	Amdinocillin is a beta-amidino penicillanic acid derivative that binds specifically to  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 2 eeeee2 
CRP11	 bbbbb1 Penicillin eeeee1 -binding protein 2 is a murein-elongation initiating enzyme and penicillin-binding protein 3 is a septal  bbbbb2 murein eeeee2 -synthesizing enzyme
CRP11	 bbbbb1 Penicillin eeeee1  bbbbb2 Penicillin-binding protein 2 eeeee2  is a murein-elongation initiating enzyme and penicillin-binding protein 3 is a septal murein-synthesizing enzyme
CRP11	 bbbbb1 Penicillin eeeee1 -binding protein 2 is a murein-elongation initiating enzyme and  bbbbb2 penicillin-binding protein 3 eeeee2  is a septal murein-synthesizing enzyme
CRP11	 bbbbb1 Penicillin eeeee1 -binding protein 2 is a  bbbbb2 murein eeeee2 -elongation initiating enzyme and penicillin-binding protein 3 is a septal murein-synthesizing enzyme
CRP11	Penicillin-binding protein 2 is a murein-elongation initiating enzyme and  bbbbb1 penicillin eeeee1 -binding protein 3 is a septal  bbbbb2 murein eeeee2 -synthesizing enzyme
CRP11	Penicillin-binding protein 2 is a murein-elongation initiating enzyme and  bbbbb1 penicillin eeeee1  bbbbb2 Penicillin-binding protein 2 eeeee2  is a murein-elongation initiating enzyme and penicillin-binding protein 3 is a septal murein-synthesizing enzyme
CRP11	Penicillin-binding protein 2 is a murein-elongation initiating enzyme and  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 3 eeeee2  is a septal murein-synthesizing enzyme
CRP11	Penicillin-binding protein 2 is a murein-elongation initiating enzyme and  bbbbb1 penicillin eeeee1  bbbbb2 murein eeeee2 -elongation initiating enzyme and penicillin-binding protein 3 is a septal murein-synthesizing enzyme
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1A eeeee2 , which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and  bbbbb1 penicillin eeeee1  bbbbb2 peptidoglycan transpeptidase eeeee2 , and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1 eeeee2 , which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1Bs eeeee2 , a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and  bbbbb1 penicillin eeeee1 -binding protein 1A, which acts as a replacement for  bbbbb2 penicillin-binding protein 1Bs eeeee2 
CRP11	Selection of mutants has shown that there are three essential proteins:  bbbbb1 penicillin eeeee1 -binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and  bbbbb2 penicillin-binding protein 1A eeeee2 , which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins:  bbbbb1 penicillin eeeee1 -binding protein 1, which is divided into penicillin-binding protein 1Bs, a  bbbbb2 peptidoglycan transpeptidase eeeee2 , and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins:  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1 eeeee2 , which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins:  bbbbb1 penicillin eeeee1 -binding protein 1, which is divided into  bbbbb2 penicillin-binding protein 1Bs eeeee2 , a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins:  bbbbb1 penicillin eeeee1 -binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for  bbbbb2 penicillin-binding protein 1Bs eeeee2 
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1A eeeee2 , which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for  bbbbb1 penicillin eeeee1  bbbbb2 peptidoglycan transpeptidase eeeee2 , and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1 eeeee2 , which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1Bs eeeee2 , a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1Bs eeeee2 
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into  bbbbb1 penicillin eeeee1 -binding protein 1Bs, a peptidoglycan transpeptidase, and  bbbbb2 penicillin-binding protein 1A eeeee2 , which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into  bbbbb1 penicillin eeeee1 -binding protein 1Bs, a  bbbbb2 peptidoglycan transpeptidase eeeee2 , and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1 eeeee2 , which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1Bs eeeee2 , a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs
CRP11	Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into  bbbbb1 penicillin eeeee1 -binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for  bbbbb2 penicillin-binding protein 1Bs eeeee2 
CRP11	Six major proteins have been defined in the Enterobacteriaceae,  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding proteins 1 to 6 eeeee2 
CRP11	 bbbbb1 Penicillin eeeee1  bbbbb2 Penicillin-binding proteins 4, 5, and 6 eeeee2  are not essential for bacterial survival
CRP11	 bbbbb1 Penicillin eeeee1  bbbbb2 Penicillin-binding proteins eeeee2  and role of amdinocillin in causing bacterial cell death
CRP11	The compound is more beta-lactamase stable than ampicillin and has no major delay in entry into the periplasmic space as do some  bbbbb1 penicillins eeeee1  bbbbb2 beta-lactamase eeeee2  stable than ampicillin and has no major delay in entry into the periplasmic space as do some penicillins
CRP11	Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1Bs eeeee2  produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CRP11	Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 3 eeeee2  produces long filaments
CRP11	Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 2 eeeee2  produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CRP11	Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1Bs eeeee2  produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CRP11	Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to  bbbbb1 penicillin eeeee1 -binding protein 2 produces round cells, and binding to  bbbbb2 penicillin-binding protein 3 eeeee2  produces long filaments
CRP11	Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 2 eeeee2  produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CRP11	Binding of penicillins to  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding protein 1Bs eeeee2  produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CRP11	Binding of penicillins to  bbbbb1 penicillin eeeee1 -binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to  bbbbb2 penicillin-binding protein 3 eeeee2  produces long filaments
CRP11	Binding of penicillins to  bbbbb1 penicillin eeeee1 -binding protein 1Bs produces lysis, binding to  bbbbb2 penicillin-binding protein 2 eeeee2  produces round cells, and binding to penicillin-binding protein 3 produces long filaments
CRP11	These proteins have been designated  bbbbb1 penicillin eeeee1  bbbbb2 penicillin-binding proteins eeeee2 
CRP11	Repeated Low Dose Administration of the  bbbbb1 Monoacylglycerol eeeee1  Lipase Inhibitor JZL184 Retains  bbbbb2 CB1 eeeee2  Receptor Mediated Antinociceptive and Gastroprotective Effects
CRP11	Repeated Low Dose Administration of the  bbbbb1 Monoacylglycerol eeeee1  bbbbb2 Monoacylglycerol Lipase eeeee2  Inhibitor JZL184 Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects
CRP11	However, repeated administration of high dose  bbbbb1 JZL184 eeeee1  (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of  bbbbb2 cannabinoid receptor eeeee2  agonists, and CB(1) receptor downregulation and desensitization
CRP11	However, repeated administration of high dose  bbbbb1 JZL184 eeeee1  (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of cannabinoid receptor agonists, and  bbbbb2 CB(1) eeeee2  receptor downregulation and desensitization
CRP11	The  bbbbb1 monoacylglycerol eeeee1  lipase ( bbbbb2 MAGL eeeee2 ) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects
CRP11	The  bbbbb1 monoacylglycerol eeeee1  bbbbb2 monoacylglycerol lipase eeeee2  (MAGL) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects
CRP11	Results from R-PIA and N6-(S-phenylisopropyl)adenosine experiments showed nearly a 40-fold greater potency of R-vs. S-diastereoisomer, suggesting predominance of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A1 eeeee2  subtype
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb1 adenosine eeeee1  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb1 adenosine eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb1 adenosine eeeee1  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb1 adenosine eeeee1  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb1 adenosine eeeee1  agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in  bbbbb1 ethanol eeeee1  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in  bbbbb1 ethanol eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in  bbbbb1 ethanol eeeee1  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in  bbbbb1 ethanol eeeee1  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in  bbbbb1 ethanol eeeee1  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb1 adenosine eeeee1  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.  bbbbb1 Enprofylline eeeee1  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.  bbbbb1 Enprofylline eeeee1 , a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.  bbbbb1 Enprofylline eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.  bbbbb1 Enprofylline eeeee1  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.  bbbbb1 Enprofylline eeeee1 , a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb1 adenosine eeeee1  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb1 adenosine eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb1 adenosine eeeee1  antagonist but potent inhibitor of  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb1 adenosine eeeee1  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively,  bbbbb1 ethanol eeeee1 -induced motor incoordination, thereby suggesting a central mechanism of  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively,  bbbbb1 ethanol eeeee1 -induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively,  bbbbb1 ethanol eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively,  bbbbb1 ethanol eeeee1 -induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively,  bbbbb1 ethanol eeeee1 -induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively,  bbbbb1 ethanol eeeee1 -induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively,  bbbbb1 ethanol eeeee1 -induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb1 cyclic AMP eeeee1  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb1 cyclic AMP eeeee1  phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb1 cyclic AMP eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb1 cyclic AMP eeeee1  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb1 cyclic AMP eeeee1  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb1 cyclic AMP eeeee1  phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb1 cyclic AMP eeeee1  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of  bbbbb1 ethanol eeeee1  and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of  bbbbb1 ethanol eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of  bbbbb1 ethanol eeeee1  and confirmed our previous reports in which  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of  bbbbb1 ethanol eeeee1  and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of  bbbbb1 ethanol eeeee1  and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of  bbbbb1 ethanol eeeee1  and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb1 adenosine eeeee1  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb1 adenosine eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb1 adenosine eeeee1  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  interactions
CRP11	Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	 bbbbb1 Adenosine eeeee1  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of  bbbbb2 adenosine eeeee2  modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	 bbbbb1 Adenosine eeeee1  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain  bbbbb2 adenosine receptor eeeee2  mechanism(s) in ethanol-adenosine interactions
CRP11	 bbbbb1 Adenosine eeeee1  bbbbb2 Adenosine eeeee2  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	 bbbbb1 Adenosine eeeee1  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which  bbbbb2 adenosine eeeee2  agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	 bbbbb1 Adenosine eeeee1  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of  bbbbb2 cyclic AMP phosphodiesterase eeeee2 , did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	 bbbbb1 Adenosine eeeee1  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol- bbbbb2 adenosine eeeee2  interactions
CRP11	 bbbbb1 Adenosine eeeee1  agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak  bbbbb2 adenosine eeeee2  antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as  bbbbb1 enprofylline eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between  bbbbb1 ethanol eeeee1  and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb2 adenosine eeeee2  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists,  bbbbb1 theophylline eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine ( bbbbb1 R-PIA eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine,  bbbbb1 5'-(N-cyclopropyl)-carboxamidoadenosine eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on  bbbbb1 ethanol eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on  bbbbb1 ethanol eeeee1  bbbbb2 adenosine eeeee2  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists,  bbbbb1 N6-(R-phenylisopropyl)adenosine eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and  bbbbb1 adenosine eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and  bbbbb1 adenosine eeeee1  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.  bbbbb2 adenosine eeeee2  agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and  bbbbb1 8-p-(sulfophenyl)theophylline eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA),  bbbbb1 N6-(S-phenylisopropyl)adenosine eeeee1  bbbbb2 adenosine eeeee2  reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod
CRP11	However, 5'-(N-cyclopropyl)-carboxamidoadenosine data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of  bbbbb1 adenosine eeeee1  bbbbb2 adenosine A2 eeeee2 
CRP11	No effect of ethanol on blood or brain levels of [3H]R-PIA was noted and sufficient amount of the latter entered the brain to suggest adenosine receptor activation  bbbbb1 adequate  eeeee1  bbbbb2 adequate  eeeee2 to produce behavioral interaction with ethanol
CRP11	No effect of ethanol on blood or brain leve bbbbb1 ls of [3H eeeee1 ]R-PIA was noted and sufficient amount of the latter entered the brain to suggest adenosine receptor activation  bbbbb2 adequate  eeeee2 to produce behavioral interaction with ethanol
CRP11	PCR and immunofluorescence/confocal microscopy analysis showed that Jurkat T cells express the NR1 and NR2B subunits of the  bbbbb1 NMDA eeeee1  bbbbb2 NR2B eeeee2  subunits of the NMDA receptors
CRP11	PCR and immunofluorescence/confocal microscopy analysis showed that Jurkat T cells express the NR1 and NR2B subunits of the  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2 
CRP11	PCR and immunofluorescence/confocal microscopy analysis showed that Jurkat T cells express the NR1 and NR2B subunits of the  bbbbb1 NMDA eeeee1  bbbbb2 NR1 eeeee2  and NR2B subunits of the NMDA receptors
CRP11	Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihy bbbbb1 dro- eeeee1 5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phos bbbbb2 phonopentan eeeee2 oic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin
CRP11	Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihy bbbbb1 dro- eeeee1  bbbbb2 dro-5H-dibenzo eeeee2 [a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin
CRP11	Stimulation of  bbbbb1 N-methyl-D-aspartate eeeee1  receptors modulates Jurkat T cell growth and adhesion to  bbbbb2 fibronectin eeeee2 
CRP11	Stimulation of  bbbbb1 N-methyl-D-aspartate eeeee1  bbbbb2 N-methyl-D-aspartate receptors eeeee2  modulates Jurkat T cell growth and adhesion to fibronectin
CRP11	However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity bbbbb1  eeeee1  bbbbb2 membra eeeee2 ne flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity
CRP11	However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity bbbbb1  eeeee1  bbbbb2 rine,  eeeee2 which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity
CRP11	However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 ac bbbbb1 ti eeeee1 vity bbbbb2  eeeee2 
CRP11	However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity bbbbb1  eeeee1  bbbbb2 membra eeeee2 ne flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity
CRP11	However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity bbbbb1  eeeee1  bbbbb2 rine,  eeeee2 which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity
CRP11	Most modifications of the PS headgroup structure decrease recognition by the plasma membrane  bbbbb1 PS eeeee1  bbbbb2 PS flippase eeeee2 
CRP11	Most modifications of the  bbbbb1 PS eeeee1  headgroup structure decrease recognition by the plasma membrane  bbbbb2 PS flippase eeeee2 
CRP11	Similar to the plasma membrane  bbbbb1 PS eeeee1  transporter,  bbbbb2 Atp8a1 eeeee2  is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer
CRP11	Similar to the plasma membrane  bbbbb1 PS eeeee1  bbbbb2 plasma membrane PS transporter eeeee2 , Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer
CRP11	A candidate  bbbbb1 PS eeeee1  flippase ATP8A1 (ATPase II), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the  bbbbb2 yeast protein Drs2 eeeee2 , which has been linked to ribosomal assembly, the formation of Golgi-coated vesicles, and the maintenance of PS asymmetry
CRP11	A candidate  bbbbb1 PS eeeee1  flippase ATP8A1 ( bbbbb2 ATPase II eeeee2 ), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the yeast protein Drs2, which has been linked to ribosomal assembly, the formation of Golgi-coated vesicles, and the maintenance of PS asymmetry
CRP11	A candidate  bbbbb1 PS eeeee1  bbbbb2 PS flippase ATP8A1 eeeee2  (ATPase II), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the yeast protein Drs2, which has been linked to ribosomal assembly, the formation of Golgi-coated vesicles, and the maintenance of PS asymmetry
CRP11	To determine if ATP8A1 has biochemical characteristics consistent with a  bbbbb1 PS eeeee1  bbbbb2 PS flippase eeeee2 , a murine homologue of this enzyme was expressed in insect cells and purified
CRP11	To determine if ATP8A1 has biochemical characteristics consistent with a  bbbbb1 PS eeeee1  bbbbb2 ATP8A1 eeeee2  has biochemical characteristics consistent with a PS flippase, a murine homologue of this enzyme was expressed in insect cells and purified
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist  bbbbb1 DPN eeeee1  were compared to Sham mice, and mice lacking either  bbbbb2 ERα eeeee2  (αERKO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist  bbbbb1 DPN eeeee1  were compared to Sham mice, and mice lacking either ERα ( bbbbb2 αER eeeee2 KO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist  bbbbb1 DPN eeeee1  were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ ( bbbbb2 βER eeeee2 KO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist  bbbbb1 DPN eeeee1  were compared to Sham mice, and mice lacking either ERα (αERKO) or  bbbbb2 ERβ eeeee2  (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist  bbbbb1 DPN eeeee1  bbbbb2 ERα eeeee2 -selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist  bbbbb1 PPT eeeee1  or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either  bbbbb2 ERα eeeee2  (αERKO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist  bbbbb1 PPT eeeee1  or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα ( bbbbb2 αER eeeee2 KO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist  bbbbb1 PPT eeeee1  or the  bbbbb2 ERβ eeeee2 -selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist  bbbbb1 PPT eeeee1  or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ ( bbbbb2 βER eeeee2 KO) were compared to WT littermates
CRP11	To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist  bbbbb1 PPT eeeee1  or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or  bbbbb2 ERβ eeeee2  (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of  bbbbb1 estradiol eeeee1  effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either  bbbbb2 ERα eeeee2  (αERKO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of  bbbbb1 estradiol eeeee1  effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα ( bbbbb2 αER eeeee2 KO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of  bbbbb1 estradiol eeeee1  effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the  bbbbb2 ERβ eeeee2 -selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of  bbbbb1 estradiol eeeee1  effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ ( bbbbb2 βER eeeee2 KO) were compared to WT littermates
CRP11	To examine receptor mediation of  bbbbb1 estradiol eeeee1  effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or  bbbbb2 ERβ eeeee2  (βERKO) were compared to WT littermates
CRP11	To examine receptor mediation of  bbbbb1 estradiol eeeee1  effects, Ovx mice replaced for 2 days with either the  bbbbb2 ERα eeeee2 -selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates
CRP11	Estradiol replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor alpha eeeee2 
CRP11	 bbbbb1 Estradiol eeeee1  replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through  bbbbb2 estrogen receptor alpha eeeee2 
CRP11	Western blot analysis of cells incubated with  bbbbb1 imatinib eeeee1  demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not  bbbbb2 Her2 eeeee2 /ErbB2
CRP11	Western blot analysis of cells incubated with  bbbbb1 imatinib eeeee1  demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and  bbbbb2 EGFR eeeee2 , but not Her2/ErbB2
CRP11	Western blot analysis of cells incubated with  bbbbb1 imatinib eeeee1  demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of  bbbbb2 mitogen-activated protein/extracellular signal-regulated kinase kinase 1 eeeee2  (MEK1) and EGFR, but not Her2/ErbB2
CRP11	Western blot analysis of cells incubated with  bbbbb1 imatinib eeeee1  demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 ( bbbbb2 MEK1 eeeee2 ) and EGFR, but not Her2/ErbB2
CRP11	Western blot analysis of cells incubated with  bbbbb1 imatinib eeeee1  demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ bbbbb2 ErbB2 eeeee2 
CRP11	An in vitro kinase assay showed that  bbbbb1 imatinib eeeee1  bbbbb2 kinase eeeee2  assay showed that imatinib did not directly affect EGFR kinase activity, suggesting involvement of EGFR-activating molecules
CRP11	Imatinib mesylate is a  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases
CRP11	Imatinib mesylate is a  bbbbb1 tyrosine eeeee1  kinase inhibitor of the ABL,  bbbbb2 platelet-derived growth factor receptor eeeee2  (PDGFR), and c-kit kinases
CRP11	Imatinib mesylate is a  bbbbb1 tyrosine eeeee1  kinase inhibitor of the  bbbbb2 ABL eeeee2 , platelet-derived growth factor receptor (PDGFR), and c-kit kinases
CRP11	Imatinib mesylate is a  bbbbb1 tyrosine eeeee1  kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit  bbbbb2 kinases eeeee2 
CRP11	Imatinib mesylate is a  bbbbb1 tyrosine eeeee1  kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and  bbbbb2 c-kit eeeee2  kinases
CRP11	Imatinib mesylate is a  bbbbb1 tyrosine eeeee1  kinase inhibitor of the ABL, platelet-derived growth factor receptor ( bbbbb2 PDGFR eeeee2 ), and c-kit kinases
CRP11	Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced  bbbbb1 imatinib eeeee1  bbbbb2 HB-EGF eeeee2 ), and to a lesser extent transforming growth factor-alpha, reduced imatinib-mediated mitogen activated protein kinase (MAPK) activation
CRP11	Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced  bbbbb1 imatinib eeeee1  bbbbb2 heparin-binding epidermal growth factor-like growth factor eeeee2  (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced imatinib-mediated mitogen activated protein kinase (MAPK) activation
CRP11	Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced  bbbbb1 imatinib eeeee1  bbbbb2 transforming growth factor-alpha eeeee2 , reduced imatinib-mediated mitogen activated protein kinase (MAPK) activation
CRP11	 bbbbb1 Imatinib eeeee1 -induced changes were blocked with the  bbbbb2 EGFR eeeee2  antagonist cetuximab, which suggested direct involvement of EGFR in this process
CRP11	Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II receptor type 1 eeeee2  antagonist, is approved in many countries worldwide for the treatment of hypertension
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the  bbbbb1 serotonin eeeee1  bbbbb2 noradrenaline transporter eeeee2  (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the  bbbbb1 serotonin eeeee1  transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory  bbbbb2 cytokine eeeee2  phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the  bbbbb1 noradrenaline eeeee1  bbbbb2 noradrenaline transporter eeeee2  (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the  bbbbb1 noradrenaline eeeee1  transporter (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory  bbbbb2 cytokine eeeee2  phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the  bbbbb1 noradrenaline eeeee1  transporter (reboxetine and desipramine), or the  bbbbb2 serotonin transporter eeeee2  (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter (fluoxetine and  bbbbb1 clomipramine eeeee1  bbbbb2 noradrenaline transporter eeeee2  (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter (fluoxetine and  bbbbb1 clomipramine eeeee1 ) were examined in terms of their ability to promote an anti-inflammatory  bbbbb2 cytokine eeeee2  phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and  bbbbb1 desipramine eeeee1 ), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory  bbbbb2 cytokine eeeee2  phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and  bbbbb1 desipramine eeeee1 ), or the  bbbbb2 serotonin transporter eeeee2  (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter ( bbbbb1 reboxetine eeeee1  and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory  bbbbb2 cytokine eeeee2  phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter ( bbbbb1 reboxetine eeeee1  and desipramine), or the  bbbbb2 serotonin transporter eeeee2  (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter ( bbbbb1 fluoxetine eeeee1  bbbbb2 noradrenaline transporter eeeee2  (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood
CRP11	In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter ( bbbbb1 fluoxetine eeeee1  and clomipramine) were examined in terms of their ability to promote an anti-inflammatory  bbbbb2 cytokine eeeee2  phenotype in human blood
CRP11	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of  bbbbb1 monoamine eeeee1  bbbbb2 cytokine eeeee2  interferon-gamma, independent of monoamine transporter blockade
CRP11	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of  bbbbb1 monoamine eeeee1  bbbbb2 monoamine transporter eeeee2  blockade
CRP11	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of  bbbbb1 monoamine eeeee1  bbbbb2 interferon-gamma eeeee2 , independent of monoamine transporter blockade
CRP11	In addition, we examined the ability of trimipramine; a tricyclic antidepressant that is devoid of  bbbbb1 monoamine eeeee1  reuptake inhibitory properties on  bbbbb2 cytokine eeeee2  production
CRP11	In addition, we examined the ability of  bbbbb1 trimipramine eeeee1 ; a tricyclic antidepressant that is devoid of monoamine reuptake inhibitory properties on  bbbbb2 cytokine eeeee2  production
CRP11	In addition, we examined the ability of trimipramine; a  bbbbb1 tricyclic eeeee1  antidepressant that is devoid of monoamine reuptake inhibitory properties on  bbbbb2 cytokine eeeee2  production
CRP11	Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived IL-10 production, with significant effects elicited by the  bbbbb1 noradrenaline eeeee1  bbbbb2 IL-10 eeeee2  production, with significant effects elicited by the noradrenaline reuptake inhibitors reboxetine and desipramine
CRP11	All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for serotonin or  bbbbb1 noradrenaline eeeee1  bbbbb2 serotonin or noradrenaline transporters eeeee2 
CRP11	All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for serotonin or  bbbbb1 noradrenaline eeeee1  bbbbb2 IFN-gamma eeeee2  production in the 10-50 microM concentration range, irrespective of their preference for serotonin or noradrenaline transporters
CRP11	All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for  bbbbb1 serotonin eeeee1  bbbbb2 serotonin or noradrenaline transporters eeeee2 
CRP11	All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for  bbbbb1 serotonin eeeee1  bbbbb2 IFN-gamma eeeee2  production in the 10-50 microM concentration range, irrespective of their preference for serotonin or noradrenaline transporters
CRP11	The fact that trimipramine also suppressed IFN-gamma production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of  bbbbb1 monoamine eeeee1  bbbbb2 IFN-gamma eeeee2  production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake
CRP11	The goal of the present study was to compare the effects of three potent reference renin inhibitors (remikiren, CGP 38560A, and enalkiren) in  bbbbb1 sodium eeeee1  bbbbb2 renin eeeee2  inhibitors (remikiren, CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys
CRP11	Extracellular Cbl (protein bound and free) and intracellular  bbbbb1 Cbl eeeee1  (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II (transcobalamin,  bbbbb2 TC eeeee2 )
CRP11	Extracellular Cbl (protein bound and free) and intracellular  bbbbb1 Cbl eeeee1  (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to  bbbbb2 transcobalamin II eeeee2  (transcobalamin, TC)
CRP11	Extracellular Cbl (protein bound and free) and intracellular  bbbbb1 Cbl eeeee1  (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II ( bbbbb2 transcobalamin eeeee2 , TC)
CRP11	Extracellular  bbbbb1 Cbl eeeee1  (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II (transcobalamin,  bbbbb2 TC eeeee2 )
CRP11	Extracellular  bbbbb1 Cbl eeeee1  (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to  bbbbb2 transcobalamin II eeeee2  (transcobalamin, TC)
CRP11	Extracellular  bbbbb1 Cbl eeeee1  (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II ( bbbbb2 transcobalamin eeeee2 , TC)
CRP11	The major form of Cbl associated with the two enzymes was OH-Cbl bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The major form of Cbl associated with the two enzymes was OH-Cbl bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (MS) and  bbbbb1 methylmalonyl-CoA eeeee1  bbbbb2 MS eeeee2 ) and methylmalonyl-CoA mutase (MU) activity
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (MS) and  bbbbb1 methylmalonyl-CoA eeeee1  bbbbb2 methylmalonyl-CoA mutase eeeee2  (MU) activity
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (MS) and  bbbbb1 methylmalonyl-CoA eeeee1  bbbbb2 methionine synthase eeeee2  (MS) and methylmalonyl-CoA mutase (MU) activity
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (MS) and  bbbbb1 methylmalonyl-CoA eeeee1  mutase ( bbbbb2 MU eeeee2 ) activity
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with  bbbbb1 methionine eeeee1  synthase ( bbbbb2 MS eeeee2 ) and methylmalonyl-CoA mutase (MU) activity
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with  bbbbb1 methionine eeeee1  synthase (MS) and  bbbbb2 methylmalonyl-CoA mutase eeeee2  (MU) activity
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase eeeee2  (MS) and methylmalonyl-CoA mutase (MU) activity
CRP11	Intracellular protein-bound [57Co]Cbl fractionated with  bbbbb1 methionine eeeee1  synthase (MS) and methylmalonyl-CoA mutase ( bbbbb2 MU eeeee2 ) activity
CRP11	As expected, cocaine patients scored significantly higher on total scores of impulsivity, aggression, and sensation seeking compared t bbbbb1 o contr eeeee1  bbbbb2 ty,  eeeee2 aggression, and sensation seeking compared to controls
CRP11	Considerable evidence indicates that serotonergic mechanisms, particularly the  bbbbb1 serotonin eeeee1  transporter ( bbbbb2 5HTT eeeee2 ), may mediate central effects of cocaine and may also be involved in impulsive and aggressive behavior
CRP11	Considerable evidence indicates that serotonergic mechanisms, particularly the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  (5HTT), may mediate central effects of cocaine and may also be involved in impulsive and aggressive behavior
CRP11	Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among  bbbbb1 cocaine eeeee1  bbbbb2 5HTT eeeee2  gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among cocaine patients
CRP11	Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among  bbbbb1 cocaine eeeee1  bbbbb2 5HTTLPR eeeee2 ) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among cocaine patients
CRP11	Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among  bbbbb1 cocaine eeeee1  bbbbb2 VNTR eeeee2 ) marker among cocaine patients
CRP11	Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among  bbbbb1 cocaine eeeee1  bbbbb2 variable-number-tandem-repeat eeeee2  (VNTR) marker among cocaine patients
CRP11	 bbbbb1 Serotonin eeeee1  bbbbb2 Serotonin transporter eeeee2  polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals
CRP11	Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American  bbbbb1 cocaine eeeee1  bbbbb2 Serotonin transporter eeeee2  polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals
CRP11	We investigated whether polymorphisms in the 5HTT gene were related to traits of impulsivity, sensation seeking, and aggression among  bbbbb1 cocaine eeeee1  bbbbb2 5HTT eeeee2  gene were related to traits of impulsivity, sensation seeking, and aggression among cocaine abusers
CRP11	Metabolites of the analogue  bbbbb1 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin eeeee1  bbbbb2 oxytocin eeeee2  (carbetocin) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated
CRP11	Metabolites of the analogue 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin ( bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin eeeee2  (carbetocin) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated
CRP11	 bbbbb1 Oxytocin eeeee1  bbbbb2 Oxytocin receptor eeeee2  binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation
CRP11	Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial  bbbbb1 oxytocin eeeee1  receptor of a similar magnitude as  bbbbb2 oxytocin eeeee2 
CRP11	Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  of a similar magnitude as oxytocin
CRP11	Both carbetocin,  bbbbb1 carbetocin eeeee1  metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as  bbbbb2 oxytocin eeeee2 
CRP11	Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 
CRP11	Both carbetocin, carbetocin metabolite I and  bbbbb1 carbetocin eeeee1  metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as  bbbbb2 oxytocin eeeee2 
CRP11	Both  bbbbb1 carbetocin eeeee1 , carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as  bbbbb2 oxytocin eeeee2 
CRP11	However, maximal contractile effect of carbetocin was approximately 50% lower than that of  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  (2.70 +/- 0.12 g compared to 5.22 +/- 0.26 g) and EC50 was approximately ten times higher (48.0 +/- 8.20 nM compared to 5.62 +/- 1.22 nM)
CRP11	However, maximal contractile effect of  bbbbb1 carbetocin eeeee1  was approximately 50% lower than that of  bbbbb2 oxytocin eeeee2  (2.70 +/- 0.12 g compared to 5.22 +/- 0.26 g) and EC50 was approximately ten times higher (48.0 +/- 8.20 nM compared to 5.62 +/- 1.22 nM)
CRP11	All three analogues bound to the myometrial  bbbbb1 vasopressin eeeee1  V1 receptor, albeit with much lower affinities than to the  bbbbb2 oxytocin receptor eeeee2 
CRP11	All three analogues bound to the myometrial  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V1 receptor eeeee2 , albeit with much lower affinities than to the oxytocin receptor
CRP11	All three analogues bound to the myometrial vasopressin V1 receptor, albeit with much lower affinities than to the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2 
CRP11	All three analogues bound to the myometrial vasopressin V1 receptor, albeit with much lower affinities than to the  bbbbb1 oxytocin eeeee1  bbbbb2 vasopressin V1 receptor eeeee2 , albeit with much lower affinities than to the oxytocin receptor
CRP11	All three compounds displayed antagonistic properties against  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)
CRP11	Carbetocin metabolite II showed the bbbbb1  weakest bi eeeee1  bbbbb2  weakest binding affini eeeee2 ty of 33.7 +/- 7.34 nM compared to 7.24 +/- 0.29 nM for carbetocin and 9.89 + 2.80 nM for carbetocin metabolite I
CRP11	These results indicate that carbetocin is a partial agonist/antagonist to the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists
CRP11	Carbetocin was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of inositol phosphates, as is the case for  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 
CRP11	 bbbbb1 Carbetocin eeeee1  was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of inositol phosphates, as is the case for  bbbbb2 oxytocin eeeee2 
CRP11	Carbetocin was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of  bbbbb1 inositol phosphates eeeee1 , as is the case for  bbbbb2 oxytocin eeeee2 
CRP11	To determine the expression and activation status of TGF-beta1 in chemically induced tumors, 6-wk-old A/J mice were injected intraperitoneally with either azoxymethane ( bbbbb1 AOM eeeee1  bbbbb2 TGF-beta1 eeeee2  in chemically induced tumors, 6-wk-old A/J mice were injected intraperitoneally with either azoxymethane (AOM) (10 mg/kg body weight, once a week for 6 wk) or normal saline solution, and colon tumors were isolated 24 wk following the last injection
CRP11	To determine the expression and activation status of TGF-beta1 in chemically induced tumors, 6-wk-old A/J mice were injected intraperitoneally with either  bbbbb1 azoxymethane eeeee1  bbbbb2 TGF-beta1 eeeee2  in chemically induced tumors, 6-wk-old A/J mice were injected intraperitoneally with either azoxymethane (AOM) (10 mg/kg body weight, once a week for 6 wk) or normal saline solution, and colon tumors were isolated 24 wk following the last injection
CRP11	With a fluorogenic peptide substrate for  bbbbb1 serine eeeee1  proteases, a deficiency in  bbbbb2 plasmin eeeee2  activity was found in the tumors
CRP11	With a fluorogenic peptide substrate for  bbbbb1 serine eeeee1  bbbbb2 serine proteases eeeee2 , a deficiency in plasmin activity was found in the tumors
CRP11	To gain further insight into the functionality of the TGF-beta1 pathway, cDNA microarrays were performed and the expression levels of a panel of 21 TGF-beta1-specific target genes were determined in  bbbbb1 AOM eeeee1  bbbbb2 TGF-beta1 eeeee2  pathway, cDNA microarrays were performed and the expression levels of a panel of 21 TGF-beta1-specific target genes were determined in AOM-induced tumors that overexpress the ligand
CRP11	To gain further insight into the functionality of the TGF-beta1 pathway, cDNA microarrays were performed and the expression levels of a panel of 21 TGF-beta1-specific target genes were determined in  bbbbb1 AOM eeeee1  bbbbb2 TGF-beta1 eeeee2 -specific target genes were determined in AOM-induced tumors that overexpress the ligand
CRP11	Effect of  bbbbb1 cyproheptadine eeeee1  on serum  bbbbb2 leptin eeeee2  levels
CRP11	Although both leptin and  bbbbb1 cyproheptadine eeeee1  bbbbb2 leptin eeeee2  and cyproheptadine are effective in controlling appetite, their interaction has not been addressed in clinical studies
CRP11	Recent studies have demonstrated the importance of the nitric oxide/cGMP/ bbbbb1 cAMP eeeee1 -responsive element-binding protein ( bbbbb2 CREB eeeee2 ) pathway to the process of learning and memory
CRP11	Recent studies have demonstrated the importance of the nitric oxide/cGMP/ bbbbb1 cAMP eeeee1  bbbbb2 cAMP-responsive element-binding protein eeeee2  (CREB) pathway to the process of learning and memory
CRP11	Recent studies have demonstrated the importance of the nitric oxide/ bbbbb1 cGMP eeeee1 /cAMP-responsive element-binding protein ( bbbbb2 CREB eeeee2 ) pathway to the process of learning and memory
CRP11	Recent studies have demonstrated the importance of the nitric oxide/ bbbbb1 cGMP eeeee1 / bbbbb2 cAMP-responsive element-binding protein eeeee2  (CREB) pathway to the process of learning and memory
CRP11	Recent studies have demonstrated the importance of the  bbbbb1 nitric oxide eeeee1 /cGMP/cAMP-responsive element-binding protein ( bbbbb2 CREB eeeee2 ) pathway to the process of learning and memory
CRP11	Recent studies have demonstrated the importance of the  bbbbb1 nitric oxide eeeee1 /cGMP/ bbbbb2 cAMP-responsive element-binding protein eeeee2  (CREB) pathway to the process of learning and memory
CRP11	Effect of  bbbbb1 amrinone eeeee1  on  bbbbb2 tumor necrosis factor eeeee2  production in endotoxic shock
CRP11	Abrupt remo bbbbb1 val of a eeeee1 mrinone or  bbbbb2 pentoxifylline fr eeeee2 om the culture medium prior to LPS stimulation, however, caused significantly augmented TNF production
CRP11	We further demonstrate that bioreductive activation of  bbbbb1 MMC eeeee1  is catalysed by a unique cytosolic activity which is related but distinct from  bbbbb2 NQO1 eeeee2 
CRP11	Among the various enzymes, dicoumarol inhibitable cytosolic  bbbbb1 NAD(P)H eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase1 eeeee2  (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity
CRP11	Among the various enzymes, dicoumarol inhibitable cytosolic  bbbbb1 NAD(P)H eeeee1 :quinone oxidoreductase1 ( bbbbb2 NQO1 eeeee2 ) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity
CRP11	Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H: bbbbb1 quinone eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase1 eeeee2  (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity
CRP11	Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H: bbbbb1 quinone eeeee1  oxidoreductase1 ( bbbbb2 NQO1 eeeee2 ) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity
CRP11	The unique cytosolic activity that activate bbbbb1 d MMC in c eeeee1 ytosolic fractions of liver and  bbbbb2 colo eeeee2 n tissues of NQO1-/- mice was designated as cytosolic MMC reductase
CRP11	The cytosolic fractions from liver and colon tissues of NQO1-/- mice showed similar amounts of DNA cross-linking upon exposure to  bbbbb1 MMC eeeee1  bbbbb2 NQO1 eeeee2 -/- mice showed similar amounts of DNA cross-linking upon exposure to MMC, as observed in NQO1+/+ mice
CRP11	Furthermore, there is a high degree of correlation between binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the  bbbbb1 LEV eeeee1  bbbbb2 SV2A eeeee2  in fibroblasts and to the LEV-binding site in brain
CRP11	LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for  bbbbb1 LEV eeeee1  bbbbb2 SV2A eeeee2  expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding
CRP11	 bbbbb1 LEV eeeee1  and related compounds bind to SV2A expressed in fibroblasts, indicating that  bbbbb2 SV2A eeeee2  is sufficient for LEV binding
CRP11	Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated  bbbbb1 LEV eeeee1  derivative, indicating that  bbbbb2 SV2A eeeee2  is necessary for LEV binding
CRP11	Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated  bbbbb1 LEV eeeee1  bbbbb2 SV2A eeeee2  do not bind a tritiated LEV derivative, indicating that SV2A is necessary for LEV binding
CRP11	Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that SV2A is necessary for  bbbbb1 LEV eeeee1  bbbbb2 SV2A eeeee2  do not bind a tritiated LEV derivative, indicating that SV2A is necessary for LEV binding
CRP11	In addition, activation of protein kinase C and increases in intracellular  bbbbb1 cAMP eeeee1  bbbbb2 protein kinase C eeeee2  and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  bbbbb2 globulin eeeee2  containing antibodies against CD2, CD7 and CD11a all increase ChAT activity, ACh synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  bbbbb2 CD2 eeeee2 , CD7 and CD11a all increase ChAT activity, ACh synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  bbbbb2 CD11a eeeee2  all increase ChAT activity, ACh synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  synthesis and release, and expression of  bbbbb2 ChAT eeeee2  and M(5) mAChR mRNAs in T cells
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  bbbbb2 ChAT eeeee2  activity, ACh synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  bbbbb2 CD11a eeeee2  monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity, ACh synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  synthesis and release, and expression of ChAT and  bbbbb2 M(5) mAChR eeeee2  mRNAs in T cells
CRP11	Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity,  bbbbb1 ACh eeeee1  bbbbb2 CD7 eeeee2  and CD11a all increase ChAT activity, ACh synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells
CRP11	The  bbbbb1 cholesterol eeeee1 -lowering drug simvastatin inhibits  bbbbb2 LFA-1 eeeee2  signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation
CRP11	The  bbbbb1 cholesterol eeeee1 -lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on  bbbbb2 CD11a eeeee2  (LFA-1 alpha chain), which leads to immunomodulation
CRP11	The  bbbbb1 cholesterol eeeee1 -lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a ( bbbbb2 LFA-1 alpha eeeee2  chain), which leads to immunomodulation
CRP11	Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of  bbbbb1 ACh eeeee1  bbbbb2 phytohemagglutinin eeeee2 , which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of ACh and up-regulates expression of ChAT and M(5) mAChR mRNAs
CRP11	Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of  bbbbb1 ACh eeeee1  and up-regulates expression of  bbbbb2 ChAT eeeee2  and M(5) mAChR mRNAs
CRP11	Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of  bbbbb1 ACh eeeee1  and up-regulates expression of ChAT and  bbbbb2 M(5) mAChR eeeee2  mRNAs
CRP11	Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of  bbbbb1 ACh eeeee1  bbbbb2 CD3 eeeee2  complex, enhances the synthesis and release of ACh and up-regulates expression of ChAT and M(5) mAChR mRNAs
CRP11	Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of  bbbbb1 ACh eeeee1  bbbbb2 T cell receptor eeeee2 /CD3 complex, enhances the synthesis and release of ACh and up-regulates expression of ChAT and M(5) mAChR mRNAs
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ( bbbbb1 ACh eeeee1 ); choline acetyltransferase (ChAT), its synthesizing enzyme; and both  bbbbb2 muscarinic and nicotinic ACh receptors eeeee2  (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ( bbbbb1 ACh eeeee1 ); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and  bbbbb2 nAChRs eeeee2 , respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine ( bbbbb1 ACh eeeee1 ); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors ( bbbbb2 mAChRs eeeee2  and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic  bbbbb1 ACh eeeee1  bbbbb2 ChAT eeeee2 ), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic  bbbbb1 ACh eeeee1  bbbbb2 muscarinic and nicotinic ACh receptors eeeee2  (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic  bbbbb1 ACh eeeee1  receptors (mAChRs and  bbbbb2 nAChRs eeeee2 , respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic  bbbbb1 ACh eeeee1  bbbbb2 choline acetyltransferase eeeee2  (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic  bbbbb1 ACh eeeee1  receptors ( bbbbb2 mAChRs eeeee2  and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including  bbbbb1 acetylcholine eeeee1  (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both  bbbbb2 muscarinic and nicotinic ACh receptors eeeee2  (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including  bbbbb1 acetylcholine eeeee1  (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and  bbbbb2 nAChRs eeeee2 , respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including  bbbbb1 acetylcholine eeeee1  (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors ( bbbbb2 mAChRs eeeee2  and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh);  bbbbb1 choline eeeee1  acetyltransferase ( bbbbb2 ChAT eeeee2 ), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh);  bbbbb1 choline eeeee1  acetyltransferase (ChAT), its synthesizing enzyme; and both  bbbbb2 muscarinic and nicotinic ACh receptors eeeee2  (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh);  bbbbb1 choline eeeee1  acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and  bbbbb2 nAChRs eeeee2 , respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh);  bbbbb1 choline eeeee1  bbbbb2 choline acetyltransferase eeeee2  (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)
CRP11	Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh);  bbbbb1 choline eeeee1  acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors ( bbbbb2 mAChRs eeeee2  and nAChRs, respectively)
CRP11	Therefore, we studied whether GLT had potential for inhibition or induction of cytochrome P450 (CYP) and an influence on the action of  bbbbb1 warfarin eeeee1  bbbbb2 cytochrome P450 eeeee2  (CYP) and an influence on the action of warfarin
CRP11	Therefore, we studied whether GLT had potential for inhibition or induction of cytochrome P450 (CYP) and an influence on the action of  bbbbb1 warfarin eeeee1  bbbbb2 CYP eeeee2 ) and an influence on the action of warfarin
CRP11	In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of CYP activities and of  bbbbb1 midazolam eeeee1  bbbbb2 CYP eeeee2  activities and of midazolam 1'-hydroxylation than grapefruit juice
CRP11	In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D3 receptor eeeee2  agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)
CRP11	Domperidone and haloperidol, which have affinity for  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D3 receptor eeeee2 , also inhibited R(+)-7-OH-DPAT-induced hypothermia
CRP11	The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2, D3 eeeee2  and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study
CRP11	The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent  bbbbb1 dopamine eeeee1  D2, D3 and  bbbbb2 5-hydroxytryptamine-3 (5-HT3) receptors eeeee2  ligand, was investigated in the present study
CRP11	The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 dopamine D2, D3 eeeee2  and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study
CRP11	The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and  bbbbb1 5-hydroxytryptamine eeeee1  bbbbb2 5-hydroxytryptamine-3 (5-HT3) receptors eeeee2  ligand, was investigated in the present study
CRP11	The anti-emetic and pharmacological profile of AS-8112 ( bbbbb1 (R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate eeeee1 ), a novel and potent  bbbbb2 dopamine D2, D3 eeeee2  and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study
CRP11	The anti-emetic and pharmacological profile of  bbbbb1 AS-8112 eeeee1  ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent  bbbbb2 dopamine D2, D3 eeeee2  and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study
CRP11	The broad-spectrum anti-emetic activity of  bbbbb1 AS-8112 eeeee1 , a novel  bbbbb2 dopamine D2, D3 eeeee2  and 5-HT3 receptors antagonist
CRP11	The broad-spectrum anti-emetic activity of AS-8112, a novel  bbbbb1 dopamine eeeee1  D2, D3 and  bbbbb2 5-HT3 receptors eeeee2  antagonist
CRP11	The broad-spectrum anti-emetic activity of AS-8112, a novel  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2, D3 eeeee2  and 5-HT3 receptors antagonist
CRP11	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including  bbbbb1 doxorubicin eeeee1  bbbbb2 neu eeeee2 , trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel
CRP11	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including  bbbbb1 doxorubicin eeeee1  bbbbb2 HER2 eeeee2 /neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel
CRP11	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and  bbbbb1 paclitaxel eeeee1  bbbbb2 neu eeeee2 , trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel
CRP11	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and  bbbbb1 paclitaxel eeeee1  bbbbb2 HER2 eeeee2 /neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel
CRP11	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin,  bbbbb1 cyclophosphamide eeeee1  bbbbb2 neu eeeee2 , trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel
CRP11	A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin,  bbbbb1 cyclophosphamide eeeee1  bbbbb2 HER2 eeeee2 /neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and paclitaxel
CRP11	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral  bbbbb1 tyrosine eeeee1  kinase inhibitor targeting HER2/ bbbbb2 neu eeeee2  as well as the epidermal growth factor receptor (EGFR), lapatinib
CRP11	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral  bbbbb1 tyrosine eeeee1  kinase inhibitor targeting HER2/neu as well as the  bbbbb2 epidermal growth factor receptor eeeee2  (EGFR), lapatinib
CRP11	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral  bbbbb1 tyrosine eeeee1  kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor ( bbbbb2 EGFR eeeee2 ), lapatinib
CRP11	The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral  bbbbb1 tyrosine eeeee1  kinase inhibitor targeting  bbbbb2 HER2 eeeee2 /neu as well as the epidermal growth factor receptor (EGFR), lapatinib
CRP11	Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of  bbbbb1 methamphetamine eeeee1  bbbbb2 VMAT2 eeeee2 : discovery of a potential clinical candidate for treatment of methamphetamine abuse
CRP11	Variation i bbbbb1 n thei eeeee1  bbbbb2 n their effecti eeeee2 veness as positive reinforcers was not a function of differences in effectiveness as DA uptake blockers, but may be related to relative potency over the concentrations that are achieved in vivo
CRP11	The hypothesis of the present study was that differences among  bbbbb1 dopamine eeeee1  transporter ( bbbbb2 DAT eeeee2 ) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors
CRP11	The hypothesis of the present study was that differences among  bbbbb1 dopamine eeeee1  bbbbb2 dopamine transporter eeeee2  (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors
CRP11	Purification of these protei bbbbb1 ns and part eeeee1 ial peptide sequence determination revealed them to be alpha1-acid glycoprotein (AGP) bbbbb2  eeeee2 
CRP11	Purification of these protei bbbbb1 ns and part eeeee1 ial peptide sequence determination revealed them to be alpha1-acid glycoprotein (AGP) bbbbb2  eeeee2 
CRP11	Purification of these proteins and partial peptide sequence determination revealed them to be alpha1-acid glycoprotein (AGP) bbbbb1  eeeee1  bbbbb2  revealed eeeee2  them to be alpha1-acid glycoprotein (AGP)
CRP11	Purification of these proteins and partial peptide sequence determination revealed them to be alpha1-acid glycoprotein (AGP) bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Purification of these proteins and partial peptide sequence determination revealed them to be alpha1-acid bbbbb1  glycoprote eeeee1 in (AGP) bbbbb2  eeeee2 
CRP11	Purification of these proteins and partial peptide sequence determination revealed them to be alpha1-acid bbbbb1  glycoprote eeeee1  bbbbb2  revealed eeeee2  them to be alpha1-acid glycoprotein (AGP)
CRP11	Knockdown of NQO1 expression attenuated the reduction of cell cycle regulators by 17-AAG treatment in AhR overexpressed cells bbbbb1  eeeee1  bbbbb2 res eeeee2 sion attenuated the reduction of cell cycle regulators by 17-AAG treatment in AhR overexpressed cells
CRP11	NAD(P)H: bbbbb1 quinone eeeee1  oxidoreductase ( bbbbb2 NQO1 eeeee2 ), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells
CRP11	NAD(P)H: bbbbb1 quinone eeeee1  oxidoreductase (NQO1), which is regulated by  bbbbb2 AhR eeeee2 , was shown to increase anticancer activity of 17-AAG in cells
CRP11	NAD(P)H: bbbbb1 quinone eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase eeeee2  (NQO1), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells
CRP11	 bbbbb1 NAD(P)H eeeee1 :quinone oxidoreductase ( bbbbb2 NQO1 eeeee2 ), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells
CRP11	 bbbbb1 NAD(P)H eeeee1 :quinone oxidoreductase (NQO1), which is regulated by  bbbbb2 AhR eeeee2 , was shown to increase anticancer activity of 17-AAG in cells
CRP11	 bbbbb1 NAD(P)H eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase eeeee2  (NQO1), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells
CRP11	NAD(P)H:quinone oxidoreductase (NQO1), which is regulated by AhR, was shown to increase anticancer activity of  bbbbb1 17-AAG eeeee1  bbbbb2 NQO1 eeeee2 ), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells
CRP11	NAD(P)H:quinone oxidoreductase (NQO1), which is regulated by AhR, was shown to increase anticancer activity of  bbbbb1 17-AAG eeeee1  bbbbb2 AhR eeeee2 , was shown to increase anticancer activity of 17-AAG in cells
CRP11	NAD(P)H:quinone oxidoreductase (NQO1), which is regulated by AhR, was shown to increase anticancer activity of  bbbbb1 17-AAG eeeee1  bbbbb2 NAD(P)H:quinone oxidoreductase eeeee2  (NQO1), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells
CRP11	We have demonstrated that  bbbbb1 aryl hydrocarbon eeeee1  bbbbb2 aryl hydrocarbon receptor eeeee2  (AhR) is overexpressed in lung adenocarcinoma (AD)
CRP11	We have demonstrated that  bbbbb1 aryl hydrocarbon eeeee1  receptor ( bbbbb2 AhR eeeee2 ) is overexpressed in lung adenocarcinoma (AD)
CRP11	 bbbbb1 Aryl hydrocarbon eeeee1  bbbbb2 Aryl hydrocarbon receptor eeeee2  is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells
CRP11	Here we investigated whether AhR plays a role in  bbbbb1 17-AAG eeeee1  bbbbb2 AhR eeeee2  plays a role in 17-AAG-mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy
CRP11	Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of  bbbbb1 17-AAG eeeee1  bbbbb2 AhR eeeee2  levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG
CRP11	Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of  bbbbb1 17-AAG eeeee1  bbbbb2 AhR eeeee2 -regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG
CRP11	Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of  bbbbb1 17-AAG eeeee1  bbbbb2 AhR eeeee2  expression increased anticancer activity of 17-AAG
CRP11	Although treatment with  bbbbb1 17-AAG eeeee1  reduced AhR levels and AhR-regulated gene expression in lung AD cells,  bbbbb2 AhR eeeee2  expression increased anticancer activity of 17-AAG
CRP11	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin ( bbbbb1 17-AAG eeeee1  bbbbb2 heat shock protein 90 eeeee2  (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CRP11	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin ( bbbbb1 17-AAG eeeee1  bbbbb2 Hsp90 eeeee2 ) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CRP11	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin ( bbbbb1 17-AAG eeeee1  bbbbb2 AhR eeeee2  is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CRP11	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm.  bbbbb1 17-Allylamino-17-demethoxygeldanamycin eeeee1  bbbbb2 heat shock protein 90 eeeee2  (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CRP11	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm.  bbbbb1 17-Allylamino-17-demethoxygeldanamycin eeeee1  bbbbb2 Hsp90 eeeee2 ) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CRP11	AhR is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm.  bbbbb1 17-Allylamino-17-demethoxygeldanamycin eeeee1  bbbbb2 AhR eeeee2  is usually associated with heat shock protein 90 (Hsp90) in the cytoplasm. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials
CRP11	In addition,  bbbbb1 17-AAG eeeee1  treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in  bbbbb2 AhR eeeee2 -expressing lung AD cells
CRP11	Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for  bbbbb1 etoricoxib eeeee1  bbbbb2 COX-2 eeeee2  translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib)
CRP11	Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for  bbbbb1 rofecoxib eeeee1  bbbbb2 COX-2 eeeee2  translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib)
CRP11	The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing  bbbbb1 prostaglandin eeeee1  bbbbb2 COX-2 eeeee2  in humans while sparing prostaglandin formation from COX-1
CRP11	The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing  bbbbb1 prostaglandin eeeee1  bbbbb2 second isoform of cyclooxygenase eeeee2  (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1
CRP11	The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing  bbbbb1 prostaglandin eeeee1  bbbbb2 COX eeeee2 ) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1
CRP11	Dicumarol, a potent inhibitor of  bbbbb1 quinone eeeee1  bbbbb2 quinone oxidoreductase eeeee2 , at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin
CRP11	Dicumarol, a potent inhibitor of quinone oxidoreductase, at high concentration (500 microm ) caused only a 72% decrease in the utilization of  bbbbb1 resorufin eeeee1  bbbbb2 quinone oxidoreductase eeeee2 , at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin
CRP11	 bbbbb1 ICI118,551 HCl eeeee1  (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective  bbbbb2 beta 1-adrenoceptor eeeee2  antagonist, did not affect it
CRP11	ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas  bbbbb1 metoprolol tartrate eeeee1  bbbbb2 beta 2-adrenoceptor eeeee2  antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it
CRP11	Intraperitoneal administration of (+/- )propranolol HCl (2.5-10 mg/kg), a nonselective beta-adrenoceptor antagonist, dose dependently attenuated the  bbbbb1 desipramine eeeee1  bbbbb2 beta-adrenoceptor eeeee2  antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses
CRP11	The effects of several beta-adrenoceptor antagonists on the  bbbbb1 desipramine eeeee1  bbbbb2 beta-adrenoceptor eeeee2  antagonists on the desipramine-induced increase in aggressive behavior in long-term isolated mice were examined
CRP11	Moreover, clenbuterol HCl (0.1-0.5 mg/kg, IP), a lipophilic beta 2-adrenoceptor agonist, significantly increased the durati bbbbb1 on of bas eeeee1 al aggressive behavior bbbbb2  eeeee2 
CRP11	Moreover, clenbuterol HCl (0.1-0.5 mg/kg, IP), a l bbbbb1 ipophilic b eeeee1 eta 2-adrenoceptor agonist, significantly increased the duration of basal ag bbbbb2 gressive behavior eeeee2 
CRP11	Metformin increases  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  activity in skeletal muscle of subjects with type 2 diabetes
CRP11	We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic  bbbbb1 glucose eeeee1  bbbbb2 AMPK eeeee2  is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production
CRP11	Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased  bbbbb1 acetyl-CoA eeeee1  bbbbb2 AMPK alpha2 eeeee2  activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity
CRP11	Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased  bbbbb1 acetyl-CoA eeeee1  bbbbb2 AMPK eeeee2  on Thr172 and decreased acetyl-CoA carboxylase-2 activity
CRP11	Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased  bbbbb1 acetyl-CoA eeeee1  bbbbb2 acetyl-CoA carboxylase-2 eeeee2  activity
CRP11	 bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis
CRP11	 bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis
CRP11	CYP2D6 inhibitors, such as  bbbbb1 paroxetine eeeee1 , are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor  bbbbb2 CYP2D6 eeeee2  metabolizers
CRP11	CYP2D6 inhibitors, such as paroxetine, are associated with changes in  bbbbb1 atomoxetine eeeee1  bbbbb2 CYP2D6 eeeee2  inhibitors, such as paroxetine, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers
CRP11	Atomoxetine has a high affinity and selectivity for  bbbbb1 norepinephrine eeeee1  transporters, but little or no affinity for various  bbbbb2 neurotransmitter receptors eeeee2 
CRP11	Atomoxetine has a high affinity and selectivity for  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporters eeeee2 , but little or no affinity for various neurotransmitter receptors
CRP11	The biguanides,  bbbbb1 phenformin eeeee1  and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating  bbbbb2 AMPK eeeee2  activity
CRP11	The  bbbbb1 biguanides eeeee1 , phenformin and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating  bbbbb2 AMPK eeeee2  activity
CRP11	The biguanides, phenformin and  bbbbb1 metformin eeeee1 , are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating  bbbbb2 AMPK eeeee2  activity
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive  bbbbb1 K+ eeeee1  bbbbb2 ATP-sensitive K+ channel eeeee2  (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive  bbbbb1 K+ eeeee1  channel ( bbbbb2 K(ATP) eeeee2 ) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive  bbbbb1 K+ eeeee1  channel (K(ATP)) regulation in cell lines expressing the cloned components of  bbbbb2 K(ATP) eeeee2  and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and  bbbbb1 rubidium eeeee1  flux assays to determine the role of these drugs in  bbbbb2 ATP-sensitive K+ channel eeeee2  (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and  bbbbb1 rubidium eeeee1  flux assays to determine the role of these drugs in ATP-sensitive K+ channel ( bbbbb2 K(ATP) eeeee2 ) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and  bbbbb1 rubidium eeeee1  flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of  bbbbb2 K(ATP) eeeee2  and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of K( bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K+ channel eeeee2  (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) eeeee2 ) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) eeeee2  and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K+ channel eeeee2  (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in  bbbbb1 ATP eeeee1 -sensitive K+ channel ( bbbbb2 K(ATP) eeeee2 ) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in  bbbbb1 ATP eeeee1 -sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of  bbbbb2 K(ATP) eeeee2  and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K( bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive K+ channel eeeee2  (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) eeeee2 ) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K( bbbbb1 ATP eeeee1 )) regulation in cell lines expressing the cloned components of  bbbbb2 K(ATP) eeeee2  and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of  bbbbb1 K eeeee1  bbbbb2 ATP-sensitive K+ channel eeeee2  (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of  bbbbb1 K eeeee1  bbbbb2 K(ATP) eeeee2 ) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of  bbbbb1 K eeeee1  bbbbb2 K(ATP) eeeee2  and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel ( bbbbb1 K eeeee1  bbbbb2 ATP-sensitive K+ channel eeeee2  (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel ( bbbbb1 K eeeee1  bbbbb2 K(ATP) eeeee2 ) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel ( bbbbb1 K eeeee1 (ATP)) regulation in cell lines expressing the cloned components of  bbbbb2 K(ATP) eeeee2  and the current natively expressed in vascular smooth muscle cells (VSMCs)
CRP11	Phenformin has a direct inhibitory effect on the ATP-sensitive  bbbbb1 potassium eeeee1  bbbbb2 ATP-sensitive potassium channel eeeee2 
CRP11	Phenformin has a direct inhibitory effect on the  bbbbb1 ATP eeeee1  bbbbb2 ATP-sensitive potassium channel eeeee2 
CRP11	Phenformin but not metformin inhibits a number of variants of K( bbbbb1 ATP eeeee1 ) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/ bbbbb2 SUR2B eeeee2 ) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of K( bbbbb1 ATP eeeee1 ) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and  bbbbb2 Kir6.2 eeeee2 /SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of K( bbbbb1 ATP eeeee1 ) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/ bbbbb2 SUR2B eeeee2  and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of K( bbbbb1 ATP eeeee1 ) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle ( bbbbb2 Kir6.1 eeeee2 /SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of K( bbbbb1 ATP eeeee1 ) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells ( bbbbb2 Kir6.2 eeeee2 /SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) eeeee2  including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of K( bbbbb1 ATP eeeee1 ) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/ bbbbb2 SUR1 eeeee2 )
CRP11	Phenformin but not metformin inhibits a number of variants of  bbbbb1 K eeeee1 (ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/ bbbbb2 SUR2B eeeee2 ) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of  bbbbb1 K eeeee1 (ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and  bbbbb2 Kir6.2 eeeee2 /SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of  bbbbb1 K eeeee1 (ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/ bbbbb2 SUR2B eeeee2  and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of  bbbbb1 K eeeee1 (ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle ( bbbbb2 Kir6.1 eeeee2 /SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of  bbbbb1 K eeeee1 (ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells ( bbbbb2 Kir6.2 eeeee2 /SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of  bbbbb1 K eeeee1  bbbbb2 K(ATP) eeeee2  including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1)
CRP11	Phenformin but not metformin inhibits a number of variants of  bbbbb1 K eeeee1 (ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/ bbbbb2 SUR1 eeeee2 )
CRP11	The extent and rate of inhibition are similar to that seen with the known K( bbbbb1 ATP eeeee1  bbbbb2 K(ATP) eeeee2  blocker PNU 37883A
CRP11	The extent and rate of inhibition are similar to that seen with the known  bbbbb1 K eeeee1  bbbbb2 K(ATP) eeeee2  blocker PNU 37883A
CRP11	The  bbbbb1 FP eeeee1  bbbbb2 FP receptor eeeee2  bound PGF2 alpha and fluprostenol with Ki values of 3-4 nM
CRP11	The EP1 receptor bound  bbbbb1 17-phenyl-PGE2 eeeee1 , sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb2 EP1 eeeee2  antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to  bbbbb1 PGE2 eeeee1  and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb2 EP1 eeeee2  antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and  bbbbb1 SC-19220 eeeee1  bbbbb2 EP1 eeeee2  receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists,  bbbbb1 AH6809 eeeee1  bbbbb2 EP1 eeeee2  receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	The EP1 receptor bound 17-phenyl-PGE2,  bbbbb1 sulprostone eeeee1  and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb2 EP1 eeeee2  antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and  bbbbb1 PGE1 eeeee1 , with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb2 EP1 eeeee2  antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and  bbbbb1 iloprost eeeee1  in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative  bbbbb2 EP1 eeeee2  antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.  bbbbb1 16,16-dimethyl-PGE2 eeeee1  bbbbb2 EP1 eeeee2  receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM. 16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor
CRP11	Ligand binding specificities of the eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  bbbbb2 mouse prostanoid receptors eeeee2  expressed in Chinese hamster ovary cells. 1
CRP11	M&B-28767, a putative EP3 agonist, and  bbbbb1 misoprostol eeeee1  bbbbb2 EP3 eeeee2  agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM. 5
CRP11	 bbbbb1 M&B-28767 eeeee1 , a putative EP3 agonist, and misoprostol, a putative  bbbbb2 EP2 eeeee2 /EP3 agonist, also bound to this receptor with Ki values of 120 nM. 5
CRP11	 bbbbb1 M&B-28767 eeeee1 , a putative EP3 agonist, and misoprostol, a putative EP2/ bbbbb2 EP3 eeeee2  agonist, also bound to this receptor with Ki values of 120 nM. 5
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands,  bbbbb1 iloprost eeeee1 , carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7 eeeee1  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7 eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7 eeeee1  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.  bbbbb1 7 eeeee1  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb1 TP eeeee1  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  and  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb1 IP eeeee1  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb1 TP eeeee1  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb1  eeeee1  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three  bbbbb1 IP eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three  bbbbb1 IP eeeee1  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost,  bbbbb1 carbacyclin eeeee1  and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1  bbbbb2 IP eeeee2  ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand,  bbbbb1 STA2 eeeee1 , bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and  bbbbb2 TP receptors eeeee2 , respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7 bbbbb2  eeeee2 
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one  bbbbb2 TP eeeee2  ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively. 7
CRP11	In addition, three IP ligands, iloprost, carbacyclin and  bbbbb1 isocarbacyclin eeeee1 , and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the  bbbbb2 IP eeeee2  and TP receptors, respectively. 7
CRP11	The two receptors were discriminated by  bbbbb1 butaprost eeeee1 , AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the  bbbbb2 EP2 eeeee2  receptor. 6
CRP11	The two receptors were discriminated by  bbbbb1 butaprost eeeee1 , AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the  bbbbb2 EP4 eeeee2  but not to the EP2 receptor. 6
CRP11	The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by  bbbbb1 1-OH-PGE1 eeeee1  bbbbb2 EP4 eeeee2  receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CRP11	The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by  bbbbb1 1-OH-PGE1 eeeee1  bbbbb2 EP2 eeeee2  receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor. 6
CRP11	The two receptors were discriminated by butaprost,  bbbbb1 AH-13205 eeeee1  and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the  bbbbb2 EP2 eeeee2  receptor. 6
CRP11	The two receptors were discriminated by butaprost,  bbbbb1 AH-13205 eeeee1  and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the  bbbbb2 EP4 eeeee2  but not to the EP2 receptor. 6
CRP11	The two receptors were discriminated by butaprost, AH-13205 and  bbbbb1 AH-6809 eeeee1  that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the  bbbbb2 EP2 eeeee2  receptor. 6
CRP11	The two receptors were discriminated by butaprost, AH-13205 and  bbbbb1 AH-6809 eeeee1  that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the  bbbbb2 EP4 eeeee2  but not to the EP2 receptor. 6
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP,  bbbbb1 cicaprost eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP,  bbbbb1 cicaprost eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP,  bbbbb1 cicaprost eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP,  bbbbb1 cicaprost eeeee1 , iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP,  bbbbb1 cicaprost eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and  bbbbb1 S-145 eeeee1  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and  bbbbb1 S-145 eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and  bbbbb1 S-145 eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and  bbbbb1 S-145 eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and  bbbbb1 S-145 eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb1 IP eeeee1  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb1 IP eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb1 IP eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb1 IP eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb1 IP eeeee1 , and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb1 IP eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb1 TP eeeee1  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb1 TP eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb1 TP eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb1 TP eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb1 TP eeeee1  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb1 TP eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and  bbbbb1 GR 32191 eeeee1  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and  bbbbb1 GR 32191 eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and  bbbbb1 GR 32191 eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and  bbbbb1 GR 32191 eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and  bbbbb1 GR 32191 eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb1 DP eeeee1 , cicaprost, iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb1 DP eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb1 DP eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb1 DP eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb1 DP eeeee1 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb1 DP eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2,  bbbbb1 BW245C eeeee1  and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2,  bbbbb1 BW245C eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2,  bbbbb1 BW245C eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2,  bbbbb1 BW245C eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2,  bbbbb1 BW245C eeeee1  and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and  bbbbb1 isocabacyclin eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and  bbbbb1 isocabacyclin eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and  bbbbb1 isocabacyclin eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and  bbbbb1 isocabacyclin eeeee1  for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and  bbbbb1 isocabacyclin eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The  bbbbb1 DP eeeee1 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The  bbbbb1 DP eeeee1 , IP and  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The  bbbbb1 DP eeeee1 ,  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The  bbbbb1 DP eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The  bbbbb1 DP eeeee1 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The  bbbbb1 DP eeeee1 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as  bbbbb1 PGD2 eeeee1 , BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as  bbbbb1 PGD2 eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as  bbbbb1 PGD2 eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as  bbbbb1 PGD2 eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as  bbbbb1 PGD2 eeeee1 , BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost,  bbbbb1 iloprost eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost,  bbbbb1 iloprost eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost,  bbbbb1 iloprost eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost,  bbbbb1 iloprost eeeee1  and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost,  bbbbb1 iloprost eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and  bbbbb1 TP eeeee1  receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and  bbbbb1 TP eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and  bbbbb1 TP eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and  bbbbb1 TP eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and  bbbbb1 TP eeeee1  receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP, IP and  bbbbb1 TP eeeee1  receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and  bbbbb1 BW868C eeeee1  for DP, cicaprost, iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and  bbbbb1 BW868C eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and  bbbbb1 BW868C eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and  bbbbb1 BW868C eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and  bbbbb1 BW868C eeeee1  for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP,  bbbbb1 IP eeeee1  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP,  bbbbb1 IP eeeee1  and  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP,  bbbbb1 IP eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP,  bbbbb1 IP eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP,  bbbbb1 IP eeeee1  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for  bbbbb2 TP eeeee2 . 3
CRP11	The DP,  bbbbb1 IP eeeee1  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145,  bbbbb1 I-BOP eeeee1  bbbbb2 IP eeeee2 , and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145,  bbbbb1 I-BOP eeeee1  bbbbb2 TP receptors eeeee2  showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145,  bbbbb1 I-BOP eeeee1  bbbbb2 IP eeeee2  and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145,  bbbbb1 I-BOP eeeee1  bbbbb2 DP eeeee2 , IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145,  bbbbb1 I-BOP eeeee1  bbbbb2 DP eeeee2 , cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP. 3
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1 ) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1 ) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1 ) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1 ) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1 ) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1 ) receptor, the  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F ( bbbbb1 FP eeeee1 ) receptor, the prostaglandin I (IP) receptor, the  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1 ) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1 ) receptor, the thromboxane A (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1 ) receptor, the thromboxane A (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1 ) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1 ) receptor, the thromboxane A (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I ( bbbbb1 IP eeeee1 ) receptor, the  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse  bbbbb1 prostanoid eeeee1  receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  (IP) receptor, the thromboxane A (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  (IP) receptor, the thromboxane A (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb1 prostaglandin I eeeee1  (IP) receptor, the  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb1 prostaglandin E eeeee1  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1 ) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1 ) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1 ) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1 ) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1 ) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A ( bbbbb1 TP eeeee1  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the prostaglandin F (FP) receptor, the  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the  bbbbb1 prostaglandin D eeeee1  (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the prostaglandin F (FP) receptor, the  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D ( bbbbb1 DP eeeee1 ) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb1 thromboxane A eeeee1  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the  bbbbb2 prostaglandin E receptor eeeee2 , were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1,  bbbbb2 EP2 eeeee2 , EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2,  bbbbb2 EP3 eeeee2  and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and  bbbbb2 EP4 eeeee2  subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  bbbbb2 mouse prostanoid receptor eeeee2 , the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  bbbbb2 prostaglandin D (DP) receptor eeeee2 , the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the  bbbbb2 EP1 eeeee2 , EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  bbbbb2 prostaglandin F (FP) receptor eeeee2 , the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  (FP) receptor, the  bbbbb2 prostaglandin I (IP) receptor eeeee2 , the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the  bbbbb1 prostaglandin F eeeee1  (FP) receptor, the prostaglandin I (IP) receptor, the  bbbbb2 thromboxane A (TP) receptor eeeee2  and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells
CRP11	An angiotensin II AT1 receptor antagonist, telmisartan augments  bbbbb1 glucose eeeee1  bbbbb2 angiotensin II AT1 receptor eeeee2  antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes
CRP11	An  bbbbb1 angiotensin II eeeee1  AT1 receptor antagonist, telmisartan augments glucose uptake and  bbbbb2 GLUT4 eeeee2  protein expression in 3T3-L1 adipocytes
CRP11	An  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II AT1 receptor eeeee2  antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes
CRP11	Evidence has accumulated that some of the  bbbbb1 angiotensin II eeeee1  AT1 receptor antagonists have  bbbbb2 insulin eeeee2 -sensitizing property
CRP11	Evidence has accumulated that some of the  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II AT1 receptor eeeee2  antagonists have insulin-sensitizing property
CRP11	We thus examined the effect of  bbbbb1 telmisartan eeeee1  on  bbbbb2 insulin eeeee2  action using 3T3-L1 adipocytes
CRP11	By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differe bbbbb1 ntiated adipocy eeeee1 tes bbbbb2  eeeee2 
CRP11	By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differe bbbbb1 ntiated adipocy eeeee1 tes bbbbb2  eeeee2 
CRP11	By contrast, telmisartan attenuated 11beta-hydrox bbbbb1 ysteroid de eeeee1 hydrogenase type 1 mRNA level in differentiated adipocytes bbbbb2  eeeee2 
CRP11	By contrast, telmisartan attenuated 11beta-hydrox bbbbb1 ysteroid de eeeee1 hydrogenase type 1 mRNA level in differentiated adipocytes bbbbb2  eeeee2 
CRP11	There are 2 forms of PHA1: the autosomal recessive form with symptoms persisting into adulthood, caused by mutations in the amiloride-sensitive luminal  bbbbb1 sodium eeeee1  bbbbb2 amiloride-sensitive luminal sodium channel eeeee2 , and the autosomal dominant or sporadic form, which shows milder symptoms that remit with age
CRP11	There are 2 forms of PHA1: the autosomal recessive form with symptoms persisting into adulthood, caused by mutations in the  bbbbb1 amiloride eeeee1  bbbbb2 amiloride-sensitive luminal sodium channel eeeee2 , and the autosomal dominant or sporadic form, which shows milder symptoms that remit with age
CRP11	For model development, we used plasma  bbbbb1 17β-estradiol eeeee1  (E2) concentrations and ovarian  bbbbb2 cytochrome P450 (CYP) 19A aromatase eeeee2  mRNA data from two time-course experiments, each of which included both an exposure and a depuration phase, and plasma E2 data from a third 4-day study
CRP11	 bbbbb1 Estrogen eeeee1  receptor (ER) antagonists are valuable in the treatment of  bbbbb2 ER eeeee2 -positive human breast cancer
CRP11	 bbbbb1 Estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 ) antagonists are valuable in the treatment of ER-positive human breast cancer
CRP11	 bbbbb1 Estrogen eeeee1  bbbbb2 Estrogen receptor eeeee2  (ER) antagonists are valuable in the treatment of ER-positive human breast cancer
CRP11	In this study, we designed and synthesized nine new derivatives of  bbbbb1 17β-estradiol eeeee1  (E2) with a bulky side chain attached to its C-7α position, and determined their  bbbbb2 ER eeeee2  antagonistic activity using in vitro bioassays
CRP11	Synthesis of novel  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  antagonists using metal-catalyzed coupling reactions and characterization of their biological activity
CRP11	Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in  bbbbb1 a manner si eeeee1  bbbbb2 an eeeee2 d showed that they could tightly bind to the ERα in a manner similar to that of ICI-182,780, a pure ER antagonist
CRP11	Here, we report that a specific 29- bbbbb1 amino acid eeeee1  peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of NGF to  bbbbb2 TrkA eeeee2 -expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling
CRP11	Here, we report that a specific 29- bbbbb1 amino acid eeeee1  peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced  bbbbb2 Erk1/2 eeeee2  and Akt signaling
CRP11	Here, we report that a specific 29- bbbbb1 amino acid eeeee1  peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of  bbbbb2 NGF eeeee2  to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling
CRP11	Here, we report that a specific 29- bbbbb1 amino acid eeeee1  peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and  bbbbb2 Akt eeeee2  signaling
CRP11	However, recent reports indicate that cAMP-specific  bbbbb1 PDE4 eeeee1  bbbbb2 cAMP-specific PDE4 eeeee2  activity in eosinophils is 10-fold that of other inflammatory cells
CRP11	However, recent reports indicate that  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-specific PDE4 eeeee2  activity in eosinophils is 10-fold that of other inflammatory cells
CRP11	Rolipram unmasked the inhibitory effect of beta(2)-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of  bbbbb1 AA eeeee1  bbbbb2 beta(2)-adrenoceptor eeeee2  stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4)
CRP11	Rolipram unmasked the inhibitory effect of beta(2)-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent  bbbbb1 LTC(4) eeeee1  bbbbb2 beta(2)-adrenoceptor eeeee2  stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4)
CRP11	Inhibition corresponded to increased cAMP production caused by rolipram al bbbbb1 one or eeeee1  bbbbb2 roduction caused b eeeee2 y rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP/B-activated eosinophils
CRP11	Inhibition corresponded to increased cAMP production caused by rolipram al bbbbb1 one or eeeee1  bbbbb2 onde eeeee2 d to increased cAMP production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP/B-activated eosinophils
CRP11	Inhibition corresp bbbbb1 onde eeeee1 d to increased cAMP p bbbbb2 roduction caused b eeeee2 y rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP/B-activated eosinophils
CRP11	Inhibition corresp bbbbb1 onde eeeee1  bbbbb2 onde eeeee2 d to increased cAMP production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP/B-activated eosinophils
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring  bbbbb1 Ca2+ eeeee1  bbbbb2 GPCR eeeee2 ) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring  bbbbb1 Ca2+ eeeee1  bbbbb2 G protein-coupled receptor eeeee2  (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring  bbbbb1 Ca2+ eeeee1  triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a  bbbbb2 PLC-beta eeeee2  hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of  bbbbb1 inositol phosphate eeeee1  bbbbb2 GPCR eeeee2 ) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of  bbbbb1 inositol phosphate eeeee1  bbbbb2 PLC-beta eeeee2 )-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of  bbbbb1 inositol phosphate eeeee1  bbbbb2 G protein-coupled receptor eeeee2  (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of  bbbbb1 inositol phosphate eeeee1  bbbbb2 Phospholipase C beta eeeee2  (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate ( bbbbb1 IP3 eeeee1  bbbbb2 GPCR eeeee2 ) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate ( bbbbb1 IP3 eeeee1  bbbbb2 PLC-beta eeeee2 )-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate ( bbbbb1 IP3 eeeee1  bbbbb2 G protein-coupled receptor eeeee2  (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate ( bbbbb1 IP3 eeeee1  bbbbb2 Phospholipase C beta eeeee2  (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays
CRP11	It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the  bbbbb1 IP3 eeeee1  bbbbb2 GPCR eeeee2  activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade
CRP11	It has been known for decades that lithium chloride (LiCl) leads to  bbbbb1 D-myo-inositol 1-phosphate eeeee1  accumulation on  bbbbb2 GPCR eeeee2  activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade
CRP11	However, in  bbbbb1 DEHP eeeee1 -treated groups, there were detectable serum testosterone concentrations and some oval-shaped  bbbbb2 3β-HSD eeeee2 (pos) cells in the interstitium
CRP11	However, in DEHP-treated groups, there were detectable serum  bbbbb1 testosterone eeeee1  concentrations and some oval-shaped  bbbbb2 3β-HSD eeeee2 (pos) cells in the interstitium
CRP11	However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the  bbbbb1 DEHP eeeee1 -treated testes, indicating that these  bbbbb2 3β-HSD eeeee2 (pos) cells were newly formed progenitor Leydig cells
CRP11	 bbbbb1 EDS eeeee1  eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no 3β-hydroxysteroid dehydrogenase positive ( bbbbb2 3β-HSD eeeee2 (pos)) cells in the interstitium
CRP11	 bbbbb1 EDS eeeee1  eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no  bbbbb2 3β-hydroxysteroid dehydrogenase eeeee2  positive (3β-HSD(pos)) cells in the interstitium
CRP11	EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no  bbbbb1 3β-hydroxysteroid eeeee1  dehydrogenase positive ( bbbbb2 3β-HSD eeeee2 (pos)) cells in the interstitium
CRP11	EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no  bbbbb1 3β-hydroxysteroid eeeee1  bbbbb2 3β-hydroxysteroid dehydrogenase eeeee2  positive (3β-HSD(pos)) cells in the interstitium
CRP11	EDS eliminated all Leydig cells in the control testis on day 4 post- bbbbb1 EDS eeeee1 , as judged by undetectable serum testosterone level and no 3β-hydroxysteroid dehydrogenase positive ( bbbbb2 3β-HSD eeeee2 (pos)) cells in the interstitium
CRP11	EDS eliminated all Leydig cells in the control testis on day 4 post- bbbbb1 EDS eeeee1 , as judged by undetectable serum testosterone level and no  bbbbb2 3β-hydroxysteroid dehydrogenase eeeee2  positive (3β-HSD(pos)) cells in the interstitium
CRP11	EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum  bbbbb1 testosterone eeeee1  level and no 3β-hydroxysteroid dehydrogenase positive ( bbbbb2 3β-HSD eeeee2 (pos)) cells in the interstitium
CRP11	EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum  bbbbb1 testosterone eeeee1  level and no  bbbbb2 3β-hydroxysteroid dehydrogenase eeeee2  positive (3β-HSD(pos)) cells in the interstitium
CRP11	These 3β-HSD(pos) cells were not stained by the antibody against  bbbbb1 11β-hydroxysteroid eeeee1  dehydrogenase 1 ( bbbbb2 11β-HSD eeeee2 1), a marker for Leydig cells at a more advanced stage
CRP11	These 3β-HSD(pos) cells were not stained by the antibody against  bbbbb1 11β-hydroxysteroid eeeee1  bbbbb2 3β-HSD eeeee2 (pos) cells were not stained by the antibody against 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), a marker for Leydig cells at a more advanced stage
CRP11	These 3β-HSD(pos) cells were not stained by the antibody against  bbbbb1 11β-hydroxysteroid eeeee1  bbbbb2 11β-hydroxysteroid dehydrogenase 1 eeeee2  (11β-HSD1), a marker for Leydig cells at a more advanced stage
CRP11	Although naturally occurring electrophilic plant compounds, such as mustard oil and  bbbbb1 cinnamaldehyde eeeee1 , are TRPA1 agonists, it is unknown whether arthropod-produced electrophiles activate  bbbbb2 mammalian TRPA1 eeeee2 
CRP11	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted  bbbbb1 cysteines eeeee1  bbbbb2 TRPA1 eeeee2  or TRPA1 with three serine-substituted cysteines crucial for electrophile activation (C621S, C641S, C665S)
CRP11	We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three  bbbbb1 serine eeeee1  bbbbb2 TRPA1 eeeee2  or TRPA1 with three serine-substituted cysteines crucial for electrophile activation (C621S, C641S, C665S)
CRP11	We characterized the effects of the electrophilic arthropod defensive compound  bbbbb1 para-benzoquinone eeeee1  (pBQN) on the  bbbbb2 human TRPA1 eeeee2  channel
CRP11	We characterized the effects of the electrophilic arthropod defensive compound para-benzoquinone ( bbbbb1 pBQN eeeee1 ) on the  bbbbb2 human TRPA1 eeeee2  channel
CRP11	Thyroid stem and progenitor cells expressed oestrogen receptor alpha and beta with an 8 time higher expression level of  bbbbb1 oestrogen eeeee1  bbbbb2 oestrogen receptor alpha eeeee2  mRNA compared to differentiated thyrocytes. 17beta-oestradiol was a potent stimulator of thyroid stem/ progenitor cell growth
CRP11	Thyroid stem and progenitor cells expressed oestrogen receptor alpha and beta with an 8 time higher expression level of  bbbbb1 oestrogen eeeee1  bbbbb2 oestrogen receptor alpha and beta eeeee2  with an 8 time higher expression level of oestrogen receptor alpha mRNA compared to differentiated thyrocytes. 17beta-oestradiol was a potent stimulator of thyroid stem/ progenitor cell growth
CRP11	Thyroid stem and progenitor cells expressed oestrogen receptor alpha and beta with an 8 time higher expression level of oestrogen receptor alpha mRNA compared to differentiated thyrocytes.  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 oestrogen receptor alpha eeeee2  mRNA compared to differentiated thyrocytes. 17beta-oestradiol was a potent stimulator of thyroid stem/ progenitor cell growth
CRP11	Thyroid stem and progenitor cells expressed oestrogen receptor alpha and beta with an 8 time higher expression level of oestrogen receptor alpha mRNA compared to differentiated thyrocytes.  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 oestrogen receptor alpha and beta eeeee2  with an 8 time higher expression level of oestrogen receptor alpha mRNA compared to differentiated thyrocytes. 17beta-oestradiol was a potent stimulator of thyroid stem/ progenitor cell growth
CRP11	Thyroid stem and progenitor cells expressed  bbbbb1 oestrogen eeeee1  receptor alpha and beta with an 8 time higher expression level of  bbbbb2 oestrogen receptor alpha eeeee2  mRNA compared to differentiated thyrocytes. 17beta-oestradiol was a potent stimulator of thyroid stem/ progenitor cell growth
CRP11	Thyroid stem and progenitor cells expressed  bbbbb1 oestrogen eeeee1  bbbbb2 oestrogen receptor alpha and beta eeeee2  with an 8 time higher expression level of oestrogen receptor alpha mRNA compared to differentiated thyrocytes. 17beta-oestradiol was a potent stimulator of thyroid stem/ progenitor cell growth
CRP11	In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the  bbbbb1 sodium iodide eeeee1  bbbbb2 sodium iodide symporter eeeee2 , was significantly inhibited by 17beta-oestradiol.In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells
CRP11	In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the sodium iodide symporter, was significantly inhibited by 17beta-oestradiol.In conclusion,  bbbbb1 oestrogen eeeee1  bbbbb2 sodium iodide symporter eeeee2 , was significantly inhibited by 17beta-oestradiol.In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb1 sodium iodide eeeee1  bbbbb2 thyroperoxidase eeeee2 , thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb1 sodium iodide eeeee1  bbbbb2 oestrogen receptors eeeee2  and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb1 sodium iodide eeeee1  bbbbb2 thyroglobulin eeeee2 , sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb1 sodium iodide eeeee1  bbbbb2 TSH receptor eeeee2 , thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb1 sodium iodide eeeee1  bbbbb2 sodium iodide symporter eeeee2  expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 thyroperoxidase eeeee2 , thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 oestrogen receptors eeeee2  and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 thyroglobulin eeeee2 , sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 TSH receptor eeeee2 , thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 sodium iodide symporter eeeee2  expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of  bbbbb1 17beta-oestradiol eeeee1  to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor,  bbbbb2 thyroperoxidase eeeee2 , thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of  bbbbb1 17beta-oestradiol eeeee1  to induce thyrosphere formation, the expression of  bbbbb2 oestrogen receptors eeeee2  and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of  bbbbb1 17beta-oestradiol eeeee1  to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase,  bbbbb2 thyroglobulin eeeee2 , sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of  bbbbb1 17beta-oestradiol eeeee1  to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation ( bbbbb2 TSH receptor eeeee2 , thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of  bbbbb1 17beta-oestradiol eeeee1  to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb2 sodium iodide symporter eeeee2  expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of  bbbbb1 17beta-oestradiol eeeee1  on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor,  bbbbb2 thyroperoxidase eeeee2 , thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of  bbbbb1 17beta-oestradiol eeeee1  bbbbb2 oestrogen receptors eeeee2  and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of  bbbbb1 17beta-oestradiol eeeee1  on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase,  bbbbb2 thyroglobulin eeeee2 , sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of  bbbbb1 17beta-oestradiol eeeee1  on growth, expression of marker of stem cells and thyroid differentiation ( bbbbb2 TSH receptor eeeee2 , thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of  bbbbb1 17beta-oestradiol eeeee1  on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb2 sodium iodide symporter eeeee2  expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of  bbbbb1 oestrogen eeeee1  receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor,  bbbbb2 thyroperoxidase eeeee2 , thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of  bbbbb1 oestrogen eeeee1  bbbbb2 oestrogen receptors eeeee2  and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of  bbbbb1 oestrogen eeeee1  receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase,  bbbbb2 thyroglobulin eeeee2 , sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of  bbbbb1 oestrogen eeeee1  receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation ( bbbbb2 TSH receptor eeeee2 , thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of  bbbbb1 oestrogen eeeee1  receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin,  bbbbb2 sodium iodide symporter eeeee2  expression) were analysed. 17beta-oestradiol induced thyrosphere formation, albeit to lower extent than other growth factors
CRP11	CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by  bbbbb1 CO eeeee1  bbbbb2 HO-1 eeeee2  substrate but abolished by CO scavenger
CRP11	 bbbbb1 CO eeeee1  donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by  bbbbb2 HO-1 eeeee2  substrate but abolished by CO scavenger
CRP11	CO donor dose-dependently inactivated CYP2E1 of  bbbbb1 ethanol eeeee1 -incubated microsome, which was mimicked by  bbbbb2 HO-1 eeeee2  substrate but abolished by CO scavenger
CRP11	Naturally occuring  bbbbb1 quercetin eeeee1  protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 ( bbbbb2 HO-1 eeeee2 ) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring  bbbbb1 quercetin eeeee1  protects hepatocytes from ethanol-induced oxidative stress, and  bbbbb2 heme oxygenase-1 eeeee2  (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (HO-1) induction and carbon monoxide ( bbbbb1 CO eeeee1  bbbbb2 HO-1 eeeee2 ) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (HO-1) induction and carbon monoxide ( bbbbb1 CO eeeee1  bbbbb2 heme oxygenase-1 eeeee2  (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (HO-1) induction and  bbbbb1 carbon monoxide eeeee1  bbbbb2 HO-1 eeeee2 ) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (HO-1) induction and  bbbbb1 carbon monoxide eeeee1  bbbbb2 heme oxygenase-1 eeeee2  (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from  bbbbb1 ethanol eeeee1 -induced oxidative stress, and heme oxygenase-1 ( bbbbb2 HO-1 eeeee2 ) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from  bbbbb1 ethanol eeeee1 -induced oxidative stress, and  bbbbb2 heme oxygenase-1 eeeee2  (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and  bbbbb1 heme eeeee1  oxygenase-1 ( bbbbb2 HO-1 eeeee2 ) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and  bbbbb1 heme eeeee1  bbbbb2 heme oxygenase-1 eeeee2  (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect
CRP11	Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by  bbbbb1 quercetin eeeee1  but further enhanced by  bbbbb2 HO-1 eeeee2  inhibition with resultant heme accumulation
CRP11	Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant  bbbbb1 heme eeeee1  bbbbb2 CYP2E1 eeeee2  upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation
CRP11	Quercetin suppressed CYP2E1-dependent ethanol hepatotoxicity via depleting heme pool and releasing  bbbbb1 CO eeeee1  bbbbb2 CYP2E1 eeeee2 -dependent ethanol hepatotoxicity via depleting heme pool and releasing CO
CRP11	However, the precise mechanism by which quercetin counteracts CYP2E1-mediated  bbbbb1 ethanol eeeee1  hepatotoxicity through  bbbbb2 HO-1 eeeee2  system is still remained unclear
CRP11	Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by  bbbbb1 quercetin eeeee1  bbbbb2 HO-1 eeeee2  with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)
CRP11	Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by  bbbbb1 quercetin eeeee1  bbbbb2 CYP2E1 eeeee2  but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.)
CRP11	To further investigate the protective effect and underlying mechanism of  bbbbb1 catalpol eeeee1 , astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) catalpol for 1h prior to LPS plus  bbbbb2 interferon-γ eeeee2  stimulation
CRP11	To further investigate the protective effect and underlying mechanism of catalpol, astrocytes were pretreated with low (0.1mM) and high dose (0.5mM)  bbbbb1 catalpol eeeee1  for 1h prior to LPS plus  bbbbb2 interferon-γ eeeee2  stimulation
CRP11	Biochemical analyses showed that  bbbbb1 NO eeeee1  and ROS production and  bbbbb2 iNOS eeeee2  activity were significantly reduced by catalpol
CRP11	Furthermore,  bbbbb1 OHT eeeee1 -stimulated cleavage of cyclin E and migration were tremendously attenuated by G15, a  bbbbb2 GPR30 eeeee2  antagonist, or siRNA against GPR30
CRP11	Furthermore,  bbbbb1 OHT eeeee1 -stimulated cleavage of cyclin E and migration were tremendously attenuated by G15, a GPR30 antagonist, or siRNA against  bbbbb2 GPR30 eeeee2 
CRP11	Over-expression of cleaved cyclin E in breast tumors is closely associated with tumor progression and resistance to antiestrogens.  bbbbb1 17β-Estradiol eeeee1  bbbbb2 cyclin E eeeee2  in breast tumors is closely associated with tumor progression and resistance to antiestrogens. 17β-Estradiol (E2) has been recently shown to induce cyclin E processing in breast cancer cells
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen ( bbbbb1 OHT eeeee1  bbbbb2 estrogen receptor α eeeee2  (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen ( bbbbb1 OHT eeeee1  bbbbb2 cyclin E eeeee2  and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen ( bbbbb1 OHT eeeee1  bbbbb2 G protein-coupled protein (GPR) 30 eeeee2  and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen ( bbbbb1 OHT eeeee1  bbbbb2 ERα eeeee2 ). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT,  bbbbb1 tamoxifen eeeee1  bbbbb2 estrogen receptor α eeeee2  (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT,  bbbbb1 tamoxifen eeeee1  bbbbb2 cyclin E eeeee2  and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT,  bbbbb1 tamoxifen eeeee1  bbbbb2 G protein-coupled protein (GPR) 30 eeeee2  and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT,  bbbbb1 tamoxifen eeeee1  bbbbb2 ERα eeeee2 ). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor α eeeee2  (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb1 estrogen eeeee1  bbbbb2 cyclin E eeeee2  and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb1 estrogen eeeee1  receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of  bbbbb2 cyclin E eeeee2  and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb1 estrogen eeeee1  bbbbb2 G protein-coupled protein (GPR) 30 eeeee2  and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb1 estrogen eeeee1  receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered  bbbbb2 cyclin E eeeee2  cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb1 estrogen eeeee1  receptor α ( bbbbb2 ERα eeeee2 ). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).  bbbbb1 4-Hydroxytamoxifen eeeee1  bbbbb2 estrogen receptor α eeeee2  (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).  bbbbb1 4-Hydroxytamoxifen eeeee1  bbbbb2 cyclin E eeeee2  and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).  bbbbb1 4-Hydroxytamoxifen eeeee1  bbbbb2 G protein-coupled protein (GPR) 30 eeeee2  and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).  bbbbb1 4-Hydroxytamoxifen eeeee1  bbbbb2 ERα eeeee2 ). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in  bbbbb1 estrogen eeeee1 -responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb2 estrogen receptor α eeeee2  (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in  bbbbb1 estrogen eeeee1  bbbbb2 cyclin E eeeee2  and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in  bbbbb1 estrogen eeeee1 -responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of  bbbbb2 cyclin E eeeee2  and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in  bbbbb1 estrogen eeeee1 -responsive MCF-7 breast cancer cells that express both  bbbbb2 G protein-coupled protein (GPR) 30 eeeee2  and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in  bbbbb1 estrogen eeeee1 -responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered  bbbbb2 cyclin E eeeee2  cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in  bbbbb1 estrogen eeeee1 -responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α ( bbbbb2 ERα eeeee2 ). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of  bbbbb1 tamoxifen eeeee1  on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and  bbbbb2 estrogen receptor α eeeee2  (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of  bbbbb1 tamoxifen eeeee1  on the generation of cleaved  bbbbb2 cyclin E eeeee2  and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of  bbbbb1 tamoxifen eeeee1  on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of  bbbbb2 cyclin E eeeee2  and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of  bbbbb1 tamoxifen eeeee1  on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both  bbbbb2 G protein-coupled protein (GPR) 30 eeeee2  and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of  bbbbb1 tamoxifen eeeee1  on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered  bbbbb2 cyclin E eeeee2  cleavage coincident with augmented migration
CRP11	We therefore addressed possible effects of  bbbbb1 tamoxifen eeeee1  on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α ( bbbbb2 ERα eeeee2 ). 4-Hydroxytamoxifen (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered cyclin E cleavage coincident with augmented migration
CRP11	 bbbbb1 OHT eeeee1 -induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor  bbbbb2 ERα eeeee2 
CRP11	 bbbbb1 OHT eeeee1 -induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack  bbbbb2 ERα eeeee2 , but not in MDA-MB-231 cells that express neither GPR30 nor ERα
CRP11	 bbbbb1 OHT eeeee1 -induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither  bbbbb2 GPR30 eeeee2  nor ERα
CRP11	Effect of long-term  bbbbb1 fluoxetine eeeee1  treatment on the  bbbbb2 human serotonin transporter eeeee2  in Caco-2 cells
CRP11	Effect of long-term fluoxetine treatment on the human  bbbbb1 serotonin eeeee1  bbbbb2 human serotonin transporter eeeee2  in Caco-2 cells
CRP11	The chronic effect of SSRIs on the activity of the  bbbbb1 serotonin eeeee1  transporter ( bbbbb2 SERT eeeee2 ) has been less studied and the results have been contradictory
CRP11	The chronic effect of SSRIs on the activity of the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  (SERT) has been less studied and the results have been contradictory
CRP11	The aim of this study was to determine the specific effect of long-term  bbbbb1 fluoxetine eeeee1  treatment on  bbbbb2 human serotonin transporter eeeee2  (hSERT) in vitro, by using the human enterocyte-like cell line Caco-2
CRP11	The aim of this study was to determine the specific effect of long-term  bbbbb1 fluoxetine eeeee1  treatment on human serotonin transporter ( bbbbb2 hSERT eeeee2 ) in vitro, by using the human enterocyte-like cell line Caco-2
CRP11	The aim of this study was to determine the specific effect of long-term fluoxetine treatment on human  bbbbb1 serotonin eeeee1  bbbbb2 human serotonin transporter eeeee2  (hSERT) in vitro, by using the human enterocyte-like cell line Caco-2
CRP11	The aim of this study was to determine the specific effect of long-term fluoxetine treatment on human  bbbbb1 serotonin eeeee1  transporter ( bbbbb2 hSERT eeeee2 ) in vitro, by using the human enterocyte-like cell line Caco-2
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic  bbbbb1 acetylcholine eeeee1  receptors ( bbbbb2 nAChR eeeee2 -APL) that shares many common structural elements with morphinan-based opioids
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 nicotinic acetylcholine receptors eeeee2  (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 AChE eeeee2 ) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic  bbbbb1 acetylcholine eeeee1  bbbbb2 acetylcholinesterase eeeee2  (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with  bbbbb1 morphinan eeeee1  bbbbb2 nAChR eeeee2 -APL) that shares many common structural elements with morphinan-based opioids
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with  bbbbb1 morphinan eeeee1  bbbbb2 nicotinic acetylcholine receptors eeeee2  (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with  bbbbb1 morphinan eeeee1  bbbbb2 AChE eeeee2 ) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CRP11	Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with  bbbbb1 morphinan eeeee1  bbbbb2 acetylcholinesterase eeeee2  (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids
CRP11	P-specific short interfering RNA produced a 2-fold decrease in pemetrexed IC(50) in MTAP(+) HeLa cells in the presence of  bbbbb1 thymidine eeeee1  bbbbb2 MTAP eeeee2 (+) HeLa cells in the presence of thymidine
CRP11	P-specific short interfering RNA produced a 2-fold decrease in  bbbbb1 pemetrexed eeeee1  IC(50) in  bbbbb2 MTAP eeeee2 (+) HeLa cells in the presence of thymidine
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 glycinamide ribonucleotide transformylase eeeee2  (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 TS eeeee2 ) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of  bbbbb1 glycinamide ribonucleotide eeeee1  transformylase ( bbbbb2 GARFT eeeee2 ) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of  bbbbb1 glycinamide ribonucleotide eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo  bbbbb1 purine eeeee1  bbbbb2 glycinamide ribonucleotide transformylase eeeee2  (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo  bbbbb1 purine eeeee1  bbbbb2 TS eeeee2 ) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo  bbbbb1 purine eeeee1  bbbbb2 GARFT eeeee2 ) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo  bbbbb1 purine eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of  bbbbb1 thymidylate eeeee1  synthase (TS) and a weaker inhibitor of  bbbbb2 glycinamide ribonucleotide transformylase eeeee2  (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of  bbbbb1 thymidylate eeeee1  synthase ( bbbbb2 TS eeeee2 ) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of  bbbbb1 thymidylate eeeee1  synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase ( bbbbb2 GARFT eeeee2 ) required for de novo purine synthesis
CRP11	Pemetrexed is a new-generation antifolate inhibitor of  bbbbb1 thymidylate eeeee1  bbbbb2 thymidylate synthase eeeee2  (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis
CRP11	The current study addresses the effect of MTAP on  bbbbb1 pemetrexed eeeee1  bbbbb2 MTAP eeeee2  on pemetrexed activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines
CRP11	The current study addresses the effect of MTAP on  bbbbb1 pemetrexed eeeee1  activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the  bbbbb2 MTAP eeeee2 (+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines
CRP11	The current study addresses the effect of MTAP on  bbbbb1 pemetrexed eeeee1  activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and  bbbbb2 MTAP eeeee2 (-) NCI-H2052 mesothelioma cell lines
CRP11	The current study addresses the effect of MTAP on  bbbbb1 pemetrexed eeeee1  activity using a highly potent transition state inhibitor of  bbbbb2 MTAP eeeee2 , MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines
CRP11	The effect of a novel transition state inhibitor of  bbbbb1 methylthioadenosine eeeee1  bbbbb2 methylthioadenosine phosphorylase eeeee2  on pemetrexed activity
CRP11	The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on  bbbbb1 pemetrexed eeeee1  bbbbb2 methylthioadenosine phosphorylase eeeee2  on pemetrexed activity
CRP11	 bbbbb1 Methylthioadenosine eeeee1  bbbbb2 Methylthioadenosine phosphorylase eeeee2  (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma
CRP11	 bbbbb1 Methylthioadenosine eeeee1  phosphorylase ( bbbbb2 MTAP eeeee2 ) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma
CRP11	Methylthioadenosine phosphorylase (MTAP) salvages  bbbbb1 purines eeeee1  bbbbb2 Methylthioadenosine phosphorylase eeeee2  (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma
CRP11	Methylthioadenosine phosphorylase (MTAP) salvages  bbbbb1 purines eeeee1  bbbbb2 MTAP eeeee2 ) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma
CRP11	A had no effect on pemetrexed activity but, when thymidine was added, the  bbbbb1 pemetrexed eeeee1  IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in  bbbbb2 MTAP eeeee2 (-) H2052 cells
CRP11	A had no effect on pemetrexed activity but, when thymidine was added, the  bbbbb1 pemetrexed eeeee1  IC(50) decreased by a factor of approximately 3 in  bbbbb2 MTAP eeeee2 (+) H28 cells with no effect in MTAP(-) H2052 cells
CRP11	A had no effect on  bbbbb1 pemetrexed eeeee1  activity but, when thymidine was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in  bbbbb2 MTAP eeeee2 (-) H2052 cells
CRP11	A had no effect on  bbbbb1 pemetrexed eeeee1  activity but, when thymidine was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in  bbbbb2 MTAP eeeee2 (+) H28 cells with no effect in MTAP(-) H2052 cells
CRP11	A had no effect on pemetrexed activity but, when  bbbbb1 thymidine eeeee1  was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in  bbbbb2 MTAP eeeee2 (-) H2052 cells
CRP11	A had no effect on pemetrexed activity but, when  bbbbb1 thymidine eeeee1  was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in  bbbbb2 MTAP eeeee2 (+) H28 cells with no effect in MTAP(-) H2052 cells
CRP11	To investigate the capacity of activated PKC to regulate homologous desensitization, we incubated the smooth muscle strips with the combination of both 1 microM PMA and 1 microM  bbbbb1 fenoterol eeeee1  bbbbb2 PKC eeeee2  to regulate homologous desensitization, we incubated the smooth muscle strips with the combination of both 1 microM PMA and 1 microM fenoterol
CRP11	Moreover, the specific PKC-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of  bbbbb1 PMA eeeee1  bbbbb2 PKC eeeee2 -inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented
CRP11	Moreover, the specific PKC-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of  bbbbb1 isoprenaline eeeee1  bbbbb2 PKC eeeee2 -inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented
CRP11	Moreover, the specific PKC-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and  bbbbb1 fenoterol eeeee1  bbbbb2 PKC eeeee2 -inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented
CRP11	Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in  bbbbb1 isoprenaline eeeee1 -induced E(max), indicating activated  bbbbb2 PKC eeeee2 -mediated heterologous beta(2)-adrenoceptor desensitization
CRP11	Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in  bbbbb1 isoprenaline eeeee1  bbbbb2 PKC eeeee2 ) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization
CRP11	Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in  bbbbb1 isoprenaline eeeee1  bbbbb2 protein kinase C eeeee2  (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization
CRP11	LDH activity measured in vitro in serum of men and hamsters was unaffected by  bbbbb1 gossypol eeeee1  bbbbb2 LDH eeeee2  activity measured in vitro in serum of men and hamsters was unaffected by gossypol
CRP11	Gossypol and its isomers were non-competitive inhibitors of huma bbbbb1 n and  eeeee1  bbbbb2 omers were non-comp eeeee2 etitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate
CRP11	Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzy bbbbb1 me NADH, eeeee1  bbbbb2 omers were non-comp eeeee2 etitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate
CRP11	Gossypol and its isomers were non-competit bbbbb1 ive inhibitor eeeee1  bbbbb2 omers were non-comp eeeee2 etitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125),  bbbbb1 Arg eeeee1 (165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125),  bbbbb1 Arg eeeee1 (165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and  bbbbb1 Arg eeeee1 (240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and  bbbbb1 Arg eeeee1 (240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165),  bbbbb1 Lys eeeee1 (169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165),  bbbbb1 Lys eeeee1 (169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues  bbbbb1 Arg eeeee1 (93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues  bbbbb1 Arg eeeee1 (93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of  bbbbb1 calcium eeeee1  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of  bbbbb1 calcium eeeee1  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of  bbbbb1 calcium eeeee1  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of  bbbbb1 calcium eeeee1  bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb1 N eeeee1 -terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb1 N eeeee1  bbbbb2 factor Xa eeeee2  that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb1 N eeeee1  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb1 N eeeee1  bbbbb2 chymotrypsin eeeee2  numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96),  bbbbb1 Arg eeeee1 (125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96),  bbbbb1 Arg eeeee1 (125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169),  bbbbb1 Lys eeeee1 (236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169),  bbbbb1 Lys eeeee1 (236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93),  bbbbb1 Lys eeeee1 (96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the  bbbbb2 proteinase eeeee2  was neutralized by physiological levels of calcium
CRP11	Recent studies have indicated that the basic residues Arg(93),  bbbbb1 Lys eeeee1 (96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic  bbbbb2 N-terminal Gla domain eeeee2  of the proteinase was neutralized by physiological levels of calcium
CRP11	Binding of a full-length heparin chain to this site of factor Xa in the presence of  bbbbb1 calcium eeeee1  makes a significant contribution to acceleration of the proteinase inhibition by  bbbbb2 antithrombin eeeee2  through a ternary complex bridging or template mechanism
CRP11	Binding of a full-length heparin chain to this site of factor Xa in the presence of  bbbbb1 calcium eeeee1  bbbbb2 factor Xa eeeee2  in the presence of calcium makes a significant contribution to acceleration of the proteinase inhibition by antithrombin through a ternary complex bridging or template mechanism
CRP11	Binding of a full-length heparin chain to this site of factor Xa in the presence of  bbbbb1 calcium eeeee1  makes a significant contribution to acceleration of the  bbbbb2 proteinase eeeee2  inhibition by antithrombin through a ternary complex bridging or template mechanism
CRP11	Contribution of the Na+- bbbbb1 K+ eeeee1 -2Cl- cotransporter  bbbbb2 NKCC1 eeeee2  to Cl- secretion in rat OMCD
CRP11	Contribution of the Na+- bbbbb1 K+ eeeee1  bbbbb2 Na+-K+-2Cl- cotransporter eeeee2  NKCC1 to Cl- secretion in rat OMCD
CRP11	Contribution of the Na+-K+- bbbbb1 2Cl- eeeee1  cotransporter  bbbbb2 NKCC1 eeeee2  to Cl- secretion in rat OMCD
CRP11	Contribution of the Na+-K+- bbbbb1 2Cl- eeeee1  bbbbb2 Na+-K+-2Cl- cotransporter eeeee2  NKCC1 to Cl- secretion in rat OMCD
CRP11	Contribution of the  bbbbb1 Na+ eeeee1 -K+-2Cl- cotransporter  bbbbb2 NKCC1 eeeee2  to Cl- secretion in rat OMCD
CRP11	Contribution of the  bbbbb1 Na+ eeeee1  bbbbb2 Na+-K+-2Cl- cotransporter eeeee2  NKCC1 to Cl- secretion in rat OMCD
CRP11	Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or  bbbbb1 NH eeeee1 , consistent with the ion dependency of  bbbbb2 NKCC1 eeeee2 -mediated Cl- transport
CRP11	 bbbbb1 Bumetanide eeeee1 -sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of  bbbbb2 NKCC1 eeeee2 -mediated Cl- transport
CRP11	Bumetanide-sensitive  bbbbb1 Cl- eeeee1  secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of  bbbbb2 NKCC1 eeeee2 -mediated Cl- transport
CRP11	Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either  bbbbb1 K+ eeeee1  or NH, consistent with the ion dependency of  bbbbb2 NKCC1 eeeee2 -mediated Cl- transport
CRP11	Bumetanide-sensitive Cl- secretion was dependent on extracellular  bbbbb1 Na+ eeeee1  and either K+ or NH, consistent with the ion dependency of  bbbbb2 NKCC1 eeeee2 -mediated Cl- transport
CRP11	In rat kidney the "secretory" isoform of the Na+- bbbbb1 K+ eeeee1 -2Cl- cotransporter ( bbbbb2 NKCC1 eeeee2 ) localizes to the basolateral membrane of the alpha-intercalated cell
CRP11	In rat kidney the "secretory" isoform of the Na+- bbbbb1 K+ eeeee1  bbbbb2 Na+-K+-2Cl- cotransporter eeeee2  (NKCC1) localizes to the basolateral membrane of the alpha-intercalated cell
CRP11	In rat kidney the "secretory" isoform of the  bbbbb1 Na+ eeeee1 -K+-2Cl- cotransporter ( bbbbb2 NKCC1 eeeee2 ) localizes to the basolateral membrane of the alpha-intercalated cell
CRP11	In rat kidney the "secretory" isoform of the  bbbbb1 Na+ eeeee1  bbbbb2 Na+-K+-2Cl- cotransporter eeeee2  (NKCC1) localizes to the basolateral membrane of the alpha-intercalated cell
CRP11	In rat kidney the "secretory" isoform of the Na+-K+- bbbbb1 2Cl- eeeee1  cotransporter ( bbbbb2 NKCC1 eeeee2 ) localizes to the basolateral membrane of the alpha-intercalated cell
CRP11	In rat kidney the "secretory" isoform of the Na+-K+- bbbbb1 2Cl- eeeee1  bbbbb2 Na+-K+-2Cl- cotransporter eeeee2  (NKCC1) localizes to the basolateral membrane of the alpha-intercalated cell
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate,  bbbbb1 risperidone eeeee1  bbbbb2 P-glycoprotein eeeee2  (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate,  bbbbb1 risperidone eeeee1  bbbbb2 P-gp eeeee2 ) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite,  bbbbb1 9-hydroxyrisperidone eeeee1  in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and  bbbbb2 P-glycoprotein eeeee2  (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite,  bbbbb1 9-hydroxyrisperidone eeeee1  in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein ( bbbbb2 P-gp eeeee2 ) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite,  bbbbb1 9-hydroxyrisperidone eeeee1  in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  bbbbb2 P-gp eeeee2  substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite,  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 P-glycoprotein eeeee2  (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite,  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 P-gp eeeee2 ) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of  bbbbb1 risperidone eeeee1  and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and  bbbbb2 P-glycoprotein eeeee2  (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of  bbbbb1 risperidone eeeee1  and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein ( bbbbb2 P-gp eeeee2 ) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of  bbbbb1 risperidone eeeee1  and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a  bbbbb2 P-gp eeeee2  substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 P-glycoprotein eeeee2  (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 P-gp eeeee2 ) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and  bbbbb1 9-hydroxyrisperidone eeeee1  bbbbb2 P-gp eeeee2  substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of  bbbbb1 risperidone eeeee1  bbbbb2 P-glycoprotein eeeee2  (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of  bbbbb1 risperidone eeeee1  bbbbb2 P-gp eeeee2 ) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats. 1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of  bbbbb1 risperidone eeeee1  bbbbb2 P-gp eeeee2  substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction
CRP11	Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of risperidone and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p < 0.001) and 1.7-fold (p < 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p < 0.05) and 2.1-fold (p < 0.01), respectively bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of  bbbbb1 risperidone eeeee1  and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p < 0.001) and 1.7-fold (p < 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p < 0.05) and 2.1-fold (p < 0.01), respectively bbbbb2  eeeee2 
CRP11	Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of risperidone and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p < 0.001) and 1.7-fold (p < 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p < 0.05) and 2.1-fold (p < 0.01), respectively bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of risperidone and  bbbbb1 9-hydroxyrisperidone eeeee1  were significantly increased to 2.4-fold (p < 0.001) and 1.7-fold (p < 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p < 0.05) and 2.1-fold (p < 0.01), respectively bbbbb2  eeeee2 
CRP11	Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving  bbbbb1 risperidone eeeee1 , the C(max) of risperidone and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p < 0.001) and 1.7-fold (p < 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p < 0.05) and 2.1-fold (p < 0.01), respectively bbbbb2  eeeee2 
CRP11	These xenobiotic/endobiotic-sensing nuclear receptors regulate phase I oxidation, phase II conjugation, and phase III transport in  bbbbb1 bile acid eeeee1  bbbbb2 xenobiotic/endobiotic-sensing nuclear receptors eeeee2  regulate phase I oxidation, phase II conjugation, and phase III transport in bile acid and drug metabolism in the digestive system
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and  bbbbb1 vitamin D eeeee1  bbbbb2 vitamin D receptor eeeee2 , and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and  bbbbb1 vitamin D eeeee1  bbbbb2 farnesoid X receptor eeeee2 , pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and  bbbbb1 vitamin D eeeee1  bbbbb2 constitutive androstane receptor eeeee2 , and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and  bbbbb1 vitamin D eeeee1  bbbbb2 pregnane X receptor eeeee2 , constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and  bbbbb1 vitamin D eeeee1  bbbbb2 nuclear receptors eeeee2 , such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive  bbbbb1 androstane eeeee1  receptor, and  bbbbb2 vitamin D receptor eeeee2 , and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive  bbbbb1 androstane eeeee1  bbbbb2 farnesoid X receptor eeeee2 , pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive  bbbbb1 androstane eeeee1  bbbbb2 constitutive androstane receptor eeeee2 , and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive  bbbbb1 androstane eeeee1  bbbbb2 pregnane X receptor eeeee2 , constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive  bbbbb1 androstane eeeee1  bbbbb2 nuclear receptors eeeee2 , such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid,  bbbbb1 glucose eeeee1  bbbbb2 vitamin D receptor eeeee2 , and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid,  bbbbb1 glucose eeeee1  bbbbb2 farnesoid X receptor eeeee2 , pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid,  bbbbb1 glucose eeeee1  bbbbb2 constitutive androstane receptor eeeee2 , and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid,  bbbbb1 glucose eeeee1  bbbbb2 pregnane X receptor eeeee2 , constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid,  bbbbb1 glucose eeeee1  bbbbb2 nuclear receptors eeeee2 , such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor,  bbbbb1 pregnane eeeee1  X receptor, constitutive androstane receptor, and  bbbbb2 vitamin D receptor eeeee2 , and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor,  bbbbb1 pregnane eeeee1  bbbbb2 farnesoid X receptor eeeee2 , pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor,  bbbbb1 pregnane eeeee1  X receptor,  bbbbb2 constitutive androstane receptor eeeee2 , and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor,  bbbbb1 pregnane eeeee1  bbbbb2 pregnane X receptor eeeee2 , constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor,  bbbbb1 pregnane eeeee1  bbbbb2 nuclear receptors eeeee2 , such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism
CRP11	Nuclear receptors in  bbbbb1 bile acid eeeee1  bbbbb2 Nuclear receptors eeeee2  in bile acid metabolism
CRP11	Boron-based inhibitors of  bbbbb1 acyl eeeee1  bbbbb2 acyl protein thioesterases 1 and 2 eeeee2 
CRP11	Inhibition of the Ras-depalmitoylating enzyme  bbbbb1 acyl eeeee1  protein thioesterases APT1 and -2 is a new approach to modulating the  bbbbb2 Ras eeeee2  cycle
CRP11	Inhibition of the Ras-depalmitoylating enzyme  bbbbb1 acyl eeeee1  bbbbb2 Ras eeeee2 -depalmitoylating enzyme acyl protein thioesterases APT1 and -2 is a new approach to modulating the Ras cycle
CRP11	Inhibition of the Ras-depalmitoylating enzyme  bbbbb1 acyl eeeee1  bbbbb2 acyl protein thioesterases APT1 and -2 eeeee2  is a new approach to modulating the Ras cycle
CRP11	Neuromuscular blocking drugs produce muscle weakness by interaction with nicotinic- bbbbb1 acetylcholine eeeee1  bbbbb2 nicotinic-acetylcholine receptors eeeee2 
CRP11	Insertion of ERα was blocked by the ER antagonist  bbbbb1 ICI 182,780 eeeee1  or with the  bbbbb2 protein kinase C eeeee2  (PKC) pathway inhibitor bisindolylmaleimide (BIS)
CRP11	Insertion of ERα was blocked by the ER antagonist  bbbbb1 ICI 182,780 eeeee1  or with the protein kinase C ( bbbbb2 PKC eeeee2 ) pathway inhibitor bisindolylmaleimide (BIS)
CRP11	Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor  bbbbb1 bisindolylmaleimide eeeee1  bbbbb2 ER eeeee2  antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)
CRP11	Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide ( bbbbb1 BIS eeeee1  bbbbb2 ER eeeee2  antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)
CRP11	Regulation of sexual reproduction by estradiol involves the activation of  bbbbb1 estrogen eeeee1  receptors ( bbbbb2 ERs eeeee2 ) in the hypothalamus
CRP11	Regulation of sexual reproduction by estradiol involves the activation of  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptors eeeee2  (ERs) in the hypothalamus
CRP11	The alpha 1-adrenoceptor alkylating agent CEC selectively inhibited the phasic component of the  bbbbb1 norepinephrine eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2  alkylating agent CEC selectively inhibited the phasic component of the norepinephrine-induced contractile response, with little effect on the tonic component
CRP11	Using the alpha 1-adrenoceptor subtype-selective antagonists  bbbbb1 chlorethylclonidine eeeee1  (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the  bbbbb2 alpha 1-adrenoceptor eeeee2  populations in rabbit aorta
CRP11	Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine ( bbbbb1 CEC eeeee1 ), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the  bbbbb2 alpha 1-adrenoceptor eeeee2  populations in rabbit aorta
CRP11	Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and  bbbbb1 5-methyl-urapidil eeeee1 , we have examined the possible heterogeneity in the  bbbbb2 alpha 1-adrenoceptor eeeee2  populations in rabbit aorta
CRP11	Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC),  bbbbb1 WB4101 eeeee1 , and 5-methyl-urapidil, we have examined the possible heterogeneity in the  bbbbb2 alpha 1-adrenoceptor eeeee2  populations in rabbit aorta
CRP11	Moreover, alpha 1-adrenoceptor-mediated  bbbbb1 phosphatidylinositol eeeee1  (PI) hydrolysis was CEC sensitive, and fractional inactivation of  bbbbb2 alpha 1 receptors eeeee2  with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated  bbbbb1 phosphatidylinositol eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2 -mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with  bbbbb1 CEC eeeee1  bbbbb2 alpha 1 receptors eeeee2  with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with  bbbbb1 CEC eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2 -mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol ( bbbbb1 PI eeeee1 ) hydrolysis was CEC sensitive, and fractional inactivation of  bbbbb2 alpha 1 receptors eeeee2  with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol ( bbbbb1 PI eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2 -mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was  bbbbb1 CEC eeeee1  sensitive, and fractional inactivation of  bbbbb2 alpha 1 receptors eeeee2  with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was  bbbbb1 CEC eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2 -mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the  bbbbb1 CEC eeeee1  bbbbb2 alpha 1 receptors eeeee2  with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the  bbbbb1 CEC eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2 -mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of  bbbbb1 PI eeeee1  bbbbb2 alpha 1 receptors eeeee2  with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of  bbbbb1 PI eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2 -mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites
CRP11	The alpha 1-adrenoceptor occupancy-response relationship defined by the  bbbbb1 phenoxybenzamine eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2  occupancy-response relationship defined by the phenoxybenzamine inactivation method was rectangular hyperbolic for the tonic response, whereas that for the phasic response was linear, indicating the different degree of receptor reserve for the two responses
CRP11	Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different  bbbbb1 Ca2+ eeeee1  bbbbb2 alpha 1-adrenoceptor eeeee2  subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role
CRP11	The small mRNA promoter resides in the 4th intron and evidence is provided that the mRNA encodes only the domain corresponding to  bbbbb1 prolyl eeeee1  bbbbb2 prolyl-tRNA synthetase eeeee2  and is functional in vivo
CRP11	Drosophila,  bbbbb1 glutamyl eeeee1  bbbbb2 glutamyl-prolyl-tRNA synthetase eeeee2  is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J. 10, 4267-4277]
CRP11	Evolution of the aminoacyl-tRNA synthetase family and the organization of the Drosophila  bbbbb1 glutamyl eeeee1  bbbbb2 glutamyl-prolyl-tRNA synthetase eeeee2  gene
CRP11	Evolution of the aminoacyl-tRNA synthetase family and the organization of the Drosophila  bbbbb1 glutamyl eeeee1  bbbbb2 aminoacyl-tRNA synthetase eeeee2  family and the organization of the Drosophila glutamyl-prolyl-tRNA synthetase gene
CRP11	Evolution of the  bbbbb1 aminoacyl eeeee1 -tRNA synthetase family and the organization of the Drosophila  bbbbb2 glutamyl-prolyl-tRNA synthetase eeeee2  gene
CRP11	Evolution of the  bbbbb1 aminoacyl eeeee1  bbbbb2 aminoacyl-tRNA synthetase eeeee2  family and the organization of the Drosophila glutamyl-prolyl-tRNA synthetase gene
CRP11	Expression of  bbbbb1 cAMP eeeee1 -responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of  bbbbb2 collagen-tailed subunit eeeee2  (ColQ) of acetylcholinesterase at the rat neuromuscular junction
CRP11	Expression of  bbbbb1 cAMP eeeee1 -responsive element binding proteins ( bbbbb2 CREBs eeeee2 ) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of acetylcholinesterase at the rat neuromuscular junction
CRP11	Expression of  bbbbb1 cAMP eeeee1 -responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of  bbbbb2 acetylcholinesterase eeeee2  at the rat neuromuscular junction
CRP11	Expression of  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-responsive element binding proteins eeeee2  (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of acetylcholinesterase at the rat neuromuscular junction
CRP11	Expression of  bbbbb1 cAMP eeeee1 -responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit ( bbbbb2 ColQ eeeee2 ) of acetylcholinesterase at the rat neuromuscular junction
CRP11	To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of  bbbbb1 cAMP eeeee1 -responsive element binding protein ( bbbbb2 CREB eeeee2 ) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats
CRP11	To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of  bbbbb1 cAMP eeeee1  bbbbb2 cAMP-responsive element binding protein eeeee2  (CREB) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats
CRP11	To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of  bbbbb1 cAMP eeeee1  bbbbb2 ColQ-1a's eeeee2  synaptic expression, here we investigated the expression and localization of cAMP-responsive element binding protein (CREB) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats
CRP11	In contrast, P-CREB was detected in both synaptic and extra-synaptic regions of slow-twitch muscle bbbbb1  eeeee1  bbbbb2 s of s eeeee2 low-twitch muscle
CRP11	Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted  bbbbb1 methionine eeeee1  bbbbb2 ACE eeeee2  inhibitors in high dieted methionine mice
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group),  bbbbb1 enalapril eeeee1  bbbbb2 ACE eeeee2  inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group),  bbbbb1 enalapril eeeee1  (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not  bbbbb2 ACE eeeee2  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without - bbbbb1 SH eeeee1  bbbbb2 ACE eeeee2  inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without - bbbbb1 SH eeeee1  group), N-acetylcysteine (only -SH group not  bbbbb2 ACE eeeee2  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without - bbbbb1 SH eeeee1  bbbbb2 ACE eeeee2 -inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of  bbbbb1 Captopril eeeee1  (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not  bbbbb2 ACE eeeee2  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of  bbbbb1 Captopril eeeee1  (an ACE inhibitor with -SH group), enalapril (an  bbbbb2 ACE eeeee2 -inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group),  bbbbb1 N-acetylcysteine eeeee1  bbbbb2 ACE eeeee2  inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group),  bbbbb1 N-acetylcysteine eeeee1  bbbbb2 ACE eeeee2 -inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only - bbbbb1 SH eeeee1  bbbbb2 ACE eeeee2  inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only - bbbbb1 SH eeeee1  group not  bbbbb2 ACE eeeee2  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only - bbbbb1 SH eeeee1  bbbbb2 ACE eeeee2 -inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by  bbbbb1 methionine eeeee1  bbbbb2 ACE eeeee2  inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by  bbbbb1 methionine eeeee1  bbbbb2 ACE eeeee2  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by  bbbbb1 methionine eeeee1  bbbbb2 ACE eeeee2 -inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with - bbbbb1 SH eeeee1  group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not  bbbbb2 ACE eeeee2  inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	We compared the effects of Captopril (an ACE inhibitor with - bbbbb1 SH eeeee1  group), enalapril (an  bbbbb2 ACE eeeee2 -inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to  bbbbb1 ACh eeeee1 , and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and  bbbbb2 SOD eeeee2  in serum by single intragastric gavaged L-methionine
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to  bbbbb1 ACh eeeee1 , and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of  bbbbb2 PON1 eeeee2  and SOD in serum by single intragastric gavaged L-methionine
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of  bbbbb1 NO eeeee1 , activity of PON1 and  bbbbb2 SOD eeeee2  in serum by single intragastric gavaged L-methionine
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of  bbbbb1 NO eeeee1 , activity of  bbbbb2 PON1 eeeee2  and SOD in serum by single intragastric gavaged L-methionine
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and SOD in serum by single intragastric gavaged  bbbbb1 L-methionine eeeee1  bbbbb2 SOD eeeee2  in serum by single intragastric gavaged L-methionine
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and SOD in serum by single intragastric gavaged  bbbbb1 L-methionine eeeee1  bbbbb2 PON1 eeeee2  and SOD in serum by single intragastric gavaged L-methionine
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of  bbbbb1 malondialdehyde eeeee1 , the decreased level of NO, activity of PON1 and  bbbbb2 SOD eeeee2  in serum by single intragastric gavaged L-methionine
CRP11	Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of  bbbbb1 malondialdehyde eeeee1 , the decreased level of NO, activity of  bbbbb2 PON1 eeeee2  and SOD in serum by single intragastric gavaged L-methionine
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 ACE eeeee2  activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde ( bbbbb1 MDA eeeee1 ), nitric oxide (NO), superoxide dismutase ( bbbbb2 SOD eeeee2 ) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde ( bbbbb1 MDA eeeee1 ), nitric oxide (NO),  bbbbb2 superoxide dismutase eeeee2  (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 PON1 eeeee2 ) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde ( bbbbb1 MDA eeeee1  bbbbb2 Paraoxonase1 eeeee2  (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO),  bbbbb1 superoxide eeeee1  bbbbb2 ACE eeeee2  activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO),  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO),  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO),  bbbbb1 superoxide eeeee1  bbbbb2 PON1 eeeee2 ) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO),  bbbbb1 superoxide eeeee1  bbbbb2 Paraoxonase1 eeeee2  (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 ACE eeeee2  activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide ( bbbbb1 NO eeeee1 ), superoxide dismutase ( bbbbb2 SOD eeeee2 ) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide ( bbbbb1 NO eeeee1 ),  bbbbb2 superoxide dismutase eeeee2  (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 PON1 eeeee2 ) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 Paraoxonase1 eeeee2  (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA),  bbbbb1 nitric oxide eeeee1  bbbbb2 ACE eeeee2  activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA),  bbbbb1 nitric oxide eeeee1  (NO), superoxide dismutase ( bbbbb2 SOD eeeee2 ) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA),  bbbbb1 nitric oxide eeeee1  (NO),  bbbbb2 superoxide dismutase eeeee2  (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA),  bbbbb1 nitric oxide eeeee1  bbbbb2 PON1 eeeee2 ) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA),  bbbbb1 nitric oxide eeeee1  bbbbb2 Paraoxonase1 eeeee2  (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity,  bbbbb1 malondialdehyde eeeee1  bbbbb2 ACE eeeee2  activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity,  bbbbb1 malondialdehyde eeeee1  (MDA), nitric oxide (NO), superoxide dismutase ( bbbbb2 SOD eeeee2 ) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity,  bbbbb1 malondialdehyde eeeee1  (MDA), nitric oxide (NO),  bbbbb2 superoxide dismutase eeeee2  (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity,  bbbbb1 malondialdehyde eeeee1  bbbbb2 PON1 eeeee2 ) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	Paraoxonase1 (PON1) and ACE activity,  bbbbb1 malondialdehyde eeeee1  bbbbb2 Paraoxonase1 eeeee2  (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and  bbbbb1 angiotensin eeeee1  bbbbb2 SOD eeeee2 , similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and  bbbbb1 angiotensin eeeee1  bbbbb2 PON1 eeeee2  and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of  bbbbb1 NO eeeee1  bbbbb2 SOD eeeee2 , similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of  bbbbb1 NO eeeee1  bbbbb2 PON1 eeeee2  and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of  bbbbb1 NO eeeee1  in the serum; but had no effects on endothelium-independent relaxation and  bbbbb2 angiotensin-converting enzyme eeeee2  activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of  bbbbb1 malondialdehyde eeeee1  and decreased the activity of PON1 and  bbbbb2 SOD eeeee2 , similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of  bbbbb1 malondialdehyde eeeee1  and decreased the activity of  bbbbb2 PON1 eeeee2  and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group
CRP11	It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of  bbbbb1 malondialdehyde eeeee1  and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and  bbbbb2 angiotensin-converting enzyme eeeee2  activity compared with the control group
CRP11	To examine the role of sulfhydryl (- bbbbb1 SH eeeee1 ) group in improvement of endothelial dysfunction with  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors in experimental high dose of methionine dieted rats
CRP11	To examine the role of sulfhydryl (- bbbbb1 SH eeeee1 ) group in improvement of endothelial dysfunction with angiotensin-converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors in experimental high dose of methionine dieted rats
CRP11	To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with angiotensin-converting enzyme (ACE) inhibitors in experimental high dose of  bbbbb1 methionine eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors in experimental high dose of methionine dieted rats
CRP11	To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with angiotensin-converting enzyme (ACE) inhibitors in experimental high dose of  bbbbb1 methionine eeeee1  bbbbb2 ACE eeeee2 ) inhibitors in experimental high dose of methionine dieted rats
CRP11	To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with  bbbbb1 angiotensin eeeee1  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors in experimental high dose of methionine dieted rats
CRP11	To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with  bbbbb1 angiotensin eeeee1 -converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors in experimental high dose of methionine dieted rats
CRP11	To examine the role of  bbbbb1 sulfhydryl eeeee1  (-SH) group in improvement of endothelial dysfunction with  bbbbb2 angiotensin-converting enzyme eeeee2  (ACE) inhibitors in experimental high dose of methionine dieted rats
CRP11	To examine the role of  bbbbb1 sulfhydryl eeeee1  (-SH) group in improvement of endothelial dysfunction with angiotensin-converting enzyme ( bbbbb2 ACE eeeee2 ) inhibitors in experimental high dose of methionine dieted rats
CRP11	HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 inducible nitric oxide synthase eeeee2  (iNOS), and tumor necrosis factor-α (TNF- α)
CRP11	HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 cyclooxygenase-2 eeeee2  (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CRP11	HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible  bbbbb1 nitric oxide eeeee1  synthase ( bbbbb2 iNOS eeeee2 ), and tumor necrosis factor-α (TNF- α)
CRP11	HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible  bbbbb1 nitric oxide eeeee1  bbbbb2 COX-2 eeeee2 ), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α)
CRP11	HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), and tumor necrosis factor-α ( bbbbb2 TNF- α eeeee2 )
CRP11	HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible  bbbbb1 nitric oxide eeeee1  synthase (iNOS), and  bbbbb2 tumor necrosis factor-α eeeee2  (TNF- α)
CRP11	 bbbbb1 Argininosuccinate eeeee1  bbbbb2 Argininosuccinate synthetase eeeee2 , arginase I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5/6 nephrectomy or sham operation
CRP11	 bbbbb1 Argininosuccinate eeeee1  synthetase,  bbbbb2 arginase I and II eeeee2  protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5/6 nephrectomy or sham operation
CRP11	Sources of L-arg include dietary proteins and endogenous synthesis by  bbbbb1 argininosuccinate eeeee1  synthetase and  bbbbb2 argininosuccinate lyase eeeee2 
CRP11	Sources of L-arg include dietary proteins and endogenous synthesis by  bbbbb1 argininosuccinate eeeee1  bbbbb2 argininosuccinate synthetase eeeee2  and argininosuccinate lyase
CRP11	Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and  bbbbb1 argininosuccinate eeeee1  bbbbb2 argininosuccinate lyase eeeee2 
CRP11	Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and  bbbbb1 argininosuccinate eeeee1  bbbbb2 argininosuccinate synthetase eeeee2  and argininosuccinate lyase
CRP11	The preferential cytotoxic effect of  bbbbb1 STZ eeeee1  on GLUT2-expressing cell lines was confirmed by in vitro analysis of GLUT2-expressing and untransfected RIN cells, as well as  bbbbb2 GLUT2 eeeee2 - and GLUT1-overexpressing AtT-20ins cells
CRP11	The preferential cytotoxic effect of  bbbbb1 STZ eeeee1  on GLUT2-expressing cell lines was confirmed by in vitro analysis of  bbbbb2 GLUT2 eeeee2 -expressing and untransfected RIN cells, as well as GLUT2- and GLUT1-overexpressing AtT-20ins cells
CRP11	The preferential cytotoxic effect of  bbbbb1 STZ eeeee1  on  bbbbb2 GLUT2 eeeee2 -expressing cell lines was confirmed by in vitro analysis of GLUT2-expressing and untransfected RIN cells, as well as GLUT2- and GLUT1-overexpressing AtT-20ins cells
CRP11	The preferential cytotoxic effect of  bbbbb1 STZ eeeee1  on GLUT2-expressing cell lines was confirmed by in vitro analysis of GLUT2-expressing and untransfected RIN cells, as well as GLUT2- and  bbbbb2 GLUT1 eeeee2 -overexpressing AtT-20ins cells
CRP11	The drug had a potent cytotoxic effect on RIN cells expressing GLUT2, but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood  bbbbb1 glucose eeeee1  bbbbb2 GLUT2 eeeee2  expression, as indicated by histological analysis and measurement of the blood glucose levels of treated animals
CRP11	The in vivo effects of  bbbbb1 STZ eeeee1  were evaluated by implantation of RIN cells expressing or lacking  bbbbb2 GLUT2 eeeee2  into athymic nude rats
CRP11	In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of glucose transporter isoforms in mediating  bbbbb1 STZ eeeee1  bbbbb2 GLUT1 eeeee2  to investigate the role of glucose transporter isoforms in mediating STZ cytotoxicity
CRP11	In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of glucose transporter isoforms in mediating  bbbbb1 STZ eeeee1  bbbbb2 glucose transporter eeeee2  isoforms in mediating STZ cytotoxicity
CRP11	In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of glucose transporter isoforms in mediating  bbbbb1 STZ eeeee1  bbbbb2 GLUT2 eeeee2  or GLUT1 to investigate the role of glucose transporter isoforms in mediating STZ cytotoxicity
CRP11	In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of  bbbbb1 glucose eeeee1  bbbbb2 GLUT1 eeeee2  to investigate the role of glucose transporter isoforms in mediating STZ cytotoxicity
CRP11	In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter eeeee2  isoforms in mediating STZ cytotoxicity
CRP11	In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of  bbbbb1 glucose eeeee1  bbbbb2 GLUT2 eeeee2  or GLUT1 to investigate the role of glucose transporter isoforms in mediating STZ cytotoxicity
CRP11	In a search for less flexible analogues of caproctamine (1), a diamine diamide endowed with an interesting AChE affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a  bbbbb1 tricyclic eeeee1  bbbbb2 AChE eeeee2  affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system
CRP11	In a search for less flexible analogues of caproctamine (1), a diamine diamide endowed with an interesting AChE affinity profile, we discovered compound 2, in which the terminal  bbbbb1 2-methoxybenzyl eeeee1  bbbbb2 AChE eeeee2  affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system
CRP11	Since this compound retains good AChE inhibitory activity and its  bbbbb1 hexahydrochromeno[4,3-b]pyrrole eeeee1  moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against  bbbbb2 human AChE eeeee2  and BChE
CRP11	Since this compound retains good AChE inhibitory activity and its  bbbbb1 hexahydrochromeno[4,3-b]pyrrole eeeee1  moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and  bbbbb2 BChE eeeee2 
CRP11	Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the  bbbbb1 hexahydropyrrolo[2,3-b]indole of physostigmine eeeee1  (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against  bbbbb2 human AChE eeeee2  and BChE
CRP11	Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the  bbbbb1 hexahydropyrrolo[2,3-b]indole of physostigmine eeeee1  (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and  bbbbb2 BChE eeeee2 
CRP11	Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized  bbbbb1 carbamates eeeee1  4-6, and their biological evaluation has been assessed in vitro against  bbbbb2 human AChE eeeee2  and BChE
CRP11	Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized  bbbbb1 carbamates eeeee1  bbbbb2 AChE eeeee2  inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE
CRP11	Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized  bbbbb1 carbamates eeeee1  4-6, and their biological evaluation has been assessed in vitro against human AChE and  bbbbb2 BChE eeeee2 
CRP11	Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H: bbbbb1 quinone eeeee1  oxidoreductase isozyme 1 ( bbbbb2 hNQO1 eeeee2 )
CRP11	Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H: bbbbb1 quinone eeeee1  bbbbb2 human NAD(P)H:quinone oxidoreductase isozyme 1 eeeee2  (hNQO1)
CRP11	Fluorescence of the reporter dye is turned on by rapid removal of the  bbbbb1 quinone eeeee1  quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 ( bbbbb2 hNQO1 eeeee2 )
CRP11	Fluorescence of the reporter dye is turned on by rapid removal of the  bbbbb1 quinone eeeee1  quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated  bbbbb2 human NAD(P)H:quinone oxidoreductase isozyme 1 eeeee2  (hNQO1)
CRP11	We have previously isolated from human hemofiltrate an  bbbbb1 N eeeee1 -terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent  bbbbb2 CCR3 eeeee2 
CRP11	We have previously isolated from human hemofiltrate an  bbbbb1 N eeeee1 -terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized HCC-1[9-74] as a strong agonist of  bbbbb2 CCR1 eeeee2 , CCR5, and to a lower extent CCR3
CRP11	We have previously isolated from human hemofiltrate an  bbbbb1 N eeeee1 -terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized  bbbbb2 HCC-1[9-74] eeeee2  as a strong agonist of CCR1, CCR5, and to a lower extent CCR3
CRP11	We have previously isolated from human hemofiltrate an  bbbbb1 N eeeee1 -terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1,  bbbbb2 CCR5 eeeee2 , and to a lower extent CCR3
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and  bbbbb1 pyridoxine 5'-phosphate eeeee1  bbbbb2 pyridoxal kinase eeeee2  (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and  bbbbb1 pyridoxine 5'-phosphate eeeee1  bbbbb2 PLK eeeee2 ) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and  bbbbb1 pyridoxine 5'-phosphate eeeee1  oxidase ( bbbbb2 PNPO eeeee2 ), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and  bbbbb1 pyridoxine 5'-phosphate eeeee1  bbbbb2 pyridoxine 5'-phosphate oxidase eeeee2  (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes,  bbbbb1 pyridoxal eeeee1  bbbbb2 pyridoxal kinase eeeee2  (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes,  bbbbb1 pyridoxal eeeee1  kinase ( bbbbb2 PLK eeeee2 ) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes,  bbbbb1 pyridoxal eeeee1  kinase (PLK) and pyridoxine 5'-phosphate oxidase ( bbbbb2 PNPO eeeee2 ), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes,  bbbbb1 pyridoxal eeeee1  kinase (PLK) and  bbbbb2 pyridoxine 5'-phosphate oxidase eeeee2  (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper
CRP11	In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of Torpedo californica AChE soaked with the reversible inhibitor  bbbbb1 edrophonium eeeee1  bbbbb2 AChE eeeee2 , a data set has been collected using the Laue technique on a trigonal crystal of Torpedo californica AChE soaked with the reversible inhibitor edrophonium, using a total X-ray exposure time of 24 ms
CRP11	Involvement of P450 mediated metabolism in  bbbbb1 the absor eeeee1 ption of darunavir could not be demonstrated in this rat model bbbbb2  eeeee2 
CRP11	Involvement of P450 mediated metabolism in the absorption  bbbbb1 of darunavir eeeee1  could not be demonstrated in this rat model bbbbb2  eeeee2 
CRP11	The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of  bbbbb1 darunavir eeeee1  with the  bbbbb2 P-gp eeeee2  inhibitor zosuquidar
CRP11	The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of  bbbbb1 darunavir eeeee1  bbbbb2 P-gp eeeee2  in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar
CRP11	The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor  bbbbb1 zosuquidar eeeee1  bbbbb2 P-gp eeeee2  in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar
CRP11	The involvement of P-gp in the absorption of  bbbbb1 darunavir eeeee1  was clearly shown by coperfusion of darunavir with the  bbbbb2 P-gp eeeee2  inhibitor zosuquidar
CRP11	As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin;  bbbbb1 meloxicam eeeee1  bbbbb2 COX-2 eeeee2  than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined
CRP11	Characterization of binding sites of a new  bbbbb1 neurotensin eeeee1  bbbbb2 neurotensin receptor eeeee2  antagonist, [3H]SR 142948A, in the rat brain
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist,  bbbbb1 levocabastine eeeee1 , revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive  bbbbb2 neurotensin NT1 receptors eeeee2  (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist,  bbbbb1 levocabastine eeeee1 , revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive  bbbbb2 neurotensin NT2 receptors eeeee2  (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive  bbbbb1 neurotensin eeeee1  bbbbb2 neurotensin NT1 receptors eeeee2  (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive  bbbbb1 neurotensin eeeee1  NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive  bbbbb2 neurotensin NT2 receptors eeeee2  (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive  bbbbb1 neurotensin eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that  bbbbb1 [3H]SR 142948A eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the  bbbbb1 levocabastine eeeee1 -insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive  bbbbb2 neurotensin NT2 receptors eeeee2  (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the  bbbbb1 levocabastine eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the  bbbbb1 histamine eeeee1  H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive  bbbbb2 neurotensin NT1 receptors eeeee2  (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the  bbbbb1 histamine eeeee1  H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive  bbbbb2 neurotensin NT2 receptors eeeee2  (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the  bbbbb1 histamine eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned  bbbbb1 levocabastine eeeee1  bbbbb2 neurotensin NT1 receptors eeeee2  (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned  bbbbb1 levocabastine eeeee1  bbbbb2 histamine H1 receptor eeeee2  antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)
CRP11	The regional distribution of [3H]SR 142948A binding in the rat brain closely matched the distribution of [125I]neurotensin binding bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The regional distribution of [3H]SR 142948A binding in the rat brain closely matched the distribution of [125I]neurotensin binding bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The regional distribution of [3H]SR 142948A binding in the rat brain closely matched the distribution of [125I]neurotensin binding bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The regional distribution of [3H]SR 142948A binding in the rat brain closely matched the distribution of [125I]neurotensin binding bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The regional distribution of [3H]SR 142948A binding in the rat brain closely matched the distribution of [125I]neurotensin binding bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The regional distribution of [3H]SR 142948A binding in the rat brain closely matched the distribution of [125I]neurotensin binding bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin. [3H]SR 142948A binding was inhibited by  bbbbb1 SR 142948A eeeee1 , the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and  bbbbb2 neurotensin eeeee2 
CRP11	The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with  bbbbb1 [3H]neurotensin eeeee1 . [3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and  bbbbb2 neurotensin eeeee2 
CRP11	The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable.  bbbbb1 [3H]SR 142948A eeeee1  bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin. [3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and  bbbbb2 neurotensin eeeee2 
CRP11	The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin. [3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist,  bbbbb1 SR 48692 eeeee1  (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and  bbbbb2 neurotensin eeeee2 
CRP11	The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin. [3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and  bbbbb1 neurotensin eeeee1  bbbbb2 neurotensin eeeee2 
CRP11	The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin.  bbbbb1 [3H]SR 142948A eeeee1  binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and  bbbbb2 neurotensin eeeee2 
CRP11	The binding of  bbbbb1 [3H]SR 142948A eeeee1  in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin. [3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and  bbbbb2 neurotensin eeeee2 
CRP11	The binding of [3H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [3H]SR 142948A bound to an apparently homogeneous population of sites, with a Kd of 3.5 nM and a Bmax value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [3H]neurotensin. [3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 ( bbbbb1 2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid eeeee1 ) and  bbbbb2 neurotensin eeeee2 
CRP11	The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of  bbbbb1 neurotensin eeeee1  bbbbb2 neurotensin receptors eeeee2 , [3H]SR 142948A (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain
CRP11	The juvenile visceral steatosis (jvs) mouse, having a mutation in the carnitine transporter gene Octn2, is a model of primary systemic  bbbbb1 carnitine eeeee1  bbbbb2 Octn2 eeeee2 , is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140)
CRP11	We find that  bbbbb1 FP eeeee1  causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 ( bbbbb2 PLA2 eeeee2 )
CRP11	We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (cPLA2), and (2) blockade of leukotriene C4 ( bbbbb1 LTC4 eeeee1  bbbbb2 cPLA2 eeeee2 ), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (cPLA2), and (2) blockade of leukotriene C4 ( bbbbb1 LTC4 eeeee1  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate ( bbbbb1 FP eeeee1 ), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 ( bbbbb2 cPLA2 eeeee2 ), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate ( bbbbb1 FP eeeee1 ), in causing (1) inhibition of nuclear translocation of  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	We examined the effect of the highly lipophilic corticosteroid,  bbbbb1 fluticasone propionate eeeee1  (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 ( bbbbb2 cPLA2 eeeee2 ), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	We examined the effect of the highly lipophilic corticosteroid,  bbbbb1 fluticasone propionate eeeee1  (FP), in causing (1) inhibition of nuclear translocation of  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (cPLA2), and (2) blockade of  bbbbb1 leukotriene C4 eeeee1  bbbbb2 cPLA2 eeeee2 ), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (cPLA2), and (2) blockade of  bbbbb1 leukotriene C4 eeeee1  bbbbb2 cytosolic phospholipase A2 eeeee2  (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro
CRP11	Inhibition of cPLA2 translocation and  bbbbb1 leukotriene C4 eeeee1  bbbbb2 cPLA2 eeeee2  translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils
CRP11	By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of  bbbbb1 LTC4 eeeee1  bbbbb2 annexin-1 eeeee2 , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)
CRP11	By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous  bbbbb1 arachidonic acid eeeee1  bbbbb2 annexin-1 eeeee2 , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)
CRP11	By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid ( bbbbb1 AA eeeee1  bbbbb2 annexin-1 eeeee2 , which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)
CRP11	Exposure to mifepristone (a glucocorticoid receptor antagonist), but not  bbbbb1 spironolactone eeeee1  (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in  bbbbb2 beta- and gamma-ENaC eeeee2  mRNA
CRP11	Exposure to mifepristone (a glucocorticoid receptor antagonist), but not  bbbbb1 spironolactone eeeee1  bbbbb2 glucocorticoid receptor eeeee2  antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA
CRP11	Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in  bbbbb1 amiloride eeeee1  bbbbb2 mineralocorticoid receptor eeeee2  antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA
CRP11	Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in  bbbbb1 amiloride eeeee1 -sensitive I(sc) and the induced changes in  bbbbb2 beta- and gamma-ENaC eeeee2  mRNA
CRP11	Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in  bbbbb1 amiloride eeeee1  bbbbb2 glucocorticoid receptor eeeee2  antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA
CRP11	Exposure to  bbbbb1 mifepristone eeeee1  (a glucocorticoid receptor antagonist), but not spironolactone (a  bbbbb2 mineralocorticoid receptor eeeee2  antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA
CRP11	Exposure to  bbbbb1 mifepristone eeeee1  (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in  bbbbb2 beta- and gamma-ENaC eeeee2  mRNA
CRP11	We hypothesized that corticosteroid exposure modulates epithelial  bbbbb1 Na(+) eeeee1  channel ( bbbbb2 ENaC eeeee2 ) expression and/or activity in bovine mammary epithelial cells
CRP11	We hypothesized that corticosteroid exposure modulates epithelial  bbbbb1 Na(+) eeeee1  bbbbb2 epithelial Na(+) channel eeeee2  (ENaC) expression and/or activity in bovine mammary epithelial cells
CRP11	Hypoxic rats displayed lower serum  bbbbb1 testosterone eeeee1  and higher  bbbbb2 LH eeeee2  and FSH
CRP11	Hypoxic rats displayed lower serum  bbbbb1 testosterone eeeee1  and higher LH and  bbbbb2 FSH eeeee2 
CRP11	Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low  bbbbb1 testosterone eeeee1  by suppressing endoplasmic reticulum stress and activated  bbbbb2 p66Shc eeeee2  in rat testes
CRP11	Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low  bbbbb1 testosterone eeeee1  bbbbb2 StAR eeeee2  and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes
CRP11	Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low  bbbbb1 testosterone eeeee1  bbbbb2 3β-HSD eeeee2  and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO ( bbbbb1 apocynin eeeee1  bbbbb2 NOX eeeee2 ), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO ( bbbbb1 apocynin eeeee1  bbbbb2 NADPH oxidase eeeee2  (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated  bbbbb1 NADPH eeeee1  oxidase ( bbbbb2 NOX eeeee2 ), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated  bbbbb1 NADPH eeeee1  bbbbb2 NADPH oxidase eeeee2  (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated  bbbbb1 NADPH eeeee1  oxidase (NOX), therefore, APO (apocynin) an inhibitor of  bbbbb2 NOX eeeee2  and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and  bbbbb1 raisanberine eeeee1  bbbbb2 NOX eeeee2 ), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and  bbbbb1 raisanberine eeeee1  bbbbb2 NADPH oxidase eeeee2  (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and  bbbbb1 raisanberine eeeee1  bbbbb2 NOX eeeee2  and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a  bbbbb1 calcium eeeee1  bbbbb2 NOX eeeee2 ), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a  bbbbb1 calcium eeeee1  bbbbb2 NADPH oxidase eeeee2  (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a  bbbbb1 calcium eeeee1  bbbbb2 NOX eeeee2  and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore,  bbbbb1 APO eeeee1  bbbbb2 NOX eeeee2 ), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore,  bbbbb1 APO eeeee1  bbbbb2 NADPH oxidase eeeee2  (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis
CRP11	Compound 2 has a significantly higher affinity for the NET than 1, and this may be a result of the different size and electronegativity of the  bbbbb1 halogen eeeee1  bbbbb2 NET eeeee2  than 1, and this may be a result of the different size and electronegativity of the halogen atoms
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ( bbbbb1 mZBrENT eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane ( bbbbb1 mZBrENT eeeee1 , 2) were synthesized and evaluated for binding to the  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin,  bbbbb1 dopamine eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin,  bbbbb1 dopamine eeeee1 , and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin,  bbbbb1 dopamine eeeee1 , and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin,  bbbbb1 dopamine eeeee1 , and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin,  bbbbb1 dopamine eeeee1  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ( bbbbb1 mZIENT eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane ( bbbbb1 mZIENT eeeee1 , 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human  bbbbb1 serotonin eeeee1 , dopamine, and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human  bbbbb1 serotonin eeeee1 , dopamine, and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human  bbbbb1 serotonin eeeee1 , dopamine, and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human  bbbbb1 serotonin eeeee1  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of  bbbbb1 carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes eeeee1 : candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of  bbbbb1 carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes eeeee1 : candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of  bbbbb1 carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes eeeee1 : candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of  bbbbb1 carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes eeeee1 : candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane eeeee1  (mZBrENT, 2) were synthesized and evaluated for binding to the  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and  bbbbb1 norepinephrine eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and  bbbbb1 norepinephrine eeeee1  transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and  bbbbb1 norepinephrine eeeee1  transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and  bbbbb1 norepinephrine eeeee1  transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and  bbbbb1 norepinephrine eeeee1  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.  bbbbb1 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane eeeee1  (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the  bbbbb1 serotonin eeeee1  transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT,  bbbbb2 DAT eeeee2 , and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the  bbbbb1 serotonin eeeee1  transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ( bbbbb2 SERT eeeee2 , DAT, and NET, respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the  bbbbb1 serotonin eeeee1  transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and  bbbbb2 NET eeeee2 , respectively) using transfected cells
CRP11	Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the  bbbbb1 serotonin eeeee1  transporter with positron emission tomography. 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the  bbbbb2 human serotonin, dopamine, and norepinephrine transporters eeeee2  (SERT, DAT, and NET, respectively) using transfected cells
CRP11	Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by  bbbbb1 naloxone eeeee1  bbbbb2 OFQ II(1-17) eeeee2 , high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone
CRP11	Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by  bbbbb1 naloxone eeeee1  bbbbb2 OFQ II(1-28) eeeee2 , stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone
CRP11	Unlike OFQ II(1-17), high concentrations of its  bbbbb1 C eeeee1  bbbbb2 OFQ II(1-17) eeeee2 , high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone
CRP11	Unlike OFQ II(1-17), high concentrations of its  bbbbb1 C eeeee1 -terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a  bbbbb2 mu (mu) opioid receptor eeeee2 -like distribution and the effect was blocked by naloxone
CRP11	Utilizing agonist-stimulated  bbbbb1 GTPgammaS eeeee1  autoradiography, we analyzed the ability of  bbbbb2 preproorphanin FQ (ppOFQ) peptides eeeee2  to stimulate [35S]-GTPgammaS binding in adult rat brain
CRP11	Utilizing agonist-stimulated GTPgammaS autoradiography, we analyzed the ability of preproorphanin FQ (ppOFQ) peptides to stimulate  bbbbb1 [35S]-GTPgammaS eeeee1  bbbbb2 preproorphanin FQ (ppOFQ) peptides eeeee2  to stimulate [35S]-GTPgammaS binding in adult rat brain
CRP11	Orphanin FQ (OFQ) stimulated  bbbbb1 [35S]-GTPgammaS eeeee1  binding in a pattern similar to that described for [125I]- bbbbb2 OFQ eeeee2  at the endogenous opioid receptor-like (ORL1) receptor
CRP11	Orphanin FQ (OFQ) stimulated  bbbbb1 [35S]-GTPgammaS eeeee1  binding in a pattern similar to that described for [125I]-OFQ at the endogenous  bbbbb2 opioid receptor-like (ORL1) receptor eeeee2 
CRP11	Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [ bbbbb1 125I eeeee1  bbbbb2 Orphanin FQ eeeee2  (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor
CRP11	Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [ bbbbb1 125I eeeee1 ]-OFQ at the endogenous  bbbbb2 opioid receptor-like (ORL1) receptor eeeee2 
CRP11	Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [ bbbbb1 125I eeeee1  bbbbb2 OFQ eeeee2 ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor
CRP11	The human ether-a-go-go-related gene (HERG), which encodes the rapidly activating delayed rectifier  bbbbb1 K+ eeeee1  bbbbb2 HERG eeeee2 ), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of cisapride
CRP11	The human ether-a-go-go-related gene (HERG), which encodes the rapidly activating delayed rectifier  bbbbb1 K+ eeeee1  bbbbb2 human ether-a-go-go-related gene eeeee2  (HERG), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of cisapride
CRP11	Blockage of the HERG human cardiac  bbbbb1 K+ eeeee1  bbbbb2 HERG human cardiac K+ channel eeeee2  by the gastrointestinal prokinetic agent cisapride
CRP11	Alcohol dehydrogenase (ADH) and  bbbbb1 aldehyde eeeee1  dehydrogenase ( bbbbb2 ALDH eeeee2 ) exhibit genetic polymorphism and tissue specificity
CRP11	Alcohol dehydrogenase (ADH) and  bbbbb1 aldehyde eeeee1  bbbbb2 Alcohol dehydrogenase eeeee2  (ADH) and aldehyde dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity
CRP11	Alcohol dehydrogenase (ADH) and  bbbbb1 aldehyde eeeee1  bbbbb2 ADH eeeee2 ) and aldehyde dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity
CRP11	Alcohol dehydrogenase (ADH) and  bbbbb1 aldehyde eeeee1  bbbbb2 aldehyde dehydrogenase eeeee2  (ALDH) exhibit genetic polymorphism and tissue specificity
CRP11	 bbbbb1 Alcohol eeeee1  dehydrogenase (ADH) and aldehyde dehydrogenase ( bbbbb2 ALDH eeeee2 ) exhibit genetic polymorphism and tissue specificity
CRP11	 bbbbb1 Alcohol eeeee1  bbbbb2 Alcohol dehydrogenase eeeee2  (ADH) and aldehyde dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity
CRP11	 bbbbb1 Alcohol eeeee1  dehydrogenase ( bbbbb2 ADH eeeee2 ) and aldehyde dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity
CRP11	 bbbbb1 Alcohol eeeee1  dehydrogenase (ADH) and  bbbbb2 aldehyde dehydrogenase eeeee2  (ALDH) exhibit genetic polymorphism and tissue specificity
CRP11	Genetic polymorphism and activities of human lung alcohol and aldehyde dehydrogenases: implications for  bbbbb1 ethanol eeeee1  bbbbb2 human lung alcohol and aldehyde dehydrogenases eeeee2 : implications for ethanol metabolism and cytotoxicity
CRP11	Genetic polymorphism and activities of human lung  bbbbb1 alcohol eeeee1  bbbbb2 human lung alcohol and aldehyde dehydrogenases eeeee2 : implications for ethanol metabolism and cytotoxicity
CRP11	Genetic polymorphism and activities of human lung alcohol and  bbbbb1 aldehyde eeeee1  bbbbb2 human lung alcohol and aldehyde dehydrogenases eeeee2 : implications for ethanol metabolism and cytotoxicity
CRP11	Protein levels of the  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter eeeee2  (GLUT4) involved in glucose transport via these two pathways were also increased
CRP11	Protein levels of the  bbbbb1 glucose eeeee1  transporter ( bbbbb2 GLUT4 eeeee2 ) involved in glucose transport via these two pathways were also increased
CRP11	Increased levels of free fatty acids ( bbbbb1 FFAs eeeee1 ), specifically saturated free fatty acids such as palmitate are associated with  bbbbb2 insulin eeeee2  resistance of muscle, fat and liver
CRP11	Increased levels of free fatty acids (FFAs), specifically saturated free fatty acids such as  bbbbb1 palmitate eeeee1  are associated with  bbbbb2 insulin eeeee2  resistance of muscle, fat and liver
CRP11	Increased levels of  bbbbb1 free fatty acids eeeee1  (FFAs), specifically saturated free fatty acids such as palmitate are associated with  bbbbb2 insulin eeeee2  resistance of muscle, fat and liver
CRP11	Increased levels of free fatty acids (FFAs), specifically  bbbbb1 saturated free fatty acids eeeee1  such as palmitate are associated with  bbbbb2 insulin eeeee2  resistance of muscle, fat and liver
CRP11	At a mechanistic level both extracts down-regulated PKC θ activation, which is associated with  bbbbb1 palmitate eeeee1 -induced  bbbbb2 insulin eeeee2  resistance
CRP11	At a mechanistic level both extracts down-regulated PKC θ activation, which is associated with  bbbbb1 palmitate eeeee1  bbbbb2 PKC θ eeeee2  activation, which is associated with palmitate-induced insulin resistance
CRP11	Rooibos (Aspalathus linearis) and its unique dihydrochalcone C-glucoside,  bbbbb1 aspalathin eeeee1 , shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of  bbbbb2 insulin eeeee2  resistance
CRP11	Rooibos (Aspalathus linearis) and its unique  bbbbb1 dihydrochalcone C-glucoside eeeee1 , aspalathin, shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of  bbbbb2 insulin eeeee2  resistance
CRP11	Amelioration of  bbbbb1 palmitate eeeee1 -induced  bbbbb2 insulin eeeee2  resistance in C2C12 muscle cells by rooibos (Aspalathus linearis)
CRP11	ARgamma controls CD1d expression by turning on  bbbbb1 retinoic acid eeeee1  bbbbb2 CD1d eeeee2  expression by turning on retinoic acid synthesis in developing human dendritic cells
CRP11	A regulates gene expression via the activation of the  bbbbb1 retinoic acid eeeee1  receptor (RAR)alpha in human DCs, and  bbbbb2 RARalpha eeeee2  acutely regulates CD1d expression
CRP11	A regulates gene expression via the activation of the  bbbbb1 retinoic acid eeeee1  receptor (RAR)alpha in human DCs, and RARalpha acutely regulates  bbbbb2 CD1d eeeee2  expression
CRP11	A regulates gene expression via the activation of the  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid receptor (RAR)alpha eeeee2  in human DCs, and RARalpha acutely regulates CD1d expression
CRP11	Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors:  bbbbb1 risperidone eeeee1  bbbbb2 alpha 1A- and alpha 1B-adrenoceptors eeeee2 : risperidone is selective for the alpha 1B-adrenoceptors
CRP11	Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit  bbbbb1 etomidate eeeee1  binding pocket at the  bbbbb2 beta/alpha interface eeeee2 
CRP11	Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit  bbbbb1 etomidate eeeee1  bbbbb2 intersubunit etomidate binding pocket eeeee2  at the beta/alpha interface
CRP11	In rat striatum and nucleus accumbens, mianserin stimulated  bbbbb1 [35S]GTPgammaS eeeee1  binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and  bbbbb2 dynorphin A eeeee2 
CRP11	In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and  bbbbb1 dynorphin A eeeee1  bbbbb2 dynorphin A eeeee2 
CRP11	In rat striatum and nucleus accumbens,  bbbbb1 mianserin eeeee1  stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and  bbbbb2 dynorphin A eeeee2 
CRP11	In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists  bbbbb1 (-)-U50,488 eeeee1  and  bbbbb2 dynorphin A eeeee2 
CRP11	In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a  bbbbb1 nor-BNI eeeee1 -sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and  bbbbb2 dynorphin A eeeee2 
CRP11	TAL APPROACH: Effects of mianserin were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of  bbbbb1 [(35)S]GTPgammaS eeeee1  binding and  bbbbb2 MAPK eeeee2  phosphorylation
CRP11	TAL APPROACH: Effects of mianserin were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of  bbbbb1 [(35)S]GTPgammaS eeeee1  bbbbb2 human opioid receptors eeeee2 , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and MAPK phosphorylation
CRP11	TAL APPROACH: Effects of  bbbbb1 mianserin eeeee1  were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and  bbbbb2 MAPK eeeee2  phosphorylation
CRP11	TAL APPROACH: Effects of  bbbbb1 mianserin eeeee1  were examined in CHO cells transfected with  bbbbb2 human opioid receptors eeeee2 , C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and MAPK phosphorylation
CRP11	KEY RESULTS:  bbbbb1 Mianserin eeeee1  displayed 12- and 18-fold higher affinity for  bbbbb2 kappa- than micro- and delta-opioid receptors eeeee2  respectively
CRP11	Mianserin and  bbbbb1 mirtazapine eeeee1  increased  bbbbb2 ERK1/2 eeeee2  phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI
CRP11	Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by  bbbbb1 nor-BNI eeeee1  bbbbb2 ERK1/2 eeeee2  phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI
CRP11	 bbbbb1 Mianserin eeeee1  and mirtazapine increased  bbbbb2 ERK1/2 eeeee2  phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate ( bbbbb1 CGP20712A eeeee1 , a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective  bbbbb2 beta(2)-adrenoceptor eeeee2  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate ( bbbbb1 CGP20712A eeeee1 , a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of  bbbbb2 beta(1)- and beta(2)-adrenoceptors eeeee2 
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and  bbbbb1 (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride eeeee1  (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of  bbbbb2 beta(1)- and beta(2)-adrenoceptors eeeee2 
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and  bbbbb1 (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for  bbbbb1 (-)-isoprenaline eeeee1  bbbbb2 beta(2)-adrenoceptor eeeee2  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for  bbbbb1 (-)-isoprenaline eeeee1 ; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of  bbbbb2 beta(1)- and beta(2)-adrenoceptors eeeee2 
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for  bbbbb1 (-)-isoprenaline eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	Pretreatment with a combination of  bbbbb1 (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate eeeee1  (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective  bbbbb2 beta(2)-adrenoceptor eeeee2  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	Pretreatment with a combination of  bbbbb1 (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate eeeee1  (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of  bbbbb2 beta(1)- and beta(2)-adrenoceptors eeeee2 
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to  bbbbb1 (+/-)-CGP12177A eeeee1  bbbbb2 beta(2)-adrenoceptor eeeee2  antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to  bbbbb1 (+/-)-CGP12177A eeeee1  was unaffected by the blockade of  bbbbb2 beta(1)- and beta(2)-adrenoceptors eeeee2 
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to  bbbbb1 (+/-)-CGP12177A eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride ( bbbbb1 ICI-118,5511 eeeee1 , a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of  bbbbb2 beta(1)- and beta(2)-adrenoceptors eeeee2 
CRP11	Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride ( bbbbb1 ICI-118,5511 eeeee1  bbbbb2 beta(1)-adrenoceptor eeeee2  antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors
CRP11	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle.  bbbbb1 (-)-Isoprenaline eeeee1  and a nonconventional  bbbbb2 beta(3)-adrenoceptor eeeee2  agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CRP11	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle.  bbbbb1 (-)-Isoprenaline eeeee1  bbbbb2 beta-adrenoceptor eeeee2  subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CRP11	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ( bbbbb1 (+/-)-CGP12177A eeeee1  bbbbb2 beta-adrenoceptor eeeee2  subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CRP11	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist,  bbbbb1 (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride eeeee1  bbbbb2 beta-adrenoceptor eeeee2  subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CRP11	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of  bbbbb1 (-)-phenylephrine eeeee1  bbbbb2 beta(3)-adrenoceptor eeeee2  agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CRP11	The present study was carried out to characterize beta-adrenoceptor subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of  bbbbb1 (-)-phenylephrine eeeee1  bbbbb2 beta-adrenoceptor eeeee2  subtypes mediating relaxation of rat abdominal aorta smooth muscle. (-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations
CRP11	 bbbbb1 Aspirin eeeee1  changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb2 mTOR eeeee2  was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	 bbbbb1 Aspirin eeeee1  changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb2 mTOR eeeee2 
CRP11	 bbbbb1 Aspirin eeeee1  changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and  bbbbb2 AMPK eeeee2 -independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	 bbbbb1 Aspirin eeeee1  changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating  bbbbb2 AMPK eeeee2 -dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	 bbbbb1 Aspirin eeeee1  changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of  bbbbb2 AMPKalpha eeeee2 , indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of  bbbbb1 aspirin eeeee1  bbbbb2 AMPK eeeee2  in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of  bbbbb1 aspirin eeeee1  bbbbb2 mTOR eeeee2  was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of  bbbbb1 aspirin eeeee1  bbbbb2 AMPKalpha eeeee2 , indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by  bbbbb1 aspirin eeeee1  bbbbb2 AMPK eeeee2  in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by  bbbbb1 aspirin eeeee1  in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb2 mTOR eeeee2 
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by  bbbbb1 aspirin eeeee1  in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and  bbbbb2 AMPK eeeee2 -independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by  bbbbb1 aspirin eeeee1  in CRC cells after siRNA knockdown of AMPKalpha, indicating  bbbbb2 AMPK eeeee2 -dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by  bbbbb1 aspirin eeeee1  in CRC cells after siRNA knockdown of  bbbbb2 AMPKalpha eeeee2 , indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 AMPK eeeee2  in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2 
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 AMPK eeeee2 -independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 AMPK eeeee2 -dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 AMPKalpha eeeee2 , indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb1 mTOR eeeee1  bbbbb2 AMPK eeeee2  in CRC cells. mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb1 mTOR eeeee1  was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of  bbbbb2 mTOR eeeee2 
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb1 mTOR eeeee1  was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and  bbbbb2 AMPK eeeee2 -independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb1 mTOR eeeee1  was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating  bbbbb2 AMPK eeeee2 -dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin changed nucleotide ratios and activated AMPK in CRC cells.  bbbbb1 mTOR eeeee1  was still inhibited by aspirin in CRC cells after siRNA knockdown of  bbbbb2 AMPKalpha eeeee2 , indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR
CRP11	Aspirin induced autophagy, a feature of  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  inhibition
CRP11	The effects of aspirin on  bbbbb1 mTOR eeeee1  signaling, the ribosomal protein S6, S6 kinase 1 ( bbbbb2 S6K1 eeeee2 ), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of aspirin on  bbbbb1 mTOR eeeee1  signaling, the ribosomal protein S6,  bbbbb2 S6 kinase 1 eeeee2  (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of aspirin on  bbbbb1 mTOR eeeee1  signaling, the  bbbbb2 ribosomal protein S6 eeeee2 , S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of aspirin on  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of aspirin on  bbbbb1 mTOR eeeee1  signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and  bbbbb2 eukaryotic translation initiation factor 4E binding protein 1 eeeee2  (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of aspirin on  bbbbb1 mTOR eeeee1  signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 ( bbbbb2 4E-BP1 eeeee2 ) were examined in CRC cells by immunoblotting
CRP11	The effects of  bbbbb1 aspirin eeeee1  on mTOR signaling, the ribosomal protein S6, S6 kinase 1 ( bbbbb2 S6K1 eeeee2 ), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of  bbbbb1 aspirin eeeee1  on mTOR signaling, the ribosomal protein S6,  bbbbb2 S6 kinase 1 eeeee2  (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of  bbbbb1 aspirin eeeee1  on mTOR signaling, the  bbbbb2 ribosomal protein S6 eeeee2 , S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of  bbbbb1 aspirin eeeee1  on  bbbbb2 mTOR eeeee2  signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of  bbbbb1 aspirin eeeee1  on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and  bbbbb2 eukaryotic translation initiation factor 4E binding protein 1 eeeee2  (4E-BP1) were examined in CRC cells by immunoblotting
CRP11	The effects of  bbbbb1 aspirin eeeee1  on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 ( bbbbb2 4E-BP1 eeeee2 ) were examined in CRC cells by immunoblotting
CRP11	Aspirin reduced  bbbbb1 mTOR eeeee1  signaling in CRC cells by inhibiting the  bbbbb2 mTOR eeeee2  effectors S6K1 and 4E-BP1
CRP11	Aspirin reduced  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1
CRP11	Aspirin reduced  bbbbb1 mTOR eeeee1  signaling in CRC cells by inhibiting the mTOR effectors  bbbbb2 S6K1 eeeee2  and 4E-BP1
CRP11	Aspirin reduced  bbbbb1 mTOR eeeee1  signaling in CRC cells by inhibiting the mTOR effectors S6K1 and  bbbbb2 4E-BP1 eeeee2 
CRP11	Aspirin reduced mTOR signaling in CRC cells by inhibiting the  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  effectors S6K1 and 4E-BP1
CRP11	Aspirin reduced mTOR signaling in CRC cells by inhibiting the  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1
CRP11	Aspirin reduced mTOR signaling in CRC cells by inhibiting the  bbbbb1 mTOR eeeee1  effectors  bbbbb2 S6K1 eeeee2  and 4E-BP1
CRP11	Aspirin reduced mTOR signaling in CRC cells by inhibiting the  bbbbb1 mTOR eeeee1  effectors S6K1 and  bbbbb2 4E-BP1 eeeee2 
CRP11	Cancer cells have defects in signaling via the mechanistic target of rapamycin ( bbbbb1 mTOR eeeee1  bbbbb2 mechanistic target of rapamycin eeeee2  (mTOR), which regulates proliferation
CRP11	Cancer cells have defects in signaling via the mechanistic target of rapamycin ( bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2 ), which regulates proliferation
CRP11	Cancer cells have defects in signaling via the mechanistic target of  bbbbb1 rapamycin eeeee1  bbbbb2 mechanistic target of rapamycin eeeee2  (mTOR), which regulates proliferation
CRP11	Cancer cells have defects in signaling via the mechanistic target of  bbbbb1 rapamycin eeeee1  ( bbbbb2 mTOR eeeee2 ), which regulates proliferation
CRP11	Aspirin and metformin (an activator of AMPK) increased inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 AMPK eeeee2 ) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells
CRP11	Aspirin and metformin (an activator of AMPK) increased inhibition of  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  and Akt, as well as autophagy in CRC cells
CRP11	Aspirin and metformin (an activator of AMPK) increased inhibition of  bbbbb1 mTOR eeeee1  and  bbbbb2 Akt eeeee2 , as well as autophagy in CRC cells
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the  bbbbb1 aspirin eeeee1 -induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in  bbbbb2 AMPK(alpha1/alpha2 eeeee2 -/-) mouse embryonic fibroblasts
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the  bbbbb1 aspirin eeeee1  bbbbb2 AMPKalpha eeeee2  on the aspirin-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the  bbbbb1 aspirin eeeee1  bbbbb2 AMPK eeeee2  was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the  bbbbb1 aspirin eeeee1 -induced effects of  bbbbb2 mTOR eeeee2  were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of  bbbbb1 mTOR eeeee1  were determined using small interfering RNA (siRNA) in CRC cells and in  bbbbb2 AMPK(alpha1/alpha2 eeeee2 -/-) mouse embryonic fibroblasts
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of  bbbbb1 mTOR eeeee1  bbbbb2 AMPKalpha eeeee2  on the aspirin-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of  bbbbb1 mTOR eeeee1  bbbbb2 AMPK eeeee2  was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts
CRP11	Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of  bbbbb1 mTOR eeeee1  bbbbb2 mTOR eeeee2  were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts
CRP11	In terms of the mechanisms, we found that  bbbbb1 fatty acid eeeee1  bbbbb2 fatty acid amide hydrolase eeeee2  (FAAH) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences
CRP11	In terms of the mechanisms, we found that  bbbbb1 fatty acid eeeee1  amide hydrolase ( bbbbb2 FAAH eeeee2 ) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences
CRP11	In terms of the mechanisms, we found that fatty acid  bbbbb1 amide eeeee1  bbbbb2 fatty acid amide hydrolase eeeee2  (FAAH) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences
CRP11	In terms of the mechanisms, we found that fatty acid  bbbbb1 amide eeeee1  hydrolase ( bbbbb2 FAAH eeeee2 ) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences
CRP11	To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1%  bbbbb1 DEHP eeeee1  bbbbb2 humanized PPARα eeeee2  (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1%  bbbbb1 DEHP eeeee1  bbbbb2 hPPARα eeeee2 ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1%  bbbbb1 DEHP eeeee1  bbbbb2 mPPARα eeeee2 ), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1%  bbbbb1 DEHP eeeee1  bbbbb2 peroxisome proliferator-activated receptor α eeeee2 -null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1%  bbbbb1 DEHP eeeee1  bbbbb2 Pparα eeeee2 -null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the  bbbbb1 fatty acid eeeee1  (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and  bbbbb2 humanized PPARα eeeee2  (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the  bbbbb1 fatty acid eeeee1  (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα ( bbbbb2 hPPARα eeeee2 ) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the  bbbbb1 fatty acid eeeee1  (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type ( bbbbb2 mPPARα eeeee2 ), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the  bbbbb1 fatty acid eeeee1  (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα),  bbbbb2 peroxisome proliferator-activated receptor α eeeee2 -null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	To identify the  bbbbb1 fatty acid eeeee1  (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null ( bbbbb2 Pparα eeeee2 -null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP
CRP11	However, DEHP exposure did not clearly influence FA desaturase 1 and 2 nor elongase 2 and 5 expressions in the liver of all maternal mice bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	However, DEHP exposure did not clearly influence FA desaturase 1 and 2 nor elongase 2 and 5 expressions in the liver of all maternal mice bbbbb1  eeeee1  bbbbb2 ssions eeeee2  in the liver of all maternal mice
CRP11	However, DEHP exposure did not clearly influence FA desatur bbbbb1 ase 1  eeeee1 and 2 nor elongase 2 and 5 expressions in the liver of all maternal mice bbbbb2  eeeee2 
CRP11	However, DEHP exposure did not clearly influence FA desatur bbbbb1 ase 1  eeeee1 and 2 nor elongase 2 and 5 expre bbbbb2 ssions eeeee2  in the liver of all maternal mice
CRP11	However, DEHP exposure did not clearly influence FA desaturase 1 and 2 nor elongase 2 and 5 expressions in the liver of all maternal mice bbbbb1  eeeee1  bbbbb2 ssions eeeee2  in the liver of all maternal mice
CRP11	A-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist  bbbbb1 bicuculline eeeee1  (IC50 = 1.7 microM), indicating expression of GABAA but not  bbbbb2 GABAC receptors eeeee2 
CRP11	A-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist  bbbbb1 bicuculline eeeee1  (IC50 = 1.7 microM), indicating expression of  bbbbb2 GABAA eeeee2  but not GABAC receptors
CRP11	In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of  bbbbb1 sulfidopeptide leuktrienes eeeee1  in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  bbbbb2 leukotriene synthetase eeeee2  of these cells
CRP11	In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  bbbbb1 leukotriene eeeee1  bbbbb2 5-lipoxygenase eeeee2  step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells
CRP11	In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the  bbbbb1 leukotriene eeeee1  bbbbb2 leukotriene synthetase eeeee2  of these cells
CRP11	Kinetic analysis revealed that the inhibition of the  bbbbb1 leukotriene C eeeee1  bbbbb2 leukotriene C synthetase eeeee2  reaction by diethylcarbamazine was competitive with respect to LTA4
CRP11	Inhibition of the  bbbbb1 leukotriene eeeee1  bbbbb2 leukotriene synthetase eeeee2  of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor
CRP11	Inhibition of the  bbbbb1 leukotriene eeeee1  synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a  bbbbb2 5-lipoxygenase eeeee2  inhibitor
CRP11	Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between  bbbbb1 diethylcarbamazine eeeee1  bbbbb2 leukotriene synthetase eeeee2  of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor
CRP11	Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and  bbbbb1 piriprost eeeee1  bbbbb2 leukotriene synthetase eeeee2  of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor
CRP11	Inhibition of the leukotriene synthetase of rat basophil leukemia cells by  bbbbb1 diethylcarbamazine eeeee1 , and synergism between diethylcarbamazine and piriprost, a  bbbbb2 5-lipoxygenase eeeee2  inhibitor
CRP11	On the other hand, low concentrations of piriprost, which had no demonstrable inhibitory activity on leukotriene formation by themselves, markedly synergized the inhibitory activity of diethylcarbamazine bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	On the other hand, low concentrations of piriprost, which had no demonstrable inhibitory activity on leu bbbbb1 kotriene fo eeeee1 rmation by themselves, markedly synergized the inhibitory activity of diethylcarbamazine bbbbb2  eeeee2 
CRP11	On the other hand, low concentrations of piriprost, which had no demonstrable bbbbb1  inhibitory activi eeeee1 ty on leukotriene formation by themselves, markedly synergized the inhibitory activity of diethylcarbamazine bbbbb2  eeeee2 
CRP11	On the other hand, low concentrations of piriprost, which had n bbbbb1 o demonst eeeee1 rable inhibitory activity on leukotriene formation by themselves, markedly synergized the inhibitory activity of diethylcarbamazine bbbbb2  eeeee2 
CRP11	The EC50 for inhibition of the  bbbbb1 leukotriene C eeeee1  bbbbb2 leukotriene C synthetase eeeee2  of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4
CRP11	The EC50 for inhibition of the leukotriene C synthetase of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM  bbbbb1 LTA4 eeeee1  bbbbb2 leukotriene C synthetase eeeee2  of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4
CRP11	The EC50 for inhibition of the leukotriene C synthetase of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM  bbbbb1 LTA4 eeeee1  bbbbb2 leukotriene C synthetase eeeee2  of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4
CRP11	Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by LTC synthetase, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to  bbbbb1 glutathione eeeee1  bbbbb2 LTC synthetase eeeee2 , a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione
CRP11	Furthermore, the AMPK activator  bbbbb1 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide eeeee1  (AICAR) significantly inhibited  bbbbb2 ghrelin eeeee2  secretion
CRP11	 bbbbb1 Metformin eeeee1  significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the  bbbbb2 AMPK eeeee2  inhibitor compound C
CRP11	Metformin directly inhibits ghrelin secretion through  bbbbb1 AMP eeeee1  bbbbb2 ghrelin eeeee2  secretion through AMP-activated protein kinase in rat primary gastric cells
CRP11	Metformin directly inhibits ghrelin secretion through  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  in rat primary gastric cells
CRP11	To test whether  bbbbb1 Metformin eeeee1  directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of  bbbbb2 ghrelin eeeee2  secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether  bbbbb1 Metformin eeeee1  directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion,  bbbbb2 proghrelin eeeee2  gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether  bbbbb1 Metformin eeeee1  directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase ( bbbbb2 AMPK eeeee2 ) were examined
CRP11	To test whether  bbbbb1 Metformin eeeee1  directly affects  bbbbb2 ghrelin eeeee2  cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether  bbbbb1 Metformin eeeee1  directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of  bbbbb2 adenosine monophosphate-activated protein kinase eeeee2  (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of  bbbbb1 adenosine monophosphate eeeee1  bbbbb2 ghrelin eeeee2  secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of  bbbbb1 adenosine monophosphate eeeee1  bbbbb2 proghrelin eeeee2  gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of  bbbbb1 adenosine monophosphate eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of  bbbbb1 adenosine monophosphate eeeee1  bbbbb2 ghrelin eeeee2  cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of  bbbbb1 adenosine monophosphate eeeee1  bbbbb2 adenosine monophosphate-activated protein kinase eeeee2  (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with  bbbbb1 Metformin eeeee1  and the levels of  bbbbb2 ghrelin eeeee2  secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with  bbbbb1 Metformin eeeee1  and the levels of ghrelin secretion,  bbbbb2 proghrelin eeeee2  gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with  bbbbb1 Metformin eeeee1  and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase ( bbbbb2 AMPK eeeee2 ) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with  bbbbb1 Metformin eeeee1  bbbbb2 ghrelin eeeee2  cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined
CRP11	To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with  bbbbb1 Metformin eeeee1  and the levels of ghrelin secretion, proghrelin gene expression and activation of  bbbbb2 adenosine monophosphate-activated protein kinase eeeee2  (AMPK) were examined
CRP11	The effects of  bbbbb1 sulfasalazine eeeee1  and its moieties on  bbbbb2 NF-kappaB eeeee2  signaling were evaluated using electromobility shift, transfection, and immune complex kinase assays
CRP11	NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by  bbbbb1 sulfasalazine eeeee1  bbbbb2 tumor necrosis factor alpha eeeee2 , 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CRP11	NF-kappaB/Rel activity induced by tumor necrosis factor alpha,  bbbbb1 12-O-tetradecanoylphorbol-13-acetate eeeee1 , or overexpression of NF-kappaB-inducing kinase, IKK-alpha,  bbbbb2 IKK-beta eeeee2 , or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CRP11	NF-kappaB/Rel activity induced by tumor necrosis factor alpha,  bbbbb1 12-O-tetradecanoylphorbol-13-acetate eeeee1 , or overexpression of NF-kappaB-inducing kinase,  bbbbb2 IKK-alpha eeeee2 , IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CRP11	NF-kappaB/Rel activity induced by tumor necrosis factor alpha,  bbbbb1 12-O-tetradecanoylphorbol-13-acetate eeeee1 , or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and  bbbbb2 IKK-beta eeeee2  mutants was inhibited dose dependently by sulfasalazine
CRP11	NF-kappaB/Rel activity induced by tumor necrosis factor alpha,  bbbbb1 12-O-tetradecanoylphorbol-13-acetate eeeee1  bbbbb2 tumor necrosis factor alpha eeeee2 , 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CRP11	NF-kappaB/Rel activity induced by tumor necrosis factor alpha,  bbbbb1 12-O-tetradecanoylphorbol-13-acetate eeeee1 , or overexpression of  bbbbb2 NF-kappaB-inducing kinase eeeee2 , IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CRP11	NF-kappaB/Rel activity induced by tumor necrosis factor alpha,  bbbbb1 12-O-tetradecanoylphorbol-13-acetate eeeee1 , or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active  bbbbb2 IKK-alpha eeeee2  and IKK-beta mutants was inhibited dose dependently by sulfasalazine
CRP11	Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun- bbbbb1 N eeeee1  bbbbb2 c-Jun-N-terminal kinase (JNK) 1 eeeee2 , and p38 was unaffected by sulfasalazine
CRP11	Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun- bbbbb1 N eeeee1 -terminal kinase (JNK) 1, and  bbbbb2 p38 eeeee2  was unaffected by sulfasalazine
CRP11	Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun- bbbbb1 N eeeee1  bbbbb2 extracellular signal-related kinase (ERK) 1 and 2 eeeee2 , c-Jun-N-terminal kinase (JNK) 1, and p38 was unaffected by sulfasalazine
CRP11	Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun-N-terminal kinase (JNK) 1, and p38 was unaffected by  bbbbb1 sulfasalazine eeeee1  bbbbb2 extracellular signal-related kinase (ERK) 1 and 2 eeeee2 , c-Jun-N-terminal kinase (JNK) 1, and p38 was unaffected by sulfasalazine
CRP11	 bbbbb1 Oxytocin eeeee1  bbbbb2 Oxytocin eeeee2  injection of the same dosage was repeated every hour for 5 hours
CRP11	Oxytocin antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 -induced uterine contractions in primates
CRP11	Oxytocin antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or  bbbbb1 oxytocin eeeee1  bbbbb2 Oxytocin eeeee2  antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates
CRP11	 bbbbb1 Oxytocin eeeee1  antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or  bbbbb2 oxytocin eeeee2 -induced uterine contractions in primates
CRP11	 bbbbb1 Oxytocin eeeee1  bbbbb2 Oxytocin eeeee2  antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates
CRP11	Each OTA was administered as a single bolus injection of 5 microg, followed by 100 mU of  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  5 minutes later, also done as a single bolus
CRP11	Experiment 2, TT-235 induced a significant decrease (p<0.05) in  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  number and binding affinity at both 0.5 and 4 hours compared with controls
CRP11	Experiment 2 determined the effect of the three OTAs on uterine  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  number (Rn) and binding affinity (Kd)
CRP11	Experiment 1, Antag I, Antag II and TT-235 inhibited the integrated uterine response to  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)
CRP11	In vivo activity of the potent  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  antagonist on uterine activity in the rat
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity s bbbbb1 ignifica eeeee1 ntly at each time point studied compared with controls bbbbb2  eeeee2 
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity s bbbbb1 ignifica eeeee1 ntly at each time poin bbbbb2 t studie eeeee2 d compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity s bbbbb1 ignifica eeeee1  bbbbb2 ignificantly at e eeeee2 ach time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity s bbbbb1 ignifica eeeee1  bbbbb2 r or bin eeeee2 ding affinity significantly at each time point studied compared with controls
CRP11	Antag I and Ant bbbbb1 ag II  eeeee1 did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb2  eeeee2 
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb1  eeeee1  bbbbb2 t studie eeeee2 d compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb1  eeeee1  bbbbb2 ignificantly at e eeeee2 ach time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb1  eeeee1  bbbbb2 r or bin eeeee2 ding affinity significantly at each time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time poin bbbbb1 t studie eeeee1 d compared with controls bbbbb2  eeeee2 
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time poin bbbbb1 t studie eeeee1  bbbbb2 t studie eeeee2 d compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time poin bbbbb1 t studie eeeee1  bbbbb2 ignificantly at e eeeee2 ach time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time poin bbbbb1 t studie eeeee1  bbbbb2 r or bin eeeee2 ding affinity significantly at each time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor numbe bbbbb1 r or bin eeeee1 ding affinity significantly at each time point studied compared with controls bbbbb2  eeeee2 
CRP11	Antag I and Antag II did not alter oxytocin receptor numbe bbbbb1 r or bin eeeee1 ding affinity significantly at each time poin bbbbb2 t studie eeeee2 d compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor numbe bbbbb1 r or bin eeeee1 ding affinity s bbbbb2 ignificantly at e eeeee2 ach time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor numbe bbbbb1 r or bin eeeee1  bbbbb2 r or bin eeeee2 ding affinity significantly at each time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb1  eeeee1  bbbbb2 t studie eeeee2 d compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb1  eeeee1  bbbbb2 ignificantly at e eeeee2 ach time point studied compared with controls
CRP11	Antag I and Antag II did not alter oxytocin receptor number or binding affinity significantly at each time point studied compared with controls bbbbb1  eeeee1  bbbbb2 r or bin eeeee2 ding affinity significantly at each time point studied compared with controls
CRP11	Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical  bbbbb1 hydrogen eeeee1  bbbbb2 S349T eeeee2  mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the KIR-Keap1 complex
CRP11	Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical  bbbbb1 hydrogen eeeee1  bbbbb2 Keap1 eeeee2  is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the KIR-Keap1 complex
CRP11	Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical  bbbbb1 hydrogen eeeee1  bbbbb2 Keap1 eeeee2  interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the KIR-Keap1 complex
CRP11	Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical  bbbbb1 hydrogen eeeee1  bbbbb2 SQSTM1 eeeee2 -Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the KIR-Keap1 complex
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for  bbbbb1 [125I]p-iodoclonidine eeeee1  binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at  bbbbb2 human alpha-2A eeeee2 , alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for  bbbbb1 [125I]p-iodoclonidine eeeee1  binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A,  bbbbb2 alpha-2B eeeee2  and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for  bbbbb1 [125I]p-iodoclonidine eeeee1  bbbbb2 I1 eeeee2 ), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for  bbbbb1 [125I]p-iodoclonidine eeeee1  bbbbb2 I1-imidazoline receptors eeeee2  (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for  bbbbb1 [125I]p-iodoclonidine eeeee1  binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and  bbbbb2 alpha-2C adrenoceptors eeeee2  stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for  bbbbb1 [125I]p-iodoclonidine eeeee1  binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of  bbbbb2 alpha-2 AR eeeee2 ) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1- bbbbb1 imidazoline eeeee1  receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at  bbbbb2 human alpha-2A eeeee2 , alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1- bbbbb1 imidazoline eeeee1  receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A,  bbbbb2 alpha-2B eeeee2  and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1- bbbbb1 imidazoline eeeee1  receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at  bbbbb2 human platelet I1-imidazoline binding sites eeeee2  (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1- bbbbb1 imidazoline eeeee1  receptors ( bbbbb2 I1 eeeee2 ), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1- bbbbb1 imidazoline eeeee1  bbbbb2 I1-imidazoline receptors eeeee2  (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1- bbbbb1 imidazoline eeeee1  receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and  bbbbb2 alpha-2C adrenoceptors eeeee2  stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1- bbbbb1 imidazoline eeeee1  receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of  bbbbb2 alpha-2 AR eeeee2 ) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under  bbbbb1 norepinephrine eeeee1  mask of alpha-2 AR) and at  bbbbb2 human alpha-2A eeeee2 , alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under  bbbbb1 norepinephrine eeeee1  mask of alpha-2 AR) and at human alpha-2A,  bbbbb2 alpha-2B eeeee2  and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under  bbbbb1 norepinephrine eeeee1  bbbbb2 human platelet I1-imidazoline binding sites eeeee2  (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under  bbbbb1 norepinephrine eeeee1  bbbbb2 I1 eeeee2 ), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under  bbbbb1 norepinephrine eeeee1  bbbbb2 I1-imidazoline receptors eeeee2  (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under  bbbbb1 norepinephrine eeeee1  mask of alpha-2 AR) and at human alpha-2A, alpha-2B and  bbbbb2 alpha-2C adrenoceptors eeeee2  stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under  bbbbb1 norepinephrine eeeee1  mask of  bbbbb2 alpha-2 AR eeeee2 ) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1- bbbbb1 imidazoline eeeee1  binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at  bbbbb2 human alpha-2A eeeee2 , alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1- bbbbb1 imidazoline eeeee1  binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A,  bbbbb2 alpha-2B eeeee2  and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1- bbbbb1 imidazoline eeeee1  bbbbb2 human platelet I1-imidazoline binding sites eeeee2  (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1- bbbbb1 imidazoline eeeee1  bbbbb2 I1 eeeee2 ), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1- bbbbb1 imidazoline eeeee1  bbbbb2 I1-imidazoline receptors eeeee2  (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1- bbbbb1 imidazoline eeeee1  binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and  bbbbb2 alpha-2C adrenoceptors eeeee2  stably expressed on transfected Chinese hamster ovary cells
CRP11	To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1- bbbbb1 imidazoline eeeee1  binding sites (analyzed under norepinephrine mask of  bbbbb2 alpha-2 AR eeeee2 ) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells
CRP11	Competition curves at the platelet I1- bbbbb1 imidazoline eeeee1  bbbbb2 I1-imidazoline binding site eeeee2  were biphasic for most compounds
CRP11	Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1- bbbbb1 midazoline eeeee1  bbbbb2 alpha-2B eeeee2 , alpha-2C and platelet I1-midazoline binding sites, respectively
CRP11	Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1- bbbbb1 midazoline eeeee1  bbbbb2 alpha-2C eeeee2  and platelet I1-midazoline binding sites, respectively
CRP11	Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1- bbbbb1 midazoline eeeee1  bbbbb2 I1-midazoline binding sites eeeee2 , respectively
CRP11	Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1- bbbbb1 midazoline eeeee1  bbbbb2 alpha-2A adrenoceptor eeeee2 , displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-midazoline binding sites, respectively
CRP11	 bbbbb1 Naphazoline eeeee1  was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than  bbbbb2 alpha-2B eeeee2 , alpha-2C and platelet I1-midazoline binding sites, respectively
CRP11	 bbbbb1 Naphazoline eeeee1  was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B,  bbbbb2 alpha-2C eeeee2  and platelet I1-midazoline binding sites, respectively
CRP11	 bbbbb1 Naphazoline eeeee1  was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet  bbbbb2 I1-midazoline binding sites eeeee2 , respectively
CRP11	Agmatine, an endogenous neurotransmitter candidate for the I1- bbbbb1 imidazoline eeeee1  receptor, was identified as the most selective agent for a subcomponent of platelet  bbbbb2 I1 sites eeeee2 
CRP11	Agmatine, an endogenous neurotransmitter candidate for the I1- bbbbb1 imidazoline eeeee1  bbbbb2 I1-imidazoline receptor eeeee2 , was identified as the most selective agent for a subcomponent of platelet I1 sites
CRP11	 bbbbb1 Agmatine eeeee1 , an endogenous neurotransmitter candidate for the I1-imidazoline receptor, was identified as the most selective agent for a subcomponent of platelet  bbbbb2 I1 sites eeeee2 
CRP11	 bbbbb1 Agmatine eeeee1 , an endogenous neurotransmitter candidate for the  bbbbb2 I1-imidazoline receptor eeeee2 , was identified as the most selective agent for a subcomponent of platelet I1 sites
CRP11	Moxonidine and  bbbbb1 tizanidine eeeee1  also displayed selectivities for a high affinity component of the platelet  bbbbb2 I1 binding sites eeeee2  over alpha-2 adrenoceptors
CRP11	Moxonidine and  bbbbb1 tizanidine eeeee1  also displayed selectivities for a high affinity component of the platelet I1 binding sites over  bbbbb2 alpha-2 adrenoceptors eeeee2 
CRP11	 bbbbb1 Moxonidine eeeee1  and tizanidine also displayed selectivities for a high affinity component of the platelet  bbbbb2 I1 binding sites eeeee2  over alpha-2 adrenoceptors
CRP11	 bbbbb1 Moxonidine eeeee1  and tizanidine also displayed selectivities for a high affinity component of the platelet I1 binding sites over  bbbbb2 alpha-2 adrenoceptors eeeee2 
CRP11	Comparison of ligand binding affinities at human I1- bbbbb1 imidazoline eeeee1  binding sites and the high affinity state of  bbbbb2 alpha-2 adrenoceptor eeeee2  subtypes
CRP11	Comparison of ligand binding affinities at human I1- bbbbb1 imidazoline eeeee1  bbbbb2 human I1-imidazoline binding sites eeeee2  and the high affinity state of alpha-2 adrenoceptor subtypes
CRP11	The affinity of  bbbbb1 agmatine eeeee1  at the high affinity component of platelet I1 sites was 1400-fold selective over alpha-2A adrenoceptors, 5000-fold selective over alpha-2B adrenoceptors and 800-fold selective over  bbbbb2 alpha-2C adrenoceptors eeeee2 
CRP11	The affinity of  bbbbb1 agmatine eeeee1  at the high affinity component of platelet  bbbbb2 I1 sites eeeee2  was 1400-fold selective over alpha-2A adrenoceptors, 5000-fold selective over alpha-2B adrenoceptors and 800-fold selective over alpha-2C adrenoceptors
CRP11	The affinity of  bbbbb1 agmatine eeeee1  at the high affinity component of platelet I1 sites was 1400-fold selective over alpha-2A adrenoceptors, 5000-fold selective over  bbbbb2 alpha-2B adrenoceptors eeeee2  and 800-fold selective over alpha-2C adrenoceptors
CRP11	The affinity of  bbbbb1 agmatine eeeee1  at the high affinity component of platelet I1 sites was 1400-fold selective over  bbbbb2 alpha-2A adrenoceptors eeeee2 , 5000-fold selective over alpha-2B adrenoceptors and 800-fold selective over alpha-2C adrenoceptors
CRP11	Norepinephrine displayed, respectively, 18- and 31-fol bbbbb1 d selectivi eeeee1  bbbbb2 nephrine displayed, respect eeeee2 ively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to alpha-2A- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet I1-imidazoline sites
CRP11	Norepinephrine displayed, respectively, 18- and 31-fol bbbbb1 d selectivi eeeee1  bbbbb2 fold selectivity for the hi eeeee2 gh affinity state of the alpha-2C adrenoceptor as compared to alpha-2A- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet I1-imidazoline sites
CRP11	Therefore, electrophysiological responses and changes in levels of intracellular  bbbbb1 Ca(2+) eeeee1  in mouse cholinergic LDT neurons following application of specific  bbbbb2 mGluR eeeee2  agonists and antagonists were examined
CRP11	Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a  bbbbb1 TTX eeeee1  bbbbb2 mGluR(5) eeeee2 specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CRP11	Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a  bbbbb1 TTX eeeee1  bbbbb2 mGlu(2/3) eeeee2 ) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CRP11	Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a  bbbbb1 TTX eeeee1  bbbbb2 group II mGluR eeeee2  (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CRP11	Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist,  bbbbb1 LY379268 eeeee1  bbbbb2 mGluR(5) eeeee2 specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CRP11	Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist,  bbbbb1 LY379268 eeeee1  bbbbb2 mGlu(2/3) eeeee2 ) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CRP11	Unexpectedly, both the mGluR(5)specific agonist,  bbbbb1 CHPG eeeee1 , and the group II mGluR ( bbbbb2 mGlu(2/3) eeeee2 ) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CRP11	Unexpectedly, both the mGluR(5)specific agonist,  bbbbb1 CHPG eeeee1 , and the  bbbbb2 group II mGluR eeeee2  (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization
CRP11	Pharmacological evidence of functional inhibitory metabotrophic  bbbbb1 glutamate eeeee1  bbbbb2 metabotrophic glutamate receptors eeeee2  on mouse arousal-related cholinergic laterodorsal tegmental neurons
CRP11	The large-conductance,  bbbbb1 Ca(2+) eeeee1  bbbbb2 Ca(2+)-dependent potassium (BK) channel eeeee2  blocker, iberiotoxin, attenuated CHPG actions
CRP11	The large-conductance, Ca(2+)-dependent potassium (BK) channel blocker, iberiotoxin, attenuated  bbbbb1 CHPG eeeee1  bbbbb2 Ca(2+)-dependent potassium (BK) channel eeeee2  blocker, iberiotoxin, attenuated CHPG actions
CRP11	The large-conductance, Ca(2+)-dependent  bbbbb1 potassium eeeee1  bbbbb2 Ca(2+)-dependent potassium (BK) channel eeeee2  blocker, iberiotoxin, attenuated CHPG actions
CRP11	Both outward currents were significantly reduced by the mGluR antagonist MCPG and the  bbbbb1 CHPG eeeee1  bbbbb2 mGluR eeeee2  antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP
CRP11	Both outward currents were significantly reduced by the mGluR antagonist MCPG and the  bbbbb1 CHPG eeeee1 -induced current was blocked by the specific  bbbbb2 mGluR(5) eeeee2  antagonist MTEP
CRP11	Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist  bbbbb1 MTEP eeeee1  bbbbb2 mGluR eeeee2  antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP
CRP11	Both outward currents were significantly reduced by the mGluR antagonist  bbbbb1 MCPG eeeee1  and the CHPG-induced current was blocked by the specific  bbbbb2 mGluR(5) eeeee2  antagonist MTEP
CRP11	As these two processes counteract each other, these surprising  bbbbb1 findings  eeeee1  bbbbb2 e surprising findings necessitat eeeee2 e revision of predictions regarding the net level of excitation generated by glutamate input to cholinergic LDT cells and, by extension, the functional outcome of glutamate transmission on processes which these neurons regulate
CRP11	Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic  bbbbb1 glutamate eeeee1  receptors and  bbbbb2 mGluR(1) eeeee2 , but also inhibition via actions at mGluR(5) and mGluR(2/3) on these neurons
CRP11	Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic  bbbbb1 glutamate eeeee1  receptors and mGluR(1), but also inhibition via actions at  bbbbb2 mGluR(5) eeeee2  and mGluR(2/3) on these neurons
CRP11	Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic  bbbbb1 glutamate eeeee1  bbbbb2 ionotropic glutamate receptors eeeee2  and mGluR(1), but also inhibition via actions at mGluR(5) and mGluR(2/3) on these neurons
CRP11	Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic  bbbbb1 glutamate eeeee1  receptors and mGluR(1), but also inhibition via actions at mGluR(5) and  bbbbb2 mGluR(2/3) eeeee2  on these neurons
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH),  bbbbb1 alamar blue eeeee1  bbbbb2 LDH eeeee2 ), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH),  bbbbb1 alamar blue eeeee1 , 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit  bbbbb2 Bsep eeeee2 , and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH),  bbbbb1 alamar blue eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue,  bbbbb1 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide eeeee1  bbbbb2 LDH eeeee2 ), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue,  bbbbb1 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide eeeee1  (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit  bbbbb2 Bsep eeeee2 , and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue,  bbbbb1 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red,  bbbbb1 lactate eeeee1  dehydrogenase ( bbbbb2 LDH eeeee2 ), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red,  bbbbb1 lactate eeeee1  dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit  bbbbb2 Bsep eeeee2 , and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red,  bbbbb1 lactate eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and  bbbbb1 propidium iodide eeeee1  bbbbb2 LDH eeeee2 ), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and  bbbbb1 propidium iodide eeeee1  assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit  bbbbb2 Bsep eeeee2 , and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and  bbbbb1 propidium iodide eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide ( bbbbb1 MTT eeeee1  bbbbb2 LDH eeeee2 ), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide ( bbbbb1 MTT eeeee1 ) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit  bbbbb2 Bsep eeeee2 , and to define the LOAEL for these xenobiotics in this system
CRP11	The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide ( bbbbb1 MTT eeeee1  bbbbb2 lactate dehydrogenase eeeee2  (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system
CRP11	Sandwich-cultured rat hepatocytes maintain functional  bbbbb1 sodium taurocholate eeeee1  bbbbb2 sodium taurocholate co-transporting polypeptide eeeee2  and Bsep transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL)
CRP11	Sandwich-cultured rat hepatocytes maintain functional  bbbbb1 sodium taurocholate eeeee1  co-transporting polypeptide and  bbbbb2 Bsep eeeee2  transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL)
CRP11	Bosentan also decreased viability as measured by the LDH,  bbbbb1 MTT eeeee1  bbbbb2 LDH eeeee2 , MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay
CRP11	Bosentan also decreased viability as measured by the LDH, MTT and  bbbbb1 propidium iodide eeeee1  bbbbb2 LDH eeeee2 , MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay
CRP11	Bosentan also decreased viability as measured by the LDH, MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the  bbbbb1 alamar blue eeeee1  bbbbb2 LDH eeeee2 , MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay
CRP11	Glibenclamide did not decrease viability with a bbbbb1 ny assay at the  eeeee1  bbbbb2  wi eeeee2 th any assay at the xenobiotic concentrations examined in this study
CRP11	An inhibitor of type B  bbbbb1 monoamine eeeee1  oxidase ( bbbbb2 MAO-B eeeee2 ), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it
CRP11	An inhibitor of type B  bbbbb1 monoamine eeeee1  bbbbb2 type B monoamine oxidase eeeee2  (MAO-B), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it
CRP11	Crystal structure of  bbbbb1 pyridoxal eeeee1  bbbbb2 pyridoxal kinase eeeee2  in complex with roscovitine and derivatives
CRP11	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 ), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ( bbbbb2 CDKs eeeee2 ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CRP11	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate ( bbbbb1 PLP eeeee1 ), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of  bbbbb2 cyclin-dependent kinases eeeee2  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CRP11	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of  bbbbb1 vitamin B6 eeeee1 , a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ( bbbbb2 CDKs eeeee2 ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CRP11	This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of  bbbbb1 vitamin B6 eeeee1 , a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of  bbbbb2 cyclin-dependent kinases eeeee2  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CRP11	This constitutes an essential step in the synthesis of  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases ( bbbbb2 CDKs eeeee2 ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CRP11	This constitutes an essential step in the synthesis of  bbbbb1 pyridoxal 5'-phosphate eeeee1  (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of  bbbbb2 cyclin-dependent kinases eeeee2  (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections
CRP11	 bbbbb1 Pyridoxal eeeee1  kinase ( bbbbb2 PDXK eeeee2 ) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+
CRP11	 bbbbb1 Pyridoxal eeeee1  bbbbb2 Pyridoxal kinase eeeee2  (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+
CRP11	To understand this interaction, we determined the crystal structure of PDXK in complex with  bbbbb1 (R)-roscovitine eeeee1 , N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to  bbbbb2 PDXK eeeee2  but not to CDKs
CRP11	To understand this interaction, we determined the crystal structure of PDXK in complex with  bbbbb1 (R)-roscovitine eeeee1 , N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to  bbbbb2 CDKs eeeee2 
CRP11	IKM-159 was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as  bbbbb1 AMPA eeeee1  bbbbb2 AMPA receptor eeeee2 -selective antagonists
CRP11	Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid ( bbbbb1 AMPA eeeee1  bbbbb2 (AMPA) receptor eeeee2  antagonist IKM-159: asymmetric synthesis, neuroactivity, and structural characterization
CRP11	Studies on an  bbbbb1 (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid eeeee1   bbbbb2 (AMPA) receptor eeeee2  antagonist IKM-159: asymmetric synthesis, neuroactivity, and structural characterization
CRP11	Racemic IKM-159 was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site bbbbb1  eeeee1  bbbbb2 GluA2 eeeee2 , and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site
CRP11	Racemic IKM-159 was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing  bbbbb1 (2R)-IKM-159 eeeee1  at the glutamate binding site bbbbb2  eeeee2 
CRP11	Racemic IKM-159 was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing  bbbbb1 (2R)-IKM-159 eeeee1  at the glutamate binding site bbbbb2  eeeee2 
CRP11	 bbbbb1 Racemic IKM-159 eeeee1  was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site bbbbb2  eeeee2 
CRP11	 bbbbb1 Racemic IKM-159 eeeee1  was crystallized with the ligand-binding domain of GluA2, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site bbbbb2  eeeee2 
CRP11	We report for the first time that VEGF-D binds heparin, and that the  bbbbb1 C eeeee1  bbbbb2 VEGF-D eeeee2  binds heparin, and that the C-terminal propeptide significantly enhances this interaction (removal of this propeptide from full-length VEGF-D completely prevents heparin binding)
CRP11	We also show that removal of either the N- or  bbbbb1 C eeeee1 -terminal propeptide is required for VEGF-D to drive formation of  bbbbb2 VEGFR-2 eeeee2 /VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting
CRP11	We also show that removal of either the N- or  bbbbb1 C eeeee1 -terminal propeptide is required for VEGF-D to drive formation of VEGFR-2/ bbbbb2 VEGFR-3 eeeee2  heterodimers which have recently been shown to positively regulate angiogenic sprouting
CRP11	We also show that removal of either the  bbbbb1 N eeeee1 - or C-terminal propeptide is required for VEGF-D to drive formation of  bbbbb2 VEGFR-2 eeeee2 /VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting
CRP11	We also show that removal of either the  bbbbb1 N eeeee1 - or C-terminal propeptide is required for VEGF-D to drive formation of VEGFR-2/ bbbbb2 VEGFR-3 eeeee2  heterodimers which have recently been shown to positively regulate angiogenic sprouting
CRP11	Recent evidence suggests that processes other than  bbbbb1 Ca(2+) eeeee1  binding, such as phosphorylation of  bbbbb2 myosin regulatory light chain eeeee2  (RLC) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys
CRP11	Recent evidence suggests that processes other than  bbbbb1 Ca(2+) eeeee1  binding, such as phosphorylation of myosin regulatory light chain ( bbbbb2 RLC eeeee2 ) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys
CRP11	We demonstrate that activation of STAT3 serine-727 and  bbbbb1 tyrosine eeeee1 -705 phosphorylations is promoted by B-RAF( bbbbb2 V600E eeeee2 ) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation
CRP11	We demonstrate that activation of STAT3 serine-727 and  bbbbb1 tyrosine eeeee1 -705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for  bbbbb2 B-RAF eeeee2 -mediated activation
CRP11	We demonstrate that activation of STAT3 serine-727 and  bbbbb1 tyrosine eeeee1 -705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a  bbbbb2 STAT eeeee2  consensus-site for B-RAF-mediated activation
CRP11	We demonstrate that activation of STAT3 serine-727 and  bbbbb1 tyrosine eeeee1 -705 phosphorylations is promoted by  bbbbb2 B-RAF eeeee2 (V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation
CRP11	We demonstrate that activation of STAT3 serine-727 and  bbbbb1 tyrosine eeeee1 -705 phosphorylations is promoted by B-RAF(V600E) activity and that the  bbbbb2 Mcl-1 promoter eeeee2  is dependent on a STAT consensus-site for B-RAF-mediated activation
CRP11	We demonstrate that activation of STAT3  bbbbb1 serine eeeee1 -727 and tyrosine-705 phosphorylations is promoted by B-RAF( bbbbb2 V600E eeeee2 ) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation
CRP11	We demonstrate that activation of STAT3  bbbbb1 serine eeeee1 -727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for  bbbbb2 B-RAF eeeee2 -mediated activation
CRP11	We demonstrate that activation of STAT3  bbbbb1 serine eeeee1 -727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a  bbbbb2 STAT eeeee2  consensus-site for B-RAF-mediated activation
CRP11	We demonstrate that activation of STAT3  bbbbb1 serine eeeee1 -727 and tyrosine-705 phosphorylations is promoted by  bbbbb2 B-RAF eeeee2 (V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation
CRP11	We demonstrate that activation of STAT3  bbbbb1 serine eeeee1 -727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the  bbbbb2 Mcl-1 promoter eeeee2  is dependent on a STAT consensus-site for B-RAF-mediated activation
CRP11	To test the hypothesis, we determined the potency and mechanism of inhibition for styrene and its metabolites toward oxidation of  bbbbb1 4-nitrophenol eeeee1  using  bbbbb2 CYP2E1 eeeee2  Supersomes® and human liver microsomes. 3
CRP11	To test the hypothesis, we determined the potency and mechanism of inhibition for  bbbbb1 styrene eeeee1  and its metabolites toward oxidation of 4-nitrophenol using  bbbbb2 CYP2E1 eeeee2  Supersomes® and human liver microsomes. 3
CRP11	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and  bbbbb1 deoxycytidine eeeee1  bbbbb2 deoxycytidine kinase eeeee2 
CRP11	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and  bbbbb1 deoxycytidine eeeee1  bbbbb2 cytidine deaminase eeeee2  and deoxycytidine kinase
CRP11	Pharmacogenomics of  bbbbb1 gemcitabine eeeee1  metabolism: functional analysis of genetic variants in cytidine deaminase and  bbbbb2 deoxycytidine kinase eeeee2 
CRP11	Pharmacogenomics of  bbbbb1 gemcitabine eeeee1  metabolism: functional analysis of genetic variants in  bbbbb2 cytidine deaminase eeeee2  and deoxycytidine kinase
CRP11	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in  bbbbb1 cytidine eeeee1  deaminase and  bbbbb2 deoxycytidine kinase eeeee2 
CRP11	Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in  bbbbb1 cytidine eeeee1  bbbbb2 cytidine deaminase eeeee2  and deoxycytidine kinase
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by  bbbbb1 cytidine eeeee1  deaminase (CDA) and deoxycytidine kinase ( bbbbb2 DCK eeeee2 ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by  bbbbb1 cytidine eeeee1  bbbbb2 cytidine deaminase eeeee2  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by  bbbbb1 cytidine eeeee1  deaminase (CDA) and  bbbbb2 deoxycytidine kinase eeeee2  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by  bbbbb1 cytidine eeeee1  deaminase ( bbbbb2 CDA eeeee2 ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  bbbbb1 deoxycytidine eeeee1  kinase ( bbbbb2 DCK eeeee2 ), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  bbbbb1 deoxycytidine eeeee1  bbbbb2 cytidine deaminase eeeee2  (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  bbbbb1 deoxycytidine eeeee1  bbbbb2 deoxycytidine kinase eeeee2  (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and  bbbbb1 deoxycytidine eeeee1  bbbbb2 CDA eeeee2 ) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear
CRP11	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( bbbbb1 dFdU eeeee1  bbbbb2 Ala70Thr eeeee2 ) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CRP11	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( bbbbb1 dFdU eeeee1  bbbbb2 DCK eeeee2  (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CRP11	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( bbbbb1 dFdU eeeee1  bbbbb2 Pro122Ser eeeee2 ) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CRP11	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( bbbbb1 dFdU eeeee1  bbbbb2 Ala119Gly eeeee2 , and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CRP11	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( bbbbb1 dFdU eeeee1  bbbbb2 Ile24Val eeeee2 , Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CRP11	Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ( bbbbb1 dFdU eeeee1  bbbbb2 Lys27Gln eeeee2  and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates
CRP11	All four DCK proteins yielded comparable metabolic activity for Ara-C and  bbbbb1 dFdC eeeee1  monophosphorylation, except for  bbbbb2 DCK eeeee2 24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)
CRP11	All four DCK proteins yielded comparable metabolic activity for  bbbbb1 Ara-C eeeee1  and dFdC monophosphorylation, except for  bbbbb2 DCK eeeee2 24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)
CRP11	All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of  bbbbb1 dFdC eeeee1  bbbbb2 DCK eeeee2  proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)
CRP11	All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for  bbbbb1 Ara-C eeeee1  bbbbb2 CDA eeeee2  proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination
CRP11	All three CDA proteins showed similar K(m) and V(max) for  bbbbb1 Ara-C eeeee1  and dFdC deamination, except for  bbbbb2 CDA eeeee2 70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination
CRP11	All three CDA proteins showed similar K(m) and V(max) for Ara-C and  bbbbb1 dFdC eeeee1  deamination, except for  bbbbb2 CDA eeeee2 70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination
CRP11	Furthermore, CaMKII inhibition in astrocytes is associated with the rapid onset of intracellular  bbbbb1 calcium eeeee1  bbbbb2 CaMKII eeeee2  inhibition in astrocytes is associated with the rapid onset of intracellular calcium oscillations
CRP11	When extracellular glutamate and  bbbbb1 ATP eeeee1  levels are measured following  bbbbb2 CaMKII eeeee2  inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas ATP levels in the extracellular environment significantly increase
CRP11	When extracellular glutamate and ATP levels are measured following CaMKII inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas  bbbbb1 ATP eeeee1  bbbbb2 CaMKII eeeee2  inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas ATP levels in the extracellular environment significantly increase
CRP11	When extracellular glutamate and ATP levels are measured following CaMKII inhibition within our enriched astrocyte cultures, no alterations in  bbbbb1 glutamate eeeee1  bbbbb2 CaMKII eeeee2  inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas ATP levels in the extracellular environment significantly increase
CRP11	When extracellular  bbbbb1 glutamate eeeee1  and ATP levels are measured following  bbbbb2 CaMKII eeeee2  inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas ATP levels in the extracellular environment significantly increase
CRP11	Surprisingly, this rapid  bbbbb1 calcium eeeee1  influx is blocked by the  bbbbb2 N-type calcium channel eeeee2  antagonist, omega-conotoxin
CRP11	Surprisingly, this rapid  bbbbb1 calcium eeeee1  influx is blocked by the N-type calcium channel antagonist,  bbbbb2 omega-conotoxin eeeee2 
CRP11	Surprisingly, this rapid calcium influx is blocked by the  bbbbb1 N eeeee1  bbbbb2 N-type calcium channel eeeee2  antagonist, omega-conotoxin
CRP11	Surprisingly, this rapid calcium influx is blocked by the  bbbbb1 N eeeee1 -type calcium channel antagonist,  bbbbb2 omega-conotoxin eeeee2 
CRP11	Surprisingly, this rapid calcium influx is blocked by the N-type  bbbbb1 calcium eeeee1  bbbbb2 N-type calcium channel eeeee2  antagonist, omega-conotoxin
CRP11	Surprisingly, this rapid calcium influx is blocked by the N-type  bbbbb1 calcium eeeee1  channel antagonist,  bbbbb2 omega-conotoxin eeeee2 
CRP11	We have previously shown that a loss of CaMKII activity in neurons is detrimental to neuronal viability by inducing excitotoxic  bbbbb1 glutamate eeeee1  bbbbb2 CaMKII eeeee2  activity in neurons is detrimental to neuronal viability by inducing excitotoxic glutamate release
CRP11	While the function of N-type calcium channels within astrocytes is controversial, these voltage-gated  bbbbb1 calcium eeeee1  bbbbb2 N-type calcium channels eeeee2  within astrocytes is controversial, these voltage-gated calcium channels have been linked to calcium-dependent vesicular gliotransmitter release
CRP11	While the function of N-type calcium channels within astrocytes is controversial, these voltage-gated  bbbbb1 calcium eeeee1  bbbbb2 voltage-gated calcium channels eeeee2  have been linked to calcium-dependent vesicular gliotransmitter release
CRP11	While the function of  bbbbb1 N eeeee1  bbbbb2 N-type calcium channels eeeee2  within astrocytes is controversial, these voltage-gated calcium channels have been linked to calcium-dependent vesicular gliotransmitter release
CRP11	While the function of  bbbbb1 N eeeee1 -type calcium channels within astrocytes is controversial, these  bbbbb2 voltage-gated calcium channels eeeee2  have been linked to calcium-dependent vesicular gliotransmitter release
CRP11	While the function of N-type  bbbbb1 calcium eeeee1  bbbbb2 N-type calcium channels eeeee2  within astrocytes is controversial, these voltage-gated calcium channels have been linked to calcium-dependent vesicular gliotransmitter release
CRP11	While the function of N-type  bbbbb1 calcium eeeee1  channels within astrocytes is controversial, these  bbbbb2 voltage-gated calcium channels eeeee2  have been linked to calcium-dependent vesicular gliotransmitter release
CRP11	Extracellular ATP accumulation associated with CaMKII inhibition bbbbb1  contribu eeeee1  bbbbb2 P accu eeeee2 mulation associated with CaMKII inhibition contributes both to calcium oscillations within astrocytes and ultimately cortical neuron toxicity
CRP11	Extracellular ATP accumulation associated with CaMKII inhibition contributes both to calcium o bbbbb1 sci eeeee1  bbbbb2 P accu eeeee2 mulation associated with CaMKII inhibition contributes both to calcium oscillations within astrocytes and ultimately cortical neuron toxicity
CRP11	Loss of Calcium/Calmodulin-Dependent Protein Kinase II Activity in Cortical Astrocytes Decreases Glutamate Uptake and Induces Neurotoxic Release of  bbbbb1 ATP eeeee1  bbbbb2 Calcium/Calmodulin-Dependent Protein Kinase II eeeee2  Activity in Cortical Astrocytes Decreases Glutamate Uptake and Induces Neurotoxic Release of ATP
CRP11	Loss of Calcium/Calmodulin-Dependent Protein Kinase II Activity in Cortical Astrocytes Decreases  bbbbb1 Glutamate eeeee1  bbbbb2 Calcium/Calmodulin-Dependent Protein Kinase II eeeee2  Activity in Cortical Astrocytes Decreases Glutamate Uptake and Induces Neurotoxic Release of ATP
CRP11	Loss of  bbbbb1 Calcium eeeee1  bbbbb2 Calcium/Calmodulin-Dependent Protein Kinase II eeeee2  Activity in Cortical Astrocytes Decreases Glutamate Uptake and Induces Neurotoxic Release of ATP
CRP11	The extent of  bbbbb1 calcium eeeee1  bbbbb2 calcium/calmodulin-dependent protein kinase II eeeee2  (CaMKII) inactivation in the brain following ischemia correlates with the extent of damage
CRP11	The extent of  bbbbb1 calcium eeeee1 /calmodulin-dependent protein kinase II ( bbbbb2 CaMKII eeeee2 ) inactivation in the brain following ischemia correlates with the extent of damage
CRP11	The binding profiles for the agonists oxytocin and  bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin eeeee2  and carbetocin were found to be similar
CRP11	The binding profiles for the agonists  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  and carbetocin were found to be similar
CRP11	In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V2 receptor eeeee2 
CRP11	In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the  bbbbb1 oxytocin eeeee1  receptor to the  bbbbb2 vasopressin V2 receptor eeeee2 
CRP11	These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the  bbbbb1 oxytocin eeeee1  bbbbb2 vasopressin V2 receptor eeeee2  and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the  bbbbb1 oxytocin eeeee1  receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the  bbbbb2 oxytocin receptor eeeee2  (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the  bbbbb1 oxytocin eeeee1  receptor into the related  bbbbb2 vasopressin V2 receptor eeeee2  and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related  bbbbb1 vasopressin eeeee1  V2 receptor and have already been successfully employed for the identification of ligand binding domains at the  bbbbb2 oxytocin receptor eeeee2  (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V2 receptor eeeee2  and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related  bbbbb1 vasopressin eeeee1  bbbbb2 oxytocin receptor eeeee2  into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996
CRP11	The binding domain of barusiban differs from the binding domain of the agoni bbbbb1 sts and  eeeee1  bbbbb2 sts and the nonse eeeee2 lective oxytocin receptor antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies
CRP11	Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin
CRP11	Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist  bbbbb1 barusiban eeeee1  in comparison to the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	Binding domains of the oxytocin receptor for the selective  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  antagonist barusiban in comparison to the agonists oxytocin and carbetocin
CRP11	Binding domains of the oxytocin receptor for the selective  bbbbb1 oxytocin eeeee1  receptor antagonist barusiban in comparison to the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	Binding domains of the oxytocin receptor for the selective  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin
CRP11	Binding domains of the  bbbbb1 oxytocin eeeee1  receptor for the selective  bbbbb2 oxytocin receptor eeeee2  antagonist barusiban in comparison to the agonists oxytocin and carbetocin
CRP11	Binding domains of the  bbbbb1 oxytocin eeeee1  receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	Binding domains of the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin
CRP11	Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and  bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and  bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin,  bbbbb1 [Arg8]vasopressin eeeee1  bbbbb2 vasopressin eeeee2 , carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin,  bbbbb1 [Arg8]vasopressin eeeee1  bbbbb2 oxytocin eeeee2 , [Arg8]vasopressin, carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]vasopressin, carbetocin, and  bbbbb1 atosiban eeeee1  bbbbb2 vasopressin eeeee2 , carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]vasopressin, carbetocin, and  bbbbb1 atosiban eeeee1  bbbbb2 oxytocin eeeee2 , [Arg8]vasopressin, carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of  bbbbb1 barusiban eeeee1  was compared with the binding profiles of the ligands oxytocin, [Arg8] bbbbb2 vasopressin eeeee2 , carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of  bbbbb1 barusiban eeeee1  was compared with the binding profiles of the ligands  bbbbb2 oxytocin eeeee2 , [Arg8]vasopressin, carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]vasopressin,  bbbbb1 carbetocin eeeee1  bbbbb2 vasopressin eeeee2 , carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]vasopressin,  bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin eeeee2 , [Arg8]vasopressin, carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands  bbbbb1 oxytocin eeeee1 , [Arg8] bbbbb2 vasopressin eeeee2 , carbetocin, and atosiban
CRP11	In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2 , [Arg8]vasopressin, carbetocin, and atosiban
CRP11	For this purpose, chimeric 'gain-in function'  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin/vasopressin V2 receptors eeeee2  were expressed in COS-7 cells
CRP11	For this purpose, chimeric 'gain-in function' oxytocin/ bbbbb1 vasopressin eeeee1  bbbbb2 oxytocin/vasopressin V2 receptors eeeee2  were expressed in COS-7 cells
CRP11	For the vasopressin V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V1A/oxytocin receptor eeeee2  antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor
CRP11	For the vasopressin V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V2 receptor eeeee2 
CRP11	For the vasopressin V1A/ bbbbb1 oxytocin eeeee1  bbbbb2 vasopressin V1A/oxytocin receptor eeeee2  antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor
CRP11	For the vasopressin V1A/ bbbbb1 oxytocin eeeee1  receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting  bbbbb2 vasopressin V2 receptor eeeee2 
CRP11	For the  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V1A/oxytocin receptor eeeee2  antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor
CRP11	For the  bbbbb1 vasopressin eeeee1  V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting  bbbbb2 vasopressin V2 receptor eeeee2 
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist  bbbbb1 atosiban eeeee1  bbbbb2 oxytocin receptor eeeee2  for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist  bbbbb1 atosiban eeeee1  bbbbb2 oxytocin receptor eeeee2  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist  bbbbb1 atosiban eeeee1  and the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb1 vasopressin eeeee1  bbbbb2 vasopressin V1A/oxytocin receptor eeeee2  antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb1 vasopressin eeeee1  bbbbb2 oxytocin receptor eeeee2  for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb1 vasopressin eeeee1  bbbbb2 oxytocin receptor eeeee2  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb1 vasopressin eeeee1  V1A/oxytocin receptor antagonist atosiban and the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for  bbbbb1 barusiban eeeee1 , a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb2 vasopressin V1A/oxytocin receptor eeeee2  antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for  bbbbb1 barusiban eeeee1 , a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective  bbbbb1 oxytocin eeeee1  receptor antagonist, in comparison to the combined  bbbbb2 vasopressin V1A/oxytocin receptor eeeee2  antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective  bbbbb1 oxytocin eeeee1  receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	We have analyzed binding domains of the  bbbbb1 oxytocin eeeee1  receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined  bbbbb2 vasopressin V1A/oxytocin receptor eeeee2  antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the  bbbbb1 oxytocin eeeee1  receptor for barusiban, a highly selective  bbbbb2 oxytocin receptor eeeee2  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the  bbbbb1 oxytocin eeeee1  receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and  bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin receptor eeeee2  for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and  bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin receptor eeeee2  antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin
CRP11	We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and  bbbbb1 carbetocin eeeee1  bbbbb2 oxytocin eeeee2  and carbetocin
CRP11	For both agonists, important binding domains were the extracellular N-terminus (=E1) and the extracellular loops E2 and E3 from the  bbbbb1 oxytocin eeeee1  bbbbb2 oxytocin receptor eeeee2 
CRP11	To identify key  bbbbb1 amino acids eeeee1  involved in factor IX activation, recombinant  bbbbb2 factor XIa eeeee2  proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay
CRP11	To identify key amino acids involved in factor IX activation, recombinant factor XIa proteins containing  bbbbb1 alanine eeeee1  bbbbb2 factor IX eeeee2  activation, recombinant factor XIa proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay
CRP11	Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the  bbbbb1 N eeeee1  terminus and for Ser(258)-Ser(264) at the C terminus of the A3 domain markedly decreased  bbbbb2 factor XI eeeee2  coagulant activity
CRP11	Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the  bbbbb1 C eeeee1  terminus of the A3 domain markedly decreased  bbbbb2 factor XI eeeee2  coagulant activity
CRP11	Olopatadine hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/ bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonistic drug that was synthesized and evaluated in our laboratories
CRP11	Olopatadine is a selective histamine H1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and  bbbbb1 thromboxane eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils
CRP11	Olopatadine is a selective  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils
CRP11	Olopatadine is a selective histamine H1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as  bbbbb1 leukotriene eeeee1  bbbbb2 histamine H1-receptor eeeee2  antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils
CRP11	Inhibition of the NF-kappaB pathway was responsible for this effect since the  bbbbb1 colchicoside eeeee1  bbbbb2 NF-kappaB eeeee2  pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB
CRP11	TAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well-established system for osteoclastogenesis, and evaluated the effect of  bbbbb1 thiocolchicoside eeeee1  on  bbbbb2 RANKL eeeee2 -induced NF-kappaB signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells
CRP11	TAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well-established system for osteoclastogenesis, and evaluated the effect of  bbbbb1 thiocolchicoside eeeee1  on RANKL-induced  bbbbb2 NF-kappaB eeeee2  signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells
CRP11	For AMP, the PC20 increased from 9.3 (range 1.0-113.3) mg/ml after placebo, to 150.2 (range 32.1-1177.7) mg/ml with terfenadine (P less than 0.0001) bbbbb1  eeeee1  bbbbb2 h terfenadine (P less eeeee2  than 0.0001)
CRP11	For AMP, the PC20 increased from 9.3 (range 1.0-113.3) mg/ml after bbbbb1  pl eeeee1 acebo, to 150.2 (range 32.1-1177.7) mg/ml wit bbbbb2 h terfenadine (P less eeeee2  than 0.0001)
CRP11	For AMP, the PC20 increased from 9.3 (range 1.0-113.3) mg/ml after placebo, to 150.2 (range 32.1-1177.7) mg/ml wit bbbbb1 h terfena eeeee1  bbbbb2 h terfenadine (P less eeeee2  than 0.0001)
CRP11	Selective histamine-H1 receptor antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of  bbbbb1 AMP eeeee1  bbbbb2 histamine-H1 receptor eeeee2  antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20)
CRP11	Selective histamine-H1 receptor antagonists inhibit  bbbbb1 adenosine 5'-monophosphate eeeee1  bbbbb2 histamine-H1 receptor eeeee2  antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20)
CRP11	Selective  bbbbb1 histamine eeeee1  bbbbb2 histamine-H1 receptor eeeee2  antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20)
CRP11	Selective histamine-H1 receptor antagonists inhibit adenosine 5'-monophosphate ( bbbbb1 AMP eeeee1  bbbbb2 histamine-H1 receptor eeeee2  antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20)
CRP11	The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related  bbbbb1 AMP eeeee1  bbbbb2 histamine-H1 receptor eeeee2  antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma
CRP11	The effect of  bbbbb1 histamine eeeee1  bbbbb2 histamine-H1 receptor eeeee2  antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma
CRP11	The purified protein showed l-serine and  bbbbb1 l-threonine eeeee1  dehydratase activity, demonstrating to be an isoform of  bbbbb2 SDH eeeee2 
CRP11	The purified protein showed l-serine and  bbbbb1 l-threonine eeeee1  bbbbb2 l-serine and l-threonine dehydratase eeeee2  activity, demonstrating to be an isoform of SDH
CRP11	The purified protein showed  bbbbb1 l-serine eeeee1  and l-threonine dehydratase activity, demonstrating to be an isoform of  bbbbb2 SDH eeeee2 
CRP11	The purified protein showed  bbbbb1 l-serine eeeee1  bbbbb2 l-serine and l-threonine dehydratase eeeee2  activity, demonstrating to be an isoform of SDH
CRP11	DNA clone similar to human  bbbbb1 serine eeeee1  bbbbb2 human serine dehydratase eeeee2  (SDH) is deposited in the GenBank/EMBL databases, but its structural and functional bases remain unknown
CRP11	DNA clone similar to human  bbbbb1 serine eeeee1  dehydratase ( bbbbb2 SDH eeeee2 ) is deposited in the GenBank/EMBL databases, but its structural and functional bases remain unknown
CRP11	Both compounds sup bbbbb1 presse eeeee1  bbbbb2  compounds suppressed HIF-1α accum eeeee2 ulation in a concentration-dependent manner
CRP11	Both compounds sup bbbbb1 presse eeeee1 d HIF-1α accumul bbbbb2 ati eeeee2 on in a concentration-dependent manner
CRP11	Both compounds sup bbbbb1 presse eeeee1 d HIF-1α accumulation in a concentration-dependent manner bbbbb2  eeeee2 
CRP11	Both compounds suppressed HIF-1α accumulation in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2  compounds suppressed HIF-1α accum eeeee2 ulation in a concentration-dependent manner
CRP11	Both compounds suppressed HIF-1α accumulation in a concentration-dependent manner bbbbb1  eeeee1  bbbbb2 ati eeeee2 on in a concentration-dependent manner
CRP11	A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the  bbbbb1 MTT eeeee1  bbbbb2 HIF-1 eeeee2  transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay
CRP11	A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the  bbbbb1 MTT eeeee1  bbbbb2 HRE eeeee2 -Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay
CRP11	A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the  bbbbb1 MTT eeeee1  bbbbb2 HRE eeeee2 -dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay
CRP11	A series of substituted  bbbbb1 ortho-carboranylphenoxyacetanilides eeeee1  were synthesized and evaluated for their ability to inhibit hypoxia-induced  bbbbb2 HIF-1 eeeee2  transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay
CRP11	A series of substituted  bbbbb1 ortho-carboranylphenoxyacetanilides eeeee1  were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct ( bbbbb2 HRE eeeee2 -Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay
CRP11	A series of substituted  bbbbb1 ortho-carboranylphenoxyacetanilides eeeee1  were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the  bbbbb2 HRE eeeee2 -dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay
CRP11	Development of hypoxia-inducible factor (HIF)-1α inhibitors: effect of  bbbbb1 ortho-carborane eeeee1  substituents on  bbbbb2 HIF eeeee2  transcriptional activity under hypoxia
CRP11	Development of hypoxia-inducible factor (HIF)-1α inhibitors: effect of  bbbbb1 ortho-carborane eeeee1  bbbbb2 hypoxia-inducible factor (HIF)-1α eeeee2  inhibitors: effect of ortho-carborane substituents on HIF transcriptional activity under hypoxia
CRP11	Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and  bbbbb1 troglitazone eeeee1  bbbbb2 uncoupling protein-3 eeeee2  gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.  bbbbb1 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid eeeee1  (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of  bbbbb2 PPAR-gamma eeeee2 , also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.  bbbbb1 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid eeeee1  (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases  bbbbb2 UCP-3 eeeee2  mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.  bbbbb1 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid eeeee1  bbbbb2 PPAR eeeee2 ), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.  bbbbb1 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid eeeee1  bbbbb2 UCP-3 eeeee2  mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.  bbbbb1 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid eeeee1  bbbbb2 peroxisome proliferator-activated receptor eeeee2  (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( bbbbb1 WY-14,643 eeeee1 ), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of  bbbbb2 PPAR-gamma eeeee2 , also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( bbbbb1 WY-14,643 eeeee1 ), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases  bbbbb2 UCP-3 eeeee2  mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( bbbbb1 WY-14,643 eeeee1  bbbbb2 PPAR eeeee2 ), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( bbbbb1 WY-14,643 eeeee1  bbbbb2 UCP-3 eeeee2  mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid ( bbbbb1 WY-14,643 eeeee1  bbbbb2 peroxisome proliferator-activated receptor eeeee2  (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  bbbbb1 troglitazone eeeee1  bbbbb2 UCP-3 eeeee2  mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  bbbbb1 troglitazone eeeee1  bbbbb2 PPAR-alpha eeeee2  subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  bbbbb1 troglitazone eeeee1  bbbbb2 PPAR eeeee2 ), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  bbbbb1 troglitazone eeeee1  bbbbb2 UCP-3 eeeee2  mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of bezafibrate, an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas  bbbbb1 troglitazone eeeee1  bbbbb2 peroxisome proliferator-activated receptor eeeee2  (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of  bbbbb1 bezafibrate eeeee1 , an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of  bbbbb2 PPAR-gamma eeeee2 , also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of  bbbbb1 bezafibrate eeeee1 , an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in  bbbbb2 UCP-3 eeeee2  mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of  bbbbb1 bezafibrate eeeee1 , an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the  bbbbb2 PPAR-alpha eeeee2  subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice
CRP11	Treatment of lactating mice with a single injection of  bbbbb1 bezafibrate eeeee1 , an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice. 4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases  bbbbb2 UCP-3 eeeee2  mRNA abundance in skeletal muscle of lactating mice
CRP11	Overexpression of hypoxia inducible factor (HIF) is also caused by the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 HIF eeeee2 ) is also caused by the mammalian target of rapamycin (mTOR), a key component of signaling pathways inside the cell, involved in cell proliferation
CRP11	Overexpression of hypoxia inducible factor (HIF) is also caused by the mammalian target of  bbbbb1 rapamycin eeeee1  ( bbbbb2 mTOR eeeee2 ), a key component of signaling pathways inside the cell, involved in cell proliferation
CRP11	Overexpression of hypoxia inducible factor (HIF) is also caused by the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 hypoxia inducible factor eeeee2  (HIF) is also caused by the mammalian target of rapamycin (mTOR), a key component of signaling pathways inside the cell, involved in cell proliferation
CRP11	Overexpression of hypoxia inducible factor (HIF) is also caused by the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin eeeee2  (mTOR), a key component of signaling pathways inside the cell, involved in cell proliferation
CRP11	 bbbbb1 Sunitinib eeeee1 , sorafenib and  bbbbb2 mTOR eeeee2  inhibitors in renal cancer
CRP11	Sunitinib,  bbbbb1 sorafenib eeeee1  and  bbbbb2 mTOR eeeee2  inhibitors in renal cancer
CRP11	Sorafenib and  bbbbb1 sunitinib eeeee1  are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an  bbbbb2 mTOR eeeee2  inhibitor
CRP11	Sorafenib and  bbbbb1 sunitinib eeeee1  are synthetic, orally active agents shown to directly inhibit  bbbbb2 vascular endothelial growth factor receptors -2 and -3 eeeee2  (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CRP11	 bbbbb1 Sorafenib eeeee1  and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an  bbbbb2 mTOR eeeee2  inhibitor
CRP11	 bbbbb1 Sorafenib eeeee1  and sunitinib are synthetic, orally active agents shown to directly inhibit  bbbbb2 vascular endothelial growth factor receptors -2 and -3 eeeee2  (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CRP11	Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while  bbbbb1 temsirolimus eeeee1  bbbbb2 PDGFR-beta eeeee2 ), while temsirolimus is an mTOR inhibitor
CRP11	Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while  bbbbb1 temsirolimus eeeee1  bbbbb2 platelet-derived growth factor receptor beta eeeee2  (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CRP11	Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while  bbbbb1 temsirolimus eeeee1  bbbbb2 VEGFR-2 eeeee2 , VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CRP11	Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while  bbbbb1 temsirolimus eeeee1  bbbbb2 VEGFR-3 eeeee2 ) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CRP11	Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while  bbbbb1 temsirolimus eeeee1  bbbbb2 vascular endothelial growth factor receptors -2 and -3 eeeee2  (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor
CRP11	Responses to the mast cell degranulator 48/80 mimicked those to 5-HT in inflamed tissue but not in controls, and more  bbbbb1 5-HT eeeee1 -containing mast cells were seen close to  bbbbb2 calcitonin gene-related peptide eeeee2 -containing fibres in inflamed serosa
CRP11	Responses to the mast cell degranulator 48/80 mimicked those to  bbbbb1 5-HT eeeee1  in inflamed tissue but not in controls, and more 5-HT-containing mast cells were seen close to  bbbbb2 calcitonin gene-related peptide eeeee2 -containing fibres in inflamed serosa
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms  bbbbb1 hydrogen eeeee1  bbbbb2 GGGGL eeeee2 (172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms  bbbbb1 hydrogen eeeee1  bbbbb2 G-rich sequence eeeee2  ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168) bbbbb1 GGGGL eeeee1  bbbbb2 GGGGL eeeee2 (172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the  bbbbb1 phosphate eeeee1  bbbbb2 GGGGL eeeee2 (172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the  bbbbb1 phosphate eeeee1  bbbbb2 G-rich sequence eeeee2  ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms hydrogen bonds with the  bbbbb1 amide eeeee1  bbbbb2 GGGGL eeeee2 (172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms hydrogen bonds with the  bbbbb1 amide eeeee1  bbbbb2 G-rich sequence eeeee2  ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of  bbbbb1 PLP eeeee1  is surrounded by a characteristic G-rich sequence ((168) bbbbb2 GGGGL eeeee2 (172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those  bbbbb1 amino acid eeeee1  bbbbb2 GGGGL eeeee2 (172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those  bbbbb1 amino acid eeeee1  bbbbb2 G-rich sequence eeeee2  ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated
CRP11	The holo-SDH contained PLP-OMS aldimine in the active site, indicating that OMS can form the  bbbbb1 Schiff base eeeee1  bbbbb2 holo-SDH eeeee2  contained PLP-OMS aldimine in the active site, indicating that OMS can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur
CRP11	Crystal structure of  bbbbb1 serine eeeee1  bbbbb2 serine dehydratase eeeee2  from rat liver
CRP11	SDH ( bbbbb1 L-serine eeeee1  bbbbb2 (L-serine dehydratase eeeee2 , EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia
CRP11	SDH ( bbbbb1 L-serine eeeee1  dehydratase,  bbbbb2 EC 4.3.1.17 eeeee2 ) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia
CRP11	SDH ( bbbbb1 L-serine eeeee1  bbbbb2 SDH eeeee2  (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia
CRP11	Formation of pyruvate by SDH is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the  bbbbb1 aminoacrylate eeeee1  bbbbb2 SDH eeeee2  is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate
CRP11	A 5'-flanking region capable of supporting RA-induced blr1 activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by  bbbbb1 RA eeeee1  bbbbb2 blr1 eeeee2  activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA
CRP11	 bbbbb1 RA eeeee1  is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of  bbbbb2 blr1 eeeee2  expression by RA
CRP11	RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by  bbbbb1 RA eeeee1  bbbbb2 Burkitt's lymphoma receptor 1 eeeee2  (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA
CRP11	RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by  bbbbb1 RA eeeee1  bbbbb2 BLR1 eeeee2 ) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA
CRP11	RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels  bbbbb1 RA eeeee1  bbbbb2 Burkitt's lymphoma receptor 1 eeeee2  (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA
CRP11	RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels  bbbbb1 RA eeeee1  bbbbb2 BLR1 eeeee2 ) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA
CRP11	RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels  bbbbb1 RA eeeee1 -induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of  bbbbb2 blr1 eeeee2  expression by RA
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  response element binding factor (CREB) site between the transcriptional start and first exon of the  bbbbb2 blr1 eeeee2  gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  bbbbb2 RAR-RXR binding element eeeee2  to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  bbbbb2 NFATc eeeee2 ) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  bbbbb2 octamer transcription factor 1 eeeee2  (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  bbbbb2 Oct1 eeeee2 ) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  bbbbb2 nuclear factor of activated T cells eeeee2  (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  bbbbb2 cyclic AMP response element binding factor eeeee2  (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a  bbbbb1 cyclic AMP eeeee1  response element binding factor ( bbbbb2 CREB eeeee2 ) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	The ability of this cis-acting RAR-RXR binding element to activate transcription in response to  bbbbb1 RA eeeee1  also depended on downstream sequences where an octamer transcription factor 1 ( bbbbb2 Oct1 eeeee2 ) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary
CRP11	A novel retinoic acid-responsive element regulates  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid-responsive element eeeee2  regulates retinoic acid-induced BLR1 expression
CRP11	A novel  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid-responsive element eeeee2  regulates retinoic acid-induced BLR1 expression
CRP11	A novel  bbbbb1 retinoic acid eeeee1 -responsive element regulates retinoic acid-induced  bbbbb2 BLR1 eeeee2  expression
CRP11	The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and  bbbbb1 retinoid eeeee1  X receptor (RXR) subtypes (as detected by Northern analysis) except  bbbbb2 RXRgamma eeeee2 
CRP11	The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and  bbbbb1 retinoid eeeee1  X receptor ( bbbbb2 RXR eeeee2 ) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and  bbbbb1 retinoid eeeee1  bbbbb2 RA receptor eeeee2  (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and  bbbbb1 retinoid eeeee1  bbbbb2 retinoid X receptor eeeee2  (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and  bbbbb1 retinoid eeeee1  bbbbb2 RAR eeeee2 ) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The RA-treated HL-60 cells used here expressed all  bbbbb1 RA eeeee1  receptor (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except  bbbbb2 RXRgamma eeeee2 
CRP11	The RA-treated HL-60 cells used here expressed all  bbbbb1 RA eeeee1  receptor (RAR) and retinoid X receptor ( bbbbb2 RXR eeeee2 ) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The RA-treated HL-60 cells used here expressed all  bbbbb1 RA eeeee1  bbbbb2 RA receptor eeeee2  (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The RA-treated HL-60 cells used here expressed all  bbbbb1 RA eeeee1  receptor (RAR) and  bbbbb2 retinoid X receptor eeeee2  (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The RA-treated HL-60 cells used here expressed all  bbbbb1 RA eeeee1  receptor ( bbbbb2 RAR eeeee2 ) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The  bbbbb1 RA eeeee1 -treated HL-60 cells used here expressed all RA receptor (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except  bbbbb2 RXRgamma eeeee2 
CRP11	The  bbbbb1 RA eeeee1 -treated HL-60 cells used here expressed all RA receptor (RAR) and retinoid X receptor ( bbbbb2 RXR eeeee2 ) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The  bbbbb1 RA eeeee1 -treated HL-60 cells used here expressed all  bbbbb2 RA receptor eeeee2  (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The  bbbbb1 RA eeeee1 -treated HL-60 cells used here expressed all RA receptor (RAR) and  bbbbb2 retinoid X receptor eeeee2  (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	The  bbbbb1 RA eeeee1 -treated HL-60 cells used here expressed all RA receptor ( bbbbb2 RAR eeeee2 ) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma
CRP11	Within this sequence DNase I footprinting revealed that  bbbbb1 RA eeeee1  bbbbb2 DNase I eeeee2  footprinting revealed that RA induced binding of a nuclear protein complex to an element containing two GT boxes
CRP11	Both GT boxes were needed for binding the complex, and mutation of either GT box caused the loss of transcriptional activation by  bbbbb1 RA eeeee1  bbbbb2 GT box eeeee2  caused the loss of transcriptional activation by RA
CRP11	The  bbbbb1 norepinephrine eeeee1  transporter ( bbbbb2 NET eeeee2 ) is a high-affinity transporter for catecholamines
CRP11	The  bbbbb1 norepinephrine eeeee1  bbbbb2 norepinephrine transporter eeeee2  (NET) is a high-affinity transporter for catecholamines
CRP11	Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity,  bbbbb1 poly ADP-ribose eeeee1  bbbbb2 poly ADP-ribose polymerase eeeee2  (PARP) cleavage and phosphatidylserine externalization
CRP11	Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity,  bbbbb1 poly ADP-ribose eeeee1  polymerase ( bbbbb2 PARP eeeee2 ) cleavage and phosphatidylserine externalization
CRP11	Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity,  bbbbb1 poly ADP-ribose eeeee1  bbbbb2 caspase-3 eeeee2  activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization
CRP11	Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (PARP) cleavage and  bbbbb1 phosphatidylserine eeeee1  bbbbb2 poly ADP-ribose polymerase eeeee2  (PARP) cleavage and phosphatidylserine externalization
CRP11	Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (PARP) cleavage and  bbbbb1 phosphatidylserine eeeee1  bbbbb2 PARP eeeee2 ) cleavage and phosphatidylserine externalization
CRP11	Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (PARP) cleavage and  bbbbb1 phosphatidylserine eeeee1  bbbbb2 caspase-3 eeeee2  activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced  bbbbb1 glutathione eeeee1  to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 ( bbbbb2 Nrf2 eeeee2 ) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced  bbbbb1 glutathione eeeee1  to oxidized glutathione (GSH/GSSG) and an increased  bbbbb2 NF-E2-related Factor 2 eeeee2  (Nrf2) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of  bbbbb1 reduced glutathione eeeee1  (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 ( bbbbb2 Nrf2 eeeee2 ) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of  bbbbb1 reduced glutathione eeeee1  (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased  bbbbb2 NF-E2-related Factor 2 eeeee2  (Nrf2) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione ( bbbbb1 GSH eeeee1 ), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 ( bbbbb2 Nrf2 eeeee2 ) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione ( bbbbb1 GSH eeeee1 ), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased  bbbbb2 NF-E2-related Factor 2 eeeee2  (Nrf2) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione ( bbbbb1 GSH eeeee1 /GSSG) and an increased NF-E2-related Factor 2 ( bbbbb2 Nrf2 eeeee2 ) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione ( bbbbb1 GSH eeeee1 /GSSG) and an increased  bbbbb2 NF-E2-related Factor 2 eeeee2  (Nrf2) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/ bbbbb1 GSSG eeeee1 ) and an increased NF-E2-related Factor 2 ( bbbbb2 Nrf2 eeeee2 ) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/ bbbbb1 GSSG eeeee1 ) and an increased  bbbbb2 NF-E2-related Factor 2 eeeee2  (Nrf2) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to  bbbbb1 oxidized glutathione eeeee1  (GSH/GSSG) and an increased NF-E2-related Factor 2 ( bbbbb2 Nrf2 eeeee2 ) activation
CRP11	Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to  bbbbb1 oxidized glutathione eeeee1  (GSH/GSSG) and an increased  bbbbb2 NF-E2-related Factor 2 eeeee2  (Nrf2) activation
CRP11	Further, mitogen-activated protein kinases (MAPKs) such as c-Jun  bbbbb1 N eeeee1 -terminal kinases ( bbbbb2 JNK eeeee2 ), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated
CRP11	Further, mitogen-activated protein kinases (MAPKs) such as c-Jun  bbbbb1 N eeeee1 -terminal kinases (JNK),  bbbbb2 extracellular signal-regulated kinases eeeee2  (Erk1/2), and p38 were all activated
CRP11	Further, mitogen-activated protein kinases (MAPKs) such as c-Jun  bbbbb1 N eeeee1  bbbbb2 mitogen-activated protein kinases eeeee2  (MAPKs) such as c-Jun N-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated
CRP11	Further, mitogen-activated protein kinases (MAPKs) such as c-Jun  bbbbb1 N eeeee1  bbbbb2 MAPKs eeeee2 ) such as c-Jun N-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated
CRP11	Further, mitogen-activated protein kinases (MAPKs) such as c-Jun  bbbbb1 N eeeee1 -terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and  bbbbb2 p38 eeeee2  were all activated
CRP11	Further, mitogen-activated protein kinases (MAPKs) such as c-Jun  bbbbb1 N eeeee1 -terminal kinases (JNK), extracellular signal-regulated kinases ( bbbbb2 Erk1/2 eeeee2 ), and p38 were all activated
CRP11	Further, mitogen-activated protein kinases (MAPKs) such as c-Jun  bbbbb1 N eeeee1  bbbbb2 c-Jun N-terminal kinases eeeee2  (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and  bbbbb1 glutathione eeeee1 -S-transferase ( bbbbb2 GST eeeee2 ) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione-S-transferase eeeee2  (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 SOD eeeee2 ) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 catalase eeeee2  (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and  bbbbb1 glutathione eeeee1  bbbbb2 CAT eeeee2 ) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that  bbbbb1 superoxide eeeee1  dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase ( bbbbb2 GST eeeee2 ) activities were depressed
CRP11	Enzyme assays showed that  bbbbb1 superoxide eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that  bbbbb1 superoxide eeeee1  dismutase (SOD) activity was elevated whereas catalase (CAT) and  bbbbb2 glutathione-S-transferase eeeee2  (GST) activities were depressed
CRP11	Enzyme assays showed that  bbbbb1 superoxide eeeee1  dismutase ( bbbbb2 SOD eeeee2 ) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that  bbbbb1 superoxide eeeee1  dismutase (SOD) activity was elevated whereas  bbbbb2 catalase eeeee2  (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that  bbbbb1 superoxide eeeee1  dismutase (SOD) activity was elevated whereas catalase ( bbbbb2 CAT eeeee2 ) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione- bbbbb1 S eeeee1 -transferase ( bbbbb2 GST eeeee2 ) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione- bbbbb1 S eeeee1  bbbbb2 superoxide dismutase eeeee2  (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione- bbbbb1 S eeeee1  bbbbb2 glutathione-S-transferase eeeee2  (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione- bbbbb1 S eeeee1  bbbbb2 SOD eeeee2 ) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione- bbbbb1 S eeeee1  bbbbb2 catalase eeeee2  (CAT) and glutathione-S-transferase (GST) activities were depressed
CRP11	Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione- bbbbb1 S eeeee1  bbbbb2 CAT eeeee2 ) and glutathione-S-transferase (GST) activities were depressed
CRP11	Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and  bbbbb1 thiazolidinediones eeeee1  bbbbb2 peroxisome proliferator-activated receptor (PPAR)-alpha eeeee2 , and thiazolidinediones are ligands of PPAR-gamma
CRP11	 bbbbb1 Fibrates eeeee1  bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and thiazolidinediones are ligands of  bbbbb2 PPAR-gamma eeeee2 
CRP11	These intracellular receptors form heterodimers with  bbbbb1 retinoid eeeee1  bbbbb2 retinoid X receptor eeeee2  to modulate gene transcription
CRP11	We identified a novel target in liver, mitogen-activated phosphokinase phosphatase 1, whose down-regulation by PPAR-alpha agonists may improve in bbbbb1 sulin sensit eeeee1  bbbbb2 tase 1, wh eeeee2 ose down-regulation by PPAR-alpha agonists may improve insulin sensitivity in that tissue by prolonging insulin responses
CRP11	We identified a novel target in liver, mitogen-activated phosphokinase phosphatase 1, whose down-regulation by PPAR-alpha agonists may improve in bbbbb1 sulin sensit eeeee1  bbbbb2  phosphoki eeeee2 nase phosphatase 1, whose down-regulation by PPAR-alpha agonists may improve insulin sensitivity in that tissue by prolonging insulin responses
CRP11	We identified a novel target in liver, mitogen-activated phosphokinase phosphatase 1, whose down-regulation by PPAR-alpha agonists ma bbbbb1 y impro eeeee1  bbbbb2 tase 1, wh eeeee2 ose down-regulation by PPAR-alpha agonists may improve insulin sensitivity in that tissue by prolonging insulin responses
CRP11	We identified a novel target in liver, mitogen-activated phosphokinase phosphatase 1, whose down-regulation by PPAR-alpha agonists ma bbbbb1 y impro eeeee1  bbbbb2  phosphoki eeeee2 nase phosphatase 1, whose down-regulation by PPAR-alpha agonists may improve insulin sensitivity in that tissue by prolonging insulin responses
CRP11	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of  bbbbb1 glucose eeeee1  transporter 4 and  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  in adipose tissue
CRP11	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of  bbbbb1 glucose eeeee1  bbbbb2 glucose transporter 4 eeeee2  and phosphoenolpyruvate carboxykinase in adipose tissue
CRP11	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of  bbbbb1 glucose eeeee1  bbbbb2 apolipoprotein C-III eeeee2  mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue
CRP11	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and  bbbbb1 phosphoenolpyruvate eeeee1  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  in adipose tissue
CRP11	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and  bbbbb1 phosphoenolpyruvate eeeee1  bbbbb2 glucose transporter 4 eeeee2  and phosphoenolpyruvate carboxykinase in adipose tissue
CRP11	Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and  bbbbb1 phosphoenolpyruvate eeeee1  bbbbb2 apolipoprotein C-III eeeee2  mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue
CRP11	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand,  bbbbb1 rosiglitazone eeeee1 , and a  bbbbb2 PPAR-alpha/-gamma eeeee2  coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CRP11	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand,  bbbbb1 rosiglitazone eeeee1  bbbbb2 PPAR-alpha eeeee2 -specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CRP11	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist,  bbbbb1 GW2331 eeeee1  bbbbb2 PPAR-gamma eeeee2 -specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CRP11	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist,  bbbbb1 GW2331 eeeee1  bbbbb2 PPAR-alpha/-gamma eeeee2  coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CRP11	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist,  bbbbb1 GW2331 eeeee1  bbbbb2 PPAR-alpha eeeee2 -specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CRP11	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound,  bbbbb1 fenofibrate eeeee1 , a  bbbbb2 PPAR-gamma eeeee2 -specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CRP11	To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound,  bbbbb1 fenofibrate eeeee1 , a PPAR-gamma-specific ligand, rosiglitazone, and a  bbbbb2 PPAR-alpha/-gamma eeeee2  coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and  bbbbb1 enoyl-CoA eeeee1  bbbbb2 enoyl-CoA hydratase eeeee2  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and  bbbbb1 enoyl-CoA eeeee1  hydratase and reduced apolipoprotein C-III and  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and  bbbbb1 enoyl-CoA eeeee1  hydratase and reduced  bbbbb2 apolipoprotein C-III eeeee2  and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and  bbbbb1 enoyl-CoA eeeee1  bbbbb2 acyl-coenzyme A (CoA) oxidase eeeee2  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of  bbbbb1 acyl-coenzyme A eeeee1  (CoA) oxidase and  bbbbb2 enoyl-CoA hydratase eeeee2  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of  bbbbb1 acyl-coenzyme A eeeee1  (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  mRNAs
CRP11	Fenofibrate and GW2331 induced expression of  bbbbb1 acyl-coenzyme A eeeee1  (CoA) oxidase and enoyl-CoA hydratase and reduced  bbbbb2 apolipoprotein C-III eeeee2  and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of  bbbbb1 acyl-coenzyme A eeeee1  bbbbb2 acyl-coenzyme A (CoA) oxidase eeeee2  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb1 phosphoenolpyruvate eeeee1  bbbbb2 enoyl-CoA hydratase eeeee2  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb1 phosphoenolpyruvate eeeee1  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb1 phosphoenolpyruvate eeeee1  bbbbb2 apolipoprotein C-III eeeee2  and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb1 phosphoenolpyruvate eeeee1  bbbbb2 acyl-coenzyme A (CoA) oxidase eeeee2  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A ( bbbbb1 CoA eeeee1 ) oxidase and  bbbbb2 enoyl-CoA hydratase eeeee2  and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A ( bbbbb1 CoA eeeee1 ) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and  bbbbb2 phosphoenolpyruvate carboxykinase eeeee2  mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A ( bbbbb1 CoA eeeee1 ) oxidase and enoyl-CoA hydratase and reduced  bbbbb2 apolipoprotein C-III eeeee2  and phosphoenolpyruvate carboxykinase mRNAs
CRP11	Fenofibrate and GW2331 induced expression of acyl-coenzyme A ( bbbbb1 CoA eeeee1  bbbbb2 acyl-coenzyme A (CoA) oxidase eeeee2  and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs
CRP11	This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  occupancy (H1RO) in the brain
CRP11	Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain  bbbbb1 histamine eeeee1  bbbbb2 histamine H1-receptor eeeee2  occupancy using 11C-doxepin positron emission tomography
CRP11	 bbbbb1 Histamine eeeee1  H1-receptor ( bbbbb2 H1R eeeee2 ) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders
CRP11	 bbbbb1 Histamine eeeee1  bbbbb2 Histamine H1-receptor eeeee2  (H1R) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders
CRP11	Although the different concentrations tested of the two selenocompounds modulate GPx1 transcript expression to various degrees, no significant change of GPx1 bbbbb1  enzymat eeeee1  bbbbb2 d of eeeee2  the two selenocompounds modulate GPx1 transcript expression to various degrees, no significant change of GPx1 enzymatic activity was detectable
CRP11	Interestingly, GPx1a was the most sensitive to  bbbbb1 selenium eeeee1  availability in non stressful conditions, whereas GPx1b1 and  bbbbb2 GPx1b2 eeeee2  were highly induced by exposure to selenium levels that had some toxic effects on the cells
CRP11	Interestingly, GPx1a was the most sensitive to  bbbbb1 selenium eeeee1  availability in non stressful conditions, whereas  bbbbb2 GPx1b1 eeeee2  and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells
CRP11	Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to  bbbbb1 selenium eeeee1  bbbbb2 GPx1a eeeee2  was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells
CRP11	Characterization of cytosolic glutathione peroxidase and phospholipid- bbbbb1 hydroperoxide eeeee1  bbbbb2 cytosolic glutathione peroxidase eeeee2  and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure
CRP11	Characterization of cytosolic glutathione peroxidase and phospholipid- bbbbb1 hydroperoxide eeeee1  bbbbb2 phospholipid-hydroperoxide glutathione peroxidase eeeee2  genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure
CRP11	Characterization of cytosolic  bbbbb1 glutathione eeeee1  bbbbb2 cytosolic glutathione peroxidase eeeee2  and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure
CRP11	Characterization of cytosolic  bbbbb1 glutathione eeeee1  peroxidase and  bbbbb2 phospholipid-hydroperoxide glutathione peroxidase eeeee2  genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure
CRP11	Characterization of cytosolic glutathione peroxidase and phospholipid-hydroperoxide  bbbbb1 glutathione eeeee1  bbbbb2 cytosolic glutathione peroxidase eeeee2  and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure
CRP11	Characterization of cytosolic glutathione peroxidase and phospholipid-hydroperoxide  bbbbb1 glutathione eeeee1  bbbbb2 phospholipid-hydroperoxide glutathione peroxidase eeeee2  genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure
CRP11	 bbbbb1 Glutathione eeeee1  peroxidase (GPxs) is the largest and the most studied  bbbbb2 selenoprotein eeeee2  family
CRP11	 bbbbb1 Glutathione eeeee1  peroxidase ( bbbbb2 GPxs eeeee2 ) is the largest and the most studied selenoprotein family
CRP11	 bbbbb1 Glutathione eeeee1  bbbbb2 Glutathione peroxidase eeeee2  (GPxs) is the largest and the most studied selenoprotein family
CRP11	Transcripts of GPx4 genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the GPx1 genes were more responsive to  bbbbb1 selenium eeeee1  bbbbb2 GPx4 eeeee2  genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the GPx1 genes were more responsive to selenium exposure in vitro, especially to the organic form
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid  bbbbb1 hydroperoxide eeeee1  glutathione peroxidase ( bbbbb2 PHGPx eeeee2 , GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid  bbbbb1 hydroperoxide eeeee1  bbbbb2 phospholipid hydroperoxide glutathione peroxidase eeeee2  (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid  bbbbb1 hydroperoxide eeeee1  bbbbb2 GPx1 eeeee2 ) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid  bbbbb1 hydroperoxide eeeee1  bbbbb2 cGPx eeeee2 , GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid  bbbbb1 hydroperoxide eeeee1  bbbbb2 Cytosolic glutathione peroxidase eeeee2  (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid  bbbbb1 hydroperoxide eeeee1  glutathione peroxidase (PHGPx,  bbbbb2 GPx4 eeeee2 ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide  bbbbb1 glutathione eeeee1  peroxidase ( bbbbb2 PHGPx eeeee2 , GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide  bbbbb1 glutathione eeeee1  bbbbb2 phospholipid hydroperoxide glutathione peroxidase eeeee2  (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide  bbbbb1 glutathione eeeee1  bbbbb2 GPx1 eeeee2 ) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide  bbbbb1 glutathione eeeee1  bbbbb2 cGPx eeeee2 , GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide  bbbbb1 glutathione eeeee1  bbbbb2 Cytosolic glutathione peroxidase eeeee2  (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide  bbbbb1 glutathione eeeee1  peroxidase (PHGPx,  bbbbb2 GPx4 eeeee2 ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic  bbbbb1 glutathione eeeee1  peroxidase (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase ( bbbbb2 PHGPx eeeee2 , GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic  bbbbb1 glutathione eeeee1  peroxidase (cGPx, GPx1) and  bbbbb2 phospholipid hydroperoxide glutathione peroxidase eeeee2  (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic  bbbbb1 glutathione eeeee1  peroxidase (cGPx,  bbbbb2 GPx1 eeeee2 ) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic  bbbbb1 glutathione eeeee1  peroxidase ( bbbbb2 cGPx eeeee2 , GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic  bbbbb1 glutathione eeeee1  bbbbb2 Cytosolic glutathione peroxidase eeeee2  (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Cytosolic  bbbbb1 glutathione eeeee1  peroxidase (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx,  bbbbb2 GPx4 eeeee2 ) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell
CRP11	Both these MAPs were found to have two to three binding sites for  bbbbb1 estramustine phosphate eeeee1  which is compatible with the reported number of basic amino acid repeats of these  bbbbb2 MAPs eeeee2 , considered to be the ultimate tubulin binding domains
CRP11	Both these MAPs were found to have two to three binding sites for  bbbbb1 estramustine phosphate eeeee1  which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate  bbbbb2 tubulin eeeee2  binding domains
CRP11	Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic  bbbbb1 amino acid eeeee1  bbbbb2 MAPs eeeee2  were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains
CRP11	In the present study the binding of  bbbbb1 estramustine phosphate eeeee1  to  bbbbb2 MAP2 eeeee2  and tau was investigated
CRP11	In the present study the binding of  bbbbb1 estramustine phosphate eeeee1  to MAP2 and  bbbbb2 tau eeeee2  was investigated
CRP11	 bbbbb1 Yohimbine eeeee1  displays marked affinity at  bbbbb2 human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs eeeee2 , significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors
CRP11	In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1B) eeeee2  agonist, GR46,611
CRP11	In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1B) eeeee2  receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611
CRP11	In guinea pigs, antagonist actions of yohimbine at  bbbbb1 5-HT eeeee1 (1B) receptors are revealed by blockade of hypothermia evoked by the  bbbbb2 5-HT(1B) eeeee2  agonist, GR46,611
CRP11	In guinea pigs, antagonist actions of yohimbine at  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1B) eeeee2  receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611
CRP11	In guinea pigs, antagonist actions of  bbbbb1 yohimbine eeeee1  at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the  bbbbb2 5-HT(1B) eeeee2  agonist, GR46,611
CRP11	In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist,  bbbbb1 GR46,611 eeeee1  bbbbb2 5-HT(1B) eeeee2  receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611
CRP11	In vivo, agonist actions of yohimbine at  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1A) eeeee2  sites are revealed by WAY100,635-reversible induction of hypothermia in the rat
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association wi bbbbb1 th f eeeee1  bbbbb2 ist propert eeeee2 ies of yohimbine increase DA and NAD levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association wi bbbbb1 th f eeeee1  bbbbb2 and NAD  eeeee2 levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine bbbbb1  eeeee1  bbbbb2 ist propert eeeee2 ies of yohimbine increase DA and NAD levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine bbbbb1  eeeee1  bbbbb2 and NAD  eeeee2 levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimb bbbbb1 ine increa eeeee1 se DA  bbbbb2 and NAD  eeeee2 levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA  bbbbb1 and  eeeee1  bbbbb2 ist propert eeeee2 ies of yohimbine increase DA and NAD levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA  bbbbb1 and  eeeee1  bbbbb2 and NAD  eeeee2 levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine bbbbb1  eeeee1  bbbbb2 ist propert eeeee2 ies of yohimbine increase DA and NAD levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine bbbbb1  eeeee1  bbbbb2 and NAD  eeeee2 levels both alone and in association with fluoxetine
CRP11	In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone an bbbbb1 d in asso eeeee1  bbbbb2 ist propert eeeee2 ies of yohimbine increase DA and NAD levels both alone and in association with fluoxetine
CRP11	Agonist and antagonist actions of  bbbbb1 yohimbine eeeee1  as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb2 dopamine D(2) and D(3) receptors eeeee2 
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb1 dopamine eeeee1  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb1 dopamine eeeee1  bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D(2) and D(3) receptors eeeee2 
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb1 dopamine eeeee1  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb1 dopamine eeeee1  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb1 dopamine eeeee1  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb1 5-HT eeeee1  bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb1 5-HT eeeee1 (1D) and  bbbbb2 dopamine D(2) and D(3) receptors eeeee2 
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb1 5-HT eeeee1  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb1 5-HT eeeee1  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s,  bbbbb1 serotonin eeeee1  (5-HT)(1A),  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s,  bbbbb1 serotonin eeeee1   bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s,  bbbbb1 serotonin eeeee1  (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb2 dopamine D(2) and D(3) receptors eeeee2 
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s,  bbbbb1 serotonin eeeee1  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s,  bbbbb1 serotonin eeeee1  (5-HT)(1A), 5-HT(1B),  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s,  bbbbb1 serotonin eeeee1  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb1 5-HT eeeee1  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb1 5-HT eeeee1  bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb1 5-HT eeeee1 (1B), 5-HT(1D) and  bbbbb2 dopamine D(2) and D(3) receptors eeeee2 
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb1 5-HT eeeee1  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb1 5-HT eeeee1 (1B),  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb1 5-HT eeeee1  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin ( bbbbb1 5-HT eeeee1 )(1A),  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin ( bbbbb1 5-HT eeeee1 )(1A), 5-HT(1B), 5-HT(1D) and  bbbbb2 dopamine D(2) and D(3) receptors eeeee2 
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 alpha(2)-adrenergic receptors eeeee2  (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin ( bbbbb1 5-HT eeeee1 )(1A), 5-HT(1B),  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin ( bbbbb1 5-HT eeeee1  bbbbb2 (AR)s eeeee2 , serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A),  bbbbb2 5-HT(1B) eeeee2 , 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at alpha(2)-adrenergic receptors (AR)s, serotonin  bbbbb2 (5-HT)(1A) eeeee2 , 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors
CRP11	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and  bbbbb2 dopamine D(2) and D(3) receptors eeeee2 
CRP11	Agonist and antagonist actions of yohimbine as compared to  bbbbb1 fluparoxan eeeee1  at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B),  bbbbb2 5-HT(1D) eeeee2  and dopamine D(2) and D(3) receptors
CRP11	This review article is an effort to sum up  bbbbb1 the  eeeee1 anti-inflammatory activities of chalcone d bbbbb2 erived chemic eeeee2 al entities
CRP11	This review article is an effort to sum up  bbbbb1 the  eeeee1 anti-inflammatory activities of chal bbbbb2 con eeeee2 e derived chemical entities
CRP11	This review article is an effort to sum up  bbbbb1 the  eeeee1 anti-inflammatory ac bbbbb2 tivities of ch eeeee2 alcone derived chemical entities
CRP11	This review article is an effort to sum up  bbbbb1 the  eeeee1 anti-inflammatory activities of chalcone derived chemical bbbbb2  ent eeeee2 ities
CRP11	This review article is an effort to sum up  bbbbb1 the  eeeee1 anti-inflamma bbbbb2 tory eeeee2  activities of chalcone derived chemical entities
CRP11	This review article is an effort to sum up  bbbbb1 the  eeeee1  bbbbb2 the anti-inflamm eeeee2 atory activities of chalcone derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entities bbbbb1  eeeee1  bbbbb2 erived chemic eeeee2 al entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entities bbbbb1  eeeee1  bbbbb2 con eeeee2 e derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entities bbbbb1  eeeee1  bbbbb2 tivities of ch eeeee2 alcone derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entities bbbbb1  eeeee1  bbbbb2  ent eeeee2 ities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entities bbbbb1  eeeee1  bbbbb2 tory eeeee2  activities of chalcone derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entities bbbbb1  eeeee1  bbbbb2 the anti-inflamm eeeee2 atory activities of chalcone derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entiti bbbbb1 es eeeee1  bbbbb2 erived chemic eeeee2 al entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entiti bbbbb1 es eeeee1  bbbbb2 con eeeee2 e derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entiti bbbbb1 es eeeee1  bbbbb2 tivities of ch eeeee2 alcone derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entiti bbbbb1 es eeeee1  bbbbb2  ent eeeee2 ities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entiti bbbbb1 es eeeee1  bbbbb2 tory eeeee2  activities of chalcone derived chemical entities
CRP11	This review article is an effort to sum up the anti-inflammatory activities of chalcone derived chemical entiti bbbbb1 es eeeee1  bbbbb2 the anti-inflamm eeeee2 atory activities of chalcone derived chemical entities
CRP11	The salivary fluid secretory mechanism is thought to require Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 -mediated Cl(-) uptake
CRP11	The salivary fluid secretory mechanism is thought to require  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 -mediated Cl(-) uptake
CRP11	The salivary fluid secretory mechanism is thought to require Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 -mediated Cl(-) uptake
CRP11	Furthermore, the ability of the parotid gland to conserve  bbbbb1 NaCl eeeee1  was abolished in  bbbbb2 NKCC1 eeeee2 -deficient mice
CRP11	Severe impairment of salivation in Na+/ bbbbb1 K+ eeeee1  bbbbb2 Na+/K+/2Cl- cotransporter eeeee2  (NKCC1)-deficient mice
CRP11	Severe impairment of salivation in Na+/ bbbbb1 K+ eeeee1 /2Cl- cotransporter ( bbbbb2 NKCC1 eeeee2 )-deficient mice
CRP11	Severe impairment of salivation in Na+/K+/ bbbbb1 2Cl- eeeee1  bbbbb2 Na+/K+/2Cl- cotransporter eeeee2  (NKCC1)-deficient mice
CRP11	Severe impairment of salivation in Na+/K+/ bbbbb1 2Cl- eeeee1  cotransporter ( bbbbb2 NKCC1 eeeee2 )-deficient mice
CRP11	Severe impairment of salivation in  bbbbb1 Na+ eeeee1  bbbbb2 Na+/K+/2Cl- cotransporter eeeee2  (NKCC1)-deficient mice
CRP11	Severe impairment of salivation in  bbbbb1 Na+ eeeee1 /K+/2Cl- cotransporter ( bbbbb2 NKCC1 eeeee2 )-deficient mice
CRP11	 bbbbb1 Cl(-) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake
CRP11	 bbbbb1 Cl(-) eeeee1 / HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking  bbbbb2 NKCC1 eeeee2  is associated with anion exchanger-dependent Cl(-) uptake
CRP11	Cl(-)/ HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent  bbbbb1 Cl(-) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake
CRP11	Cl(-)/ HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent  bbbbb1 Cl(-) eeeee1  bbbbb2 NKCC1 eeeee2  is associated with anion exchanger-dependent Cl(-) uptake
CRP11	Cl(-)/  bbbbb1 HCO(3)(-) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake
CRP11	Cl(-)/  bbbbb1 HCO(3)(-) eeeee1  exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking  bbbbb2 NKCC1 eeeee2  is associated with anion exchanger-dependent Cl(-) uptake
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional  bbbbb1 Na(+) eeeee1  bbbbb2 AE2 eeeee2  was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional  bbbbb1 Na(+) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the  bbbbb1 Cl(-) eeeee1 / HCO(3)(-) exchanger  bbbbb2 AE2 eeeee2  was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the  bbbbb1 Cl(-) eeeee1 / HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	Indeed, expression of the  bbbbb1 Cl(-) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the Cl(-)/  bbbbb1 HCO(3)(-) eeeee1  exchanger  bbbbb2 AE2 eeeee2  was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the Cl(-)/  bbbbb1 HCO(3)(-) eeeee1  exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	Indeed, expression of the Cl(-)/  bbbbb1 HCO(3)(-) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 AE2 eeeee2  was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 AE2 eeeee2  was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Cl(-)/ HCO(3)(-) exchanger eeeee2  AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter isoform 1 eeeee2  (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of  bbbbb1 Na(+) eeeee1 /K(+)/2Cl(-) cotransporter isoform 1 ( bbbbb2 Nkcc1 eeeee2 ), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of  bbbbb1 Na(+) eeeee1 /K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter isoform 1 eeeee2  (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/ bbbbb1 K(+) eeeee1 /2Cl(-) cotransporter isoform 1 ( bbbbb2 Nkcc1 eeeee2 ), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/ bbbbb1 K(+) eeeee1 /2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter isoform 1 eeeee2  (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 Nkcc1 eeeee2 ), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter isoform 1 eeeee2  (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary  bbbbb1 Na(+) eeeee1  bbbbb2 Nkcc1 eeeee2 ), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary  bbbbb1 Na(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter isoform 1 eeeee2  (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Nkcc1 eeeee2 ), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/ bbbbb1 K(+) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter isoform 1 eeeee2  (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  cotransporter isoform 1 ( bbbbb2 Nkcc1 eeeee2 ), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter
CRP11	To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/ bbbbb1 2Cl(-) eeeee1  cotransporter isoform 1 (Nkcc1), the gene encoding the salivary  bbbbb2 Na(+)/K(+)/2Cl(-) cotransporter eeeee2 
CRP11	Consistent with defective  bbbbb1 Cl(-) eeeee1  uptake, a loss of bumetanide-sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking  bbbbb2 NKCC1 eeeee2 
CRP11	Consistent with defective Cl(-) uptake, a loss of bumetanide-sensitive  bbbbb1 Cl(-) eeeee1  influx was observed in parotid acinar cells from mice lacking  bbbbb2 NKCC1 eeeee2 
CRP11	Consistent with defective Cl(-) uptake, a loss of  bbbbb1 bumetanide eeeee1 -sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking  bbbbb2 NKCC1 eeeee2 
CRP11	Similarly, (R)-omeprazole HI i bbbbb1 n hmEMs, htEMs eeeee1 , and PMs were 5.6, 3.1, and 0.3, respectively, which were significantly different, but no significant difference was present in the (S)-omeprazole  bbbbb2 HI eeeee2 
CRP11	Similarly, (R)-omeprazole HI in hmEMs, htEMs, and PMs were 5.6, 3.1, and 0.3, respectively, which we bbbbb1 re significantly d eeeee1 ifferent, but no significant difference was present in the (S)-omeprazole  bbbbb2 HI eeeee2 
CRP11	Similarly, the PSS1 enzyme level did not change after  bbbbb1 ethanol eeeee1  exposure but  bbbbb2 PSS2 eeeee2  could not be probed with the antibody available currently
CRP11	Anti- bbbbb1 estrogens eeeee1  (AEs) and  bbbbb2 aromatase eeeee2  inhibitors (AIs) are used clinically to arrest the estrogen-dependent growth of BC
CRP11	Anti-estrogens (AEs) and aromatase inhibitors (AIs) are used clinically to arrest the  bbbbb1 estrogen eeeee1  bbbbb2 aromatase eeeee2  inhibitors (AIs) are used clinically to arrest the estrogen-dependent growth of BC
CRP11	 bbbbb1 Estrogen eeeee1  bbbbb2 Estrogen receptor eeeee2  signaling as a target for novel breast cancer therapeutics
CRP11	The partners of extra-nuclear ERα include PI3K and the  bbbbb1 tyrosine eeeee1  bbbbb2 ERα eeeee2  include PI3K and the tyrosine kinase Src
CRP11	The partners of extra-nuclear ERα include PI3K and the  bbbbb1 tyrosine eeeee1  bbbbb2 tyrosine kinase eeeee2  Src
CRP11	The partners of extra-nuclear ERα include PI3K and the  bbbbb1 tyrosine eeeee1  bbbbb2 PI3K eeeee2  and the tyrosine kinase Src
CRP11	The partners of extra-nuclear ERα include PI3K and the  bbbbb1 tyrosine eeeee1  kinase  bbbbb2 Src eeeee2 
CRP11	Chemokine-mediated signaling also modulates the  bbbbb1 estrogen eeeee1  bbbbb2 Chemokine eeeee2 -mediated signaling also modulates the estrogen response
CRP11	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide ( bbbbb1 CO eeeee1  bbbbb2 HO-1 eeeee2  siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CRP11	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide ( bbbbb1 CO eeeee1  bbbbb2 HO-1 eeeee2  gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CRP11	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide ( bbbbb1 CO eeeee1  bbbbb2 NF-kappaB eeeee2  activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CRP11	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with  bbbbb1 carbon monoxide eeeee1  bbbbb2 HO-1 eeeee2  siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CRP11	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with  bbbbb1 carbon monoxide eeeee1  bbbbb2 HO-1 eeeee2  gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CRP11	Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with  bbbbb1 carbon monoxide eeeee1  bbbbb2 NF-kappaB eeeee2  activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CRP11	Interestingly, the inhibitory effect of  bbbbb1 H(2)S eeeee1  on NF-kappaB activation was reversed by the transient transfection with  bbbbb2 HO-1 eeeee2  siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1
CRP11	Interestingly, the inhibitory effect of  bbbbb1 H(2)S eeeee1  on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of  bbbbb2 HO-1 eeeee2 
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine beta-synthase eeeee2  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine gamma-lyase eeeee2  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb1 cystathionine eeeee1  bbbbb2 CSE eeeee2 ) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or  bbbbb1 cystathionine eeeee1  beta-synthase ( bbbbb2 CBS eeeee2 ) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in  bbbbb1 nitric oxide eeeee1  bbbbb2 cystathionine beta-synthase eeeee2  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in  bbbbb1 nitric oxide eeeee1  bbbbb2 cystathionine gamma-lyase eeeee2  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in  bbbbb1 nitric oxide eeeee1  bbbbb2 CSE eeeee2 ) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in  bbbbb1 nitric oxide eeeee1  bbbbb2 CBS eeeee2 ) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb1 cystathionine eeeee1  gamma-lyase (CSE) and/or  bbbbb2 cystathionine beta-synthase eeeee2  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb1 cystathionine eeeee1  bbbbb2 cystathionine gamma-lyase eeeee2  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb1 cystathionine eeeee1  gamma-lyase ( bbbbb2 CSE eeeee2 ) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by  bbbbb1 cystathionine eeeee1  gamma-lyase (CSE) and/or cystathionine beta-synthase ( bbbbb2 CBS eeeee2 ) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 cystathionine beta-synthase eeeee2  (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 cystathionine gamma-lyase eeeee2  (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 CSE eeeee2 ) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide ( bbbbb1 NO eeeee1  bbbbb2 CBS eeeee2 ) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored
CRP11	CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB bbbbb1  eeeee1  bbbbb2 ia its in eeeee2 activation of NF-kappaB
CRP11	CO treatment also inhibited LPS-induced NO production and bbbbb1  i eeeee1 NOS expression v bbbbb2 ia its in eeeee2 activation of NF-kappaB
CRP11	CO treatment also inhibited LPS-induced NO production and bbbbb1  i eeeee1 NOS expression via its inactivation of NF-kappaB bbbbb2  eeeee2 
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of  bbbbb1 L-Cys eeeee1 , a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the  bbbbb2 CBS eeeee2  inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of  bbbbb1 L-Cys eeeee1 , a substrate for H(2)S, but enhanced by the selective  bbbbb2 CSE eeeee2  inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor  bbbbb1 beta-cyano-L-alanine eeeee1  bbbbb2 CSE eeeee2  mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor  bbbbb1 beta-cyano-L-alanine eeeee1  but not by the  bbbbb2 CBS eeeee2  inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for  bbbbb1 H(2)S eeeee1  bbbbb2 CSE eeeee2  mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for  bbbbb1 H(2)S eeeee1 , but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the  bbbbb2 CBS eeeee2  inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for  bbbbb1 H(2)S eeeee1 , but enhanced by the selective  bbbbb2 CSE eeeee2  inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	Moreover,  bbbbb1 NO eeeee1  production in LPS-stimulated macrophages that are expressing  bbbbb2 CSE eeeee2  mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	Moreover,  bbbbb1 NO eeeee1  production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the  bbbbb2 CBS eeeee2  inhibitor aminooxyacetic acid
CRP11	Moreover,  bbbbb1 NO eeeee1  production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective  bbbbb2 CSE eeeee2  inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor  bbbbb1 aminooxyacetic acid eeeee1  bbbbb2 CSE eeeee2  mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor  bbbbb1 aminooxyacetic acid eeeee1  bbbbb2 CSE eeeee2  inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO eeeee2  inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO eeeee2  activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO-1 eeeee2  expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO-1 eeeee2  small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of  bbbbb1 H(2)S eeeee1  on iNOS expression and NO production,  bbbbb2 HO-1 eeeee2  overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and  bbbbb1 NO eeeee1  bbbbb2 HO eeeee2  inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and  bbbbb1 NO eeeee1  bbbbb2 HO eeeee2  activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and  bbbbb1 NO eeeee1  bbbbb2 HO-1 eeeee2  expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and  bbbbb1 NO eeeee1  bbbbb2 HO-1 eeeee2  small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and  bbbbb1 NO eeeee1  production,  bbbbb2 HO-1 eeeee2  overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO eeeee2  inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO eeeee2  activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 iNOS eeeee2  expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO-1 eeeee2  expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO-1 eeeee2  small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S
CRP11	While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of  bbbbb1 H(2)S eeeee1  bbbbb2 HO-1 eeeee2  overexpression produced the same inhibitory effects of H(2)S
CRP11	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit  bbbbb1 NO eeeee1  production and inducible NO synthase (iNOS) expression via  bbbbb2 heme oxygenase eeeee2  (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CRP11	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit  bbbbb1 NO eeeee1  production and inducible NO synthase (iNOS) expression via heme oxygenase ( bbbbb2 HO-1 eeeee2 ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CRP11	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible  bbbbb1 NO eeeee1  synthase (iNOS) expression via  bbbbb2 heme oxygenase eeeee2  (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CRP11	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible  bbbbb1 NO eeeee1  synthase ( bbbbb2 iNOS eeeee2 ) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CRP11	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible  bbbbb1 NO eeeee1  bbbbb2 inducible NO synthase eeeee2  (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CRP11	Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible  bbbbb1 NO eeeee1  synthase (iNOS) expression via heme oxygenase ( bbbbb2 HO-1 eeeee2 ) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)
CRP11	Hydrogen sulfide inhibits  bbbbb1 nitric oxide eeeee1  production and  bbbbb2 nuclear factor-kappaB eeeee2  via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide
CRP11	Hydrogen sulfide inhibits  bbbbb1 nitric oxide eeeee1  production and nuclear factor-kappaB via  bbbbb2 heme oxygenase-1 eeeee2  expression in RAW264.7 macrophages stimulated with lipopolysaccharide
CRP11	Both H(2)S solution prepared by bubbling pure H(2)S gas and  bbbbb1 NaSH eeeee1 , a H(2)S donor, dose dependently induced  bbbbb2 HO-1 eeeee2  expression through the activation of the extracellular signal-regulated kinase (ERK)
CRP11	Both H(2)S solution prepared by bubbling pure H(2)S gas and  bbbbb1 NaSH eeeee1 , a H(2)S donor, dose dependently induced HO-1 expression through the activation of the  bbbbb2 extracellular signal-regulated kinase eeeee2  (ERK)
CRP11	Both H(2)S solution prepared by bubbling pure H(2)S gas and  bbbbb1 NaSH eeeee1 , a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase ( bbbbb2 ERK eeeee2 )
CRP11	Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a  bbbbb1 H(2)S eeeee1  donor, dose dependently induced  bbbbb2 HO-1 eeeee2  expression through the activation of the extracellular signal-regulated kinase (ERK)
CRP11	Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a  bbbbb1 H(2)S eeeee1  donor, dose dependently induced HO-1 expression through the activation of the  bbbbb2 extracellular signal-regulated kinase eeeee2  (ERK)
CRP11	Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a  bbbbb1 H(2)S eeeee1  donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase ( bbbbb2 ERK eeeee2 )
CRP11	Both H(2)S solution prepared by bubbling pure  bbbbb1 H(2)S eeeee1  gas and NaSH, a H(2)S donor, dose dependently induced  bbbbb2 HO-1 eeeee2  expression through the activation of the extracellular signal-regulated kinase (ERK)
CRP11	Both H(2)S solution prepared by bubbling pure  bbbbb1 H(2)S eeeee1  gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the  bbbbb2 extracellular signal-regulated kinase eeeee2  (ERK)
CRP11	Both H(2)S solution prepared by bubbling pure  bbbbb1 H(2)S eeeee1  gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase ( bbbbb2 ERK eeeee2 )
CRP11	Localization of the  bbbbb1 ammonium eeeee1  bbbbb2 ammonium transporter proteins eeeee2  RhBG and RhCG in mouse kidney
CRP11	Localization of the  bbbbb1 ammonium eeeee1  transporter proteins  bbbbb2 RhBG eeeee2  and RhCG in mouse kidney
CRP11	Localization of the  bbbbb1 ammonium eeeee1  transporter proteins RhBG and  bbbbb2 RhCG eeeee2  in mouse kidney
CRP11	Colocalization of RhBG with carbonic anhydrase II, the  bbbbb1 thiazide eeeee1 -sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated  bbbbb2 RhBG eeeee2  immunoreactivity in all CNT cells and all CCD and ICT principal cells
CRP11	Colocalization of RhBG with carbonic anhydrase II, the  bbbbb1 thiazide eeeee1 -sensitive transporter, and the anion exchangers  bbbbb2 AE1 eeeee2  and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells
CRP11	Colocalization of RhBG with carbonic anhydrase II, the  bbbbb1 thiazide eeeee1 -sensitive transporter, and the  bbbbb2 anion exchangers eeeee2  AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells
CRP11	Colocalization of RhBG with carbonic anhydrase II, the  bbbbb1 thiazide eeeee1  bbbbb2 carbonic anhydrase II eeeee2 , the thiazide-sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells
CRP11	Colocalization of RhBG with carbonic anhydrase II, the  bbbbb1 thiazide eeeee1 -sensitive transporter, and the anion exchangers AE1 and  bbbbb2 pendrin eeeee2  demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells
CRP11	Immunoreactivity for a second putative  bbbbb1 ammonium eeeee1  transporter, RhCG, was present in the apical region of cells with almost the same distribution as  bbbbb2 RhBG eeeee2 
CRP11	Immunoreactivity for a second putative  bbbbb1 ammonium eeeee1  bbbbb2 ammonium transporter eeeee2 , RhCG, was present in the apical region of cells with almost the same distribution as RhBG
CRP11	Immunoreactivity for a second putative  bbbbb1 ammonium eeeee1  transporter,  bbbbb2 RhCG eeeee2 , was present in the apical region of cells with almost the same distribution as RhBG
CRP11	Recent studies have identified a family of putative  bbbbb1 ammonium eeeee1  transporters; mRNA for two members of this family,  bbbbb2 Rh B-glycoprotein eeeee2  (RhBG) and Rh C-glycoprotein (RhCG), is expressed in the kidney
CRP11	Recent studies have identified a family of putative  bbbbb1 ammonium eeeee1  transporters; mRNA for two members of this family, Rh B-glycoprotein (RhBG) and Rh C-glycoprotein ( bbbbb2 RhCG eeeee2 ), is expressed in the kidney
CRP11	Recent studies have identified a family of putative  bbbbb1 ammonium eeeee1  transporters; mRNA for two members of this family, Rh B-glycoprotein (RhBG) and  bbbbb2 Rh C-glycoprotein eeeee2  (RhCG), is expressed in the kidney
CRP11	Recent studies have identified a family of putative  bbbbb1 ammonium eeeee1  transporters; mRNA for two members of this family, Rh B-glycoprotein ( bbbbb2 RhBG eeeee2 ) and Rh C-glycoprotein (RhCG), is expressed in the kidney
CRP11	Recent studies have identified a family of putative  bbbbb1 ammonium eeeee1  bbbbb2 ammonium transporters eeeee2 ; mRNA for two members of this family, Rh B-glycoprotein (RhBG) and Rh C-glycoprotein (RhCG), is expressed in the kidney
CRP11	Discovery of aryl ureas and aryl amides as potent and selective  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 receptor eeeee2  antagonists for the treatment of obesity (Part I)
CRP11	A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective  bbbbb1 histamine eeeee1  H3 receptor ( bbbbb2 H3R eeeee2 ) antagonists
CRP11	A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective  bbbbb1 histamine eeeee1  bbbbb2 histamine H3 receptor eeeee2  (H3R) antagonists
CRP11	As the RTH mutant, R316C, was new, the optimum dose of  bbbbb1 levothyroxine eeeee1  bbbbb2 R316C eeeee2 , was new, the optimum dose of levothyroxine was unclear
CRP11	The patient was a newborn female having severe hypothyroidism with a free  bbbbb1 thyroxine eeeee1  level of 0.36 ng/dL and a serum  bbbbb2 TSH eeeee2  level of 177 microU/mL
CRP11	However, a glutathione- bbbbb1 S eeeee1 -transferase pull-down assay showed reduced binding of R316C with  bbbbb2 NCoR eeeee2  in the absence of T3 and impaired release in the presence of T3
CRP11	However, a glutathione- bbbbb1 S eeeee1 -transferase pull-down assay showed reduced binding of  bbbbb2 R316C eeeee2  with NCoR in the absence of T3 and impaired release in the presence of T3
CRP11	However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with NCoR in the absence of  bbbbb1 T3 eeeee1  bbbbb2 NCoR eeeee2  in the absence of T3 and impaired release in the presence of T3
CRP11	However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with NCoR in the absence of  bbbbb1 T3 eeeee1  bbbbb2 R316C eeeee2  with NCoR in the absence of T3 and impaired release in the presence of T3
CRP11	However, a  bbbbb1 glutathione eeeee1 -S-transferase pull-down assay showed reduced binding of R316C with  bbbbb2 NCoR eeeee2  in the absence of T3 and impaired release in the presence of T3
CRP11	However, a  bbbbb1 glutathione eeeee1 -S-transferase pull-down assay showed reduced binding of  bbbbb2 R316C eeeee2  with NCoR in the absence of T3 and impaired release in the presence of T3
CRP11	The characteristics of the R316C mutant differed from those of the R316H mutant bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	The characteristics of the R316C mutant differed from those of the R316H mutant bbbbb1  eeeee1  bbbbb2  R316 eeeee2 C mutant differed from those of the R316H mutant
CRP11	Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits copr bbbbb1 ecip eeeee1  bbbbb2 ecipitated wit eeeee2 h the NR2A subunit, indicating that native human spinal cord NMDA receptors are heteroligimeric receptors assembled by at least three different receptor subunits
CRP11	A receptors in postmortem human spinal cord were analyzed using [3H]MK-801 ligand binding and immunoblotting with  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  subunit-specific antibodies
CRP11	A receptors in postmortem human spinal cord were analyzed using  bbbbb1 [3H]MK-801 eeeee1  ligand binding and immunoblotting with  bbbbb2 NMDA receptor eeeee2  subunit-specific antibodies
CRP11	Immunoblotting of native  bbbbb1 NMDA eeeee1  receptors showed that NR1, NR2A, NR2C, and NR2D subunits could all be found in the human spinal cord of which  bbbbb2 NR1 eeeee2  was preferentially located to the dorsal half
CRP11	Immunoblotting of native  bbbbb1 NMDA eeeee1  receptors showed that NR1, NR2A,  bbbbb2 NR2C eeeee2 , and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half
CRP11	Immunoblotting of native  bbbbb1 NMDA eeeee1  receptors showed that NR1,  bbbbb2 NR2A eeeee2 , NR2C, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half
CRP11	Immunoblotting of native  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptors eeeee2  showed that NR1, NR2A, NR2C, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half
CRP11	Immunoblotting of native  bbbbb1 NMDA eeeee1  receptors showed that NR1, NR2A, NR2C, and  bbbbb2 NR2D eeeee2  subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half
CRP11	Immunoblotting of native  bbbbb1 NMDA eeeee1  receptors showed that  bbbbb2 NR1 eeeee2 , NR2A, NR2C, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half
CRP11	Activation of caspases 9 and 3/7 was observed in  bbbbb1 AMD eeeee1 / bbbbb2 TNF eeeee2 -cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity
CRP11	Activation of caspases 9 and 3/7 was observed in  bbbbb1 AMD eeeee1  bbbbb2 caspases 9 and 3/7 eeeee2  was observed in AMD/TNF-cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity
CRP11	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and bbbbb1  RO eeeee1 S generation, prevente bbbbb2 d AMD t eeeee2 oxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity
CRP11	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and bbbbb1  RO eeeee1 S generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/TNF c bbbbb2 otr eeeee2 eatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity
CRP11	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and bbbbb1  RO eeeee1 S bbbbb2  ge eeeee2 neration, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity
CRP11	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/T bbbbb1 NF  eeeee1  bbbbb2 d AMD t eeeee2 oxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity
CRP11	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/T bbbbb1 NF  eeeee1 c bbbbb2 otr eeeee2 eatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity
CRP11	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/T bbbbb1 NF  eeeee1  bbbbb2 herol (T eeeee2 OCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity
CRP11	On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/T bbbbb1 NF  eeeee1  bbbbb2  ge eeeee2 neration, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity
CRP11	Tumor necrosis factor-alpha potentiates the cytotoxicity of  bbbbb1 amiodarone eeeee1  in Hepa1c1c7 cells: roles of  bbbbb2 caspase eeeee2  activation and oxidative stress
CRP11	Tumor necrosis factor-alpha potentiates the cytotoxicity of  bbbbb1 amiodarone eeeee1  bbbbb2 Tumor necrosis factor-alpha eeeee2  potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress
CRP11	 bbbbb1 AMD eeeee1  caused cell death in Hepa1c1c7 cells, and  bbbbb2 TNF eeeee2  cotreatment potentiated its toxicity
CRP11	We demonstrated previously that tumor necrosis factor-alpha (TNF-α) plays an important role in a rat model of  bbbbb1 AMD eeeee1  bbbbb2 TNF-α eeeee2 ) plays an important role in a rat model of AMD-induced hepatotoxicity under inflammatory stress
CRP11	We demonstrated previously that tumor necrosis factor-alpha (TNF-α) plays an important role in a rat model of  bbbbb1 AMD eeeee1  bbbbb2 tumor necrosis factor-alpha eeeee2  (TNF-α) plays an important role in a rat model of AMD-induced hepatotoxicity under inflammatory stress
CRP11	Adding water-soluble antioxidants (trolox, N-acetylcysteine,  bbbbb1 glutathione eeeee1 , or ascorbate) produced only minor attenuation of AMD/ bbbbb2 TNF eeeee2 -induced cytotoxicity and did not influence the effect of AMD alone
CRP11	Adding water-soluble antioxidants ( bbbbb1 trolox eeeee1 , N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of AMD/ bbbbb2 TNF eeeee2 -induced cytotoxicity and did not influence the effect of AMD alone
CRP11	Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or  bbbbb1 ascorbate eeeee1 ) produced only minor attenuation of AMD/ bbbbb2 TNF eeeee2 -induced cytotoxicity and did not influence the effect of AMD alone
CRP11	Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of AMD/TNF-induced cytotoxicity and did not influence the effect of  bbbbb1 AMD eeeee1  bbbbb2 TNF eeeee2 -induced cytotoxicity and did not influence the effect of AMD alone
CRP11	Adding water-soluble antioxidants (trolox,  bbbbb1 N-acetylcysteine eeeee1 , glutathione, or ascorbate) produced only minor attenuation of AMD/ bbbbb2 TNF eeeee2 -induced cytotoxicity and did not influence the effect of AMD alone
CRP11	Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of  bbbbb1 AMD eeeee1 / bbbbb2 TNF eeeee2 -induced cytotoxicity and did not influence the effect of AMD alone
CRP11	In this study, we developed a model in vitro to study the roles of caspase activation and oxidative stress in TNF potentiation of  bbbbb1 AMD eeeee1  bbbbb2 TNF eeeee2  potentiation of AMD cytotoxicity
CRP11	In this study, we developed a model in vitro to study the roles of caspase activation and oxidative stress in TNF potentiation of  bbbbb1 AMD eeeee1  bbbbb2 caspase eeeee2  activation and oxidative stress in TNF potentiation of AMD cytotoxicity
CRP11	Intracellular reactive oxygen species (ROS) generation and lipid peroxidation were observed after treatment with  bbbbb1 AMD eeeee1  and were further elevated by  bbbbb2 TNF eeeee2  cotreatment
CRP11	Intracellular reactive  bbbbb1 oxygen eeeee1  species (ROS) generation and lipid peroxidation were observed after treatment with AMD and were further elevated by  bbbbb2 TNF eeeee2  cotreatment
CRP11	In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'),  bbbbb1 ARC-239 eeeee1  bbbbb2 alpha 2B- (and alpha 2C)-adrenoceptor eeeee2  ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive
CRP11	In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'), ARC-239,  bbbbb1 BRL 41992 eeeee1  bbbbb2 alpha 2B- (and alpha 2C)-adrenoceptor eeeee2  ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive
CRP11	In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'), ARC-239, BRL 41992 and  bbbbb1 prazosin eeeee1  bbbbb2 alpha 2B- (and alpha 2C)-adrenoceptor eeeee2  ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist,  bbbbb1 BRL 44408 eeeee1  bbbbb2 alpha 2-adrenoceptor eeeee2  antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist,  bbbbb1 BRL 44408 eeeee1  bbbbb2 alpha 2A-adrenoceptor eeeee2  antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist,  bbbbb1 BRL 44408 eeeee1  bbbbb2 alpha 2-adrenoceptor eeeee2  agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist,  bbbbb1 UK 14,304 eeeee1 , was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential  bbbbb2 alpha 2A-adrenoceptor eeeee2  antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist,  bbbbb1 UK 14,304 eeeee1 , was abolished by the  bbbbb2 alpha 2-adrenoceptor eeeee2  antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist,  bbbbb1 UK 14,304 eeeee1 , was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent  bbbbb2 alpha 2A-adrenoceptor eeeee2  antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist,  bbbbb1 RX 821002 eeeee1  and the preferential  bbbbb2 alpha 2A-adrenoceptor eeeee2  antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist,  bbbbb1 RX 821002 eeeee1  bbbbb2 alpha 2-adrenoceptor eeeee2  antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist,  bbbbb1 RX 821002 eeeee1  bbbbb2 alpha 2-adrenoceptor eeeee2  agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist,  bbbbb1 idazoxan eeeee1 , the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential  bbbbb2 alpha 2A-adrenoceptor eeeee2  antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist,  bbbbb1 idazoxan eeeee1 , the potent  bbbbb2 alpha 2A-adrenoceptor eeeee2  antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist,  bbbbb1 idazoxan eeeee1  bbbbb2 alpha 2-adrenoceptor eeeee2  agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408
CRP11	After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a  bbbbb1 dopamine eeeee1  bbbbb2 dopamine D2 eeeee2  antagonist
CRP11	After that, a wide range of concentrations of drugs, concomitantly with  bbbbb1 ATR eeeee1  (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a  bbbbb2 dopamine D2 eeeee2  antagonist
CRP11	Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase  bbbbb1 ACh eeeee1  release by blocking  bbbbb2 AChE eeeee2  activity but not acting on nicotinic receptors
CRP11	Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase  bbbbb1 ACh eeeee1  bbbbb2 Nicotinic-receptor eeeee2  potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors
CRP11	Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase  bbbbb1 ACh eeeee1  release by blocking AChE activity but not acting on  bbbbb2 nicotinic receptors eeeee2 
CRP11	The main goal of the present study was to analyse the effects of (+/-)-huprine X ((+/-)-HX) and galantamine (GAL), with potentiating action on nicotinic receptors, and huperzine A (HPA), devoid of nicotinic activity, on  bbbbb1 [3H]-acetylcholine eeeee1  bbbbb2 nicotinic receptors eeeee2 , and huperzine A (HPA), devoid of nicotinic activity, on [3H]-acetylcholine ([3H]-ACh) release in striatal slices of rat brain
CRP11	The main goal of the present study was to analyse the effects of (+/-)-huprine X ((+/-)-HX) and galantamine (GAL), with potentiating action on nicotinic receptors, and huperzine A (HPA), devoid of nicotinic activity, on [3H]-acetylcholine ( bbbbb1 [3H]-ACh eeeee1  bbbbb2 nicotinic receptors eeeee2 , and huperzine A (HPA), devoid of nicotinic activity, on [3H]-acetylcholine ([3H]-ACh) release in striatal slices of rat brain
CRP11	To test the role of nicotinic receptors in the drugs' effects on  bbbbb1 [3H]-ACh eeeee1  bbbbb2 nicotinic receptors eeeee2  in the drugs' effects on [3H]-ACh release, mecamylamine (MEC) 100 microM was used to block such receptors
CRP11	This model is a hypomorph, with reduced  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase reductase eeeee2  activity, thus avoiding the lethality associated with the absence of methionine synthase activity
CRP11	This model is a hypomorph, with reduced  bbbbb1 methionine eeeee1  synthase reductase activity, thus avoiding the lethality associated with the absence of  bbbbb2 methionine synthase eeeee2  activity
CRP11	This model is a hypomorph, with reduced methionine synthase reductase activity, thus avoiding the lethality associated with the absence of  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase reductase eeeee2  activity, thus avoiding the lethality associated with the absence of methionine synthase activity
CRP11	This model is a hypomorph, with reduced methionine synthase reductase activity, thus avoiding the lethality associated with the absence of  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase eeeee2  activity
CRP11	Mtrr(gt/gt) mice have increased plasma  bbbbb1 homocyst(e)ine eeeee1  bbbbb2 Mtrr eeeee2 (gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma methionine, and increased tissue methyltetrahydrofolate
CRP11	Mtrr(gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma  bbbbb1 methionine eeeee1  bbbbb2 Mtrr eeeee2 (gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma methionine, and increased tissue methyltetrahydrofolate
CRP11	Mtrr(gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma methionine, and increased tissue  bbbbb1 methyltetrahydrofolate eeeee1  bbbbb2 Mtrr eeeee2 (gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma methionine, and increased tissue methyltetrahydrofolate
CRP11	Metabolic derangement of  bbbbb1 methionine eeeee1  and folate metabolism in mice deficient in  bbbbb2 methionine synthase reductase eeeee2 
CRP11	Metabolic derangement of methionine and  bbbbb1 folate eeeee1  metabolism in mice deficient in  bbbbb2 methionine synthase reductase eeeee2 
CRP11	Metabolic derangement of methionine and folate metabolism in mice deficient in  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase reductase eeeee2 
CRP11	Complete ablation of  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase eeeee2  activity in mice results in embryonic lethality
CRP11	We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying methionine synthase reductase, an enzyme essential for the activity of  bbbbb1 methionine eeeee1  bbbbb2 Mtrr eeeee2  gene specifying methionine synthase reductase, an enzyme essential for the activity of methionine synthase
CRP11	We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying methionine synthase reductase, an enzyme essential for the activity of  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase reductase eeeee2 , an enzyme essential for the activity of methionine synthase
CRP11	We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying methionine synthase reductase, an enzyme essential for the activity of  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase eeeee2 
CRP11	We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying  bbbbb1 methionine eeeee1  bbbbb2 Mtrr eeeee2  gene specifying methionine synthase reductase, an enzyme essential for the activity of methionine synthase
CRP11	We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase reductase eeeee2 , an enzyme essential for the activity of methionine synthase
CRP11	We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying  bbbbb1 methionine eeeee1  synthase reductase, an enzyme essential for the activity of  bbbbb2 methionine synthase eeeee2 
CRP11	In humans, methionine synthase deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and  bbbbb1 thymidylate eeeee1  bbbbb2 methionine synthase eeeee2  deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis
CRP11	In humans, methionine synthase deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for  bbbbb1 purine eeeee1  bbbbb2 methionine synthase eeeee2  deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis
CRP11	In humans, methionine synthase deficiency results in the accumulation of methyltetrahydrofolate at the expense of  bbbbb1 folate eeeee1  bbbbb2 methionine synthase eeeee2  deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis
CRP11	In humans,  bbbbb1 methionine eeeee1  bbbbb2 methionine synthase eeeee2  deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis
CRP11	Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and  bbbbb1 Cl(-) eeeee1  bbbbb2 P2Y(2) eeeee2  agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF
CRP11	The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for  bbbbb1 Cl(-) eeeee1  secretion is enhanced by the effect of  bbbbb2 P2Y(2) eeeee2  activation to also inhibit epithelial Na(+) transport
CRP11	The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for  bbbbb1 Cl(-) eeeee1  bbbbb2 CFTR eeeee2  pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport
CRP11	The  bbbbb1 Cl(-) eeeee1  secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of  bbbbb2 P2Y(2) eeeee2  activation to also inhibit epithelial Na(+) transport
CRP11	The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial  bbbbb1 Na(+) eeeee1  bbbbb2 P2Y(2) eeeee2  activation to also inhibit epithelial Na(+) transport
CRP11	The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial  bbbbb1 Na(+) eeeee1  bbbbb2 CFTR eeeee2  pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport
CRP11	Here we show that puerarin increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two  bbbbb1 estrogen eeeee1  bbbbb2 estrogen receptor eeeee2  (ER) isoforms
CRP11	Here we show that puerarin increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two  bbbbb1 estrogen eeeee1  receptor ( bbbbb2 ER eeeee2 ) isoforms
CRP11	 bbbbb1 Puerarin eeeee1  promotes proliferation by altering cell cycle distribution whereas puerarin-mediated survival may be associated with up-regulation of  bbbbb2 Bcl-xL eeeee2  expression
CRP11	In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB  bbbbb1 telmisarta eeeee1  bbbbb2 ACE eeeee2  inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg
CRP11	In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic  bbbbb1 hydrochlorothiazide eeeee1  bbbbb2 ACE eeeee2  inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg
CRP11	Agents inhibiting the renin-angiotensin- bbbbb1 aldosterone eeeee1  bbbbb2 renin eeeee2 -angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease
CRP11	Agents inhibiting the renin-angiotensin- bbbbb1 aldosterone eeeee1  bbbbb2 angiotensin eeeee2 -aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of  bbbbb1 citric acid eeeee1  bbbbb2 delta-opioid receptor eeeee2  (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of  bbbbb1 citric acid eeeee1  bbbbb2 kappa-opioid receptor eeeee2  (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of  bbbbb1 citric acid eeeee1  bbbbb2 mu-opioid receptor eeeee2  (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor ( bbbbb1 BRL 52974 eeeee1  bbbbb2 delta-opioid receptor eeeee2  (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor ( bbbbb1 BRL 52974 eeeee1  bbbbb2 mu-opioid receptor eeeee2  (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor ( bbbbb1 codeine eeeee1  bbbbb2 delta-opioid receptor eeeee2  (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor ( bbbbb1 codeine eeeee1  and hydrocodone), and  bbbbb2 kappa-opioid receptor eeeee2  (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor ( bbbbb1 SB 227122 eeeee1 ), mu-opioid receptor (codeine and hydrocodone), and  bbbbb2 kappa-opioid receptor eeeee2  (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor ( bbbbb1 SB 227122 eeeee1 ),  bbbbb2 mu-opioid receptor eeeee2  (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and  bbbbb1 hydrocodone eeeee1  bbbbb2 delta-opioid receptor eeeee2  (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and  bbbbb1 hydrocodone eeeee1 ), and  bbbbb2 kappa-opioid receptor eeeee2  (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively
CRP11	The nonselective opioid receptor antagonist,  bbbbb1 naloxone eeeee1  (3 mg/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is  bbbbb2 opioid receptor eeeee2 -mediated
CRP11	In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and  bbbbb1 norbinaltorphimine eeeee1  bbbbb2 mu-receptor eeeee2  antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CRP11	In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and  bbbbb1 norbinaltorphimine eeeee1  (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of  bbbbb2 mu- and kappa-receptor eeeee2  agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CRP11	In contrast, combined pretreatment with  bbbbb1 beta-funaltrexamine eeeee1  (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine ( bbbbb2 kappa-receptor eeeee2  antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CRP11	In contrast, combined pretreatment with  bbbbb1 beta-funaltrexamine eeeee1  (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of  bbbbb2 mu- and kappa-receptor eeeee2  agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CRP11	In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of  bbbbb1 SB 227122 eeeee1  bbbbb2 mu-receptor eeeee2  antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CRP11	In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of  bbbbb1 SB 227122 eeeee1  bbbbb2 kappa-receptor eeeee2  antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CRP11	In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of  bbbbb1 SB 227122 eeeee1  bbbbb2 mu- and kappa-receptor eeeee2  agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.)
CRP11	In this study, the activity of the delta-opioid receptor subtype-selective agonist, SB 227122, was investigated in a guinea pig model of  bbbbb1 citric acid eeeee1  bbbbb2 delta-opioid receptor eeeee2  subtype-selective agonist, SB 227122, was investigated in a guinea pig model of citric acid-induced cough
CRP11	This study involved development of a peptide to characterize the intrinsic structure of the  bbbbb1 LPA eeeee1 (1) GPCR second  bbbbb2 EL eeeee2 
CRP11	This study involved development of a peptide to characterize the intrinsic structure of the  bbbbb1 LPA eeeee1  bbbbb2 LPA(1) eeeee2  GPCR second EL
CRP11	This study involved development of a peptide to characterize the intrinsic structure of the  bbbbb1 LPA eeeee1 (1)  bbbbb2 GPCR eeeee2  second EL
CRP11	The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint ( bbbbb1 LPA eeeee1  bbbbb2 coiled-coil eeeee2 , which served as a receptor-mimetic folding constraint (LPA(1)-CC-EL2 peptide)
CRP11	The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint ( bbbbb1 LPA eeeee1 (1)-CC- bbbbb2 EL2 eeeee2  peptide)
CRP11	The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint ( bbbbb1 LPA eeeee1  bbbbb2 LPA(1) eeeee2 -CC-EL2 peptide)
CRP11	The EL of the  bbbbb1 LPA eeeee1  bbbbb2 LPA(1) eeeee2  receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures
CRP11	The EL of the  bbbbb1 LPA eeeee1  bbbbb2 EL eeeee2  of the LPA(1) receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures
CRP11	The NMR ensemble was combined with a computational model of the  bbbbb1 LPA eeeee1  bbbbb2 LPA(1) eeeee2  receptor that had previously been validated
CRP11	Nevertheless, PPARγ is involved in the expression of genes that control  bbbbb1 glucose eeeee1  bbbbb2 PPARγ eeeee2  is involved in the expression of genes that control glucose and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease
CRP11	The present study examined the effect of insulin-mediated activation of the mammalian target of  bbbbb1 rapamycin eeeee1  complex 1 ( bbbbb2 MTORC1 eeeee2 ) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells
CRP11	The present study examined the effect of insulin-mediated activation of the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 mammalian target of rapamycin complex 1 eeeee2  (MTORC1) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells
CRP11	The present study examined the effect of insulin-mediated activation of the mammalian target of  bbbbb1 rapamycin eeeee1  bbbbb2 insulin eeeee2 -mediated activation of the mammalian target of rapamycin complex 1 (MTORC1) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells
CRP11	Furthermore, adapalene does not bind to members of the cellular  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid binding protein eeeee2  family
CRP11	It has a particular selectivity profile for the known nuclear  bbbbb1 retinoic acid eeeee1  bbbbb2 retinoic acid receptors eeeee2  with low affinity for RAR alpha and no transactivating potential for RXR alpha
CRP11	It has a particular selectivity profile for the known nuclear  bbbbb1 retinoic acid eeeee1  receptors with low affinity for RAR alpha and no transactivating potential for  bbbbb2 RXR alpha eeeee2 
CRP11	It has a particular selectivity profile for the known nuclear  bbbbb1 retinoic acid eeeee1  receptors with low affinity for  bbbbb2 RAR alpha eeeee2  and no transactivating potential for RXR alpha
CRP11	KA markedly reduced these  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 -stimulated FSHβ responses at both low and high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also att bbbbb1 enua eeeee1  bbbbb2 sed  eeeee2 to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also att bbbbb1 enua eeeee1  bbbbb2 tent eeeee2  by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also att bbbbb1 enua eeeee1  bbbbb2 enua eeeee2 ted by overexpression of DNPKA at both low and high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also att bbbbb1 enua eeeee1  bbbbb2 act eeeee2 ivity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increa bbbbb1 sed  eeeee1  bbbbb2 sed  eeeee2 to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increa bbbbb1 sed  eeeee1 to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also att bbbbb2 enua eeeee2 ted by overexpression of DNPKA at both low and high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increa bbbbb1 sed  eeeee1 to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both lo bbbbb2 w an eeeee2 d high pulse frequencies
CRP11	Correlating with FSHβ activation, both PKA activity and levels of pCREB were increa bbbbb1 sed  eeeee1  bbbbb2 act eeeee2 ivity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies
CRP11	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  bbbbb2 DNPKA eeeee2 ) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  bbbbb2 pCREB eeeee2  and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  bbbbb2 dominant negative PKA eeeee2  (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 -stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1  bbbbb2 DNPKA eeeee2 ) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1 -stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and  bbbbb2 FSHβ eeeee2 LUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1 -stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on  bbbbb2 LHβ eeeee2 LUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1  bbbbb2 dominant negative PKA eeeee2  (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1 -stimulated pCREB and markedly decreased GnRH stimulation of  bbbbb2 FSHβ eeeee2  mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1 -stimulated pCREB and markedly decreased  bbbbb2 GnRH eeeee2  stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	A dominant negative PKA (DNPKA) reduced  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 -stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile  bbbbb1 GnRH eeeee1 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates  bbbbb2 CREB eeeee2  activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile  bbbbb1 GnRH eeeee1 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of  bbbbb2 FSHβ eeeee2  gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile  bbbbb1 GnRH eeeee1 , is essential for fertility. cAMP response element-binding protein ( bbbbb2 CREB eeeee2 ) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile  bbbbb1 GnRH eeeee1 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb2 GnRH eeeee2  regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile  bbbbb1 GnRH eeeee1 , is essential for fertility.  bbbbb2 cAMP response element-binding protein eeeee2  (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 LH eeeee2 , under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 FSHβ eeeee2  gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 CREB eeeee2 ) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 FSH eeeee2  and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 GnRH eeeee2  regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb1 GnRH eeeee1  bbbbb2 cAMP response element-binding protein eeeee2  (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates  bbbbb2 CREB eeeee2  activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  bbbbb2 LH eeeee2 , under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  bbbbb2 GnRH eeeee2 , is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  response element-binding protein (CREB) has been implicated in the regulation of  bbbbb2 FSHβ eeeee2  gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  response element-binding protein ( bbbbb2 CREB eeeee2 ) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  bbbbb2 FSH eeeee2  and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile  bbbbb2 GnRH eeeee2  regulates CREB activation remain poorly understood
CRP11	Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility.  bbbbb1 cAMP eeeee1  bbbbb2 cAMP response element-binding protein eeeee2  (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood
CRP11	Since their discovery, the role of LXR in the control of  bbbbb1 cholesterol eeeee1  bbbbb2 LXR eeeee2  in the control of cholesterol homeostasis has been widely described
CRP11	Liver X Receptor (LXR) α and LXR β are nuclear receptors activated by oxysterols, oxidized derivatives of  bbbbb1 cholesterol eeeee1  bbbbb2 LXR β eeeee2  are nuclear receptors activated by oxysterols, oxidized derivatives of cholesterol
CRP11	Liver X Receptor (LXR) α and LXR β are nuclear receptors activated by oxysterols, oxidized derivatives of  bbbbb1 cholesterol eeeee1  bbbbb2 Liver X Receptor (LXR) α eeeee2  and LXR β are nuclear receptors activated by oxysterols, oxidized derivatives of cholesterol
CRP11	Liver X Receptors and female reproduction: when  bbbbb1 cholesterol eeeee1  bbbbb2 Liver X Receptors eeeee2  and female reproduction: when cholesterol meets fertility! The role of cholesterol in female reproductive physiology has been suspected for a long time, while the molecular bases were unknown
CRP11	Liver X Receptors and female reproduction: when cholesterol meets fertility! The role of  bbbbb1 cholesterol eeeee1  bbbbb2 Liver X Receptors eeeee2  and female reproduction: when cholesterol meets fertility! The role of cholesterol in female reproductive physiology has been suspected for a long time, while the molecular bases were unknown
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1 -transferase (GST) did not reverse the inhibitory effect of DMF on  bbbbb2 TGF-beta eeeee2 -induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1  bbbbb2 HO-1 eeeee2  and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1  bbbbb2 ARE eeeee2 )-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1 -transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an  bbbbb2 ARE eeeee2 -independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1  bbbbb2 Nrf2 eeeee2  target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1  bbbbb2 antioxidant response element eeeee2  (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1 -transferase ( bbbbb2 GST eeeee2 ) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione  bbbbb1 S eeeee1  bbbbb2 NQO1 eeeee2 , HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 TGF-beta eeeee2 -induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 HO-1 eeeee2  and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 ARE eeeee2 )-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 Nrf2 eeeee2  target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 antioxidant response element eeeee2  (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 GST eeeee2 ) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of  bbbbb1 DMF eeeee1  bbbbb2 NQO1 eeeee2 , HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of  bbbbb1 DMF eeeee1  on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an  bbbbb2 ARE eeeee2 -independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  S-transferase (GST) did not reverse the inhibitory effect of DMF on  bbbbb2 TGF-beta eeeee2 -induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  bbbbb2 glutathione S-transferase eeeee2  (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  bbbbb2 HO-1 eeeee2  and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  bbbbb2 ARE eeeee2 )-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an  bbbbb2 ARE eeeee2 -independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  bbbbb2 Nrf2 eeeee2  target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  bbbbb2 antioxidant response element eeeee2  (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  S-transferase ( bbbbb2 GST eeeee2 ) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and  bbbbb1 glutathione eeeee1  bbbbb2 NQO1 eeeee2 , HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA),  bbbbb2 fibronectin eeeee2  and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin ( bbbbb2 alpha-SMA eeeee2 ), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1,  bbbbb2 alpha-smooth muscle actin eeeee2  (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased  bbbbb2 PAI-1 eeeee2 , alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and  bbbbb2 type 1 collagen eeeee2  expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad- bbbbb2 Nrf2 eeeee2 ) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in  bbbbb2 TGF-beta eeeee2 -treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that  bbbbb1 DMF eeeee1  increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of  bbbbb2 Nrf2 eeeee2  (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  bbbbb2 Nrf2 eeeee2 , and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Results showed that DMF increased nuclear levels of Nrf2, and both  bbbbb1 DMF eeeee1  and adenovirus-mediated overexpression of Nrf2 (Ad- bbbbb2 Nrf2 eeeee2 ) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)
CRP11	Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the bbbbb1  ob eeeee1  bbbbb2 brosis a eeeee2 nd alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively
CRP11	Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the bbbbb1  ob eeeee1  bbbbb2 d alp eeeee2 ha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively
CRP11	Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the bbbbb1  ob eeeee1  bbbbb2 in  eeeee2 and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively
CRP11	Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the bbbbb1  ob eeeee1  bbbbb2 ctio eeeee2 n (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively
CRP11	Additionally,  bbbbb1 DMF eeeee1  and Ad- bbbbb2 Nrf2 eeeee2  repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression
CRP11	Additionally,  bbbbb1 DMF eeeee1  and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of  bbbbb2 Nrf2 eeeee2  expression
CRP11	This study examines whether dimethylfumarate ( bbbbb1 DMF eeeee1 ), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of  bbbbb2 TGF-beta eeeee2  signaling
CRP11	This study examines whether dimethylfumarate ( bbbbb1 DMF eeeee1 ), which stimulates  bbbbb2 Nrf2 eeeee2 , prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling
CRP11	This study examines whether dimethylfumarate ( bbbbb1 DMF eeeee1 ), which stimulates Nrf2, prevents renal fibrosis via the  bbbbb2 Nrf2 eeeee2 -mediated suppression of TGF-beta signaling
CRP11	This study examines whether  bbbbb1 dimethylfumarate eeeee1  (DMF), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of  bbbbb2 TGF-beta eeeee2  signaling
CRP11	This study examines whether  bbbbb1 dimethylfumarate eeeee1  (DMF), which stimulates  bbbbb2 Nrf2 eeeee2 , prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling
CRP11	This study examines whether  bbbbb1 dimethylfumarate eeeee1  (DMF), which stimulates Nrf2, prevents renal fibrosis via the  bbbbb2 Nrf2 eeeee2 -mediated suppression of TGF-beta signaling
CRP11	Nicotinamide  bbbbb1 N eeeee1  bbbbb2 Nicotinamide N-methyltransferase eeeee2  (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions
CRP11	Nicotinamide  bbbbb1 N eeeee1 -methyltransferase ( bbbbb2 NNMT eeeee2 ) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions
CRP11	 bbbbb1 Nicotinamide eeeee1  bbbbb2 Nicotinamide N-methyltransferase eeeee2  (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions
CRP11	 bbbbb1 Nicotinamide eeeee1  N-methyltransferase ( bbbbb2 NNMT eeeee2 ) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions
CRP11	Adipose tissue as a source of nicotinamide N-methyltransferase and  bbbbb1 homocysteine eeeee1  bbbbb2 nicotinamide N-methyltransferase eeeee2  and homocysteine
CRP11	Adipose tissue as a source of  bbbbb1 nicotinamide eeeee1  bbbbb2 nicotinamide N-methyltransferase eeeee2  and homocysteine
CRP11	Adipose tissue as a source of nicotinamide  bbbbb1 N eeeee1  bbbbb2 nicotinamide N-methyltransferase eeeee2  and homocysteine
CRP11	 bbbbb1 Homocysteine eeeee1  release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the  bbbbb2 NNMT eeeee2  inhibitor 1-methylnicotinamide
CRP11	Extracellular loop II modulates GTP sensitivity of the  bbbbb1 prostaglandin eeeee1  bbbbb2 prostaglandin EP3 receptor eeeee2 
CRP11	Extracellular loop II modulates GTP sensitivity of the  bbbbb1 prostaglandin eeeee1  bbbbb2 Extracellular loop II eeeee2  modulates GTP sensitivity of the prostaglandin EP3 receptor
CRP11	Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the W203A receptor, conditions where high GTP levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of  bbbbb1 GTP eeeee1  bbbbb2 W203A eeeee2  receptor, conditions where high GTP levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of GTP
CRP11	Moreover, mutation of ECII can alter this coupled equilibrium from GTP-insensitive agonist binding to more conventional GTP-sensitive bindin bbbbb1 g eeeee1  bbbbb2 pled eeeee2  equilibrium from GTP-insensitive agonist binding to more conventional GTP-sensitive binding
CRP11	Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) ( bbbbb1 PGE(2) eeeee1  bbbbb2 prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor eeeee2  binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) ( bbbbb1 PGE(2) eeeee1  bbbbb2 G protein-coupled receptors eeeee2 , the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate ( bbbbb1 GTPγS eeeee1  bbbbb2 G protein-coupled receptors eeeee2 , the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	Unlike the majority of G protein-coupled receptors, the  bbbbb1 prostaglandin E(2) eeeee1  bbbbb2 prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor eeeee2  binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	Unlike the majority of G protein-coupled receptors, the  bbbbb1 prostaglandin E(2) eeeee1  bbbbb2 G protein-coupled receptors eeeee2 , the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) (PGE(2))  bbbbb1 E-prostanoid eeeee1  bbbbb2 prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor eeeee2  binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) (PGE(2))  bbbbb1 E-prostanoid eeeee1  bbbbb2 G protein-coupled receptors eeeee2 , the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of  bbbbb1 guanosine 5[prime]-O-(3-thio)triphosphate eeeee1  bbbbb2 G protein-coupled receptors eeeee2 , the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS)
CRP11	In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or  bbbbb1 ADP eeeee1  bbbbb2 GP IIb/IIIa eeeee2  inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or ADP-stimulated CD62P expression
CRP11	In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or  bbbbb1 ADP eeeee1  bbbbb2 GP IIb/IIIa eeeee2  inhibitors on basal or ADP-stimulated CD62P expression
CRP11	In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or  bbbbb1 ADP eeeee1  bbbbb2 HPA-1 eeeee2  genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or ADP-stimulated CD62P expression
CRP11	The effects of abciximab (1-10 microg/ml),  bbbbb1 tirofiban eeeee1  (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and ADP (3 microM)-induced  bbbbb2 CD62P eeeee2  externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease
CRP11	The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and  bbbbb1 ADP eeeee1  (3 microM)-induced  bbbbb2 CD62P eeeee2  externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease
CRP11	The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or  bbbbb1 eptifibatide eeeee1  (0.3-3 microg/ml) on basal and ADP (3 microM)-induced  bbbbb2 CD62P eeeee2  externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease
CRP11	Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or  bbbbb1 ADP eeeee1  bbbbb2 HPA-1 eeeee2  genotype did not influence basal or ADP-induced CD62P expression
CRP11	 bbbbb1 Retigabine eeeee1 , a novel anti-convulsant, enhances activation of  bbbbb2 KCNQ2/Q3 eeeee2  potassium channels
CRP11	Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3  bbbbb1 potassium eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  potassium channels
CRP11	Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3  bbbbb1 potassium eeeee1  bbbbb2 potassium channels eeeee2 
CRP11	Retigabine (0.1 to 10 microM) induced a  bbbbb1 potassium eeeee1  current and hyperpolarized CHO cells expressing  bbbbb2 KCNQ2/Q3 eeeee2  cells but not in wild-type cells
CRP11	 bbbbb1 Retigabine eeeee1  (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing  bbbbb2 KCNQ2/Q3 eeeee2  cells but not in wild-type cells
CRP11	Retigabine (0.1 to 10 microM) also slowed the rate of channel deac bbbbb1 tivation,  eeeee1  bbbbb2 microM)  eeeee2 also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component
CRP11	Retigabine (0.1 to 10 microM) also slowed the rate of channel deac bbbbb1 tivation,  eeeee1 predominantly by increasing the  bbbbb2 contribu eeeee2 tion of a slowly deactivating tail current component
CRP11	In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and KCNQ2/Q3  bbbbb1 K(+) eeeee1  channels expressed in Chinese hamster ovary cells (CHO- bbbbb2 KCNQ2/Q3 eeeee2 )
CRP11	In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and KCNQ2/Q3  bbbbb1 K(+) eeeee1  bbbbb2 K(+) channels eeeee2  expressed in Chinese hamster ovary cells (CHO-KCNQ2/Q3)
CRP11	In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and KCNQ2/Q3  bbbbb1 K(+) eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  K(+) channels expressed in Chinese hamster ovary cells (CHO-KCNQ2/Q3)
CRP11	The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM  bbbbb1 retigabine eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine)
CRP11	The mechanism by which  bbbbb1 retigabine eeeee1  enhanced  bbbbb2 KCNQ2/Q3 eeeee2  currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine)
CRP11	Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker,  bbbbb1 linopirdine eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM)
CRP11	Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker,  bbbbb1 linopirdine eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM)
CRP11	Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by  bbbbb1 BaCl(2) eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM)
CRP11	Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by  bbbbb1 BaCl(2) eeeee1  bbbbb2 KCNQ2/Q3 eeeee2  cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM)
CRP11	 bbbbb1 Retigabine eeeee1 -induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the  bbbbb2 KCNQ2/Q3 eeeee2  blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM)
CRP11	 bbbbb1 Retigabine eeeee1 -induced currents in CHO- bbbbb2 KCNQ2/Q3 eeeee2  cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM)
CRP11	The CCL2/CCR2 pathway and the energy sensor  bbbbb1 AMP eeeee1 -activated protein kinase ( bbbbb2 AMPK eeeee2 ) are attractive therapeutic targets as a part of preventive management of disease
CRP11	The CCL2/CCR2 pathway and the energy sensor  bbbbb1 AMP eeeee1  bbbbb2 AMP-activated protein kinase eeeee2  (AMPK) are attractive therapeutic targets as a part of preventive management of disease
CRP11	The CCL2/CCR2 pathway and the energy sensor  bbbbb1 AMP eeeee1  bbbbb2 CCR2 eeeee2  pathway and the energy sensor AMP-activated protein kinase (AMPK) are attractive therapeutic targets as a part of preventive management of disease
CRP11	The CCL2/CCR2 pathway and the energy sensor  bbbbb1 AMP eeeee1  bbbbb2 CCL2 eeeee2 /CCR2 pathway and the energy sensor AMP-activated protein kinase (AMPK) are attractive therapeutic targets as a part of preventive management of disease
CRP11	Cimetidine therapy used for bbbbb1  the trea eeeee1  bbbbb2  the treatment of gas eeeee2 tric bleeding due to tolazoline therapy in a newborn infant was temporally associated with episodes of severe hypoxemia
CRP11	The role of extranuclear signaling actions of  bbbbb1 progesterone eeeee1  bbbbb2 progesterone receptor eeeee2  in mediating progesterone regulation of gene expression and the cell cycle
CRP11	Human  bbbbb1 progesterone eeeee1  bbbbb2 Human progesterone receptor eeeee2  (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor
CRP11	Human  bbbbb1 progesterone eeeee1  receptor ( bbbbb2 PR eeeee2 ) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor
CRP11	Human  bbbbb1 progesterone eeeee1  receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of  bbbbb2 Src eeeee2  and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor
CRP11	Human  bbbbb1 progesterone eeeee1  receptor (PR) contains a motif that interacts with the SH3 domain of  bbbbb2 Src eeeee2  and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor
CRP11	Human  bbbbb1 progesterone eeeee1  receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream  bbbbb2 MAPK eeeee2  (Erk-1/-2) without relying on the transcriptional activity of the receptor
CRP11	Human  bbbbb1 progesterone eeeee1  receptor (PR) contains a motif that interacts with the  bbbbb2 SH3 domain eeeee2  of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor
CRP11	Human  bbbbb1 progesterone eeeee1  receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK ( bbbbb2 Erk-1/-2 eeeee2 ) without relying on the transcriptional activity of the receptor
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on PR activation of the  bbbbb2 Src eeeee2 /MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on  bbbbb2 PR eeeee2  activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with  bbbbb2 PR eeeee2  activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  bbbbb2 progesterone response element eeeee2 , was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on PR activation of the Src/ bbbbb2 MAPK eeeee2  pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  bbbbb2 cyclin D1 eeeee2  gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb2 progesterone response element eeeee2  was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk ( bbbbb2 serum and glucocorticoid regulated kinase eeeee2 ) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the  bbbbb2 Sgk eeeee2  (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a  bbbbb1 progesterone eeeee1  response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of  bbbbb2 Src eeeee2 
CRP11	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with  bbbbb2 PR eeeee2  activation of Src
CRP11	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a  bbbbb2 progesterone response element eeeee2 , was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb2 progesterone response element eeeee2  was unaffected by mutations that interfere with PR activation of Src
CRP11	 bbbbb1 Progestin eeeee1  induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of  bbbbb2 Src eeeee2 
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 Src eeeee2 /MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 PR eeeee2  activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  response element was unaffected by mutations that interfere with  bbbbb2 PR eeeee2  activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 progesterone response element eeeee2 , was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 MAPK eeeee2  pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 cyclin D1 eeeee2  gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 progesterone response element eeeee2  was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 serum and glucocorticoid regulated kinase eeeee2 ) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  bbbbb2 Sgk eeeee2  (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src
CRP11	Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional  bbbbb1 progesterone eeeee1  response element was unaffected by mutations that interfere with PR activation of  bbbbb2 Src eeeee2 
CRP11	Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of  bbbbb1 progestin eeeee1  bbbbb2 PR-BDeltaSH3 eeeee2 ) that do not affect the transcriptional activity of PR, were compared for effects of progestin on endogenous target gene expression and cell proliferation
CRP11	Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of  bbbbb1 progestin eeeee1  bbbbb2 PR eeeee2 , were compared for effects of progestin on endogenous target gene expression and cell proliferation
CRP11	Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of  bbbbb1 progestin eeeee1  bbbbb2 PR-B eeeee2  or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of progestin on endogenous target gene expression and cell proliferation
CRP11	Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of  bbbbb1 progestin eeeee1  bbbbb2 PR-B eeeee2  with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of progestin on endogenous target gene expression and cell proliferation
CRP11	Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of  bbbbb1 progestin eeeee1  bbbbb2 SH3 domain binding motif eeeee2  (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of progestin on endogenous target gene expression and cell proliferation
CRP11	Since all of the  bbbbb1 AII eeeee1  antagonists are selective for the  bbbbb2 AT(1) receptor eeeee2 , these drugs should exhibit similar cardiovascular effects
CRP11	Since all of the  bbbbb1 AII eeeee1  bbbbb2 AII eeeee2  antagonists are selective for the AT(1) receptor, these drugs should exhibit similar cardiovascular effects
CRP11	Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population bbbbb1  eeeee1  bbbbb2 r class with p eeeee2 roven benefit in this population
CRP11	Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population bbbbb1  eeeee1  bbbbb2 r class with p eeeee2 roven benefit in this population
CRP11	Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population bbbbb1  eeeee1  bbbbb2 r class with p eeeee2 roven benefit in this population
CRP11	Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population bbbbb1  eeeee1  bbbbb2 r class with p eeeee2 roven benefit in this population
CRP11	Clinical experience in hea bbbbb1 rt failu eeeee1 re is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibito bbbbb2 r class with p eeeee2 roven benefit in this population
CRP11	Losartan: a selective  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II type 1 (AT1) receptor eeeee2  antagonist for the treatment of heart failure
CRP11	Losartan (COZAAR) is the prototype of a new class of potent and selective angiotensin II ( bbbbb1 AII eeeee1  bbbbb2 angiotensin II (AII) type 1 (AT(1)) receptor eeeee2  antagonists with the largest published preclinical and clinical data base
CRP11	Losartan (COZAAR) is the prototype of a new class of potent and selective  bbbbb1 angiotensin II eeeee1  bbbbb2 angiotensin II (AII) type 1 (AT(1)) receptor eeeee2  antagonists with the largest published preclinical and clinical data base
CRP11	IPI-926 is not a potent reversible inhibitor of CYP1A2, 2C8, 2C9 or 3A4 ( bbbbb1 testosterone eeeee1  bbbbb2 CYP1A2, 2C8, 2C9 or 3A4 eeeee2  (testosterone)
CRP11	 bbbbb1 IPI-926 eeeee1  is not a potent reversible inhibitor of  bbbbb2 CYP1A2, 2C8, 2C9 or 3A4 eeeee2  (testosterone)
CRP11	 bbbbb1 IPI-926 eeeee1  is a moderate inhibitor of  bbbbb2 CYP2C19, 2D6 and 3A4 eeeee2  (midazolam) with KI values of 19, 16 and 4.5 µM, respectively
CRP11	IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 ( bbbbb1 midazolam eeeee1  bbbbb2 CYP2C19, 2D6 and 3A4 eeeee2  (midazolam) with KI values of 19, 16 and 4.5 µM, respectively
CRP11	A (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a  bbbbb1 lysine eeeee1  analogue and exogenous  bbbbb2 t-PA eeeee2  or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue
CRP11	A (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a  bbbbb1 lysine eeeee1  analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous  bbbbb2 t-PA eeeee2  and a lysine analogue
CRP11	A (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a  bbbbb1 lysine eeeee1  bbbbb2 t-PA eeeee2  or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue
CRP11	A (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a  bbbbb1 lysine eeeee1  bbbbb2 t-PA eeeee2  and a lysine analogue
CRP11	The  bbbbb1 lysine eeeee1  analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator ( bbbbb2 t-PA eeeee2 )
CRP11	The  bbbbb1 lysine eeeee1  analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received  bbbbb2 tissue plasminogen activator eeeee2  (t-PA)
CRP11	The lysine analogues epsilon-aminocaproic acid (EACA) and  bbbbb1 trans-4-amino-methyl cyclohexane carboxylic acid eeeee1  (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator ( bbbbb2 t-PA eeeee2 )
CRP11	The lysine analogues epsilon-aminocaproic acid (EACA) and  bbbbb1 trans-4-amino-methyl cyclohexane carboxylic acid eeeee1  (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received  bbbbb2 tissue plasminogen activator eeeee2  (t-PA)
CRP11	The lysine analogues  bbbbb1 epsilon-aminocaproic acid eeeee1  (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator ( bbbbb2 t-PA eeeee2 )
CRP11	The lysine analogues  bbbbb1 epsilon-aminocaproic acid eeeee1  (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received  bbbbb2 tissue plasminogen activator eeeee2  (t-PA)
CRP11	The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid ( bbbbb1 AMCA eeeee1 ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator ( bbbbb2 t-PA eeeee2 )
CRP11	The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid ( bbbbb1 AMCA eeeee1 ) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received  bbbbb2 tissue plasminogen activator eeeee2  (t-PA)
CRP11	The lysine analogues epsilon-aminocaproic acid ( bbbbb1 EACA eeeee1 ) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator ( bbbbb2 t-PA eeeee2 )
CRP11	The lysine analogues epsilon-aminocaproic acid ( bbbbb1 EACA eeeee1 ) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received  bbbbb2 tissue plasminogen activator eeeee2  (t-PA)
CRP11	Insulin levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, GLP-1 first and second phases, and  bbbbb1 arginine eeeee1  bbbbb2 GLP-1 eeeee2  first and second phases, and arginine)
CRP11	In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be  bbbbb1 RA eeeee1  bbbbb2 Cyp26A1 eeeee2  and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye
CRP11	In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be  bbbbb1 RA eeeee1  bbbbb2 Cyp26B1 eeeee2  which are known to be RA-responsive were not expressed at all in the developing eye
CRP11	The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [(3)H]-MRP4 and [ bbbbb1 (3)H eeeee1  bbbbb2 MRP4 eeeee2  and [(3)H]-SSB siRNA, respectively)
CRP11	CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and  bbbbb1 prostaglandins eeeee1  bbbbb2 cytokines eeeee2  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)
CRP11	CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins (PGs), thus inducing the secretion of Na(+) and  bbbbb1 Cl(-) eeeee1  bbbbb2 cytokines eeeee2  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)
CRP11	CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins (PGs), thus inducing the secretion of  bbbbb1 Na(+) eeeee1  bbbbb2 cytokines eeeee2  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)
CRP11	CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins ( bbbbb1 PGs eeeee1  bbbbb2 cytokines eeeee2  and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)
CRP11	Synaptic pathology in SAMP8 mice, as shown by decreases in synaptophysin and BDNF, was also counteracted by  bbbbb1 propranolol eeeee1  bbbbb2 BDNF eeeee2 , was also counteracted by propranolol treatment
CRP11	Synaptic pathology in SAMP8 mice, as shown by decreases in synaptophysin and BDNF, was also counteracted by  bbbbb1 propranolol eeeee1  bbbbb2 synaptophysin eeeee2  and BDNF, was also counteracted by propranolol treatment
CRP11	Tau hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of  bbbbb1 propranolol eeeee1 -treated mice, an effect probably related to a decrease in  bbbbb2 JNK1 eeeee2  expression
CRP11	Tau hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of  bbbbb1 propranolol eeeee1  bbbbb2 Tau eeeee2  hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of propranolol-treated mice, an effect probably related to a decrease in JNK1 expression
CRP11	 bbbbb1 Propranolol eeeee1  restores cognitive deficits and improves amyloid and  bbbbb2 Tau eeeee2  pathologies in a senescence-accelerated mouse model
CRP11	 bbbbb1 Propranolol eeeee1  restores cognitive deficits and improves  bbbbb2 amyloid eeeee2  and Tau pathologies in a senescence-accelerated mouse model
CRP11	Interestingly,  bbbbb1 propranolol eeeee1  also phosphorylated  bbbbb2 Akt eeeee2  in SAMP8 mice, which was associated with an increase of glycogen synthase kinase-3β phosphorylation, contributing therefore to the reductions in Tau hyperphosphorylation
CRP11	Interestingly,  bbbbb1 propranolol eeeee1  also phosphorylated Akt in SAMP8 mice, which was associated with an increase of glycogen synthase kinase-3β phosphorylation, contributing therefore to the reductions in  bbbbb2 Tau eeeee2  hyperphosphorylation
CRP11	Interestingly,  bbbbb1 propranolol eeeee1  also phosphorylated Akt in SAMP8 mice, which was associated with an increase of  bbbbb2 glycogen synthase kinase-3β eeeee2  phosphorylation, contributing therefore to the reductions in Tau hyperphosphorylation
CRP11	By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that  bbbbb1 comp eeeee1  bbbbb2 tion eeeee2  of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of cAMP in individual subcellular compartments
CRP11	Such organization results in the local activation of PKA subsets through the generation of confined intracellular gradients of cAMP, but the mechanisms responsible for limiting the diffusion of  bbbbb1 cAMP eeeee1  bbbbb2 PKA eeeee2  subsets through the generation of confined intracellular gradients of cAMP, but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified
CRP11	Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/human  bbbbb1 thiamin eeeee1  bbbbb2 placental protein 20 eeeee2  (PP20)/human thiamin pyrophosphokinase (hTPK)
CRP11	Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/human  bbbbb1 thiamin eeeee1  bbbbb2 PP20 eeeee2 )/human thiamin pyrophosphokinase (hTPK)
CRP11	Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/human  bbbbb1 thiamin eeeee1  pyrophosphokinase ( bbbbb2 hTPK eeeee2 )
CRP11	Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/human  bbbbb1 thiamin eeeee1  bbbbb2 human thiamin pyrophosphokinase eeeee2  (hTPK)
CRP11	Full-length cDNAs of placental protein 20 (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human  bbbbb1 thiamin eeeee1  bbbbb2 human thiamin pyrophosphokinase eeeee2  (hTPK) as confirmed by protein sequence analysis
CRP11	Full-length cDNAs of placental protein 20 (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human  bbbbb1 thiamin eeeee1  pyrophosphokinase ( bbbbb2 hTPK eeeee2 ) as confirmed by protein sequence analysis
CRP11	Full-length cDNAs of placental protein 20 (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human  bbbbb1 thiamin eeeee1  bbbbb2 PP20 eeeee2 ) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human thiamin pyrophosphokinase (hTPK) as confirmed by protein sequence analysis
CRP11	Full-length cDNAs of placental protein 20 (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human  bbbbb1 thiamin eeeee1  bbbbb2 placental protein 20 eeeee2  (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human thiamin pyrophosphokinase (hTPK) as confirmed by protein sequence analysis
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb1 creatine eeeee1  bbbbb2 FN eeeee2 ); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb1 creatine eeeee1  bbbbb2 ColIV eeeee2 ), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb1 creatine eeeee1  bbbbb2 collagen IV eeeee2  (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb1 creatine eeeee1  clearance ratio (Ccr) and  bbbbb2 MMP-9 eeeee2  protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb1 creatine eeeee1  bbbbb2 albumin eeeee2  creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb1 creatine eeeee1  bbbbb2 fibronectin eeeee2  (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with  bbbbb1 creatine eeeee1  bbbbb2 TIMP1 eeeee2 , collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin  bbbbb1 creatine eeeee1  ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin ( bbbbb2 FN eeeee2 ); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin  bbbbb1 creatine eeeee1  ratio (ACR), TIMP1, collagen IV ( bbbbb2 ColIV eeeee2 ), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin  bbbbb1 creatine eeeee1  ratio (ACR), TIMP1,  bbbbb2 collagen IV eeeee2  (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin  bbbbb1 creatine eeeee1  ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and  bbbbb2 MMP-9 eeeee2  protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin  bbbbb1 creatine eeeee1  bbbbb2 albumin eeeee2  creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin  bbbbb1 creatine eeeee1  ratio (ACR), TIMP1, collagen IV (ColIV), and  bbbbb2 fibronectin eeeee2  (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	Interestingly, miR-21 expression positively correlated with urine albumin  bbbbb1 creatine eeeee1  ratio (ACR),  bbbbb2 TIMP1 eeeee2 , collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein
CRP11	In these tissues, JTH-601,  bbbbb1 prazosin eeeee1  (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an  bbbbb2 alpha(1A)-adrenoceptor eeeee2  antagonist) competitively antagonized contraction in a concentration-dependent manner
CRP11	In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and  bbbbb1 tamsulosin eeeee1  bbbbb2 alpha(1)-adrenoceptor eeeee2  antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner
CRP11	In these tissues,  bbbbb1 JTH-601 eeeee1 , prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an  bbbbb2 alpha(1A)-adrenoceptor eeeee2  antagonist) competitively antagonized contraction in a concentration-dependent manner
CRP11	In contrast, synaptotagmin-1-deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any Ca(2+) / bbbbb1 H(+) eeeee1  bbbbb2 synaptotagmin-1 eeeee2 -deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any Ca(2+) /H(+) -antiport activity
CRP11	In contrast, synaptotagmin-1-deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any Ca(2+) / bbbbb1 H(+) eeeee1  bbbbb2 synaptotagmin-1 eeeee2  was acutely photo-inactivated - were devoid of any Ca(2+) /H(+) -antiport activity
CRP11	In contrast, synaptotagmin-1-deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any  bbbbb1 Ca(2+) eeeee1  bbbbb2 synaptotagmin-1 eeeee2 -deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any Ca(2+) /H(+) -antiport activity
CRP11	In contrast, synaptotagmin-1-deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any  bbbbb1 Ca(2+) eeeee1  bbbbb2 synaptotagmin-1 eeeee2  was acutely photo-inactivated - were devoid of any Ca(2+) /H(+) -antiport activity
CRP11	Pharmacological stimulation of KCa3.1 unexpectedly suppressed proliferation by inhibiting the rise in [ bbbbb1 Ca(2+) eeeee1 ]i and abolishing the expression and activity of KCa3.1 and  bbbbb2 PDGF β-receptors eeeee2 
CRP11	Pharmacological stimulation of KCa3.1 unexpectedly suppressed proliferation by inhibiting the rise in [ bbbbb1 Ca(2+) eeeee1 ]i and abolishing the expression and activity of  bbbbb2 KCa3.1 eeeee2  and PDGF β-receptors
CRP11	Pharmacological stimulation of KCa3.1 unexpectedly suppressed proliferation by inhibiting the rise in [ bbbbb1 Ca(2+) eeeee1  bbbbb2 KCa3.1 eeeee2  unexpectedly suppressed proliferation by inhibiting the rise in [Ca(2+)]i and abolishing the expression and activity of KCa3.1 and PDGF β-receptors
CRP11	The intermediate-conductance  bbbbb1 calcium eeeee1  bbbbb2 intermediate-conductance calcium-activated potassium channel KCa3.1 eeeee2  contributes to a variety of cell activation processes in pathologies such as inflammation, carcinogenesis and vascular remodeling
CRP11	The intermediate-conductance calcium-activated  bbbbb1 potassium eeeee1  bbbbb2 intermediate-conductance calcium-activated potassium channel KCa3.1 eeeee2  contributes to a variety of cell activation processes in pathologies such as inflammation, carcinogenesis and vascular remodeling
CRP11	After KCa3.1 blockade, the characteristic round shape of VSMCs expressing high l-cal bbbbb1 desmon eeeee1  bbbbb2 ockade eeeee2 , the characteristic round shape of VSMCs expressing high l-caldesmon and low calponin-1 (dedifferentiation state) was maintained, whereas KCa3.1 stimulation induced a spindle-shape cellular appearance, with low l-caldesmon and high calponin-1
CRP11	Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular  bbbbb1 Ca(2+) eeeee1  bbbbb2 PDGF eeeee2 )-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i
CRP11	Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular  bbbbb1 Ca(2+) eeeee1  bbbbb2 Platelet-derived growth factor-BB eeeee2  (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i
CRP11	Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [ bbbbb1 Ca(2+) eeeee1  bbbbb2 PDGF eeeee2 )-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i
CRP11	Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [ bbbbb1 Ca(2+) eeeee1  bbbbb2 Platelet-derived growth factor-BB eeeee2  (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i
CRP11	Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([ bbbbb1 Ca(2+) eeeee1  bbbbb2 PDGF eeeee2 )-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i
CRP11	Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([ bbbbb1 Ca(2+) eeeee1  bbbbb2 Platelet-derived growth factor-BB eeeee2  (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i
CRP11	The Intermediate-conductance  bbbbb1 Calcium eeeee1  bbbbb2 Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 eeeee2  Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling
CRP11	The Intermediate-conductance Calcium-activated  bbbbb1 Potassium eeeee1  bbbbb2 Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 eeeee2  Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated  bbbbb1 cAMP eeeee1  bbbbb2 KCa3.1 eeeee2  blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated  bbbbb1 cAMP eeeee1  response element binding protein ( bbbbb2 CREB eeeee2 ), c-fos and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated  bbbbb1 cAMP eeeee1  response element binding protein (CREB),  bbbbb2 c-fos eeeee2  and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated  bbbbb1 cAMP eeeee1  response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 ( bbbbb2 NOR-1 eeeee2 )
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated  bbbbb1 cAMP eeeee1  bbbbb2 phosphorylated cAMP response element binding protein eeeee2  (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated  bbbbb1 cAMP eeeee1  response element binding protein (CREB), c-fos and  bbbbb2 neuron-derived orphan receptor-1 eeeee2  (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [ bbbbb1 Ca(2+) eeeee1  bbbbb2 KCa3.1 eeeee2  blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [ bbbbb1 Ca(2+) eeeee1 ]i and attenuating the expression of phosphorylated cAMP response element binding protein ( bbbbb2 CREB eeeee2 ), c-fos and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [ bbbbb1 Ca(2+) eeeee1 ]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB),  bbbbb2 c-fos eeeee2  and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [ bbbbb1 Ca(2+) eeeee1 ]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 ( bbbbb2 NOR-1 eeeee2 )
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [ bbbbb1 Ca(2+) eeeee1 ]i and attenuating the expression of  bbbbb2 phosphorylated cAMP response element binding protein eeeee2  (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1)
CRP11	KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [ bbbbb1 Ca(2+) eeeee1 ]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and  bbbbb2 neuron-derived orphan receptor-1 eeeee2  (NOR-1)
CRP11	LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of  bbbbb1 LPA eeeee1  bbbbb2 LPA1 eeeee2 -induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J
CRP11	Using a mouse peritoneal fibrosis model, we demonstrate central roles for  bbbbb1 LPA eeeee1  and  bbbbb2 LPA1 eeeee2  in fibroblast proliferation
CRP11	There has been much recent interest in lysophosphatidic acid (LPA) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which  bbbbb1 LPA eeeee1  bbbbb2 LPA1 eeeee2 , in fibrotic diseases, but the mechanisms by which LPA-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated
CRP11	There has been much recent interest in lysophosphatidic acid ( bbbbb1 LPA eeeee1 ) signaling through one of its receptors,  bbbbb2 LPA1 eeeee2 , in fibrotic diseases, but the mechanisms by which LPA-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated
CRP11	There has been much recent interest in lysophosphatidic acid ( bbbbb1 LPA eeeee1 ) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which LPA- bbbbb2 LPA1 eeeee2  signaling promotes pathological fibrosis remain to be fully elucidated
CRP11	There has been much recent interest in  bbbbb1 lysophosphatidic acid eeeee1  (LPA) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which LPA- bbbbb2 LPA1 eeeee2  signaling promotes pathological fibrosis remain to be fully elucidated
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  absorption and metabolism (NPC1L1,  bbbbb2 ABCG5/8 eeeee2 , HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  bbbbb2 TNFα eeeee2 ) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA,  bbbbb2 ACAT eeeee2 ) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  absorption and metabolism ( bbbbb2 NPC1L1 eeeee2 , ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  bbbbb2 IL-1β eeeee2 , IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  bbbbb2 IL-8 eeeee2 , IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb2 HMGCoA eeeee2 , ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to  bbbbb1 cholesterol eeeee1  bbbbb2 IL-10 eeeee2 , TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1  bbbbb2 ABCG5/8 eeeee2 , HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1  bbbbb2 TNFα eeeee2 ) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1 ,  bbbbb2 ACAT eeeee2 ) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1  bbbbb2 NPC1L1 eeeee2 , ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1  bbbbb2 IL-1β eeeee2 , IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1  bbbbb2 IL-8 eeeee2 , IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1  bbbbb2 HMGCoA eeeee2 , ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8,  bbbbb1 HMGCoA eeeee1  bbbbb2 IL-10 eeeee2 , TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells
CRP11	Cell-pre-incubation with  bbbbb1 bradykinin eeeee1  bbbbb2 bradykinin eeeee2  induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells
CRP11	Cell-pre-incubation with  bbbbb1 bradykinin eeeee1  induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced  bbbbb2 NPC1L1 eeeee2  expression only in 7-ketocholesterol-incubated cells
CRP11	Cell-pre-incubation with  bbbbb1 bradykinin eeeee1  induced changes in  bbbbb2 ABCG eeeee2  expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells
CRP11	Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after  bbbbb1 7-ketostigmasterol eeeee1 -incubation; however, the energetic metabolism inhibition reduced  bbbbb2 NPC1L1 eeeee2  expression only in 7-ketocholesterol-incubated cells
CRP11	Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in  bbbbb1 7-ketocholesterol eeeee1  bbbbb2 bradykinin eeeee2  induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells
CRP11	Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in  bbbbb1 7-ketocholesterol eeeee1  bbbbb2 ABCG eeeee2  expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells
CRP11	Relative expression of  bbbbb1 cholesterol eeeee1  bbbbb2 holesterol transport-related proteins eeeee2  and inflammation markers through the induction of 7-ketosterol-mediated stress in Caco-2 cells
CRP11	In non-pre-treated cells,  bbbbb1 HMG-CoA eeeee1  bbbbb2 HMG-CoA eeeee2  was up-regulated by both 7-ketosterols
CRP11	Ex vivo,  bbbbb1 lumiracoxib eeeee1  inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas  bbbbb2 COX-2 eeeee2 -derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CRP11	Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) ( bbbbb1 PGE(2) eeeee1  bbbbb2 COX-1 eeeee2 -derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CRP11	Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) ( bbbbb1 TxB(2) eeeee1 ) generation with an ID(50) of 33 mg kg(-1), whereas  bbbbb2 COX-2 eeeee2 -derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CRP11	Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of  bbbbb1 prostaglandin E(2) eeeee1  bbbbb2 COX-1 eeeee2 -derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CRP11	Ex vivo, lumiracoxib inhibited COX-1-derived  bbbbb1 thromboxane B(2) eeeee1  (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas  bbbbb2 COX-2 eeeee2 -derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1). 6
CRP11	In cellular assays,  bbbbb1 lumiracoxib eeeee1  had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with  bbbbb2 human COX-1 eeeee2 ). 3
CRP11	Pretreatment with ceruletide (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by  bbbbb1 SMS 201-995 eeeee1 , but not that induced by  bbbbb2 arginine-vasopressin eeeee2  (1 microgram/rat, ICV)
CRP11	Pretreatment with ceruletide (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by  bbbbb1 arginine-vasopressin eeeee1  bbbbb2 arginine-vasopressin eeeee2  (1 microgram/rat, ICV)
CRP11	Pretreatment with ceruletide (40 micrograms/100 g b. wt., IP) 3 days or 7 days prior to the injection of  bbbbb1 SMS 201-995 eeeee1  significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by  bbbbb2 arginine-vasopressin eeeee2  (1 microgram/rat, ICV)
CRP11	Intracerebroventricular administration of SMS 201-995 (5 micrograms/rat), a  bbbbb1 somatostatin eeeee1  bbbbb2 somatostatin eeeee2  analogue, induced barrel rotation in rats
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astroc bbbbb1 ytes is mediate eeeee1  bbbbb2 in rat astrocytes is mediated by MCT1 an eeeee2 d/or MCT2
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astroc bbbbb1 ytes is mediate eeeee1 d by MCT1 and/or MCT2 bbbbb2  eeeee2 
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astroc bbbbb1 ytes is mediate eeeee1 d by MCT1 and bbbbb2 /or  eeeee2 MCT2
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2 bbbbb1  eeeee1  bbbbb2 in rat astrocytes is mediated by MCT1 an eeeee2 d/or MCT2
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2 bbbbb1  eeeee1  bbbbb2  eeeee2 
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2 bbbbb1  eeeee1  bbbbb2 /or  eeeee2 MCT2
CRP11	Because l-lactate reduced to 67% of the nicotina bbbbb1 te u eeeee1 ptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2 bbbbb2  eeeee2 
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2 bbbbb1  eeeee1  bbbbb2 in rat astrocytes is mediated by MCT1 an eeeee2 d/or MCT2
CRP11	Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2 bbbbb1  eeeee1  bbbbb2 /or  eeeee2 MCT2
CRP11	This process was reduced by a protonophore,  bbbbb1 carbonylcyanide p-trifluoromethoxyphenylhydrazone eeeee1 , and a typical monocarboxylate transporter ( bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore,  bbbbb1 carbonylcyanide p-trifluoromethoxyphenylhydrazone eeeee1 , and a typical  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore,  bbbbb1 carbonylcyanide p-trifluoromethoxyphenylhydrazone eeeee1 , and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.  bbbbb1 [(3)H]Nicotinate eeeee1  bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.  bbbbb1 [(3)H]Nicotinate eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.  bbbbb1 [(3)H]Nicotinate eeeee1  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical  bbbbb1 monocarboxylate eeeee1  transporter ( bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical  bbbbb1 monocarboxylate eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical  bbbbb1 monocarboxylate eeeee1  transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by  bbbbb1 H(+) eeeee1  bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by  bbbbb1 H(+) eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various  bbbbb1 monocarboxylic acids eeeee1  bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various  bbbbb1 monocarboxylic acids eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various  bbbbb1 monocarboxylic acids eeeee1  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor,  bbbbb1 alpha-cyano-4-hydroxycinnamic acid eeeee1 , suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and  bbbbb1 pyruvic acid eeeee1  bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and  bbbbb1 pyruvic acid eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and  bbbbb1 pyruvic acid eeeee1  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled  bbbbb1 monocarboxylate eeeee1  bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled  bbbbb1 monocarboxylate eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled  bbbbb1 monocarboxylate eeeee1  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that  bbbbb1 nicotinate eeeee1  bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that  bbbbb1 nicotinate eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as  bbbbb1 l-lactic acid eeeee1  bbbbb2 MCT eeeee2 ) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as  bbbbb1 l-lactic acid eeeee1  bbbbb2 monocarboxylate transporter eeeee2  (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system. [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as  bbbbb1 l-lactic acid eeeee1  bbbbb2 monocarboxylate transport system eeeee2 . [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)
CRP11	The pharmacological characteristics of [3H]dofetilide binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing human ether-a-go-go related gene (HERG)  bbbbb1 K+ eeeee1  bbbbb2 human ether-a-go-go related gene (HERG) K+ channels eeeee2 
CRP11	The pharmacological characteristics of [3H]dofetilide binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing human  bbbbb1 ether eeeee1  bbbbb2 human ether-a-go-go related gene (HERG) K+ channels eeeee2 
CRP11	The pharmacological characteristics of  bbbbb1 [3H]dofetilide eeeee1  binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing  bbbbb2 human ether-a-go-go related gene (HERG) K+ channels eeeee2 
CRP11	Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.  bbbbb1 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  bbbbb2 transforming growth factor-β type I receptor eeeee2  inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CRP11	Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 ( bbbbb1 TASP0382088 eeeee1  bbbbb2 transforming growth factor-β type I receptor eeeee2  inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CRP11	Discovery of  bbbbb1 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or  bbbbb2 ALK5 eeeee2 ) inhibitor
CRP11	Discovery of  bbbbb1 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as  bbbbb2 activin receptor-like kinase 5 eeeee2  or ALK5) inhibitor
CRP11	Discovery of  bbbbb1 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole eeeee1  (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as  bbbbb2 transforming growth factor-β (TGF-β) type I receptor eeeee2  (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CRP11	Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole ( bbbbb1 TASP0382088 eeeee1 ): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or  bbbbb2 ALK5 eeeee2 ) inhibitor
CRP11	Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole ( bbbbb1 TASP0382088 eeeee1 ): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as  bbbbb2 activin receptor-like kinase 5 eeeee2  or ALK5) inhibitor
CRP11	Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole ( bbbbb1 TASP0382088 eeeee1 ): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia. 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as  bbbbb2 transforming growth factor-β (TGF-β) type I receptor eeeee2  (also known as activin receptor-like kinase 5 or ALK5) inhibitor
CRP11	 bbbbb1 Serotonin eeeee1  bbbbb2 Serotonin transporter eeeee2  gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity
CRP11	 bbbbb1 Serotonin eeeee1  transporter gene regulatory region polymorphism ( bbbbb2 5-HTTLPR eeeee2 ), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity
CRP11	The aim of this study was to investigate  bbbbb1 [3H]paroxetine eeeee1  binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (5-HTT) polymorphism ( bbbbb2 5-HTTLPR eeeee2 )
CRP11	The aim of this study was to investigate  bbbbb1 [3H]paroxetine eeeee1  binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region  bbbbb2 serotonin transporter eeeee2  (5-HTT) polymorphism (5-HTTLPR)
CRP11	The aim of this study was to investigate  bbbbb1 [3H]paroxetine eeeee1  binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter ( bbbbb2 5-HTT eeeee2 ) polymorphism (5-HTTLPR)
CRP11	The aim of this study was to investigate [3H]paroxetine binding and impulsivity in  bbbbb1 alcohol eeeee1 -dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (5-HTT) polymorphism ( bbbbb2 5-HTTLPR eeeee2 )
CRP11	The aim of this study was to investigate [3H]paroxetine binding and impulsivity in  bbbbb1 alcohol eeeee1 -dependent and age-matched control subjects in relation to a 5'-promoter region  bbbbb2 serotonin transporter eeeee2  (5-HTT) polymorphism (5-HTTLPR)
CRP11	The aim of this study was to investigate [3H]paroxetine binding and impulsivity in  bbbbb1 alcohol eeeee1 -dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter ( bbbbb2 5-HTT eeeee2 ) polymorphism (5-HTTLPR)
CRP11	The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region  bbbbb1 serotonin eeeee1  transporter (5-HTT) polymorphism ( bbbbb2 5-HTTLPR eeeee2 )
CRP11	The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region  bbbbb1 serotonin eeeee1  bbbbb2 serotonin transporter eeeee2  (5-HTT) polymorphism (5-HTTLPR)
CRP11	The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region  bbbbb1 serotonin eeeee1  transporter ( bbbbb2 5-HTT eeeee2 ) polymorphism (5-HTTLPR)
CRP11	Blood samples were taken from both  bbbbb1 alcohol eeeee1 -dependent and control subjects to determine  bbbbb2 5-HTTLPR eeeee2  genotypes using PCR of lymphocyte DNA, and to perform platelet [3H]paroxetine binding (binding capacity: B(max); and dissociation constant: K(D))
CRP11	Alcohol-dependent subjects were hypothesized to show a decreased number of bindings sites and a lower dissociation constant. 5-HTTLPR S-genotype carriers in both  bbbbb1 alcohol eeeee1  bbbbb2 5-HTTLPR eeeee2  S-genotype carriers in both alcohol-dependent and control subjects were expected to show significantly fewer binding sites and a lower dissociation constant
CRP11	This was the first study to investigate platelet [3H]paroxetine binding in  bbbbb1 alcohol eeeee1 -dependent and age-matched control subjects in relation to the  bbbbb2 5-HTTLPR eeeee2  genotype
CRP11	No differences concerning 5-HTTLPR-alleles were found in these groups Furthermore, no significant interaction between these parameters and impulsivity was shown in  bbbbb1 alcohol eeeee1  bbbbb2 5-HTTLPR eeeee2 -alleles were found in these groups Furthermore, no significant interaction between these parameters and impulsivity was shown in alcohol-dependent subjects
CRP11	Protein  bbbbb1 tyrosine eeeee1  phosphatase 1B (PTP1B) is an important factor in non- bbbbb2 insulin eeeee2 -dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity
CRP11	Protein  bbbbb1 tyrosine eeeee1  phosphatase 1B ( bbbbb2 PTP1B eeeee2 ) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity
CRP11	Protein  bbbbb1 tyrosine eeeee1  bbbbb2 Protein tyrosine phosphatase 1B eeeee2  (PTP1B) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity
CRP11	Protein  bbbbb1 tyrosine eeeee1  bbbbb2 Protein tyrosine phosphatase 1B eeeee2  inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins
CRP11	We demonstrate that two  bbbbb1 flavin eeeee1  mono-oxygenase family members, FMO1 and  bbbbb2 FMO3 eeeee2 , oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO
CRP11	We demonstrate that two  bbbbb1 flavin eeeee1  bbbbb2 flavin mono-oxygenase eeeee2  family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO
CRP11	We demonstrate that two  bbbbb1 flavin eeeee1  mono-oxygenase family members,  bbbbb2 FMO1 eeeee2  and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO
CRP11	FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases  bbbbb1 TMAO eeeee1  bbbbb2 FMO3 eeeee2  overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases TMAO levels
CRP11	FMO3 overexpression in mice significantly increases plasma  bbbbb1 TMAO eeeee1  levels while silencing  bbbbb2 FMO3 eeeee2  decreases TMAO levels
CRP11	FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activate bbbbb1 d nu eeeee1  bbbbb2 farn eeeee2 esoid X receptor (FXR), a bile acid-activated nuclear receptor
CRP11	GW660511X and omapatrilat reduced the production of  bbbbb1 BrBK1-5 eeeee1  and  bbbbb2 BrBK1-7 eeeee2  with more effect being observed with omapatrilat
CRP11	GW660511X and omapatrilat reduced the production of  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7 with more effect being observed with omapatrilat
CRP11	GW660511X and omapatrilat reduced the production of BrBK1-5 and  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-7 eeeee2  with more effect being observed with omapatrilat
CRP11	GW660511X and omapatrilat reduced the production of BrBK1-5 and  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7 with more effect being observed with omapatrilat
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1 , BrBK1-5 and  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1 ,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 ,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 , BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 , BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb1 BrBK eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb1 BrBK eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  and  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	In human plasma the  bbbbb1 BrBK eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or  bbbbb1 omapatrilat eeeee1  (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or  bbbbb1 omapatrilat eeeee1  (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or  bbbbb1 omapatrilat eeeee1  (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or  bbbbb1 omapatrilat eeeee1  (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or  bbbbb1 omapatrilat eeeee1  (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe eeeee1  bbbbb2 Br-Phe eeeee2 
CRP11	In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe eeeee1  bbbbb2 BrBK1-5 eeeee2  and Br-Phe
CRP11	GW660511X and omapatrilat increased the production of both BrBK1-8 bbbbb1  and Br-Phe eeeee1 5 but not that of BrBK4-8 and BrBK2-8 bbbbb2  eeeee2 
CRP11	The production of  bbbbb1 Br-Phe5 eeeee1  bbbbb2 Br-Phe5 eeeee2  was reduced with GW660511X while no significant change was observed with omapatrilat after 4 h of incubation
CRP11	In addition the production of  bbbbb1 BrBK1-8 eeeee1  bbbbb2 BrBK1-8 eeeee2  was enhanced in the presence of these inhibitors with a greater accumulation being observed with omapatrilat
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  and Br-Phe5 plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  and Br-Phe5 plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  and  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 , BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 , BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 , BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1 ,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb1 BrBK1-8 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb1 BrBK2-8 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1 ,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1 , BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb1 BrBK2-9 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or  bbbbb1 omapatrilat eeeee1  (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1 , BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1 , BrBK1-5 and Br-Phe5 plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1 , BrBK1-5 and  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1 ,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb1 BrBK eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb1 BrBK4-8 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of  bbbbb1 GW660511X eeeee1  (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7,  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8,  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the  bbbbb1 BrBK eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  bbbbb2 BrBK1-8 eeeee2 , BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  plus BrBK2-9,  bbbbb2 BrBK4-8 eeeee2  and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  plus  bbbbb2 BrBK2-9 eeeee2 , BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  bbbbb2 Br-Phe5 eeeee2  plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  plus BrBK2-9, BrBK4-8 and  bbbbb2 BrBK2-8 eeeee2  metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  bbbbb2 BrBK eeeee2  was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  bbbbb2 BrBK1-5 eeeee2  and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  bbbbb2 BrBK1-7 eeeee2 , BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and  bbbbb1 Br-Phe5 eeeee1  bbbbb2 BrBK eeeee2  half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and  bbbbb1 omapatrilat eeeee1  bbbbb2 BrBK eeeee2  in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and  bbbbb1 omapatrilat eeeee1  bbbbb2 79/81 Br-Phe5 eeeee2 ) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and  bbbbb1 omapatrilat eeeee1  bbbbb2 BK eeeee2  (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81  bbbbb1 Br-Phe5 eeeee1 )  bbbbb2 BrBK eeeee2  in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81  bbbbb1 Br-Phe5 eeeee1  bbbbb2 79/81 Br-Phe5 eeeee2 ) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81  bbbbb1 Br-Phe5 eeeee1 ) BrBK in the presence of two new dual  bbbbb2 ACE eeeee2 /NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81  bbbbb1 Br-Phe5 eeeee1  bbbbb2 BK eeeee2  (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81  bbbbb1 Br-Phe5 eeeee1 ) BrBK in the presence of two new dual ACE/ bbbbb2 NEP eeeee2  inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled  bbbbb1 BK eeeee1  (79/81 Br-Phe5)  bbbbb2 BrBK eeeee2  in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled  bbbbb1 BK eeeee1  ( bbbbb2 79/81 Br-Phe5 eeeee2 ) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled  bbbbb1 BK eeeee1  (79/81 Br-Phe5) BrBK in the presence of two new dual  bbbbb2 ACE eeeee2 /NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled  bbbbb1 BK eeeee1  bbbbb2 BK eeeee2  (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled  bbbbb1 BK eeeee1  (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/ bbbbb2 NEP eeeee2  inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5)  bbbbb1 BrBK eeeee1  bbbbb2 BrBK eeeee2  in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5)  bbbbb1 BrBK eeeee1  bbbbb2 79/81 Br-Phe5 eeeee2 ) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5)  bbbbb1 BrBK eeeee1  in the presence of two new dual  bbbbb2 ACE eeeee2 /NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5)  bbbbb1 BrBK eeeee1  bbbbb2 BK eeeee2  (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5)  bbbbb1 BrBK eeeee1  in the presence of two new dual ACE/ bbbbb2 NEP eeeee2  inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors ( bbbbb1 GW660511X eeeee1  bbbbb2 BrBK eeeee2  in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors ( bbbbb1 GW660511X eeeee1  bbbbb2 79/81 Br-Phe5 eeeee2 ) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors ( bbbbb1 GW660511X eeeee1  bbbbb2 BK eeeee2  (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial
CRP11	Unlike  bbbbb1 GW660511X eeeee1 , omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no  bbbbb2 NEP eeeee2  activity was found
CRP11	Unlike  bbbbb1 GW660511X eeeee1 , omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better  bbbbb2 ACE eeeee2  inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and  bbbbb1 BrBK1-7 eeeee1 , suggesting a better ACE inhibition effect over GW660511X as no  bbbbb2 NEP eeeee2  activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and  bbbbb1 BrBK1-7 eeeee1  bbbbb2 BrBK1-7 eeeee2 , suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and  bbbbb1 BrBK1-7 eeeee1 , suggesting a better  bbbbb2 ACE eeeee2  inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X,  bbbbb1 omapatrilat eeeee1  abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no  bbbbb2 NEP eeeee2  activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of  bbbbb1 BrBK1-5 eeeee1  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of  bbbbb1 BrBK1-5 eeeee1  and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no  bbbbb2 NEP eeeee2  activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of  bbbbb1 BrBK1-5 eeeee1  and  bbbbb2 BrBK1-7 eeeee2 , suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of  bbbbb1 BrBK1-5 eeeee1  and BrBK1-7, suggesting a better  bbbbb2 ACE eeeee2  inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over  bbbbb1 GW660511X eeeee1  bbbbb2 BrBK1-5 eeeee2  and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CRP11	Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over  bbbbb1 GW660511X eeeee1  bbbbb2 BrBK1-7 eeeee2 , suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found
CRP11	Several studies have suggested that the accumulation of  bbbbb1 bradykinin eeeee1 , or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various  bbbbb2 ACE eeeee2 i
CRP11	Several studies have suggested that the accumulation of  bbbbb1 bradykinin eeeee1  bbbbb2 bradykinin eeeee2 , or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi
CRP11	Investigation of  bbbbb1 bradykinin eeeee1  bbbbb2 bradykinin eeeee2  metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat
CRP11	Investigation of  bbbbb1 bradykinin eeeee1  metabolism in human and rat plasma in the presence of the dual  bbbbb2 ACE eeeee2 /NEP inhibitors GW660511X and omapatrilat
CRP11	Investigation of  bbbbb1 bradykinin eeeee1  metabolism in human and rat plasma in the presence of the dual ACE/ bbbbb2 NEP eeeee2  inhibitors GW660511X and omapatrilat
CRP11	The effects of  bbbbb1 vitamin B6 eeeee1  deficiency on hepatic AGT isoenzymes, designated AGT 1 and AGT 2, respectively, were examined with male rats;  bbbbb2 AGT 1 eeeee2  is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria
CRP11	The effects of  bbbbb1 vitamin B6 eeeee1  deficiency on hepatic AGT isoenzymes, designated AGT 1 and AGT 2, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and  bbbbb2 AGT 2 eeeee2  only in the mitochondria
CRP11	The effects of  bbbbb1 vitamin B6 eeeee1  deficiency on hepatic  bbbbb2 AGT eeeee2  isoenzymes, designated AGT 1 and AGT 2, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria
CRP11	The effects of  bbbbb1 vitamin B6 eeeee1  deficiency on hepatic AGT isoenzymes, designated  bbbbb2 AGT 1 eeeee2  and AGT 2, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria
CRP11	The effects of  bbbbb1 vitamin B6 eeeee1  deficiency on hepatic AGT isoenzymes, designated AGT 1 and  bbbbb2 AGT 2 eeeee2 , respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria
CRP11	The effect of vitamin B6 deficiency on alanine:  bbbbb1 glyoxylate eeeee1  bbbbb2 alanine: glyoxylate aminotransferase eeeee2  isoenzymes in rat liver
CRP11	The effect of  bbbbb1 vitamin B6 eeeee1  deficiency on  bbbbb2 alanine: glyoxylate aminotransferase eeeee2  isoenzymes in rat liver
CRP11	The effect of vitamin B6 deficiency on  bbbbb1 alanine eeeee1  bbbbb2 alanine: glyoxylate aminotransferase eeeee2  isoenzymes in rat liver
CRP11	When the defect in the glyoxylate transamination in vivo in vitamin B6 deficiency is considered, these findings suggest t bbbbb1 hat it is  eeeee1  bbbbb2 ate t eeeee2 ransamination in vivo in vitamin B6 deficiency is considered, these findings suggest that it is due to the deficiency of AGT 1
CRP11	Urinary excretion of  bbbbb1 oxalate eeeee1  began to increase in 8-9 days, when AGT 2 remained intact but most of  bbbbb2 AGT 1 eeeee2  is depleted
CRP11	Urinary excretion of  bbbbb1 oxalate eeeee1  began to increase in 8-9 days, when  bbbbb2 AGT 2 eeeee2  remained intact but most of AGT 1 is depleted
CRP11	The holo activity of combined peroxisomal and mitochondrial AGT 1 with a low Km for L-alanine rapidly decreased after a lag time of about 2 days during feeding of the  bbbbb1 vitamin B6 eeeee1  bbbbb2 AGT 1 eeeee2  with a low Km for L-alanine rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days)
CRP11	Glutamate receptors of the N-methyl-D-asparate ( bbbbb1 NMDA eeeee1  bbbbb2 Glutamate receptors eeeee2  of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels
CRP11	Glutamate receptors of the N-methyl-D-asparate ( bbbbb1 NMDA eeeee1 -) subtype are tetrameric allosteric and  bbbbb2 ligand-gated calcium channels eeeee2 
CRP11	 bbbbb1 Glutamate eeeee1  bbbbb2 Glutamate receptors eeeee2  of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels
CRP11	 bbbbb1 Glutamate eeeee1  receptors of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and  bbbbb2 ligand-gated calcium channels eeeee2 
CRP11	Glutamate receptors of the  bbbbb1 N-methyl-D-asparate eeeee1  bbbbb2 Glutamate receptors eeeee2  of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels
CRP11	Glutamate receptors of the  bbbbb1 N-methyl-D-asparate eeeee1  (NMDA-) subtype are tetrameric allosteric and  bbbbb2 ligand-gated calcium channels eeeee2 
CRP11	This fundamental significance of  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2 -related excitotoxicity is discussed in the context of the developing clinical success of Memantine, but moreover set into relation to various proteomic and genetic markers of said diseases
CRP11	DA receptors are not alone: dynamic regulation of  bbbbb1 NMDA eeeee1  bbbbb2 NMDA receptor eeeee2  structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of  bbbbb1 NMDA eeeee1  receptor structure and function by neuregulins and  bbbbb2 transient cholesterol-rich membrane domains eeeee2  leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of  bbbbb1 NMDA eeeee1  receptor structure and function by  bbbbb2 neuregulins eeeee2  and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient  bbbbb1 cholesterol eeeee1  bbbbb2 NMDA receptor eeeee2  structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient  bbbbb1 cholesterol eeeee1  bbbbb2 transient cholesterol-rich membrane domains eeeee2  leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient  bbbbb1 cholesterol eeeee1  bbbbb2 neuregulins eeeee2  and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of  bbbbb1 glutamate eeeee1  bbbbb2 NMDA receptor eeeee2  structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of  bbbbb1 glutamate eeeee1  bbbbb2 transient cholesterol-rich membrane domains eeeee2  leads to disease-specific nuances of glutamate-signalling
CRP11	DA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of  bbbbb1 glutamate eeeee1  bbbbb2 neuregulins eeeee2  and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling
CRP11	Results indicate that imiquimod and  bbbbb1 resiquimod eeeee1  induce IFN-alpha and  bbbbb2 IFN-omega eeeee2  from purified pDC, and pDC are the principle IFN-producing cells in the blood
CRP11	We provide evidence that defective  bbbbb1 amino acid eeeee1  catabolism promotes the development of fasting hypoglycemia in  bbbbb2 KLF15 eeeee2 -/- mice by limiting gluconeogenic substrate availability
CRP11	Furthermore, the enzymatic activity of  bbbbb1 alanine eeeee1  aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in  bbbbb2 KLF15 eeeee2 -/- hepatocytes
CRP11	Furthermore, the enzymatic activity of  bbbbb1 alanine eeeee1  aminotransferase ( bbbbb2 ALT eeeee2 ), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes
CRP11	Furthermore, the enzymatic activity of  bbbbb1 alanine eeeee1  bbbbb2 alanine aminotransferase eeeee2  (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes
CRP11	Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic  bbbbb1 amino acid eeeee1  alanine into pyruvate, is decreased (approximately 50%) in  bbbbb2 KLF15 eeeee2 -/- hepatocytes
CRP11	Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into  bbbbb1 pyruvate eeeee1 , is decreased (approximately 50%) in  bbbbb2 KLF15 eeeee2 -/- hepatocytes
CRP11	Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid  bbbbb1 alanine eeeee1  into pyruvate, is decreased (approximately 50%) in  bbbbb2 KLF15 eeeee2 -/- hepatocytes
CRP11	KLF15-/- liver and skeletal muscle show markedly reduced mRNA expression of  bbbbb1 amino acid eeeee1  bbbbb2 KLF15 eeeee2 -/- liver and skeletal muscle show markedly reduced mRNA expression of amino acid-degrading enzymes